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FOREWORD
The National Institute on Drug Abuse (NIDA) is pleased to publish
Progress in Opioid Research, 1986, the proceedings of the 17th annual
scientific meeting of the International Narcotic Research Conference
(INRC). This meeting was held in San Francisco in July 1986.
The INRC is a unique international organization seeking to develop a
fundamental understanding of the basic mechanisms of action of
opioids, opioid peptides, and their receptors, research supported in
large part by NIDA. This group and its meetings are different from
others in the field because a definite effort is made to have young
as well as senior investigators attend and present data and results
of current, ongoing studies. For instance, in recent years, 75 per
cent of the travel funds provided by the Division of Preclinical
Research of NIDA for attendance at the meeting have been allocated
to young investigators involved in laboratory research on opioids or
related subjects. As is true for many other fields, excellence
attracts more participants every year and this publication is the
largest of any INRC Proceedings, with 155 papers and 113 abstracts
included. The trio of editors worked swiftly and vigorously to
review and assemble this compendium for publication by NIDA.
We are sure that this significant "state-of-the-art" volume of the
latest research on the basic mechanisms of drug abuse will be of
great value to members of the scientific community and other readers
interested in the prevention and treatment of substance abuse.
Monique C. Braude, Ph.D.
Division of Preclinical Research
National Institute on Drug Abuse
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PREFACE
From our "bay view" in South San Francisco, we witnessed the recent
developments in opioid research and reflected on the many notable scientific
revelations from prior meetings of the INRC. Historically, the thrust of
opioid research has progressed from classic in vivo and in vitro pharmacology
toward a molecular description of events at a cellular and sub-cellular level.
The 1966 Meeting of the INRC has provided us with an opportunity to view the
cutting edge of research defining opioid ligands, receptors, and their
functional consequences.
In many ways, the opiates have been at the forefront of scientific
advances which were subsequently applied to other areas of biochemical,
pharmacological, physiological and behavioral research. For example, the
early definition of opiate receptors in 1973 has resulted in experimental
strategies which have been directly applied to many other endogenous
receptor systems. Clearly, the initial description of endogenous peptide
ligands for opioid receptors in 1975 provided the major impetus for research in
the neurobiology of many other opioid and non-opioid peptides. Likewise, the
current emphasis on molecular biology as a means by which to define the
biosynthesis and metabolism of endogenous opioids has obvious pertinence to
other biologically active peptides. The complex biochemical procedures that
have been developed to isolate and purify opiate receptors are already being
applied to other receptor systems. Finally, the experimental strategies used
to define the functional effects of endogenous opioids have resulted in a
further understanding of the interactions between opioid and non-opioid
systems.
Once again, this year’s International Narcotics Research Conference
provided a stimulating environment for the exchange of the most recent
advances in opioid research. The program not only reflected many
outstanding voluntary papers, but also included four invitational symposia and
plenary lectures by international luminaries in pharmacology and the
neurosciences. It was the intent of the program committee, under the
leadership of Drs. Horace Loh and Nancy Lee, to utilize the plenary lectures
as a means by which to acquaint opioid researchers with recent advances in
related non-opioid fields. The first plenary lecturer, Dr. Daniel Koshland,
discussed bacterial chemotaxis as a model sensory system. Dr. Julius Axelrod
presented an update on the transduction of receptor mediated signals and the
release of adrenocorticotropin. CTP binding proteins in signal transduction
was the topic of the lecture by Dr. John Northrup, and Dr. 5. Numa provided
the final plenary lecture on a molecular approach to the function of ionic
channels. These outstanding presentations provided a refreshing break from
the tachyphylactic effects of continued "opioid exposure", and also fostered
new ideas and perspectives with pertinence to opioid research.
Unfortunately, despite the tireless efforts of many of our participants,
the structures of isolated, purified opiate receptors were not available for
presentation at this conference. Additionally, the fundamental problems of
tolerance and physical dependence were only minimally addressed. Hopefully,
future meetings of the INRC will provide a forum to reveal these advances as
prior meetings have served to define the many advances described above.
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Immediately following the INRC Meetings, the editorial board met for
two days to review the papers and organize the monograph. In organizing this
volume, it was our intention to provide a flowing framework, with related
areas presented in logical groupings. We have attempted to arrange the
papers into chapters which progress sequentially from biochemical studies of
receptors and ligands through morphological descriptions of their localization
to the final chapters defining the functional effects of opioid systems.
Following the manuscripts, we have included the abstracts that were not
submitted as papers.
As editors of this volume and participants in this year’s meetings, we
feel that the outstanding efforts of Dr. Horace Loh, Dr. Nancy Lee, Barbara
Halperin and their colleagues in San Francisco, and Jean Paige in Washington,
D.C., ensured both an outstanding scientific and social agenda for the
meetings and the timely review and assemblage into this monograph of the
many manuscripts based on those meetings. Their work was complemented by
the tireless efforts of Dr. Eddie Way in his capacity as secretary to the
IN RC. This meeting was generously supported by the National Institute on
Drug Abuse, the U.S. Army Medical Research and Development Command,
and several sponsors and contributors as listed in the program. Finally, Dr.
Monique Braude, of the National Institute on Drug Abuse, provided guidance in
our preparation of Progress in Opioid Research for publication in the NIDA
Research Monograph series.
JOHN W. HOLADAY
PING-YEE LAW
ALBERT HERZ
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PURIFICATION OF KAPPA-OPIOID RECEPTOR SUBTYPE TO
APPARENT HOMOGENEITY FROM FROG BRAIN
A. Borsodi, A. Khan, J. Simon, S. Benyhe, J. Hepp*,
M. Wollemann, K. Medzihradszky*
Institute of Biochemistry, Biological Research Center of
the Hungarian Academy of Sciences, H-6701 Szeged,
P.O.Box 521, Hungary, and Central Research Institute
for Chemistry of the Hungarian Academy of Sciences,
II-1025, Budapest, P.O.:Box 17, Hungary.
A B S T R A C T
Kappa-opioid receptor subtype was purified from digitonin
solubilized preparation of frog brain membranes by
hydrophobic and Sepharose 6B chromatography. 4800-fold
purification over the membrane-bound receptors was achieved.
The kappa receptor activity resides in a homo-oligomer of a
single polypeptide of Mr 65,000.
INTRODUCTION
The opioid receptor system displays heterogeneity and
consists of at least four major subtypes; i.e. mu, delta,
kappa and sigma (Zukin & Zukin 1934). Recently, several
laboratories have reported a partial purification of active
opioid mu and delta binding sites (Cho et al. 1983,
Gioannini et al. 1934 & 1985, Maneckjee et al. 1985, Fujioka
Fujioka et al. 1935, Simonds et al. 1985, Demoliou-Mason &
Barnard 1986). We have described earlier a succesful
solubilization of opioid receptors from frog brain by the
use of digitonin (Simon et al. 1984). This preparation was
found to be a rich source of the kappa-subtype (72%). In
solution this subclass was completely separated from the mu-
and delta-sites by gel filtration on Sepharose-6B column
(Simon et al. 1985) and it was purified on an affinity
column (Simon et al. 1986). In the present work We purified
the receptor by the use of hydrophobic chromatography.
MATERIALS AND METHODS
3H-Ethylketocyclazocine (3H-EKC: 0.74 TBq/mmol, 19.9
Ci/nmol) was purchased fron New England Nuclear. 3H-Dansyl
chloride (0.53 TBq/mmol, 14.2 Ci/mmol) was from Amersham.
1
Digitonin, bacitracin, phenylmethylsulfonyl fluoride
(PMSF), dansyl chloride and polyethyleneimine (PEI) were
obtained from Sigma Chemicals Co. Sepharose-6B beads, HMW
calibration kit for gel filtration and LMW kit for gel
electrophoresis were purchased by Pharmacia Fine
Chemicals. All other chemicals were of analytical grade.
Particulate membrane fraction of frog (Rana esculenta)
brain was prepared in Tris buffer and solubilized with 1%
digitonin as described earlier ($imon et al. 1984).
Specific binding was measured with 3H-EKC in the presence
of blocking agents for mu and delta sites (Simon et al.
1934). Protein concentration was determined as described
by Bradford (1976), or with 3H-Dansyl chloride method
(Schultz & Wassarman 1977). SDS polyacrylamide gel
electrophoresis was carried out by the method of Laemmli
(1970) with slight modifications.
RESULTS AND DISCUSSION
Frog (Rana Esculenta) brain membranes were solubilized in
1% (ligitonin (Simon et al. 1984) and applied on Phenyl-
Sepharose CL-B column with high salt concentration (0.5 M
(NH4)2SO4), after the removal the excess of the detergent.
Proteins were eluted with decreasing salt concentration. 3H-
KC binding of the fractions was measured. The highest
activity was found at low salt (0.06M-H2O) concentration
(fig. 1) indicating a hydrophobic character.
FIGURE 1. Phenyl-Sepharose CL-4B chromatography
Solubilized opioid receptors were applied on Phenyl-
Sepharose CL-4B column (32x0.8 cm) in 0.5M
(NH4)2S04. Elution was carried out by decreasing salt
concentration.EKC binding was measured.
2
The preparation exhibited high affinity for kappa-ligands as
it is shown in table 1.
TABLE 1.
Relative potencies of opioid ligands
in displacing 3H-EKC binding
Unlabelled ligands IC50(nM)
Ethylketocyclazocine
Dynorphin(1-13)
U-50, 488 H
30
10
11
The pooled and concentrated fractions were applied on
Sepharose 6B column, where a complete separation of the
kappa subtype can be obtained (Simon et al. 1985). Fractions
with high 3H-EKC specific binding were collected and their
protein contents were measured. Because of the   very low
mount, the ultrasensitive (5-10 ng per assay) 3H-Dansyl
chloride method was used .
FIGURE 2. SDS polyacrylanide gelelectrophoresis
Lane 1.: molecular weight markers, lane 2.: digitonin
extract, lane 3.: purified kappa fraction.
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About 3360 pmol of 3H-EKC per mg protein specific activity
was obtained compared to 0.7 pmol/mg in the original
membrane fraction. Approximately 4800-fold enrichment Of
kappa-subtype over the menbrane-bound receptors was
achieved. The kappa receptor activity resides in a homo-
oligomer of a
shown on fig. 2.
single polypeptide of Mr 65,000, as it is
Results from other laboratories and our recent data suggest
a general pattern of opioid receptors in which each subtype
is due to a sinqle, specific type of subunit.
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ABSTRACT
The brain of the frog R. ridibunda contains a major opioid binding
site which in vitro pharmacological profile is different from those of
mammalian µ, - and -opioid sites. In digitonin extracts, this major
opioid site exists as two molecular forms -10S and 12S- which are
clearly resolved by sedimentation in sucrose gradients and which are
thought to represent the opioid receptor alone (10S) or associated
(12S) with a guanine nucleotide regulatory protein. Purification of
the digitonin extracts by affinity chromatography on immobilized
dynorphin, results in a single major protein component of apparent
M r˜ 64,000.
INTRODUCTION
Amphibian brain membranes display high levels of opioid binding (Ruegg
.et al  1981, Puget et al. 1983, Simon et al. 1984). In addition,
amphibian brain opioid receptors are readily solubilized under active
form in reasonably high yields with digitonin alone (Ruegg et al.
1981, Simon et al. 1984). Therefore, the amphibian brain designates
itself as a suitable source wherefrom to purify opioid receptors by
affinity chromatography.
In this report, we have characterized the types of opioid sites
present in frog brain membranes and we have analyzed the sedimentation
behavior of the digitonin solubilized opioid receptors. Our results
suggest that in the preparation, there is a major opioid receptor type
different from mammalian µ, and types and which appears to exist
independently of as well as in association with a guanine nucleotide
regulatory protein.
MATERIALS AND METHOOS
Preparation and solubilization of the crude membrane fraction (O°C).
Freshly dissected whole brains from R. ridibunda frogs were
homogeneized in 50 mM tris-HCl pH 7.4 ("buffer") and the homogenate
was centrifuged in a Beckman rotor type 30 for 35 min at 28,000 rpm.
The pellet was washed and resuspended in enough buffer to obtain a
crude membrane fraction containing about 5 mg of protein per ml. The
suspension was made 1 % (w/v) with digitonin (Fluka AG) and gently
stirred for 30 min after which it was centrifuged in a Beckman rotor
type 30 for 30 min at 35,000 rpm. The supernatant (2 mg of protein/ml)
was taken as the soluble extract.
Equilibrium binding studies (25°C).
Equilibrium binding studies were carried out on 50 µl either of the
crude membrane fraction (diluted 1 : 5) or on 30 µl aliquots of the
soluble extract in a final volume of 0.5 ml using 3H-etorphine (30-60
Ci/mmol, Amersham) or 3H-diprenorphine (25-50 Ci/mmol, Amersham). All
assays were in triplicate and incubation was for 1 hr at 25°C.
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Nonspecific binding was determined in the presence of 10 µM diprenor-
phine. Free and bound radioligand were separated by rapid filtration
on glass fiber disks (Whatman GF/B) which, in the case of the soluble
extract, had been presoaked in PEI according to Bruns et al. (1983).
Sedimentation in sucrose gradients
0.4 ml aliquots of digitonin extract were layered on top of 10.6 ml
linear 5 to 20 % (w:v) sucrose gradients in 50 mM tris-HCl pH 7.4
containing 0.01 % (w:v) digitonin. Centrifugation was at 40.000 rpm
for 16 hrs in a Beckman rotor type SW 41 Ti after which fractions of
0.16 ml were collected. Each fraction was assayed for 3H-etorphine
(2 nM) or 3H-diprenorphine (2 nM) in a final volume of about 0.2 ml by
the rapid filtration method as modified by Bruns et al. (1983).
RESULTS AND DISCUSSION
The frog brain contains a major opioid receptor type that is neither
µ, nor or
Equilibrium saturation binding of the agonist 3H-etorphine (3H-ETO)
and of the antagonist 3H-diprenorphine (3H-DIP) in frog brain
membranes was clearly biphasic (figure 1). Sodium ions (120 mM NaCl)
selectively reduced binding of 3H-ET0 at the high affinity site but
not at the low affinity site suggesting the opioid nature of the
former but not of the latter.
Examination of the potency of various unlabelled opioid ligands to
compete with binding of 0.1 nM 3H-ET0 at the high affinity site
revealed that the latter actually consisted of a mixture of several
types including a major one (70 %) "pharmacological profile" in vitro
was clearly different from those of mammalian µ-, and -opioid
sites. In particular, the major opioid site of the frog brain
displayed moderate affinity toward DAGO (Ki = 60 nM) and DTLET (Ki =
120 nM) and low affinity toward U-50488 (Ki = 1,200 nM), i.e. toward
selective ligands that normally bind µ, and sites respectively
with nanomolar affinities.
Frog brain opioid receptors exist independently of and in association
with a guanine nucleotide regulatory protein.
Because of the limited space allowed to the present report, only data
from assays with 3H-DIP in the presence cf 120 mM NaCl will be
presented. Under these conditions, digitonin extracts from frog brain
were found to contain in the range 1.2-1.5 pmol (/mg of protein) of a
homogenous population of sites that bind 3H-DIP with high affinity (Kd
= 0.2 nM). Interestingly, the binding characteristics of 3H-DIP were
not modified in the least had the soluble extract been derived from
NaCl (120 mM) or GppNHp (50 µM) pretreated membranes.
In contrast, the sedimentation profiles of opioid binding activity in
the soluble extract were clearly heterogenous (figure 2). Opioid
binding activity was found to be associated with a minor component at
position 12S and with a major component at position 10S.
In extracts from membranes that had been incubated with 120 mM NaCl or
with 50 µM GppNHp prior to solubilization, no activity was recovered
at position 12S while, under these conditions, higher levels of 3H-DIP
binding were observed in association with the 10S component.
A simple way to explain these results is that the frog brain opioid
receptor exists independently of (10S) as well as in association with
(12S) a guanine nucleotide regulatory protein (N). The antagonist
W-DIP does not discriminate the two forms in question hence linear
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Figure 1: Scatchard transforms of the equilibrium adsorption
isotherms of 3H-etorphine (a) and of 3H-diprenorphine in the
crude membrane fraction from the brain of R. ridibunda. (a) in 50
mM tris-HCl pH 7.4. The insert is the Scatchard transform of an
isotopic dilution experiment using 0.1 nM 3H-etorphine. The
preparation contained 0.7-0.8 pmol/mg protein of a high affinity
site (Kd = 0.1 nM) and 3.2-3.3 pmol/mg protein of a low affinity
site (Kd = 10 nM). (b) in 50 mM tris-HCl pH 7.4 + 120 mM NaCl.
The histogram at the right indicates the proportions of the
various types of binding sites that were labelled in the presence
of 0.1 nM 3H-etorphine. Op represents the major opioid site and
LAS the low affinity site.
Figure 2: Sedimentation profiles of the opioid binding activity
in digitonin extracts from the crude membrane fraction of the
brain of R. ridibunda. Opioid binding activity was assayed for in
each fraction of the gradients with 3H-DIP (2 nM) in the presence
of 120 mM NaCl. Solid line: the detergent extract was from
untreated membranes. Dashed line: the detergent extract was from
NaCl (120 mM) or from GppNHp (50  µM) preincubated membranes. Note
that under these conditions no binding activity is recovered in
association with the component that is sedimented slightly faster
than catalase (C) used as velocity marker.
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Scatchard transforms from equilibrium binding studies. 12S receptors
appear to be converted into 10S receptors in the presence not only of
sodium ions but also and most significantly of GppNHp, an effector of
N proteins : this conversion manifests itself, in sedimentation
studies, by a decreased binding of 3H-DIP to the 12S component and by
a concomittant increased binding of 3H-DIP to the 10S component.
Purification
Opioid receptors in digitonin extracts from several thousands of frog
brains are now being purified by affinity chromatography on
immobilized dynorphin 1-13 and following essentially the protocol of
Gioannini et al. (1985) for the purification of an active
opioid-binding protein from bovine striatum. Our results are still
very preliminary yet a purified preparation is routinely obtained that
contains a major protein component of apparent Mr = 64.000. However,
it has not been unambiguously shown yet that the purified protein
actually carries the opioid binding site.
CONCLUSION
In addition to the frog brain opioid receptor, the µ-opioid receptor
from rabbit cerebellum (Jauzac et al. 1986) and the -opioid receptor
from guinea-pig cerebellum (Frances et al., unpublished) display the
10S and 12S forms which are thought to represent the receptor alone
(10S) and the receptor associated (12S) with a N protein. It is
therefore possible that all opioid receptor types share the property
of interacting with a N-protein and it is tempting to speculate that
opioid agonists in general modulate the permeability of the neuronal
membrane (North 1986) through, primarily, the receptor-mediated
activation of a N-protein. In this respect, opioid agonists in general
would act, at the molecular level, in a way that is not any different
from that of classical neuromodulators, serotonin, acetylcholine or
noradrenaline (Siegelbaum and Tsien 1983).
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AGONISTS TO DIGITONIN-SOLUBILIZED OPIOID RECEPTORS
FROM BOVINE STRIATUM
G. Crema, T.L. Gioannini, J.M. Hiller and E.J. Simon
Depts. of Psychiatry and Pharmacology
New York Univ. Med. Ctr., New York, New York, 10016,
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ABSTRACT
Active opioid binding sites, that retain the ability to
bind tritiated agonists  have been obtained in good yield
in digitonin /NaCl/Mg2+ extracts of morphine protected
bovine striatal membranes. Ligand protection of binding
sites and the presence of Mg ions were found to be
absolute requirements for agonist binding in this
solubilized opioid receptor preparation. Soluble
preparations contained a ratio of mu: delta:kappa similar
to that in the membranes.
INTRODUCTION
Solubilization, attempted purification and separation of
the various opioid receptor types are important steps
toward the elucidation of the molecular basis of receptor
heterogeneity. Earlier studies from this laboratory
demonstrated successful solubilization of active opioid
binding sites from mammalian brain, using digitonin and
high concentrations of NaCl (Howells et al. 1982).
Binding was measured using antagonists because under these
conditions little or no tritiated agonist binding could be
detected. Recently Itzhak et al. (1984) were able to
obtain opioid agonist binding after fractionation of the
soluble binding sites on a sucrose density gradient.
Opioid agonist binding activity has also been reported to
Mg2+/digitonin solubilized receptors from rat brain
membranes (Demoliou-Mason and Barnard 1986) and to CHAPS-
solubilized receptors (Simonds et al. 1980) In addition,
some progress has been made in the identification of the
ligand binding subunits of mu and delta receptors, using
the technique of affinity labeling (Newman and Barnard
1984; Howard et al. 1985, 1986). In the present study, we
describe a modification of our method for extracting from
bovine striatal membranes active opioid binding sites that
retain the ability to bind tritiated agonists as well as
antagonists, with high affinity and in good yield.
MATERIALS AND METHODS
Particulate membrane fractions from fresh bovine striatum
were
The
prepared as previously described by this laboratory.
membrane preparations were stored at -70° in 0.32 M
sucrose (1:6 w/v) until needed. For solubilization, crude
9
membrane preparations were thawed, diluted 1:l with 50 mM
Tris (buffer
A) and
HCl containing 1 mM K2 EDTA, and 10 mM MgSO4
incubated with 1 uM morphine sulfate, for 30 min at
room temperature. The mixture was diluted with an equal
volume of buffer A containing 1% digitonin/l M NaCl and
stirred on ice for 30 min followed by centrifugation at
100,000 x g at 4°C. The supernatant was removed and mixed
1:1 with 40% polyethylene glycol 6000 (PEG) in presence of
0.1% IgG. The suspension was then spun at 12,000 x g for
15 min at 4°C. The resulting pellet was rinsed twice with
7.5% PEG and resuspended in buffer A, 0.1 mM leupeptin
NaCl. Duplicate 1 ml samples were incubated with
tritiated ligands 1 uM unlabeled naloxone, for 60 min at
25°C. After incubation, samples were precipitated with 13%
PEG in the presence of 0.15% IgG prior to filtration.
Specific binding was assayed using membranes and
solubilized preparations derived from equal amounts of
tissue, at the same concentrations of radioligand and
under identical conditions.  Protein was determined by
the method of Bradford (1972). 3H-bremazocine (30 Ci/mmoll
and 3H[Tyr-D-Ser-Gly-Phe-Leu-Thr] enkephalin
Ci/mmol) were purchased from NEN and
(DSTLE, 30
3H-[D-Ala2-Me-Phe4-
Gly-011 enkephalin (DAGO, 60 Ci/mmol) from Amersham. The
following unlabeled drugs were used: Naloxone (Endo
Laboratories), morphine sulfate (Merck). Other chemicals
used were: digitonin (US Biochemical Corp.), polyethylene
glycol 6000 (PEG) and bovine gamma-globulin (IgG) from
Sigma, guanosine-5'triphosphate (GTP) from Boehringer.
RESULTS AND DISCUSSION
In an attempt to protect the opioid agonist binding from
the detrimental effect of digitonin and NaCl present
during the extraction procedure (Method I), bovine
striatal membranes were incubated with morphine and MgSO4
prior to solubilization (Method II).
no specific binding of selective
As shown in table 1,
3H-labeled
peptides occurred under conditions of method I,
opioid
while, as
expected for 3H-bremazocine and H-naltrexone the specific
binding recovered represented 30-35%. In contrast,
solubilization of membranes under conditions of method II,
produced a good yield of soluble receptor activity for
opioid peptides.
binding
This represented an 11-30% yield of
activity. Saturation curves of 3H-bremazocine
binding yielded linear Scatchard plots for both soluble
preparations with KD = 1.9 nM, Bmax = 349 fmol/mg protein
and KD =1.5 nM, Bmax = 292 fmol/mg protein for methods I
IIand respectively (table II). The binding of selective
opioid ligands to soluble binding sites (from method II)
was saturable and of high affinity as indicated by the
apparent KD
demonstrates
and Bmax values summarized in table II. This
that distinct subtype specificities,
characteristic of membrane-bound receptors, were still
retained in the soluble preparation. In addition, the
ratio of mu:delta:kappa was similar in the soluble
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fraction as in the membranes.
Table I
Yields* of agonist and antagonist binding in soluble
receptors extracted from bovine striatal membranes
using methods I and II
Extract PEG Protein Recovery of specific binding (%)
pptation % Naltr. Bremaz. DAGO DSTLE
(3nM) (3nM) (6nM) (6nM)
Method I - ** 50 30 35 0 0
+ 30 18 21 0 0
Method II + 25 21 19 20 11
*Percent yields were calculated as follows:
(Specific binding to soluble fraction/specific
binding to membrane fraction x 100)
**Binding in extract not precipitated by PEG was
carried out after 1:5 dilution to reduce digitonin
concentration to 0.1%.
Table II
Comparison of affinity constants and maximal binding
values or solubilized bovine striatal membranes,
processed by methods I and II
Method I Method II
Ligand Kd(nM) Bmax Kd(nM) Bmax
(fmol/mg (fmol/mg
protein) protein)
3H-Bremazocine 1.9 0.2 349 32 1.5 0.13 292 21
3H-Bremazocine
(+100 mMDAG0 N.D.* N.D. 1.5 135
+ 100mM DPDPE)
3H-DAGO N.D. N.D. 2.5 0.2 65 12
3H-DSTLE N.D. N.D. 6.2 45
*N.D. - not detectable
Values represent mean of at least 3 determinations
S.E.
When no S.E. is given only 2 determinations were done.
As shown in table III, specific mu opioid binding to the
solubilized receptors was still sensitive to the
inhibitory effect of GTP. In fact at 100 uM GTP it
seemed to be more sensitive than to membrane-bound
receptors. In the membrane Mg2+ was able to reverse the
GTP-induced reduction in 3H-DAGO binding. A similar
11
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reversal of GTP-induced decrease in 3H-dihydromorphine
binding by manganese was reported by Childers and Snyder
(1980).
Effect of GTP and Mg2+ on  mu type opioid binding to
Table III
membranes* and solubilized fraction of
bovine striatum
Specific binding of 3H-DAGO (fmol/mg protein)
Conc
NaCl A d d i t i o n s
(mM) None GTP(l00uM) Mg
2+(10mM) Mg2++GTP
0 64 45 60 74
10 50 30 56 85
Membranes 25 33 20 58 75
100 13 7.5 42 47
Soluble 0 0 0 43 0
(Method II) 100 0 0 42 0
Results are the average of duplicate experiments.
*Specific binding was determined following incubation
of 1 ml striatal membrane (1 mg/protein/ml) with 3H-
DAGO (1 nM) in the absence and presence of 1 uM
unlabeled naloxone for 60 min, 25°C.
**Specific binding was determined following
incubation of 1 ml solubilized stria al membranes
"Method II" (0.6 mg/protein/ml) with
the absence
3H-DAGO (6 nM)
in and presence of 1 uM unlabeled
naloxone for 60 min, 25°C.
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IDENTIFICATION OF RAT BRAIN OPIOID (ENKEPHALIN) RECEPTOR BY
PHOTOAFFINITY LABELING
Clement W.T. Yeung
Playfair Neuroscience Unit and Department of Biochemistry, University
of Toronto, Toronto, Ontario M5T 2S8 CANADA
ABSTRACT
A photoreactive, radioactive enkephalin derivative was prepared and
purified by high performance liquid chromatography. Rat brain and
spinal cord plasma membranes were incubated with this radioiodinated
photoprobe and were subsequently photolysed. Autoradiography of the
sodium dodecyl sulfate gel electrophoresis of the solubilized and
reduced mernbranes showed that a protein having an apparent molecular
weight of 46,000 daltons was specifically labeled, suggesting that
this protein may be the opioid (enkephalin) receptor.
INTRODUCTION
Extensive studies have been made on the endogenous opioid peptides
and their interactions (Smith and Loh 1981; Barnard and Demolion-
Mason 1983; Zukin 1984).
lin) receptor in situ,
In order to identify the opioid (enkepha-
the technique of photoaffinity labeling was
employed. The usse of photogenerated reagents for the labeling of
biological receptor sites has been reviewed (Bayley and Knowles 1977;
Eberle and de Graan 1985). A number of photoreactive enkephalin
derivatives designed to investigate the opioid receptor have been
reoorted (Hazum et al. 1979: Lee et al. 1979; Smolarskv and Koshland
1980; Garbay-Jaurequiberry et al. 1984; Zioudron et al.’ 1983; Fujioka
et al. 1984; Yeung 1985). In this communication, we report the
preparation and purification of a radioiodinated, para-azido-L-
phenylalanyl derivative of enkephalin. This photosensitive and
radioactive enkephalin tracer was used to identify the opioid
receptor in the plasma membranes from rat neural tissues. A plasma
membrane protein with an apparent molecular weight of 46,000 daltons
was specifically labeled. It is likely that this protein is a
protein of the opioid (enkephalin) receptor.
MATERIALS AND METHODS
Preparation and Purification of 125I(D-Ala2,  p-N3-Phe
4-Met5)Enkepha-
Purified (D-Ala2, p-N3-Phe
4-Met5)enkephalin (AP-Enk) (Yeung 1985) was
radioiodinated with carrier free 125I (Amersham Radiochemicals) and
chloramine-T as described by Hunter and Greenwood (1962). Separation
of the iodinated mixture on a Sep-Pak C18 reverse phase cartridge was
carried out as described by Yeung (1984). The radioactive photoprobe
was further purified by high performance liquid chromatography (HPLC)
on a Lichrosorb RP-8 (5 micron) column (0.4 x 25 cm) using a linear
gradient of 0.05% trifluoroacetic acid in water and acetonitrile, pH
3.0. Fractions collected from the column were analyzed by thin-layer
chromatography (tlc) on a cellulose Chromagram sheet (Eastman type
13255), developed in I-butanol:ethanol:2 N NH4OH (v/v, 5:1:2),
followed by autoradiography on Kodak AR5-X-OMat film. The extent of
radioiodination of AP-Enk was determined by alkaline hydrolysis,
(125I)diiodotyrosine on tlc.
followed by analyzing the hydrolysate for (125I) monoiodotyrosine and,
13
Binding and Photoaffinity Labeling
Plasma membranes from the rat brain (minus cerebellum), spinal cord
and cerebellum were prepared as the microsomal fractions from 250 g
male Wister rats according to the method of Posner et al. (1974).
These membrane preparations (3-4 mg/ml) were incubated in the dark in
a polypropylene microfuge tube containing 275 µ1 of 0.05 M Tris-HCl,
pH 7.5, 0.05 mM each of benzamidine hydrochloride and phenylmethyl-
sulfonyl fluoride and approximately 0.5 µCi/ml of the purified radio-
active photoreactive enkephalin at 24°C for 30 minutes. (D-Ala2
Met5)Enkephalin (4.3 nmol) was added where appropriate to determine
the non-specific binding. The reaction mixture was photolysed for 30
seconds using a 100-W high pressure mercury lamp, and was analyzed by
sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis on a
gradient slab of 10-15% (Yip et al. 1982). The membrane was reduced
bv boiling for 15 minutes in U.l M dithiothreitol and 3% SDS.
solubilized material was run on the gel. After staining, destaining
and drying, the gel was exposed to Kodak AR5-X-OMat film, using an
intensifying screen (Swanstrom and Shank 1978).
RESULTS AND DISCUSSION
The crude radioactive photoreactive enkephalin analogue recovered
from Sep-Pak minicolumn (SP-2) was further ourified bv HPLC. Four
radioactive fractions were eluted from the Lichrosorb column (Figure
1a). The purity of the fractions were assessed by tlc. Figure lb
shows the relative mobilities of the fractions. The Rf values of
HPLC-1 and HPLC-2 were similar to that of radioactive iodine stan-
dard. HPLC-3 and HPLC-4 (Rf values 0.72 and 0.76 respectively)
showed single major component with a trace amount of free iodine.
Alkaline hydrolysis of HPLC-3 and HPLC-4 followed by tlc showed that
both of these fractions were monoiodinated. Although HPLC-1 was a
major radioactive component, both HPLC-1 and HPLC-2 did not show any
specific binding by rat brain plasma membranes. In contrast, the
specific binding for HPLC-3 and HPLC-4 were estimated to be 90% and
FIGURE 1. (a) Llution profile of 125I-AP-Enk recovered from
Sep-Pak minicolumn (SP-2). Radioactive fractions 1-4 were
pooled for further characterization.
thin-layer chromatography of pooled fractions.
(b) Autoradiogram of
carrier free Na125I standard in water; 0 and F indicate
origin and solvent front respectively.
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72% respectively of the total binding. Since HPLC-3 was found to be
more active in radioreceptor binding assay, while HPLC-4 retained
some binding activity, HPLC-3 was used for the photoaffinity labeling
experiment.
Binding of HPLC-3 to rat brain (minus cerebellum) plasma membrane,
followed by photolysis, led to covalent labeling of membrane protein
as shown by autoradiography (figure 2). A radioactive band was
specifically labeled (lane 1) since the labeling of the band was
abolished in the presence of an excess (2.5 µg) of (D-Ala2, Met5)-
enkephalin (lane 20). Such labeling was most likely the result of net
cross-linking of 125I(AP-Enk) HPLC-3 to the protein through the
para-azido-L-phenylalanine. The apparent molecular weight of the
radioactive band was estimated to be 46 kDa (ranqe 44 to 48 kDa).
Considering the anomalous behavior of glycoprotein in SDS-gel elec-
trophoresis, the molecular weight of the labeled band may be less
than 46 kDa. The labeling of this membrane protein was totally
dependent on photolysis. since a control not exoosed to liaht showed
no such labeling (lane 3). Prephotolysing the radioactive tracer for
5 minutes before use resulted in no specific labeling of the 46-kDa
protein (lanes 6-8). Exposure of the membrane to the light source
for 1 minute before use in incubation and subsequent experiments did
not seem to affect the ability of the photoprobe to label the speci-
fic 46-kDa protein. A similar 46 kDa radioactive band was also found
to be covalently cross-linked and identified in the rat spinal cord
plasma membranes. However, no such protein or any other protein band
were specifically labeled when rat cerebellum plasma membrane was
used. These observations strongly suggest that the 46-kDa protein
may be the opioid receptor. It is apparent that a wide range of
FIGURE 2.
brain plasma membranes labeled with
Autoradiogram of an SDS gradient gel of rat:
125I-Ap-Enk HPLC-3,
enatured and reduced. Excess (D-Ala2, Met5)enkephalin was
used in lanes 2, 5 & 7; while lines 3 and 8 served as dark
control. The band (Mr 46 kDa) specifically photolabeled is
indicated by an arrow. The molecular weight standards
(Biorad) used were myosin (200,000), galactosidase
116,250), phosphorylase B (92, 500), bovine serum albumin
(66,200), ovalbumin (45, 000), carbonic anhydrase (31,000),
soybean trypsin inhibitor (21,500) and lysozyme (14,400).
molecular weights for the opioid receptor complex and its subunit has
been obtained from a number of direct and indirect approaches. In
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this study using the direct photoaffinity labeling approach, we
estimate the molecular weight of the opioid (enkephalin) receptor
protein to be 46 kDa. This molecular weight estimate is within the
range of the reported values of 25-65 kDa for the subunit.
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PHOTOAFFINITY LABELING OF OPIATE RECEPTORS WITH 3H-ETORPHINE:
POSSIBLE SPECIES DIFFERENCES IN GLYCOSYLATION
Wayne D. Bowen and Grace Kooper
Section of Biochemistry
Division of Biology and Medicine
Brown University
Providence, R.I. 02912
ABSTRACT
Opiate receptors from whole rat brain (minus cerebellum) and cow
striatum were labeled irreversibly using the intrinsic photolability
of 3H-etorphine. After incubation with 2 nM 3H-etorphine and
centrifugal washing, membranes were irradiated with light of 254 nm.
Non-specific binding was determined by carrying out incubations in
presence and absence of 10 uM levallorphan. Specific binding in
photolabeled membranes was 75-80%, with a photo-incorporation yield
of approximately 50%. Photolabeled membranes were extracted with
CHAPS/Lubrol and unbound 3H-etorphine was removed by dialysis and
passage over Sephadex G-25. Solubilized proteins were then
subjected to chromatography on wheat germ agglutinin, and retained
proteins were eluted with N-acetyl D-glucosamine (NAG). Protein
profiles from rat brain and cow striatum were identical, with 89% of
the total protein flowing through unretained and 11% eluted by NAG.
However, the profile of radioactivity was markedly different in the
two species. With rat, the specific activity (cpm/A280) was the
same for flow-through and NAG-eluate. With cow, the  specific
activity of the NAG-eluate was 17 times greater than the flow-
through. These results indicate that cow striatum and rat whole
brain contain populations of opiate receptors which are glycosylated
differently.
INTRODUCTION
Gioannini et al. (1982) have shown that opiate receptors from
several species are retained by wheat germ agglutinin and can be
eluted with N-acetyl D-glucosamine. This indicates that opiate
receptors are glycoproteins. These workers also found that varying
proportions of the total binding activity appeared in flow-through
and NAG-eluate in different species, indicating a possible
heterogeneity in receptor glycosylation across species. Howevever,
results are difficult to interpret in this regard since the 3H-
ligand could dissociate from receptor and appear in the flow-
through. We have developed a method to irreversibly label receptors
by utilizing the intrinsic photolability of various 3H-opiates
(Bowen et al. 1985, Kooper et al. 1985, submitted). Using this
method, opiate receptors can be irreversibly labeled with high
specificity and yield. Here we report that rat whole brain and cow
striatal receptors photolabeled with 3H-etorphine exhibit
differences in their ability to be retained on wheat germ
agglutinin. Therefore, opiate receptors may be glycosylated
differently across species or across brain regions.
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METHODS
Lysed P2 membrane fraction was prepared from the brains (minus
cerebellum) of male Sprague-Dawley rats (150-200 gm) and freshly'
obtained cow striatum. Membranes (1 mg protein/ml) were incubated
with 2 nM 3H-etorphine in 10 mM TRIS-HCl pH 7.4 at 25°C for 90 min.
Non-specific binding was determined by incubating in presence of 10
uM levallorphan. Labeled membranes were washed twice by repeated
centrifugation and resuspension in ice-cold incubation buffer.
Resuspended membranes were either irradiated on ice for 10 min with
ultraviolet light of 254 nm (Mineralight R52G, Ultra-Violet
Products, San Gabriel, CA.) at a distance of 2 cm or allowed to
stand in room light (DARK-treated) for 10 min. Denaturation was
carried out by heating for 10 min at 90°C. To determine results of
these treatments, 500 ul aliquots were filtered over glass fiber
filters and washed with ice-cold TRIS-HCl pH 7.4. Filters were
counted after overnight extraction in scintillation cocktail.
Photolabeled membranes were solubilized by homogenization in 13 mM
CHAPS/1% Lubrol. The homogenate was incubated for 15-30 min at 25°.
The 105,000 x g supernatant was then dialyzed overnight at 4°C
against 10 mM TRIS-HCl pH 7.4 or gel filtered on Sephadex G-25
(eluted with buffer containing 10 mM CHAPS) to remove free 3H-
etorphine.
Chromatography on wheat germ Lectin-Sepharose 6MB was carried out as
follows. Extract was applied to the column in 1 ml aliquots and
allowed to incubate in the bed for 15 min at 25°C. The column was
washed with 10 mM TRIS-HCl pH 7.4 containing 10 mM CHAPS and 1 mM
EDTA. Retained proteins were eluted with the same buffer containing
.5 M N-acetyl D-glucosamine. Protein was estimated by absorbance at
280 nm and a 50 ul aliquot of each 1 ml fraction was counted in a
scintillation spectrometer to detect tritium. Specific activities
of labeled proteins in the flow-through and NAG-eluate were
estimated by determining the areas under the cpm and A280 peaks and
taking their ratios.
RESULTS AND DISCUSSION
Table 1 shows results of photolabeling of rat whole brain and cow
striatal receptors with 3H-etorphine. After incubation with 3H-
etorphine and washing to remove unbound ligand, membranes were
irradiated at 254 nm or allowed to stand in room light.
Irreversible binding was assessed by heat denaturation.
Denaturation after dark treatment caused a loss of 97% and 95% of
specific binding in rat and cow membranes, respectively. However,
irradiation before denaturation markedly reduced the loss of
specific binding, For rat, 60% of specific binding in irradiated
membranes survived denaturation. For cow, 39% remained.
Importantly, the percent specific binding in irradiated/denatured
samples was 75% and 79% for rat and cow, respectively. Thus this
method produced covalent labeling of opiate receptors in rat and
cow. The receptors were labeled in high yield and with high signal-
to-noise ratio.
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TABLE 1. Photolabeling of Rat and Cow Membranes with 3H-Etorphine
RAT COW
BK TOT SB % S B  B K TOT S B % S B
Dark 405 2363 1958 83 279 4007 3728 93
Dark/Denat. 376 433 57 13 192 365 173 47
UV 312 1455 1143 79 268 2465 2197 89
UV/Denat. 231 971 686 75 225 1076 851 79
Yield 60% Yield 39%
Membranes photolabeled with 3H-etorphine were solubilized with 13 mM
CHAPS/1% Lubrol and the soluble proteins were subjected to
chromatography on wheat germ Lectin-Sepharose 6MB. The elution
profile is shown in Figure 1. For both rat and cow, approximately
89% of the total protein flowed through the column unretained, while
11% was retained and eluted with NAG. However, the profile of
radioactivity was markedly different for the two preparations.
Table 2 shows an analysis of the specific activity in the flow-
through and NAG eluate from the two preparations, estimated by
determining the areas under the cpm and A280 peaks. For rat, the
specific activity of the flow-through and NAG eluate were the same.
However, for cow striatal receptors, the specific activity of the
NAG eluate was 17 times higher than that in the flow-through.
FIGURE 1. Wheat
germ agglutinin
chromatography of
CHAPS/Lubrol
extracts from
membranes
photolabeled with
3H-etorphine.
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TABLE 2. Comparison of Specific Activities of Peaks from WGA-
Chromatography
RAT cow
area (cm2) area (cm2)
cpm A 2 8 0 cpm/A280 cpm A 2 8 0 cpm/A280
FLOW-THRU 26.73 47.38 0.56 7.26 14.85 0.49
NAG-ELUATE 3.99 5.95 0.67 14.57 1.75 8.33
SP. ACT. RATIO
NAG-ELUATE : FLOW-THRU 1.2 : 1 17.0 : 1
These results are consistent with th se of Gioannini et al. (1982)
who observed that of total soluble 3H-diprenorphine binding in rat,
23% was recovered in the flow-through and 31% was recovered in NAG-
eluate. For cow striatum, these values were 11% in flow-through and
47% in NAG-eluate. In the study described here, we utilized
covalently bound H-etorphine, so that dissociation of ligand is not
a factor. The results reported here have several interpretations.
Opiate receptors in different species may be glycosylated
differently. In this case, rat brain would contain a larger
population of receptors which lack affinity for wheat germ
agglutinin. Alternatively, different brain regions may contain
receptors which are glycosylated differently. The cow preparation
is from striatum while the rat preparation is from whole brain
(minus cerebellum). Striatal receptors from the two species would
have to be compared to resolve this issue. Finally, 3H-etorphine
will label mu, delta, and kappa receptors. The differences in the
species and/or regions may reflect a difference in glycosylation
among receptor types. Further purification of receptors will be
needed in order to determine glycosylation state of receptor types.
The method of photolabeling utilized here may facilitate achieving
this goal.
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BINDING TO MU AND DELTA OPIOID SITES BUT NOT KAPPA
SITES IS INHIBITED BY FAB FRAGMENTS FROM A MONOCLONAL
ANTIBODY DIRECTED AGAINST THE OPIOID RECEPTOR
Jean M. Bidlack
Center for Brain Research, University of Rochester,
School of Medicine and Dentistry, Rochester, NY 14642, U.S.A.
ABSTRACT
noncompetitively inhibited the binding of the selective peptide
[3H][D-Ala2,MePhe4,Gly-ol6] enkephalin (DAGO) and the selective 
peptide,[3H][D-Pen2,D-Pen5] enkephalin (DPDPE), to neural membranes.
Fab fragments from a monoclonal antibody, OR-689.2.4, directed against
the opioid receptor selectively inhibited opioid binding to rat and guinea
pig neural membranes. In a titrable manner, the Fab fragments
The binding of [125I-Tyr27] endorphin was   also blocked by the Fab
fragments. In contrast, opioid binding, as measured by the binding of
[3H]bremazocine to rat neural membranes and guinea pig cerebellum in
the presence of µ and blockers was not significantly altered by the Fab
fragments. When µ sites were blocked with DAGO, the Fab fragments
suppressed the binding of [3H]DPDPE to the same degree as when the µ
binding sites was not blocked. The Fab fragments also inhibited binding
to the µ site regardless of whether or not the site was blocked. This
monoclonal antibody is directed against a 35,000 dalton protein. Since
the antibody is able to inhibit µ and binding but not opioid binding, it
appears that the 35,000 dalton protein is an integral component of µ and
opioid receptors but not receptors.
INTRODUCTION
As a tool to probe the molecular basis of the multiple opioid receptors, a
monoclonal antibody, OR-689.2.4, capable of partially inhibiting opioid
binding to rat neural membranes has been produced (Bidlack and Denton
1984). This IgM was able to block and displace opioid ligands from rat
neural membranes. The specificity of this immunoglobulin has been
demonstrated by its inability to inhibit the binding of 5 different
nonopioid ligands to neural membranes and the ineffectiveness of other
mouse immunoglobulins to block the binding opioids to neural membranes
(Bidlack and Denton 1985). The antibody, directed against a 35,000 dalton
protien, immunoprecipitated opioid binding sites from a solubilized
preparation (Bidlack and Denton 1985). Because it is an IgM with a
molecular weight of 980,000, the ability of the antibody to penetrate
tissue is hampered. As a consequence, a procedure was developed for
obtaining Fab fragments, with a molecular weight of 48,000, from this
IgM (Bidlack and Mabie in press). This study describes the selective
inhibition of opioid ligands by OR-689.2.4 Fab fragments.
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MATERIALS AND METHODS
Generating the OR-689.2.4 monoclonal IgM and Fab fragments
The IgM, OR-689.2.4, was produced by immunizing a BALB/c mouse with
a partially purified opioid receptor complex consisting of proteins with
molecular weights of 43,000, 35,000 and 23,000 (Bidlack et al. 1981;
Harwell et al. 1984). The monoclonal IgM was detected by
radioimmunoassay using the 125I-labeled antigen and by its ability to
inhibit opioid binding to rat neural membranes (Bidlack and Denton 1984).
The Fab fragments from the IgM were generated by digesting the IgM
with trypsin in the presence of 10 mM cysteine and were purified by gel
filtration (Bidlack and Mabie in press).
Opioid binding to rat and guinea pig neural membranes in the presence of
OR-689.2.4 Fab fragments
Neural membranes from male Sprague-Dawley and Hartley guinea pigs
were prepared, excluding cerebellar tissue, as previously described by
Pasternak et al. (1975). Guinea pig cerebellar membranes were prepared
in a similar manner, In a final volume of 1 ml, 0.25 mg of neural
membranes
min at
protein was incubated wth OR-689.2.4 Fab fragments for 60
25 C. Radiolabeled ligand was
continued for 60 min. Binding of [125I-Tyr27] h-endorphin was measured
then added and the incubation
in the presence of 0.2% bovine serum albumin and 100 µg/ml bacitracin.
The glass fiber filters were soaked in 0.2% polyethylenimine prior to use.
Bound radioactivity was determined by filtering samples through Whatman
GF/B glass fiber filters. All results are reported as specific binding- the
difference between binding in the presence and absence of 10 µM
unlabeled ligand. Binding of 0.1 nM [3H]bremazocine to rat neural
membranes and guinea pig cerebellum in the presence of 100 nM DAGO
and either 100 nM DADLE or 1 µM CPDPE was regarded as binding to
sites.
Measuring the ability of the OR-689.2.4 Fab fragments to inhibit
binding to membranes when binding sites are blocked
To determine if the Fab fragments could inhibit the binding to µ sites
when sites were blocked, the following protocol was followed.
Membranes were incubated with 100 nM DPDPE for 30 min to block
sites.
added.
OR-689.2.4 Fab fragments at a concentration of 250 nM were
Following a 60 min incubation, 0.5 nM [3H]DAGO was added.
After an additional 60 min incubation, the samples were filtered.
RESULTS AND DISCUSSION
As shown in Fig. 1, OR-689.34 Fab fragment% inhibited binding to the
binding of [125I]endorphin , [3H]DAGO, and [3H]DPDPE to rat neural
membranes in a titrable manner. The IC50 value for the inhibition of
[125I] endorphin binding was 400 nM, while the IC50 value for the
inhibition of binding of the µ and ligands was about 3-fold greater. As
previously shown, the Fab fragments are noncompetitive inhibitors of µ
and binding to rat neural membranes (Bidlack and O’Malley in press).
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FIGURE 1. Inhibition of opioid binding to rat neural membranes
by OR-689.2.4 Fab fragments. Binding was measured as
described in “Materials and Methods.”
Kappa binding to rat neural membranes and guinea pig cerebellum was
determined by the binding of 0.1 nM [3H]bremazocine in the presence of
µ and blockers. In the absence of blockers, 500 nM OR-689.2.4 Fab
fragments inhibited the binding of 0.1 nM [3H]bremazocine to rat neural
membranes by 27% (Bidlack and O’Malley in press). However, in the
presence of 100 nM DAGO and 100 nM DADLE, the Fab fragments did
not have a significant effect on the binding of 0.1 nM [3H]bremazocine.
The Fab fragments did not alter the binding of 0.1 nM [3H]bremazocine
to guinea pig cerebellum regardless of whether µ and blockers were
present (Bidlack and O’Malley in press). The antibody inhibited the
binding of [3H]DAGO and [3H]DPDPE to guinea pig neural membranes.
Since the antibody is directed against a 3-dimensional epitope on the
35,000 dalton protein (Bidlack and Denton 1985), it may be possible to
use the antibody to probe conformational changes of the receptor. In an
attempt to address the question of interconversion between µ and
binding sites, the ability of the OR-689.2.4 Fab fragments to inhibit the
binding of 0.5 nM [3H]DAGO to neural membranes was determined after
suppression of sites by 100 nM DPDPE. As detailed in Bidlack and
O'Malley (in press), the Fab fragments inhibited the binding of 0.5 nM
[3H]DAGO to the same degree regardless of whether sites were or were
not blocked by DPDPE. The same results were obtained when µ sites
were block with DAGO and the ability of the Fab fragments to inhibit
the binding of [3H]DPDPE was measured. Under the experimental
conditions used, there is not an interconversion of µ and sites that
results in the inability of the antibody to inhibit binding to the other site
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when one site is blocked.
The monoclonal antibody is directed against a 35,000 dalton protein
(Bidlack and Denton 1985). Evidence supporting the role of the 35,000
dalton protein as a component of the opioid receptor includes crosslinking
studies using enkephalin-like peptides (Zukin and Kream 1979; Zukin et
al. 1980), human [125I-Tyr27] endorphin (Howard et al. 1985; Howard
et al. 1986) and [125I-Tyr27,Leu5], endorphin (Helmeste et al. in.
press). Affinity labeling studies using [125I]14-bromoacetamidomorphine
also resulted in the specific labeling of the 35,000 dalton protein (Bidlack
et al. 1982). Purification studies using an opioid agonist affinity column
(Bidlack et al. 1981; Maneckjee et al. 1985) and an opioid antagonist
affinity column (Bidlack et al. 1982) have resulted in the specific elution
of a 35,000 dalton protein. The monoclonal antibody directed against the
35,000 dalton protein immunoprecipitated opioid binding sites from a
solubilized preparation of rat neural membranes (Bidlack and Denton
1985). These studies strongly suggest that the 35,000 dalton protein is a
component of the opioid receptor, probably of the µ and receptors but
not the receptor.
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MONOCLONAL ANTIIDIOTYPIC ANTIBODIES WHICH RECOGNIZED THE BINDING
SITE OF DELTA RECEPTOR :
FINE SPECIFICITY OF THE ANTIIDIOTYPIC ANTIBODIES
Anny Cupo and Pierre Kaldy
Centre d'Immunologie INSERM-CNRS de Marseille-Luminy
Case 936, 13288 Marseille Cedex 9, France.
ABSTRACT
Monoclonal antiidiotypic antibodies (Mab2), specific for the binding
unit of the opiate receptor , were generated in rats immunized with
rabbit anti-DADLE antibodies (ab1). The fine specificity of the seven
clones screened in the fusion was studied using a solid phase test where
the abl antibodies were coated to the plate. In this respect, 4
different set of monoclonal antibodies can be distinguished. The
antibody affinities were comparable (Kd 1.10-8 M), but the specificity
patterns were completely different.
INTRODUCTION
A powerful approach to the production of antireceptor antibodies is now
fully exploited for a number of different cell receptors. This approach
employs the concept that antibodies directed against pharmacologically
active ligands have a three dimensional binding site which is somewhat
analogous to the natural receptor. Consequently, when antiidiotypic
antibodies (ab2) are produced against these anti-ligand antibodies
(ab1), some of the antiidiotypic antibodies, which mimic the original
ligand, are able to bind to cell surface receptors. Anti-idiotypic
antibodies, which have specificity of a variety of hormone and
neuro-transmetter receptors have been produced following immunization
against specific anti-ligand antibodies (Cleveland et al. 1983, Farid
and Lo 1985, David and Isom 1985). Using the antiidiotypic approach, we
developed monoclonal anti-idiotypic antibodies, specific for the binding
site of the receptor. These (ab2) antibodies were generated in rats
immunized with rabbit anti-DADLE antibodies. These anti-idiotypic
antibodies bind the cell surface of the NG108-15 cells and precipitated
a surface exposed 53Kd protein on the same cells (Cupo et al. data to be
published). The present study reports a detailed analysis of the
specificity of the seven monoclonal antiidiotypic antibodies screened in
the fusion and allows us to distinguish four different antiidiotypic
antibodies sets according to their structural requirements.
MATERIALS AND METHODS
Purification of monoclonal antibodies from ascitic fluids
3.106 hybridoma cells of each different clone were intraperitoneally
injected in nude mouse: (Swiss strain) in order to produce ascitic
fluids. After collection, 5 ml of each ascitic fluid were precipitated
by 50% ammonium sulfate and purified by DEAE-A52 chromatography
according to the Bazin's procedure for the IgG2a isotype (Bazin et al.
1974).
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Anti-idiotypic test
DADLE was cross-linked by carbodiimide with bovine serum albumin (as
irrelevant carrier). Flexible PVC microtiter plates (Limbro plate SMRC
96) were coated with 50 µl of conjugate solution (1 nmole of DADLE) for
4 h at room temperature. The solution was then removed and the wells
were filled for 4 hours with PBS-0.5% BSA to saturate the remaining
binding site of the wells. The plates were washed 3 times with PBS, then
dried and stored at 4°C for weeks until used. A cascade of monoclonal
antibody dilutions and a solution of rabbit anti-DADLE immunserum
(diluted l/2000 in PBS-0.1% BSA) were preincubated at 37°C for 2 h 30 in
plastic tube. Then 50 µl of this mixture was transfered into
conjugate-coated wells at 4°C for 2 h. The wells were washed 3 times
with PBS, then incubated with 50 µl of iodinated protein A (1.105 cpm)
for 30 min at room temperature then washed again and counted. Polyclonal
rat immunserum (anti-anti-DADLE, diluted l/100) and irrelevant rat
monoclonal antibodies (anti-AMPc) served as controls.
Affinity and cross-reactivity measurements
The rabbit anti-DADLE antibodies (ab1) were purified onto a protein
A-Sepharose column. The total IgG solution (1.10 M) was coated on PVC
plates (50 µl/well) following the same procedure than in the
antiidiotypic test. The seven monoclonal antiidiotypic antibodies were
125I-iodinated, diluted in PBS-0.1% BSA and stored at 4°C. The
inhibition of binding of iodinated antiidiotypic antibodies Mab2, by ab2
was assessed by simultaneous incubation in abl (anti-DADLE antibodies)
coated wells of 25 µl of iodinated Mab2 (100,000 cpm) and 25 µl of ab2
at concentrations ranging from 10-5 M to 10-11 M. The incubation was
performed for 24 h at 4°C, the wells were then washed 3 times in PBS and
counted.
RESULTS AND DISCUSSION
Antiidiotypic activity
The antiidiotypic activity of each purified monoclonal antibody (Mab2)
was characterized by its ability to inhibit the interaction ab1-DADLE.
The 11 and 141 clones were able to inhibit 100% of the interaction
ab1-DADLE, The plateau was reached with an Mab2 concentration around
1.5 x 10-7M. For the 5 and 106 clones, the ab2 concentration necessary
to reach a plateau was identical, but these antibodies were able to
inhibit 85-90% of the abl-DADLE interaction. The 51 and 70 clones and 16
clone inhibited only 50% and 30% of the interaction ab1-DADLE,
respectively. To obtain this inhibition, the Mab2 concentration was
around 1.5.10-6 M. We can conclude, that the 11 and 141 antibodies
recognized all the abl population in a same manner or more probably the
same epitope exhibited by all the polyclonal anti-ligand antibodies
while the other clones 5-106, 51-70 and 16 recognized 85-90%, 50% and
30% of the abl population, respectively.
26
The results were shown in Figure 1.
FIGURE 1. Competition curve for the purified monoclonal antibodies.
Fine specificity of the anti-idiotypic antibodies (Mab2)
The affinity and the specificit of each purified Mab2 was realized byy
competition studies using 125I-labelled purified Mab2. The table
exhibited the results. The affinity (IC50) was expressed in term of
concentration (M) able to inhibit 50% of the 125I-MabZ-ab1 interaction.
The specificity pattern allows us to distinguish 4 different Mab2 sets.
Appeared to be identical 5 and 106 clones, 51 and 70 clones and 11 and
141 clones. Their affinities are similar and close to 1.10-8M but their
specificities are different. The 5, 11 and 16 Mab2 did not recognized
the epitope recognized by the 51 Mab2; moreover the fixation of these
Mab2 on their respective epitope did not interfere with the specific
binding of the 5 Mab2. For sake of clarity , we will named the epitope
recognized by the monoclonal antibody according to the number of the
antibody. The 11 and 51 Mab2 did not recognized the 16 epitope but the 5
Mab2 might be, either, exhibited a weak cross-reaction with the 16
epitope (f around 930) or its fixation on its specific epitope weakly
disturbed the specific binding of the 16 Mab2. We can propose the same
explanation for the specificity study of the 11 Mab2 ; the 16 and 51
Mab2 did not recognize the 11 epitope and the 5 Mab2 cross-reacted
weakly with the 11 epitope directly or not. The specificity pattern of
the 5 cloned showed that 16 and 51 clones did not recognize the 5
epitope but the 11 Mab2 strongly inhibited the 5 specific binding.
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TABLE. FINE SPECIFICITY OF THE ANTI-IDIOTYPIC ANTIBODIES (versus ab1)
Iodinated M,ab
5 106 51 70 11 141 16
5 9.10-9M 7.10-9M nI nI 1.25 1.12 nI
106 7.10-9M 7.1.10-9M nI nI 2.5 2.5 nI
51 nI nI 1.2.10-8M 1.2.10-8M nI nI nI
70 nI nI 1.2.10-8M 1.2.10-8M nI nI nI
11 240 240 nI nI 1.10-8M 1.10-8M nI
141 150 75 nI nI 1.10-8M 9.7.10-8M nI
16 930 320 nI nI nI nI 3,10-9M
nI= no inhibition was observed using high concentration of Mab2 (C >
10-6M). The number expressed the cross-reactive factor f=IC5O analogue
versus IC5O homologue.
We can imagine either that the 11 and 5 epitopes are structurally
related epitopes or that the binding of the 11 Mab2 induced dramatically
structural change of the 5 epitope, but clearly the two epitopes were
carried by the same abl antibodies.
In conclusion, using the antiidiotypic approach, we have obtained 7
monoclonal antibodies (Mab2) which recognized the binding unit of the
receptor. These 7 Mab2 exhibit similar affinity but the antiidiotypic
activity and the specificity pattern allows us to distinguish four
different monoclonal antibody sets.
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ANTI-IDIOTYPIC ANTIBODIES RAISED AGAINST
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ABSTRACT
Anti-idiotypic antibodies were raised in rabbits immunized against immunoglobulins
purified from anti-metenkephalin antibody. The antibodies competed dose-dependently
with metenkephalin in binding to anti-metenkephalin antibody on a solid phase
metenkephalin enzyme-linked immunosorbant assay ( ELISA ). The titers of the anti-
idiotypic activity appeared characteristically in transient peaks and troughs in alterna-
tion with anti-metenkephalin activities and were retained after purification on various
affinity columns.
INTRODUCTION
Anti-idiotypes (anti-idiotypic antibody)
and antibodies have been proved to be use-
ful tools in the study of receptor structure
and function (Venter et al. 1984). The
mechanism of interaction between a ligand
and its antibody might be quite different
from its binding to a receptor. However,
when an idiotypic antibody, raised from an
anti-ligand antibody, binds to the receptor,
it is always directed at the active binding
site of the receptor. This implies that,
under circumstances when it is difficult to
prepare anti-receptor antibodies from the
purified receptor directly, it might be feasi-
ble to use the anti-idiotypic approach. In
this way one obtains an anti-receptor anti-
body without purifying the receptor (fig. 1).
FIGURE 1. Anti-idiotypic approach of producing
anti-receptor antibodies. L: ligand, R: receptor,
Anti-R: anti-receptor antibody.
While working on opiate receptors, we have been trying to produce polyclonal and mono-
clonal anti-idiotypic antibodies as an immunological reagent and pharmacological tool to
study the structure and function of opiate receptors. We have succeeded in raising anti-
metenkephalin antibody (Ab1) in rabbits and use the purified anti-metenk immunoglobulin
as immunogen to produce polyclonal anti-idiotypic antibody (Ab2) against it.
METHODS
1. Immunization of rabbits:
Rabbits were immunized at multiple spots intradermally over the back with metenkepha-
lin (metenk) conjugated to thyroglobulin at a dosage of 200 µg of free metenk emulsified
in complete Freund’s adjuvant for primary immunization, and 100 µg for monthly boost-
ings thereafter. The animals were bled to death when a reasonable high titer of anti-
metenk antibody was detected in the serum. The antiserum was then purified down to its
IgG (IgG,) with a Protein A-Sepharose 4B column. This purified Ab1 was used as immuno-
gen at 2 mg in complete Freund’s adjuvant for primary immunization and 1 mg
thereafter to raise Ab2 in rabbits. The best protocol we followed finally was to immunize
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the rabbits once a week within the first month and biweekly thereafter or whenever
necessary.
2. ELISA for the characterization of anti-metenk antibody and Ab2 against it:
Multicell polystyrene plate coated with metenk-BSA conjugate 0.1 µg/well was incubated
with the rabbit anti-metenk antibody to be characterized, followed by goat-antirabbit
IgG horseradish peroxidase conjugate and then OPD added with H2O2 as its substrate, to
develop a color reaction readable at 492 nm with a spectrometer. For anti-idiotypic anti-
body against anti-metenk antibody, the anti-serum to be characterized was first incu-
bated with a standard Ab1, before they were added to the well and proceed as mentioned
above.
3. Purification of the anti-idiotypic antiserum:
Normal rabbit IgG or metenk was coupled to CNBr-activated Sepharose 4B to form nor-
mal IgG-Spherose 4B and metenk-Sepharose 4B affinity columns. These are used to
separate anti-metenk and non-specific anti-IgG activities included in the anti-metenk
anti-idiotypic antiserum.
RESULTS
1. The specificity and sensitivity of the ELISA (Liu et a1. 1985), developed for the charac-
terization of anti-metenk antibody and anti-idiotypic antibody against it:
The readings of O.D. at 492 nm on ELISA were linear with serial dilutions of anti-metenk
antibody or its IgG; it was even more sensitive than radio-immunoassay in monitoring the
titer of anti-metenk antibody (fig. 2). The binding of Ab1 or its IgG to the solid phase
metenk was displaceable by free metenk in the solution and is sensitive up to less than 0.5
µg or 1 nmol of free metenk (fig. 3). So it could also be utilized for the characterization
of the anti-idiotypic activities developed against Ab2.
FIGURE 2. Rabbit anti-metenk
antiserum dilution curve.
FIGURE 3. Inhibitory effect of free
metenk on the binding of antiserum or its
IgG to metenk-BSA conjugate coated on
the polystyrene plate. 50 µl of either
antiserum or its IgG were preincubated
with 50 µ1 of free metenk in twofold
serial dilutions at 37°, 1 hr, before
ELISA.
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2. The development of anti-iditiotypic antibody against Ab, in rabbits:
Rabbits immunized against anti-metenk IgG, were bled at different intervals after
immunization and monitored for their titer of anti-idiotypic activities in their serum. As
shown in fig. 4A and 4B, in three out of four rabbits immunized with IgG1, their anti-
idiotypic activities went up and down in peaks and troughs, and did not follow closely the
protocol of immunization.
FIGURE 4. (A) The inhibitory effect of anti-metenk anti-idiotypic antiserum on the binding of
anti-metenk antiserum and solid phase metenk. (B) The binding of anti-metenk anti-idiotypic
antiserum on solid phase metenk. The anti-metenk anti-idiotype antiserum was drawn after
immunization with anti-metenk IgG at diIferent time intervals as indicated on the abscissa.
Number in parenthesis indicates the number of rabbits.
At the same time, there were corresponding fluctuations of anti-metenk activities in the
serum, interlocking with anti-idiotypic activities, as demonstrated clearly in fig. 5 for
individual rabbits.
FIGURE 5. The generation of anti-idiotypic antibodies following immunization with anti-
metenk IgG in Rabbit #2 (left) and #4 (right). (A) The inhibitory effect of anti-metenk anti-
idiotypic antiserum on the binding of anti-metenk antiserum and solid phase metenk. (B) The
binding of the antiserum to solid phase metenk.
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3. The effect of purification of anti-idiotypic activities on normal rabbit IgG- and
metenk- Sepharose 4B columns:
The anti-idiotypic activities were retained in effluents when the anti-idiotypic antiserum
was added in batches to normal IgG- or metenk- Sepharose 4B affinity gels. At the
same time the eluates or the filtrates, obtained after the gels were treated with 0.1 M
acetic acid (pH 2.4) and neutralized immediately by saturated Tris buffer, showed no
significant anti-idiotypic activities (fig. 6).
FIGURE 6. The inhibition of purified anti-metenk anti-idiotypic antibody on the binding of
anti-metenk with solid phase metenk. serum, IgG, effluent
from normal IgG-Sepharose 4B, effluent from metenk-Sepharose 4B.
DISCUSSION
Our results indicate that anti-idiotypic antibody could be generated against anti-
metenk antibody in rabbits immunized against anti-metenk IgG. Their appearance is
in line with the “immune network theory” proposed by Jerne (1974). The characteris-
tic peaks and troughs, in alternation with anti-metenk activities, were probably the
result of a self-regulatory mechanism within the immune system of the body. Analo-
gous findings have been reported in the literature with rabbits immunized against
anti-alprenolol IgG by Strosberg’s group (Couraud et al. 1983). Our results also indi-
cate a transient nature of the anti-idiotypic activity. No definite relation could be
found between its appearance in the serum and the protocol of immunization so that
optimal timing of its presence in the serum was only arbitrary. The amount of blood
that could be drawn from the animal was also limited. Further characterization of the
anti-idiotypic antiserum we obtained are now still underway, especially with regard to
its direct binding to opiate receptors. At the same time efforts are being made to
repeat the same procedure in BALB/c mice in an attempt to obtain an almost unlim-
ited supply of monoclonal anti-idiotypic antibody.
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OPIOID RECEPTORS
Günther Hochhaus, Bradford W. Gibson and Wolfgang Sadée
Department of Pharmacy and Pharmaceutical Chemistry
University of California, San Francisco, CA 94143, U.S.A.
ABSTRACT
Biotinylated derivatives of -endorphin -EP) with C6 spacer arm,
inserted between biotin and -EP, were synthesized and isolated by
HPLC. Liquid secondary ion mass spectrometry (LSIMS) indicated the
presence of 1 to 4 biotin substituents per -EP molecule, and in
combination with the analysis of tryptic peptide fragments, specified
the location of the biotinylated lysine residue. Affinities to µ
receptors decreased with increasing biotinylation number.
Association of the biotinylated ligands with avidin retained or even
enhanced IC50 values at the µ site, thus, matching the relative
binding affinity of underivatized -EP with the monobiotinylated
derivatives. Hence, monobiotinylated -EP represents a versatile
opioid receptor probe.
INTRODUCTION
The avidin-biotin sandwich system represents a versatile tool in
biochemistry and molecular biology (Korpela 1984). Bifunctional
biotinylated receptor ligands have been employed for purification
(Finn et al. 1984) or histochemical detection of hormone and
neurotransmitter receptors with high resolution (Childs et al. 1983,
Atlas et al. 1978). Previously reported biotinylated leucine-
enkephalin derivatives failed to crosslink the opioid receptor and
avidin with sufficiently high affinity (Koman and Terenius 1980).
Here we report the synthesis of several biotinylated -EP analogs
with a C6 spacer arm and varying positon and number of
biotinylation. Among these, avidin-bound monobiotinylated
derivatives, modulated near the COOH terminal end were found to bind
to the µ receptor with a similar affinity to that of underivatized
-EP and hence, represent a promising probe for the opioid receptor.
MATERIALS AND METHODS
-EP was kindly provided by Dr. Chao Hao Li (University of
California, San Francisco). The following compounds were obtained
from the indicated sources: dimethylsulfoxide (DMSO), bacitracin,
trifluoroacetic acid (TFA), bovine serum albumin (BSA), 2-(4'-
hydroxyazobenzene)-benzoic acid (HABA) from Sigma, egg white avidin
(binding capacity: 12.8 µg biotin/mg), biotinyl- -aminocaproic acid-
N-hydroxysuccinimide ester (biotin-XNHS), D(+)-biotin from
Calbiochem, [3H]DAGO (50 Ci/mmol) from Amersham and diprenorphine-HCl
from NIDA.
Synthesis and identification
-EP (100 µg in 100 µl of 0.1 M NaHC03, pH:8.3) was mixed with
300 µl of biotin-XNHS (20 µg in DMSO). After 30 min, the reaction
was stopped by addition of 100 µl 1M acetic acid. Separation of
mono- and bis-biotinylated products was performed by reversed phase
HPLC (µ Bondpack Cl8 column, Waters) using a 40 min linear gradient
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(initial solvent:acetonitrile/0.1% TFA in H2O (28/72, v:v); final
solvent: acetonitrile/0.1% TFA in H2O (34/66, v:v> with a flow rate
of 1 ml/min. UV detection was performed at 210 nM. Peaks were
collected and concentrated under a stream of nitrogen. Reaction
products were identified by LSIMS, as described by Gibson et al.
(1984), with or without prior tryptic digestion and subsequent HPLC
separation.
Binding studies
Ability of biotinylated analogs to bind to avidin was tested
spectrometrically, by displacing HABA from avidin (Green, 1970).
Competitive receptor binding studies were performed in washed rat
brain membranes (brain without cerbellum, Sprague-Dawley, male, 120-
140 g) with [3H]DAGO tracer (1 nM) at 20°C, as described by Yu et al.
(1986) with the exception of the incubation buffer (50mM Tris-HCl,
0.1% BSA, 0.01% bacitracin, pH:7.4). Ligands were used after
rechromatography of isolated peaks, shown in figure 1. Binding in
the presence of avidin was tested with preformed ligand-avidin
complexes at a fixed avidin concentration of 0.5 µM. Bound and
unbound tracers were separated by filtration through Whatman GF/B
filters. Relative receptor affinities were calculated from IC50
values according to Yu et al. (1986).
FIGURE 1. HPLC separation of monobiotinylated analogs.
For separation conditions see materials and methods (B1
B1 B1 monobiotinylated isomers; B2: mixture of bis-
biotinylated products).
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RESULTS AND DISCUSSION
We used -EP as parent compound for developing bifunctional ligands,
since it binds to the opioid receptor with high affinity (Ho et al.
1983) and slow dissociation kinetics (Howard et al. 1985). Further,
-EP
al.
can be covalently crosslinked to the receptor sites (Howard et
1985), which could serve to establish avidin-affinity
chromatography for receptor purification. -EP can be readily
biotinylated via free amino groups of lysine that are mainly located
in the a helical part, near the COOH terminal end, where modulations
may have little affect on receptor binding (Taylor et al. 1983).
Biotin was introduced via a C6 spacer arm, since systemic studies
showed the necessity of a spacer of at least 8 length to fully
retain avidin binding to macromolecule biotin-conjugates (Green et
al. 1971). Reaction of -EP with biotin-XNHS resulted in a mixture
of mono- to tetra-biotinylated analogs, that were separated by
reversed phase HPLC according to their biotinylation number (data not
shown). Mono-biotinylated derivatives were further resolved by two-
step chromatography into several isomers (figure 1). Identification
was performed by LSIMS, with or without prior tryptic digestion.
Biotinylation of a lysine eliminates a potential tryptic cleavage
site; thus, in place of two peptides generated from trypsin cleavage
of native -EP only one new peptide containing biotin will be
generated. LSIMS of peptide fragments, after HPLC separation readily
specified number and position of the biotin residue (table 1).
TABLE 1. Relative IC50 values for µ receptor binding of
biotinylated -EP derivatives. Relative IC50 values are
calculated as described in materials and methods. IC50
values of -EP for µ sites were 1.6 0.7 (n=7) and were
identical in the presence of absence of avidin. B1 and B2
represent derivatives, separated according to the biotiny-
lation number (mixture of isomers).
Ligand Rel IC50 Position of
biotinylation
without with
avidin avidin
-EP 1 1
B1 4 monobiotinylated
B1 4.3(4.1-4.5) 1.1(0.7-1.4) Lys 28, 29 or 24
B1 5.5(3.5-7.8) 3.0(2.0-4.0) Lys 9
B1 8.5(6.5-10.5) 2.9(1.7-4.2) Lys 19
B2 18 (16-19) 10 bisbiotinylated
Mono- and bis-biotinylated compounds displaced HABA from avidin in a
stoichiometric manner directly related to the biotinylation number,
which suggested that each biotin residue was accessible to avidin.
Affinities to µ sites were determined in rat brain homogenate, using
underivatized -EP (figure 1) as internal standard (IC50: 1.6 0.7
nM, n=7). There was a decrease of binding affinity as a function of
biotinylation number (table 1). Monobiotinylated derivatives
exhibited binding affinities approximately 5 times less than that of
the parent compound, with no significant effect of the biotin
position on the binding potency. The hydrophilic region between
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residues 6-12 is thought to be responsible for the potency of
-EP binding to the µ sites (Taylor et al. 1982), however,
biotinylation at Lys 9 did not affect the binding potency relative to
biotinylation near the COOH terminal.
In order to test the ability of the bifunctional ligands to crosslink
receptor sites with avidin, binding studies were performed in the
presence of excess of avidin (0.5 µM). This insured the presence of
biotinylated -EP-avidin complexes at a 1:1 ratio over the whole
spectrum of ligand concentrations. Neither tracer binding nor the
IC50 value of -EP were affected by this concentration of avidin.
IC50 values of mono- and bis-biotinylated analogs shifted to higher
affinities by a factor of 2-4. A decrease of IC50 values in the
presence of avidin has not been previously reported for biotinylated
receptor ligands. However from these data alone, a higher receptor
affinity of the complex cannot be readily deduced. High nonspecific
binding to glass and plastic presents problems in receptor assays
with -EP. Assuming that nonspecific binding is reduced for avidin
associated ligand, a shift of the competition curve to lower IC50
values will be the result, without any change in intrinsic receptor
affinity of the complex over that of the free ligand. Because of the
high affinity of the monobiotinylated -endorphin Bla (with the
substituent near the COOH terminal), which is retained or even
enhanced after tight association with avidin, this derivative
represents the most promising probe of the opioid receptor.
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CONSIDERATIONS ON THE NATURE OF a n d RECEPTORS
Alexander Gero
Department of Pharmacology, Hahnemann University School of
Medicine, Philadelphia, Pennsylvania 19102
ABSTRACT
It is assumed that opioid receptors are flexible, distorted by
agonists but not by antagonists. Combined with Martin’s model of
the receptors, this assumption permits reasonable interpreta-
tion of experimental facts.
This is a progress report on an attempt to reinterpret Martin’s
picture of opioid receptors (1983) in light of the hypothesis
that receptors are flexible, inactive in their native conforma-
tion but activated when drugs distort them (Gero 1973). Drugs at-
taching without distortion have no effect and thus function as
competitive antagonists and may furnish information on the native
receptor. Agonists tell about the nature of receptor distortion.
Space limitation precludes reporting all results so far obtained.
Only some of the more important findings and the principal items
of evidence will be presented.
Martin distinguishes two “nuclear” sites in opioid receptors, an
aromatic ring binding site A and an anionic site B, and six major
(plus several minor) “satellite” sites which either reinforce
drug binding to the nuclear sites or (keeping the drug away from
the nuclear sites) hinder it. The location of the binding sites
around the morphine molecule is shown in the following sketch:
This writer also postulated two nuclear sites (Gero 1978), as-
suming further that the two sites are so located that they can
bind a drug molecule strainlessly if its cationic group is a-
bout 6½ from the center of the benzene ring. The cation-binding
nuclear site in µ receptors is C, not B, and it binds not the N
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atom but the methyl goup attached to it which, for instance in mor-
phine, the quintessential µ agonist, carries the bulk of the cationic
charge (Kaufman et al. 1974). In morphine and its derivatives, in-
cluding morphinans and benzomorphans, the N-methyl is only 4½ from
the center of the benzene ring, and the rigidity of the polycyclic
ring system permits no alteration of this distance. Binding can
therefore occur only by forcing the receptor to narrow the A-C dis-
tance, hence such drugs are generally µ agonists. If, however,
allyl replaces the N-methyl, resonance shifts the cationic charge to
the terminal C atom of the allyl group. This C atom is 6½ from the
center of the benzene ring, hence nalorphine, levallorphan, etc. do
not distort the receptor and are µ antagonists. A similar charge
shift occurs in N-cyclopropylmethyl and N-cyclobutylmethyl.
The first step in the attachment of the drug to the receptor is pro-
bably the attraction of the cationic head of the drug to the anionic
receptor site. Then the other sites come into play and add their
binding energy to the formation of the drug-receptor complex. It is
possible that not all other sites come close enough to the drug
molecule to contribute to binding. The final conformational adjust-
ment of the drug-receptor interaction will be that which provides
the greatest free-energy decrease and therefore the most stable -
i.e. strongest - attachment. In this the benzene ring of the drug
plays a special role: if in the aggregate more free energy is lost
by binding it to site A even at the cost of receptor distortion,
the drug will be an agonist, otherwise an antagonist. The signifi-
cance of the nuclear sites IS that their distance from each other
in the drug-receptor complex determines whether or not a drug is an
agonist. It is also apparent that there must be a great variety of
possibilities for antagonistic binding: a drug needs to occupy only
part of the binding sites in the receptor - of which site A may or
may not be one - in order to function as an antagonist.
Among the satellite sites, site F seems to be particularly impor-
tant. We think that it is an electrophilic site with particular
affinity for a carbonyl oxygen at about 8 from the N-methyl (or
7 ½ from the N), therefore it favors the attachment of hydromor-
phone, naloxone, etc. In some cases sites C and E may hold a drug
molecule quite strongly, and if no steric factors keep the drug
molecule from pivoting around the axis formed by these two sites
and away from site A, we have an antagonist. On the other hand, in
a drug like meperidine sites C and F can also bind the N-methyl
and the carbonyl 0, but then site A-binds the benzene ring with its
center 4½ from the N-methyl. Hence meperidine is an agonist. In
fentanyl this distance is 7½ , so here sites A and C are forced
apart rather than together. That is still a distortion, and fent-
anyl is also an agonist.
Site G appears to be a pocket that can accomodate both the polar
14-OH of oxymorphone, naloxone, etc. and the nonpolar hydrocar-
bon group of etorphine and other oripavines at the same place.
The receptor follows Martin’s model: the nuclear sites are A
and B, and C is a satellite site that can bind large alkyl -
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groups. The electrophilic site F is important also: the antagonists
naloxone, naltrexone and WIN 44:441-3 all have a carbonyl group 7½
from the N atom. The case of WIN 44,441-3 is particularly instruc-
tive: it is a benzomorphan with the center of the benzene ring 4½
from the N-methyl (and 4 from the N) and should therefore be an
agonist, but since it has only a methyl group attached to the N,
binding to site C would be weak. On the other hand, just below the
N-methyl (when drawn like morphine in the illustration above) there
is a cyclopentyl ring which can bind strongly to site C. The mole-
cule can therefore attach its N to site B, then turn clockwise so
that the cyclopentyl group faces site C and the carbonyl 0 site F,
but then the benzene ring is too far from site A to attract it and
to deform the receptor.
Where the receptor fits in remains to be seen.
As to receptors, a number of benzomorphans, morphinans and mor-
phines have been listed as weak to moderate agonists or antago-
nists, but the really potent agonists are phencyclidine and ket-
amine, which have very little resemblance to opioid agonists, and
really potent antagonists are butyrophenones such as haloperi-
dol and spiperone, which have just as little obvious resemblance
to opioid antagonists. However, if we write the structure of bu-
tyrophenones as N-H O=C chelates (which is certainly proper) we
see a benzene ring and an alkylated N in similar mutual position
as in µ antagonists. The receptor therefore may contain sites
A, B and C, also site E attracted to the fluorine atom, the strong-
ly negative end of a dipole, and perhaps site F as welI (see
next paragraph).
Among morphine derivatives nalorphine is an agonist, naloxone an
antagonist, morphine a weak antagonist. Thus here, too, the allyl
is just a large alkyl group attaching to site C after site B has
bound the N. In nalorphine this places the benzene ring close
enough to site A to bind it, necessarily with distortion. If nal-
orphine distorts the receptor but naloxone does not, we must con-
clude that, as with receptors, the 6-carbonyl binds strongly to
site F and allows the molecule to pivot away from site A. Mor-
phine-has no 6-carbonyl and only methyl on the N which does not
bind site C strongly enough to bring the benzene ring within
binding distance of site A. Hence morphine is attached only to
site B and functions simply as a weak antagonist.
Phencyclidine and ketamine can attach strongly to sites A, B
and C, but only at the cost of very great distortion: here
the N is closer to the benzene ring and sites A and B are
forced together to fit an N-to-phenyl distance-of only 3
in contrast to 4 in µ and agonists.
It is an intriguing question why µ, , and receptors have
so much in common that some of the same drugs can act on them.
This writer would answer that the basic features of these re-
ceptors - that is, sites A, B and C - must occur rather common-
ly in proteins, and when they are-present where appropriate
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drugs can cause protein distortion with physiological consequences,
we are dealing with a receptor. The individual characteristics that
differentiate the several receptors will most probably lie in the
satellite sites. It will be an interesting challenge to molecular
pharmacology to unravel both the similarities and the differences
between the classes of opioid receptors and to find what features
they correlate with.
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ABSTRACT
A new, comprehensive opiate-receptor model based on calculations
of possible events at the molecular level is proposed. Agonist
versus antagonist action, ultra long-lasting activity and
N-dealkylation accompanying receptor binding are included.
MATERIALS AND METHODS
The syntheses and pharmacological characterization of the
ultra-long lasting compounds in this study are described by Kolb
et al. (1985) and Koman et al. (1986). Theoretical calculations
were carried out as described by Snyder et al. (1985, 1986).
RESULTS AND DISCUSSION
Recently we proposed a mu-opiate receptor model (Snyder et al.
1985) predicated on the concept that analgesia is the end-result
of proton transfer from nitrogen of piperidine ring-containing
opiates to the receptor (Dimaio et al. 1979). In this
communication we extend the outlines of the model to include the
phenomenon of long-lasting antagonist activity and
N-demethylation attending receptor action.
According to the present model the agonists bear equatorial N-CH3
and axial N-H functions, while the receptor features two negative
centers anchoring the positively charged ammonium head group by
means of intermolecular electrostatic bridges. Coulombic
attraction is dominated by the role of polar C-H bonds on the
rigid opiate (Sites 1 and 2, Fig. 1).
FIGURE 1. Antagonist and agonist cations bind to the
receptor through polar bonds. The antag-
onist N-R group hinders proton transfer; the
agonist N-H is readily deprotonated.
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Biological action is initiated by transfer of the N-H proton from
the drug to the receptor. In response to the proton shift, the
receptor protein undergoes a conformational interconversion
inducing the amplification required for the ultimate effect.
Simultaneously, the agonist salt is converted to a neutral free
base. Positive charge at the N-head group is eliminated,
electrostatic binding is seriously weakened and the agonist is
released from the receptor binding pocket.
The positive, protonated head group of an antagonist, typically
carrying a somewhat bulky N-allyl or N-cyclopropylmethyl
substituent, binds in a similar fashion. However, by virtue of
the binding at Site 1 (fig. 1), the equatorial N-alkyl assumes a
rotational state which hinders proton transfer and displaces site
2 (Snyder et al. 1985). Head group charge is retained, receptor
conformation is conserved and the antagonists remain bound longer
than the agonists. The latter is supported by the experimentally
observed slower off-rates for antagonists (Kurowski et al.
1982). The former is substantiated by pharmacological evidence
that the mu-opiate receptor exists in two distinct molecular
forms assigned as agonist and antagonist (Snyder 1975).
Recently, we have discovered a series of novel ultra-long lasting
opiate antagonists (Kolb et al. 1985; Koman et al. 1986).
These compounds combine two chemically discrete and spatially
demanding molecular fragments. The one is an opiate antagonist,
e.g. naloxone. The second is a bulky moiety such as a
fluorescein or a steroid bound to the C-6 position of the rigid
antagonist via a thiosemicarbazone or an azine spacer,
respectively. The azino-compounds are prolonged blockers in the
brain opiate-receptor preparation, but not in the guinea pig
ileum. By contrast, the thiosemicarbazones are long lasting in
both preparations. Displacement studies with [3H] DHM indicate
that all compounds in question access the same overall receptor
binding site.
Selected conformations of examples in the mono-axine,
double-azine and thiosemicarbazone classes were geometrically
relaxed by molecular mechanics. The naloxone moieties of each
were subsequently superimposed by a least squares fit.
Examination of the extended non-opiate fragments by computer
graphics portrays a qualitative structural differentiation among
the classes. In particular, the preliminary analysis suggests
distinct subsidiary binding sites for the various bulky groups.
Superposition of the double azines, e.g. the hybrid azine between
naloxone and androstene dione (NAL-AD-NAL), and the
naloxone-estrone mono-azine (NAL-E) intimates the presence of two
common binding sites. One is a hydrophobic patch which can
accept the nonpolar steroidal moieties. The other is a
hydrogen-bond-accepting site which can access the -OH group of
the phenol ring in either the estrone unit of NAL-E or the second
naloxone component of NAL-AD-NAL (fig. 2). In this scheme the
two classes -- mono and double azines -- are able to stimulate
similar receptor responses.
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FIGURE 2. NAL-E (dark) and NAL-AD-NAL superimposed
at the naloxone fragment. The circled
OH’s may access a common receptor site.
The thiosemicarbazones, e.g. 6-fluoresceinyl- and 6-rhodaminyl
naloxone thiosemicarbazones (NAL-F and NAL-R respectively), are
characterized by a bulky 2,5-dibensopyran end group. The latter
is calculated to be nearly perpendicular to the rest of the
planar C-6 attachment (fig. 3).
FIGURE 3. NAL-E and NAL-F superimposed at the naloxone
fragment. The dibenxopyran group (light) is
perpendicular to the average molecular
plane.
No meaningful superposition was possible between the end groups
of the hybrid opiate-steroid mono-axines and the opiate-
fluorescein thiosemicarbazones because of profound structural
differences. The thiosemicarbaxone spacer is highly polar and
thus would appear incompatible with the above described
hydrophobic patch,
(fig. 4). Furthermore, the planar dibenzopyran moieties are
although it occupies the same molecular space
complemented by highly polar substituents that conceivably
associate with a polar peptide region of the receptor or possibly
the lipid head-groups of an adjacent membrane. In conclusion,
the thiosemicarbazones are proposed to achieve their long-lasting
effects by binding to either of the latter polar regions. This
suggests in addition that both the brain preparation and the gpi
contain similar environments for accommodating the fluorescein
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derivatives in the antagonist receptor conformation. The action
of long-lasting agonists (Koman et al., 1986) can likewise be
incorporated in this scheme as will be discussed in a forthcoming
paper.
FIGURE 4. NAL-F (dark) and NAL-E superimposed at the
naloxone fragment. The polar thiosemi-
carbazone of the former spatially matches the
nonpolar steroid of the latter.
Finally, transformation of the receptor protein to the agonist
conformation may activate N-dealkylases which convert a fraction
of the freed agonists to their nor-congeners. Evidence that this
reaction is initiated by oxidative electron transfer from
nitrogen has been summarized by Kolb (Kolb 1984). The process
was previously thought to be the genesis of the analgesic
response, though calculations on the energetics of N radical
cation formation render this speculation unlikely (Snyder et al.
1986). Presently, we consider oxidative N-dealkylation to be a
secondary event possibly associated with side effects such as
euphoria and addiction.
REFERENCES
Dimaio, J., Ahmed, F.R., Shiller, P. and Belleau, B. In:
Gualtieri, F., Giannella, M., and Melchiorre, C., eds. Recent
Advances in Receptor Chemistry. Amsterdam: Elsevier, 1979.
pp. 221-234.
Kolb, V.M. J Pharm Sci, 73: 715-719, 1984.
Kolb, V.M., Koman, A., and Neil, A. Pharmaceutical Res, 6:
266-271, 1985.
Koman, A., Kolb, V.M., and Terenius, L. Pharmaceutical Res, 3:
56-60, 1986.
Kurowski, M., Rosenbaum, J.S., Perry, D.C., and Sadee, W.
Brain Res, 249: 345-352, 1982.
Snyder, S.H. In: Matthysse, S. and Snyder, S.H. eds. Opiate
Receptor Mechanisms. Cambridge, Mass: MIT Press, 1975.
pp. 137-141.
Snyder, J.P., Mabilia, M., and Kolb, V.M. In: Dahlbom, R., and
Nilsson, J.L.G., eds. Proceedings from the VIIIth
International Symposium on Medicinal Chemistry. Stockholm:
Swedish Pharmaceutical Press, 1985. pp. 171-173.
Snyder, J.P., Halgren, T.A., and Kolb, V.M. submitted, 1986.
44
STEREOCHEMISTRY OF NOVEL DELTA SELECTIVE OPIATE
ANTAGONISTS
Vera M. Kolb, Duy H. Hua* and William L. Duax**
Department of Chemistry
University of Wisconsin-Parkside
Kenosha, Wisconsin 53141, U.S.A.
*Department of Chemistry
Kansas State University
Manhattan, Kansas 66506, U.S.A.
**Research Laboratories
Medical Foundation of Buffalo
73 High Street
Buffalo, New York 14203-1196, U.S.A.
ABSTRACT
We have discovered novel delta selective opiate
antagonists of a non-peptide nature. Our lead compound
at the present time is the mixed azine between estrone
and naloxone, the compound named EH-NAL. In this paper
we describe the stereochemistry of EH-NAL and an EH-NAL
analog, the mixed azine between pregnenolone and
naltrexone, the compound named PH-NX. The stereochemical
assignments are based on the high-resolution 13C-NMR
studies and on the X-ray structural determinations.
INTRODUCTION
Koman (1985) and Koman et al. (1986) studied the
interaction of the mixed azines between steroids and
naloxone with various opioid receptor types in vitro. We
summarize here their findings for the EH-NAL, the mixed
azine between estrone and naloxone. The potency of EH-
NAL as an antagonist of opioid effects on the
electrically evoked contractions of the mouse vas
deferens (M.v.d.) and guinea-pig ileum myenteric plexus-
longitudinal muscle (G.p.i) preparations was compared to
that of naloxone. EH-NAL was 9-fold more potent than
naloxone in antagonizing the effects of D-Ala2-Leu5-
enkephalin in the M.v.d., and 22-fold less potent in
antagonizing normorphine in the G.p.i. The two compounds
were also compared for their capacity to displace the
binding of [3H]-dihydromorphine, [3H]-D-Ala2-Leu5-
enkephalin and [3H]-ethylketocyclazocine to rat brain
membranes. The relative affinities for delta-, mu- and
kappa-sites were 0.70, 0.16, 0.14 for EH-NAL and 0.05,
0.87, 0.08 for naloxone, respectively. Thus, in contrast
to naloxone which is mu selective, EH-NAL is a delta-
selective antagonist.
In order to explain the unexpected delta selectivity of
EH-NAL, we undertook a detailed stereochemical analysis
of this molecule. Also, we designed another probe for
delta receptor, the mixed azine between pregnenolone and
naltrexone, the compound named PH-NX. In PH-NX the
steroidal unit is separated from the opiate unit by an
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extra carbon as compared to EH-NAL. PH-NX has an OH
group at the same steroidal carbon as EH-NAL (C-3 of the
ring A), but lacks the aromatic pi cloud of the phenol
ring of EH-NAL (Fig. 1). A comparison of the delta
selectivities of EH-NAL and PH-NX thus may help elucidate
the biological roles of the phenolic pi cloud and the
absolute length of the steroidal unit in imparting the
delta selectivity.
MATERIALS AND METHODS
The 13C-NMR spectra were taken on a 400 MHz IBM-Bruker
WM-400 instrument. The X-ray measurements were performed
on a Nonius CAD4- and a Syntex P3 diffractometers.
The mixed azines between estrone and naloxone (EH-NAL)
and pregnenolone and naltrexone (PH-NX) were prepared by
reacting the free base of the opioid ketone naloxone or
naltrexone with the steroidal hydrazone estrone hydrazone
(EH) or pregnenolone hydrazone (PH), respectively. The
experimental procedure of Kolb and Hua (1984) was
followed. EH was prepared as described by Dandliker et
al. (1978). PH was synthesized by the same method.
Stereochemical determinations by 13C-NMR described below
were done in a manner analogous to that described by Kolb
and Gober (1983) and Kolb and Hua (1984).
RESULTS AND DISCUSSION
Stereochemistry of EH, a precursor of EH-NAL: Based on
the 13C-NMR, EH was a single hydrazone; only one C-17
(hydrazone carbon) was observed (at 157.76 ppm), and only
one azine with acetone-d, was found (C-17 of the azine at
173.56 ppm) (solvent CHCl3: acetone-d,). C-l 124.98; C-
2 111.66; C-3 153.73; C-4 114.01; C-5 136.32; C-6
29.08: C-7 25.79: C-8 37.25: C-9 42.98: C-10 129.84;
C-11 26.01; C-12 33.03; C-13 43.31; C-14 51.20; C-15
25.14; C-16 21.72; C-17 157.76 (the hydrazone carbon);
C-18 15.41. The stereochemistry of the hydrazone was
assigned to be anti since the syn isomer is sterically
very crowded. Namely, the distance between the syn NH,
and 12 H is only 1.2 (based on Dreiding models).
Stereochemistry of PH, a precursor of PH-NX: In the 13C-
NMR only one peak per carbon was observed, indicating the
presence of only one isomer. The inspection of the
Dreiding model of PH suggests the anti isomer as a more
favorable one, since the syn isomer is sterically crowded
due to a clashing between the NH, group of the hydrazone
and the angular C-18 methyl group and also the 16 H and
12 H. The X-ray structural determination confirms the
anti orientation in PH. Some characteristic 13C-NMR
shifts (dmso-d6): C-1 38.43; C-3 70.06; C-4 42.22; C-
5 141.31; C-6 120.42; C-9 49.83: C-10 36.16: C-11
22.73; C-13 43.13; C-14 55.75; C-16 36.99; C-17
58.35; C-18 13.04; C-19 19.20; C-20 147.28 (the
hydrazone carbon): C-21 15.81.
Stereochemistry of EH-NAL: Based on the 
13C-NMR, EH was
a single azine; only one peak per carbon was observed.
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The stereochemistry of the azine bond was assigned to be
anti on the steroidal C-17, because of the anti
orientation of EH, and anti on the opiate C-6 due to the
preference for the formation of the anti azine of
naloxone (Kolb and Hua 1984). Some characteristic 13C-
NMR shifts for the opiate and steroidal units of EH-NAL
are given (in CDCl3): The opiate unit: C-l 119.76; C-2
118.01: C-3 139.59; C-4 143.70; C-5 87.80; C-6 162.30
(the azine carbon); C-9 63.38: C-11 124.01; C-12
129.61; C-13 49.96: C-14 70.31; C-16 44.75: C-17
57.64: C-18 137.70; C-19 118.34. The steroidal unit:
C-l 126.29; C-2 113.83; C-3 153.52; C-4 115.90; C-5
135.20; C-8 37.95: C-9 43.68: C-10 131.51; C-13
44.25: C-14 52.12; C-17 175.79 (the azine carbon): C-
18 16.60.
Stereochemistry of PH-NX: The crude PH-NX was subjected
to a 13C-NMR analysis, which revealed the presence of two
azine isomers: steroid C-20 anti-opiate C-6 anti (major)
and steroid C-20 anti-opiate C-6 syn (minor). The
recrystallization of the crude PH-NX from EtOH-CHCl,
provided a single azine isomer (by 13C-NMR). The
structure of the latter isomer was determined by X-ray
and found to be anti (steroid)-anti (opiate) gauche azine
(Fig. 2). The C=N-N=C torsion angle was -123°,
indicating gauche geometry of the azine bond. Some
characteristic 13C-NMR shifts (in dmso-d6) of the latter
anti-anti azine: The opiate unit: C-1 118.57; C-2
117.00; C-3 139.12; C-4 143.68; C-5 87.56: C-6 159.12
(the azine carbon): C-9 61.47; C-11 123.85; C-12
130.63; C-13 47.89; C-14 69.51; C-16 43.36; C-18
9.17; C-19 3.70; C-20 3.47 (the latter two shifts could
be interchanged). The steroidal unit: C-1 38.23: C-3
69.96: C-4 42.16; C-5 141.25; C-6 120.27: C-9 49.63;
C-14 55.85: C-18 13.16; C-19 19.09; C-20 157.24 (the
azine carbon): C-21 18.51. Some characteristic 13C-NMR
shifts for the opiate unit of the minor isomer: C-6
160.17 (the azine carbon): C-1 118.93; C-2 117.18; C-5
89.34: C-14 69.67: C-9 61.39. The steroidal azine
carbon: C-20 156.92.
Both EH-NAL and PH-NX are configurationally much more
rigid than typical delta substrates which are peptides.
Namely, both EH-NAL and PH-NX have as a major point of
flexibility in the molecule just one bond -- the N-N bond
of the azine linkage. Thus, these azines may be useful
as semi-rigid probes for mapping the delta receptor. EH-
NAL contains an aromatic ring (steroidal A ring) which
can be overlapped with Ph4-residue of enkephalins (Koman
1985; Koman et al. 1986; Pilipauskas et al. 1986). PH-
NX was found to be an active opiate antagonist (more
active than EH-NAL) on G.p.i. (Koman private
communication). The biological tests for the delta
selectivity of PH-NX are underway.
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FIGURE 1. Structures of EH-NAL and PH-NX.
FIGURE 2. The X-ray structure of PH-NX.
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ABSTRACT
A series of 4-(m-OH phenyl)-piperidine analogs with R4=methyl
or t-butyl and NR=methyl, allyl and phenethyl have been synthe-
sized; and their receptor affinities, in vivo analgetic agonism and
antagonism, and energy-conformational profiles determined. These
analogs bind selectively and with moderate to high affinity to
opioid µ-receptors. Binding in their preferred phenyl axial
conformation appears to lead to meperidine-like agonism. In addi-
tion, for some R4=methyl but not t-butyl compounds, binding of an
energy-accessible phenyl equatorial conformation produces
antagonism.
INTRODUCTION
The 4 piperidine class of opioids, I, are thought to bind
and act at the same type of µ-receptors as morphine. Unlike mor-
phine in which the phenyl ring is fused in a fixed axial position
with respect to the piperidine ring, these fragments are more flex-
ible and can assume both phenyl axial and phenyl equatorial confor-
mations. Consequently, in the 4 piperidines, antagonism was
found to be modulated primarily by the R4 substituent and the pre-
sence of a j-methyl and a m-OH phenolic group, rather than by N-
substituents as in morphine. In particular, potent pure antago-
nists have been prepared in this family (Zimmerman et al. 1978),
for a number of R4 substituents with a 3-methyl group trans t o
them.
Previous theoretical studies (Burt and Loew 1980; Loew et al.
1981; Froimowitz and Kollman 1984), strongly indicate that the
observed antagonism is initiated by binding of an energy-preferred,
phenyl-equatorial conformer of these
analogs in an orientation relative to
morphine with overlapping m-OH phenyl
groups, as shown in figure la.
However, both phenyl equatorial and
phenyl axial conformers have been
implicated in agonist activity.
In order to further investigate
the role of relative stabilities of
phenyl axial versus phenyl equatorial
conformers in modulating relative
agonist/antagonist activity, a number
of 4-(m-OH ) piperidine derivatives
in which the R4 group alone could
affect conformational preferences
were selected for synthesis and
Fig. 1a: Proposed antagonist conformer
and receptorsite orientation relative
to morphine for 4 piperidines.
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analyses. In particular, the effects of replacing a compact methyl
group by a bulky tertiary butyl group at the R4 position and of N-R
variations (analogs l-2a-c) on conformation, receptor affinity, and
in vivo analgetic agonism and antagonism were investigated.
METHODS AND PROCEDURES
A.
B.
C.
D.
CHEMICAL SYNTHESIS: All analogs, 1-2a-c were produced by
modification of a known procedure (McElvain and Clemens 1958).
OPIOID RECEPTOR BINDING: Competitive inhibition by analogs 1-
2a-c in rat brain homogenate of four tritium labled ligandc
(naloxone, D-Ala, D-Leu enkephalin, ethylketocyclazocine and
dihydromorphine) was determined by procedures and data analy-
sis described previously (Cheng et al. 1986). Data obtained
were analysed by a modified version of the program LIGAND
(Munson and Rodbard 1980) which predicts a set of self consis-
tent receptor binding affinities and capacities assuming dif-
ferent receptor site models.
IN VIVO PHARMACOLOGY: Analgesic agonist activity and antago-
nism to morphine analgesia of compounds 1-2a-c and of
morphine, meperidine and nalorphine as standards were evalu-
ated in the mouse tail flick test by procedures which we have
described previously. (Cheng et al. 1986).
THEORETICAL STUDIES: All
calculations were performed
using a molecular mechanics
method called MOLMEC (Oie et
al. 1981). The initial geome-
tries were optimized with
respect to all variables. To
obtain energy profiles for
phenyl ring rotation, con-
strained optimizations were
performed keeping the dihedral
angle C8C7C4Cm fig. 1b) fixed
Fig. 1b: Overlap of the optimized phenyl
axial conformer of 4 butyl-4-(m-OH)-
at a set of values with inter- phenyl piperidine with the benromorphan
vals of 30 degrees.
ring of morphine.
RESULTS AND DISCUSSION
The results of a 5-receptor site model obtained when all the
data was analyzed simulaneously are shown in table 1. The five
TABLE 1. Receptor Affinities(Kd n=) site model identifies sites we
Maximum Binding Capacities(pmol/gm) have called µ1, µ2, delta and
notkappa. A fifth site,
shown, with very high capacity
and low affinities for all
ligands is most likely unre-
lated to opioid activity. The
six 4-phenyl piperidines
studied (1-2a-c) are all µ-
selective having high to moder-
ate affinities at µ1 an µ2,
with values at delta and kappa
being one to two orders of
magnitude lower. The results
of in vivo studies of analgetic
agonist and antagonist potencies are shown in table 2.
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The 4-t-butyl series are pure agonists with potencies about 1/10th
that of morphine, similar to meperidine, while two of the 4-methyl
analogs, 1b, 1c, show measurable antagonist activity, about 1/20
that of nalorphine. TABLE 2. Analgesic Agonist and Antagonist
The results of energy Potencies (µmol/kg.s.c.) in House Tall-
conformation studies of of flick Procedure
four 4-(m-OH-phenyl) pipe- 
ridines with R4=t-butyl
(2a) , methyl (1a) and the 
latter with an a-or -3-
methyl substituent ( )
are summarized in table
3. As seen in this table,
a piperidine chair conform-
er is much more stable than
a twist boat conformer.
The analogs are ordered in
decreasing stability of the
optimized phenyl
axial piperidine
TABLE 3. Optimized Conformational Energiesa for 
4-(m -OH phenyl) Piperdines
chair conformer.
The phenyl ring
torsion angle
( ), for the
lowest energy form
is given in
parenthesis. The
energy ( min/
morph) required to rotate the optimum axial phenyl ring conformer
to a morphine-like value ( =32’) is also shown.
Previous theoretical studies (Loew et al. 1980, Burt and Loew
1981) have led to the hypothesis that in meperidine- and prodine-
like compounds, both agonist and antagonist activity appear to be
elicited by lowest energy piperidine-chair, phenyl equatorial con-
formers binding to the µ-receptor in a different orientations. For
the 4-alkyl-4-(m-OH phenyl)-piperidines, however, a different rela-
tionship between relative agonist/antagonist potency and phenyl
equatorial and axial conformations is emerging. As summarized in
table 3, our results reinforce the previous association of phenyl
equatorial conformers with antagonist activity but demonstrate for
the first time a clear association of phenyl axial conformations
with the initiation of agonist activity. The 4-t-butyl compounds
are the first simple 4-alkyl-4-arylpiperidines predicted to have a
definitive phenyl axial conformation. These compounds are pure
agonists, providing strong evidence that a phenyl axial conforma-
tion leads to agonist activity. As shown in table 3, the 4-methyl
compound, la, also has a preferred phenyl axial conformation but
with a much more accessible phenyl equatorial conformation. While
the N-methyl analog is in fact a pure agonist, the N-phenethyl
analog lc has significant antagonist activity.
axial and phenyl equatorial
Because both phenyl
conformers have energies within 1
Kcal/male, the N-substituent appears to affect the relative extent
to which each conformer binds to the receptor. Thus lc can bind in
both phenyl axial and phenyl equatorial conformations and exhibits
agonist and antagonist activity.
Further evidence for association of phenyl equatorial conform-
ers with antagonist activity and phenyl axial conformers with ago-
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nist activity comes from our energy conformation study of the
effect of adding a 3-methyl group cis and trans to the 4-
methyl group. As shown in table 3, the pure antagonism of 2
appears to be due to the preferential stabilization of the phenyl
equatorial conformer by 3.5 kcal/mole and verifies the role of
phenyl equatorial conformers in initiating antagonist activity. By
contrast, in the cis isomer, , the phenyl axial and phenyl
equatorial conformed are within 1kcal/mole, consistent with its
observed mixed agonist/antagonist activity.
Our studies not only provide further evidence for phenyl
equatorial conformers initiating antagonist activity and phenyl
axial conformers agonist activity, they also provide insight into
why N-substituent variations do not modulate agonist/antagonist
activity as they do in fused ring opioids. Previously, we have
postulated that important overlaps of both the amine nitrogen and
phenolic OH must be preserved in opioids for N-substituent modula-
tion to correspond to that in fused ring analogs. Thus, since the
phenyl ring is axial in these rigid opioids, it is possible that,
at least in the 4-t butyl series in which the axial conformer is
the most definitive low energy form, N-substituent modification
could lead to an agonist/antagonist profile similar to morphine.
However, as shown in table 3 and in figure lb, for both 1a and 2a
in the lowest energy phenyl axial conformer, the phenylring is
nearly perpendicular to the piperidine ring, a very different rela-
tive orientation than in morphine. Thus, in neither series does
the optimum torsion angle of the phenyl group resemble that of
morphine and considerable energy is required (table 3) to rotate it
to that angle. As a results, no N-substituent variation effects
similar to those in fused ring opioids are observed in these 4-
alkyl piperidines.
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THEORETICAL STRUCTURE-ACTIVITY STUDIES OF METHYL-SUBSTITUTED
4-(m-OH PHENYL) PIPERIDINES
Gernot Frenking, Gilda H. Loew and John Lawson
Life Sciences Division
SRI International, Menlo Park, California 94025, USA
ABSTRACT
The theoretically determined molecular structures of
N-protonated 1,3,4,6 methyl-substituted 4-(m-OH phenyl) piperidines
are correlated to their experimentally derived analgesic activities.
It is concluded that the orientation of the 3-methyl group plays a
crucial role in determining agonism and antagonism.
INTRODUCTION
The 4 piperidines are known since 1939 to be capable -of
exhibiting strong analgesic agonism. In 1977 the first example of
this class of compounds was found (Zimmerman and Nickander 1977)
which is a pure narcotic antagonist. Unlike the fused-ring
molecules, antagonism was not obtained by varying the N-methyl
substituent, but rather by introducing two methyl substituents in
the 3,4-trans position of the piperidine ring. Subsequently,
several analogs with methyl groups mainly in the 1,3,4,6 positions
have been synthesized and tested (Zimmerman et al. 1980, Huegi et
al. 1984), and it has been suggested (Zimmerman et al. 1980) that
antagonism is introduced by a phenyl equatorial conformer.
Molecular mechanics calculations of the various isomers were
performed in order to better understand conformational features
which modulate their agonist and antagonist activity.
METHODS AND PROCEDURES
All calculations were carried out
using the molecular mechanics program
MOLMEC (Oie et al. 1981). Unless
otherwise noted, all geometries and
energies are the result of a complete
optimization with respect to bond
lengths, bond angles, and torsion
angles. In all studies the piperidine
ring was calculated with a chair
conformation and protonated nitrogen
atom. In cases where several rotamers
exist with different values of the
torsion angle t (t = C8C7C4X, fig. 1)
we report only the energetically FIGURE 1
lowest-lying conformer.
RESULTS AND DISCUSSION
The theoretically obtained structures of the various isomers
are shown in figures 1 and 2. For each isomer only the global
minimum is shown, which represents one of the diastereomers
corresponding to the (-) 3-methyl and (+) 6-methyl group,
respectively. The value of E indicates the relative energy of the
higher energy conformer due to piperidine-ring inversion
(equatorial-axial) with the N-methyl group kept in an equatorial
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position. The figures also exhibit the value for t calculated for
each global minimum. In some cases, the energy E to rotate the
phenyl group to a constrained value for t is given in parenthesis.
The experimentally derived analgesic activities were taken from Loew
et al. (this volume) for 1, from Zimmerman et al. (1980) for
compounds 2 - 7, and from Huegi et al. (1984) for compound 8. We
assume that the published results relate to racemates, since the
separation of the optical isomers was not reported.
Structure 1 has a methyl substituent only in the 4-position.
The phenyl-axial conformer is favored by 1.0 kcal/mol relative to
the phenyl-equatorial form, and this compound is reported as a pure,
moderate agonist (fig. 1). If an additional methyl group is added
in the 3-position trans to the 4-methyl (2, fig. 2), the
phenyl-equatorial conformer is now favored by 2.3 kcal. 2 is a
pure, potent antagonist. If still another methyl group is added to
2 in the equatorial 6-position, compound 3 results. The shapes of
2 and 3 are nearly identical except for- the additional methyl
group in 3. Like 2, 3 is a pure,
conclusion is that the methyl group
potent antagonist. The
in the 6-position of 3 is
unimportant for analgesic antagonism.
If the 3,4 methyl groups in 3 are not trans, but cis to each
other, compound 4 is formed. AS in 3, the phenyl equatorial
conformer of 4 is clearly favored over the phenyl axial form.
However, 4 is a pure, potent agonist! Two structural differences
may be related to this reversal of activity: The 3-methyl group is
equatorial in 4, but axial in 3, and the torsion angle t is very
different for both compounds. The energy to rotate the phenyl group
of 3 and 4 from their respective equilibrium values to the
constraint value of the other isomer is quite high (fig. 2). Thus,
at this point it can not be decided which structural difference
between  3 and 4 is responsible for the change in activity.
Compound 5 has an all-equatorial arrangement of the
3,4,6-trimethyl, groups. The phenyl-axial isomer is favored by 2.4
kcal/mol (fig. 2), and 5 is a pure, potent agonist. Comparing 5
with 4 shows that the-4-methyl and 4-phenyl groups are reversed,
while the rest of the structure is the same. The interesting
conclusion is that both phenyl axial and phenyl equatorial
conformers can lead to agonist activity.
In compound 6 the two methyl groups in the 3,4 position are
cis to each other. The phenyl equatorial form is favored for 6,
which is a mixed, moderate analgesic agonist/antagonist (fig. 2).
The structure of 6 is nearly identical to 4, except that the
methyl group in the 6 position is missing. What introduces
antagonism in 6? For 3, the 6-methyl group was found to be
unimportant for antagonism. Unless the 6-methyl group has a
different effect on antagonism in 4 compared to 6, the only
remaining explanation for the occurence of antagonism in 6 is the
reduced energy difference to the less stable conformer, which is
only 1.8 kcal/mol in 6, but 4.2 kcal/mol in 4. Thus, antagonism
would be introduced by the presence of the energetically higher,
phenyl axial form, 6a. This prediction can be tested by additional
studies of compound 7 (fig. 2). In 7, the additional methyl
group in the 6 position stabilizes the structure of the phenyl axial
minor isomer 6a sufficiently to become clearly the most stable form.
Unfortunately, 7 was only tested for analgesic agonism, not for
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antagonism. If 7 were an antagonist, it would clearly implicate
phenyl axial conformers for the first time in such activities.
Analog 8, which has two methyl groups in the 3 position (fig.
2) does not bind to opiate receptor sites, and shows no analgesic
agonism or antagonism. The phenyl equatorial form is favored, and a
comparison with 2, a pure antagonist, and with 6 in which the
3-methyl equatorial form is most likely the agonist -(compare 4),
shows that the value of t in 8 is intermediate between 2 and 6.
However, the different t value of 8 should not cause the lack of
activity since rotation from the-equilibrium value of t = 36° to
the value for 2 (t = 68°) and 6 (t = 0°) is within the feasible
energy range (fig. 2). The only remaining explanation for the
inactivity of 8 as an opiate is the presence of two methyl groups
in the 3 position, each of which requires different orientations of
the compound at the receptor binding site to be accomodated.
The combination of all conclusions reached so far lead to a
picture which is different, but compatible with previous
suggestions. We conclude that for 1,3,4,6 methyl substituted
4 piperidines, a dominant factor in the structure activity
correlation of opiate activity is the orientation of the methyl
group in the 3 position of the piperidine ring. If this methyl
group is axial, the compound will be an antagonist, if it is
equatorial, it should be an agonist. If both orientations are
occupied by dimethyl groups, the compound is inactive. This points
to a mechanism where the 3-methyl group occupies a crucial steric
position in the molecule. It may be compared with a key which fits
in the "agonist key-hole" when the 3-methyl group is equatorial, and
it fits in the "antagonist key-hole" when the 3-methyl group is
axial. Both keys cannot fit into these key holes simultaneously if
methyl groups are found in both orientations in the same molecule.
This conclusion may now be used to predict activities of the
unknown compounds 9 and 10. In 9, the phenyl equatorial conformer
with the methyl group equatoria1 is clearly favored (fig. 2) and
thus, is expected to exhibit analgesic agonism. For 10, with the
methyl group in the axial position, the phenyl equatorial conformer
is the more stable form, but only by 1.5 kcal/mol. Consequently,
10 is expected to be an antagonist with the possibility to show
mixed activity since the less stable isomer with the methyl group in
the equatorial position might also be active.
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FIGURE 2
CONFORMATIONAL STUDIES AND RECEPTOR BINDING OF DELTA
SELECTIVE OPIOID PEPTIDES
Christopher Keys, Peter Amsterdam, Philip Payne,
Lawrence Toll and Gilda Loew.
Life Sciences Division
SRI International, Menlo Park, California 94025, U.S.A.
ABSTRACT
Detailed energy-conformation studies of a linear (DTLET) and
four cyclic (DPDPE, DPLPE, DPLCE, DCLPE), selective opioid
peptides were combined with computer assisted detailed receptor
binding studies. The results of these studies have allowed the
identification of a low energy conformer common to all of these
analogs which could be responsible for their high affinity
receptor binding. This conformer contains multiple intramolecular
H-bonds and is very different from the beta-II type structure
previously postulated to lead to high affinity µ-receptor
binding. This µ-binding conformer was found either to have higher
energies or be greatly distorted in these selective analogs.
INTRODUCTION
selective
analogs has
been accom-
plished, the conformational requirements for high affinity binding
to receptors and how these are different from those favorable for
µ-receptor binding are not yet understood. Nor have commonalities
between linear and cyclic selective analogs been explored. In
previous studies of highly µ-selective morphiceptin analogs (Loew
et al. 1986) and enkephalins (Loew et al. 1982), we have identified
and characterized common candidate BII1-Type peptide conformers
leading to high affinity binding to µ-receptors. In a
complementary fashion, the energy conformational studies reported
here of one linear (DTLET) and the four cyclic selective peptides
binding has
been done
for the six
selective
peptides
shown in
table 1.
While
the success-
ful design
of
Receptor binding studies (Chang and Cuatrecasas 1979) of
enkephalin analogs in rat brain homogenates have established that
these peptides bind to at least two distinct classes of opioid
receptor sites called µ and Further studies of the biochemistry
and pharmacology of receptors will be aided by the recent
discovery of two linear, elective, hexapeptides, Tyr-D-Ser(D-
Thr)-Gly-Phe-Leu-Thr(DSLET, DTLET) (Zajac et al. 1983) as well as a
series of selective cyclic enkephalin pentapeptides (Mosberg et
al. 1983): (D-Pen2, D-Pen5 enkephalin, (DPDPE), its isomer
(DPLPE), and two analogs with a cysteine replacing one penicil-
laminone residue (DCLPE, DPLCE). To more clearly delineate
affinities to µ- and receptors, detailed computer assisted
TABLE 1. Receptor Affinitiesa and Calculated Relative Energiesb and 
Overlapc of Candidate High-Delta Affinity Conformers for Linear
and Cyclic Opioid Peptides.
57
shown in table 1, were designed to identify and characterize pep-
tide conformations leading to high affinity binding to receptors.
METHODS AND PROCEDURES
OPIOID RECEPTOR BINDING: Competitive inhibition of all pep-
tide analogs in rat brain homogenate of five labeled ligands [3H]
Naloxone, DADL, DSLET, EKC AND DHM were determined by procedures
and data analysis described previously (Cheng et al. 1986). Data
obtained were analyzed by a modified version of the program LIGAND
(Munson and Rodbard 1980) which predicts a set of self consistent
receptor binding affinities and capacities assuming different
receptor site models.
Conformational energies were calculated using a modified ver-
sion of the potential energy terms in the Empirical Conformational
Energy Program, ECEPP, (Momany et al. 1975), and optimized using a
new energy minimization program (PEP) developed in our
laboratory. Initial conformations to be optimized were constructed
using effficient interactive structure generating programs coupled
to graphics displays contained in the programs called MOLECULE
(Egan et al. 1982) Coordinates and atomic parameters of the un-
usual L-and D-penicillamines were developed systematically from a
related known X-Ray structure (Rosenfield and Parthasarathy
1975). The extent of overlap between any two conformers was deter-
mined by using a program called MOBLS, which determines the minimum
root mean square (rms) distance between user-selected, matched
atoms in two rigid molecules.
Different search strategies were used to span the conforma-
tional space for the linear and cyclic peptides studies. For the
linear haxapeptide, DTLET, an “aufbau” procedure was used, starting
with optimized conformers for each single amino acids, and linking
these to form initial hexapeptide conformers. This procedure led
to 30 different optimized structures with a relative energy range
of 7.5 kcal/mol. For the cyclic peptide DPLPE, the main
search strategy used involved a systematic exploration to determine
sets of 14 ring torsion angle values that allowed cyclic structures
to be formed, using a program developed in our laboratory based on
an existing ring closing algorithm (Go and Scheraga 1970). A
total of 248,000 conformations were subjected to cyclic ring
closure searches. These conformations were screened using
distance, energy and similarity criteria. Screening of all of the
successfully cyclized structures, resulted in 31 unique conformers
with optimized energies within 7.5 Kcal/mol of the lowest energy
structures. These 31 unique DPLPE conformers were used to con-
struct initial conformations for the three remaining cyclic pep-
tides DPDPE, DPLCE and DCLPE and additional conformers for the
linear peptide DTLET. Conversely, the 30 lowest energy DTLET
conformers were used as templates to construct additional initial
conformer for each of the four cyclic peptides. In this way a set
of 62 energy optimized conformers were obtained for DTLET and the
four cyclic peptides DPDPE, DPLPE, DPDCE and DCDPE.
RESULTS AND DISCUSSION
The receptor binding data was analyzed using a five-receptor
site model which gave the best fit to all of the experimental data.
called µ1, µ2, and and a fifth site with very high capacity and
low affinities for all ligands, most likely unrelated to opioid
activity. Table 1 shows the affinities of the six analogs studies
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for sites labeled µ1,µ2 and verifying their high affinity at
and indicating that DPDPE and DPLPE have the most pronounced
selectivity with respect to both sites 31 cyclic structures. After
optimization of the three other cyclic analogs, using low energy
DPLPE conformers as templates, a single common low energy conformer
for all four cyclic analogs resulted. Moreover, when these 31 low
energy conformers were used as templates to construct initial con-
formers for the linear peptide DTLET, all resulting optimized con-
formers had energies more than 7.5 kcal/mole higher than the lowest
energy conformer found independently for DTLET by the aufbau proce-
dure.
The search for
common low energy
conformers was much
more fruitful when the
reverse strategy was
tried, using the low
energy DTLET struc-
tures found from the
aufbau procedure as
templates for the
cyclic analogs. After
optimization, 16 con-
formers of DPLPE had
energies less than 7.5
kcal/mol above their
lowest energy conform-
ers. These DPLPE
conformers were then
used as templates for
the remaining cyclic
peptides, and the
optimized conformers
were all examined for
similarities to their corresponding DTLET conformer using the rms
procedure. One low energy DTLET structure, with three strong
intramolecular H-Bonds (fig. 1) and a relative energy of 1.6
kcal/mol, was the template for the lowest energy conformer of DPLPE
found by any of the search strategies used. Furthermore, this
DPLPE conformer yielded low energy optimized structures for the
three other cyclic analogs with great similarity to DTLET. No
other conformer was found which was more similar, or had lower
energies for all 5 analogs. This conformer is then an excellent
candidate for high affinity binding to the receptor. Figure 1
shows the superposition of this candidate conformer for DTLET and
DPLPE and illustrates their similarity and internal H-bonding.
Given in table 1, is the correlation of receptor affinities,
with calculated relative energies and overlap of the candidate
conformer of each cyclic analog with that of DTLET. Consistent
with its lower affinity, only DPDPE seems appreciably different
from the others in its extent of similarity with DTLET. These
results indicate that a conformational effect, and perhaps the
position of the terminal COOH group and its involvment in two
internal H bonds, one to the TyrOH and the other to the DPEN-2
carbonyl, rather than an energy difference, could account for its
lower delta affinity. The candidate low energy conformers chosen
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for DPDPE and DPLPE are also consistent with preliminary conforma-
tional results for these analogs using NMR methods (Mosberg 1986)
and should aid in their further interpretation.
The candidate peptide conformer leading to high affinity
receptor binding is very different from the form previously
proposed for favorable µ-receptor binding of D-Ala2-met-enkephalin
amide. Preliminary studies indicate that such conformers favorable
to µ-receptor binding are either higher energy forms or are greatly
distorted in these selective analogs.
The conformer identified in this study as responsible for high
affinity selective binding, clearly illustrates the key role for
the two threonine residues in DTLET. They are involved in two very
strong intramolecular H bonds: Thr2 with the Tyr-OH and Thr6 with
the Leu C=O. This latter moiety is also involved in H-Bonding with
the Tyr-OH. The multiple intramolecular H-bonds formed by these
residues apparently ensures a compact conformation very suitable to
selective binding. Cyclization appears to accomplish this same
purpose, cyclic analogs favoring a conformation very similar to the
multiply H-bonded linear peptide DTLET. This conformation retains
one strong H-bond between the TyrOH and the terminal carbonyl
group. The unique H-bonded conformations of these analogs must be
well suited for interaction with a receptor site. High affinity
could be the result of an excellent steric fit at this site,
assured by the internal H-bonds or the cyclization. Additionally,
once this fit is assured, the intramolecular H-bonds can be
replaced by more favorable interactions with appropriate receptor
residues to which the opioid peptide has been guided by its unique
conformat ion.
REFERENCES
Cheng, A., Uyeno, E.T., Polgar, W., Toll, L., Lawson, J.A., Degraw,
J.I. Loew, G.H., Camerman, A. and Camerman, N.J. J Med Chem, 29:
531-537, 1986.
Chang, K.J. and Cuatrecasas, P.J. J Biol Chem, 254:2610-1618, 1979.
Egan, J.T., Hart, J., Burt, S.K. and MacElroy, R.D. Comput
Graphics, 6:177-199, 1982.
Loew, G.H., Hashimoto, G., Williamson, L. Burt, S.K. and Anderson,
W. Mol Pharm, 22:667-677, 1982
Loew, G.H., Keys, C., Luke, B., Polgar, W., and Toll, L. Mol Pharm,
29 (#6): 546-553, 1986.
Momany, F.A., McGuire, R.F., Burgess, A.W. and Scheraga, H.A.
J Phys Chem, 79(22): 2361-2381, 1975.
Mosberg, H.J., Hurst, R., Hruby, V.J., Gee, K., Yamamura, H.I.,
Galligan, J.J. and Burks, T.F. Life Sci, 33 Sup 1: 447-450,
1983.
Mosberg, H.J. private commm, 1986.
Munson, P.J. and Rodbard, D. Anal Biochem, 107:220-239, 1980.
Rosenfeld, R.E. and Parthasarathy, R. Aut, B31: 462-466,
1975.
Zajac, J.M., Gacel, G., Petit, F., Dodey, P.I., Rossignol, P. and
Roques, B.P. Biochem Biophys Res Commun, 111: 390-397, 1983.
ACKNOWLEDGEMENTS
Dr. H. Mosberg kindly supplied samples of the 4 cyclic analogs used
in binding studies. Support for this work from NIDA grant 02662 is
gratefully acknowledged.
60
SITE-DEPENDENT EFFECTS OF IONS ON µ-, A N D OPIOID BINDING
IN SUSPENSIONS OF GUINEA-PIG BRAIN MEMBRANES
Linda E. Robson, Stewart J. Paterson and Hans W. Kosterlitz
Unit for Research on Addictive Drugs,
University of Aberdeen, Marischal College, Aberdeen, U.K.
ABSTRACT
NaCl, LiCl, NH4Cl and KC1 inhibit the equilibrium binding of peptide
agonists at each of the µ-, and sites; the orders of potencies
and the slopes of the dose-response curves are site-dependent. In
contrast, the monovalent salt choline chloride inhibits µ- and
binding but has little effect on binding. The profiles of activ-
ity of MnCl2, CaC12 and MgCl2 are also site-dependent but differ
markedly from those of the monovalent salts.
INTRODUCTION
In many of the early investigations of the effects of monovalent and
divalent salts on opioid binding, the opioids used were interacting
with more than one of the µ-, or sites. In more recent papers,
in which more selective labelling techniques have been used, site-
dependent differences in the effects of salts on opioid binding in
rat brain have been indicated by several groups. The aim of this
investigation was to compare systematically the effects of the
chloride salts of monovalent and divalent ions on equilibrium bind-
ing at µ-, and K-binding sites of guinea-pig brain, using select-
ive labelling conditions. A detailed report of the results will be
published elsewhere (Paterson et al. 1986).
MATERIALS AND METHODS
The effects of monovalent and divalent salts on equilibrium binding
at µ-, and opioid sites were investigated in membrane suspen-
sions (10 mg tissue/ml 50 mM Tris-HCl, pH 7.4 at 25°C) of guinea-pig
brain. In the brain minus cerebellum the µ-sites were labelled with
[3HI-[D-Ala2 ,MePhe4,Gly-o15]enkephalin (1 nM; 1221-2442 GBq/mmol,
Amersham International) and the sites with [3H]-[D-Pen2,D-Pen5]
enkephalin (1.5 nM; 1665 GBq/mmol, Amersham International). For
investigations at the site, binding of [3H]-dynorphin A (1-9) (0.1
nM; 1258 GBq/mmol, Amersham International) was determined in the
cerebellum, in which 84% of the opioid binding sites are of the
type; bestatin (30 µM) and captopril (300 µM) were added to reduce
the degradation of the labelled peptide. Specific binding was the
difference between the binding in the absence and presence of dipre-
norphine (1.2 µM; Reckitt and Colman). For a detailed account of
the experimental design see Paterson et al. (1986).
RESULTS
NaCl, LiCl, NH4Cl and KCl caused a dose-dependent inhibition of the
binding of the peptide agonists at each of the µ-, and sites.
On the other hand, choline chloride, which produced dose-dependent
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inhibition of µ- and binding had, at concentrations up to 100 mM,
no inhibitory effects on binding. The orders of potencies of the
salts were different at each site, as seen from the values for thres-
hold of inhibition (fig. 1). Furthermore, the slopes of the dose-
FIGURE 1. Thresholds of inhibition for effects of the
chloride salts of monovalent ions on binding at , µ-
and opioid sites. Values are the means s.e.m. of 3-10
observations and were obtained by extrapolation of the linear
regression of log mM salt against change (%) in binding.
Ch: choline.
response curves also differed at each site. They were highest at
the site (mean = 51% change in binding/log mM salt), intermediate
at the µ-site (mean = 38% change in binding/log mM salt) and lowest
at the site (mean = 28% change in binding/log mM salt).
The effects of divalent salts differed from those of monovalent salts
and were also site-dependent. At the site, MnCl2, MgCl2 and CaCl2
markedly potentiated binding by up to 50%; no inhibition of binding
was observed at the highest concentration used (16 mM). In con-
trast, at the µ-site low concentrations of MnCl2 and MgCl2, but not
CaCl2, slightly potentiated binding and at higher concentrations all
three salts inhibited binding. In further contrast, binding was
inhibited by MnCl2, MgCl2 and CaCl2 but no potentiation was observed.
DISCUSSION
Since throughout this investigation chloride salts have been used the
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differences in their effects can be attributed to the cations.
Since the orders of potencies and the slopes of the dose-response
curves are site-dependent, the mechanisms by which the monovalent
cations inhibit binding appear to differ at each site. Further-
more, the actions of divalent salts differ from those of monovalent
salts. For inhibition of µ- and binding by monovalent salts the
slopes of the dose-response curves are shallower than would be ex-
pected for competitive interactions, a finding in contrast to obser-
vations for NaCl in rat brain (Kouakou et al. 1982; Zajac and Roques
1985). These discrepancies may be due to differences in the species
or in the assay conditions.
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BINDING CHARACTFRISTICS OF [D-Ala2-MePhe4-Glyol5] ENKEPHALIN
AND [D-Pen2,D-Pen5] ENKEPHALIN IN RAT BRAIN: INHIBITION STUDIES
WITH FENTANYL-LIKE DRUGS
M. Yeadon and I. Kitchen
Department of Biochemistry, Division of Pharmacology & Toxicology,
University of Surrey, Guildford, Surrey GU2 5XH, U.K.
ABSTRACT
We have investigated the binding characteristics of two tritiated enkephalin
analogues [D-Ala2-MePhe4-Glyol5]enkephalin (DAGO) and [D-Pen2, D-
Pen5]enkephalin (DPDPE) which are highly selective for µ and opioid sites
respectively, in homogenates of whole rat brain and of the pons/medulla region.
In addition, we have explored the binding profile of four 4-anilinopiperidine drugs
(fentanyls) by means of inhibition studies. Our studies show that the
involvement in pons/medulla of rat is small compared with that in whole brain
and with µ binding in both whole brain and pons/medulla. In addition the rank
order of affinities of the fentanyl series is the same at the µ and site, but the
affinities are between 1 and 600-fold greater at the former site.
INTRODUCTION
Foremost of the adverse effects observed with the use of opioid drugs as
analgesics or anaesthetic/analgesics is respiratory depression. Although this has
been known for a considerable time, little progress has been made in
determining the mechanism of action of opioids in this regard. Investigations at
the receptor level have until recently been impeded by the lack of highly
specific, high affinity ligands for µ- and -opioid sites. The advent at DAGO
and DPDPE has overcome this problem and these enkephalin analogues are now
available at usefully high specific activities.
We have begun in vitro experiments into the binding characteristics of these
ligands and of an homologous series of potent synthetic opioids, the fentanyls, in
rat brain homogenates, in particular from areas known to be involved- in
respiratory control.
METHODS AND MATERIALS
Adult male Wistar albino rats, University of Surrey strain (25Og) were killed by
decapitation, the brains rapidly removed and quickly dissected according to the
procedure of Glowinski and Iversen (1966). The procedure for preparation of
membranes for use in binding studies was identical to that of Gillan and
Kosterlitz (1982)
Saturation assay mixtures comprised a 2ml final volume of the membrane
preparation, containing 19mg original wet weight of tissue. Non-specific and
total binding of the 3H-DAGO and 3H-DPDPE was determined in the presence
and absence, respectively, of 100-fold excess of unlabelled diprenorphine or
naloxone. The assay tubes were incubated in a shaking water bath for 40 mins
(3H-DAGO) or 50 mins (3H-DPDPE) at 25°C, and incubation was terminated by
rapid filtration over glass fibre filters (Whatman GF/B), then immediately
washed three times with 5ml ice-cold buffer. The filters were transferred to
scintillation vials and extracted overnight in 0.5ml Triton X100: Toluene (20:80)
before addition of 3.5ml Unisolve 1 scintillant followed by liquid scintillation
counting. A 3H-Hexadecane internal standard was included for quench
correction, and all assays were performed in triplicate.
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For inhibition studies, the protocol above was followed, but the concentration of
3H ligand was held constant whilst that of the cold displacing drug was
increased. Non-specific binding was assessed both in the presence and absence
of the displacing drug.
Data from saturation experiments were analysed by Scatchard plots and those
from inhibition assays by Hill plots. Slopes and intercepts were calculated from
the values of at least four independent experiments, derived by linear regression
of the data.
3H-DAGO (57.5 Ci/mmole) and 3H-DPDPE (28.0 Ci/mmole) were obtained from
Amersham International, U.K. Alfentanil, carfentanil, fentanyl and sufentanil
were gifts fron Janssen Pharmaceuticals, Belgium. Naloxone was a gift from
Endo Laboratories, U.S.A., and Diprenorphine, a gift from Reckitt and Colman,
U.K. The labelled peptides were highly purified by HPLC.
RESULTS AND DISCUSSION
Binding of tritiated enkephalin analogues:
The specific binding of both 3H-DAG0 and 3H-DPDPE to whole brain and
pons/meduIla membranes demonstrated a rectangular hyperbolic relationship to
free ligand concentration, and Scatchard plots were always linear. However, it
was not possible to obtain acceptable correlation coefficients for Scatchard plots
from single experiments with 3H-DPDPE in pons/meduIla homogenates.
Accordingly, binding constants were determined by simultaneous analysis of the
data from five separate experiments, with r = 0.95. There was no significant
difference between the Bmax or the K values for the µ specific ligand in the
two tissues (table 1). Whilst this was also true for the KD value for 
3H-DPDPE
in pons/medulla homogenate, the maximum number of binding sites for 3H-
DPDPE in pons/medulla homogenates was less than one third that of the whole
brain. Moreover, the specific binding of 3H-DAGO in whole brain at 1nM
represented 91% of the total binding, but the equivalent value for H-DPDPE at
D in pons/medulla was only 38%. There was a positive correlation between the
non-specific binding of both ligands in both tissues and the time taken at 25°C
for half-maximal specific binding of the ligand to be reached (r = 0.98), and also
between the non-specific binding and the time taken for a constant ratio of
specific/non-specific binding to be reached (r = 0.99).
TABLE 1. Comparative binding characteristics of 3H-DAG0 and 3H-DPDPE
in whole brain and pons/medulla homogenates of rat.
3 H - D A G 0 3H-DPDPE
Whole brain pans/medulla Whole brain *pons/medulla
Bmax (fmol mg
-1
protein) 167 11 145 6 175 23 54.9
D(nM) 1.1 0.2
Non-specific
binding (% of 8.7
total binding)
Time to half-
maximal specific 8.8
binding (mins)
Time to constant
ratio of specific to 15
non-specific binding (mins)
1.5 0.1 9.4 1.0 10.2
13.6 30.6 61.7
9.4 13.1 27.5
25 50 <120
Each value is the mean s.e.m. of at least four independent determinations.
*n = 5, but determined by simultaneous analysis of all the data.
65
Several studies have concluded that the depression of respiration produced by
opioids is mediated via µ or but not receptors (Santiago and Edelman
1985). However, the low selectivity of some of the ligands used has presented
difficulties in interpretation. Our quantitative studies show that the
involvement in rat pons/meduila is small compared with that in whole brain, and
with µ binding in both regions. This militates against mediation of respiratory
depression, but does not exclude it.
Inhibition studies:
The majority of inhibition studies produced Hill plots with near-integral slopes
and correlation coefficients, indicating interaction of the tracer Iigands with one
receptor population (table 2). We have thus far found no evidence for the
existence of µ-isoreceptors (Pasternak 3986) in rat brain.
The rank order of affinities of the fentanyl series is the same at the µ and
site, (and also the same as the rank order of potency in production of respiratory
depression by these drugs in rats (Janssen 1982), but the affinities are between 1
and 600-fold greater at the former site. This appears to implicate a µ receptor
involvement in the depression of respiration caused by the fentanyls. However,
the considerable differences in the relative affinities of the drug series at the µ
and sites provides a potential tool for testing this hypothesis.
TABLE 2. Binding profile of a series of 4-anilinopiperidine drugs at the µ and
opioid receptors of rat brain
I at
site (nM)
Carfentanil
0.44 0.02
Hill plot slope 1.00 0.03
I at
µ site (nM)
0.42 0.04
Hill plot slope 0.96 0.01
1.1 0.05
Relative µ
affinity
Relative
affinity
(fentanyl = 1.000)
7.9
47.8
Sufentanil Fentanyl
21.1 0.8 259 4.3
1.1 0.06
0.77 0.10
0.97 0.01
0.91 0.13
3.3 0.45
28 1.0
4.3
0.98 0.01
78 13
1.000
12.3 1.000
Alfentanil
22100 3700
0.83 0.07
38.9 3.7
0.97 0.01
570 90
0.085
0.012
Each value is the mean s.e.m. of at least four independent determinations.
*The marker ligand was 3H DPDPE at 0.5 KD.
**The marker ligand was 3H DAGO at KD.
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DEVELOPMENT OF -OPIOID RECEPTORS IN RAT BRAIN
CHARACTERISED BY [3H]-[DPen2,D-Pen3]
ENKEPHALIN BINDING
Ian Kitchen and Julia McDowell
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ABSTRACT
The development of rat brain -opioid receptors has been studied in the
posnatal period using the highly selective -site ligand [3H]-[D-Pen2,D-
Pen3] enkephalin (DPDPE) in binding studies. Between day 10 and day 25 there
was a three-fold increase in the number of binding sites (expressed per mg
protein) and the D was constant throughout
binding could not be detected earlier than day 10.
the postnatal period. Specific
INTRODUCTION
There is good evidence that there is differential development of µ, - and
opioid binding sites (Spain et al. 1985). The understanding of this heterogeneity has
been hampered, however, because of the lack of selective ligands for the
receptor subtypes.
With the recent availabilty of 3H-DPDPE which has been shown to be a highly
selective binding ligand for the -opioid receptor (Cotton et al. 1985) an
accurate determination of -site ontogeny has become possible. We report here
3H-DPDPE binding in the postnatal period and reveal inconsistencies with
previous ontogenetic studies using less selective ligands.
METHODS
Wistar albino rats of mixed sexes were used in all experiments and receptor
binding assays (in Tris HCl, pH 7.4 at 25°C for 40 mins) were carried out as
described by Cotton et al. (1985) in whole brain homogenates. 3H-DPDPE (25-
27Ci/mmol, Amersham) was purified by HPLC prior to use. Scatchard analysis
of saturation curves was used to determine D and Bmax.
RESULTS AND DISCUSSION
Table 1 shows the maximal binding capacities and affinities for 3 H - D P D P E
during postnatal development. Specific binding was absent in animals less than
10 days old and this contrasts with data for [3H]-[D-Ala2,D-Leu5] enkephalin
(DADL) where binding was reported during the first postnatal week (Spain et al.
1985). In addition the three-fold increase in number of binding sites between the
second and fourth postnatal week is of a greater magnitude than reported for
3H-DADL. In common with all ontogenetic binding studies using opioid ligands
the affinity of 3H-DPDPE remains constant during postnatal development.
In conclusion this study is the first report of A-receptor ontogeny using a ligand
highly selective for this receptor and confirm that the major development of
receptors occurs between the second and fourth postnatal weeks. It should be
pointed out however that difficulties were encountered in obtaining acceptable
Scatchard plots in young animals due to the low specific binding of 3H-DPDPE
and this poses problems in the use of this ligand for ontogenetic studies.
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TABLE 1. Binding characteristics of [3H] - [D-Pen2, D-Pen5I
enkephalin in the developing rat brain
Age Dissociation constant
(days) D, nM)
Binding capacity
(Bmax, fmol/mg protein)
10
15
21
25
30
35
40
45
50
10.5 1.9
10.2 1.7
9.7 1.1
12.7 2.7
9.7 0.9
9.7 1.4
8.5 0.5
11.1 1.8
7.2 0.4
34.5 6.2
49.3 4.6
78.6 7.5
102.8 13.6
107.6 6.1
111.8 15.2
103.3 11.5
119.4 11.2
99.9 12.0
Values are the mean s.e.m. of 4 Scatchard plots.
REFERENCES
Cotton, R., Kosterlitz, H.W., Paterson, S.J., Rance, M.J. and Traynor, J.R. Brit
J Pharmacol, 84: 927-932, 1985.
Spain, J.W., Roth, B.L. and Coscia, C.J., J Neurosci, 5: 584-588, 1985.
ACKOWLEDGEMENTS
This work was supported by a project grant from The Wellcome Trust.
68
COMPARISON OF THE EFFECTS OF CALCIUM CONCENTRATION ON MU
AND KAPPA AGONIST ACTIONS IN THE GUINEA PIG ILEUM
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ABSTRACT
The effect of calcium on responses to selective mu
(fentanyl and DAGO) and selective kappa agonists was
investigated on guinea pig ileum. The dose-response
curves were shifted to the right in a non-parallel
fashion with increasing calcium concentration (0.9-3.6
mM).  However U50488 was shifted more than either
fentanyl or DAGO. Both fentanyl and U50488 could not
produce 100% inhibition of twitch in 3.6mM calcium. It
is concluded that the efficacy of the agonists changes
with calcium concentration and that the kappa agonist
U50488 is affected more than the mu agonists because
kappa receptor activation directly inhibits calcium
entry whereas mu receptors inhibit calcium by increasing
potassium conductance.
INTRODUCTION
It has been shown that kappa receptor activation
probably inhibits calcium entry in neurons of the
myenteric plexus (Cherubini & North 1985). This is in
contrast to mu agonists which appear to indirectly
reduce calcium-entry by increasing potassium
conductance. Although there have been previous reports
of the effect of varying calcium concentration on
morphine actions in the guinea pig ileum (Opmeer & van
Ree 1979) there is little information available on the
effect of such manipulation on kappa agonists. We have
compared the effect of a range of calcium concentrations
on the actions of the kappa selective agonist U50488 and
the mu selective compounds fentanyl and
[D-Ala2,MePhe4,Gly(ol)5]-enkephalin (DAGO) on the guinea
pig isolated ileum.
MATERIALS AND METHODS
Male Dunkin-Hartley guinea pigs (250-400g) were killed
by cervical dislocation and the ileum removed and placed
in Tyrode's solution of the following composition: (mM)
NaCl 136.9, NaH2PO4 0.42, NaHCO3 11.9, KCl 2.7, MgCl2
1.05, D-glucose 5.55 and CaCl2 1.8. The pieces of ileum
were then mounted on coaxial electrodes and electrically
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stimulated with 0.5ms pulses at 0.1Hz at supramaximal
voltage. The 10ml organ baths were maintained at 37°C
and the solutions bubbled with 95%O2/5%CO2. Washing was
by overflow. The ability of the agonist to inhibit the
electrically evoked twitch was measured in Tyrode's with
0.9, 1.8 and 3.6mM calcium. The calcium concentration of
the solutions was altered by adding calcium chloride to
the reservoir. The osmolarity of the solution varied
between 282 and 287 milliosmoles.
RESULTS
FIGURE 1 Dose-response curves for the kappa
selective compound U50488. The curves were
shifted to the right in a non-parallel
fashion with increasing calcium
concentration.( =0.9mM, =1.8mM and
=3.6mM calcium). In 3.6mM calcium 100%
inhibition of the twitch was not seen.
The mu and kappa ligands tested in this study reduced
the electrically evoked twitch of guinea pig isolated
ileum. This effect was found to be dependent upon
external calcium concentration.
As is shown in table 1, the dose ratio produced by the
change from 1.8 to 3.6mM calcium for U50488 is
significantly greater than that for either fentanyl or
DAGO. The dose-response curves were shifted to the right
in a non-parallel fashion with increasing concentration
of calcium. At the highest calcium concentration (3.6mM)
it was not possible to obtain 100% suppression of twitch
with either fentanyl or U50488 (figures 1,2).
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FIGURE 2 Dose-response curves for the mu
selective ligands fentanyl and DAGO in
increasing calcium concentration. The curves
were shifted to the right. Allthough the DAGO
curves appeared to be parallel the fentanyl
curves were not and did not reach maximum
inhibition.( =0.9mM, =1.8mM and
=3.6mM calcium)
DISCUSSION
The data presented suggest that mu and kappa agonists
may inhibit calcium entry by differing mechanisms. This
supports the finding that kappa agonists reduce
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TABLE 1 The effect of calcium concentration
on the effectiveness of U5C488, fentanyl and
DAGO, in reducing the electrically evoked
twitch of guinea pig ileum. The potencies of
all three agonists are reduced by increasing
the calcium concentration. However the
dose-ratio for U50488 in 1.8 and 3.6 mM
calcium is significantly larger (*p<0.1,
Student's unpaired t-test) than for either
fentanyl or DAGO.
transmitter release directly by inhibiting calcium entry
(Cherubini & North 1985) whereas mu agonists act
indirectly by increasing potassium conductance to
hyperpolarise the nerve terminal and subsequently reduce
calcium entry. Hayes and Sheehan (1986) have shown that
compounds which appear to be partial agonists and
antagonists on the rat vas deferens, a tissue with a low
receptor reserve, increase their efficacy in lowered
calcium concentrations suggesting an increase in the
receptor reserve. Therefore it is possible that in
higher calcium concentrations the receptor reserve for
both mu and kappa receptors is reduced in guinea pig
ileum and so the efficacy of what appear to be full
agonists is reduced to that of partial agonists. This
could explain the reduced maximum responses seen with
fentanyl and U50488. The ability of DAGO to produce a
full inhibition of the twitch in the presence of 3.6mM
calcium suggests a high efficacy, in comparison with
fentanyl. The possibility that the guinea pig ileum
opioid receptor reserve is calcium dependent could only
be adequately investigated, however, by using an
irreversible receptor antagonist such as -CNA (Takemori
et al. 1986).
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ABSTRACT
The spinal cord of the rat is shown to contain only a low level of
kappa-binding sites, comparable to rat brain. [3H]Bremazocine
appears to label an additional class of sites which do not appear to
be of mu, delta, or kappa specificity.
INTRODUCTION
Intrathecally administered opioids are believed to act directly at
the spinal level to prevent the passage of nociceptive information
to higher centres (Yaksh 1981). Pharmacological studies of opioids
after intrathecal administration show that ligands with mu, delta,
and kappa selectivity are active in various test systems used'to
evaluate analgesia (Tung and Yaksh 1982, Schmauss and Yaksh 1984).
Characterisation of opioid receptors in the rat cord by ligand
binding assays have demonstrated the presence of a large number of
putative kappa sites (Gouarderes et al. 1981, Traynor and Rance
1984). Such sites have properties inconsistent with a single site
(Traynor and Rance 1985) and the existence of sub-types has been
suggested (Attali et al. 1982). In this paper we present a partial
characterization of these sites.
MATERIALS AND METHODS
The followinq labelled ligands were used: [3H]Bremazocine
(30 Ci.mmol-1) (New England Nuclear) and [3H]Dynorphin(1-9)
(26 Ci.mmol-1) (Amersham International). Unlabelled ligands used
were Tyr-D-Ala-Gly-MePhe-NHCH2-CH2OH (GLYOL), D-Ala2-D-Leu5-
Enkephalin (DADLE) (Sigma U.K.) and Trans-3,4-dichloro-N-methyl-N-
[2-(1-pyrrolidinyl)-cyclohexyl]-benzene acetamide (U-50488H)
(Upjohn). Peptidase inhibitors used were Bestatin (Cambridge
Research Biochemicals) and Captopril (Merck).
Binding to rat lumbo-sacral spinal cord membranes was performed in
Tris buffer, pH 7.4, at 37°C or 25°C (for [3H]Dynorphin(1-9)) as
previously described (Traynor and Rance 1985). In the case of
[3H]Dynorphin(1-9) the peptidase inhibitors bestatin (30µM) and
captopril (300µM) were included to prevent degradation of the
labelled ligand. Binding to homogenates of guinea-pig cerebellum
(Robson et al 1984) was performed in 20mM Hepes buffer or
Hepes-buffered Krebs solution containing 10µM GppNHp for 40 min at
25°C. Non-specific binding was defined using 1µM Diprenorphine.
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RESULTS AND DISCUSSION
[3H]Bremazocine exhibited high affinity binding to rat lumbo-sacral
cord membranes. However, after suppression of binding to mu and
delta sites, with 1OOnM each of GLYOL and DADLE per 0.5nM
[3H]ligand, displacement of the remaining bound [3H]Bremazocine was
not consistent with a single kappa site. Thus ligands for mu
(GLYOL), delta (DADLE) and kappa (U-50488H) sites displaced the
remaining specifically bound [3H]Bremazocine with low Hill
coefficients (table 1). Indeed for DADLE it was possible to discern
two definite components with affinities of 321nM and 25890nM respect-
ively . Displacement by naloxone suggested all of the specifically
bound [3H]Bremazocine was opioid in nature.
TABLE 1. Inhibitory effects of opioids on the binding
of [3H]Bremazocine to rat lumbo-sacral membranes in the
presence of GLYOL (100nM) and DADLE (100nM).
Competing Ligand Ki(nM) Hill Coefficient
GLYOL 1338 309 0.83 0.04 (3)
DADLE 8945 825 0.61 0.07 (3)
U-50488H 57.3 7.8
Naloxone* 11.0
0.52 0.01(4)
* Naloxone displaced a mean of 99.1% of the specifically bound
[3H]Bremazocine in the two experiments.
In order to gain further insight into the heterogeneous site we have
studied the binding of [3H]Bremazocine in the presence of a high
concentration of DADLE (5-10µM) to suppress the higher affinity of
the two kappa components. The remaining binding is characteristic
of a classical kappa site (table 2).
TABLE 2. Inhibitory effects of opioids on the binding
of [3H]Bremazocine to rat lumbo-sacral membranes in the
presence of DADLE (5µM).
Competing Ligand Ki(nM) Hill Coefficient
GLYOL 6306 1333 1.12 0.13 (3)
DADLE 2573 638 0.84 0.10 (3)
U-50488H 15.63 2.84 0.77 0.08 (3)
Furthermore. in the presence of this high DAOLE concentration the
number of [3H]Bremazocine binding sites was markedly reduced bring-
ing it into line with the number of sites labelled by the
kappa-selective peptide [3H]Dynorphin(1-9) (table 3). These
findings suggest that the true kappa site accounts for only 13% of
the total [3H]Bremazocine binding in the cord, rather than the much
higher percentage previously supposed (Gouarderes et al. 1981,
Traynor and Rance 1984). This low level of kappa binding agrees
with the findings of Lahti et al. (1985) who were unable to detect
binding of the kappa selective [3H]U69593 to rat cord membranes.
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TABLE 3. Binding of [3H]ligands to rat lumbo-sacral
spinal cord membranes. Bmax
[3H]ligand
KD
(nM)
(fmols,mg-l
protein)
Bremazocine 0.47 0.05 89.6 5.3 (3)
Bremazocine with 10µM DADLE* 0.20 0.02 11.9 0.4 (3)
Dynorphin(1-9) with 0.28 0.03 10.1 0.8 (4)
mu and delta suppression**
GLYOL+
DADLE+
1.95 0.2 24.2 1.3 (3)
1.92 0.3 11.1 0.6 (3)
* 10µM DADLE to 1 x KD of the [
3H]ligand and ** 100 µM
each of GLYOL and DADLE to 1 x KD of the [
3H]ligand.
+ Taken from Traynor and Rance, 984.1
It is well known that apparently heterogeneous binding may be a
consequence of using non-physiological conditions (Creese 1985).
To determine if this could explain our findings we have used the
largely kappa containing guinea-pig cerebellum (Robson et al. 1984).
In this tissue, in Hepes buffer, [3H]Bremazocine (0.2nM) is
displaced by U-50488H with an IC 5 0 of 10.3nM but a Hill coefficient
of only 0.59 which was similarly shallow even in the presence of
3µM DADLE. Using Hepes buffered Krebs containing the stable GTP
analogue GppNHp the dose-response curve for U-50488H is shifted
twenty-fold to the right but the slope remains at 0.59, suggestive
of true heterogeneity. Further studies are in progress to confirm
whether the nature of this heterogeneity is the same as that seen
in the rat cord.
The results demonstrate that the rat spinal cord contains a small
population of classical kappa sites, similar to that reported in rat
brain (Gillan and Kosterlitz 1982), and that [3H]bremazocine, but
not the peptide [3H]Dynorphin(1-9), labels a site which is
apparently not of mu, delta or kappa specificity. It is unlikely
that this should be considered as a sub-type of the kappa site in
view of its inability to reccgnise Dynorphin(1-9). It will be of
interest to determine what role, if any, this site plays in
spinally-mediated analgesia.
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ABSTRACT
Intact neurosecretosomes (NSS) from bovine posterior pituitary were
prepared and characterized. Ligand binding studies were performed,
using 3H-[D-Ala2-D-Leu5]enkephalin (DADL), 3H-etorphine and
3H-ethylketocyclazocine (EKC). The absence of specific binding of
3H-DADL and the inability of DADL to displace 3H-etorphine,
implies the absence of mu, delta, or DADL-suppressible benzomorphan
("kappa-2") sites. Self- and cross displacement studies for
etorphine and EKC suggested receptor heterogeneity. EKC fails to
displace - 20% of specific binding of etorphine. Mathematical
modelling indicates the presence of three classes of sites. The
present findings imply that bovine posterior pituitary opioid
receptors are exclusively of the kappa type.
INTRODUCTION
Opioid peptides are present in the neural lobe of the pituitary.
Modulation of the secretion of oxytocin and vasopressin by opioid
peptides directly at the neural lobe level has been widely studied.
Although the coexistance of vasopressin and oxytocin with opioid
peptides in neurosecretory vesicles of nerve terminals themselves is
now accepted, the underlying mechanisms of the modulation of the
secretion and the type or subtype of opioid receptors involved
remains unclear. Several reports suggested that opioid receptors
are present primarily in the pituicytes (astrocytoglia), rather than
on the nerve terminals (Bunn et al. 1985; Lightman et al. 1983).
The present study was undertaken to determine whether opioid binding
sites are also present on neurosecretosomes (i.e., nerve terminals)
and to characterize the types of these receptors. We used DADL as a
probe of mu and delta receptors. Etorphine and EKC were selected,
following protocols similar to that used by another laboratory
(Castanas et al. 1985) and ourselves to characterize 3 subtypes of
kappa receptors in bovine adrenal medulla.
MATERIALS AND METHODS
Neurosecretosome preparation: Fifteen to twenty bovine posterior
pituitaries were suspended in 0.25 M sucrose, 10 mM HEPES-Tris
buffer (pH 7.3) and homogenized with a teflon-glass homogenizer.
The homogenate was centrifuged at 750 x g for 2 min and the
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supernatant was centrifuged at 5.000 x g for 20 min. The pellet was
resuspended in sucroserpercoll (30%) medium and centrifuged at
50,000 x g for 45 min. The particulate band at the 1.045-1-055 g/ml
density region of the gradient was collected as purified
neurosecretosomes (NSS). The purity of the preparation was assayed
both by enzyme analysis and electron microscopy (Russell, in
preparation).
Opiate binding assay: Binding studies were performed in isotonic
sucrose solution with the following characteristics: sucrose 0.25 M;
HEPES-Tris, 10 mM (pH 7.3); PMSF, 3 pg/ml; aprotonin, 1000 U/ml;
bacitracin, 0.02% (w/v). The samples were incubated at 37°C for 30
min and then filtered through Whatman GF/B filters.
Mathematical and statistical analysis: Data were analyzed with the
computer program ALLFIT to estimate IC50 values and pseudo-Hill
coefficients, as described elsewhere (De Lean et al. 1978). Binding
parameters were obtained using program LIGAND, employing a weighted
non-linear regression analysis (Munson and Rodbard 1980; Cruciani
et al. in press).
Materials: 3H-etorphine (40 Ci/mmol) was obtained from Amersham,
Arlington Heights, IL. 3H-EKC (24 Ci/mmol) and 3H-DADLE (45
Ci/mmol) were obtained from New England Nuclear Corp., Boston, MA.
RESULTS AND DISCUSSION
Competition studies for 3H-etorphine by DADL were performed (fig. 1).
Fig. 1. Displacement of 3H-etorphine from neurosecreto-
somes of bovine posterior pituitary by unlabeled etorphine
and DADL.
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DADL failed to displace specific binding of etorphine even when
10-4M unlabeled ligand was used as displacer, implying the absence
of mu, delta, and benzomorphan binding sites. This observation was
further confirmed by the absence of specific binding for 3H-DADL.
Self-displacement curves for etorphine and EKC, using a fixed
concentration of labeled ligand showed a complex isotherm that
suggested hetereogeneity of binding sites. When each of these
curves were analyzed individually or by pooling results from several
experiments, one could reject a model involving a single class of
sites (p < 0.01). In each case a model involving two classes of
sites was sufficient, and further complexity was not supported by
analysis of data from homologous displacement curves considered
alone. Etorphine showed apparent Kd's of 1 and 100 nM; EKC showed
Kd's of 5 nM and > 100 µM.
Complete self- and cross-displacement study: We next sought to
study whether the two sites for etorphine and EKC were independent
or whether the two ligands shared the high affinity site.
Accordingly, a complete self- and cross-displacement study for
labeled etorphine and EKC was performed (table 1). Mathematical
modelling of the data with program LIGAND indicated that a model
involving three classes of sites was significantly better than a
model involving two classes of sites (p < 0.01). Parameters of the
"3-site" model are shown in Table 1. The data did not support a
more complex model with 4 classes of sites. R1 showed high affinity
for both etorphine and EKC, with approximately two-fold higher
affinity for etorphine. R2 has a 750-fold higher binding capacity
than R1, with low affinity for etorphine (320 nM) and negligible
affinity for EKC. The third site, R3 showed an even larger binding
capacity but with an extremely low affinity for both ligands (Kd's
in the µM range).
TABLE 1. Binding parameters of opioid binding to NSS.
Kd and binding capacities for a model involving three
classes of sites (R1-R3. A complete set of four self-
and cross-displacement curves for labeled and unlabeled
etorphine and EKC was analyzed simultaneously using the
computer program LIGAND.
Class Receptor Etorphine EKC
of concentration K D K D
site (pmol/gr tissue) (nM) (nM)
R1 4 0.9 2
R2 320 150 > 10000
R3 1700 7300 2300
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The present studies have shown that the neurosecretosomes from the
bovine posterior pituitary have kappa opioid receptors characterized
by high affinity for etorphine and EKC and complete lack of affinity
for the relatively delta/mu selective ligand DADL. It is possible
that R1 of the NSS (Table 1) corresponds to the "kappa-l" or
"kappa-3" subtypes of bovine adrenal medulla which have high
affinity for both etorphine and EKC, but are not suppressible by
DADL (Castanas et al. 1985). In contrast, in bovine adrenal
medulla, 80% of kappa receptors are present as "benzomorphan sites,"
also designated as the "kappa-2 subtype." This receptor was defined
operationally as sites with Kd - 1 nM for both etorphine and EKC,
but which could be suppressed by 1-100 µM DADL. The failure of
10-4M DADL to displace labeled etorphine from NSS implies that the
kappa receptor of bovine posterior pituitary NSS differs from the
major form in membranes from bovine adrenal medulla.
The present findings are in agreement with recent reports of
autoradiographic data (Herkenham et al. 1985, Gerstgerger and
Bardin 1986) and with other radioreceptor  binding studies (Martin
and Falke 1985) that indicate predominance of kappa binding sites
in the neural lobe.
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ABSTRACT
The opioid receptor selectivity of BAM 18 was determined by radioligand
binding and peripheral tissue bioassay. Using selective radioligand binding
conditions, BAM 18 bound to the µ opioid receptor with an affinity twice that
of the K receptor and over 10 times that of the opioid receptor (Ki = 0.29,
0.84 and 3.9 nM, respectively). Ke values for naloxone antagonism of BAM 18
activity in the electrically stimulated guinea pig ileum and the mouse vas
deferens were 4.3 and 9.9 nM respectively. The pharmacological profile of
BAM 18 was similar to that of metorphamide.
INTRODUCTION
BAM 18 is an 18 amino acid peptide derived from proenkephalin A. Although
it is present in rat and guinea pig CNS in relatively high concentrations (Evans
et al. 1985), the pharmacological properties and physiological function of this
peptide are presently unknown. In the present study we have compared the
pharmacological properties of BAM 18 to that of another proenkephalin
A-derived peptide, metorphamide. Our data indicate that the pharmacological
profile of BAM 18 is similar to that of metorphamide, in that both peptides
display high affinity for the µ opioid receptor.
MATERIALS AND METHODS
Radioligand binding.
Male guinea pigs (350-400 g) were obtained from Simonsen Labs., Gilroy, CA.
Brain homogenates were prepared as described previously (Leslie et al. 1982).
Brain membranes (10 mg original tissue wet weight) were incubated for 90 min
at 22°C in 1 ml 50 mM Tris-HCl buffer (pH 7.4) containing radioligand,
appropriate competing ligand and enzyme inhibitors (bestatin, 10 µM, and
thiorphan, 0.1 µM). Selective binding conditions for each receptor subtype
were utilized. The µ binding site was labelled with [3H] DAGO, the binding
si te  with  [ 3H] DADLE in  the  presence  o f  300  nM D-Pro 4 -morphicept in
(PLO17) (to saturate all µ sites), and the K binding site with [3H] EKC in the
presence of 100 nM DSLET and 300 nM PLO17 (to saturate all and µ binding
sites, respectively). Specific binding was defined as the difference in bound
radioactivity in the absence and presence of 1 µM levallorphan. Following
incubation, membranes were filtered through GF/C paper and rinsed with
16 ml of ice cold buffer. Saturation curves were constructed using increasing
concentrations of radioligand. The equilibrium dissociation constant (Kd) and
binding capacity (Bmax) of each radioligand were derived by non-linear, least
squares regression analysis using the computer program LIGAND (Munson and
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Rodbard 1980). Both BAM 18 and metorphamide were used to competitively
displace radioligand binding. The dissociation constant of each inhibiting
ligand (Ki) was determined using the Cheng-Prusoff equation (Cheng and
Prusoff 1973).
Bioassay
Male guinea pigs and Balb C mice were obtained from Simonsen Labs., Gilroy,
CA. Myenteric plexus-longitudinal muscle strips (GPI) and mouse vas deferens
(MVD) were prepared as described previously (Leslie et al. 1980). Enzyme
inhibitors (bestatin, 1 µM, and thiorphan, 0.1 µM) and drugs were added to the
tissue baths at 20 min intervals for the GPI, and at 8 min intervals for
the MVD. Dose response curves were constructed by adding increasing
concentrations of the test drug to the organ bath and IC50 values determined.
Ke values for naloxone antagonism of agonist activity were determined by the
'single dose' method of Kosterlitz and Watt (1970).
RESULTS
Affinity constants for inhibition of radioligand binding are shown in table 1.
BAM 18 displaced the binding of all three radioligands. Although it exhibited
h i  h e s t  a f f i n i t y  f o r  t h e  µ  b i n d i n g  s i t e ,  i t  a l s o  p o t e n t l y  d i s p l a c e d
[3H] EKC binding from the K site. In contrast, BAM 18 had a 10-fold lower
af f in i ty  for  the binding site. Metorphamide displayed a similar receptor
selectivity profile. I t  was  a  potent  d isplacer  o f  both  [ 3H] DAGO and
[3H] EKC binding, with a lower affinity for the binding site. IC 50  values
TABLE 1. Potencies of opioid peptides for displacement of
radioligand binding to guinea pig brain homogenates.
DRUG Ki (nM)
[3H] DAGO  [3H] EKC  [3H] DADLE
BAM 18 0.29 0.063 0.75 0.26 3.17 0.60
Metorphamide 0.06 0.005 0.23 0.08 1.76 0.07
Values represent the mean SEM of 3-8 observations.
determined in bioassay preparations are shown in table 2. Both BAM 18 and
metorphamide were more potent inhibitors of twitch contraction in GPI than
MVD. In both tissues, Ke values for naloxone antagonism were intermediate
between those previously reported for antagonism of µ and K agonists (table 3;
Lord et al. 1977).
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TABLE 2. Potencies of opioid peptides for inhibition of stimulated
twitch contraction in GPI and MVD.
DRUG IC50 (nM)
GPI MVD
BAM 18 1.37 0.30 26.2 6.34
Metorphamide 0.51 0.08 6.53 2.50
Values represent the mean SEM of 3-6 observations.
TABLE 3. Naloxone antagonism of BAM 18 and Metorphamide
agonist activity in GPI and MVD.
DRUG Naloxone Ke (nM)
GPI MVD
BAM 18 4.34 1.31 9.86 2.17
Metorphamide 4.88 1.43 10.6 0.97
Values represent the mean SEM of 3-6 observations.
DISCUSSION
Data from both receptor binding and bioassay indicate that BAM 18 has high
affinity for µ and K opioid receptors, with somewhat lower affinity for the
opioid receptor. This receptor selectivity profile is similar to that of
metorphamide (present study; Weber et al. 1983). In contrast, met-enkephalin
has a different pattern of pharmacological activity, exhibiting the highest
affinity for the receptor, with lower affinities for µ and K receptors.
BAM 18 is present in higher concentrations in the CNS of rat than is
metorphamide (Evans et al. 1985; Weber et al. 1983). Its regional distribution
throughout brain is similar to that of enkephalin (Evans et al. 1985; Sanders et
al. 1984; Hong et al. 1977; Zamir et al. 1985). It has previously been noted
that the anatomical distribution of proenkephalin-derived peptides does not
correspond precisely to that of receptors (Moss et al. 1986). In several brain
regions, however, there is a significant overlap between the pattern of
enkephalin immunoreactivity and that of µ receptors (Laughlin et al. 1985).
Based on our present findings that BAM 18 has highest affinity for the µ
binding site, we propose that this peptide may mediate its physiological
actions in certain brain regions via the µ opioid receptor. The functional
significance of BAM 18 remains to be determined.
63
REFERENCES
Cheng, Y. and Prusoff, W.H. Biochem Pharmacol, 22:3099-3108, 1973.
Evans, C.J., Erdelyi, E., Makk, G. and Barchas, J.D. Fed Proc, 44:422, 1985.
Hong, J.S., Yang, Y.T., Fratta, W. and Costa, E. Br Res, 134:383-386, 1977.
Kosterlitz, H.W. and Watt, A.J. Br J Pharmac, 39:398-413, 1970.
Leslie, F.M., Chavkin, C., and Cox, B.M. J Pharm Exp Ther, 214:395-402,
1980.
Leslie, F.M., Tso, S. and Hurlbut, D.E. Life Sci, 31:1393-1396, 1982.
Lord, J.A., Waterfield, A.A., Hughes, J. and Kosterlitz, H.W. Nature,
267:495-499, 1977.
Loughlin, S.E., Massamiri, T.R., Kornblum, H.I. and Leslie, F.M.
Neuropeptides, 5:469-573, 1985.
Moss, I.R, Denavit-Saubie, M., Eldridge, F.L., Gillis, R.A., Herkenham, M.
and Lahiri, S. Fed Proc, 45:2133-2147, 1986.
Munson, P.J. and Rodbard, D. Analyt Biochem, 107:220-239, 1980.
Sonders, M., Barchas, J.D. and Weber, E. Biochem Biophys Res Comm,
122:892-898, 1984.
Weber, E., Esch, F.S., Bohlen, P., Paterson, S., Corbett, A.D., McKnight, A.T.,
Kosterlitz, H.W., Barchas, J.D., and Evans, C.J. Proc Natl Acad Sci USA,
80:7362-7366, 1983.
Zamir, N., Plakovits, M. and Brownstein, M. Br Res, 326:1-8, 1985.
ACKNOWLEDGEMENTS
Supported by NIH Grant NS 18843.
84
CROSS-PROTECTION OF µ AND OPIOID RECEPTORS
IN THE MOUSE VAS DEFERENS.
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ABSTRACT
Opioid receptors in the C57/BL mouse vas deferens can be
irreversibly blocked by pre-treatment with -chlomaltrexamine.
Pre-incubation with the highly selective receptor antagonist
ICI 174864 concentration-dependently protected -receptors from
inactivation, but the same concentrations similarly protected µ
receptors. Pre-incubation with selective µ-receptor agonist,
[D-Ala2, MePhe4, Gly(ol)5]enkephalin, also protected both µ and
receptors to the same degree. Neither ligand protected opioid
receptors. The results suggest that there may be a structural
interaction between µ and receptors in the mouse vas deferens.
INTRODUCTION
Much effort has been expended in demonstrating the existence of
multiple types of opioid receptor (Martin et al. 1976, Lord et
al. 1977). There is, nevertheless, a growing body of evidence
for interaction between the types, particularly µ and receptors
in vitro (Rothman and Westfall 1981) and in vivo (Holaday and
D’Amato 1983). It has even been suggested that the two receptors
may be interconvertible forms of a single macromolecule (Bowen et
al. 1981). In this study we have taken advantage of the presence
in the mouse vas deferens of all three established types of
opioid receptor (µ,  and : Lord et al. 1977; Miller and Shaw
1984) to-attempt to selectively protect one opioid receptor type
from inactivation while irreversibly blocking the remainder. The
irreversible antagonist used was -chlornaltrexamine CNA), an
alkylating agent selective for opioid receptors but which does
not discriminate between the three types (Ward et al. 1982). The
protecting ligands used were the highly selective receptor
antagonist ICI 174864 (Cotton et al. 1984) and the selective
µ-agonist, [D-Ala2, MePhe4, Gly(ol)5] enkephalin (DAGO; Corbett
et al. 1984). The results are interpreted as supporting an
interaction between µ and receptors in this tissue.
MATERIALS AND METHODS
Vasa deferentia from mature Glaxo-bred C57/BL mice were mounted
and field-stimulated as described in Hayes et al. (1985).
Cumulative concentration-response curves were constructed in
random order for the µ-selective agonist DAGO, the k-selective
agonist U50488 (trans- -3, 4-dichloro-N-methyl-[2-(1-pyroll-
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idinyl) cyclohexyl] benzene acetamide methanesulphonate), and a
selective a onist, [D-Pen2, L-Pen5] enkephalin (DPLPE) or
[D-Pen2, D-Pen5] enkephalin (DPDPE). Tissues being treated with
irreversible antagonist were incubated with -CNA for 15 min,
after which any non-covalently bound antagonist was removed by
extensive washing at 5 min intervals for 90 min. For protection
experiments, the protecting ligand was incubated with the tissue
for 10 min (DAGO) or 30 min (ICI 174864) before and during the
CNA treatment. Control experiments showed that the 90 min
washout period was also enough to remove any remaining ICI
174864. Concentration-response curves for each agonist were
re-determined in the treated tissues and, where a parallel shift
was obtained, a dose-ratio was calculated.
DPLPE and DPDPE were supplied by Peninsula and DAGO by Cambridge
Research Biochemicals. U50488 was a gift from Dr. P.F. von
Voigtlander of the Upjohn Company, ICI 174864 was a gift from Dr.
R. Cotton of ICI. -CNA was synthesised by Dr. A. McElroy of the
Chemical Research Dept., Glaxo Group Research Ltd.
RESULTS
In the absence of any protecting ligand, -CNA (10-8M - 10-7M, 15
min) caused a concentration-dependent antagonism of the responses
to DAGO, DPLPE and U50488 which was not significantly reversed by
3hr of extensive washing of the tissues. The receptor reserve
for each agonist can be estimated by the extent to which an
irreversible antagonist can produce a parallel rightward shift of
the concentration-response curve without diminution of the
maximum available response (Furchgott 1966); these shifts were
about 30-fold for DAGO and 10-fold for DPLPE, while a parallel
shift for U50488 was rarely obtained.
Pre-incubation with the selective antagonist ICI 174864
(10-7-5x10-5M) protected the response to DPLPE in a
concentration-dependent manner, but also protected the response
to DAGO to a similar extent (table 1). There was no significant
protection of the response to U50488 at any but the highest
concentration of ICI 174864 (data not shown).
Similar experiments were performed using DAGO (10-6-3x10-5M) to
protect µ-opioid receptors. As before, there was little
protection of the response to U50488 (data not shown) but their
responses to DAGO and DPDPE were protected to a similar extent
(table 2).
In order to investigate whether there was an interaction between
the agonist effects mediated by µ and receptors,
concentration-response curves were constructed to one agonist in
the presence of low concentrations of the other.
The concentrations used were either just sub-threshold, causing
no inhibition of twitch by itself, or a concentration causing
about 10% inhibition of twitch. When tested thus, DAGO had no
significant effect on the concentration-response curve to DPDPE,
and was itself unaffected by low concentrations of DPDPE.
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TABLE 1 Protection against --CNA by ICI 174864 in the mouse
vas deferens
The values given are the dose ratios (mean S.E.M., n = 4-8)
for the parallel rightward shifts in the
concentration-response curves for the µ-selective agonist,
DAGO, and the selective agonist, DPLPE. Below it is given
the ratio of the µ-shift/ -shift. The larger this figure,
the greater the selective protection of d-receptors. NT, not
tested.
TABLE 2 Protection against -CNA by DAGO in the mouse vas
deferens
Details are as in the legend to Table 1. In this context the
ratio of the µ-shift/ -shift is smaller for greater degrees
of µ-receptor protection.
DISCUSSION
The -receptor antagonist ICI 174864 was able to protect the
response to DPLPE from blockade by -CNA in the C57/BL mouse vas
deferens, but it also protected the response to DAGO to a similar
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extent, even at concentrations which occupy only a small
proportion of µ-receptors (Ki at -receptors = 30nM and at
µ-receptors > 5000nM : Cotton et al. 1984). It thus appears
that occupation of -receptors by ICI 174864 can make µ-receptors
inaccessible to B-CNA. Similarly, DAGO was able to protect its
own agonist effect from -CNA but often produced an even greater
degree of protection of the response to DPDPE. The Ki value for
DAGO in displacing [3H]-naloxone from µ-receptors in a
physiological medium is 1300 nM (calculated from Carroll et al.
1984); the comparable value at -receptors has not been reported
but the binding selectivity of DAGO for µ-over -receptors in
Tris buffer is 185-fold (Corbett et al. 1984). Ward et al.
(1982) selectively protected -receptors from B-CNA in the mouse
vas deferens using an agonist, [D-Ser2, Leu5] enkephalinyl-Thr,
as protecting ligand. Our own studies using this ligand did not
improve upon the low degree of selective -receptor protection
seen with some of the treatments shown in table 1 (unpublished
observations).
Our results suggest that there may be a structural interaction
between µ- and -opioid receptors in the C57/BL mouse vas
deferens, but not between k-opioid receptors and either of the
other types. However, since there was no synergism or antagonism
between DAGO and DPDPE in this tissue, this putative interaction
does not appear to alter the transduction of the agonist effects
mediated by µ and receptors.
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ABSTRACT
Affinity crosslinking of human 125I- -Endorphin to cell
lines possessing either mu or delta binding sites was car-
ried out. Autoradiography of SDS-PAGE gels from these
crosslinked cell lines revealed that these two sites
contain major peptide subunits that differ in molecular
size. This confirms our earlier finding in mammalian
brain which demonstrated separate and distinct subunits
for mu and delta opioid receptors.
INTRODUCTION
To contribute to our understanding of the molecular basis
of opioid receptor heterogeneity our laboratory has used
affinity crosslinking of iodinated human beta-endorphin
( 125I- -EndH) to membrane preparations. In previous
studies (Howard et al. 1985) two major peptide bands were
.
identified by autoradiography of SDS-PAGE gels namely a 65
kDa peptide which displayed mu characteristics and a 53
kDa peptide which displayed delta characteristics. The
assignment of mu or delta characteristics was based on
differential displacement by the highly mu-selective
ligand Tyr-D-DAla-Gly-MePhe-Gly-ol(DAGO) or by the highly
delta- selective ligand [D-Pen2-D-Pen5]-enkephalin (DPDPE)
and on the distribution and levels of the 65 kDa and 53
kDa peptides in membranes having various mu:delta ratios
(Howard et al. 1985, 1986).
In order to further support these findings, we have
studied the specific labeling pattern of opioid receptor-
related peptides in two cell lines, NG-108-15 which
contains exclusively delta binding sites (Klee and
Nirenberg 1974) and SK-N-SH which contains mainly mu
binding sites (Yu et al. 1986).
MATERIALS AND METHODS
The SK-N-SH cell line was a gift of Dr. W. Sadee
(University of California, San Francisco). The NG-108-15
cell line was a gift of Dr. A.J. Blume (Hoffman-La Roche).
1 2 5I- -EndH (2,000 Ci/mmol) was purchased from Amersham
and 3H-bremazocine (30 Ci/mmol) was obtained from NEN.
Bis [2-(succinimidooxycarbonyloxy)ethyl]sulfone (BOSCOES)
was from Pierce Chemical Corp, electrophoresis chemicals
were from Bio-Rad.
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Cell cultures - SK-N-SH cells were grown in RPMI 1640
medium supplemented with 10% fetal calf serum, 40 U/ml
penicillin and 40 U/ml streptomycin. NG-108-15 hybrid
cells were grown in Dulbecco' s modified Eagle's medium
(DMEM) containing HAT (0.1 mM hypoxanthine, 1 uM
aminopterin, 16 uM thymidine), supplemented with 10% fetal
calf serum, 1 mM sodium pyruvate, 40 U/ml penicillin and
40 U/ml streptomycin.
Membrane preoaration At confluency the SK-N-SH cells were
washed and harvested by mechanical agitation in a Ca++
Mg++-free phosphate buffered saline containing 0.04% EDTA.
After 10 min centrifugation at 1,000 x g, the cells were
homogenized in 50 mM Tris-HCl buffer pH 7.4 containing 1
mM EDTA. The homogenate was spun at 20,000 x g for 20 min
at 4°C and the resulting pellet was resuspended in 0.32 M
sucrose and stored at -70°C. At confluency, the NG-108-15
cells were washed and then harvested by mechanical
agitation in DMEM medium. After centrifugation at 1,000 x
g for 10 min, the cell pellet was washed with 25 mM Tris-
HCl buffer containing 290 mM sucrose, 1 mg/ml BSA and 0.1
mg/ml bacitracin and stored at -70°C. Membranes were
prepared, as described above, freshly before each
experiment,
0.2 mM PMSF,
in K2HP04 buffer pH 7.4 containing 1 mM EDTA,
10 ug/ml leu-peptin and 50 ug/ml bacitracin.
Affinity crosslinkinq - Membranes prepared from both cell
lines were diluted 4 fold (approx. 0.5 mg/ml) in K2HP04
buffer pH 7.4 containing protease inhibitors (see above).
125I- - EndH (1 nM) was bound and crosslinked to the mem-
branes by the crosslinking reagent BOSCOES (1 mM) as des-
solubilized membranes were subjected to SDS-polyacrylamide
by Howard et al. (1985). The crosslinked
gel electrophoresis (PAGE) and autoradiography of the gels
was performed [Howard et al. 1985).
RESULTS
Yu et al. (1986) have shorn by saturation binding experi-
ments that the human neuroblastoma cell line SK-N-SH con-
tains mainly mu opioid binding sites (mu:delta ratio 5:l).
Similar results were obtained by us in competition experi-
ments with the mu-selective ligand DAGO and the delta-
selective ligand, DPDPE against 3H-bremazocine. When
crosslinking of 125I- -EndH to membranes prepared from SK-
N-SH cells was performed, 3 major bands were visible after
gel-electrophoresis of the solubilized membranes and
autoradiography of the gel, a large peptide band which
corresponds to molecular weight 65 kDa and two narrow
bands of 92 kDa and 25 kDa (Fig. 1).
All three peptide bands are opioid receptor related since
they are eliminated when binding of 125I- -EndH to the
membranes is conducted in the presence of 3 uM naloxone.
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Crosslinking of 125I- -EndH to membranes prepared from NG-
108-15 cells, which contain exclusively delta opioid
binding sites, revealed a different labeling pattern of
peptides. Two major peptide-bands were observed,
corresponding to molecular weights of 53 and 25 kDa
(fig.1). Both peptides are opioid
their labeling was reduced when binding of 125I- -EndH
receptor-related, as
was conducted in the presence of 3 uM naloxone.
FIGURE 1. SDS-PAGE of NG-108-15 or
membranes crosslinked with 125I- -EndH. A. Binding
SK-N-SH cell
of 125I- -EndH was carried out in the absence or
presence of DAGO (20 nM, 50 nM). B. Binding of 125I-
-EndH was carried out in the absence or presence of
20 nM DPDPE.
In order to label selectively peptides containing mu or
delta opioid binding-sites, membranes prepared from both
cell lines were bound with 125I- -EndH in the presence of
20 nM and 50 nM of the mu-selective ligand DPDPE. Fig. 1A
presents the labeling patterns observed when binding of
1 2 5I- -EndH was carried out in the presence of DAGO.
While DAGO, up to a concentration of 50 nM, had no effect
on the labeling of the peptides derived from the NG-108-15
cells, labeling of the 65 kDa peptide, and to a lesser
extent, the 92 kDa peptide, derived from SK-N-SH cells was
reduced.
when binding of 125I- -EndH was performed in membrane
Fig. 1B presents the labeling patterns observed
preparations from both cell lines in the presence of
DPDPE. As shown, DPDPE displaced the labeling of both 53
kDa and 25 kDa peptides, derived from NG-108-15 cells,
while it had no effect on the labeling of peptides derived
from SK-N-SH cells.
91
DISCUSSION
The labeling patterns observed after crosslinking of these
two cell lines with 125I- -EndH were different. In NG-
108-15 cells, two major peptides were labeled,
corresponding to molecular weights of 53 kDa and 25 kDa.
Both peptides displayed delta characteristics, i.e., their
labeling was reduced by DPDPE but not by DAGO. In  SK-N-SH
cells, three major peptides were labeled by 125I- -EndH
corresponding to molecular weights of 92, 65 and 25 kDa:
The labeling of the 65 kDa peptide, and to a lesser
extent, the 92 kDa peptide, was reduced by DAGO but not by
DPDPE.
When 125I- -EndH was crosslinked to membranes prepared
from different brain regions of various species by Howard
et al. (1985,1986), 2 major peptides were labeled, a 65
kDa and a 53 kDa peptide, which displayed mu and delta
characteristics respectively. Our present results confirm
these findings. The major peptide labeled in SK-N-SH
cells was a 65 kDa peptide, while a 53 kDa peptide was
labeled in the NG-108-15 cells. Two other peptides were
also labeled in SK-N-SH cells. The labeling of both
peptides was eliminated by an excess of naloxone.
However, only the labeling of the 92 kDa peptide was
affected by DAGO. The identity of these peptides is not
clear. The 92 kDa peptide may represent a lower-affinity
binding site for mu-selective ligands. In agreement with
previous results (Howard et al. 1985), in NG-108-15 cells
a 25 kDa peptide was labeled in addition to the 53 kDa
peptide. Preliminary results suggest that this peptide
may be a breakdown product of the 53 kDa peptide, but
more experiments are needed to confirm this finding.
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ABSTRACT
Rats treated chronically with morphine were found to have an
increased number of mu-noncompetitive delta binding sites. The
increase in the Bmax was 39% and the enhancement was blocked hy
pre-incubation in 50 mM Tris. pH 7.4 with 400 mM NaCl for one hour at
25oC. These findings are' .consistent with the removal of newly
manifested binding sites being a specific property of sodium, by
analogy with previous studies where sodium has been shown to extract
extrinsic proteins from red cell ghosts.
INTRODUCTION
We have previously shown that mu-noncompetitive delta binding sites
were upregulated after chronic morphine treatment (Rothman et al.
1986). These results were obtained in membranes that were not
pre-incubated in high concentrations of sodium, a technique reported
by Pasternak et al. (1975) to remove any endogenous ligand bound to
the opiate receptor.
The present studies were performed to investigate the possible effect
of pre-incubation,
hour at 25°C,
in 50 mM Tris, pH 7.4 with 400 mM NaCl for one
on the binding parameters of the two delta binding
sites in rats treated chronically with morphine. In these studies
pretreatment with the site-directed acylating agents, BIT
(1-[2-(diethylamino)-ethyl]-2-(4-ethoxybenzyl)-5-isothiocyanato--
benzi-midazole) and FIT (N-[1-[2(4-isothiocyanatophenyl]-
4-piperi-dinyl]-N-phenyl-propanamide) were used to enrich membranes
with the mu-competitive or mu-noncompetitive delta binding sites
respectively (Rothman et al. 1984).
MATERIAL AND METHODS
Male Sprague-Dawley rats (200-250 g; Zivic-Miller Labs., Allison
Park, PA) were acclimatized for six days. They were then implanted
with 2 morphine pellets (75 mg) on day 1 and 4 morphine pellets on
day 2 (Holaday et al. 1982). The rats were rapidly decapitated on
day 5, exactly 96 hours after the first implantation. A control
group of rats were implanted with placebo pellets with precisely the
same protocol.
A lysed mitochondrial P2 membrane preparation was made, by
differential centrifugation, using the whole rat brain (minus
cerebellum) following a modified method of Gray and Whittaker (1962).
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The mitochondrial pellet was split into two aliquots; one aliquot was
incubated in 50 mM Tris, pH 7.4 with 400 mM NaCl for one hour at
25°C, while the other was kept on ice. The pre-incubated pellet was
centrifuged at 4825 xg for 15 minutes and the pellet resuspended in
ice-cold Tris, pH 7.97. This washing step (resuspension and
centrifugation) was repeated three times, in total, to ensure that
all sodium ions had been removed. After this point both aliquots
were treated identically.
The pellets were then treated with
(1 µM) for one hour at 25°C in 0.01
the acylating agents, BIT and FIT
M MOPS (3-(N-Morpholino)pro-
panesulphonic acid) and 3 mM MnCl2. The pellets were centrifuged and
resuspended, as they were after the sodium pre-incubation. The final
pellet was resuspended in 0.75 ml/g original weight of Tris, pH 7.97.
Tritiated D-ala2-D-leu5-enkephalin was used as the ligand in the
binding assays. The incubation medium contained 10 mM Tris, pH 7.4,
100 mM choline chloride and 3 mM MnC12. [
3H]DADL was added to the
assay in a protease inhibitor cocktail, which consisted of bacitracin
(0.1 mg/ml), Leupeptin (0.004 mg/ml), chymostatin (0.002 mg/ml),
bestatin (0.01 mg/ml), Captopril (1 µg/el), 2-mercaptoethanol (1 mM)
and phosphoramidone (1 pM).
'Binding surfaces' were used (Rothman et al. 1985), to describe the
binding sites. For both washed and control membranes, complete
saturation curves (0.25 nM to 95.6 nM) were constructed using
isotopic dilution; the Kd and Bmax were determined using computer
curve fitting methods.
RESULTS
The results set out in table 1 are from studies carried out in
membranes that had been pre-incubated in 50 mM Tris, pH 7.4 with 400
mM NaCl at 25°C for one hour. It should be noted that there is no
increase in the Bmax in either of the delta binding sites when rats
receive chronic morphine treated (n=3), although there were
significant increases in the dissociation constants of both the
mu-noncompetitive delta binding sites.
TABLE 1: The effect of Morphine tolerance on the two [3H]DADL.
binding sites in membranes that have been pre-incubated with 50
mM Tris, pH 7.4 and 400 mM NaCl for 1 hr at 25°C.
K d SD B m a x SD
(Nm) (fmol/mg prot)
MU-COMPETITIVE
(BIT-treated) Placebo 0.74 0.08 72 4
Tolerant 1.02 0.09 72 4
% of Control 158* 100
MU-NONCOMPETITIVE
(FIT-treated) Placebo 4.3 0.2 86 7
Tolerant 6.8 0.4 97 14
% of Control 158* 113
*P <0.05, n=3
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The results of the studies with membranes that were not greincubated
in 50 mM Tris, pH 7.4 with 400 mM NaCl for one hour at 25°C are shown
in table 2. The Bmax of the mu-noncompetitive delta binding sites in
morphine pre-treated rats was significantly elevated (39%) above the
controls. In contrast, the Bmax of the mu-competitive delta binding
site was not significantly altered. The dissociation constants of
both the mu-competitive and the mu-noncompetitive delta binding sites
were significantly increased (52% and 111%, respectively).
TABLE 2: The effect of chronic Morphine treatment on the two
[3H]DADL binding sites in membranes that have not been
pre-incubated with 50 mM Tris, pH 7.4 and 400 mM NaCl for 1 hr at
25 C.
K d S D
(Nm)
B m a x S D
(fmol/mg prot)
MU-COMPETITIVE
(BIT-treated) Placebo 0.92 0.08 64 4
Tolerant 1.4 0.1 55 5
% of Control 152* 86
MU-NONCOMPETITIVE
(FIT-treated) Placebo 3.6 0.2 76 5
Tolerant 7.6 0.4 106 ll
% of Control 211* 139”
*P <0.05, n=3
DISCUSSION
The findings of this study demonstrate that our regime of chronic
morphine administration results in a significant increase in the
number of mu-noncompetitive delta binding sites, an increase which is
not seen when brain membranes are pre-incubated in 50 mM Tris, pH 7.4
with 400 mM NaCl for one hour at 25°C. In contrast, the elevation in
the dissociation constant for both delta binding sites was present,
regardless of whether or not the membranes were pre-incubated.
Our previous work (Rothman et al. 1986) indicated there was an
increase in the number of mu-noncompetitive binding sites after-
chronic morphine treatment compared with rats not so treated. While
earlier studies (Klee and Streaty 1974) failed to find any
significant alteration in opioid binding parameters following chronic
morphine treatment, these studies used mu-selective radioligands, and
therefore the findings primarily concern the mu binding sites. There
are also reports in which [3H]DADL, the specific delta ligand, was
used in studies on membranes from chronically morphinized animals
(Holaday et al. 1982). These authors found that there was an
increase in the number of delta binding sites.
The experimental finding that pre-incubation in high sodium for one
hour was not followed by an increase in the Bmax of the
mu-noncompetitive delta binding site appears worthy of discussion.
Since the report by Pasternak et al. (1975) that pre-incubation of
membranes in sodium removed endogenous ligand bound to the opiate
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receptor, this step has become an integral part of the preparation of
brain membranes for radioligand assay, despite the fact that the
range of radioligands have increased. The decrease in the number of
binding sites with pre-incubation may be explained by the finding
that the sodium ion reportedly extracts extrinsic membrane proteins
as has been shown for red cell ghosts (Capaldi 1972). This effect of
pre-incubation in high sodium upon delta opiate binding sites will
thus be investigated further, using appropriate biochemical
techniques. It is possible that these sodium-labile binding sites
may be different biochemically from those unaffected by the sodium
preincubation.
In summary, our findings are that chronic morphine treatment
upregulates the mu-noncompetitive delta binding site, and that this
upregulation can be blocked by pre-incubation in a high sodium
medium.
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ABSTRACT
Possible interactions between µ- and receptors in the rat spinal
cord were studied using the radiant-heat-induced tail flick response
and the highly selective µ- or ligands: [NMePhe3,D-Pro4]
morphiceptin(PL-17) and cyclic[D-Pen2,D-Pen5]enkephalin(DPDPE).
Intrathecal infusions of PL-17(0.5µg/hr) for 5 days caused 61- and
6-fold shifts to the right of the dose-response curves for PL-17 and
DPDPE, respectively. Since PL-17 and DPDPE are highly selective
agonists for µ- and receptors, the partial cross-tolerance to the
agonist induced by PL-17 is probably not resultant from a
cross-reactivity between these ligands. These data suggest that
there may be an interaction between µ- and receptors in the rat
spinal cord.
INTRODUCTION
Several opioid receptor types and subtypes as well as their
endogenous opioid peptide ligands comprise complex pharmacologic
systems (Chang 1986). Despite the heterogeneity of these opioid
systems and a wide spectrum of biologic activities ascribed to them,
clinical interactions with opioid receptors are predominantly for
analgesia. The speculated roles of the endorphins in a variety of
physiologic and disease states are becoming more easily testable
with the development of highly receptor-specific ligands.
Such ligands are also powerful tools for examining the biochemical
nature of opioid receptor systems. For example, interactions
between opioid receptor types have recently been suggested by data
from D'Amato and Holaday (1984) and Rothman et al. (1985). Such
interactions, if present, may complicate the pharmacology of opioid
agonists' cross-reactivities. In order to relate the issues of
tolerance and cross-tolerance to the concept of µ- receptor
interactions we used two highly specific µ- or agonists: PL-17
(Chang et al. 1983) and DPDPE (Mosberg et al. 1983).
This study examines the cross-reactivity between these two highly
receptor-selective opioids by employing an assay of spinal analgesic
activity and a paradigm for inducing chronic opioid tolerance at the
rat spinal cord level. The µ- versus selectivity of our ligands
has allowed us to speculate regarding the mechanisms of ligand
cross-reactivities.
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MATERIALS AND METHODS
Materials
The following ligands were used: [N-Methyl-Phe3,D-Pro4]morphiceptin
(PL-17), a highly specific µ-agonist (Chang et al. 1983); cyclic
[D-Penicillamine2, D-Penicillamine5]enkephalin(DPDPE), a highly
specific agonist (Mosberg et al. 1983); funaltrexamine(R-FNA),
an irreversible µ-antagonist (Takemori et al. 1981) and naloxone
HCl, a competitive, relatively selective µ-antagonist. Ligands were
prepared in normal saline and diluted such that bolus doses equalled
twenty microliters.
Methods
400 gram male Sprague-Dawley rats had two polyethylene lo-gauge
catheters passed to the lumbar enlargement via the atlanto-occipital
membrane, following the technique of Yaksh and Rudy (1976). The
nociceptive assay was the tail-flick response to a radiant-heat
source beneath the tail (D'Armour and Smith 1941). The mean base-
line latency response was 4 seconds: the cut-off time was 10 sec-
onds. Each rat was tested 4-6 times over 6 minutes--beginning 30
minutes after intrathecal test doses. Tail-flick data were con-
verted to maximum percent effects (MPE): (latency-response - base-
line/cut-off - baseline) x 100. Responses of each rat were averaged
and a mean MPE was calculated based upon N=6-8 rats at each dose.
Spinal opioid tolerances were induced by infusing PL-17 (0.5 µg/µl)
intrathecally at 1 µl/hr for 5 days using subcutaneously implanted
osmotic pumps. Tolerance assessments were performed using the
second catheter while pumps were still attached. The dose-response
curve for PL-17 following a 5-day infusion of normal saline was not
shifted from the baseline curve for PL-17 (Figure 1). Scarcity of
materials precluded a similar vehicle-infusion control for DPDPE.
ED50's were calculated from the linear regression equations.
Dose-response curve shifts are reported as the ratios of
after-to-before treatment ED50 values. ED50's whose 95% C.I.'s do
not overlap are significantly different at the P<.05 level. Tests
of the null hypothesis, Ho=homogeneity of slopes, (conducted at
P<.05) for before- and after-treatment dose-response curves
indicated that all dose-response curve shifts were parallel.
RESULTS
Both PL-17 and DPDPE given as acute lumbar-intrathecal bolus doses
elicited antinociceptive effects. However, DPDPE was much less
potent and exhibited a flatter dose-response curve than PL-17
(Figure 1). The ED,, values were 0.06 µg (95% C.I., 0.05-0.07) and
3.56 µg (2.64-4.90) for PL-17 and DPDPE, respectively. Their µ- and
receptor selectivities were confirmed by the relative potencies of
naloxone or FNA in antagonizing their analgesic effects. The
doses of i.p. naloxone required to reduce the effects of an ED,,
dose of PL-17 or DPDPE to 50 percent effectiveness were 0.09
(0.08-0.11) and 2.71 (1.81-4.34) mg/kg, respectively, This differ-
ence is about 30-fold.
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Sixty hours following a 2.3 µg intrathecal FNA pretreatment
(Figure 1) the dose-response curve for PL-17 was shifted parallel
and to the right 25-fold. PL-17-ED50 values before and after FNA
were 0.06 µg (0.05-0.07) and 1.50 µg (1.09-l-98), respectively.
FNA pretreatment had no significant effect upon the DPDPE
dose-response curve. DPDPE-ED50 values before and after FNA were
3.56 µg (2.64-4.90) and 5.65 µg (4.04-8.64), respectively. These
data suggest that PL-17 and DPDPE elicit antinociceptive effects
through µ- and receptors, respectively.
A chronic PL-17 infusion of 0.50 µg/hr for 5 days (Figure 2)
effected a parallel and right shift of the PL-17 dose-response
curve: ED50 after infusion, 3.65 µg (2.71-5.19)/ED50 before
infusion, 0.06 µg (0.05-0.07)--a 60.8-fold parallel shift.
Cross-tolerance to the highly selective agonist DPDPE was smaller
but significant at the P<.05 level: ED,, after infusion, 21.00 µg
(17.88-26.57)/ED50 before infusion, 3.56 µg (2.64-4.90)--a 5.9-fold
parallel shift.
DISCUSSION
The existence of some cross-tolerance between opioid agonists with
differing receptor-selectivities may be explained by cross-
reactivities of the compounds examined. However, the affinity of
PL-17 to receptors is 2000 times less than to µ-receptors (Chang
et al. 1983). The hourly infusion dose of PL-17 in this experiment
was only eight times a baseline PL-17 bolus-ED,, dose. It appears
unlikely that the partial cross-tolerance to DPDPE induced by PL-17
resulted from cross-reactivity of PL-17 to receptors. Further-
more, PL-17 has been shown to exert its activity via the µ-receptor
even in a receptor dominated tissue, the isolated mouse vas
deferens (Chang et al. 1983). Since the affinity of DPDPE to
receptors is at least 300 times greater than to µ-receptors
(Mosberg et al. 1983) and there is no FNA treatment effect upon
DPDPE-induced analgesia and the potency of naloxone against DPDPE is
30-times lower than that against PL-17, it is unlikely that DPDPE
interacts with µ-receptors at doses employed in this study.
These data suggest that the PL-17 infusion caused an interaction
between µ- and receptors resulting in a partial cross-tolerance to
DPDPE. This finding supports similar µ- receptor interactions
described in rat brain membrane receptor-binding studies by Rothman
et al. (1985) and postulated for an in vivo system from endotoxic
shock experiments in rats by D’Amato and Holaday (1984). The nature
of this µ- receptor interaction remains to be explored. The
suitability of spinal tissues for use in biochemical studies and the
in vivo nature of this model offer significant opportunities for
correlating the cellular biology of opioid receptor systems with
physiologic parameters.
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FIGURE 1. Analgesic dose-response curves for PL-17 and
DPDPE Depicted is the curve for PL-17 and the data
points for DPDPE 60 hours following µ-receptor antagonism
with a 2.3µg i.t. bolus dose of FNA.
FIGURE 2. Analgesic dose-response curves: baseline curves for
PL-17 and DPDPE Depicted are the curves for PL-17
and DPDPE following 5 day i.t. infusions of PL-17, 0.5 µg/hr
and the data points for PL-17 following a vehicle-control
infusion
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ABSTRACT
The electrophysiological actions of normorphine and dynorphin-A
were compared in the dentate gyrus and CA1 regions of the rat
hippocampus. In both regions, these opioids increased cell
excitability and induced afterpotentials following electrical
stimulation of synaptic afferents. Based upon apparent naloxone
dissociation constants, we conclude that normorphine activated µ
receptors in both regions. However, dynorphin-A appears to act via
µ receptors in CA1, but receptors in the dentate gyrus.
INTRODUCTION
High concentrations of opioid peptides have been detected in the
dentate region of the hippocampus, suggesting that this brain
region is a likely site of endogenous opioid action (McGinty et al.
1983, Chavkin et al. 1985b). µ, and binding sites have been
detected throughout the hippocampus (Zamir et al. 1985), and opioid
receptor mediated actions in the different hippocampal regions are
beginning to be described. In CA1, opioids have been found to
increase the excitability of pyramidal cells, probably by reducing
the inhibitory effects of GABAergic interneurons (Zieglgansberger
et al. 1979). The role of opioids in the dentate region was
previously studied (Tielen et al. 1981; Linseman and Corrigall
1982). To further characterize the potential sites of endogenous
opioid action, we have compared the receptor types mediating the
effects of opioids in the CA1 and dentate regions of the rat
hippocampus.
MATERIALS AND METHODS
Hippocampal slices (500 µm) were prepared from Sprague-Dawley rats
(150-250g) using methods previously described (Siggins and Schubert
1981). Extracellularly recorded responses were evoked by
stimulation of the dorsal blade of the dentate gyrus with a
concentric bipolar electrode placed in the center of the outer
molecular layer at least 400 µm away from the recording electrode
and recorded in the stratum granulosum using glass microelectrodes
(l-2 µm tip, 4-10 Healthy responses in the dentate granule
cell layer were typically 3-5 mV without afterpotentials even at
supramaximal stimuli (figure 1A). CA1 pyramidal cell responses
were similarly evoked and recorded as described (Chavkin et al.
1985a). Responses recorded in the cell body layers are likely to
be due to the orthodromic activation of presynaptic inputs as the
evoked responses were blocked by the addition of 10 mM MgC12 to the
superfusion buffer (data not shown).
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RESULTS AND DISCUSSION
Dynorphin-A(1-17) (DYN) and normorphine (NM) were applied to the
tissue either by bath superfusion (0.01-10 µ) or by a pressure
micropipette (100 µM in 10 mM HEPES buffered saline, pH 7.4) placed
near the recording site. The effect of DYN delivered by pressure
pulse in the dentate region is shown in figure 1B. DYN and NM had
identical actions.
Figure 1. DYN increased cell excitability in the dentate
granule cell layer. Each response in A, B, and C was
evoked by a near maximal stimulus; arrows mark the
primary spike and asterisks mark the afterpotential. A)
control. B) 100 µM DYN was delivered by pressure pipette
(80 msec, 275 KPa) 10 sec prior to electrical
stimulation. C) DYN was delivered (as in B) in the
presence of 500 nM NAL. D) stimulus-response curve of
the primary population response before and during DYN
exposure (1 sec, 275 KPa).
The response to opioids was similar but not identical in the CA1
and dentate regions. As has been previously reported, opioids
induced both afterpotentials (APs) and a profound reduction in the
threshold for electrically stimulated primary spikes in the CA1
region. In the dentate region opioids did not effect the threshold
for primary spikes, but consistently induced APs (figure 1A-C). In
CA1 only sigmoidally shaped stimulus-response (S/R) curves were
observed; whereas, dentate S/R curves were either sigmoidal or
biphasic, depending on the precise placement of the stimulating
electrode. An example of a biphasic S/R curve is shown in figure
1D. When the dentate responses demonstrated biphaaic S/R curves,
opioids induced a change from a biphasic to a sigmoidal shape
(figure 1D). We presume that the biphasic response is due to the
activation of inhibitory pathways at higher stimulation
intensities. Differences in the nature of the opioid responses
between the CA1 and dentate region are likely to reflect
differences in synaptic circuitry.
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Figure 2. The amplitude of the afterpotential induced by
DYN was measured in the dentate region. Log
dose-response curve for DYN (100 µM, 275 KPa) and
DYN in the presence of 100 nM NAL In this example
the NAL Ki value was 55 nM.
NAL (1 µM) completely blocked DYN and NM effects in both regions.
Apparent equilibrium dissociation constants (Ki) for NAL were
determined by Schild analysis at several NAL concentrations
(Arunlakshana and Schild 1959). We used bath application of NAL
(10-100 nM) while applying DYN or NM by pressure pipette (100 µM,
140-275 KPa) and measured the change in AP amplitudes. NAL caused
a parallel shift in the DYN sensitivity (figure 2); DYN sensitivity
returned to control levels following washout of NAL for 30-60 min.
The NAL Ki value for NM in CA1 was 2.7 0.3 nM (n=3) and 2.2 1.6
nM (n=4) in the dentate region (figure 3). These values are not
significantly different (p>0.5, Wilcoxon rank sum test), and
suggest the presence of µ receptors in both regions (Lord et al.
1977). The NAL Ki value for DYN in CA1 was 5.2 1.8 nM (n=3) and
32 11 (n=4) in the dentate gyrus. The NAL Ki value for DYN in
CA1 is not statistically different from the value for NM,
suggesting that DYN may also act at µ receptors in CAl. This
result is in agreement with our previous finding that
funaltrexamine, a µ-selective irreversible antagonist, inhibits
NM and DYN but not DADLE action in CA1 (Chavkin et al. 1985a). In
contrast, the NAL Ki value for DYN is significantly larger than the
value for NM in the dentate region (p<0.05), suggesting that DYN
acts at different receptors than NM in this region, presumably via
receptors. Therefore, although DYN is active in both the CA1
and dentate regions, it appears to act via different receptors in
these regions.
[D-Ser2,Leu5,Thr6]enkephalin and [D-Pen2,L-Pen5]enkephalin show
Preliminary studies using the selective peptides
that receptors exist in both the CA1 and dentate region and cause
very similar responses to those produced by NM and DYN.
The demonstration of opioid receptor mediated effects and the
detection of endogenous opioids in the dentate region support the
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Figure 3. NAL Ki values for NM and DYN in the CA1 and
dentate regions.
hypothesis that endogenous opioids may be neurotransmitters at this
site. In addition, the presence of receptors suggests that
dynorphin may be released locally in the dentate gyrus. The
excitatory actions of opioids in the dentate gyrus imply that
opioids act via presynaptic disinhibition as has been shown in the
CA1 region, although the synaptic circuitry is likely to differ.
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ABSTRACT
Delta and kappa opioid receptors have been characterized in the central ear
artery of the rabbit. The selective D-Pen2,D-Pen5-enkephalin and the highly
selective antagonist ICI 174864 have been used for the opioid receptors. Ke
values were determined and compared to that of the electrically stimulated
mouse vas deferens preparation. In case of opioid receptors, Dynorphin (1-13)
and Ethylketazocine were used as agonists and Mr 2266 as antagonist. Because
of the relatively low selectivity of the antagonist (it is only twice as active at
the than at the µ receptor sites) the Ke values obtained in the rabbit ear
artery were compared to both the normal and beta-funaltrexamine treated vasa
deferentia. In the rabbit ear artery, the K2 values of Mr 2266 were also
determined in the presence of the selective antagonist ICI 174864. The Ke
values for the receptors were close in the two assay systems, suggesting that
the receptors have similar properties in rabbit ear artery and mouse vas
deferens. As for the receptors, the Ke values in the rabbit ear artery were not
significantly different in the presence or absence of the antagonist compound,
nor were they different from the Ke values obtained on the normal mouse vas
deferens. However, they were significantly different from that of the
funaltrexamine treated mouse vas deferens. Further experiments need to be
done to interpret the meaning of these results.
INTRODUCTION
Since the introduction of the isolated central ear artery of the rabbit (De la
Lande and Harvey 1965) it has been widely used as a pharmacological tool to
study the perivascular sympathetic neurotransmission. After the discovery that
some opioid peptides inhibit the electrically induced vasoconstriction of the
rabbit ear artery (REA) (Knoll 1976) much work has been done to investigate the
mode of action and characterize the opioid receptors present in this tissue (Illes
et al. 1983, Illes et al. 1985, Illes and Bettermann 19861. It has been established
that the postganglionic sympathetic neurons innervating the rabbit ear artery
possess inhibitory presynaptic receptors of the and but not of the µ subtypes.
In our present study we characterized the and opioid receptors with the help
of selective agonists and antagonist and the results obtained were compared to
that of the mouse vas deferens (MVD).
METHODS
Rabbit ear artery (REA). Male rabbits of 2.5-3 Kg weight were decapitated, and
the proximal 3 to 4 cm of the central ear artery was dissected. The arteries
were cleaned with the help of a dissecting microscope and cannulated at both
ends. To prevent longitudinal displacement, both cannulae were tightly fixed.
The vessels were perfused with Krebs solution at a steady rate of 2.4-2.6 ml/min
by means of a multichannel peristaltic pump. The perfusion pressure was
determined with a Statham P23 Db transducer and potentiometric recorder. The
preparation was equilibrated for 60 min before the beginning of electrical
stimulation. The platinum electrodes were placed at the top and the
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bottom of the tissue-bath. A Grass S-88 electrostimulator was used for field
stimulation. The parameters of stimulation were as follows: short trains (5 HZ,
5 shocks) of supramaximal rectangular pulses of 1 msec duration were delivered
every minute. The composition of Krebs solution used was as follows (in mM):
NaCl, 118; KCl, 4.8; CaC12, 2.5; KH2PO4, 1.2; NaHCO3, 25; MgS04, 1.2 and
glucose 11.5. It was saturated with 95% O2 5% CO2 and kept at 37°C. The
agonists were added extraluminally into the tissue-bath, while the antagonists
were present both extra and intraluminally. The tissue was incubated for at
least 60 min with the antagonist.
Mouse vas deferens (MVD). Swiss Webster mice of 30-35 g weight were used.
The vasa deferentia were prepared according to Hughes et al. (1975) and bathed
at 31°C in Mg2+-free Krebs solution, bubbled with a mixture of 02 and CO2
(95:5). An initial tension of 100-150 mg was used. The experiments were carried
out in an organ-bath of 10 ml capacity. The parameters of field stimulation
were slightly modified (Ronai et al. 1977). Paired shocks with 100 msec delay
between the supramaximal rectangular pulses of 1 msec duration were used,
delivered at a rate of 0.1 Hz. Contractions were recorded using an isometric
transducer (Statham UC2) and potentiometric recorder. In order to eliminate
the µ receptors present in this preparation, the highly selective non-equilibrium
µ antagonist, -funaltrexamine (Takemori et al. 1981, Ward et al. 1.982) was
added into the tissue-bath for 30 min in the concentration of 2 x 10-7 M.
In kinetic studies complete dose-response curves were determined in the absence
and presence of antagonist. The antagonist activities were expressed in terms of
Ke (dissociation equilibrium constant) values (Kosterlitz and Watt 1968). The
antagonism was designated as competitive if it met the criteria proposed by
Arunlakshana and Schild (1959).
RESULTS AND DISCUSSION
Ke values are listed in table 1 for different agonists with the selective opioid
receptor antagonist ICI 174864 in rabbit ear artery and mouse vas deferens
preparations. The  resul ts  show that Leu-enkephalin and D-Pen2 ,
D-Pen5-enkephalin (DPDPE) act on relatively homogenous receptor population in
both systems and that the receptors are similar in these two tissues.
TABLE 1. Comparison in MVD and REA of Ke values for the selective
antagonist, ICI 174864, using three different agonists
AGONISTS MOUSE VAS DEFERENS RABBIT EAR ARTERY
Ke (nM) Ke (nM)
MET-ENKEPHALIN 43.3 7.1 40.0 12.0
(16) (11)
LEU-ENKEPHALIN 17.5 3.1 12.3 2.5
(9) (9)
DPDPE 17.0 1.8 12.9 3.5
(10) (10)
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To characterize the opioid receptors, Ke values were determined in "normal"
and -funaltrexamine ( -FNA) treated vasa deferentia for Dynorphin (1-13)
and Ethylketazocine with the non-selective receptor antagonist Mr 2266. The
significantly different Ke values (table 2) in the “normal” and “µ -less” MVD are
in good agreement with results of binding studies (Kosterlitz et al. 1981,
Paterson et al. 19831, which proved that Dynorphin (1-13) and Ethylketazocine as
well as Mr 2286 partially act on µ receptor sites.
TABLE 2.  Comparison o f  K e  va lues  o f opioid agonists with
non-selective  antagonist compound (Mr 2266) on “normal” and
-funaltrexamine treated mouse vas deferens preparations.
AGONISTS Ke (nM) and Schild slope
on "normal" MVD on -FNA MVD
DYNORPHIN (1-13) 3.86 0.4 -0.875 1.94 0.2 -0.979
(12) (8)
ETHYLKETAZOCINE 2.28 0.1 -0.925 0.63 0.1 -0.766
(6) (6)
According to the results obtained in the -FNA treated vasa deferentia, we
expected similar data on REA, which is known to contain only and receptor
subtypes. Surprisingly enough, the Ke values were (table 3) similar to the ones
obtained in the “normal” MVD. To eliminate the possible interaction of the
compounds with the receptors, the experiments were repeated in the presence
of 2 x 10-7 M ICI 174864.
TABLE 3. Characterization of the opioid receptor in the rabbit ear
artery with Mr 2266 in the presence and absence of ICI 174864.
AGONISTS Ke(nM) Schild slope Ke (nM) Schild slope
(in the presence of 2 x 10-7M
ICI 1748641
DYNORPHIN (1-13) 3.88 0.5 -0.98 3.49 1.1 -1.08
(8) (6)
ETHYLKETAZOCINE 2.91 0.2 -0.97 2.62 0.2 -1.02
(3) (5)
Further experiments need to be done to understand and correctly interpret the
data obtained for the receptors.
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A COMPARISON OF MICROSOMAL AND SYNAPTIC SITE BINDING KINETICS
James W. Spain, Dulcy E. Petta and Carmine J. Coscia
E.A. Doisy Department of Biochemistry
St. Louis University School of Medicine
1402 S. Grand Blvd., St. Louis, MO 63104, U.S.A.
ABSTRACT
High-affinity binding of the agonist, [3H]D-ala2-D-leu5-enkephalin
(DADLE), to sites on bovine hippocampal synaptic plasma membranes
(SPM) entails a multi-step association process. Microsomal binding
sites, which are thought to originate from internal membranes (golgi,
ser, etc.), display kinetic patterns that differ from SPMs. This is
evidenced by the absence of an association time dependent rate of
dissociation from microsomal binding sites. Although high affinity
steady state binding of agonists to microsomes occurs, kinetic
analysis indicates little or no formation of the high affinity slowly
dissociating complex. This slowly dissociating complex of SPMs is
most sensitive to guanine nucleotides. Consequently, the effect of
Gpp(NH)p on dissociation is significantly less for microsomes.
INTRODUCTION
We had previously demonstrated that agonist binding to µ and opioid
receptors displays a multi-step association while antagonists appear
to undergo simple bimolecular association (Schiebe et al. 1984). It
was determined that the dissociation rate for agonist binding is
association time dependent, i.e., a high affinity slowly dissociating
state is formed over time. The occurrence of high and low affinity
states for agonist binding was later corroborated by others using
different techniques (Law et al. 1985; Costa et al. 1985). We
postulated that the high affinity state may be linked to some aspect
of the signal-transduction functionality of the receptor such as
receptor-effector coupling. The hypothesis might be tested if a
preparation could be obtained which is composed of uncoupled
receptors.
A body of evidence has accumulated to suggest that opioid receptors
exist primarily in two subcellular pools; SPMs and microsomes (Pert
et al. 1974; Simantov et al. 1976; Smith and Loh 1976; Glasel et al.
1980; Roth et al. 1981; Klein et al. 1986). Despite their early
recognition, the functional significance of intracellular sites is
still not completely clear. We had shown that the binding
characteristics of opioid receptors on purified SPMs and microsomes
differ (Roth et al. 1981; Roth and Coscia 1984) with microsomes being
less sensitive to the effects of guanine nucleotides. These results
suggest that microsomal sites may be only partially coupled to a
guanine nucleotide binding protein. We now report an impaired
formation of a high affinity agonist state by microsomal receptors.
It is this slowly dissociating state which is most sensitive to
guanine nucleotides in SPMs and consequently there is a decreased
effect on microsomal dissociation rate.
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M E T H O D S
Subcellular fractions were prepared by sucrose density gradient as
previously described (Roth et al. 1981). Rapid filtration was used
to-quantify bound ligand while site selectivity for 3H-DADLE was
ensured by a 40 min pre-incubation of membranes with 20 nM d-Ala2-
mePhe4-Glyo15-enkephalin prior to addition of radioligand (Spain et
al. 1985). Dissociation was initiated by 1 µM DADLE.
R E S U L T S
As reported previously, the binding kinetics of 3H-DADLE to the
site in bovine hippocampal SPMs display characteristics which
suggest a multi-step association (Schiebe et al. 1984). During the
association process, there is an association time dependent formation
of a high affinity slowly dissociating state. GTP and its analogs
have been shown to increase the rate of agonist dissociation (Blume
et al. 1978; Roth et al. 1981). The effect of guanine nucleotides
appears to be limited to a transformation of the slowly dissociating
state to a lower affinity state (fig. 1A). This is demonstrated by
the profound effect of 50 µM Gpp(NH)p on the off-rate when added
following a 60 min incubation (fig. 1A) while there is little effect
on rate following a 7 min association (data not shown).
In contrast, the rate of 3H-DADLE dissociation from receptors
present on highly purified microsomes is not dependent upon
association time (fig. 1B) suggesting a less complex association
process. Although high affinity agonist binding to microsomes is
still detected (KD=0.86 0.09 nM), the formation of the high affinity
slowly dissociating state occurs to a much lesser extent, resulting
in a rate of dissociation which is similar to that seen from SPMs
after a 7 min. association period. The addition of 50 µM Gpp(NH)p at
the onset of dissociation from microsomes resulted in a modest
acceleration of the off-rate (fig. 1B).
DISCUSSION
Past work had demonstrated that differences exist between the
receptors of SPM and microsomal origin (Roth et al. 1981; Roth and
Coscia 1984). In this study, we have found that the kinetics of
agonist binding to microsomal receptors also differ from SPMs. An
association time dependency for the rate of dissociation that is
readily demonstrated for SPM receptors was not detected with
microsomes. This suggests that the association process to the site
of microsomes does not procede in the same multi-step manner which
has been shown to occur to SPMs. In specific, the time dependent
formation of the high affinity slowly dissociation state does not
occur with microsomal receptors. Interestingly, in a previous study
(Moudy et al. 1985) we suggested that crude membranes (polytron, P20)
contain vesicles which are a mixture of internal and synaptic sites.
A single receptor type found in crude membranes can, therefore, be a
heterologous population of receptors and result in confused analysis.
Several studies have reported a decreased formation of the high
affinity state of opioid receptors in preparations which have become
expermentally uncoupled from guanine nucleotide binding protein, Ni.
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FIGURE 1. Dissociation of DADLE from SPMs and microsomes.
(A) SPMs were incubated with 1 nM 3H-DADLE for 7 min or
60 min prior to dissociation with 1 µM DADLE. Binding
at 7 min was 46.0 2.6 % of the 60 min value (942 86 specific
dpm/tube). (B) Microsomes were incubated with radioligand
for 6 min or 60 min prior to dissociation with 1 µM
DADLE. Binding at 6 min was 68.9 10.2 % of the steady state
value (60 min, 652 100 specific dpm/tube). 50 µM Gpp(NH)p
was added to each preparation following a 60 min
incubation. Each line is the best fit for a bi-exponential
decay determine by non-linear regression.
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Pertussis toxin (IAP) acts through ADP-ribosylation (Katada and Ui
1982) of Ni to uncouple receptors from the inhibition of adenylate
cyclase. The uncoupling procedure can result in a receptor
population which is much less able to form agonist high affinity
binding (Hsia et al. 1984) as determined by displacement of
antagonist. Similarly, desensitization by chronic agonist treatment
can produce a uncoupled receptor population (Sharma et al. 1975;
Blasig et al. 1979) and has been shown to decrease formation of the
agonist high affinity state (Law et al. 1983).
The decreased effect of guanine nucleotides on binding to microsomes
suggests that an interaction with a GTP binding protein is less
effective in this preparation and is analogous to membranes treated
with pertusis toxin or desensitized receptors. These results argue
for the existence of at least a three step association for agonists
to SPM opioid receptors whereas microsomes display one less step,
i.e., there is no formation of the slowly dissociating high affinity
complex which is most sensitive to guanine nucleotides. Studies are
now in progress to examine this hypothesis further.
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MULTIPLE SITES OF DIVALENT CATION MODULATION
OF OPIOID RECEPTOR BINDING
Maria Szücs, Gregory M. Oetting and Carmine J. Coscia
Department of Biochemistry, St. Louis University, Medical School
1402 S. Grand Blvd., St. Louis, MO 63104
ABSTRACT
Having established differential ontogeny for rat brain µ, and
opioid receptors (Spain et al. 1985) we have examined the effect of
divalent cations on receptors during postnatal development. The
pronounced inhibition of the binding of 1 nM [3H]D-Ala2-D-Leu5-
enkephalin (DADLE) by 100 mM Na was reversed by Mn to the levels
seen in the absence of ions both in adults and in lo-day-old
neonates. Mg++ and Ca++ on the other hand were much less potent in
adults, and ineffectjve in neonates.
the presence of Na+, regulation of
These results suggest that, in
emerges subsequent to Mn++ modulation in postnatal development.
binding with Mg++ or Ca++
Dose-dependency studies in adults performed with each ion in the
presence of fixed concentrations
that while Mg++ or Ca++ antagonized stimulation of
of either of the other ions revealed
and vice versa, Mg++ and Ca++ displayed no antagonism toward each
binding by Mn++
other. Our data suggest the existence of at least two divalent ca-
tion regulatory sites for opioid receptors, one of which appears to
be specific for Mn++ and can readily be detected in the presence of
Na+.
INTRODUCTION
Previous studies from our laboratory (Wohltmann et al. 1982; Spain et
al. 1985) and from others (Coyle and Pert 1976; Leslie et al. 1982;
Tsang et al. 1982) revealed that while high affinity µ and opioid
receptors are present in rat brain at birth, receptors appear
later. Using the bis-penicillamine enkephalin derivative, [3H]DPDPE
(thought to be highly specific, Mosberg et al. 1983) authentic
binding sites in low levels were detected in the 5-day-old neonates
(Szücs et al. 1986). In this report, divalent cation modulation of
neonatal opioid receptors in the presence and absence of Na+ is
described and compared with that of adult rat brain. In adults, Na+
inhibits opioid agonist binding and divalent cations (Me++) reverse
this effect (Pasternak et al. 1975; Simon et al. 1975; Simantov et
al. 1976). Divalent cations are also known to play an important role
in the physiological action of morphine (for a review see Chapmann
and Way 1980). The results presented in this paper suggest the
development of two divalent cation regulatory sites for the
receptors.
METHODS
Rat forebrain membranes (20,000 g x 25 min) were prepared as prev-
iously described (Spain et al. 1985). Binding assays were erformed
with 1 nM [3H]DADLE (in the presence of 10 nM D-Ala2-MePhe4Glyo15-
enkephalin) in a final volume of 1 ml for 1 hr at 25°C. Nonspecific
binding was determined with 10 nM unlabeled DADLE and subtracted.
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RESULTS AND DISCUSSION
Delta receptors present in 10-day-old neonates were slightly, but
significantly, more inhibited (62 6% of control binding) by 100 mM
Na+ than those of adults (46 2%). figure 1. Manganese ion reversed
FIGURE 1: Divalent cation reversal of Na+ inhibition of 6
binding in adult (A) and 10-day-old neonate (B). Membranes
were incubated with 1 nM [3H]DADLE, 100 mM NaCl alone
or in the presence of Mn++ ; Mg++ ; or Ca++
Specific control binding (binding in the absence of ions)
was 2214 157 cpm x mg protein -1 in adult, and 763 283 cpm
x mg protein -1 in neonate. Each point is the mean S.E. of
3-7 experiments.
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FIGURE 2: Effect of Mn++ in the presence of Mg++ on 1 nM
[3H]DADLE binding.  Membranes were incubated with varying
concentrations of Mn++alone or in the presence of
2 mM or 20 mM Mg
++
(p<0.05, T-test) inhibition of the Mn effect is shown
Statistically significant
by *. Each point is the mean of 3 experiments.
FIGURE 3: Effect of Ca++ in the presence of Mg++ on 1 nM
[3H]DADLE binding. Membranes were incubated with Ca++
alone or in the presence of 2 mM or 20 mM Mg++
Each point is the mean of 3 experiments.
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the Na+-induced decrease of binding to the level seen in the absence
of ions in adults (fig.
and Ca++ were much less potent than Mn++ in reversing inhibition of
1A); as well as in neonates (fig. 1B). Mg++
binding by Na+ in adults. These results are in a good agreement with
those of Pasternak et al. (1975) obtained for a µ selective ligand,
[3H]-dihydromorphine. In contrast, our data show that Mg++ or Ca++
are not able to reverse Na+ inhibition of [3H]DADLE binding in
10-day-old neonate (fig. 1B).
regulation of binding with Mg++ or Ca++ emerges later than Mn
Thus, these results suggest that
modulation during postnatal development.
To elaborate on these results, dose-dependency studies in adult rat
brain membranes for each ion were performed in the presence of fixed
concentrations of either of the other Me++. The fixed ion concentra-
tions were chosen so that one represented the maximal, while the
other a submaximal effect.
summarized in Figs. 2-3. Ca++ or Mg++ antagonized the effect of Mn++
The results of these experiments are
and vice versa, especially at higher concentrations (>5 mM). Mg++
and Ca++ alternatively displayed no antagonism toward each other.
Thus, data presented in this report suggest the existence of two
divalent cation regulatory sites for opiod receptors: one site
binds Mg++ and Ca++, a distinct one binds Mn++ with an allosteric
interaction between the two.
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EFFECTS OF MORPHINE AND B-ENDORPHIN ON
Ca2+-ATPASE ACTIVITY OF SYNAPTIC PLASMA MEMBRANES
Shih-chia C. Lin and E.Leong Way
Department of Pharmacology
School of Medicine, University of California,
San Francisco, CA 94143, USA
ABSTRACT
Morphine and B-endorphin were found to inhibit the high calcium
-affinity Ca2+-ATPase of synaptic plasma membranes which is
believed to be involved in the regulation of intracellular Ca2+ that
triggers the release of neurotransmittera. The inhibition was
blocked by naloxone and reversed by calmodulin. Kinetic analyses
revealed that opioida decreased the affinity of Ca2+-ATPase for
Ca2+ and calcium bound to the enzyme decreased the affinity of the
enzyme for opioida.
INTRODUCTION
It is well established that calcium antagonizes morphine analgesia,
but the mechanism of calcium-morphine interaction is still unknown.
However, morphine action has been hypothesized to be caused by
morphine's interference with neurotransmission through the
disturbance of intracellular calcium disposition.
The high Ca2+-affinity Ca2+-ATPase of the synaptic plasma
membrane (SPM) is believed to be involved in the regulation of
intracellular Ca2+ (Lin and Way 1982a) which triggers the release
of neurotransmittera from synaptic vesicles (SV) (Miledi 1973).
This process involves the fusion of the SV with the SPM (Palade
1975). Nevertheless, the protein components for the attachment of
the two membranes have not been identified. The high
Ca2+-affinity Mg2+-independent Ca2+-ATPases of SPU and SV
are of particular interest because their Km values for Ca
2+
assayed either in the absence or presence of Mg2+ are close to
the concentration of the intracellular Ca2+ (Lin and Way 1982)
and because Ca2+ binding is required for membrane attachment.
It should be noted that although the high Ca2+-affinity Ca2+
activity can be measured both in the absence and th presence of
Mg2+, Mg2+ is not required for the activation by Ca2+(Lin
1991; Lin and Way 1984). This differentiates it from the
Ca2+/Mg2+-ATPases reported by others (Schatzmann and Rossi 1971;
Duncan 1976) which require the simultaneus  presence of Mg2+ for
stimulating ATP hydrolysis by Ca2+. The Ca
2+-ATPase of SPM is
found to be localized on the cytoaolic aide (Lin and Way 1982) and
that on SV, dispersed in the cytosol near SPM. The localization of
the Ca2+-ATPases in the two organelles would appear to provide the
proper condition for membrane attachment. The present study was
designed to examine the effects of morphine and B-endorphin on SPM
Ca2+-ATPase activity.
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MATERIAL AND METHODS
Morphine hydrochloride was purchased from Merck Chemical Division,
Rahway, New Jersey. All chemicals were of the highest grade
available and used without further purification. Calmodulin were
gifts from Dra. W.Y. Cheung and Jim Potter, B-endorphin, from Dr.
C.H. Li and naloxone, from Du Pont, Welmington, Delaware.
Synaptosomes from brain of male ICR mice were prepared by
differential and Ficoll gradient centrifugations as described
previously (Lin and Way 1984). SPM were fractionated by sucrose
gradient centrifugation of lysed synaptosomes and collected between
0.6M-0.8M sucrose-HEPES (SPM,) and 0.8M-1.1M sucrose-HEPES (SPM2)
solutions.
imidazole buffer, pH 7.5, at 37°C in 15 min (Lin and Way 1984). In
the inorganic phosphate (Pi) liberated from ATP by Ca in
experiments with morphine (or B-endorphin), naloxone, calmodulin,
alone or in combination, the enzyme preparation in HEPES buffer was
first mixed with the compound(a) and allowed to stand in ice-bath for
30 min before adding other constituents.
Ca2+-ATPase activity was determined by measuring colorimetrically
The double reciprocal plots were drawn by programmed least squares
linear regression. Ki and K'i
dissociation constants for morphine (or B-endorphin) complexes of
represent respectively the
enzyme and of enzyme-Ca2+ complex and were calculated according to
a model for a simplest mixed-type inhibition system (see Segel 1975).
It was considered that the enzyme-substrate-inhibitor complex was
non-productive.
RESULTS
Ca2+-ATPase activity in SPM
10-6 morphine as shown in fig. 1A. The double reciprocol plots
was decreased in the presence of
intersect at a point at the left aide of vertical-axis above the
1/Ca2+-axis. Morphine increased Km and decreased Vmax values.
This suggests that the binding of morphine to the enzyme reduced the
affinity of the enzyme for Ca2+ and the enzyme-morphine-Ca2+
complex is less or non-productive. The morphine inhibition was
reversed by naloxone and calmodulin. The addition of 10-7M
naloxone restored the Km and Vmax to near control values.
Calmodulin, on the other hand, lowered Km and increased Vmax to
exceed their control values.
Similarly in SPM2, morphine was also shown to inhibit Ca
2+-ATPase
activity. Again, the inhibition was reversed by naloxone and
calmodulin (fig. 1B) .
Fig. 1C shows the inhibition of Ca2+-ATPase activity of SPM2 by
B-endorphin (10-6M). The addition of 10-7M naloxone reversed the
Km and Vmax values of the enzyme in the presence of B-endorphin
to near control
Vmax further beyond the controls.
values and 6X10-7M calmodulin reversed the Km and
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FIGURE 1. Effect of morphine and B-endorphin on
Ca2+-ATPase activity in synaptic plasma membranes.
(A),SPM1,(B) and (C), SPM2. The incubation medium
contained membrane protein of about 100 ug, 1mM ATP, 1mM
mixtures without or with 10-6M morphine (or
MgC12, various CaCl2 (0 to 950 uM) -EGTA (1.0mM)
B-endorphin) 10-6M morphine (or B-endorphin)+
1 0 - 7 Mnaloxone or 10-6M morphine (or B-endorphin) +
6X10-7M or 1.2X10-6M calmodulin as indicated
Incubation was at 37°C for 15 min. P represents the
difference between Pi liberated by (Ca
12+ + Mg2+) and
by Mg2+ alone.
DISCUSSION
SPM Ca2+-ATPase is believed to be of special importance in synaptic
transmission because the enzyme has binding sites for both Ca2+ and
ATP (Lin and Way 1982a). Moreover, Ca2+-binding is required for
membrane fusion and ATP is required for secretion (Woodin and
Wienieke 1964; Douglas 1968). It has been shown that SPM Ca
2+-ATPase
activity is regulated by calmodulin both in the absence (Lin,
unpublished data) and the presence (see Roufogalis 1979) of Mg2+ and
that calmodulin decreases Km and increased Vmax values as
compared to control values.
considered to interact with the catalytic site. The dissociation
constants Ki and K'i calculated (see Methods) from the slopes and
intercepts in fig.1 are, respectively, 2.84 and 5.05 (M-SPM1),
2.56 and 9.09 (M-SPM2) and 2.88 and 5.68 (B-endorphin -SPM2). Thus,
morphine and B-endorphin are less firmly bound to the enzyme-Ca2+
complex than to the free enzyme. However, the precise site for
morphine (or B-endorphin) binding remains unresolved at present.
The mode of morphine (or B-endorphin) inhibition of Ca2+-ATPase
suggests
Ca2+ at distinctly different sites, hence morphine cannot be
that morphine can bind to the enzyme simultaneously with
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There are several possibilities that may explain the morphine and
B-endorphin effect. The opioid may interfere with the Ca2+
binding of calmodulin to the enzyme subunit and result in
a decrease of the amount of active form of the enzyme, or the opioid
may distort the enzyme conformation and render the
enxyme-substrate-opioid complex non-productive (or less productive).
In conclusion, the present results demonstrate that opioids decrease
the affinity of SPM Ca2+-ATPase for Ca2+, and Ca2+ decreases
the binding affinity of the enzyme for opioids. Since SPM
Ca2+-ATPase is believed to be regulated by intracellular Ca2+
which triggers the release of neurotransmitter through
Ca2+-dependent membrane fusion. The present findings may provide
the underlying basis for opioid action as well as the antagonistic
effect between calcium and opioids.
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OPIOIDS AND RAT ERYTHROCYTE DEFORMABILITY
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ABSTRACT
In previous studies from this laboratory, it was noted that
opioids in vitro reduced human red blood cell deformability. The
effect was found to be dose-dependent, naloxone reversible and
preferentially selective kappa ligands exhibited the highest
potency. To extend these findings studies were carried out using
rat erythrocytes. The time required for erythrocytes to pass
through a 5.0 um pore membrane was determined and used as
an index of deformability. Opioids added in vitro produced
inhibition of deformability in a dose-dependent, naloxone
reversible manner. Injecting naive animals with morphine or
nalbuphine also produced dose related reductions in red cell
deformability. The degree of inhibition produced by nalbuphine
correlated well with its plasma concentrations as measured by
high performance liquid chromatography (HPLC). Chronic morphine
treatment by pellet implantation resulted in-the development of
tolerance as evidenced by a loss in the ability of morphine in
vitro to inhibit red cell deformability. Addition of naloxone
resulted in a decrease in filtration time. Thus, the data confirm
and extend previous findings on human red blood cells. In as
much as previous data from this laboratory demonstrated that
opioids inhibit calcium flux from erythrocytes by inhibiting
calcium-ATPase and calcium efflux is necessary for normal
deformability, it is concluded that opioids act to reduce red
cell deformability by inhibition of the calcium pump.
INTRODUCTION
Opioids cause a reduction in the ability of human red blood
cells to deform in a dose dependent, naloxone reversible,
stereoselective manner. Relatively selective kappa ligands
are more potent in eliciting this effect and extended opioid
incubation with erythrocytes produces tolerance and a rebound
phenomenon upon exposure to naloxone (Rhoads et al.1985).
To extend these findings studies were carried out using rat
erythrocytes.
MATERIALS AND METHODS
Heparinized blood was obtained from Sprague Dawley rats
(200-300g) under CO2 anesthesia by cardiac puncture. The
time necessary for 1 ml of blood to pass through a 5 um pore
Nucleopore membrane under 5 ml water pressure was measured and
used as an index of the ability of the erythrocytes to deform
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(Reid et al 1976).
The effects of chronic opioid treatment on deformability were
studied by making rats morphine tolerant and dependent. One 75
mg morphine-base pellet was implanted on day 0 and 2 pellets on
days 1 and 2. Pellets were removed on day 3 and with some rats
naloxone was either injected intraperitoneally (5 mg/kg) or added
in vitro (0.2 uM) immediately afterwards.
In order to study the correlation between drug concentration
and deformability, rats were injected with nalbuphine HCl
intraperitoneally and the plasma concentration of nalbuphine was
determined according to the HPLC method described by Lo et al.
(1984). Nalbuphine was extracted from plasma and separated using
a C8, 5 um (4.6 x 250 mm) column, with a mobile phase of 27%
CH3CN, 0.035% H3PO4 at a flow rate of 1.4 ml/min using an
amperometric detector.
RESULTS
All opioids used in the study inhibited rat erythrocyte
deformability dose-dependently. Dynorphin A(1-13) and
1-pentazocine showed the highest potency, the IC50 being 0.3
nM and 0.5 nM respectively (figure 1). The lowest potency
was observed for D-ala-D-leucine enkephalin (800 nM) and
d-pentazocine (925 nM).
FIGURE 1. Dose response curves of opioids increasing
erythrocyte filtration time. Erythrocytes were incubated
with opioids in vitro at 37°C for 15 minutes prior to the
measurement of filtration time.
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In erythrocytes obtained from morphine tolerant/dependent rats,
morphine added in vitro exhibited reduced ability to inhibit
deformability when compared to those from naive animals (figure
2). An increasing shift of the dose response curve to the right
occured with increasing pellet implantation time and when the
pellets were removed after the third day of implantation the
curves shifted back toward the naive state (figure 2). Addition
of naloxone resulted in a rebound effect with an increased
deformability of the red cells, as evidenced by a reduction in
the filtration time to one half (data not shown).
FIGURE 2. Chronology of development and loss of tolerance
to morphine inhibition of erythrocyte deformability. Rats
were implanted with one pellet of morphine base on day 0,
two pellets on days 1 and 2. Blood was withdrawn and the
filtration time of the erythrocytes in the presence of
varying concentrations of morphine was measured on day 0, 1,
2, 3 and on day 3, six and 12 hours after pellet removal.
HPLC measurement of the plasma concentrations of nalbuphine
yielded values that correlated directly with the degree of
inhibition of rat erythrocyte deformability (figure 3).
Dose (mg/kg)
FIGURE 3. Nalbuphine plasma concentrations (left y-axis,
open symbols and dotted lines) and changes in red cell
deformability (right y-axis, closed symbols and solid
lines) 40 and 80 minutes after 10, 30, and 100 mg/kg
intraperitoneally injected nalbuphine HCl.
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DISCUSSION
Our results demonstrate that opioids inhibit rat erythrocyte
deformability in a dose dependent, stereoselective manner
with relatively selective kappa ligands exhibiting the highest
potency. Chronic treatment of rats with morphine resulted in
tolerance and a rebound effect occured upon addition of naloxone.
These results extend and confirm similar results with human
erythrocytes (Rhoads et al. 1985). The HPLC measurements revealed
that the deformability changes correlated well with the amount
of opioid available in plasma; higher nalbuphine plasma
concentrations produced a higher inhibition of deformability.
The change of deformability in erythrocytes is often postulated
as a symptom for an existing pathological condition and many
agents can increase or decrease the ability of erythrocytes to
deform. Intracellular calcium is believed to play a piv tol role
in the deformability of red cells and because Yamasaki and Way
(1983) found that the calcium-ATPase of rat red cells can be
inhibited by opioids, we suggest that such an action inhibits
calcium efflux and decreases erythrocyte deformability.
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Calmodulin Content in Rabbit Reticulocyte and the Influence of Opioid
Peptides on Cslmodulin Activity in its Membrane.
Liu Jingsheng, Liu Ye, Jiao Haiyan, and Chin Yinchang.
Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences,
Faculty of Basic Medicine, Peking Union Medical College. Beijing, China.
ABSTRACT
Calmodulin (CaM) content in rabbit reticulocyte and the influence of opioid peptides on
CaM activity in its membrane were studied by a highly sensitive assay of CaM activity
based on the stimulation of Calcium-dependent phosphodiesterase activity. The CaM
contents in reticulocytes were higher than those in normal erythrocytes, both in the cyto-
sol fraction and in the membrane fraction. Among the opioid peptides, endorphin
EP) and dynorphin-A-(1-13) (dyn) had a significant inhibitory effect on CaM activity in
reticulocyte membrane. The effect was not antagonized by naloxone or Mr. 2286, nor
influenced by increase of Ca2+ concentration, but was reversed by the addition of exo-
genous CaM. This implies that the action of EP and dyn on reticulocyte membranes
probably involves an non-opioid mechanism, in which CaM may be an important key of
linkage.
INTRODUCTION
Calmodulin (CaM) has a wide distribution in the body. While calcium is important in the
stimulation-activation coupling of the central nervous system or hormonal effects, CaM
plays an important role in these calcium-dependent processes. It has been reported that
EGTA, the Ca2+ chelating agent, inhibited phosphodiesterase (PDE) activity as a result
of CaM inactivation (Lin et al. 1975, Teo and Wang 1973). Neuropeptides or opioid pep-
tides like ACTH, dynorphin, and beta-endorphin were also found to have an inhibitory
effect on CaM activity (Simantov et al. 1982, Barnette and Weiss 1983, 1984). Among
them, EP was the most potent, and its IC50 was 3 µM (Clouet et al. 1983).
Rat reticulocytes have been used as a convenient model for the study of the interaction of
receptor and second messenger systems. In the course of maturation, they showed a
marked loss of adenylate cyclase responsiveness to catecholamines and guanine nucleo-
tides without significant loss of basal enzyme activity (Limbird et al. 1984). So we tried
rabbit reticulocyte membrane to study the molecular basis of the functional activity of
opioid peptides.
MATERIALS AND METHODS
1. Chemicals:
3H-cGMP (23 ci/mmole) was obtained from Institute of Atomic Energy, Chinese
Academy of Science; endorphin, dynorphin-A-(1-13), met-enkephalin, leu-enkephalin,
were from Sigma; QAE-Sephadex A-25 was from Pharmacia; CaM-deficient PDE was
extracted from bovine heart (Liu et al 1985) at a concentration of 0.5 unit/µl; and
CaM was prepared from rat testes.
2. Solutions for CaM assay:
Assay buffer consisted of Tris-HCl 45 mmol/L, Imidazole 45 mmol/L, Mg-acetate 5.5
mmol/L, pH 7.5. All the following solutions were prepared with assay buffer: CaCl,
4.5 mmol/L, EGTA 4.5 mmol/L, cobra venom 10 u/ml, and 3H-cGMP 100,000 cpm /
50 µl (~250 pmole / 50 µl).
3. Generation of rabbit reticulocytes and the preparation of membranes (Tucker and
Young 1982):
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Healthy male New Zealand white rabbits, about 2 kg in body weight, were used. Subcu-
taneous injection of vitamin B12 1 mg / 1 ml and folic acid 10 mg/l ml were given on the
first day, followed by subcutaneous injection of phenylhydrazine HCl in saline (10 mg/kg)
once daily for 5 days. On the 6th day, examination of blood sample taken from the ear
vein and stained on slide with brilliant cresyl blue showed that more than 98% of the red
blood cells were reticulocytes. The rabbit was bled from the carotid artery on the 7th
day, and blood collected and heparinized (1 mg heparin / 100 ml blood), centrifuged
under 1,000 x g for 15 minutes. After washing thrice with normal saline, the blood cells
were suspended in normal saline, counted and made up the EGTA-buffer to concentration
of 109 cells / ml. The cells were then homogenized under supersonic treatment (15 sec x
4) at 4° C, and centrifuged under 40,000 x g for GO minutes to yield sediments of cell
membranes, which were then kept, in aliquots and frozen under -65°C before use.
4. Determination of CaM activity in rabbit reticulocyte membrane:
CaM activity was determined by a highly
sensitive assay based on the stimulation of
calcium-dependent phosphodiesterase
activity (Liu et al. 1985). Rabbit reticulo-
cyte membrane preparations (109 cells /
ml) were serially diluted into five different
dilutions of 1:5, 1:10, 1:20, 1:40, and 1:80.
The CaM content in 20 µl of each were
measured according to the methods of
Thompson et al. (1971). The activity of
CaM in the rabbit reticulocyte membrane
which activated 20 µl of PDE from bovine
heart to 50% of its full activity was desig-
nated as 1 unit (Thompson and Appleman
1971). It can be seen clearly from fig. 1
that in our experimental conditions, the
CaM activity in 20 µl of 1:15 dilution of
membrane. preparation was equivalent to
FIGURE 1. CaM activity in rabbit reticulocyte
1 unit.
membrane.
RESULTS
1. CaM content in the cytosol and membrane fractions of normal rabbit erythrocyte and
reticulocyte:
The separated whole cells, suspended in EGTA-buffer and homogenized by supersonic
treatment, were kept in 100°C water bath for 5 minutes and centrifuged under 40,000 x g
for GO minutes. Assay of the supernatants (cytosols) as compared to the membrane frac-
tions showed that most of the CaM content was found in the cytosol and the contents of
CaM in reticulocytes were much higher than those in normal erythrocytes both in the
cytosol fraction or within the cell membrane (table 1).
2. The effect of dyn on CaM activity in rabbit reticulocyte membranes:
Different amounts of dyn were added into reticulocyte cell membranes (1:15 dilution) to
make up a serial final concentrations of 0.5, 1.0, 2.0, 4.0, and 16.0 µM in the presence of
Ca2+ 2 mM, with 10 units (20 µl) of PDE extract from bovine heart and 3H-cGMP
(100,000 cpm / 50 µl) as substrate. Dose-dependent inhibition of PDE activation in reti-
culocyte membranes was observed (fig. 2). The inhibitory effect of dyn was not reversed
by 50 µl of naloxone, and Mr. 2266 (Vonvoigtlander et al. 1984), the antagonist, up to
a maximal concentration of 100 µM.
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TABLE 1. CaM content of normal rabbit erythrocyte and and reticulocyte
(ng/109 cells)
Sample C a M ( SD)
Erythrocyte Cytosol 6.05 2.37 (N=5)
Membrane 0.26 0.09 (N=2)
Retieulocyte Cytosol 37.40 8.69 (N=6)
Membrane 1.71 0.56 (N=6)
FIGURE 2. Effect of dyn on the activity of CaM in FIGURE 3. Activation of PDE by rabbit reticulocyte
rabbit reticulocyte membrane. membrane in the presence and the absence of dyn.
T)yn at 4 µM also exerts a significant inhibitory effect on the stimulation of PDE activity
by CaM present in reticulocyte membrane preparation across various amounts of PDE
from 10 to 60 µl, corresponding to 5 to 20 units. The curve of PDE activity shifts paral-
lelly to the right in the presence of dyn (fig. 3). Similar results were obtained as the
experiment was repeated three times. The inhibitory effect of dyn on CaM-stimulated
PDE activity was not influenced by the addition of Ca2+ to 4 mM, but reversed by CaM
in a dose-dependent manner (fig. 4).
FIGURE 4. Effect of dyn on CaM activity in rabbit
reticulocyte membrane. 1: Control. 2: 4 µl dyn.
3,4,5: CaM 0.2,0.8,3.2 ng. 6: Ca2+added to 4 mM.
FIGURE 5. Activation of PDE by rabbit reticulocyte
membrane in the presence and the absence of EP.
3. The effect of EP on CaM activity in rabbit reticulocyte membranes:
EP had a similar and even stronger antagonistic effect on the activity of CaM in rabbit
reticulocyte membranes than dyn. EP, like dyn, does not affect PDE activity directly,
but inhibited the CaM PDE activating effect in 20 µl reticulocyte membranes preparation
(1:15 dilution). The effect of 1 µM of EP corresponded to 4 µM of dyn and caused a
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parallel shift of the curve of CaM-activated PDE activity to the right (fig. 5). The effect
of EP was not antagonized by 50 nM of naloxone, not affected by an increase of Ca2+
concentration to 4 mM, but was reversed by the addition of CaM. The results implied
that EP antagonized the activating effect of CaM probably by competition with PDE
for CaM.
Besides, opiate alkaloids and endogenous opioid peptides like met-enkephalin, leu-
enkephalin, morphine, and etorphine were all not effective up to 10 µM. Naloxone had
also no effect on CaM activated PDE activity up to 50 µM.
DISCUSSION
CaM was assayed according to its ability to activate PDE and hydrolyze cGMP. Our
experimental results indicate that the CaM content in the cytosol and membranes of reti-
culocyte were much higher than those in normal erythrocytes. This is probably related to
the maturation process of red cells and coincides with the findings of Limbird who
reported a marked loss of adenylate cyclase responsiveness to catecholamines and guanine
nucleotides in the course of maturation (Limbird et al. 1984). High CaM content in reti-
culocyte facilitates its applications in the study of the mechanism of drug action upon
second messenger systems. Reticulocyte could be easily obtained in practically pure form
and changes involved during its maturation could be followed in cell culture.
Dyn at a concentration of 4 µM, which did not affect PDE basal activity, already showed
a significant inhibitory effect (around 50%) on the CaM activity of rabbit reticulocyte.
The effect was dose related (between 0.5 - 16.0 µM) and was not blocked by an increase of
Ca2+ concentration, but could be reversed by adding CaM. Naloxone and Mr 2266 did
not block the inhibitory effect of dyn on rabbit reticulocyte CaM. These implied that dyn
probably acts directly upon CaM and inhibits the activity of CaM in activating PDE.
EP, similar to but stronger than dyn, also inhibits CaM activity at a lower concentra-
tion of 1 µM. Although as opioid ligands, EP and dyn, which belonged to different
classes, had similar effect on CaM in cell membranes; morphine, met-enkephalin and leu-
enkephalin showed no significant effect. These are additional proofs to the fact the EP
and dynorphin act directly through CaM irrelevant to opiate receptors.
Known antipsychotics, e.g. fluphenazine, show a strong specific binding to CaM and com-
petes with dyn and EP in binding with CaM (Prozialeck and Weiss 1982, Weiss et al.
1982). It is interesting to explore further the mechanism of action of EP and dyn on
CaM and its relation to anti-psychotic therapy.
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ADRENAL MEDULLARY OPIOID RECEPTORS ARE LINKED TO
GTP-BINDING PROTEINS, PERTUSSIS TOXIN SUBSTRATES
Keita Kamikubo, Hiroshi Murase, Masayuki Niwa*, Kiyoshi Miura,
Masakatu Nozaki* and Kaito Tsurumi*
Departments of Internal Medicine (III) and *Pharmacology
Gifu University School of Medicine. Gifu 500. Japan
ABSTRACT
Effects of Gpp(NH)p and pretreatment of membranes with pertussis
toxin (PT) were studied on opioid binding to bovine adrenal medullary
opioid receptors. Gpp(NH)p inhibited [3H]DADLE binding by increasing
the dissociation constant. PT treatment reduced [3H]DADLE binding and
almost abolished the Gpp(NH)p inhibition of [3H]DADLE binding.
Levorphanol did not show any significant effect on bovine adrenal
medullary adenylate cyclase activity. These results suggest that
bovine adrenal medullary opioid receptors are linked to PT-sensitive
GTP-binding proteins which are not directly coupled to adenylate
cyclase.
INTRODUCTION
At the present time, molecular mechanisms underlying opioid
inhibition of hormone or neurotransmitter release is still obscure.
Recently, GTP-related processes of signal transduction have been
suggested for the possible molecular mechanism of opioid action.
These suggestions are based on findings that GTP or its stable
analogs inhibits binding of opioid agonists to receptors. It has been
also shown that opioid receptors in neuroblastoma-glioma hybrid cells
(NG 108-15 cells) (Kurose et al. 1983) and-rat caudate nucleus
(Kamikubo et al. 1981, Law et al. 1981. Abood et al. 1985) are
coupled to inhibition of adenylate cyclase through a pertussis toxin
(PT)-sensitive GTP-binding protein.
In also adrenal medulla, it has been shown that opioids inhibit
hormone (catecholamine) secretion from chromaffin cells (Kumakura et
al. 1980, Barron and Hexum 1986). Because of the relative homogeneity
of composing cells, adrenal medulla may be a suitable model system to
study post-receptor mechanisms of opioid action. In the present
study, we have investigated the possible coupling of bovine adrenal
medullary opioid receptors to PT-sensitive GTP-binding proteins and
adenylate cyclase. The results suggest that adrenal medullary opioid
receptors are coupled to PT-sensitive GTP-binding proteins but not to
inhibition of adenylate cyclase.
MATERIALS AND METHODS
[3H]D-Ala2-D-Leu5-enkephalin ([3H]DADLE) (49.3 Ci/mmol) was from
Amersham. Guanylyl imidodiphosphate (Gpp(NH)p) was from Sigma. PT was
a generous Dr. Ui (Hokkaido University) and Kaken
Pharmaceuticals.  [125I]cAMP and anti-CAMP antibody were obtained from
Yamasa.
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Pretreatment of membranes with PT
Bovine adrenal medullary crude plasma membranes, prepared as
described elsewhere (Kamikubo et al. 1986b), were incubated in 2 mM
NAD, 8 mM DTT, 1 mM ATP, 2 mM MgCl2, 10 mM thymidine and 50 mM Tris-
HCl (pH 7.4) with or without PT (20 pg/ml) at 37°C for 30 min and
washed twice with ice-cold 50 mM Tris-HCl (pH 7.4).
Opioid binding assay
Binding of [3H]DADLE to membranes was assayed in 50 mM Tris-HCl (pH
7.4) at 25°C for 30 min. Bound and free ligands were separated by
rapid vacuum filtration through Whatman GF/C filters. Non-specific
binding was determined in the presence of 1 pM DADLE. Saturation
binding data were analyzed by the computerized non-linear least
squares curve fitting procedure (Kamikubo et al. 1986a).
Adenylate cyclase assay
Adenylate cyclase activity was measured at 37°C for 10 min by the
method of Katada and Ui (1981). Incubation mixture contained 0.5 mM
ATP, 5 mM MgCl2, 0.1 mM EGTA, 0.5 mM isobutyl methylxantine, 7.2 mM
phosphocreatine, 40 U/ml creatine phosphokinase, 0.1% BSA, 10 µM GTP,
0.1 M NaCl and 25 mM Tris-HCl (pH 7.4). Cyclic AMP produced was
measured by sensitive and specific radioimmunoassay.
RESULTS AND DISCUSSION
Gpp(NH)p inhibited [3H]DADLE binding to bovine adrenal medullary
membranes in a concentration-dependent manner. The primary action of
Gpp(NH)p on the [3H]DADLE binding was an increase in the dissociation
constant (from 2.9 to 3.9 nM).
Pretreatment of the membranes with PT resulted in a 29% reduction of
[3H]DADLE binding (Table 1). In addition, the pretreatment abolished
almost completely the Gpp(NH)p inhibition of [3H]DADLE binding.
TABLE 1 Effects of pertussis toxin treatment on [3H]DADLE
binding to bovine adrenal medullary membranes
[3H]DADLE binding (%)
Addition PT (-) PT (+)
None 100 71 5
GPP(NH)p (10 uM) 36 3 65 3
Specific binding of 5 nM [3H]DADLE to bovine adrenal
medullary membranes treated with (PT (+)) or without
(PT (-))PT was shown. The control binding (100%) was 21
1 fmole/mg protein.
These results suggest that adrenal medullary opioid (DADLE) receptors
are regulated by Gpp(NH)p and that the Gpp(NH)p regulation may be
mediated by PT-sensitive GTP-binding proteins. The existence of PT-
sensitive GTP-binding proteins in bovine adrenal medulla was
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demonstrated by PT-catalyzed [32P]ADP-ribosylation of the proteins
(Kamikubo et al. manuscript in preparation). In several receptor
systems, it has been known that PT inhibits agonist binding to
hormone receptors and reduces GTP inhibition of agonist binding by
uncoupling PT-sensitive GTP-binding proteins from receptors (Kurose
et al. 1983, Hsia et al. 1984, Cote et al. 1984). From the present
observations, therefore, it seems likely that the PT-sensitive and
ADP-ribosylatable GTP-binding proteins mediate the Gpp(NH)p
regulation of adrenal medullary opioid receptors.
In NG 108-15 cells and rat caudate nucleus, it is likely that opioid
receptors are coupled to inhibition of adenylate cylase through the
PT-sensitive inhibitory GTP-binding protein (Ni) (Kurose et al. 1983,
Abood et al. 1985). In membranes from rat brain caudate nucleus,
levorphanol inhibited adenylate cyclase activity as previously shown
by us (Kamikubo et al. 1981) and by others (Law et al. 198l)(Table
2). However, in bovine adrenal medullary membranes, levorphanol
showed no clear inhibitory action on adenylate cyclase activity. PT
TABLE 2 Effects of levorphanol on adenylate cyclase
activity in rat caudate nucleus and bovine adrenal medulla
Adenylate cyclase activity
(% of control)
Addition Rat caudate nucleus Bovineadrenal medulla
None 100 100
Levorphanol 1 nM 92 4 96 5
Levorphanol 10 nM 83 3 98 4
Levorphanol 100 nM 76 5 97 3
Levorphanol 1 uM 74 5 93 6
Data are the means SD of triplicates. The control
activity was 148 9 pmole/mg protein/min for rat caudate
nucleus and 83 6 pmole/mg protein/min for bovine adrenal
medulla.
treatment showed only modest. if any, enhancing effect on GTP
activation of adrenal medullary adenylate cyclase.
The reason for the discrepancy between the actions of levorphanol in
rat caudate nucleus and in bovine adrenal medulla is not known.
However, it may be possible that adrenal medullary opioid (DADLE)
receptors are coupled mainly to other PT-sensitive GTP-binding
proteins than Ni. In addition to Ni, there are several functionally
or molecularly distinct classes of PT-sensitive GTP-binding proteins,
such as the stimulatory GTP-binding protein of phospholipase C in
certain cells (Nakamura and Ui 1985) and the GTP-binding protein with
39,000 dalton A subunit (No) (coupled to potassium channel?)
(Sternweis and Robinshaw 1984). PT treatment of adrenal medullary
membranes did not significantly modified the GTP activation of
adenylate cyclase. This finding may suggests that activity or content
of Ni in adrenal medulla is not high to significantly inhibit
adenylate cylase. Functional linkage of opioid (DADLE) receptors to
Ni may be scarce in adrenal medulla.
131
The present observations provide indirect evidence for the functional
linkage of adrenal medullary opioid (DADLE) receptors to PT-sensitive
GTP-binding proteins which are not directly coupled to adenylate
cyclase. Post-receptor mechanisms of signal transduction other than
adenylate cyclase regulation, such as K channel regulation etc., may
be involved in opioid (DADLE) action in bovine adrenal medulla
(Figure 1).
FIGURE 1 Linkage of bovine adrenal medullary opioid
(DADLE) receptors (OR)to pertussis toxin-sensitive GTP-
binding protein (No?) not directly coupled to adenylate
cyclase (AC).
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ABSTRACT
The expression of opioid receptors and GTP-binding proteins was
studied in 14 pheochromocytomas. The amount of [3H]diprenorphine
bound to membranes varied from 13 to 62 fmole/mg protein, but
significantly higher in adrenaline-secreting tumors than in nor-
adrenaline-secreting tumors. None of [3H]DADLE, [125I] endorphin or
[ 3H]ethylketocyclazocine binding was correlated with
[3H]diprenorphine binding. Gpp(NH)p inhibition of [3H]DADLE binding
was evident in all four normal human adrenal medullae but in only 8
out of 14 pheochromocytomas. The extent of Gpp(NH)p inhibition was
not correlated with the amount of pertussis toxin (PT)-sensitive GTP-
binding proteins as measured by PT-catalyzed [32P]ADP-ribosylation.
The present findings suggest that opioid receptors and PT-sensitive
GTP-binding proteins are variously expressed in transformed
chromaffin cells, pheochromocytoma.
INTRODUCTION
It has been shown that various amounts of opioid peptides derived
from proopiomelanocortin, proenkephalin A or proenkephalin B are
produced in transformed chromaffin cells, pheochromocytoma (Imura et
al. 1984). In addition to the production of opioid peptides,
expression of opioid receptors and GTP-binding proteins and their
functional coupling may be modified in pheochromocytomas. The present
study was undertaken to demonstrate such modification of the opioid
receptor system in pheochromocytomas. In addition, possible
correlation between the modification of opioid receptor system and
the clinical feature of pheochromocytoma has been studied.
MATERIALS AND METHODS
[3H]Diprenorphine (41 Ci/mmol). [3H]D-Ala2-D-Leu5-enkephalin
([3H]DADLE) (49.3 Ci/mmol), and [125I] human endorphin
(approximately 2000 Ci/mmol) were from Amersham. [3H] Ethylketo-
cyclazocine ([3H]EKC) (23 Ci/mmol) was from New England Nuclear.
Pertussis toxin (PT) was a generous gift from Dr. Ui (Hokkaido
University) and Kaken Pharmaceuticals.
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Subjects
In 7 out of 14 patients with pheochromocytoma, urinary excretion of
only noradrenaline was increased (Noradrenaline type). In other 7
patients, urinary excretions of both noradrenaline and adrenaline
were increased (Adrenaline type). Pheochromocytomas were obtained
surgically and kept -80°C until use. Four normal human adrenal
medullae were obtained at autopsy and kept -80°C until use.
Preparation of membranes
Pheochromocytomas were homogenized in 0.3 M sucrose and 10 mM Tris-
HCl (pH 7.4) and centrifuged at 800 g for 10 min. The supernatant was
centrifuged at 30,000 g for 20 min. The pelleted membranes were
washed with 50 mM Tris-HCl (pH 7.4) and resuspended in 50 mM Tris-HCl
(pH 7.4).
Opioid binding
The binding of [3H]diprenorphine. [3H]DADLE and [3H]EKC was assayed
in 50 mM Tris-HCl (pH 7.4) at 25°C for 30 min. The binding of
[1251] endorphin was assayed in 0.1% BSA, 0.01% bacitracin and 50 mM
Tris-HCl (pH 7.4) at 25°C for 30 min (Kamikubo et al 1986). Bound and
free ligands were separated by rapid vacuum filtration through
Whatman GF/C filters. Non-specific binding was determined in the
presence of 1 µM of each unlabelled ligand.
Quantitation of PT-sensitive GTP-binding proteins
The amount of PT-sensitive GTP-binding proteins in pheochromocytoma
membranes was measured by the method of Pobiner et al. (1985) by
using the ability of PT to catalyze [32P]ADP-ribosylation of the
proteins. GTP-binding proteins were extracted from membranes by
incubating membranes in 1 mM EDTA, 1 mM DTT, 100 mM NaCl, 1% (w/v)
sodium cholate and 20 mM Tris-HCl (pH 8.0) at 4°C for 60 min. The
extract was centrifuged at 12,000 g for 15 min, and the solubilized
proteins were used as the source of GTP-binding proteins. PT-
catalyzed [32P]ADP-ribosylation was performed in 100 µl of solution
containing PT (25 µg/ml), 10 µM [32P]NAD (5-10 µCi), 10 mM DTT, 1 mM
ATP, 2 mM MgCl2, 10 mM thymidine and 50 mM Tris-HCl (pH 7.4) at 35°C
for 30 min. The reaction was terminated by adding 1 ml of 10%
trichloric acid. Proteins were precipitated by centrifugation at
12,000 g for 5 min and solubilized in Laemli's sample buffer. SDS-
polyacrylamide gel electrophoresis was run on 10% polyacrylamide gel.
Autoradiography was performed at -80°C using Kodak XO-AR film. Gel
was cut, and radioactivity incorporated into proteins was counted in
a liquid scintillation counter.
RESULTS AND DISCUSSION
In all normal human adrenal medullae and pheochromocytomas examined,
specific binding sites for [3H]diprenorphine, [3H]DADLE, [125I]
endorphin and [3H]DADLE were demonstrated in the membrane fraction. The
amount of [3H]diprenorphine bound to normal adrenal medullary
membranes was 40.5 5.5 fmole/mg protein (mean SD). The amount of
[3H]diprenorphine bound to pheochromocytoma membranes varied from 13
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to 62 fmole/mg protein. As shown in figure 1, the adrenaline type
pheochromocytomas showed higher [3H]diprenorphine binding (40.6
11.7 fmole/mg protein) than the noradrenaline type (25.0 10.7
fmole/mg protein). These findings suggest that adrenaline-secreting
FIGURE 1 [3H]Diprenorphine binding to pheochromocytoma
membranes.
pheochromocytoma sells bear more [3H]diprenorphine-binding sites than
noradrenaline-secreting cells. Considering the relative non-
selectivity of diprenorphine to opioid receptor subtypes, it seems
likely that the total content of opioid receptors is also higher in
adrenaline-secreting pheochromocytoma cells than in noradrenaline-
secreting cells.
The amount of [3H]DADLE, [3H]EKC or [125I] endorphin bound to pheo-
chromocytoma membranes was not correlated with that of [3H]dipre-
norphine bound. These findings suggest that the subtype composition
of opioid receptors varies considerablely in pheochromocytomas.
Effects of Gpp(NH)p on [3H]DADLE binding were examined to study the
possible coupling of opioid receptors to GTP-binding proteins in
human adrenal medulla. Gpp(NH)p inhibited [3H]DADLE binding to normal
adrenal medulla, suggesting the coupling of opioid (DADLE) receptors
to GTP-binding proteins. The extent of Gpp(NH)p inhibition of
[3H]DADLE binding was 37 8% in normal adrenal medulla. In
pheochromocytomas, Gpp(NH)p inhibited [3H]DADLE binding in only 8 out
of 14 tumors. Apparent Gpp(NH)p inhibition of [3H]DADLE binding
varied from 19 to 76% inhibition in these 8 tissues.
PT-sensitive GTP binding proteins were demonstrated in normal human
adrenal medulla by using the ability of PT to [32P]ADP-ribosylate the
proteins (1.05 0.24 pmol/mg protein). In pheochromocytomas, the
amount of PT-sensitive GTP-binding proteins was not correlated with
the extent of Gpp(NH)p inhibition of [3H]DADLE binding.
In the present study, the presence of opioid receptors and PT-
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sensitive GTP-binding proteins were demonstrated in normal and
transformed human adrenal medullae. Our results suggest that the
subtype composition of opioid receptors varies considerablely in
pheochromocytoma. The amount of [3H]diprenorphine bound, as a measure
of total opioid receptor content, was higher in adrenaline type than
in noradrenaline type pheochromocytomas. These findings may be in
line with the observations that naloxone increases plasma adrenaline
but not noradrenaline in the normal human (Mannelli et al. 1984) and
increases plasma catecholamines in adrenaline type but not in
noradrenaline type pheochromocytomas (Maggi et al. 1985). Interest-
ingly, enkephalins are more rich in adrenaline cells than in
noradrenaline cells of bovine (Livett et al. 1982) and hamster
adrenal medulla (Pelto-Huikko et al. 1982). In addition, tissue
content of opioid peptides is higher in adrenaline type than in
noradrenaline type pheochromocytomas (Imura et al. 1984). Taken to-
gether, these findings may suggest that opioid peptides and opioid
receptor systems are located mainly in adrenaline-secreting
chromaffin cells in adrenal medulla and that this preferential local-
ization is maintained in neoplasmic adrenal medulla.
The Gpp(NH)p inhibition of opioid binding was modifed variously in
pheochromocytomas. These findings suggest that functional aspects of
opioid receptor system is also important as the quantitative one to
consider modulatory action of opioid peptides in pheochromocytoma. In
addition. the observation that the extent of the Gpp(NH)p inhibition
was not correlated with the amount of PT-sensitive GTP-binding
proteins may suggest the uncoupling of opioid receptors from PT-
sensitive GTP-binding proteins. In conclusion, it was shown that
adrenal medullary opioid receptor-GTP-binding protein system is
variously modified by neoplasmic changes of chromaffin cells.
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ABSTRACT
After treatment of mouse spinal cord-ganglion explants with pertus-
sis toxin (PTX), the acute depressant effects of opioids on sensory-
evoked dorsal-horn network responses are markedly attenuated, and
characteristic cord discharges can then occur even in the presence
of >100-fold higher opioid concentrations, as observed after chronic
exposure to opioids. The usual acute depressant effects of
serotonin, norepinephrine, and oxotremorine on dorsal-horn dischar-
ges are similarly attenuated in PTX-treated cultures. These results
together with our previous physiologic and biochemical analyses of
adenylate cyclase (AC) and cyclic AMP (cAMP) activities in cord-
ganglion cultures suggest that the neuromodulatory effects of
opioid, monoaminergic and muscarinic agonists on primary afferent
networks in the spinal cord may be mediated by binding to neuronal
receptor subtypes that are negatively coupled via Gi to a common
pool of AC.
INTRODUCTION
Exposure of cord-DRG explants to opiates or opioid peptides results
in stereospecific, naloxone-reversible, dose-dependent depression of
sensory-evoked dorsal-horn synaptic-network responses within a few
minutes (Crain et al.1978). When cord-DRG explants are treated
briefly with CAMP analogs or forskolin (a selective activator of AC;
Seamon & Daly 1981), the usual depressant effects of opioids, as
well as serotonin and norepinephrine, on sensory-evoked dorsal-horn
responses are markedly attenuated (Crain et al.1986), resembling
some aspects of the tolerance that develops in cord-DRG explants
after chronic exposure to opioids (Crain 1984; Crain et al.1979;
1982). PTX is known to interfere with the guanine nucleotide
protein Gi. that is required for opioid, -adrenergic, and mus-
carinic receptor-mediated inhibition of AC in various cells (Katada
& Ui 1982; Kurose et al. 1983; Ui 1984). The present study shows
that PTX selectively blocks the depressant effects of opioid and
other Gi mediated agonists on dorsal-horn responses in cord-DRG
explants, consonant with PTX effects on guinea pig ileum (Lujan et
al.1984; Tucker 1984) and isolated DRG neurons (Holz et al.1986).
MATERIALS AND METHODS
Spinal cord cross-sections with attached DRGs from 13-day fetal mice
were explanted onto collagen-coated coverglasses and incubated at
35°C in Maximow slide culture chambers. Extracellular recordings
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were made with Ag-AgCl electrodes via micropipettes (3-5 um tips)
filled with isotonic saline. Electric stimuli were applied through
pairs of similar pipettes with 10 um tips. Recordings were made in
0.5 ml of BSS (pH 7.2; temp., 33°C; see technical details in Crain
1976; Crain et al.1978,1982). Pertussis toxin was obtained from
List Co., DADLE from Peninsula Co., oxotremorine from Research
Biochemicals Co., and other chemicals from Sigma Co.
RESULTS AND DISCUSSION
Focal DRG stimuli elicit negative slow-wave potentials restricted to
dorsal regions of spinal cord explants, arising abruptly after
latencies of 2-3 msec, and often lasting more than 500 msec. These
extracellularly recorded field-potentials resemble sensory-evoked
synaptic-network responses in dorsal spinal cord in situ (Crain
1976). Introduction of morphine or DADLE into these cultures
regularly led to sustained, dose-dependent, naloxone-reversible
depression of DRG-evoked dorsal cord responses within 3-10 min
(table 1). Measurements of the opioid sensitivity of dorsal cord
responses in these explants were made systematically in the present
study (n>40), (see also Crain et al.1978,1979,1982,1986). Similar
dose-dependent depressant effects on these cord responses were
produced by brief exposures (<10 min) to serotonin, norepinephrine,
carbamylcholine and the muscarinic agonist, oxotremorine (table 1).
The depressant effects of both cholinergic agonists were reversed or
prevented by atropine (1-10 uM), but not naloxone, whereas the
opioid-depressant effects were not antagonized by atropine.
In contrast, after pretreatment of cord-DRG explants with PTX (10
ug/ml for >1-2 days or 1 ug/ml for >4-5 days), the depressant
effects of all of these opioid, monoaminergic and cholinergic agents
failed to occur, and DRG-evoked cord responses were stably main-
tained during 10-30 min tests, often even with concentrations
>100-fold -higher than levels which strongly depressed control
explants (table 1). On the other hand, agents which produce depres-
sant effects by more direct actions on ionic channels were still as
effective on PTX-treated explants as in controls, e.g. Mg++ (5 mM,
GABA (1 mM), xylocaine (ca. 100 uM), and ethanol (ca. 1-2%).
The blockade by PTX of the depressant effects of opioid, monoaminer-
gic and muscarinic agonists on dorsal-horn responses in cord-DRG
explants is consonant with our demonstration that elevation of
intracellular CAMP levels produces similar, though less effective,
interference with these depressant actions (Crain et al. 1986). The
electrophysiologic data, together with correlative assays of AC
activity (see below), suggest that opioid, serotonergic, noradrener-
gic and muscarinic agonists may all act on receptor subtypes on DRG
and cord neurons that are negatively coupled via Gi to a common pool
of AC. The resulting decrease in AC/cAMP levels may, in turn,
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TABLE 1
PTX-Blockade of Acute Depressant Effects of Opioid,
Monoaminergic, and Muscarinic Agonists on Dorsal-Horn Responses
Effective Depressant Concentration (uM)
a
Agonist PTX-Treated
b *
Control n
morphine 0.1 - 1 >10 - 100 10
DADLE 0.03 - 0.3 >1 - 10 4
serotonin 0.01 - 0.1 >10 6
norepinephrine 0.1 - 1 >30 - 50 4
carbachol 0.3 - 3 >50 2
oxotremorine 0.1 - 1 >10 - 25 5
a
 Concentration required to depress sensory-evoked dorsal-horn
b
response in DRG-cord explant by >50% (Crain et al. 1978).
DRG-cord explants (ca. 2 wks in vitro) were pretreated with
* 10 ug/ml PTX for 1-2 days (see text).
Number of PTX-treated explants tested; 108 for each agent
in tests on control cultures.
regulate phosphorylation-dependent gates in K+ (e.g. Siegelbaum et
al.1982) and/or Ca++ channels (Reuter 1983) of DRG neurons, so that
Ca++ influx in presynaptic terminals as well as in the perikarya is
attenuated (Crain et al.1986). Our data do not preclude possible
PTX interference with Gi. coupling to other second messengers in
these neurons (Holz et al. 1986; Miller 1985).
The >100-fold tolerance to the depressant actions of opioids that
develops in cord-DRG explants after chronic exposure to PTX, as well
as to opioids (Crain et al.1979; Crain 1984), correlates well with
the stable increase in AC activity observed after similar treatments
of these explants (Crain & Makman 1986; Dvorkin et al.1985). In
addition, PTX-treatment attenuated the inhibition of AC produced in
control cord-DRG explants by levorphanol, and in preliminary assays,
by serotonin and norepinephrine (Crain & Makman 1986). Our studies
are consonant with the hypothesis that neurons may develop tolerance
and/or dependence during chronic opioid exposure by a compensatory
enhancement of their AC/cAMP system following initial opioid depres-
sion of AC activity (e.g. Collier 1980; Crain et al.1986; Klee et
al.1984; Sharma et al.1977). Further studies with this in vitro
model may help to determine the degree to which alterations in
opiate receptor linkages to AC/cAMP and other second messenger
systems are involved in the expression of physiological tolerance in
the CNS.
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ABSTRACT
Using crude P2 membranes of adult rat spinal cord we were able to
show that the opiate agonist U50488 significantly and dose-depen-
dently inhibited the basal cyclase activity, while µ (DAGO) and
(DADL) agonists were ineffective. The regulatory action was stereos-
pecific and required the presence of GTP plus Na+ as well as
Ca2+ ions. This inhibitory effect of K agonists was also observed when
the cyclase activity was stimulated by forskolin. Similar inhibition
was observed in spinal cord-dorsal root ganglion cocultures.
Following chronic exposure of cultured cells to etorphine or U50488,
the agonists lost their ability to inhibit the cyclase.
Furthermore, the desensitization process appeared to be. heterologous,
since the 2 adrenergic agonist, norepinephrine and the muscarinic
agonist, carbachol exhibited significant lawer potency for inhibiting
cyclase activity when compared to control cultures. These data sug-
gest that in spinal cord, opiate receptors of the K type are neg-
atively coupled to adenylate cyclase and the induction of tolerance
produced by K agonists is related to alterations of post-receptor
regulatory components.
INTRODUCTION
Many lines of evidence suggest that the spinal cord is an important
site for the mediation of the antinociceptive action of opiates and
endogenous opioids (Yaksh 1983). Pharmacological studies showed
antagonism of opiate analgesia by injections of cAMP (Ho et al. 1973)
or inhibitors of cAMP phosphodiesterase (Juma 1984). Furthermore,
biochemical studies demonstrated that opiate agonist binding in rat
spinal cord membranes is regulated by GTP and Na+ (Kelly et al. 1982)
suggesting a possible coupling to the adenylate cyclase system. The
rat spinal cord contains high concentrations of K receptor sites
(Gouarderes et al. 1985). However, contrary to the receptors very
little is known about the modulation of adenylate cyclase activity by
opiate ligands. The present communication shows that K opiate
receptors are negatively coupled to adenylate cyclase in rat spinal
cord and that K agonists induce heteroloqous desensitization upon
chronic treatment.
METHODS
Rat (Sprague Dawley, male adult) spinal cords were homogenized in 10%
sucrose (wt/wt) containing 1mM DTT and 1M Tris-HCL (pH 7.4). Nuclei
and cell debris were discarded by centrifugation (800xg, 10min) end
the supematant was centrifuged at 27,500xg for 3min. The crude P2
membranes were washed twice and assayed for cyclase activity
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according to the procedure of Salomon et al. (1974). Rat dorsal root
ganglion-spinal cord primary cocultures were prepared according to
routine methods (Ransom et al. 1977). After 3 weeks in culture the
cells were washed twice with PBS and homogenized in 1mM DTT, 5mM
MgCl2 and 10mM Tris-HCL (pH=7.4).
RESULTS
We found that the K selective opiate agonist U50488 significantly and
dose-dependently inhibited the basal cyclase activity of membranes
from adult rat spinal cord (table 1), while µ (DAGO 10 µM) and
(DADL10µM) agonists were ineffective. Etorphine (1µM) and levorpha-
nol (1µM), two non-selective opiate agonists significantly affected
the enzyme activity as well. The regulatory action was stereospecific
since dextrorphan was unable to inhibit the basal cyclase activity.
In all cases GTP (10µM) and NaCl(100mM) were required for the expres-
sion of agonist inhibitory action (data not shown). Naloxone, a non
selective opiate antagonist fully antagonized etorphine inhibition
whereas it partially reversed the U50488 response.
TABLE 1. Effect of opiates on basal adenylate cyclase activity in
adult rat spinal cord membranes.
Untreated membranes EGTA-treated membranes
(% of control) (% of control)
etorphine 1µM
etorphine 1µM
+naloxone 10µM
U50488 10µM
U50488 10µM
+naloxone 10µM
naloxone 10 µM
Levorphanol 1µM
dextrorphan 10µM
80 3** 99 4
97 2 109 9
69 5 * 102 3
87 4
102 3 101 3
79 2** 91 5
103 5 95 5
The experiments were performed in the presence of 10µM GTP
and 100mM NaCl. When EGTA(was included, it was present at
1mM concentration throughout the membrane preparation and
the assay. The adenylate cyclase activity of EGTA-treated
membranes and untreated membranes was 0.81 0.03 and
3.89 0.01 nmoles cAMP/15 min/mg protein, respectively. The
results are expressed as percent of control. The data rep-
resent the mean +SEM of 2-6 separate experiments performed
in triplicate. The significance of the data was calculated
by unpaired student t tests (*p<0.01; **p<0.001).
When the membranes were treated with 1mM EGTA, the basal cyclase
activity decreased by 4-fold and the opiate inhibition was no
longer observed. To study opioid regulation of cyclase following
chronic agonist treatment, we used homogenates of rat spinal cord-
dorsal root ganglia primary cocultures (3 weeks in vitro). In control
cultures, we found that the K agonist inhibitory action exhibited
similar properties to those displayed in adult spinal cord prepara-
tions.
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TABLE 2. Effect of chronic treatment of rat spinal cord-dorsal root
ganglion primary cultures with etorphine on adenylate cyclase inhib-
ition by opiates, carbachol and norepinephrine.
untreated cells
(% activity)
Etorphine treated cells
(% activity)
basal activity
+U50488 10µM
+U50488 10µM
+naloxone 100µM
+naloxone 100µM
Forskolin stimulated
activity (25µM)
+U50488 10µM
+U50488 10µM
+naloxone 100µM
+naloxone 100µM
+carbachol 1mM
+norepinephrine 1mM
100 (4.97 0.14) 100 (4.87 0.33)
86 2**
98 1
99 2
102 7+
1 0 0 1
102 1
100 (13.76 0.84)
78+10*
100 (13.66 0.43)
101 4++
94 7
98 3
79 3 
57+5
97 4
97 6
97 7++
761;2+++
Cells were grown for 3 weeks in vitro, the last 4 days in
the presence of etorphine (1µM). Assays were performed in
the presence of 10µM GTP, 100mM NaCl and included the opi-
ates, forskolin, carbachol and norepinephrine in the con-
centration stated. Cells remained in the. presence of
etorphine. until the assay. Then numbers in parentheses cor-
respond to the adenylate cyclase activity in moles/15 min/
mg protein. Results are expressed as percent of activity.
The data correspond to the mean SEM of 2-6 separate exper-
iments performed in triplicate. For each experiment, at
least 2 different cultures were used. The significant of
thedatawas calculated by unpaired student t test (signif-
icance versus basal or forskolin stimulated activities in
control cells*, *p<0.01; **p<0.001; significance versus
untreated cells in etorphine treated cells +p<0.05,
++p<0.02, +++p<O.O01).
In addition, as with the spinal cord tissue the forskolin stimulated
cyclase was inhibited by norepinephrine and carbachol (43 and 21%
respectively). Following chronic exposure of cells to U50488 (10µM)
or etorphine (1µM) for 4 days, the K agonist U50488 lost its ability
to inhibit the cyclase, while the basal as well as the forskolin-
stimulated enzyme activities remained identical to those of paired
control cultures (table 2). Furthermore, the addition of opiate
antagonists such as naloxone (100µM) did not produce any overshoot of
adenylate cyclase activity. Interestingly, the desensitization of
the agonist action on cyclase activity was found to be heteroloqous
since norepinephrine and carbachol exhibited significant lower
potency for inhibiting spinal adenylate cyclase following chronic
treatment by the opioid ligands as compared to control untreated cul-
tures.
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DISCUSSION
Our biochemical data demonsirate that in the spinal cord, opiate
receptors are negatively coupled to adenylate cyclase. The ineffec-
tiveness of µ and ligands as well as the ability of K agonists to
modulate the enzyme activity suggest that the receptors involved are
likely of the K type. The lack of effect of K agonists on basal
enzyme level upon EGTA treatment of membranes suggests the partici-
pation of Ca2+-calmodulin in K opiate-dependent inhibitory circuits.
such involvement of Ca 2 +-Calmodulin has been suggested for adenosine
and enkephalin inhibition of rat hippocampal cyclase (Girardot et al.
1983). Interestingly, the desensitization process was shown to be
heteroloqous, since the 2 adrenergic agonist norepinephrine and the
muscarinic agonist carbachol exhibited lower potency on cyclase
activity after chronic exposure of cultured cells to opiate agonists.
This is in good agreement with recent electrophysiologic studies
showing that cAMP or forskolin not only attenuate the depressant
effects of opioids on sensory-evoked dorsal horn responses in mouse
spinal cord-ganglion explants but antagonized as well the depressant
action of norepinephrine and serotonin (Crain et al. 1986). Such a
pattern of regulation completely differs from that observed in NG108
15 cells, where chronic agonist treatment leads to homologous desen-
sitization with a concomittant increase in adenylate cyclase activity
and subsequent receptor down-regulation (Law et al. 1983). In con-
trast, K receptors in spinal cord cultures only poorly down-regulate
(Attali et al. this volume). Furthermore, the lack of compensatory
increase in adenylate cyclase activity as well as the heterologous
pattern of desensitization rather suggest that the induction of tol-
erance produced by K opiates in the spinal cord is related to altera-
tions of post-receptor regulatory mechanisns such as changes in the
balance of Gi/Gs or in the functional state of Gi.
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SPARE LIGAND BINDING SITES IN THE COUPLING OF OPIOID
RECEPTOR TO BRAIN GTPase
Mary J. Clark and Fedor Medzihradsky
Departments of Biological Chemistry and Pharmacology
The University of Michigan Medical School
Ann Arbor, Michigan 48109-0010
ABSTRACT
Receptor alkylation with 10 µM superfit (SF), an irreversible delta-
specific opioid ligand, in rat brain membranes abolished 73% of
available binding sites for 3H-DSLET without affecting the stimula-
tion of high affinity GTPase by DSLET. Alkylation with 25 µM SF
further decreased the number of low affinity sites and revealed a
slight inhibition of GTPase stimulation. Membrane treatment with 75
µM SF abolished high affinity 3H-DSLET binding and reduced GTPase
stimulation to below 50% of control accompanied by a 10-fold decrease
in the potency of DSLET. Protective alkylation with 25 µM CNA in
the presence of DSLET yielded similar results. The findings describe
spare delta receptors in their coupling to the GTPase effector
component in brain, and reveal possible functional significance of
the low affinity ligand binding sites.
INTRODUCTION
In rat brain membranes opioid agonists stimulate high affinity GTPase
(Barchfeld et al. 1984), recently identified as the inhibitory
guanine nucleotide binding protein in brain (Milligan and Klee 1985).
The stereospecific effect is blocked by opioid antagonists, and the
stimulation by mu, kappa, or delta ligands can be prevented by alky-
lating the respective opioid receptors (Clark and Medzihradsky 1985,
Clark et al. 1986). In the present study, we have investigated the
correlation between delta receptor occupancy and GTPase stimulation
by gradual alkylation of the receptor with superfit, a
delta-selective (Smith et al. 1985) irreversible ligand.
MATERIALS AND METHODS
Membrane preparation (Fischel and Medzihradsky 1981). Membranes from
rat cerebrum were isolated bv differential centrifuaation as des-
cribed. Aliquots of the membrane suspension were kept frozen until
use.
Receptor alkylation (Clark et al. 1986). Membranes were incubated at
25" with different concentrations of SF (methylfentanrlisothiocya-
nate) and subsequently washed by centrifugation and resuspension.
Alternatively, the membranes were incubated with CNA in the
presence of protecting concentrations of DSLET.
Binding assay (Fischel and Medzihradsky 1981). After incubation at
25° to reach binding equilibrium, the suspension of brain membranes
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in the assay medium containing 120 mM Na+ was quickly filtered and
the bound radioactivity determined. Opioid receptor binding of
3H-DSLET was determined as the difference between binding in the
absence and presence of 50 µM unlabeled DSLET. Kd and Bmax were
estimated from Scatchard plots after resolving the high and low
affinity binding components according to Neal (1972). Final values
for the binding parameters were derived through the use of computer
analysis and statistical evaluation as described (Fischel and
Medzihradsky 1981 1986). Presented are the means of results
obtained in 3-5 experiments, with each sample carried out in dupli-
cate.
GTPase assay (Clark et al. 1986). The assay is based on the release
of inorganic phosphate from (gamma- 32P)GTP in the presence of diffe-
rent concentrations of opiates (and 120 mM NaCl). The released
32P-phosphate was separated from the nucleotides by adsorption on
charcoal, and the radioactivity determined by liquid scintillation
counting. The results are expressed as concentration of a compound
to produce half-maximal stimulation of GTPase (KS) and as maximal
stimulation of basal rate (Smax). Shown are the means of data from
3-5 experiments, each sample run in triplicate
RESULTS AND DISCUSSION
Pretreatment with 10 µM SF markedly reduced 3H-DSLET binding to
opioid receptor (fig. 1). Scatchard analysis showed the presence of
both high and low affinity sites with little effect on the respective
Kd's (table 1). In these membranes the ratio of Kd/Ks for the high
affinity binding component was essentially unchanged from that in
control membranes (table 1), suggesting the importance of these
binding sites for coupling to the effector component (Fantozzi et al.
1981). However, following alkylation with 75 µM SF, high affinity
3H-DSLET binding was undetectable but GTPase stimulation, although
impaired relative to control, still occurred. Work is in progress to
elucidate the role of the high and low affinity opioid receptor sites
in the interaction with the guanyl nucleotide binding protein and
adenylate cyclase.
The possibility was considered that at the higher concentration of
SF, partial alkylation of the mu receptor could interfere with the
interpretation of our results. However, membrane treatment with 25
µM of the nonspecific alkylator CNA in the presence of 400 µM DSLET
(Clark et al. 1986) reduced 3H-DSLET binding by 72% without affecting
GTPase stimulation by the delta opiate (KS 6.5 µM, Smax 33%).
In the receptor alkylated membranes GTPase stimulation by DSLET was
blocked by ICI 174,864, a delta specific antagonist. The treatment
of membranes did not increase the basal rate of GTPase activity, and
similar correlations between occupancy of delta receptor and GTPase
stimulation were observed if 3H-DSLET binding was determined in the
GTPase assay medium. It should also be emphasized that the treat-
ments with superfit did not significantly alter the Kd values of
either the high or low affinity receptor binding sites for 3H-DSLET
(table 1), thus indicating the lack of allosteric binding of the
alkylator.
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FIGURE 1. Opioid receptor binding of 3H-DSLET in rat
brain membranes. Cerebral membranes were incubated
with and without  )1O µM superfit as described
under MATERIALS AND METHODS. Subsequently, the
membranes were incubated with different concentrations
of 3H-DSLET to reach binding equilibrium at 65 min.
Plotted is specifically bound radiolabeled ligand
against the concentration of free DSLET in the medium.
TABLE 1
Parameters of opioid receptor binding and GTPase
stimulation in brain membranes
Receptor Binding GTPase stimu-
(3H-DSLET) lation (DSLET)
Membrane Available
treatment Bmax1 Bmax2 receptor
Kd1 Kd2 (fmol/ (fmol/ sites KS Smax
(µM SF) (nm) (nm) mg) mg) (% control) (µM) (%)
0 1.43 19.3 1 5 122 100 5.6 27
10
10
1.37 19.2 5 34 27 7.5 2 5
1.20 13.5 6 23 21 11.0 19
75 18.3 *
100 1 0 0  - *
18 13 57.0 13
* * *-
* undetectable
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To what extent maximal GTPase stimulation reflects inhibition of
adenylate cyclase, the putative effector, is uncertain at this time.
It is of interest to note the similar magnitude of Smax (table 1) and
of maximal inhibition of adenylate cyclase in rat brain membranes
(Law et al. 1981). Spare receptors have been implicated in the
coupling of opioid receptor to adenylate cyclase in NG108-15 hybrid
cells (Fantozzi et al. 1981, Law et al. 1983), and as determinants of
dynorphin potency in smooth muscle preparation (Cox and Chavkin
1983).
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COMPARATIVE PROPERTIES OF SH-GROUPS
AT MU. DELTA AND KAPPA OPIOID RECEPTOR
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ABSTRACT
Crude synaptosomal membrane from rat brain was treated with three
kinds of DTNB analogs. The receptor bindings of opioids were inhib-
ited on a concentration dependent manner by 5-nitro-2-PDS and DTNHEB,
regardless of the receptor types. DTNB showed complete inhibition of
the bindings of mu and delta agonists. But, the effect of DTNB on the
binding of kappa agonist was incomplete, resulting in approximately
50% inhibition at the maximal effective concentration. Treating the
membrane with DTNB, but not with DTNHEB and 5-nitro-2-PDS. completely
eliminated inhibitory effects of guanine nucleotides on agonist bind-
ing. These results suggest that one SH-group, being sensitive to
DTNHEB, exists at an active center of the receptor binding site(R) and
another SH-group, blocked by DTNB, forms a binding site for GTP in
GTP-binding protein(Ni), and that a coupling mechanism between R and
Ni at kappa receptor differs from those at mu and delta receptor.
INTRODUCTION
It is well known that sulfhydryl covalent linking agents such as
NEM and DTNB discriminate between agonist and antagonist bindings to
membrane bound and partially purified opioid receptor, particularly
when DTNB is used (Pasternak et al. 1975, Nozaki and Cho 1985). DTNB
specifically reacts with all the surface SH-groups of protein which
is not influenced by negative charge of DPNB. A SH-group in the opioid
receptor binding site should interact with positively charged N-atom
of opiate. Therefore, without too great difficulty, DTNB can react
with the SH-group in the binding site. We compared the effects of
differently charged DTNB analogs on the opioid receptor binding.
MATERIALS AND METHOD
DTNB and 5-nitro-2-PDS, positively charged analog of DTNB, were
obtained from Dojindo Laboratories (Kumamoto, Japan). DTNHEB was newly
synthesized. Tritiated DHM(80Ci/mmol), DADLE(45Ci/mmol), EKC(23.3Ci/
mmol) and phencyclidine(43.5Ci/mmol) were purchased from New England
Nuclear. Tritiated naloxone(45Ci/mmol). diprenorphine (25Ci/mmol) and
dynorphin-A(1-9)(25.3Ci/mmol) were obtained from Amersham.
Abbreviations used: NEM, N-ethylmaleimide; DTNB, 5,5'-dithiobis-
(2-nitrobenzoic acid); DTNHEB, 5,5'-dithiobis-(2-nitro-n-2'-hydroxyl
ethylbenzamide); 5-nitro-2-PDS, 2.2'-dithiobis-(5-nitropyridine);
DHM, dihydromorphine; EKC, ethylketocyclazocine.
Crude synaptosomal membrane from rat brain without cerebellum was
preincubated at 20°C for 20 minutes with DTNB analog. After washing
the membrane by centrifugation, the membrane was incubated at 20°C for
30 minutes with 3H-opioid ligand and filtered over glass filter
(GF/B). In the case of dynorphin-A(1-9). the binding assay was carried
out with incubation at 4°C for 90 minutes. All assay tubes were
coated with silicon to prevent adsorption of dynorphin. The filter was
pre-soaked with pH 7.4, 50 mM Tris-buffer containing 0.4% BSA and 0.1%
polylisine. The filtrated residue was washed with the ice-cold buffer
containing 0.1% BSA and 100 mM cholin chloride.
RESULTS AND DISCUSSION
The P2-membrane was pretreated with varying concentrations of DTNB,
DTNHEB or 5-nitro-2-PDS. The inhibition profiles of the receptor bind-
ings of a variety type of opioid by DTNB analogs are shown in fig.1.
Positively charged analog of DTNB, 5-nitro-2-PDS, and neutral
analog, DTNHEB, inhibited the receptor bindings of all types of opioid
ligands except phencyclidine on a concentration dependent manner. The
effect of 5-nitro-2-PDS was more potent than that of DTNHEB. DTNB
inhibited agonist bindings of mu and delta ligands. and showed no
effect on the binding of naloxone. In the case of EKC and dynorphin-
A(1-9) bindings, the inhibitory effects of DTNB were incomplete,
resulting in only 50% at the maximum inhibition. When DTNHEB was
applied to the DTNB-treated membrane which showed the maximum inhibi-
tion on the binding of EKC, DTNHEB exerted an additional inhibitory
effects on EKC and dynorphin bindings (Niwa et al. 1983).
These suggest that a state of SH-group at kappa receptor, being
sensitive to DTNB, might be different from that of mu or delta
receptor. No influences of DTNB and its analogs were observed at the
binding of phencyclidine.
After preincubating the membrane with 50 nM DADLE for 20 minutes,
500 µM DTNB or 10 µM DTNHEB was added. At appropriate time, the
membrane was washed and DADLE binding was evaluated. The inhibitory
effect of DTNB on DADLE binding to the membrane was not modified by
the preincubation with DADLE. However, the effect of DTNHEB decreased
at the DADLE-pretreated membrane.
DTNB and its analogs potentiated sodium effects on opioid agonist
binding. There is no difference in the potentiation effects between
DTNB- and DTNHEB-treatment.
Guanine nucleotide inhibits opioid agonist binding to the receptor.
When the membrane was pretreated with DTNB, the inhibitory effect of
guanine nucleotide completely disappeared, but DTNHEB showed no effect
(fig. 2). Preteating the membrane with guanine nucleotide diminished
the effect of DTNB, but not DTNHEB. A SH-group, blocked by DTNB, may
be different on a role from a SH-group, blocked by DTNHEB.
These results suggest that DTNB-sensitive SH-group exists in a
binding site of guanine nucleotide in GTP binding protein and DTNHEB-
sensitive SH-group is a functional group in the center of the receptor
binding site.
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FIGURE 1
Inhibitory effects of DTNB analogs on the receptor binding
of a variety type of opioid; A, dihydromorphine: B, DADLE;
C, naloxone; D, ethylketocyclazocine; E, dynorphin-A(1-9)
and F, phencyclidine.
DTNB, ; DTNHEB, and 5-nitro-2-PDS,
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FIGURE 2
Effects of guanine nucleotides on 3H-DADLE specific bindings
to (A) 500 µM DTNB- and (B) 10 µM DTNHEB-treated membranes.
Open symboles represent results at non-treated membrane
(control) and closed symbols represent results at DTNB- and
DTNHEB-treated membranes: GTP, and GPP(NH)p,
Reactivity of a SH-group in protein depends on its environmental
factor, such as steric interactions and electrostatic effects. There
are little differences in molecular size and general reactivity,
except the effect of attracting force of charged group, among DTNB.
DTNHEB and 5-nitro-2-PDS.
One SH-group in the opioid receptor may be located in an active
center of an anionic binding site for the ligand binding. This SH-
group is blocked by DTNHEB and 5-nitro-2-PDS. Another SH-group
which is located in GTP-binding protein, is in a positively charged
environment and specifically blocked by DTNB. The fact that opioid
agonist binding is selectively inhibited by DTNB supports this
conclusion.
Finally, since the maximum inhibitory effect of DTNB on kappa
agonist binding is approximately 50%, a coupling mechanism at kappa
receptor between the ligand binding site and GTP-binding protein may
be different from those of mu and delta receptors.
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ENHANCEMENT OF PERFORANT PATH TRANSMISSION BY ENKEPHALIN
ANALOGUES; ALTERATION OF GRANULE CELL INHIBITION/POTENTIATION
James B. Wiesner and Steven J. Henriksen
Preclinical Neuroscience and Endocrinology
Research Institute at Scripps Clinic
La Jolla, California 92037, U.S.A.
ABSTRACT
Enkephalin analogues were electrophoretically applied into the den-
tate granule cell layer of the hippocampus in vivo to determine
opioid effects on granule cell responsiveness to afferent input. The
results indicate that opioids, probably acting at µ receptors,
enhance dentate responsiveness to perforant path transmission. This
enhancement includes decreased inhibition and increased potentiation.
INTRODUCTION
Immunocytochemical studies have shown that the dentate gyrus of the
hippocampus of the rat contains endogenous opioid peptides (Gall
et al. 1981, McGinty et al. 1984). To begin to understand the roles
of these opioids, we have applied opioid peptides locally to the
dentate granule cells, in vivo, to determine the effects of opioids
on responsiveness of these cells to afferent input. In addition, we
examined the relative potencies of selective opioid agonists in
exerting these effects.
MATERIALS AND METHODS
These studies involved stimulation of the perforant path, which
evokes an excitatory response by the granule cells. The excitatory
response was recorded as a 'population spike' (PS) within the evoked
field potential. Using halothane-anesthetized rats (250-350), a
concentric bipolar stimulating electrode was stereotactically posi-
tioned within the perforant path (AP -8.1, L 4.4, V dura-3.5), and a
glass 5-barrel recording pipet (8-12 m) was positioned within the
ipsilateral granule cell layer (AP -4.0, L 2.5, V dura-2.7 to -3.5).
The center barrel of the pipet contained Pontamine Sky Blue (2% in
0.5 M sodium acetate), used for marking the recording site. The
outside barrels contained opioid peptides (5mM, pH 7-8 in saline) for
electrophoresis; one barrel contained 3 M NaCl for current balancing.
Input/output (I/O) curves were constructed by plotting PS amplitude
as a function of stimulus intensity. Paired-pulse data were obtained
by presenting pairs of identical stimulus pulses (a Conditioning
pulse followed by a Test pulse) at varying interpulse intervals; the
paired-pulse curves represent the amplitude of the second evoked PS
(Test PS) expressed as a percentage of the first evoked PS
(Conditioning PS) for each interpulse interval.
RESULTS AND DISCUSSION
To obtain an initial assessment of opioid effects on dentate
responsiveness to single or paired-pulse stimulation, analogs of
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methionine-enkephalin or leucine-enkephalin were electrophoresed
within the granule cell layer. The analogs, [2-D-Ala,5-
Met]enkephalinamide (DAMEA) and [2-D-Ala,5-D-Leu]enkephalin exerted
similar effects. Figure 1 illustrates the effect of DAMEA (25 and 75
nA) on responsiveness to single-pulse stimulation. DAMEA shifted the
I/O curve to the left and increased the maximum PS amplitude,
indicating an increased responsiveness to perforant path stimulation.
This effect was reversed by intravenous naloxone administration
(figure 1) as well as by local electrophoretic naloxone
administration (not shown).
FIGURE 1. Effect of DAMEA (25 and 75 nA) on I/O curves, and
blockade by naloxone (5 mg/kg i.v.); N=5.
* p<.05 vs. Control; + p<.05 vs. 75 nA DAMEA [ANOVA].
In order to investigate potential opioid modulation of local
hippocampal circuitry characteristic of the dentate gyrus, we have
employed a standard paired-pulse paradigm of stimulation. When the
stimulus current employed is adjusted to evoke a half-maximal
conditioning PS, two local circuitry effects characteristic of the
dentate gyrus can be observed (figure 2, Control). One such effect,
that of recurrent (or feed-forward) inhibition, is associated with
interpulse intervals of less than 45 msec and is marked by an
inhibited test response. A second, potentiating effect is observed
at interpulse intervals ranging from 50-150 msec.
DAMEA increased the Test PS relative to the Conditioning PS at
interpulse intervals ranging from 30 to 120 msec (figure 2). This
effect could be antagonized by both intravenous and local naloxone
administration. Since the effect of DAMEA is observed over a wide
range of interpulse intervals, the increase could be due to a change
in the sequential inhibition or in the sequential potentiation. We
have found, however, that these two phenomena can be partially
dissociated by altering the experimental parameters. When the
electrophoretic application of the opioid is restricted to a short
time period (eg. less than 11 min.), the relative enhancement of the
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test response is restricted to the portion of the curve dominated by
the sequential inhibitory effect (Wiesner and Henriksen 1986). This
result suggests that DAMEA is able to exert a disinhibitory action in
the dentate similar to that seen in the CA subfields
(Zieglegansberger et al. 1979). Alternatively, when the stimulus
current is adjusted to evoke only a threshold conditioning PS, the
effect of sequential inhibition is minimized, essentially isolating
the sequential potentiation effect. Under these experimental
conditions, DAMEA greatly increased the relative amplitude of the
test response over a broad range (not shown). It therefore appears
that DAMEA increases sequential potentiation as well as decreasing
sequential inhibition.
FIGURE 2. Effect of DAMEA (25 and 75 nA) on paired-pulse
curves (see MATERIALS AND METHODS); N=5. * p<.05
To obtain an initial indication of the specific opioid receptor
type(s) which may be involved in these opioid effects on perforant
path transmission, we applied various selective opioid agonists to
the granule cell layer. Figure 3 shows a comparison of effects on
the I/O curve of a few prototypic agonists, along with DAMEA (25 nA
for 4-6 min). The most effective of the selective agonists was the µ
agonist PL017 morphiceptin. Neither the 6 agonist D-pen,L-pen-
enkephalin (DPLPE), nor the agonist U-50488H were effective at this
dose level. Similar differential effects were observed using paired
pulse paradigm. These results are suggestive that the opioid effects
may be mediated at µ receptors.
We conclude from these results that opioid peptides,by acting at
opioid (possibly µ) receptors, can enhance dentate responsiveness to
perforant path input. Components of this enhanced responsiveness are:
(1) increased primary responsiveness to single stimuli; (2) decreased
sequential inhibition; and (3) increased sequential potentiation. In
excitatory effects of opioids in the CA subfields (Zieglegansberger
et al. 1979), it seems likely that the disinhibitory effect indicated
in the present studies may in turn be responsible for the increased
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FIGURE 3. Effect on the I/O curve of DAMEA, PL017 (µ
agonist), DPLPE ( agonist), and U-50488H( agonist),
(25 nA, 4-6 min, N=3-6). Stimulus levels were threshold
(T), half-maximal (1/2 MAX), or maximal (MAX) for response
levels of each animal; responses were normalized as a
percentage of the Control maximum for each test.
primary responsiveness. Finally, our studies of single unit activity
have shown that, while exerting these facilitatory effects on
perforant path transmission, opioids, in fact, suppress the
spontaneous activity of individual granule cells (Wiesner and
Henriksen 1986). The facilitating effect reported here, therefore,
may be specific to perforant path transmission.
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ABSTRACT
Quantitative autoradiographic distribution patterns of /PCP and
NMDA receptors show striking similarities but not in all brain
areas. We have identified an endogenous ligand of brain PCP recep-
tors which noncompetitively antagonizes NMDA-induced neurotransmit-
ter release from brain slices. These data support the concept that
the  ( /PCP receptor ligands may exert their unique behavioral effects
by indirect modulation of NMDA-mediated transmission.
INTRODUCTION
Binding of SKF10,047-like benzomorphans, phencyclidine (PCP) deriva-
tives, dioxolanes, and benz-f-isoquinolines to /PCP receptors se-
lectively modulates the excitatory effects of the prototypic exci-
tatory amino acid agonist n-methyl-d-aspartate (NMDA). Such drugs
potently and stereoselectively antagonize the excitatory effects of
NMDA on spinal neurones noncompetitively (Berry et al. 1984). In
addition PCP-like drugs potently inhibit NMDA-stimulated acetylcho-
line and dopamine release from rat striatal slices (Snell and John-
son 1985). These effects are selective in that these drugs fail to
modulate the excitatory responses to quisqualate (q) or kainate (k)
type excitatory amino acid receptors. In this study we investigate
the neuroanatomical and functional relationships between /PCP and
NMDA receptors by autoradiographic and biochemical techniques using
exogenous and endogenous ligands of the ( /PCP receptor.
MATERIALS AND METHODS
1. Comparative Quantitative Autoradiographic Localizations:
Adult male Sprague-Dawley rats were decapitated and brains were
rapidly removed and frozen on powdered dry ice, 6 µ sections were
cut at various levels of the brain. Alternate sections were radio-
labeled for PCP and NMDA receptors.
a) [3H]TCP Binding to PCP Receptors:
Brain sections were preincubated in 5 mM Tris-HCl at 37°C for 30
min, then incubated with 5nM [3H]TCP (52.9 Ci/mmol, NEN, MA) in 5 mM
Tris-HCl ph 7.4 at 4°C for one hr (Sircar and Zukin 1985). Adjacent
sections were incubated under the same conditions but in the pre-
sence of 10 µm non-radioactive PCP. At the end of incubation,
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slides were washed sequentially through 6 rinses (6 sec each) of 5
mM Tris-HCl, pH 7.4 At 4°C. Slides were rapidly dried under a
stream of cold air. They were tightly juxtaposed against tritium
sensitive film (Ultrofilm, LKB Instruments, Gaithersburg, MD) at
room temperature for 4 weeks. 10 µ thick sections were cut from a
tritium standard (3H-microscale block, Amersham, IL). These sec-
tions were dry-fixed to slides and at least one such 3H-microscale
containing slide was placed against each film.
b) [3H]L-Glutamate Binding to NMDA Receptors:
Slides containing brain sections were preincubated at 30°C for 10
min to remove endogenous
30 min at 4°C in 100 nM [3H]L-glutamate
lutamate. The sections were incubated for
(47.7 Ci/mmol, NEN, MA) in
50 mM Tris-acetate ph 7.2 at 4°C (Monaghan and Cotman 1985). Alter-
nate sections were incubated under the same conditions but in the
presence of 100 um NMDA. Following incubation the sections were
washed four times in ice-cold 50 mM Tris-acetate buffer for a total
time of 30 sec. Sections were dried and tightly juxtaposed against
tritium-sensitive film for 1-3 weeks at 4°C. Each film also carried
3H-microscale-containing slides.
c) Development and Quantification of Films:
Following exposure, films were developed in Kodak D19 for 5 min at
20°C, rinsed in water for 20 sec and fixed for 10 min. Autora-
diograms were analyzed by an image processor (Quantimet 920, Camb-
ridge Instruments, UK) which produced an electronic image of the
autoradiographic section with point-to-point digitization to give
optimal resolution and gray-scale separation. The system was then
calibrated to convert gray levels into optical density values by
using standards of known optical density. Color-coded images of the
brain section for receptor density (fmol/mg tissue) were generated.
FIGURE 1: Effect of Hippocampal HPLC Fractions 23-38 (1) and 56-
66 (2) on NMDA-stimulated [3H]DA and [14C] ACh Release
2. Extraction of Endogenous PCP-like Ligand:
Six hundred bovine hippocampi were freshly dissected from fresh
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whole brains, immediately frozen on dry ice and lyophilized. Dried
fragments (1 fragment = 1 hippocampus) were acetone-defatted and
hot-acid extracted using the method of Vale et al. (1983). Extracts
were further purified with 300 g Vydac reverse phase C18 sorbent.
Prior to assay, aliquots of starting material were again purified by
adsorption to hydrophobic derivatized gel using prepacked 6-ml bond
elute columns containing 500 mg C18 sorbent. The crude starting
material showed dose-dependent inhibition of [3H]TCP binding at
doses up to 100 millifragments (mf) per assay tube. This material
was further purified by HPLC on a Vydac C18 preparative cartridge (5
X 30 cm) using a TFA/CH3CN solvent system consisting of buffer A:
0.1% TFA and buffer B: 40% buffer A and 60% CH3CN at a flow rate of
75 ml/min (Zukin et al. submitted for publication).
3. Effect of Endogenous Ligand on NMDA-Induced ACh and NE Release:
Male Sprague Dawley rats were decapitated and the corpora striata
were removed, sliced and preincubated in a modified Tyrode's buffer
adjusted to pH 7.4 for 10 min at 4°C. [3H]choline hydrochloride or
[3H]dopamine was added to the buffer at final concentrations of 50
and 100 mM, respectively. Slices were then su erfused with the
buffer solution containing 10 µM hemicholinium ([3H]choline release)
or 10 µM pargyline ([3H]DA release). The superfusate was then
collected and radioactivity was determined. NMDA-stimulated tritium
release was calculated by the method of Snell and Johnson (1985).
Assays were carried out in the absence of magnesium ions, which
inhibit NMDA-induced neurotransmitter release.
RESULTS AND DISCUSSION
TABLE 1: Regional Distributions:A Similarities
REGION RECEPTOR DENSITY RECEPTOR DENSITY
[3H]TCP* [3H]L-glutamate**
CA1 98.4% 100.0%
CA2 100.0% 97.0%
Dentate gyrus 87.7% 93.3%
Medial amygdala 71.9% 55.9%
CA3 54.3% 62.0%
VMH 53.3% 34.8%
Post. cingulate cortex 38.2% 37.6%
Entorhinal cortex 36.4% 48.0%
Median eminence 34.2% 44.9%
Arcuate nucleus 33.9% 36.3%
Subiculum 28.7% 24.8%
Substantia nigra 25.4% 13.1%
Superior colliculus 17.9% 29.4%
Cerebellum 8.1% 13.7%
Ventral tegmental area 6.6% 20.9%
Pontine ret. Formation 5.1% 13.1%
Globus pallidus 1.3% 10.6%
* data expressed relative to CA2 (receptor density = 100%)
** data expressed relative to CA1 (receptor density = 100%)
We have demonstrated neuroanatomical and functional relationships
between /PCP and NMDA receptors by autoradiographic, biochemical
and bioassay techniques. Regional distribution of NMDA and PCP
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receptors show striking similarities in certain brain areas (table
1) in agreement with Maragos et al. (1986). Hippocampus had the
highest level of both types of receptors with hippocampal fields
CA1, CA2, and dentate gyrus having higher levels than CA3. Other
regions that showed similar distributions included medial amygdala,
VMH, various cortical areas, substantia nigra, cerebellum, ventral
tegmental area, arcuate nucleus, median eminence, subiculum, pontine
reticular formation and globus pallidus. NMDA and PCP receptor
distributions were dissimilar in certain regions, most notably cen-
tral gray, anterior cingulate cortex, caudate-putamen, nucleus ac-
cumbens, dorsal thalamus, septal area and preoptic nucleus (table
2). The endogenous ligand of /PCP receptors which we have identi-
fied mimics the effects of PCP-like drugs on the NMDA system. Par-
tially purified bovine hippocampal extract was found to have PCP-
like inhibitory effects on both NMDA-stimulated DA and ACh release
(figure 1).
TABLE 2: Regional Distributions: Dissimilarities
REGION RECEPTOR DENSITY RECEPTOR DENSITY
[3H]TCP* [3H]L-glutamate**
Dorsomedial hypothalamus 68.9% 44.5%
Central gray 30.5% 11.0%
Ant. cingulate cortex 26.9% 88.1%
Auditory cortex 22.0% 53.1%
Interpeduncular nucleus 21.9% 4.2%
Caudate-putamen 12.4% 60.7%
Preoptic 11.0% 33.5%
Laterodorsal thalamus 6.4% 81.5%
Mediodorsal thalamus 6.3% 36.4%
Nucleus accumbens 5.3% 83.8%
Lateral septum 3.9% 87.4%
Medial septum 1.7% 22.9%
* data expressed relative to CA2 (receptor density = 100%)
** data expressed relative to CA1 (receptor density = 100%)
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ABSTRACT
Using preparative HPLC, Sephadex G-25 and analytic HPLC, we
obtained an active peak inhibiting (3H) PCP receptor binding, with
a molecular weight of 3,000 daltons. Another isolation process
included acetic acid extraction, Toyopearl HW gel filtration,
Sephadex G-10 chromatography and analytic HPLC. An active peak was
also observed, which was consistent with that from the first
isolation process.
INTRODUCTION
Phencyclidine (1-(1-phenylcyclohexyl) piperidine, PCP) is a psycho-
tomimetic drug. The existence of specific, high-affinity, stereo-
selective PCP binding site in mammalian brains has been reported by
various groups since 1979 (Zukin and Zukin 1979, Vincent et al. 1979).
Elucidation of endogenous ligand for PCP receptor may bring important
imformation to the studies on mental activities and related diseases.
Quirion et al. (1984) reported a fraction of PCP-like peptide isolated
from the porcine brains. But the sequence has not been published yet.
In our laboratory, an active peak inhibiting (3H) PCP receptor
binding was observed from human brains (Lu et al. 1986). I- this
paper, we report further isolation and purification of this fraction.
METHODS
First isolation process: Human brains (willed contribution) were
processed into acetone powder, extracted by acids and chromatographed
on a preparative HPLC (Lu et al. 1986). The fractions containing
activity were lyophilized and chromatographed by Sephadex G-25 (total
volume 55 ml, superfine), and eluted with 0.5 M acetic acid. Then the
active fraction from Sephadex G-25 was further purified by analytic
HPLC with µ Bondapak Cl8 column, and eluted with a gradient of
acetonitrite.
Second isolation process: Sample was extracted by 0.5 M acetic acid
from acetone powder, and chromatographed on Toyopearl HW column
(total volume 400 ml) at a flow rate of 40 ml/hr. The active fraction
was processed through Sephadex G-10 for desalination and analytic HPLC
for further purification.
(3H) PCP receptor binding assay: Same as which described in our
privious paper (Lu et al. 1986).
RESULTS
The 10th min fraction eluted by 30% acetonitrile in preparative HPLC
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Fig. 1. Active peak (B) eluted
from Sephadex G-25 column and
peaks monitored by U.V. 254 nm
(A); a further purification for
active fraction obtained from
preparative HPLC. The column
was eluted by 0.5 M acetic acid,
and collected by O.D. peaks and
screened with (3H) PCP binding
assay.
Fig. 2. Molecular weight of endo-
genous PCP-like substance. MW of
fraction 3 from Sephadex G-25
(in fig.1) was determined on
Sephadex G-25 column, checked
with standards: insulin (MW
5,200), insulin B-chain (MW
3,200) and LH-RH (MW 1,000).
was chromatographed on a Sephadex G-25 column. An active peak
(fraction 3) was overlapped with the main peptide peak monitored
under U.V. 254 nm (fig.1). The molecular weight of the active
substance is around 3,000 daltons (fig.2). The fraction 3 under-
went through analytic HPLC; the active peak was located at around
30% acetonitrile elutions and the recovery was about 1 %, so
another isolation process was used. As shown in fig. 3, desalted
fraction G from Toyopearl HW gel filtration potently inhibited (3H)
PCP receptor binding, to non-specific binding level. The fraction
G was not degraded by pronase (Sigma) (fig. 4). After the fraction
G was chromatographed with analytic HPLC, the activity was
decreased about 99 %.
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Fig. 3. Chromatogram (A) and peaksdetecting (3H) PCP receptor
activity (B), sodium (C) and potassium (D) content of fractions
from Toyopearl HW gel filtration. Sample was extracted by 0.5
M acetic acid from acetone powder, and eluted by the same acid.
Fractions were collected according to peak of O.D. under 254 nm
ultraviolet spectrum. The fraction G and H were processed
through Sephadex G-10 for desalination before (3H) PCP receptor
binding assay.
DISCUSSION
Many authors reported that known neurotransmitters and neuropeptides
could not inhibit (3H) PCP receptor binding (Quirion et al. 1984).
In our experiments, the endogenous PCP-like substance was obtained
with both isolatIon processes. Other factors, pH and salts, which
interfere with (3H) PCP binding, were ruled out in our experiments.
So we consider that the active peak obtained in present studies
represents the endogenous ligand for PCP receptors.
Quirion et al. (1984) reported that the PCP-like substance was a
peptide. Analytic HPLC with reverse phase C18 column was usually
used for purification of peptides, but in our experiment, the
recovery of both preparative HPLC and analytic HPLC were as low as
1 %. Now we are trying new methods for purification of PCP-like
substances.
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Fig. 4. Effect of pronase on fraction G from Toyopearl HW gel
filtration and Sephadex G-10. In control (below), sample of
fraction G was incubated with unactive pronase, which pretreated
in boiling water for 10 min, in Tris-HCl buffer (pH 7.5) at
37°C for 30 min, then isolated by Sephadex G-25. Only one peak
was observed, with receptor binding activity and a MW of around
3,000 daltons. But in incubation with enzyme (upper), the 3,000
daltons peak with (3H) PCP binding activity was remained intact.
Beside, there was a smaller peak (without binding activity,
MW around 1,000) behind the active peak.
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ABSTRACT
anceran just before the salts in Sephadex G-25 column and was
luted with low concentrations of acetonitrile in reverse phase HPLC
predicating that it may be a small hydrophilic compound with a MW.
of less than 1,000 daltons.
A fraction which potently and specifically competed-with 3H-PCP
binding to rat membranes was isolatedfrom human CSF. This subst-
INTRODUCTION
Phencyclidine(PCP) has received increasing attention recently not
only because of its abuse hazards, but also its unique CNS effects.
PCP-induced psychosis resembles schizophrenia. Various laboratories
described the specific binding sites of PCP in rat and human brains
with characteristic regional distribution (Vincent et al.1979;Zukin
and Zukin 1979;Sircar and Zukin 1983). Several papers suggested that
PCP receptors were well related to its psychotomimetic effects and
that endogenous ligands for the receptors might be present in CNS
(Quirion et al. 1984). Therefore, a search for this kind of ligand
will cast some light on the pathogenesis of schizophrenia. Quirion
et al.(1984) reported a peptide ligand in porcine brain. In our
laboratory, with preparative HPLC, a fraction which inhibited 3H-
PC? binding to rat membrane was found in human brain (Lu et al.
1986). Here, we report a fraction isolated from human CSF with
potent 3-PCP binding activity.
MATERIALS AND METHODS
(+)-3H-PCP (48 Ci/mmol; 1 Ci=37 G Bq, New England Nuclear). PCP
was synthesized by Dept. of Pharmaceutical Chemistry of this Univ.
CSF was collected via lumbar puncture at 8-9 A.M. from patients su-
ffering from peripheral neuritis or myelopathy without any psycho-
tropic medication. It was frozen immediately after the collection,
then lyophilized (5 ml in each tube) for use.
The lyophilizsd samples were resuspended in 0.5 M acetic acid and
chromatographed on column of Sephadex G-25 fine (1.2x60 cm, 9 ml/
hr) eiuted with 0.5 M acetic acid using LKB automatic collector,
Aliquots were collected, lyophilized for H-PCP receptor binding
assay. The fractions containing 3H-PCP binding activity were pooled
and chromatographed in 0.1% heptafluorobutyric acid, They were chro-
matographed on 3.9x30 cm u Bondapak C18 column at a flow rate of
0.6 ml/min. eluted with gradient 0-40% acetonitrile and were moni-
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tored under 230 nm ultraviolet wave spectrum. The samples from analy-
tical HPLC were further screened by 3H-PCP binding assay.
Rat brain membranes were prepared according to Quirion et al.(1984)
with a few modifications. For 3H-PCP receptor binding assay, dupli-
cate assay tubes contained 8 nM 3H-PCP, membrane preparation of 10 mg
tissue and chromatographic fractions (their pH was adjusted to 7.6)
or standards(PCP) all in 5 mM Tris-Hcl/5O mM sucrose pH 7.6 at 4°C
in a final volume of 0.5 ml. Incubation took 45 min.at 4°C, then the
samples were filtered under reduced pressure through GF/C fiters(Wha-
tman) which presoaked for at least two hrs. at 4°C in 0.05% polyeth-
lenimine, then rapidly washed with 2x5 ml aliquots of ice cold 5.0 mM
Tris-Hcl buffer. Each filter was dried by infrared lamp, then placed
in vials containing 5 ml of liquid (TP 0.3%, POPOP
and counted by liquid scintillation spectrometry.
0.03% in toluene)
3H-PCP specific
binding to synaptic membranes was defined as the difference in radio-
activity bound in the-absence and presence of 20 uM PCP. In a typical
experiment, total binding was 2,400 cpm and non-specific binding was
800 cpm.
RESULTS
1. Human CSF went through Sephadex G-25 fine column
Human CSF was applied to a Sephadex G-25 fine column at a flow rate
of 9 ml/hr and monitored under UV 254 nm. Aliquots of the 3 ml elua-
te in each tube were collected and lyophilized. Each fraction was
assayed with 3H-PCP receptor binding and salt concentrations measured
by Beckmenn system E-4A electrolites analyze.(See fig.1)
Fig.1 Human CSF went through Sephadex
G-25 fine column
2. Active peak and salt peaks
As fig.2 shows, human CSF contains an active fraction No.17-19 and
salts peaks No.20-21. The pH of all fractions for binding assay
were 7.5. Some were adjusted by 5 mM Tris solution(pH 8.5 at room
temperature). The experiment was repeated three times. Since the
salt will interfere the 3H-PCP binding, the salt containing fractions
(20,21) were discarded. The fractions No.17-19 were combined and
lyophilized for analytical HPLC.
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3. Analytical HPLC elution pattern of fraction No.17-19
Fig.2. Active peaks and salt peaks screened by
3H-PCP binding assay and salt analyzer respectively
active peaks
sodium peak
potassium peak
Fig.3 Analytical HPLC elution pattern of fraction
No.17-19 from Sephadex G-25 chromatography
Fig.3 showed the peaks within 30 min. elution after injection of
fraction No.l7-19(see Fig.2). Elutes were collected by eaks moni-
tored with UV 230 nm and lyophilized, then screened by 3H-PCP binding
assay. The bared peaks possessed activity for inhibiting 3H-PCP
binding.
DISCUSSION
According to work of many laboratories, including our past work, 3H-
PCP binding assay was specific, and none of the known neurotransmitters
and neuropeptides could displace its binding in reasonable concentra-
tions(Quirion et al.1984;Lu et al.1986). In this experiment, we ex-
cluded the factors which might interfere with binding, such as pH
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and salts. Therefore, we consider the endogenous ligand in human CSF
is conceivable. It may be released directly from brain or as active
metabolite of some authentic forms of PCP-like substance. Unlike the
neuropeptide reported by Quirion et al., our fraction may be small
hydrophilic compound, since it ran just before the salts in Sephadex
G-25 column and was rapidly eluted with low concentrations of aceto-
nitrile in reverse phase HPLC. Its molecular weight may be less than
1,000 daltons. The biochemical properties of the ligand are to be
determined.
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ABSTRACT
Radio-binding assay, bioassay and HPLC detection were used to observe
the antagonistic effects of dextrorphan on PCP's actions. Dextrorphan
displayed high affinity to PCP receptors and it had weak PCP-like
bioactivity, but could antagonize PCP's action dose-dependetly in
vitro and shift the dose-response curve to the right. PCP increased
the contents of norepinephrine in bath medium, which was reversed by
dextrorphan. Thus, the results suggest that dextrorphan is a partial
antagonist for PCP receptors.
INTRODUCTION
Using radio-binding assay, we have demonstrated phencycliding(PCP)
receptors in the blood vessel and in vitro bioassay showed that PCP
markedly enhanced the electrical field stimulated construction of
rabbit central ear artery(ESC)(Zhu et al.1986). Dextrorphan, a d-iso-
mer of levorphanol, could displace PCP binding to the membrane prepa-
ration of blood vessels and it could decrease the excitatory effects
of PCP on ESC. In this paper, we used three different ways to demons-
trate dextrorphan being a partial antagonist for PCP receptors.
METHODS AND MATERIALS
Animal: New Zealand rabbit weighting 2-2.5 Kg.
Materials: 3H-PCP(38Ci/mmol) and PCP were made by Drs. Gong JL and
Sun OF in the school of pharmacy of this university. Dextrorphan and
levorphanol were generous gifts of Dr. Avram Goldstein, Addition Re-
search Foundation, U.S.A. Phentolamine was made by the pharmaceutic
factory of this university, and norepinephrine bitartratis, by Shang-
hai Tenth Pharmaceutic Factory.
Radio-binding assay: Rabbit mesenteric blood vessels were homogenized
in ice-cold 5mM Tris-HCl, pH7.4. The homogenate was centrifuged at
500xg for 10 min and at 16,500xg for 30 min(4°C). The pellet (2.4mg
ptotein) and 3H-PCP(5.2nM) were incubated with various ligands with a
final volume of 0.5ml at 4°C for 60 min and terminated by rapid fil-
tration(GF/C or GF/B filters preincubated in 0.05& polyethylenimine).
Non-specific binding and specific binding
sence or absence of unlabelled PCP (20µM). Filters were counted by
were abserved in the pre-
liquid scintillation spectrometry.
Bioassay: The central ear artery of rabbit was prepared in a length
of 4-5mm. The preparation was suspended under 0.5g of tension and
incubated in 4ml bath organ containing Krebs solution at 37°C through
a mixture of 95% O2 and 5% CO2 and equilibrated for 4-5hrs prior to
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receiving electrical field stimulation(25v, 5-6Hz, trains of 5 pulses,
lms per pulse, 2.5 min of interval between trains). Dextrorphan and
levorphanol were given 10 min before administration of PCP. Dose-
response curves of PCP were constructed by increasing bath medium
concentration of PCP cumulatively.
High performance liquid chromatography(HPLC): The amine was separated
on a GYT-C18 column (20x0.5cm I.D., 1OµM partical size) and 0.15M
chloracetic acide-sodium hydroxide buffer with 0.83 nM EDTA, 9 nM D-
Campher sulfonic acide, pH 4.2 and methanol (92:8) at a flow rate of
1.5ml/min and detected by a LC-4B/17 electro-chemical detector.
RESULTS
Radio-binding assay showed that 3H-PCP could bind with high specifi-
city to rabbit blood vessel membranes with Kd=31.9±3.0nM, Bmax=4.96±
0.29pmol/mg protein. Dextrorphan and levorphanol could displace 3H-
PCP binding to rabbit blood vessel with IC50=3.01±0.19 and 18.2±1.2
µM, respectively (fig.1).
In bioassay, the ESC was enhanced by PCP in a dose-dependent manner.
Dextrorphan reduced, even abolished the effect of PCP on ESC and
shifted its dose-response curve to the right (fig.2 and fig.3). Dex-
trorphanand levorphanol decreased the maximum effect of PCP, the pD2'
for them were 6.8463 and 5.5862, respectively.
The contents of norepinephrine in bath medium were 16.53±0.37ng/ml
after 20 min electrical field stimulation only. The contents were in-
creased to 20.36±1.13 nq/ml after administration of 10-5M of PCP, and
decreased to 17.04±0.698 ng/ml after using 10-6M of dextrorphan (fig.
4).
displacing 50% of specific
bound. The experiment has
been replicated three times.
DISCUSSION
detection, we have demons-Using the binding assay, bioassay and HPLC
trated that dextrorphan is a specific antagonist for PCP receptors.
Fig.1 Displacement curves
of ligands inhibiting 3H-
PCP binding to the homoge-
nate of mensenteric blood
vessel.
The ordinate represents
persentage inhibition of
specific binding of 3H-PCP
(5.2nM) to the homogenate(
2.4mg protein per assay
tube). IC50s represent cone
centrations of ligands that
In radio-binding assay, we have found that specific, saturable and
stereoselective PCP binding sites in the blood vessels(Zhu et al.
1986). The binding sites could be displaced by PCS analogs and some
benzomorphan derivatives. Here, we observed that H-PCP binding to
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the blood vessel could be displaced by dextrorphan dose-dependently
and sereospecifically, thus demonstrating that dextrorphanhad high
affinity to PCP receptor.
Fig.2 The effects of dextrorphan
on ESC and the reversal effects
of it on PCP's action.
The vasoconsitriction was induced
by electric-field stimulation. PCP
enhanced such vasoconstriction
and dextrorphan reversed the effe-
ct of PCP(left). Dextrorphan alone
has a slight excitatory effect on
the vasoconstriction(right).
Fig.3 Right-shited dose-response curves of PCP by dextrorphan
(left) and levorphanol(right).
The ordinates showed vasoconstrictive responses of ligands
compared with the maximum effect of PCP. Dextrorphan or le-
vorphanol was added in the medium 10 min before administration
of PCP. Dextrorphan(1O-8M) significantly shifted the dose-res-
ponse curves to the right with a pD2'=6.8463, while levorphanol
showed an effect about 10 times less potent(pD2'=5.5864).
Bioassay showed that PCP could markedly and dose-dependently enhance
the ESC. The concentrations for half maximum effect of PCP(pD2) were
6.5928 to 6.6665. Dextrorphan showed very weak PCP-like bioactivity
(fig.2), but it could antagonize the enhancing ESC by PCP and shifte
the dose-response curves of PCP to the right. Levorphanol, a l-enan-
timer, also had such antagonizing effect, but with lower pontency(fig.
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33). The bioactivity of d- and l-isomers in antagonizing PCP's action
on ESC was consistent with the affinity of those ligands to PCP re-
ceptor, which also was the same as that obtained from radio-binding
assay in the rat brain(Tam 1983). In both binding assay and bioassay,
dextrorphan was about 10 times more potent than that of levorphanol,
which is another evidence for dextrorphan being an antagonist for PCP
receptors.
Fig.4 The norepinephrine contents
in the medium after administration
of PCP or PCP and dextrorphan.
The bath medium was collected after
20 min of electric-field stimulated
without any drugs or with PCP(10-5M
or/and dextrorphan(10 M). The nore
pinephrine contents in the bath me-
dium were measured by PHLC.
The effects of PCP on ESC could be abolished by phentolamine and the
norcpinephrine contents in bath medium detected by HPLC was markedly
increased after administration of PCP, suggesting that the vasoconstr-
iction induced by PCP may be produced by increasing the release of
norepinephrine from the nerve terminals. On the contrary, dynorphin
could inhibit the ESC and its action may produced by inhibiting the
release of norepinephrine(Sun et al 1983 and Illes et al 1983). In
this paper, we showed that dextrorphan could antagonize the increment
of norepinephrine content in bath medium by PCP. This result have
further supplied the evidence that dextrorphan is a PCP antagonist.
Since dextrorphan per se showed weak PCP-like effect and it decreased
the maximum effect of PCP, we considered it a partial antagonist for
PCP receptor.
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HIGH AND LOW AFFINITY PSYCHOTOMIMETIC OPIOID BINDING SITES:
CHARACTERIZATION BY A NOVEL 3H-PCP-ANALOG
Yossef Itzhak
Dept. of Pharmacology, Hadassah School of Medicine, The Hebrew
University, Jerusalem, Israel
ABSTRACT
1-[1-(3-Hydroxyphenyl)cyclohexyl]piperidine (PCP-3-OH) is one of the
most potent analogs of phencyclidine (PCP). In the present study we
describe the binding properties of 3H-PCP-3-OH to guinea pig brain
membranes. Scatchard analysis of saturation binding studies revealed
the existence of high (0.44nM) and low (17nM) affinity binding
components. High affinity binding sites were completely blocked in
the presence of (+)SKF 10047 (50nM). In competition studies PCP
analogs compete for 3H-PCP-3-OH specific binding in a monophasic
manner whereas psychotomimetic opioid ligands compete for this
binding in a biphasic manner. Results from both saturation and
competition experiments suggest the existence of a common high
affinity binding site for psychotomimetic opioid ligands and PCP
analogs and a low affinity binding component primarily for
phencyclidines.
INTRODUCTION
On the basis of behavioral experiments (Shanon 1981; Brady et al.
1982) and binding studies (Zukin and Zukin 1979; Vincent et al. 1979;
Quirion et al. 1981; Zukin and Zukin 1981; Itzhak et al. 1981a) it
has been suggested that PCP and psychotomimetic opioids, such as
SKF-10047, may share a common binding site in CNS. Sigma opioid
receptors, originally proposed for SKF 10047 and related benzo-
morphans (Martin et al. 1976), are now termed "sigma opioid/PCP"
receptors. The biochemical characterization of these binding sites is
somewhat hampered, compared to mu, delta and kappa opioid receptors,
primarily by the lack of highly potent and/or selective "sigma"
ligands. The high dissociation constant of 3H-PCP (ca. 200nM) (Zukin
and Zukin 1979; Vincent et al. 1979) may give rise to difficulties in
receptor binding studies involving such a ligand. However, recently
by utilizing 3H-(+)SKF 10047 we reported the existence of common high
affinity (Kd=20nM) dextrorotatory-opioid binding sites for psychoto-
mimetic opioids and phencyclidines in rat CNS (Itzhak et al. 1985).
The aim of this study was to determine whether "sigma opioid/PCP"
binding sites represent a single or multiple binding components.
Utilizing PCP-3-OH, which produces strong psychotomimetic PCP-like
effects (Kalir et al. 1978) in its radiolabeled form (3H-PCP-3-OH),
we present evidence for the existence of multiple binding components
for psychotomimetic opioids and phencyclidines in guinea pig brain.
MATERIALS AND METHODS
3H-PCP-3-OH (9.8 Ci/mmole) was purchased from Israel Nuclear Research
Center-Negev, Israel. The purity of the drug as determined by thin
layer chromatography and U.V. spectrophotometer was > 99%. PCP and
its derivatives: PCP-3-OH, 1-[1-(3-aminophenyl)cyclohexyl]piperidine
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(PCP-3-NH2), 1-phenylcyclohexylamine (PCNH2), N-ethyl-phenylcyclo-
hexylamine (PCNHEt), and 1-(1-phenylcyclohexyl)-4-piperidinol (PCP-
4'-OH), were synthesized as previously described (Kalir et al. 1978;
Itzhak et al. 1981b). The two stereoisomers of SKF 10047 were
generously supplied by Dr. R. Hawks National Institute on Drug Abuse.
Other drugs were purchased from commercial sources. Crude guinea pig
brain (minus cerebellum) membranes were prepared as previously
described (Simon et al. 1975). Binding assays were carried out in
HEPES-KOH buffer 1OmM (pH 7.7; 25°C) as previously described (Itzhak
et al. 1985). Specific binding of 3H-PCP-3-OH was assessed in the
absence and presence of 1µM unlabeled PCP-3-OH or PCP, which resulted
in similar levels of non specific binding.
RESULTS AND DISCUSSION
In typical experiments specific binding of 3H-PCP-3-OH (3nM) to
guinea pig brain membranes represented 80±3% of total binding. Radio-
activity absorbed to GF/B filter blanks was usually less than 5% of
the total binding. Specific binding increased linearly within protein
concentration of 0.2-1.7mg/ml and was reduced in the presence of
trypsin (20µg/ml) or N-ethylmaleimide (0.5mM) by 66 and 54%, respect-
ively, from control binding. Preincubation of membranes at 60°C/20
min resulted in 90±5% decrease in specific binding. These findings
are consistent with the requirements for drug-receptor interaction
and indicate the protein nature of the binding sites. Saturation
binding experiments of 3H-PCP-3-OH were carried out at concentrations
of 0.2-40nM and revealed two saturable binding components. Scatchard
analysis of the specific binding resulted in a biphasic plot (Fig.
1). Apparent Kd values, calculated as described by Munson and Rodbard
(1980), are 0.44nM and 17nM for high and low affinity binding
components, respectively.
The ability of various PCP-analogs and psychotomimetic opioid ligands
to compete for 3H-PCP-3-OH (3nM) specific binding was also studied.
The rank order of potency among PCP analogs was as follows: PCP-3-OH>
PCP=PCNHEt>PCP-3-NH2>PCNH2>PCP-4'-OH. The IC50 determined for PCP-3-
OH was 7nM, whereas the I? 50 for the least potent analog, PCP-4'-OH,
was 860nM. This rank order of potency is consistent with that found
in behavioral studies (Kalir et al. 19 8; Shanon 1981; Solomon et al.
1982) and competition studies for 3H-(+)SKF 10047 binding sites
(Itzhak et al. 1985). All PCP analogs competed for 3H-PCP-3-OH
specific binding in a monophasic manner yielding Hill coefficient
values near 1.
Psychotomimetic opioids, such as (+)SKF 10047, ketocyclazocine,
pentazocine, nalorphine and dextrallorphan competed for 3H-PCP-3-OH
specific binding in a biphasic manner (Fig. 2). About 30% of the
binding was readily inhibited by low concentrations (1-25nM) of these
opioids, whereas the residual binding of 3H-PCP-3-OH was far less
sensitive (Fig. 2). The levorotatory isomer of SKF 10047 (Fig. 2),
levorphanol and levallorphan inhibited 3H-PCP-3-OH specific binding
only at high concentrations and in a monophasic manner, yielding IC
values of 350-800nM. However, morphine (u-agonist) naloxone, DADL
( -prefering ligand) and tifluadom (K-agonist) as well as non-opioid
ligands, such as haloperidol and atropine (each at 1nM-10µM) did not
affect the binding of 3H-PCP-3-OH.
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FIGURE 1. Scatchard plot of 3H-PCP-3-OH specific binding to
guinea pig brain membranes. Binding of tritiated ligand
(0.2-40nM) was carried out at 25°C for 40 min. Specific binding
was assessed in the absence and presence of PCP-3-OH (1µM).
Points represent a typical experiment which was repeated three
times with similar results.
FIGURE 2. Inhibition of 3H-PCP-3-OH (3nM) specific binding to
guinea pig brain membranes by unlabeled PCP-3-OH and selected
opioids. Assays were carried out at 25°C for 40 min. Control
specific binding was 1630±80 cpm. Results represent the mean of
three separate determinations (SEM < 10%).
NANM = N-allylnormetazocine (SKF 10047)
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The ability of (+)SKF 10047 and the racemic mixture of other psycho-
tomimetic opioids, at rather low concentrations, to inhibit a portion
of 3H-PCP-3-OH specific binding,
levorphanol
and the inability of (-)SKF 10047,
and levallorphan to inhibit this binding, at low
3H-PCP-3-OH displays dextrorotatory stereospecificity. Moreover,
concentrations, suggests that the high affinity binding component of
saturation binding studies of 3H-PCP-3-OH in the presence of (+)SKF
10047 (50nM) yielded a linear Scatchard plot (Kd=21nM). These results
indicate that high affinity binding sites for 3H-PCP-3-OH were
completely blocked in the presence of (+)SKF 10047, whereas the low
affinity binding component was practically unaffected.
We have previously demonstrated that 3H-(+)SKF 10047 binds to a
single high affinity binding component and both psychotomimetic
opioids and PCP analogs competed for 3H-(+)SKF 10047 binding sites in
a monophasic manner (Itzhak et al. 1985). These findings together
with the present results strongly support the view that the high
affinity binding component, labeled by 3H-PCP-3-DH, corresponds to a
common high affinity binding site for both phencyclidines and psycho-
tomimetic opioids. The low affinity binding component may correspond
to subpopulation of the sigma binding sites, which interact primarily
with PCP analogs. Thus, it is proposed that "sigma-opioid/PCP
receptor" may represent two distinct subtypes of binding sites.
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ABSTRACT
A new selective opiate antagonist has been synthesised in which the
two glycine residues of diallyl leucine enkephalin have been replaced
by 4-aminobenzoic acid. The compound has a different conformation to
that of ICI 174,864 (N,N-diallyl-Tyr-Aib-Aib-Phe-Leu).
INTRODUCTION
Diallyl enkephalin analogues have been reported by Shaw et al. (1982)
and by Cotton et al. (1984) with selective antagonist activity at the
-opioid receptor in which the amidic link between Gly3 and Phe4 has
been replaced by a methylenethio link (ICI 154.129, structure 1 in
the results table) or in which the two glycine residues have been
replaced by two aminoisobutyric acid residues (ICI 174,864, structure
2 in the results table). We now report the synthesis of the series
of diallyl enkephalin analogues in which the two glycine residues
have been replaced by a single 4-aminobenzoic acid residue or one of
its close relatives. The objectives of the study were to examine the
structure activity relationships of the compounds as opiate
antagonists and to compare the conformation of the most potent and
selective agents with that of the selective -receptor antagonist,
ICI 174,864 (N,N-diallyl-Tyr-Aib-Aib-Phe-Leu).
MATERIALS AND METHODS
Synthetic methods
The novel compounds indicated in the results table were prepared by
standard chemical methods. The route to the 4-aminobenzoic acid
analogue, 4, is indicated in figure 1. The 4-methylaminobenzoic acid
analogue, 6, was prepared by N-methylation (NaH/DMF/MeI) of the amide
formed by the mixed anhydride coupling of 4-aminobenzoic acid ethyl
ester with N,N-diallyl-Tyr(But)-OH. The 3-aminobenzoic acid
derivative, 7, the 4-aminophenylacetic acid derivative, 8, and the 4-
carboxybenzylamine derivative, 9. were made by initial chain
extension at the carboxy-terminus (H-Phe-Leu-OBut, mixed anhydride)
of the starting benzyloxycarbonyl protected amino-acid and subsequent
N-acylation with N,N-diallyl-Tyr(But)-OH. For compound 10, the
coupling of 4-benzyloxycarbonylaminobenzoic acid with N—
methylphenylalanylleucine methyl ester was accomplished with
dicyclohexylcarbodiimide and hydroxybenztriazole. The 4-amino-2-
methylbenzoic acid analogue was prepared starting from 2-methyl-4-
nitrobenzoic acid which was used to acylate the dipeptide ester,
H-Phe-Leu-OBut, by mixed anhydride coupling. Catalylic hydrogenation
(Pd/H2) then reduced the nitro-group to an amino-group for subsequent
177
acylation with N,N-diallyl-Tyr(But)-OH. Mixed anhydride (M/A)
couplings were carried out using ethyl chloroformate and
triethylamine and t-butyl ethers and esters were cleaved by 90%
trifluoroacetic acid.
FIGURE 1. Synthetic route
Biological methods
The compounds were tested as opioid antagonists on the field
stimulated mouse vas deferens against the selective -agonist, [Leu5]
enkephalin and the µ-agonist, normorphine, as previously described
by Miller et al. (1986)
RESULTS
The results in the table indicate that the 4-aminobenzoic acid
derivative, 4, is the most potent -receptor antagonist with a
selectivity ratio of about 100 between the - and µ-receptors. The
presence of methyl substituents on the aromatic ring (11) on the
amino-group (6) or on the nitrogen of the adjacent phenylalanine (10)
all led to loss of potency at the -receptor. Similarly the
inclusion of an extra methylene group as in compounds 8 and 2 caused
loss of activity. These observations were of value in studying the
conformation of the most potent -receptor antagonist, the 4-
aminobenzoic acid derivative, 4, (ICI,167,853).
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TABLE 1. Assay for opiate antagonist activity on field stimulated
mouse vas deferens
Conformational Studies
A major source of flexibility within the diallyl-[Leu5]-enkephalin
molecule is the central Gly2-Gly3 dipeptide unit which can adopt more
than 100 conformations. Energy calculations using ECEPP (Momany et
al. 1975) identified 18 distinct, accessible conformers. Following
earlier studies with L- and D-alanine at the 2 and 3 positions, where
it was shown that only the D-Ala3 analogue was as potent as the
parent compound, two conformers were selected for further study where
the conformation of residue 2 was the same (C7 ax: phi = 80, psi = -
80). The other residue of conformer 1 was relatively extended (phi
= 65, psi = -175), whereas in conformer 2 the right-handed alpha
helical conformation (AR: phi = -54, psi = -60) was postulated.
Substitution of a-aminoisobutyric acid (Aib) for glycine at the 2
and 3 positions led to a 6 fold increase in -antagonist potency.
Further energy calculations on N,N-diallyl-Tyr-Aib-Aib-Phe-Leu
suggested that the conformation adopted by the central dipeptide was
helical but could be either right- or left-handed. Indeed the right-
handed form could be related to conformer 2, in that the tyramine and
phenylalanine entities could be superposed with an RMS deviation of
about 1.5 , however the relative orientations of the leucine side
chains were different.
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In the current work, aminobenzoic acids and homologues were
incorporated as replacements for the two glycine residues. These
"dipeptide mimics" are conformationally restricted ie. the
conformation of the p-aminobenzoic acid (PABA) analogue can be
defined in terms of two torsions corresponding to rotation about the
N-C bond (phi2) and the C-CO bond (psi3). The energetically
accessible values for these torsions are:
phi2 +45,-45,+135,-135
psi3 +50,-50,+130,-130
There are 16 possible combinations of these angles, however, because
of the symmetry and planarity of the phenyl ring, there are only 4
distinct conformations. In addition to the considerable reduction in
flexibility when compared with the Gly2-Gly3 unit (>100
conformations), the PABA moiety cannot mimic the spatial
characteristics of a helical dipeptide such as that suggested for the
Aib2-Aib3 analogue. It was thus intriguing to discover that the
PABA derivative was equipotent with diallyl-[Leu5]-enkephalin, whilst
the meta counterpart (MABA) was an order of magnitude poorer.
CONCLUSIONS
Although energy calculations have suggested a low energy conformation
of the PABA analogue which can be related to the originally
identified conformer 2. the spatial relationships between the PABA
and Aib2-Aib3 analogues are, at best, unclear.
It would appear that the two types of conformational restriction have
both generated potent delta-receptor antagonists, but the restricted
conformations adopted differ in the two cases. This conclusion is
unusual if not unique and was certainly unexpected.
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ABSTRACT
Symmetrical and unsymmetrical dimeric pentapeptide opioid antagonists
have been prepared and studied on the mouse vas deferens preparation.
The findings do not support the hypothesis that such agents bind to
dimeric -opioid receptors.
INTRODUCTION
Dimeric opioid peptides have been reported which have enhanced
selectivity for the opioid b-receptor compared to their monomeric
analogues. Those dimers, prepared by linking two tetrapeptides as
amides of -alkylenediamines, have receptor binding affinities at
the -receptor similar to those of pentapeptide monomers but some
achieve high &selectivity through loss of affinity for the µ-
receptor. However, where two molecules of the pentapeptide Tyr-D-
Ala-Gly-Phe-Leu. were linked as amides of ethylenediamine, a compound
was obtained with a ten-fold enhanced affinity for -receptors and
similar affinity for p-receptors as Tyr-D-AlaXly-Phe-Leu-NH2, as
measured by binding studies. (Shimohigashi et al.1982).
The hypothesis has been advanced that the -selectivity observed is
as a consequence of the dimeric ligands interacting with two, closely
associated, receptors. The objective of this study was to explore
the hypothesis that dimeric peptides have enhanced b-selectivity
because of interaction with a dimeric -receptor. Antagonists
rather than agonists were chosen for investigation so that Ke values
obtained from isolated tissue assays would be a reflection of
affinity rather than affinity and intrinsic activity. The key
experiment was the comparison of symmetrical and unsymmetrical
dimeric pentapeptides as antagonists of [Leu5] enkephalin and
normorphine in the electrically stimulate mouse vas deferens
preparation.
Theoretical Considerations
For the binding of a ligand to a receptor, the free energy of
interaction, G, is related to the affinity constant by the
expression :-
where AH is the change in enthalpy, AS the change in entropy and T
the absolute temperature. Thus, if it were possible to dimerise a
ligand and to allow it to associate with a dimeric receptor such that
the value of G were to be doubled, then the doubling of log K would
be reflected in a squaring of the value of K. Consequently, one
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might see a change of affinity from say 10-7M to 10-14M.
Such enhancements in potency have not been observed for opioid
peptide dimers. On the dimeric receptor theory this could be
explained by entropic factors involved in the association of two
receptors into a dimer, by entropic factors associated with the
flexible linkage in the dimer between the two pharmacophores, or by
unfavourable interactions between the receptor and the polymethylene
chain linking the two monomeric pentapeptides.
MATERIALS AND METHOD
Synthetic methods
Peptide dimers were prepared in which the carboxyl termini of the two
peptide chains were held together as amides of ethylenediamine. The
synthesis used an orthoganol protection strategy in which one arm of
the dimer was elaborated using t-butyloxycarbonyl nitrogen protection
(deprotection with acid) and the other arm was elaborated using
benzyloxycarbonyl nitrogen protection (deprotection with catalytic
hydrogenation). Standard peptide methodology was used throughout the
synthesis.
Thus t-butyloxycarbonyl ethylenediamine, 1a, was elaborated first to
the unsymmetrically protected leucine dimer 1b, and thence to the
phenylalanylleucine dimer, 1c. Peptide chain extension was
accomplished either by the use of protected amino-acid active esters
(4-nitrophenol or 3, 4, 5 - trichlorophenol esters) or by the mixed
anhydride method employing ethyl chloroformate and triethylamine.
The intermediate 1c, was extended to give 2 by a fragment coupling
employing the t-butyl ether of N,N-diallyltyrosinylglycylglycine and
mixed anhydride activation. Similar extension on the second
phenylalanine gave the symmetrical dimer. 3, the unsymmetrical dimer,
4, and the truncated acetyl derivative, 5. The fragment couplings to
convert 2 to 3 and 4 were accomplished using dicyclohexylcarbodiimide
and hydroxybenztriazole activation.
Biological methods
The compounds were tested as opioid antagonists on the field
stimulated mouse vas deferens against the selective -agonist, [Leu5]
enkephalin and the p-agonist. normorphine, as previously described by
Miller et al. (1986).
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RESULTS AND DISCUSSION
FIGURE 1. Assay for opioid antagonist activity on the field
stimulated mouse vas deferens
The symmetrical dimer (3) is a more potent -antagonist than the
monomeric ethylamide but is only comparable in potency to and less
selective as a -antagonist than the monomeric pentapeptide ICI
174,864 (diallyl-Tyr-Aib-Aib-Phe-Leu). The unsymmetrical dimer (4)
is 80 times less potent than 3 but retains some -selectivity. The
most surprising finding is that the truncated dimer (5) is almost as
potent as the symmetrical dimer (3) and has a high -selectivity.
The increase in potency at the -receptor caused by dimerisation is
about nine-foid in this series and is comparable to that obtained in
other compounds with a single tyrosine moiety such as ICI 194,864.
The 80-fold loss of potency at the -receptor caused by the removal
of one hydroxyl moiety from 3 to give 4 is of interest. If the two
peptide chains do not interact with each other, then such a compound
would be expected to be two-fold less potent for a monomeric receptor
system. However, the 80-fold loss of potency going from compound 3
to 4 and the nine-fold difference between the monomeric and dimeric
amide antagonists are still small compared to the orders of magnitude
which might be expected. The high potency and selectivity of the
truncated dimer (5) suggests that the -receptor, but not the µ-
receptor, can tolerate lipophilic residues beyond the normal binding
site of the pentapeptide carboxy-terminus.
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Thus part, if not all, of the potency and selectivity of dimeric
enkephalins can be explained without invoking a dimeric -receptor
system. The differences in potency between dimers and monomers and
between symmetrical and unsymmetrical dimers could be a consequence
of conformational factors whereby a dimer folds as a single large
molecule rather than as a linked pair of monomers each with the
tertiary structure it has in the monomeric state.
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MELPHALAN-CONTAINING N,N-DIALKYLENREPHALIN
ANALOGS AS POTENTIAL IRREVERSIBLE ANTAGONISTS
OF THE OPIOID RECEPTOR
Jane A. Lovett1 and Philip S. Portoghese
Department of Medicinal Chemistry, College of Pharmacy
University of Minnesota, Minneapolis, MN 55455, U.S.A.
ABSTRACT
N,N-Dialkylated leucine enkephalin analogs containing melphalan in
place of Phe4 were synthesized  as potentially irreversible antagonists of
the opioid receptor. These compounds, along with the corresponding
Phe4 pe tides, were tested for both agonist and antagonist activity in the
GPI and MVD smooth muscle preparations. All but one of the com-
pounds showed antagonist activity at 10-6M against [D-Ala2,D-Leu5]-
enkephalin in the MVD when tested under reversible conditions; in all
cases the Mel4 peptide had lower activity against DADLE than did the
corresponding Phe4 peptide. At high concentrations (10-5M) the active
Mel4 analogs, (benzyl)2Tyr-Gly-Gly-Mel-Leu and (allyl)2Tyr-Aib-Aib-
Mel-Leu, both showed weak irreversible antagonism at the receptor.
INTRODUCTION
Selective irreversible opioid receptor antagonists can be valuable
pharmacological tools, as evidenced by the use in a variety of studies of
funaltrexamine -FNA) (Portoghese et al. 1980, Takemori and
Portoghese 1985), an irreversible antagonist of the µ receptor.
N,N-Diallyl leucine enkephalin analogs are selective reversible
antagonists of the opioid receptor (Shaw et al. 1982, Cotton et al. 1984)
which have been useful in studying the role of the receptor in various
physiological processes. In a combination of these two approaches,
several enkephalin analogs with the eneral structure
R2Tyr-Y-Y-X-Leu, where R = allyl or benzyl, X = Gly or Aib
aminoisobutync acid) and X = Mel (melphalan), the nitrogen
mustard-containing analog of phenylalanine, were synthesized and
tested as potential irreversible antagonists of the opioid receptor. Here
we present the results of the biological evaluations for this series on the
guinea pig ileum and the mouse vas deferens preparations.
MATERIALS AND METHODS
Synthesis
Melphalan-containing peptides were synthesized in solution by mixed
anhydride couplings of R2Tyr(OtBu)-X-X with Mel-LeuOtBu, followed
by deprotection with trifluoroacetic acid. Except for compound 2b (ICI
174,864), which was a gift from ICI Pharmaceuticals Division,
Macclesfield, Cheshire, England, the corresponding phenylalanine-
1Current address: Department of Chemistry, California State
University Sacramento, Sacramento, CA 95819, U.S.A.
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containing peptides were synthesized in a similar manner, or were
prepared by dialkylation of a protected pentapeptide followed by
deprotection. Details of these syntheses will be published elsewhere.
Biological Evaluation
Compounds were evaluated in the electrically stimulated longitudinal
muscle of the guinea pig ileum (GPI) (Rang 1965) and in the mouse vas
deferens (Henderson et al. 1972). The melphalan-containing
compounds were added to the tissues as a solution in methanol; in the
concentrations used methanol had no effect on the tissues. Agonist
activity is expressed as the percent inhibition of the twitch after a 10
minute incubation of the tissue with the test compound. The reversible
antagonist potency was determined against morphine, ethylketazocine
(EK), or [D-Ala2,D-Leu5]enkephalin (DADLE), and is expressed as the
ratio of the IC50 of the agonist in the presence of the test compound to the
IC50 in the absence of the test compound in the same preparation.
Irreversible antagonism was evaluated by incubating the MVD with the
antagonist for 10 minutes, washing the tissue 30 times, and then
determining the IC50 of DADLE; the activity is expressed as the ratio of
the IC of DADLE after exposure to the antagonist to that of the same
tissue before exposure.
RESULTS AND DISCUSSION
All but one of the compounds were reversible antagonists in the MVD
when tested against DADLE, a receptor agonist (table 1). Of the Phe4
peptides, all of which were active, 2b (ICI 174,864) was significantly
more potent than the corresponding dibenzyl analog 3b. The N,N-di-
benzyl modification was chosen for further examination because for the
Gly-containing peptides the reverse was true; lb was 2.5-fold more
potent than N,N-diallyl leucine enkephalin (IC50 ratio = 2.7±0.6, n = 3).
Possible contributing factors to this reversal are conformational changes
in the peptide chain imposed by the Aib residues which alter the position
of the alkyl groups attached to the amine terminus and the greater
lipophilicity of peptides containing both the benzyl groups and the Aib
residues. The two dibenzyl peptides lb and 3b showed similar antagonist
activities against DADLE.
Replacement of phenylalanine by melphalan, the para-substituted
nitrogen mustard analog of phenylalanine, resulted in decreased affinity
for the receptor. The decrease in activity was only 2.2-fold in the case
of the dibenzyl leucine enkephalin analog la, but was larger for the Aib-
containing peptides. The 4.7-fold decrease in activity for 3a resulted in
an inactive compound at 10-6M. The decrease for 2a was approximately
3.1-fold, but the resulting compound was still more potent than la.
Most of the compounds showed little or no activity in the remaining
tests. Only one compound, 2a, had an IC50 ratio against morphine in the
MVD which was greater than one. The compounds did show some
agonism in the MVD at 10-6M, but the activity was weak (7.4% to 25.7%
inhibition of the twitch, see table 1). One compound, 3b, showed
significant agonist activity in the GPI (68.7±6.7% inhibition of the twitch
at 10-6M (n = 3), IC50 = 2.7 x 10
-7±1.4 x 10-7M (n = 4)); the remaining
compounds at 10-6M showed some agonism in the GPI, but the activity
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was much weaker (less than 10% inhibition of the twitch for compounds
la, 1b, and 3a, 11.4±3.3% inhibition (n = 2) for 2a, and 27.0±10.8%
inhibition (n = 2) for 2b). These compounds were inactive as antagonists
at 10-6M in the GPI against both morphine and EK (data not shown).
TABLE 1. Reversible Agonism and Antagonism in the MVD
of N,N-Dialkyl Leucine Enkephalin Analogs,
R2Tyr-Y-Y-X-Leu.
Agonism: Antagonism:
Percent IC50 Ratio
1
C m p d . R  X  Y Inhibition
1 D A D L E Morphine
1a benzyl  Gly Mel 16.2 1.7%2 3.0 0.52 1.0 0.4
1 b  "  " Phe 11.4 5.9% 6.6 1.42 0.6 0.2
2a allyl Aib Mel 20.6 6.5% 5.0 0.9 2.2 0.72
2 b  "  " Phe 7.4 7.4% 15.6 2.4 0.8 0.1
3 a benzyl  " Mel 22.5 5.2% 1.2 0.2 1.0 0.3
3 b  "  " Phe 25.7 4.9% 5.6 1.7 1.0 0.1
1Compounds were tested at 10-6M. Results are ± standard
error of the mean (S.E.M); n = 3 unless otherwise indicated.
2n = 4.
The two melphalan-containing peptides which showed reversible
antagonist activity were tested for irreversibility against DADLE in the
MVD. At 10-6M no irreversible antagonism was observed (table 2), but
at 10-5M both compounds did show weak irreversible antagonist activity.
The irreversible antagonism was similar for the two compounds in spite
of the 2.5-fold higher reversible antagonism of 2a. Although extremely
high concentrations were required to demonstrate any irreversibility,
these results do demonstrate the potential feasibility of developing
irreversible antagonists based on the enkephalins. Other less bulky and
TABLE 2. Reversible and Irreversible antagonism of 1a and
2a against DADLE in the MVD.
10 - 6M
DADLE IC50 Ratio
1
10 - 5M
Cmpd Reversible Irreversible Reversible2 Irreversible
1a 3.0 0.5(4)  1.2 0.2 (4)3  7.7 3.3(4) 2.4 0.8 (5)
2a 5.0 0.9 (3)  1.1 0.2 (3) 19.4 4.7 (4) 2.9 0.9 (5)
1 S.E.M. (n).
2At 10-5M both 1a and 2a showed significant reversible
agonism (47.8±5.7% and 42.9±7.0% inhibition of the twitch,
respectively).
3After 30 minutes incubation.
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more reactive functional groups at the para position of the phenyl-
alanine ring may result in increased affinity of the peptide for the
receptor and greater irreversible antagonism at lower concentrations.
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DIHYDROMORPHINE-PEPTIDE HYBRIDS HAVE MU RECEPTOR ANTAGONISTIC AND
DELTA RECEPTOR AGONISTIC ACTIVITY ON THE MOUSE VAS DEFERENS AND
BIND WITH HIGH AFFINITY TO OPIOID RECEPTORS IN RAT BRAIN
C.B. Smith, F. Medzihradsky and J.H. Woods
Departments of Pharmacology and Biological Chemistry
The University of Michigan, Ann Arbor, Michigan 48109
ABSTRACT
The actions of three morphine derivatives with short peptide side
chains were evaluated upon the contraction of the isolated, elec-
trically stimulated mouse vas deferens preparation and upon dis-
placement of specifically bound 3H-etorphine in rat brain mem-
branes. NIH-9834 (N-[6, 14-endoetheno-7, 8-dihydromorphine-7-al-
pha-carbonyl]-L-phenylalanyl-L-leucinol) and its ethyl ester, NIH-
9833, were potent agonists upon the vas deferens. ICI-174864, 100
nM, markedly antagonized the actions of both NIH-9833 and NIH-9834
which indicates that these are delta receptor agonists. NIH-9835
(N-[6, 14-endoetheno-7, 8-dihydromorphine-7-alpha-carbonyl]-L-gly-
cyl-L-phenylalanyl-L-leucine ethyl ester HCl) differs from NIH-9833
and NIH-9834 by the presence of a single amino acid residue. Al-
though this drug had no agonistic activity on the vas deferens, it
was a potent antagonist of mu agonists. All three hybrids were po-
tent displacers of 3H-etorphine in rat cerebral membranes. The ob-
servation that addition of a single glycyl residue changes dihy-
dromorphine-peptide analogs from potent delta receptor agonists to
equally potent mu receptor antagonists suggests that the two recep-
tor sites might be structurally quite similar.
INTRODUCTION
Morphine is a mu receptor agonist on the mouse vas deferens. In
contrast, the enkephalins are most potent as delta receptor ago-
nists in that preparation (Lord et al. 1977). The purpose of the
present study was to evaluate the effects of several dihydromor-
phine-peptide analogs upon the mouse vas deferens preparation and
examine their binding to opioid receptor in rat brain membranes.
These analogs incorporate peptide fragments of the enkephalins into
the dihydrcmorphine molecule.
METHODS
In the binding assay, the competition of the investigated compounds
with 3H-etorphine for opioid receptor sites in a membrane
preparation from rat brain cerebrum was determined (Medzihradsky et
al. 1984). After incubation at 25°C to reach binding equilibrium,
the suspension of brain membranes in the assay medium was quickly
filtered and the bound radioactivity determined. The binding
affinity of the tested compounds is expressed as their EC 50 (from
log-probit plots) in displacing specifically bound 3H-etorphine.
For the vas deferens experiments, male, albino ICR mice, weighing
between 25 and 30 g, were used. The mice were decapitated, the
vasa deferentia removed, and 1.5 cm segments were suspended in or-
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gan baths which contained 30 ml of a modified Kreb's physiological
buffer. The buffer contained the following (mM): NaCl, 118; KCl,
4.75; CaCl2 2.54; MgSO4, 1.19; KH2PO4, 1.19; glucose, 11; NaHCO3,
25; pargyline HCl, 0.3, tyrosine, 0.2; ascorbic acid, 0.1;  and
Na2EDTA, 0.03.
kept at 37 C.
The buffer was saturated with 95% 02 - 5% CO2 and
The segments were attached to strain gauge transduc-
ers and suspended between two platinum electrodes. After a 30-min
equilibration period, the segments were stimulated once every 10
sec with pairs of pulses of 2 msec duration, 1 msec apart and at
supramaximal voltage. Naltrexone, ICI-174864 or NIH-9835 were
added to the organ baths 15 minutes before the determination of cu-
mulative concentration-effect relationships for the various ago-
nists. beta-FNA was added to the organ baths after the initial
equilibration period. Thirty min later the beta-FNA was removed
from the organ baths by repeated washings with fresh buffer. The
tissues were washed three times every 5 min for 15 min. Cumulative
concentration-effect relationships for the various agonists were
then determined 20 min after the last wash (i.e. 30 min after the
beta-FNA was removed from the organ baths). The EC 50's were cal-
culated by probit analysis. All values are the means of at least 6
determinations ± the standard error of the mean. The following
drugs were studied: ethylketazocine, etorphine, DSLET [Tyr-D-Ser-
Gly-Phe-Leu-Thr], NIH-9824, NIH-9833, the ethyl ester of NIH-9834,
NIH-9835, naltrexone HCl, ICI-174864 [N,N-diallyl-Tyr-Aib-Aib-Phe-
Leu-OH], morphine sulfate, U50, 488H [trans-3, 4-dichloro-N-methyl-N
(2- (1-pyrrolidinyl) cyclohexyl) benzeneacetamide methanesulfonate
hydrate] and beta-funaltrexamine (beta-FNA).
RESULTS AND DISCUSSION
NIH-9833 was an extremely potent agonist upon the mouse vas defer-
ens preparation with an EC 50 of 0.85 + 0.53 nM (n=8, FIGURE 1).
Naltrexone, 100 nM, beta-FNA, 1 µM, and ICI-174864, 100 nM, antago-
nized the actions of NIH-9833. EC 50's were 1.7 0.3 nM in the
presence of naltrexone and 2.4 0.5 nM in the presence of beta-
FNA. Naltrexone competitively blocks mu, kappa and delta recep-
tors, and beta-FNA blocks mu and delta, but not kappa receptors in
the mouse vas deferens preparation (Smith in press). In the pres-
ence of ICI-174864 the EC 50 for NIH-9833 was 1.9 nM 0.5. ICI-
174864 is a highly selective delta receptor antagonist (Cotton et
al. 1984, Smith et al. 1984), and blockade by ICI-174864 suggests
that NIH-9833 acts primarily upon delta opioid receptors. Similar
results were obtained with NIH-9834.
NIH-9835 was a potent mu receptor antagonist upon the mouse vas
deferens preparation. It caused a parallel shift (12.3-fold shift)
to the right in the morphine concentration-effect curve. In con-
trol experiments the EC 50 for morphine was 350 nM 117 (n=3), and
in the presence of NIH-9835, 100 nM, the EC 50 for morphine was 4.3
µ M 1.48. NIH-9835 caused a slight shift (3-fold) to the right
in the DSLET concentration-effect curve. In control experiments,
the EC 50 for DSLET was 0.49 nM 0.08 (n=4), and in the presence
of NIH-9835, 100 nM, was 1.6 nM 0.2. NIH-9835 did not signifi-
cantly shift the U50,488H concentration-effect curve. In control
experiments, the EC 50 for U50,488H was 473 nM 145, and in the
presence of NIH-9835, 100 nM, the EC 50 was 473  nM 125. Thus,
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FIGURE 1. Antagonism of the effects of NIH-9833 upon the
electrically stimulated mouse vas deferens. Abscissa:
concentration of NIH-9833; Ordinate: percent inhibition
of the twitch. Each point represents the mean of 6-9
preparations in the absence of antagonist (circles) or in
the presence of 100 nM naltrexone (triangles), 100 nM
ICI-174864 (squares), or after pretreatment with 1 µM
beta-FNA (diamonds). Vertical bars, S.E.M.
FIGURE 2. Antagonism by NIH-9835 of the effects of mor-
phine upon the mouse vas deferens preparation. Abscissa:
concentration of morphine; ordinate: percent inhibition
of the twitch. Circles, controls; triangles, observa-
tions in the presence of 100 nM NIH-9835. Each value is
the mean of 6-9 determination. Vertical bars, S.E.M.
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NIH-9835 is a potent opioid antagonist which appears to act primar-
ily upon mu receptors, although it is slightly active upon delta
receptors. Its activity is different than that of naltrexone which
blocks mu, kappa and delta receptors and which is more potent as an
antagonist at kappa receptors than at delta receptors.
All three hybrids displaced bound 3H-etorphine in rat cerebral mem-
branes. The antagonist, NIH-9835, was less potent than naltrexone
as a displacer (TABLE 1). The two agonists, NIH-9833 and NIH-9834
were extremely potent displacers of 3H-etorphine with EC 50's in
the range of etorphine.
TABLE 1. EC 50's of NIH-9833, NIH-9834 and NIH-9835 com-
pared to those of representative opiate agonists and an-
tagonists in displacing 0.5 nM 3H-etorpine in a membrane
preparation from rat cerebrum (in the presence of Na+).
Compound EC 50 (nM)
Morphine 23.60
Ethylketazocine 6.60
NIH-9835 1.70
Naltrexone 0.87
NIH-9833 0.58
Etorphine 0.37
NIH-9834 0.34
The observation that the addition of a single glycyl residue
changes a dihydromorphine-peptide analog from a potent delta recep-
tor agonists to an equally potent and quite specific mu receptor
antagonists suggests that the two receptor sites on noradrenergic
nerve terminals in the mouse vas deferens might be structurally
quite similar.
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CHARACTERIZATION OF D-ALA2,LEU5,CYS6-ENKEPHALIN:
A NOVEL SYNTHETIC OPIOID PEPTIDE WITH SLOWED DISSOCIATION FROM DELTA
RECEPTORS
Wayne D. Bowen, Mark Kelemen,
Roger Huey, and D. Stewart
Section of Biochemistry
Division of Biology and Medicine
Brown University
Providence, Rhode Island 029 12
ABSTRACT
D-Ala2,Leu5,Cys6-enkephalin (DALCE) is a synthetic enkephalin analog
which contains a reduced sulfhydryl group.It exhibited moderate
delta selectivity (mu/delta IC50 ratio 13), but was not as selective
as the disulfide-containing peptide, D-Pen2,5-enkephalin (DPDPE)
(mu/delta ratio 1121). However, unlike other delta-selective
peptides, DALCE exhibited a markedly slowed dissociation from
receptors after pretreatment of membranes with micromolar
concentrations. Pretreatment of membranes with 10 uM DALCE,
followed by extensive
binding sites. D-Ala2,D-Leu5-enkephalin (DADLE), D-Ser2,Leu5,Thr6-
washing produced an 85-90% loss of 3H-DPDPE
enkephalin (DSTLE) and DPDPE produced losses of 59%, 70%, and 19%,
respectively. The effect of DALCE was not reversed by a 60 min
post-incubation in buffer containing 250 mM NaCl + 100 uM GMPPNP, a
condition which produced nearly complete reversal of loss of sites
by DADLE and DSTLE. DPDPE could be dissociated merely by post-
incubation in TRIS-buffer alone for 15 min. The order for ease of
dissociation after preincubation was DPDPE > DADLE > DSTLE >>>
DALCE. The effect of DALCE was selective for delta sites, although
higher concentrations of DALCE produced loss of mu sites. DALCE
pretreatment had no effect on recovery of kappa sites. These
results indicate that DALCE binds essentially irreversibly to delta
receptors.
INTRODUCTION
In the search for more selective and stable delta receptor ligands,
several analogs of enkephalins have been synthesized. Examples are
DADLE and DSTLE (Kosterlitz et al. 1980, Gacel et al. 1980) which
make use of the incorporation of D-amino acids for proteolytic
stability. Recently, conformationally restricted enkephalin analogs
have been produced by disulfide bridge cyclization of the peptide
chain. This is accomplished by introduction of cysteine or
penicillamine at positions 2 and 5, followed by oxidation to form
Pen2,5-enkephalin is the most delta selective enkephalin analog to
the disulfide bond (Schiller et al. 1981, Mosberg et al. 1983). D-
date (Mosberg et al. 1983). Although these disulfide-containing
peptides have been thoroughly characterized in binding assays and
bioassays, the effect of introducing a reduced thiol group has not
yet been studied. We report here the synthesis and characterization
of D-Ala2,Leu5,Cys6-enkephalin (DALCE). This peptide makes use of
the D-Ala2 residue for stability, but is unique in that it contains
a sulfhydryl group at the C-terminus. Although this analog is not
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as delta-selective as the disulfide-containing peptides, the free
sulfhydryl group endows this peptide with a property lacking in
other enkephalin analogs. DALCE has a markedly slowed rate of
dissociation from delta and mu receptors. This is quite interesting
in view of the fact that delta and mu opiate receptors contain an
essential sulfhydryl group (Smith and Simon 1980). DALCE may bind
covalently by formation of a disulfide bond to receptor.
METHODS
Tyr-D-Ala-Gly-Phe-Leu-Cys was custom synthesized by Peninsula Labs
using solid phase techniques. Purity was established by TLC, paper
electrophoresis, and reversed phase HPLC. The peptide tended to
dimerize during storage due to sulfhydryl oxidation. This was
prevented by storage in presence of 20 mM beta-mercaptoethanol in
acidic solution at -20°C.
Lysed P2 membrane preparations were prepared from brains (minus
cerebellum) of male Sprague-Dawley rats (150-200 g). Membranes (650
ug protein/ml) were incubated with peptides for 60 min at 25° in 50
mM TRIS-HCl pH 7.4 containing 100 mM NaCl, 3 mM Mn acetate, 2 uM
guanosine 5'-triphosphate (GTP), and the following protease
inhibitors to protect susceptible peptides: bacitracin (100 ug/ml),
leupeptin (4 ug/ml) chymostatin (2 ug/ml), bestatin (10 ug/ml).
Following pelleting and resuspension in an equal volume of the
buffers specified in table 1 and figure 1, membranes were incubated
for the specified times to effect dissociation of the bound peptide.
After this dissociation period (post-incubation), the membranes were
washed and incubated with 3H-ligand to assess recovery of binding
sites compared to controls which were incubated with no peptide.
Except where indicated otherwise, incubations with 3H-ligand were
oarried out for 90 min at 25°C in a total volume of 500 ul
containing 10 mM TRIS-HCl pH 7.4 325 ug of membrane protein, and
the components specified below. 3H-DPDPE. 100 mM NaCl, 3 mM Mn
acetate, 2 uM GTP; 3H-DAGO (D-Ala2,NMe-Phe4,Gly-ol5-enkephalin): 3
mM Mn acetate; H-BREM (bremazocine):
DAGO to suppress mu and delta binding. 3H-Ligand concentration was
100 nM unlabeled DSTLE and
2 nM. Non-specific binding was determined in presence of 10 uM
unlabeled levallorphan. The incubation was terminated by filtration
of inoubation mixture through glass fiber filters under reduced
pressure and washing with ice-cold buffer.
RESULTS AND DISCUSSION
The receptor selectivity of DALCE was compared to other enkephalin
analogs by competition binding assays using 3H-DPDPE, 3H-DAGO, and
3H-BREM to label delta, mu, and kappa receptors, respectively (10 mM
TRIS-HCl pH 7.4, 90 min, 25°C). Delta, mu, and kappa IC50 values
for the following unlabeled peptides were: DALCE - 4.1, 55; >10,000
nM; DADLE - 3.4, 151, >10,000 nM; DSTLE - 4.0, 250, kappa not
determined; DPDPE - 5.5, 6167, >10,000 nM. Therefore, DALCE
exhibited moderate delta selectivity with roughly a 10-fold
selectivity for delta sites over mu sites. Like the other
enkephalin derivatives, DALCE had very low affinity for kappa
receptors. As reported by others (Mosberg et al. 1983), the
disulfide-containing peptide DPDPE exhibited the highest delta
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selectivity. All the analogs had similar IC50 values at the delta
site.
Table 1 shows the effect of various dissociation conditions on
occupation of delta sites after preincubation with various delta-
selective peptides at a concentration of 10 uM. After a 15 min
dissociation period in 50 mM TRIS-HCl, all peptides produced a
residual blockade of sites. However, DALCE produced the greatest
loss of sites while DPDPE produced the least. Increasing the
dissociation time in this buffer to 60 min caused moderate increases
in recovery of sites after preincubation with DADLE and DSTLE.
Recovery of sites with DALCE was unaffected and remained low.
Sodium ion and guanine nucleotides have been shown to lower the
affinity of opiate receptors for ligand, therefore inhibiting
binding or promoting dissociation (Simon et al. 1975, Childers and
Snyder 1980, Zukin and Gintzler 1980). Dissociation in buffer
containing 250 mM NaCl an
nearly complete recovery of 3H-DPDPE binding sites with DADLE and
d 100 uM GMPPNP resulted in complete and
DSTLE, respectively. However, the marked loss of sites produced by
DALCE was unaffected by post-incubation in this buffer. Therefore,
DADLE, DSTLE, and DPDPE can readily dissociate from delta receptors,
while DALCE remains tightly bound. This effect required both opiate
receptor recognition as well as a thiol group since preincubation
with 25 uM beta-mercaptoethanol or dithiothreitol had no effect on
recovery of sites (not shown).
TABLE 1. Pretreatment of membranes with peptides and effect of
various dissociation conditions on recovery of delta binding sites
Dissociation Condition and
% Recovery of 3H-DPDPE Binding
Peptide
Pretreatment (10 uM) 15 min
60 min,
60 min NaCl/GMPPNP
DADLE 41 50 100
DSTLE 30 50 80
DPDPE 81 -- --
DALCE 11 17 14
Figure 1 shows the receptor selectivity of the DALCE effect.
Membranes were preincubated with various concentrations of DALCE,
post-incubated in buffer containing 250 mM NaCl and 100 uM GMPPNP
for 60 min, and recovery of mu, delta, and kappa sites was assessed
by binding of 3H-DAGO, 3H-DPDPE, and 3H-BREM, respectively. Delta
sites were most sensitive to DALCE. Half maximal loss of sites
occurred at 2-3 uM DALCE. Mu sites were not affected at 2 uM and
only reached 50% loss at 20 uM DALCE. Kappa sites were not affected
by DALCE pretreatment at concentrations up to 20 uM. These results
are consistent with the receptor selectivity of DALCE (delta > mu >>
kappa).
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FIGURE 1. Receptor
selectivity of the
DALCE effect.
In conclusion, DALCE is a sulfhydryl-containing enkephalin analog
with preference for delta receptors. It exhibits a markedly slowed
rate of dissociation from delta and mu receptors compared to other
delta receptor peptides. Taken together with the presence of a
critical sulfhydryl group at the ligand binding site of mu and delta
receptors (Smith and Simon 1980), it is possible that DALCE binds
covalently by forming a disulfide bond with receptor. This is
supported by preliminary results suggesting that the effects of
DALCE are attenuated by post-incubation with a reducing agent. It
would be interesting to ascertain whether incorporation of free
sulfhydryl groups into other opioid peptides results in slowed
dissociation from receptors.
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ABSTRACT
The binding properties of the new agonist Tyr-D-Ser(OtBu)-Gly-
Phe-Leu-Thr, DSTBULET, in rat brain tissue shows that insertion of a
bulky t.butyl group into the sequence of DSLET leads to a
conformationally-induced large increase in selectivity for opioid
receptors (KI( )/KI(µ) = 0.012). In addition to its similar
selectivity to that of the cyclic enkephalins DPDPE and DPLPE. the
affinity of [3H]DSTBULET for sites (KD = 2.9 nM) is significantly
better than that of [3H]DPDPE (KD˜10.5 nM) or DPLPE (KI( ) ˜ 19 nM).
DSTBULET is therefore the most appropriate probe for both binding
studies and pharmacological investigations of -receptors as
illustrated by a comparison of the analgesic properties of DAGO,
DSTBULET and DPLPE.
INTRODUCTION
A clear distinction between the pharmacological responses induced by
stimulation of opioid µ or -receptors requires highly potent and
selective ligands. In the case of receptors, linear hexapeptides
(DSLET and DTLET) were the first really -selective ligands
(Fournié-Zaluski et al. 1981; Gacel et al. 1980; Zajac et al.
1983). Recently, two cyclic enkephalins DPDPE and DPLPE have been
shown to exhibit even better -selectivity than the linear peptides
(Mosberg et al. 1983). Unfortunatly this is associated with a large
decrease in affinity, preventing the use of [3H]DPDPE for
competition studies or for acute quantitative determinations of
-sites in brain after biochemical lesions or pharmacological
manipulations (Delay-Goyet et al. 1985). We report here the binding
properties in rat brain tissue, of a new -ligand [3H]DSTBULET which
shows both a high selectivity and a high affinity.
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MATERIALS AND METHODS
The linear hexapeptide Tyr-D-Ser(OtBu)-Gly-Phe-Leu-Thr, DSTBULET, was
prepared by the liquid phase method as described for DSLET and DTLET
(Gacel et al. 1981). [3H]DSTBULET (70 Ci/mmol) was obtained from the
2,5-dibromotyrosyl precursor. [3H]DPDPE was from Amersham and
[3H]DTLET and [3H]DAG0 from CEA (France). Binding assays (in
triplicate) were carried out at 37°C using a crude rat brain membrane
preparation as described (Zajac and Roques 1985). KD and KI values
were obtained from computerized linear regression analysis.
Inhibition of electrically evoked contractions of GPI or MVD was
performed as described. Analgesic potency of the various compounds
was evaluated using the hot-plate test in mice.
RESULTS AND DISCUSSION
Pharmacological profile of DSTBULET v DPDPE. The selectivity of
DSTBULET was compared to that of DSLET, DTLET and DPDPE using : i)
bioassays on peripheral organs (GPI enriched in µ sites and MVD in
sites), ii) inhibition of the binding to rat brain tissue of [3H]DAGO
(µ selective ligand) and [3H]DTLET (nearly -selective ligand). AS
shown in table 1, the introduction of the bulky O.tBu. group on DSLET
leads to a large improved -selectivity, as occurs with the cyclic
enkephalins. At the level of the brain receptors, DSTBULET was at
least as selective as DPDPE but its apparent affinity was
significantly better. Besides, DSTBULET is unable (IC50>10,000 nM) to
interact with receptors labelled with [3H]EKC.
Binding characteristics of [3H]DSTBULET on rat brain. Binding
equilibrium of [3H]DSTBULET (5 nM) was reached in 30 min at 35°C.
Saturation experiments were performed under these conditions and
binding parameters (KD and Bmax) calculated from linear regression
analysis of the saturation isotherms. As shown in fig.1, [3H]DSTBULET
interacts with a single class of site (0.5-15 nM) (equilibrium
dissociation constant KD = 2.90 0.33 nM and Bmax = 98.8 9.4
femtomoles/mg. In addition to its better -affinity than [3H)DPDPE
(KD = 10.5 nM) it is very important to observe that [
3H]DSTBULET
displayed 55% specific binding at 63% saturation against 26% at 67%
saturation for [3H]DPDPE. Moreover, as expected from its high
selectivity, the Bmax of [
3H]DSTBULET was not affected by blocking of
u-sites with high concentration of DAGO (300 nM) and as a consequence
of its higher affinity, the binding parameters can be determined with
greater accuracy.
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TABLE 1. Pharmacological profile of linear and cyclic
enkephalins on peripheral organs and rat brain tissue.
FIGURE 1. Eadie-Hofstee and Scatchard analyses of the
specific binding of [3H]DSTBULET to rat brain membranes.
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Correlation between supraspinal analgesia and affinity for opioid µ
sites. As expected, the pharmacological properties of DSTBULET are
in agreement with its binding characteristics to brain tissue. This
is clearly demonstrated by its 130 fold lower potency than DAGO, a
typical µ agonist, to inhibit nociceptive stimuli induced in mice
through the hot plate test after i.c.v. administration. The low
analgesic potency of DSTBULET and DPLPE, contrasting with their
affinity for -sites, reinforces the suggested preferential
involvement of µ-receptors in the supraspinal control of pain
(Chaillet et al. 1984).
CONCLUSION
The new linear hexapeptide DSTBULET possesses the main requirements
for both accurate biochemical and pharmacological investigations on
delta opioid receptors : - a high affinity with a low non specific
binding ; - a good selectivity for the delta sites ; - a
satisfactory resistance to peptidases ; - a favourable
hydrophobic-hydrophilic balance. Finally DSTBULET belongs to a large
series of linear analogues with /µ selectivities ranging between 1
and 120. Taken together [3H]DSTBULET and its analogues behave as
useful compounds for a complete study of the physiological relevance
of delta opioid receptors.
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ABSTRACT
The binding of the delta selective agonist [3H]DPDPE to diencephalic
rat brain tissue was examined. Although most material examined gave
rise to a single receptor model, one commercial preparation
(Amersham, batch 8) suggested a two receptor model. Purification by
HPLC removed a minor component and restored a single receptor model
to the major component.
INTRODUCTION
The endogenous opioid peptides are known to interact with several
classes of opioid receptors. The synthetic peptide
(2-D-penicillamine, 5-D-penicillamine) enkephalin (DPDPE) is a
conformationally restricted enkephalin analogue which has been shown
to be a selective delta agonist (Mosberg et al. 1980) and is useful
in autoradiographic differentiation of delta receptors in rat brain
(Mansour et al. 1986). During the course of these studies several
different batches of [3H]DPDPE were utilized. One of these, Amersham
batch #8, exhibited binding characteristics different from previous
and subsequent batches of synthetic [3H]DPDPE.
METHODS AND MATERIALS
Slide-mounted brain sections (25 um) from the diencephalon were
incubated with 200 ul of [3H]DPDPE (Amersham, 41.5 Ci/mmol, batch 8)
in a 50 mM Tris buffer (pH 7.5 at 25°C). The concentrations of
[3H]DPDPE ranged from 0.1 to 14 nM. After a 60 minute incubation,
the slides were drained and washed in four consecutive 250 ml 50 mM
Tris washes (pH 7.6, 4°C) for 30 seconds. The slides were then dried
with a portable hair dryer and the binding was quantified using
liquid scintillation counting (Packard, 2000 CA). Non-specific
binding was evaluated by treating a parallel set of slides with the
same [3H]DPDPE concentrations with a 1 uM final concentration of
unlabelled DSLET (Tyr-D-Ser-Gly-Phe-Leu-Thr). The data were graphed
as Scatchard plots and the KD and Bmax values determined with the
LIGAND program (Munson and Rodbard 1980). Similar studies were done
on other batches of [3H]DPDPE (Amersham, batch 9) and purified
[3H]DPDPE from batch 8.
The liquid chromatography was done on an HPLC system comprised of two
Altex 110 pumps coupled to an Altex model 420 controller, a Rheodyne
7125 injection valve, a Waters 3.9 mm X 30 cm uC18 reverse phase
column and a Pharmacia model 100 fraction collector. The flow rate
was 1.5 ml/min; the elution solvent was 10-60% (over 80 minutes)
acetonitrile/0.1% TFA. Samples were collected every minute and a 50
ul aliquot was examined for [3H] activity by liquid scintillation
counting.
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FIGURE 1. Scatchard plots of selected DPDPE batches
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Figure 2. HPLC Chromatograms for DPDPE Batches
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RESULTS
The Scatchard plot from the "LIGAND" analysis for DPDPE binding to
rat brain diencephalic tissue for Amersham batch 8 is shown in figure
1(A). The best "LIGAND" fit for this data was a two receptor model
with a KD1 of 2.4 nM and a KD2 of 13.8 nM. The corresponding Bmax
values were 44 and 189 pM respectively.
The Scatchard plot from the "LIGAND" analysis for binding of the
major component of batch 8 (which had the same elution volume as
authentic DPDPE, figure 2(A) and (C)) to diencephalic tissue is shown
in figure l(B). The best "LIGAND" fit was for a single receptor site
having a KD of 7.6 nm with a Bmax of 146 pM.
The Scatchard plot from the "LIGAND" analysis of the binding of most
batches of DPDPE was typified by batch 9 as shown in figure 1(C).
The HPLC chromatogram of this material is shown in figure 2(B). This
gives rise to a single receptor model with a KD = 17 nM and a Bmax =
157 pM.
CONCLUSIONS
Amersham DPDPE, batch 8, contained an easily removable impurity which
altered the binding characteristics of this material.
The binding of purified DPDPE to diencephalic sections of rat brain
is consistent with a single receptor model having a KD = 7.6 nM and a
Bmax of 146 pM.
KEFERENCES
Mansour, A. et al. Brain Res, in press.
Mosberg, H. et al. Proc Natl Acad Sci USA, 80:5871-5874, 1980.
Munson, P.J. and Rodbard, D. Anal Biochem, 107:220-229, 1980.
ACKNOWLEDGMENTS
Financial assistance from NIDA Grants #DA02265 and DA00254 is
gratefully acknowledged.
204
COMPARISON OF THE OPIOID ANTAGONIST PROPERTIES OF A CYCLIC
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INTRODUCTION
We have recently developed a conformationally constrained analog of
somatostatin-14 called CTP (D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2)
which shows a high degree of affinity and selectivity for the mu
opioid receptor in binding assays using homogenized rat brains
(Pelton et al. 1985; 1986; Gulya et al. 1986). The purpose of
these investigations was to determine the opioid pharmacology of CTP
in the guinea pig isolated ileum, mouse isolated vas deferens, and in
analgesic and gastrointestinal transit time tests in mice.
MATERIALS AND METHODS
In Vitro Bioassays: The guinea pig ileum longitudinal muscle-
myenteric plexus (GPI) and mouse vas deferens (MVD) were used to
determine the mu/kappa and mu/delta selectivity of CTP respectively.
The GPI (Kosterlitz et al. 1970) and MVD (Hughes et al. 1975) were
run according to standard procedures.
In Vivo Bioassays: CTP was tested for antagonism of mu, delta and
kappa selective agonists in two models of analgesia in male ICR mice
(20-25 g), the hotplate and abdominal stretch tests. The hotplate
(55°C) test was run according to the methods of Porreca et al. (1984).
For the abdominal stretch test, mice received intrathecal (5 ul)
distilled water or drug, followed immediately by an intraperitoneal
(i.p.) injection of 1.2% acetic acid. Mice were then observed for
stretching behaviors for 5 min.
The rate of gastrointestinal transit in mice was determined by the
geometric center method as described by Porreca et al. (1984).
Peptides: The following peptides were used as mu, delta and kappa
selective agonists respectively: PLO17 (Chang et al, 1983), DPDPE
(Mosberg et al. 1983) and U50,488H (VonVoigtlander 1983). PLO17 and
DPDPE were purchased from Peninsula Labs., Belmont CA., and U50,488H
was purchased from Upjohn, Kalamazoo, MI. CTP was synthesized as
previously described (Pelton et al. 1986). All peptides were
dissolved in distilled water.
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FIGURE 1. The effect of pretreatment with 1.0 uM CTP on the inhibitory
actions of PLO17 (0.1 uM) and U50,488H (0.1uM) in the guinea pig ileum
and of PLO17 (1.0 uM) and DPDPE (0.01 uM) in the mouse vas deferens.
Significant differences between control (open bars) and CTP treated
(hatched bars) are indicated by **, p<0.01, n=4.
FIGURE 2. The effect of icv distilled water (open bars) or icv 1.0 ug
CTP (hatched bars) pretreatment on the analgesic actions of PLO17
(0.3 ug, icv). DPDPE (3.0 ug, icv) or U50,488H (0.1 ug, icv) in the hotplate
test and PLO17 (0.3 ug, it). DPDPE (1.0 ug, it) or U50,488H (0.1 ug, it) in
the abdominal stretch test. Significant differences are indicated by **,
p< 0.01, n = 6/dose.
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RESULTS
In Vitro Bioassays: In the GPI, pretreatment with CTP antagonized the
actions of PLO17 but not U50,488H (figure 1). The actions of PLO17
were also blocked by CTP in the MVD. In contrast, CTP did not
antagonize the effects of DPDPE in this tissue (figure 1).
In Vivo Bioassays: PL017, DPDPE and U50,488H given intracerebro-
ventricularly (icv) all produced increases in the latency to display
escape behaviors in the hotplate test (figure 2). The increased
latency caused by U50,488H appeared to be related to the production
of immobility rather than true analgesia. Pretreatment with CTP
antagonized the analgesic actions of PLO17 and DPDPE in the hotplate
test, but did not block the actions of U50,488H (figure 2). Schild
analysis of the interaction of supraspinal CTP with PLO17 or DPDPE
showed that CTP antagonized PLO17 in a competitive fashion (pA2 11.9
1.3, slope -0.85 0.5) but antagonized DPDPE in some complex,
noncompetitive fashion (slope -0.55 ± 0.3). Likewise, in the
abdominal stretch test, CTP again blocked the analgesic actions of
PLO17 and DPDPE, but did not block that produced by U50,488H (figure
2). The actions of all 3 agonists were reversed by naloxone in both
analgesic tests (data not shown).
Both PLO17 and DPDPE also slowed the rate of gastrointestinal transit
after spinal administration to mice (table 1). While pretreatment
with CTP antagonized the antitransit effects of PL017, it did not
block the effects of DPDPE (table 1). Naloxone (1.0 ug, it)
antagonized the antitransit effects of both agonists (data not shown)
Table 1. The effect of intrathecal CTP (1.0 ug)
pretreatment on the rate of gastrointestinal transit.
34 9CTP 26 10*
*p<O.O5; n=5/dose.
% Inhibition of Gastrointestinal Transit
Pretreatment PLO17 (3 ug, it) DPDPE (3 ug, it)
vehicle 60 16 40 8
DISCUSSION
Results from the GPI and MVD studies indicate that CTP possesses mu
selective antagonist properties with no delta or kappa antagonist
actions. These findings support the conclusions of Pelton et al.
(1985, 1984; Gulya et al. (1984, who have shown that CTP displays a
high degree of selectivity for the mu receptor in binding assays
using homogenized rat brains.
The selective antagonism of mu but not delta related inhibition of
gastrointestinal transit shows that CTP retains its mu selectivity in
vivo. And, as expected from the results of the GPI studies, CTP had
no kappa antagonist properties when tested in vivo.
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Despite the consistent mu selectivity of CTP (no delta or kappa anta-
gonism) seen in the binding assays, GPI, MVD and gastrointestinal
transit time tests, CTP antagonized the analgesia evoked by both mu
and delta agonists. The antagonism of mu related analgesia was shown
to be of a competitive nature while that of the delta agonist was not
competitive. These findings may indicate that certain mu and delta
receptors which mediate analgesia are functionally coupled, and that
through its interaction with the mu receptor, CTP can also block
delta related analgesia.
In conclusion, CTP appears to produce mu selective antagonism both
in vitro and in vivo. CTP may prove useful in studying the possible
link between analgesic mu and delta receptors, and may also help in
determining if mu and delta receptors which mediate other functions
are also coupled.
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H-D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2:  A POTENT AND
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ABSTRACT
H-D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2(CTOP) exhibited high
affinity (IC50 = 2.80 nM) in displacing [
3H]naloxone binding
(nH = 0.89 0.1) and showed an exceptional selectivity for mu
opioid receptors with an IC50(DPDPE)/IC50(naloxone) ratio of
4,840, while it displayed very low affinity for somatostatin
receptors (IC50 = 22,700 nM) in rat brain binding assays.
[3H]CTOP was recently custom synthesized (spec. act.: 84 Ci/mmol)
and evaluated for its in vitro binding properties towards the mu
opioid receptors in rat brain membrane preparations. Association
and dissociation of [3H]CTOP binding to mu opioid receptors were
rapid at 25°C with a kinetic Kd value of 0.67 nM. Saturation
experiments gave apparent Kd value of 1.11 nM and Bmax value of
136 13 fmol/mg prot at 25°C. Specific [3H]CTOP binding was
inhibited by a number of different opioid and opiate ligands. Among
them, putative mu opioid receptor-specific ligands, such as
naloxone, naltrexone and CTOP inhibited the binding with high
affinity, while delta opioid receptor-specific compounds or
non-opioid drugs inhibited specific [3H]CTOP binding with low
affinity or they were ineffective.
INTRODUCTION
In an attempt to study the selectivity, potency and conformational
requirements of somatostatin-related peptides for the mu opioid
receptor, we prepared a series of cyclic conformationally restricted
penicillamine ( -dimethylcysteine) containing somatostatin
octapeptide analogues by standard solid phase synthetic methods and
tested them for their ability to inhibit specific [125I]CGP 23,996
(des-Ala1-,Gly2-[desamino-Cys3Tyr11]-dicarba3,14-somatostatin),
[3H]naloxone or [3H]DPDPE ([D-Pen2,D-Pen5]enkephalin) binding
in rat brain membrane preparations: Our most potent and mu receptor-
selective octapeptide CTOP was recently custom labeled and its
binding characteristics were evaluated toward the mu opioid receptors.
MATERIALS AND METHODS
[3H]CTOP (84 Ci/mmol), [3H]naloxone (57 Ci/mmol) and [3H]DPDPE
(33.6 Ci/mmol) were from New England Nuclear. [125I]CGP 23,996, a
relatively nonhydrolysable analogue of somatostatin, was prepared
according to Czernik and Petrack (1983). Inhibition studies
employing [125I]CGP 23,996, [3H]naloxone or [3H]DPDPE were
carried out as described elsewhere (Pelton et al. 1985a, b; Gulya et
al. 1986). [3H]CTOP binding was carried out in 50 mM Na/K-PO4
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Table 1. IC50 value and selectivity of CTOP for
somatostatin, mu- and delta opioid receptors in
rat membrane preparation
IC50 values represent the geometric mean with the range
of values from at least three separate experiments done in
duplicates shown in parentheses. The average Hill values
represent the Hill coefficients from the unweighted best-
fits of the computer-generated regression curves. N.D. =
not determined.
1IC5O(somatostatin)/IC5O(mu); 
2IC50(delta)/IC50(mu).
buffer (pH 7.4 at 25°C) containing 5 mM MgCl2, 1 mg/ml bovine
serum albumin (BSA) and 100 uM phenylmethylsulfonylfluoride (PMSF).
For kinetic studies or
[3H]CTOP binding,
experiments involving the inhibition of
a total concentration of 0.5 nM [3H]CTOP was
incubated with 400-450 ug protein. For saturation experiments,
twelve concentrations of [3H]CTOP ranging from 0.1 nM to 16 nM
were used. 1 uM naltrexone was used to determine nonspecific
binding. The reaction was terminated by rapid vacuum filtration
through 0.1% polyethylenimine-pretreated Whatman GF/B glass
filters. The filters were then rinsed three times with 3 ml saline
solution and dried. Scintillation fluid (6 ml) was added and the
samples were counted by liquid scintillation spectrophotometry (44%
efficiency).
RESULTS AND DISCUSSION
The potency and selectivity of CTOP on inhibiting somatostatin, mu-
and delta opioid receptors are shown in table 1.
[125I]CGP 23,996 and [3H]DPDPE bindings were inhibited by CTOP
Specific
with low affinity, while [3H]naloxone binding was displaced with
high affinity from an apparently single population of binding sites
(nH = 0.89 ± 0.1). The exceptional selectivity of CTOP toward mu
opioid receptors (IC5O(delta)/IC5O(mu) = 4,840) is the result of
its high affinity for mu opioid receptors combined with very low
affinity for the delta sites. No substantial interaction to
somatostatin receptors was observed at low concentrations of CTOP.
Because of its high affinity and selectivity for the mu opioid
receptor binding sites, it seemed to be the ligand of choice for
further characterization of this class of opioid receptors using
direct radioligand binding studies.
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Table 2. Determination of the nonspecific binding of
[3H]CTOP using selected mu opioid compounds in rat brain
membranes at 25°C
Displacer Nonspecific binding
drug (% of total)
naloxone 37
naltrexone 39
naloxonazine 40
DAG0 34
PL017 38
CTOP 24
[3H]CTOP (0.5 nM) was incubated with 400-450 ug protein
in 50 mM Na/K-PO4 buffer (pH 7.4 at 25°C) containing 5
mM MgCl2, 1 mg/ml BSA and 100 uM PMSF for 120 min at
25°C. Nonspecific binding was determined in the presence
of different putative mu opioid receptor-selective drugs at
a final concentration of 1 uM.
Table 3. Inhibition of specific [3H]CTOP binding by
selected opioid and non-opioid compounds in rat brain
membrane preparations
Drug IC50 (nM) Ki (nM) nH
opioids
naltrexone
naloxone
C T O P
D A G O
morphine
PLO17
D A D L E
DSLET
DPDPE
0.37 (0.33-0.42) 0.26
0.97 (0.59-1.64) 0.67
4.62 (3.52-4.19) 2.19
1.33 (0.78-2.05) 0.92
7.32 (6.06-8.14) 5.08
44.1 (34.1-70.1) 30.4
14.3 (10.5-21.0) 9.9
46.5 (31.1-63.4) 32.1
845 (645-1,246) 583
1.112 0.06
1.084 0.08
1.344 0.25
0.826 0.12
0.713 0.04
0.707 0.03
0.817 0.13
0.883 0.20
0.711 0.11
non-opioids (at 10 uM) % of control
somatostatin 94
substance P 70
phenoxybenzamine 69
picrotoxin 68
atropine 86
The inhibition of [3H]CTOP binding by 1 uM naltrexone was used to
define nonspecific binding (table 2) to the mu opioid receptor since
CTOP inhibited [3H]CTOP binding an additional 15% from a putative
non-opioid site.
Results of kinetic experiments performed to determine association
(k+1) and dissociation (k-1) rate constants at 25°C show that
specific [3H]CTOP binding reached steady-state after 45 min of
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incubation (k+1 = 2.04 M
-1 min-1), while dissociation of
specific [3H]CTOP binding was
value of 1.62x10-1 min-1.
rapid (t1/2=4.40 min) with a k-l
The kinetic Kd was found to be 0.67
nM at this temperature.
Computer-assisted nonlinear least squares regression analyses of
saturation isotherms of specific [3H]CTOP binding gave an apparent
dissociation constant (Kd) of 1.11 nM and a Bmax value (maximal
number of binding sites) of 136 13 fmoles/mg protein in rat brain
membranes.
Inhibition curves were obtained for several opioid and opiate
compounds as well as non-opioid drugs in order to determine the
specificity of [3H]CTOP binding to mu opioid receptors (table 3).
[3H]CTOP binding was displaced with high affinity (Ki values from
0.26 nM to 2.19 nM) by opioid antagonists such as naloxone,
naltrexone and CTOP from a single population of binding sites, while
putative mu opioid agonists such as
ol), morphine and PLO17 ([NMePhe3, D-Pro5]morphiceptin) had nH
DAGO (Tyr-D-Ala-Gly-NMePhe-Gly-
values significantly less than one, indicating the presence of
multiple affinity states of mu opioid receptors. Delta opioid
receptor-specific compounds like DADLE ([D-Ala2,
D-Leu5]enkephalin), DSLET ([D-Ser2]Leu-enkephalin-Thr) or DPDPE
Inhibited [3H]CTOP binding with much lower affinity (Ki values
from 9.90 to 583 nM) and Hill coefficients less than one. Non-opioid
compounds were very weak in displacing [3H]CTOP binding, or they
were ineffective.
In summary, we designed and synthesized a somatostatin-related
conformationally restricted octapeptide analogue highly specific for
the mu opioid receptor site. This peptide antagonist has high
affinity and exceptional selectivity for this class of opioid
receptors virtually without any interaction to other neurotransmitter
systems at lower concentrations. This octapeptide might be the
ligand of choice for further characterization of mu opioid receptors.
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ABSTRACT
The opioid agonist and antagonist effects of two configurational
aminotetralin stereoisomers, namely, the cis-(MRSAL) and trans-
(RMG) diastereo isomers of 3-(dimethylamino)-2,2-dimethyl-7-hydroxy-
1-tetralol were studied using the guinea pig ileum longitudinal
muscle preparation. MRSAL demonstrated opioid antagonist activity
but failed to show agonist effects. In contrast, RMG showed agonist
activity which was partially reversed by NX and MRSAL. RMG also ex-
hibited weak antagonist activity towards DHM, NM and DADLE. These
results showed that MRSAL was an opioid antagonist while RMG pos-
sessed weak mixed opioid agonist-antagonist activities.
INTRODUCTION
Aminotetralins are considered A, B ring structural analogs of mor-
phine. Martin and Kandeel (1973) showed that these compounds had
opioid agonist activity. Subsequently, Fries and Bertelli (1982)
synthesized aminotetralin analogs which were capable of producing
mixed opioid agonist-antagonist activities. More recently, we have
reported on several structural modifications of aminotetralins
(Lippman et al. 1985) , the most potent being 3-(dimethylamino)-2,2-
dimethyl-7-hydroxy-1-tetralone (J). In vitro and in vivo testing of
J showed only mu agonist activity. Reduction of the C-1 carbonyl on
J to a hydroxyl group resulted in an opioid antagonist, MRSAL
(Lippman et al. 1985/1986).
Recently we purified the diastereo isomers of 3-(dimethylamino)-2,2-
dimethyl-7-hydroxy-1-tetralol. We now report on the pharmacological
properties of these two isomers on the guinea pig ileum longitudinal
muscle (GPI).
MATERIALS AND METHODS
Male guinea pigs (400-500 g) were decapitated and the ileum longitu-
dinal muscle was removed and prepared as described by Kosterlitz et
al. (1981). The longitudinal muscle with its myenteric plexus was
mounted in a 5 ml tissue bath (37°C) between two platinum electrodes
containing oxygenated (95% 02 :5% CO2 ) Krebs-bicarbonate buffer so-
lution with the following composition (mM): NaCL, 118.40; KCl, 4.75;
CaCl2, 2.54; MgSO4, 1.20; KH2PO4, 1.19; NaHC03, 25; glucose, 11.10;
choline chloride, 20 uM; and pyrilamine maleate, 0.125 uM. The
muscle strip was connected to a Grass transducer (FT.03) and isomet-
ric contractions were induced by a Grass Model S44 stimulator at 0.1
Hz, 0.25 msec, 80-90v and recorded on a Grass Model 7B polygraph.
The tension was set at 1.0 g. After equilibrium was reached the
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compounds were added to the bath and the effects recorded for 5 min.
In agonist experiments the maximum effect (5 min) of the compound
was recorded, then naloxone (NX) was added to the bath. In antago-
nist experiments, the compounds were incubated for 5 min before the
agonists prototypes dihydromorphine (DHM), normorphine (NM) and
DADLE were added to the bath.
The diastereo isomers were assigned relative configurations by FT-
NMR and mass spectroscopy.
RESULTS
The effects of MRSAL and RMG on the electrically stimulated contrac-
tion of the GPI are shown in table 1. RMG caused a maximal decrease
TABLE 1. Effects of MRSAL and RMG in the electrically-
stimulated guinea pig ileum.
Concentration % Change in Effect (mean S.E.)
(uM)
N MRSAL N RMG
42.5 19 3.21 0.5 -- NT
85.0 55 9.94 1.1 18 21.6 1.7
170.0 7 11.34 1.2 5 17.6 2.0
NT= not tested
in contraction of 21% at 85 uM, while MRSAL caused increases in con-
tractions of 3-11% at concentrations of 42.5-170 uM. The maximal
agonist effect of RMG was partially antagonized by NX (53%) and
MRSAL (63%) (table 2). suggesting that RMG had some opioid agonist
Table 2. Antagonism of RMG agonist activity by naloxone
and MRSAL.
RMG N % Antagonist Concn %
(uM) Decrease Blockade
85.0 7 21.6 1.7 NX 176 nM 53.9 2.9
170.0 3 17.6 2.0 NX 704 nM 44.3 3.0
85.0 4 20.7 1.9 MRSAL 85 uM 63.3 3.1
% is expressed as the mean S.E.
activity. Both compounds were able to antagonize selected opioid
agonists (table 3). However, MRSAL was more potent than RMG. MRSAL
was able to antagonize nearly equally NM and DHM by 89% and DADLE by
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81%, while RMG antagonized NM by 65%, DHM by 47% and DADLE by 37%.
The above data demonstrated that MRSAL was an opioid antagonist de-
void of agonist activity, while RMG had mixed opioid agonist-antago-
nist activities at equiconcentrations of the two isomers.
Table 3. Effect of Opioid Antagonist Activity of MRSAL and
RMG Against Selected Opioid Agonists in guinea pig ileum.
Opioid N Opioid %
Antagonist Agonist Blockade
MRSAL 14 NM 89.9 1.9
MRSAL 4 DHM 89.0 1.8
MRSAL 7 DADLE 81.1 1.8
RMG 4 NM 65.5 7.7
RMG 6 DHM 47.8 3.8
RMG 3 DADLE 37.5 1.9
Concentration used for MRSAL and RMG was 85 uM. Results
are expressed as the mean S.E.
DISCUSSION
We had previously demonstrated that 3-(dimethylamino)-2,2-dimethyl-
7-hydroxy-1-tetralone (J) to be a mu opioid agonist. When the C-l
carbonyl on J was reduced to a hydroxyl, at least two diastereo
isomers were formed as shown in figure 1. When these isomers were
FIGURE 1. Cis-(MRSAL) and trans-(RMG) isomers of 3-(di-
methylamino)-2,2-dimethyl-7-hydroxy-1-tetralol.
tested in the GPI bioassay in this study, it was clear that the ago-
nist activity present in J was significantly decreased by this very
slight alteration in the molecular structure. The trans-isomer
(RMG) inhibited the muscle contraction only 21% at 85 uM of which
53% was reversed by NX as compared to 70% inhibition by J at 30 uM
and was completely reversed by NX (Matos et al. this volume). The
cis-isomer (MRSAL) was devoid of agonist activity and instead in-
creased slightly the muscle contraction of the ileum. This latter
effect is similar to that of NX as has been shown by many investi-
gators. When these two isomers were tested against prototype opioid
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agonists, both isomers showed antagonist activity.
The orientation of the hydroxyl group about the C-l position appear-
ed to be important for both agonist and antagonist activities. If
the hydroxyl was trans to the nitrogen, then agonist and antagonist
activities were conferred. Whereas if the hydroxyl was cis, only
antagonist activity was observed. In addition the cis-isomer rever-
sed the opioid agonist activities of DHM, NM and DADLE more effec-
tively than did the trans-isomer. Thus, it appeared that the pre-
ferred configuration for antagonism of opioid agonists was the cis-
isomer.
Since the optical isomers of these diastereo isomers were also pres-
sent, final conclusions about antagonism of opioid agonists by these
compounds must await final determination of the absolute configura-
tion of the active isomer. Nevertheless, since the cis-isomer ef-
fects in the GPI were very similar to that of NX, it is possible
that these two antagonists are acting via similar mechanisms at the
level of the mu-opioid receptor. If this is true, then these small
molecules might be good pharmacological tools to be used in increas-
ing our knowledge about the interaction of opioid agonists and an-
tagonists at the molecular level of the opioid receptor(s).
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ABSTRACT
Two substituted analogs of 3-amino-2,2-dimethyltetralin,
namely 3-dimethylamino-2,2-dimethyl-7-hydroxy-1-tetra-
lone HBr (J) and 3-dimethylamino-2,2-dimethyl-7-hydroxy-
1-tetralol (MRSAL), were evaluated for opioid agonist
and antagonist activity using the electrically driven
guinea pig ileum longitudinal muscle preparation (GPI).
Compound J appeared to be an opioid agonist with a
preference for mu receptors while MRSAL was an opioid
antagonist with-little selectivity for mu or kappa re-
ceptors,
INTRODUCTION
Aminotetralins with opioid analgesic activity were first
studied by Martin et al. (1969). Subsequently, Kandeel
and Martin (1973) reported a number of aminotetralins
with potent opioid agonist activity. Such compounds
also have the potential for opioid antagonist as well as
agonist activity. In the present report, two new amino-
tetralin analogs, J and MRSAL (figure 1), were studied
for both opioid agonist and antagonist activities using
FIGURE 1. Aminotetralin chemical structures.
the electrically stimulated GPI. Opioid receptor selec-
tivity for the agonist was studied by using naloxone
(NX) as a prototype antagonist. The potency of MRSAL
antagonism was evaluated by using agonist prototypes
such as N-normorphine HCl (NM), dihydromorphine (DHM),
ethylketocyclazocine methanesulfonate (EKC) and eptides
such as dynorphin 1-13 (DYN 1-13) and (D-alanine2, D-
leucine5) enkephalin (DADLE).
MATERIALS AND METHODS
Male guinea pigs (400-550 g) were decapitated and ileums
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removed. Each longitudinal muscle with myenteric plexus
attached was prepared as described by Kosterlitz et al.
(1970) from a 6-cm segment 10-15 cm proximal to the ileo-
caecal valve using the method of Su et al, (1981). The
muscle was set up between two platinum electrodes in a 5-
ml bath containing oxygenated (95% O2:5% CO2) Krebs bi-
carbonate buffer solution with the following composition
(mM): NaCl 118.4, KCl 4.75, CaCl2 2.54, MgSO4 1.2, KH2PO4
1.19, NaHCO3 25.0, glucose 11.1 plus choline chloride 20
µM and pyrilamine maleate 0,125 µM. The strip was con-
nected to a transducer, allowed to equilibrate with con-
stant electrical stimulation (0.1 Hz, 0.25 msec, 80-90 V)
and isometric contractions polygraphically recorded. The
resting tension was 1 g. After equilibrium, the agonists
were added to the bath and the effects recorded until the
maximum effect had been reached. The antagonists were
either preincubated for 3 min (NX) and 5 min (MRSAL) or
added after the agonist.
RESULTS AND DISCUSSION
The results of this study demonstrate that J behaved as
an opioid agonist producing a concentration-response re-
lated decrease in contractions with the effects antagon-
ized by NX. On the other hand, MRSAL demonstrated sig-
nificant opioid antagonist activity in a manner similar
to that of NX. Figure 2 shows the concentration-effect
agonist curves for NM (mu-receptor prototype) and NM
FIGURE 2. Agonist capacity in GPI. Slope (b)
values are: NM 38.6 (r-0.62, N = 300), MRSAL +
NM 42.9 (r = 0.86, N = 50), J 34.1 (r = 0.74,
N = 174), MRSAL + J 33.5 (r = 0.93, N = 49), NX
+ J 38.8 (r = 0.90, N = 57).
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TABLE 1: Calculated pA2 values for NX and MRSAL
antagonism of selected opioid agonists
Antagonist Agonist N pA2 S.E.M.
NX NM 15 8.40 0.06
NX EKC 14 7.62 0.08
NX J 30 8.17 0.071
MRSAL NM 28 5.41 0.02
MRSAL DHM 21 5.53 0.05
MRSAL EKC 25 4.50 0.07
MRSAL J 20 5.09 0.04
MRSAL DYN 1-13 24 5.10 0.05
MRSAL DADLE 20 5.22 0.03
1Significantly different from corresponding
values for NX + NM (P <0.05) and NX + EKC
(P <0.001).
antagonism by MRSAL. In addition, the concentration-
effect curve for J is shown and the antagonism of J by NX
and MRSAL. The concentrations (nM) of the agonists caus-
ing 50% inhibition of maximum response (IC50) as calcu-
lated from the respective regression-line equations are:
NM 110.2, DHM 45.1, EKC 1.3, DYN 1-13 1.8, DADLE 19.9
and J 9625.0. Compound J was completely and reversibly
antagonized by low concentrations of NX (88 nM) suggest-
ing a specificity for mu receptors (pA2 = 8.17, table 1).
The pA2 values for MRSAL antagonism of selected opioid
agonists are also shown in table 1. MRSAL demonstrated
low affinity but behaved as a full antagonist of opioid
receptors. Its highest affinity was seen toward mu rath-
er than kappa opioid receptors. Prototypes selective for
mu receptors (NM, DHM) and J were antagonized with con-
centrations of 21.2 µM while kappa agonists (EKC, DYN
1-13) required higher concentrations such as 85 µM.
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ABSTRACT
Oxymorphazone is a 14-hydroxydihydromorphinone derivative which
contains C-6 hydrazone group and hence could serve as an irreversible
lahel for opioid receptors.
3H-oxynorphazone was synthesized by the reaction of 3H-oxymorphone
with excess hytirazine, with 640 GBq/mmol specific radioactivity. Both
the unlabelled compound and the tritiated ligand show high affinity to
mu and kappa opiate receptor subtypes in rat brain membranes. TWO
binding sites were detected by equilibrium binding studies. About 60%
of the 3H-oxymorphazone specific binding is irreversible at 10nM
ligand concentration. Preincubation of the membranes with unlabelled
oxymorphazone resulted in an irreversible blockade of the high
affinity 3H-naloxone binding sites.
INTRODUCTION
Using ligands of high specific radioactivity two classes of binding
sites - low and high affinity - is detectable for mu and delta
opioid receptor subtypes. 14-Hydroxydihydromorphinone hydrazones and
azines, first synthesized by Pasternak et al.(1980) have been proved
to be a useful tools in elucidation of their pharmacological role and
involvement in opiate analgesia.
For the detailed investigation of the mechanism and kinetics of the
irreversible binding tritiated oxymorphazone was needed.
We have synthesized 3H-oxymorphazone and studied its binding
characteristics on rat brain membranes.
MATERIALS AND METHODS
Synthesis of 8-3H-oxymorphazone:
a/ Synthesis of 8-3H-oxymorphone: The precursor molecule (14-hydroxy-
codeinone) was prepared by the method of Iiyima et al.(1978), and O-
demethylated by BBr3 to give 14-hydroxy-morphinone, which was
tritiated in the psesence of PdO catalyst.
b/ Synthesis of 8-3H-oxymorphazone:
The product was reacted with tenfold excess of hydrazine at room
temperature. Specific radioactivity of 640 GBq/mmol was obtained.
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Chemicals:
3H-EKC was purchased from New England Nuclear (specific activity: 0.74
TBq/mmol), 3H-DAGO was from Amersham (specific activity: 1.67
TBq/mmol), 3H-DALE (1.37 TBq/mmol) and 3H-naloxone (3.09 TBq/mmol) was
synthesized by Toth (1982,1985). DADLE was purchased from Sigma,
morphine was a commercial product. Unlabelled oxymorphazone was
synthesized by our laboratory, all other chemicals were of analytical
grade.
Membrane preparation:
Crude membrane fraction from rat (PVG/C) brain was prepared as
described earlier (Simon et al. 1986). Protein content was estimated
by the method of Bradford (1976).
Binding Assay:
Membrane suspension in 50 mM Tris-HCl buffer, (pH=7.4) was incubated
with 3H-oxymorphazone in the presence or absence of unlabelled ligands
in a final volume of 1 ml. Specific binding was defined as the
difference between the bound radioactivity in the absence and presence
of unlabelled ligand. Incubation was started by addition of the
membrane protein and stopped by rapid filtration of the mixtures
through Whatman GF/C filters, which were presoaked in 10 µM unlabelled
oxymorphazone solution for 1 hour.
Radioactivity was determined in toluene based scintillation cocktail
by LKB Minibeta Liquid scintillation spectrometer.
Irreversibility studies:
500 ul of membrane suspension was incubated with 200 µl 3H-
oxymorphazone solution in the presence or absence of excess
levorphanol (10 µM)in a final volume of 2 ml. After 90 min
incubation  at 0°C samples were diluted with ice cold Tris-HCl  buffer
and centrifuged. The pellets were resuspended in 30 ml buffer,
incubated for 10 min and recentrifuged. This washing step was
repeated 4 times. 1 ml aliquots of the homogenized final pellets were
filtered through presoaked GF/C filters. The washing experiments with
unlabelled ligands were performed as previously described (Szucs et
al. 1983).
RESULTS AND DISCUSSION
The binding reached equilibrium at about 90 min at 0°C. All further
experiments were carried out at 0°C in order to minimize the
possibility of azine formation.
Dissociation of the radiolabelled ligand was extremely slow as
measured by dilution or after addition of excess of reversible
(levorphanol) or irreversible (unlabelled oxymorphazone) compounds
(data not shown).
Scatchard analysis of 3-H-oxymorphazone saturation curve is shown on
fig.1. On the basis of computerized fit of data two classes of
binding sites were identified with dissociation constants of 0.62 and
28 nM, and Bmax: 18 and 134 fmol/mg respectively.
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FIGURE 1.
of 3H-oxymorphazone
Scatchard plot
binding.
Rat brain membranes were
incubated at 0°C for 90
min with 3H-oxymorphazone
in the presence or absence
of 10 µM unlabelled
oxymorphazone. B: bound
ligand (fmol/mg protein)
F: free ligand (nM).
Competition experiments were carried out with 3H-oxynorphazone and
with sub-type specific tritiated ligands (Kosterlitz et al. 1951).
From these data it became evident that oxymorphazone exhibits high
extremely low affinity  for delta (IC50:2000 nM) sites.
affinity for mu IC50:0,4 nM) and kappa (IC50:2 nM) sites and
FIGURE 2.
of 3H-oxymorphazone
Irreversibility
binding.
Irreversible labelling of
rat brain membranes was
carried out as described
in Materials and Methods.
Control values repres nt
specific binding of 3H-
oxymorphazone on membrane
preparations incubated
with buffer and washed in
the same way.
As shown in fig. 2. the binding of 3H-oxymorphazone is irreversible
in about 20% at 1nM isotope concentration despite of extensive
washings, and this irreversible binding greatly increased at higher
concentrations. The irreversible binding blocks mainly the high
affinity (mu,) opioid binding site as shown in fig. 3.
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FIGURE 3. Scatchard
analysis of 3H-naloxone
binding.
Rat brain membranes
preincubated with 10 µM
oxymorphazone were
labelled with naloxone
after extensive washing
Control was treated
in the same way without
addition of oxymorphazone
In this case the membrane was incubated with unlabelled
oxymorphazone (10 µM) and the remaining 3H-naloxone binding was
measured. These results are in agreement of earlier investigations
(Pasternak et al. 1980).
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ABSTRACT
CAM has been shown to produce opiate agonist and antagonist activi-
ties. Based on its potent agonist activity in rabbit vas deferens
and the low potency of naloxone to antagonize its agonist effect in
the guinea pig ileum and mouse vas deferens, CAM can be considered
as kappa agonist. It is further supported by its diuretic effect and
the estimated "apparent pA2" values with naloxone and Mr-2266BS. How-
ever, in the rabbit ear artery and cat nictitating membrane, ethyl-
ketazocine (EK) produced agonist activity, while CAM produced antag-
onist activity, Also, EK differs from CAM in mouse vas deferens in
the presence of 4-aminopyridine. It is concluded, that CAM might be
an agonist on kappa type (subtype) of opiate receptors, although its
spectrum of activity was found to be different from EK or hremazocine.
INTRODUCTION
The most widely accepted classification of opioid receptors (OR) is
mu, kappa and delta (Iwamoto and Martin 1981, Lord et al. 1977). Pre-
viously we reported the peculiar spectrum of activity of CAM, produc-
ing strong agonist and antagonist effects in several in vivo and in
vitro tests /Knoll 1977, Furst and Knoll 1982, 1985). In an attempt
to define OR subtype(s) involved in the effects of CAM, various iso-
lated organ preparations, containing different OR-s were used, to-
gether with some in vivo tests. The sensitivity to naloxone (NX) and
Mr-2266BS was also studied in various assays.
MATERIALS AND METHODS
The effects of the test substances on OR-s in isolated tissue pre-
parations were compared using the electrically stimulated myenteric
plexus-longitudinal muscle of the guinea pig ileum (GPI), electrically
stimulated mouse, rat and rabbit vasa deferentia (MVD, RVD and LVD,
resp.), electrically stimulated isolated cat nictitating membrane
(CNM) and rabbit ear artery (REA) with the following parameters;
0.1 HZ, 1 ms (GPI,RVD); 0.01 HZ, 1 ms (CNM); 0.05 HZ, 1.0 ms (LVD) 3
pulses of 10 Hz, 1.0 ms per 10 s (MVD); 5 pulses of 5 Hz, 1.0 ms per
60 s (REA). Supramaximal voltage of field stimulation was used in all
experiments. The antinociceptive activity of the test substances was
assessed using the acetic acid writhing test, in the mouse. Urine
output measures were carried out according to Leander (1983a). Intra-
thecal injections (i.t.) were made to rats as described by Yaksh and
Rudy (1976).
Drugs: Morphine HCl, normorphine, N-cyclopropylmethylnorazidodihydro-
isomorphine (Alkaloida, Hungary), naloxone HCl (Endo), ethylketazocine
EK (Sterling Winthrop), Mr-2266BS (Boehringer, Ingelheim) hremazocine
1
N-cyclopropylmethylnorazidodihydroisomorphine
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HCl, BR (Sandoz) 4-aminopyridine 4-AP (Sigma), Thiobutabarbital-
Natrium (INACTIN, Byk-Gulden, Hamburg), [D-Ala2,Leu5] enkephalin
(DALE), [D-Ala2, D-Leu5] enkephalin (DADL), [D-Ala2, MePhe4, Gly-ol5]
enkephalin (DAGO). (Central Res. Inst. for Chemistry, Budapest,
Hungary)
RESULTS AND DISCUSSION
The rabbit vas deferens has been shown to be especially useful for
identifying kappa agonists. Such compounds are potent inhibitors of
electrically induced contraction in this tissue, whereas mu and
delta agonists are virtually ineffective (Oka 1981). CAM vas found to
be agonist, similarly to EK and other kappa agonists (table 1). For
the antagonism of the agonist action of CAM and EK in GPI, 10-11
and in MVD 6-7 times more NX was required than was needed to
TABLE 1. The agonist activities of CAM and EK in isolat-
ed organs (IC50;nM S.E.M.)
GPI M V D
4-AP1
L V D C N M
control
C A M 0,3 0.07 1.7 0.2 * 18.3 1.6 **
E K 1.2 0.22 3.8 21.03.9 0.4 19.8 5.3 5.7 0.3
*the maximum inhibition <40% 1with 4-AP 2x10-5M
**agonist activity undetectable n:5-12
antagonize the effect of normorphine. In RVD, CAM and EK had no
agonist activities but antagonized the effect of DALE. However, in
REA and CNM, EK produced opiate agonist action while CAM showed only
antagonist activity. In CNM the agonist actions of morphine, DALE
and EK were antagonized by CAM. In REA the mu agonists normorphine
and DAGO did not show agonist effect. The delta agonist DADL was
FIGURE 1. The effects of various doses of CAM S.C.
i.t. nalorphine S.C. bremazocine, S.C. on
cumulative urine output at 2 hr (left) and 5 hr (right)
in the Sprague Dawley rats weighing between 160-220 g.
The points and bars are the mean S.E. for 8-14 rats.
Controls above 0 
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potent agonist indicating a lack of mu receptors in this preparation
supporting the existence of enkephalinergic receptors as it was
first suggested by Knoll (1976). The difference observed between the
effects of CAM and EK was further supported by the facts that in MVD
in the presence of 4-AP (2x10-5M) which increased the electrically
evoked noradrenaline release (Friedmann et al. 1994) CAM proved to
be only partial agonist. When the maximal agonist effect of CAM was
already reached (<40%) DADL and EK further reduced the contractions.
In the presence of 4-AP, CAM (2.5x10-7M) diminished the marked
agonist actions of DADL and EK. Recently, it has been shown (Slizgi
and Ludens 1982, Leander 1983a) that kappa opioid agonists -such as
EK, BR, etc. - have a marked diuretic effect in rat, and it was
antagonized by opioid antagonists in a potency order which indicated
that the effects were due to an action at kappa OR-s. Figure 1 shows
the effect of CAM on urine output in normally hydrated rats, compared
to other drugs. CAM produced dose related (0.01-2.5 mg kg-1) diuresis
similarly to BR, by S.C. administration, This effect was more pro-
nounced when CAM was given i.t. This diuretic effect was antagonized
by kappa antagonist dose of NX(10 mg kg-1, 0.5-2.5 mg kg-1 dose of
Mr-2266BS, and blocked by 20 mg kg-1 morphine administration
(table 2). Mr-2266BS was more potent than NX in antagonizing the
TABLE 2. Antagonism of CAM (0.5 mg kg-1 s.c.) induced
urination. Data are the mean S.E. in mls for 8-15 rats.
dose mg kg-1 0.5 mg kg-1CAM + antagonists
of antagonist 2 hr 5 hr
+ 0 (control) 6.6 0.3 7.7 0.6
+ 1 naloxone 5.6 0.8 6.8 0.6
+10 naloxone 3.4 0.5 4.7 0.4
+2.5 Mr-2266BS 1.19 0.2 2.3 0.25
+20 morphine 1.73 0.2 5.5 3.6
diuretic effect of CAM, as it was found against BR and U-50488H,
reported by Leander (1983b). It is interesting, however, that while
the diuretic effects of two other kappa agonists: proxorphan or BR
are not affected significantly by morphine, supposingly because of
TABLE 3. Sedative effects of morphine, CAM and bremazo-
cine and their antagonism by naloxone and Mr-2266BS
(n=10 rat/dose)
increase of control sleeping time. The AD50 is defined
as the dose of the antagonist needed to reduce by 50% the
narcosis potentiating effect of equi-active doses (ED90)
of the agonist.
A D 5 0
(mg kg-1 naloxone 1.2 3.8 3.5
s.c.) MR-2266BS 0.1 0.1 0.3
The ED50 is defined as the dose that induced a fivefold
morphine C A M bremazocine
ED50 (mg kg
-1i.v.) 0.7 0.28 0.036
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effects by naloxone and Mr-2266BS is also presented in table 3. It is
remarkable, that Mr-2266RS was 10 times more potent than NX in antago-
nizing morphine and BR induced prolongation of sleeping time. Our
data demonstrate that the opioid agonist effects of CAM are mediated
by similar type of receptor (kappa or subtype of kappa receptors) as
the effects of classical kappa agonists: EK or BR in GPI, LVD and MVD
preparations and in the sedation, diuresis and writhing test. However,
CAM failed to show agonist activity in CNM and REA and we could not
elicit full effect in MVD in the presence of 4-AP in tests where the
classical kappa agonist drugs e.g. EK or BR proved to be agonists.
These results indicate the existence of OR population of kappa recep-
tor subtype/s/ or others/?/ which are stimulated by EK or BR but not
by CAM. In the RVD, BR, CAM and EK in some analgesic-tests CAM (Furst
and Knoll 1985) and BR (unpublished observation) proved to be antag-
onists while in some assays, where CAM showed antagonistic activity
(CNM, REA and MVD in the presence of 4-AP) EK did not (mu, delta,
kappa subtype). In the latter two tests BR also exhibited antag-
onist activity (unpublished data).
their mu opioid receptor antagonist activity (Leander 1983b). The
effect of CAM was found to be suppressed by morphine in spite of its
strong mu antagonist activity demonstrated by several tests, as it
was published elsewhere (Furst and Knoll 1982, 1985) and in this
paper. The analgesic effect of CAM in the writhing test was found to
be 37 times stronger than that of morphine (ED50 s.c.: 0.015 and
0.43 mg kg-1 resp.) The pA2 for naloxone antagonism of morphine(6.9)
was much higher than that for CAM (5,6). Conversely, Mr-2266BS a
reported kappa antagonist (Romer et al. 1980), has a higher pA2 for
CAM (6.2) than for morphine (5.8) in the acetic acid induced writhing
test. This observation also supports the concept, that CAM and
morphine exert their analgesic effect through different receptors.
As another possible measurement of kappa activity, we also evaluated
the sedative effects of this class of drugs, as the prolongation of
barbiturate narcosis (table 3.) BR was observed as the most potent
drug, while morphine the less active one. The reversal of these
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ABSTRACT
Three dynorphin A(1-9) pyrrolidine analogs were
synthesized by substituting isoleucine at position 8
with alanine (Ala), D-alanine (D-ala), and D-leucine
(D-leu), and assayed for their effect on electrically
induced twitches of the isolated guinea pig ileum and
mouse vas deferens. All three dynorphin A(1-9)
pyrrolidine analogs caused inhibition of the evoked
twitches of the two preparations dose-dependently that
was reversed by naloxone. However, the substitution by
alanine or D-alanine resulted in a decrease in potency
on guinea pig ileum when compared to dynorphin A(1-9)
pyrrolidine and substitution by D-leucine caused a
considerable loss of potency in both mouse vas deferens
and guinea pig ileum. Although these substitutions
reduced overall potency, a change of potency ratio
towards more delta selectivity resulted.
INTRODUCTION
It has been shown that incorporating amino-acids at
different positions of dynorphin A(1-13) and its
fragments greatly modifies potency and affinity of the
resulting peptides to multiple opiate receptors.
For example, Chavkin and Goldstein (1981) reported
that substitutions at arg7 and lys11 reduce
selective binding of dynorphin in the guinea pig ileum.
Also, Rezvani et al. (1984) evaluated seven dynorphin
A(1-9) analogs on the guinea pig ileum and mouse vas
deferens and concluded that protection of the carboxy
terminal with a pyrrolidine group results in
prolongation of dynorphin A(1-9) action. Furthermore,
Turcotte et al. (1984) replaced the amino acids in
positions 1-12 of dynorphin A(1-13) by ala and concluded
that only replacement at position 8 results in a higher
potency of the peptide in the mouse vas deferens. In
order to investigate whether other substitutions at
position 8 will change the potency of dynorphin (1-9) we
have synthesized three dynorphin A(1-9) pyrrolidine
analogs by substituting iso-leucine at position 8 with
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alanine, D-alanine or D-leucine and evaluated their
effects on the guinea pig ileum and mouse vas deferens.
The results are presented in this communication.
MATERIALS AND METHODS
Ala8 dynorphin A (1-91, D-ala8 dynorphin A(1-9) and
D-leu8 dynorphin A(1-9) were synthesized by the solid
phase method and the pyrrolidine group was attached by
treatment of the peptide-resins with pyrrolidine-DMF
(1:1 mixture). The peptides were purified by
reverse-phase column chromatography using C-18 resin.
The purity was checked by HPLC, TLC and electrophoresis.
The isolated longitudinal muscle with the attached
myenteric plexus from the guinea pig ileum was mounted
in a chamber containing Ringers' solution and the
excised mouse vas deferens in Krebs' solution. The
tissues were stimulated electrically and the induced
twitches recorded. Agonists were added to the media in
increasing concentrations and a dose response curve was
plotted. The concentration which inhibits maximally
induced contractions by one-half (IC5O) was then
determined from the dose response curve.
RESULTS
High performance liquid chromatography showed the three
peptides to be pure as evidenced by a single peak for
each (figure 1).
FIGURE 1: High performance liquid
chromatography of three dynorphin A(1-9)
pyrrolidine analogs
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All three dynorphin A(1-9) pyrrolidine analogs
inhibited electrically induced twitches of the guinea
pig ileum and the mouse vas deferens dose-dependently.
Ala8 dynorphin A(1-9) pyrrolidine showed the highest
potency in the guinea pig ileum, while D-ala8
dynorphin A(1-9) pyrrolidine and Ala8 dynorphin A
(1-9) pyrrolidine showed the highest potency in the
mouse vas deferens. However, based on their relative
activities in both tissues the D-ala8 analog exhibited
more selective delta activity. D-leucine8 dynorphin A
(1-9) pyrrolidine showed the lowest potency both in the
guinea pig ileum and mouse vas deferens. The IC50 and
relative potencies of three peptides in guinea pig ileum
and mouse vas deferens are shown in Table 1. The effect
of all three compounds could be blocked by naloxone.
TABLE 1. Potency of dynorphin A(1-9)
pyrrolidine analogs on the guinea pig ileum
and mouse vas deferens
Peptide IC50 nM
G P I  M V D  Ratio
G/M
2.6
10
0.2
0.04
0.2
ALA8dynorphin A(1-9) pyrrolidine 200 75
D-ALA8dynorphin A(1-9) pyrrolidine 750 75
D-LEU8 dynorphin A(1-9) pyrrolidine 250 1250
Dynorphin A(1-9) pyrrolidine 7.5 160
Dynorphin A(1-13) 0.8 2.8
DISCUSSION
Our results demonstrate that all three modified
dynorphin A(1-9) pyrrolidine analogs inhibit
electrically induced twitches of the guinea pig ileum
and mouse vas deferens in a dose-dependent manner.
However, the substitution of iso-leucine by alanine or
D-alanine decreases potency in the guinea pig ileum but
increases potency in the mouse vas deferens. These
results are consistent with those obtained by Turcotte
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et al. (1984) who observed an increase in potency for
dynorphin A(1-13) in mouse vas deferens by replacing
iso-leucine with alanine at position 8. Other
substitutions on dynorphin A(1-13) resulted in decreased
potency in both the guinea pig ileum and mouse vas
deferens. For example, replacement of residues at
positions 1,2, and 4 inside the leu-enkephalin core
causes a decrease in biological activity (Turcotte et
al. 1984), and positions 6 and 7 are found to be the
most important site outside the enkephalin moiety
(Chavkin et al.1982) for biological activity.
With respect to substitution at position 8,
replacement of iso-leucine by D-leucine causes a
decrease of potency of the resulting peptides both in
the guinea pig ileum and mouse vas deferens. On the
other hand, substitution of iso-leucine by alanine or
D-alanine, seems to favor delta-like activity, since the
alteration decreases potency in the guinea pig ileum
much greater than in the mouse vas deferens.
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ABSTRACT
Iodination of the -selectfve peptide DPDYN, [D-Pro10]-dynorphin
(1-11), has been performed. The non radioactive monoiodo derivative of
DPDYN retains -selectivity ( /µ =  48 and = 140), despite a
general but moderate decrease in affinity. Radioiodination of DPDYN
leads to the monoiodinated peptide (S,A 700-800 Ci/mmol) which
interacts specifically and reversibly with the -sites in guinea-pig
cerebellum membranes with high affinity (KD = 0.12-0.18 nM). In
guinea-pig brain ( ) and rabbit cerebellum ( <<µ), 125I-DPDYN
discriminates between - and other (µ, ) binding sites. We have used
this new labelled probe for the direct, precise and rapid (exposure
time less than 100 hours) visualization of -sites in guinea-pig and
rabbit cerebellar slices using autoradiography.
INTRODUCTION
Biochemical and pharmacological studies on a particular opioid
receptor type (µ, or ) are greatly
ligands. DPDYN ([D-Pro10]-dynorphin (1-11)),
facilitated by use of selective
derived from dynorphin A,
displays high affinity and selectivity for the opioid receptor type
(Gairin et al. 1984). So, it was of interest to obtain a labelled
K-probe derived from this selective ligand. Here we would like to show
that the radiolabelled monoiodo derivative 125I-DPDYN appears to be an
effective and useful tool for the biochemical studies on kappa opioid
receptors.
MATERIALS AND METHODS
Preparation of iodinated derivatives of DPDYN.
Radioiodination of DPDYN was performed as described elsewhere (Gairin
et al. 1986). Non radioactive iodination was performed according to
the same method however on milligram quantities.
Binding studies
Crude membrane fractions were prepared according to Meunier et al.
(1983). Affinities of DPDYN and of its non radioactive mono and diiodo
derivatives at µ, and sites were determined by measuring their
inhibitory effects respectively on the binding of [3H]-DAGO (1.5 nM)
and [3H]-DSLET (2.5 nM) in rat brain membranes and of [3H]-bremazocine
(0.5 nM) in guinea-pig cerebellum membranes at 25°C in tris-HCl
pH 7.4. Saturation and kinetic binding studies of 125I-DPDYN to
-sites were carried out on crude guinea-pig cerebellum membranes at
25°C as previously described (Gairin et al. 1986).
Autoradiographic studies
After preincubation at room temperature in 50 mM tris-HCl buffer
pH 7.4, slices (20 µm section) of guinea-pig or rabbit cerebellum were
incubated with 125I-DPDYN for 40 min. at 25°C in the presence (non
specific binding) or absence (total binding) of 1µM unlabelled
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peptide. Sections were then washed (6 x 40 min.) in cold tris-HCl
buffer -2 % BSA and quickly dried. Autoradiograms were exposed for 3-5
days at 4°C.
RESULTS AND DISCUSSION
Binding properties of mono an diiodo derivatives of DPDYN
As shown in table 1, incorporation of one iodine atom on the tyrosyl
phenolic ring of DPDYN results in a decrease of affinity for binding
site (KI = 0.38 nM). Interestingly, weaker affinities are also
observed for µ- and binding sites, so that selectivity /µ = 48
and = 140) is preserved. Incorporation of an additional bulky
iodine atom (diiodo derivative) leads to a further decrease in
affinity and selectivity of the peptide for binding sites.
TABLE 1. Binding selectivity profilesa of DPDYN and of its non
radioactive mono- and diiodo- derivatives.
peptide Binding site
µ
DPDYN 62 233 [10.49]
monoiodo-DPDYN 48 139 [ 9.42]
diiodo-DPDYN 25 102 [ 8.57]
aNumber in brackets is -log Ki(nM) at the preferred site.
Other numbers are binding selectivities defined as the ratio of
Ki at each non-preferred site over Ki at the preferred site.
Saturation equilibrium and kinetic binding studies
Equilibrium binding experiments have been performed at 25°C in
guinea-pig cerebellum membranes, containing essentially (> 80 %)
binding sites. The linear Scatchard transformation of the data
indicates that 125I-DPDYN interacts specifically with one (kappa)
single class of site with high affinity (KD = 0.12 nM).The maximum
binding capacity value (Bmax = 120 fmol/mg protein is quite
comparable to the ones observed by Robson et al. (1984) (110 fmol/mg
protein) or Frances et al. (1985) (180 fmol/mg protein) in the same
tissue preparation. The low proportion of other opioid sites (µ or
was not detected.
TABLE 2. Parameters of the binding of 125I-DPDYN in guinea-pig
cerebellum membranes at 25°C.
parameter value
thermodynamic
kinetic
Bmax 118 11 fmol/mg protein
KD 0.12 0.01 nM
k a 1.9 0.2 x 10
7 M-1s-1
k d 3.5 0.2 x 10
-3 s-l
KD=kd/ka 0.18 nM
Equilibrium of the binding of 125I-DPDYN (0.2 nM) to guinea-pig brain
membranes is reached after 10-15 minutes at 25°C. In the presence of
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an excess of unlabelled peptide, 125I-DPDYN dissociates from its
complex with the receptor,
The linear
as a result of a reversible binding
process. semi-logarithmic representation of the
dissociation kinetic data indicates a first-order reaction. The
calculated association and dissociation rate constants (ka,kd) are
reported in table 2. It is interesting to note that KD values from
kinetics or equilibrium experiments are very close to ea
and 0.12 nM) and in good agreement with the KI
ch other (0.18
value (0.38 nM) of the
non radioactive monoiodo derivative at -site s.
Specific binding of 125I-DPDYN (0.15 nM) to guinea-pig brain and
rabbit cerebellum membranes
In guinea-pig brain, containing equal proportions of µ-, and
SiteS, 125 I-DPDYN (0.15 nM) binds selectively to sites. As shown
in table 3, the binding capacities of the labelled peptide are
rigorously comparable without (B (µ + + ) = fmol/mg protein)
or with suppression of µ- and b i n d i n g 71 9 fmol/mg
protein). No specific binding at µ- or sites can be detected after
suppression of binding. A comparable binding pattern is obtained in
the rabbit cerebellum containing essentially (> 75 %) u-binding sites
and low content (< 20 %) of sites.
TABLE 3. Binding capacity (fmol/mg protein) of 125I-DPDYN
(0.15nM) at 25°C pH 7.4 to crude membrane fractions of
guinea-pig brain and rabbit cerebellum in presence (single
binding site) or absence (multiple binding sites) of selective
(µ, or ) unlabelled liganda.
multiple binding sites single binding site
µ + + µ
guinea-pig brain 73 9 n.d. n.d. 71 9
rabbit cerebellum 63 10 n.d. n.d. 47 4
a µ-, or K-binding were respectively suppressed by 200nM
DAGO, 100 nM DSLET or 3 nM DPDYN. n.d.: not detectable.
These results clearly show that 125I-DPDYN at 0.15 nM selectively
discriminates between and other (µ, ) sites in nerve tissues
containing various proportions of opioid binding sites.
Autoradiographic studies
Figure 1 shows that binding sites labelled with 125I-DPDYN (0.3 nM)
are localized mainly in the molecular layer of the guinea-pig
cerebellum (A,B). This result is in complete agreement with that found
by Robson et al. (1984) in the same tissue. In the rabbit cerebellum,
very similar autoradiograms are obtained with (C,D) or without (E,F)
suppression of µ- and binding. Interestingly, in the rabbit
cerebellum, the 125DPDYN binding sites are restricted to the Purkinje
cell layer while in the guinea-pig cerebellum they are present
throughout the molecular layer. All these results clearly confirm the
selectivity of the labelled probe.
In summary, 125I-DPDYN can be considered as an useful tool for the
study of opioid receptor, particularly for their direct (no
suppression of µ- and binding is needed), precise and rapid
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(exposure time less than 100 hours) visualization in nerve tissues by
autoradiography.
FIGURE 1: Autoradiographic localization of 125I-DPDYN (0.3nM)
binding sites to sagittal sections of guinea-pig (A,B) and
rabbit (C,D,E,F) cerebellar slices. Left side of the figure
(A,C,E) represents total binding and right side (B,D,F) non
specific binding. Autoradiograms of rabbit cerebellum slices
were obtained in presence (C,D) or absence (E,F) of 1OOnM DAGO +
200nM DSLET (suppression (or not) of µ- and binding).
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ABSTRACT
Changes of endogenous opioid peptide system by pain stimuli were ex-
amined using adjuvant-induced arthritic rats. Following the 5th day
after adjuvant inoculation, met-enkephalin(ME)-like peptide content
in plasma decreased, while after the 12th day, the peptide content
increased in adrenal medulla. A significant correlationship was
found between pain threshold and plasma ME-like peptide content.
Y-20003, a new nonsteroidal agent without inhibition of prostaglan-
din biosynthesis, showed an analgesic effect which was significantly
antagonized by naloxone or Win 44,441-3, suggesting that endogenous
opioid peptide system may be involved in the analgesic mechanism of
Y-20003.
INTRODUCTION
It has been reported that the contents of opioid peptides in plasma
or cerebrospinal fluids decreased in patients with chronic pain (
Panerai et al. 1982, Simonnet et al. 1986), although the physiologi-
cal significance was unclear. On the other hand, it has been also
reported that endorphin(B-ED) content in human plasma was increas-
ed by diclofenac, a nonsteroidal antiinflammatory agent, (Martini et
al. 1984). ED content in rat pituitary gland was reduced and the
content in rat hypothalamus was increased by this agent (Sacerdote
et al. 1985), suggesting that ED might be involved in the analge-
sic mechanism of diclofenac, in addition to inhibition of prosta-
glandin synthesis. Furthermore, it has been known that in vitro
experiments, indomethacin enhanced release of ED from neurointer-
mediate lobe of the rat pituitary gland (Knepel et al. 1985). In the
present study, it was examined what changes of the endogenous
opioid peptide contents could be shown in adjuvant-induced arthritis
of the rat, a model of chronic pain diseases, and then whether the
analgesic action of Y-20003 [10-amino-6-methyl-1,2,3,4,7,8,9,10-
tetrahydrobenzo(f)quinolin-3-one] in the rat could be mediated
through the endogenous opioid peptide system or not.
MATERIALS AND METHODS
Male rats (Lewis strain) were used. Animals were intradermally inje-
cted at the base of the tail with 0.1 ml of adjuvant. The adjuvant
was a 0.5 % suspension of dead tubercle bacilli (R35H5) in liquid
paraffin. The foot was pressed to measure pain threshold and the
foot volume was determined by volumetry before and 5, 12 and 20 days
after inoculation. In addition, the adrenal medulla, incisor pulps
and blood were collected. Plasma from the blood, including heparin
and actinonin(20 µM), were deproteinized with HCl-ethanol. Adrenal
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TABLE  1. % Changes of endogenous opioid peptide contents after adjuvant inoculation
Opioids Tissues Days after adjuvant inoculation
0 5 12 20
ME-like adrenal medulla 100.0 13.6(7) 110.0 9.5(7) 191.9 17.9(7)** 186.8 9.7(7)**
peptides
tooth pulp 100.0 5.1(6) 90.8 5.5(6) 96.5 5.8(7) 98.2 7.1(7)
plasma 100.0 6.1(5) 63.2 4.3(7)** 59.8 4.1(7)** 47.5 4.9(7)**
**p<0.01, significantly different from the corresponding 0 day value, respectively. Each value represents the
mean SEM. Numbers in parentheses are the numbers of animals used.
TABLE 2. Influences of Y-20003 on pain threshold and foot volume
Treatments
Days after adjuvant inoculation
15 16 18 20
pain threshold control -63.1 0.6(10) -64.8 15.7(10) -57.7 13.7(10) -48.3 16.9(10)
( g ) Y-20003 -61.1 13.0(10) -10.2 16.7(10)* -10.1 15.6(10)* -9.4 12.7(10)*
foot volume control 1.84 0.06(10) 1.98 0.06(10) 1.87 0.07(10) 1.95 0.08(10)
( ml ) Y-20003 1.87 0.05(10) 1.93 0.05(10) 1.94 0.06(10) 2.01 0.07(10)
*p<0.05 significantly different from the corresponding control value, respectively. Each value represents
the mean SEM. Numbers in parentheses are the numbers of animals used. Y-20003 was daily administered in
a dose of 50 mg/kg/day, p.o. from 15th day after adjuvant inoculation.
medulla and tooth pulps were homogenized with 0.1 N HCl. These
materials were centrifuged and the supernatants were lyophilized.
The lyophilized materials were radioimmunoassayed to measure the
ME-like peptide contents, as described previously (Kudo et al.
1983).
FIGURE 1. Correlationship between pain threshold and plasma
ME-like peptide content. The data from control, 12th and
20th days after adjuvant inoculation were plotted.
TABLE 3. Antagonism of naloxone or Win 44,441-3 against
the analgesic effect of Y-20003
Treatments Doses(mg/kg) n g of pain threshold
control 0 10 -75.1 21.3
Y-20003 50 10 - 7.2 16.9*
Y-20003 50
+ } 10 -55.0 14.0#
naloxone 2
Y-20003 50
+ } 10 -78.6 15.6##
Win 44,441-3 1
*p<0.05, significantly different from the control. #p<0.05
and ##p<0.01, significantly different from the Y-20003 group.
Each value ( g ) represents the mean SEM. Y-20003 was
orally administered. Naloxone and Win 44,441-3 were injected
subcutaneously 10 min before Y-20003. The data are from
those of 18th day after adjuvant inoculation.
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RESULTS AND DISCUSSION
In the present study, it was examined what changes of endogenous opi-
oid peptide contents could be shown in adjuvant-induced arthritis of
the rats. It was found that pain threshold decreased and foot volume
increased significantly following the 12th day after adjuvant inocu-
lation. These indices did not show any changes at the 5th day, sug-
gesting that the day was on the latent stage of the arthritis (data
not shown). However, the content of plasma ME-like peptides were
significantly reduced following 5th day, while the content of adrenal
medullary ME-like peptides was elevated after the 12th day(table 1).
These results may suggest that a long term of lowering of plasma
opioid peptide levels is necessary to lower the pain threshold. Fur-
thermore, it is conceivable that at the initial stage of adjuvant
inoculation(5th day), the lowering of the peptide level is due to
activation of some degrading enzymes in plasma, followed by compen-
satory promotion of opioid peptide processing in adrenal medulla
since 12th day. In fact, as shown in fig. 1, a significant correla-
tionship was found between pain threshold and plasma ME-like peptide
content. On the other hand, in the present study, we investigated
whether analgesic action of Y-20003 which did not inhibit prostaglan-
din biosynthesis could be mediated through the endogenous opioid
peptide system in the adjuvant-induced arthritis or not. The pain
threshold, but not the foot volume, was recovered near the normal
level after Y-20003(table 2). The analgesic effect of Y-20003 was
antagonized by naloxone or Win 44,441-3, a antagonist(table 3). In
addition to these results, we have previously certified that adrenal
medullary ME-like peptide content was markedly reduced and in contr-
ast, plasma ME-like peptide content showed a tendency to be increased
by Y-20003 in normal rats(data not shown). From these findings, it
may be concluded that 1) plasma opioid peptide levels are closely
related to pain threshold in the arthritic rats and 2) the analgesic
action of Y-20003 on the adjuvant-induced arthritis is mediated
through endogenous opioid peptide.
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PROHORMONE PROCESSING REACTIONS: DISCRETE STAGES
IN THE FORMATION OF ENDORPHIN RELATED PEPTIDES
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The Ridgeway, Mill Hill, London NW7 1AA, U.K.
ABSTRACT
Analysis of lipotropin from the pars intermedia of
bovine pituitary showed that it contained the full COOH-
terminal sequence of endorphin. In contrast the
endorphin related peptides exhibited a high degree of
C-terminal proteolysis. The implications of these
findings are discussed with reference to the cellular
compartments where the processing reactions take place.
INTRODUCTION
It is well appreciated that peptide hormones and trans-
mitters are formed by proteolytic cleavage of prohormone
Precursors and their formation may involve the proteo-
lysis of more than one peptide bond. It is not known,
however, whether these cleavages take place simultane-
ously and competitively or whether they take place
independently and in a predetermined order. The
formation of endorphin 1-27 offers an example of a
prohormone fragment that requires two processing
reactions for its release, one cleavage to free the NH2-
terminus of the peptide and the second to release the
COOH-terminus. We present evidence that the two
reactions take place consecutively. They may occur in
different cellular compartments.
METHODS
Peptides were extracted from 4 bovine anterior pituitaries
or pars intermedia by homogenisation in acid acetone
(Smyth et al. 1978). The extracts were dried and
fractionated by gel exclusion chromatography on Sephadex
G75 (100 x 2cm) in 20% acetic acid. Lipotropin and
endorphin related peptides were located by RIA with a
endorphin antiserum (Zakarian and Smyth 1979) and the
lipotropin containing fraction was re-chromatographed
under the same conditions to ensure complete removal of
the endorphin related peptides.
To determine whether the lipotropin molecules contained
the full 31 residue sequence of endorphin or were
shortened at the COOH-terminus, the lipotropin containing
fractions were subjected to citraconylation and trypsin
digestion. This procedure allowed limited proteolytic
cleavage to take place at arginine residues, thus
releasing the C-terminal sequence. After removal of
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the citraconyl groups, the corresponding forms of
endorphin were identified chromatographically. The
lipotropin obtained from 2 pituitaries was reacted with
40µ1 of citraconic anhydride (in 160µl dioxan) in 2ml of
400mM sodium phosphate at pH 9. The reaction mixture
was vortexed until no further change in pH was observed,
the pH being maintained by automatic addition of 1M-NaOH.
The reaction mixture was then treated with TPCK trypsin
(2µg) and digestion carried out at 37°C for 16 h. The
reaction was terminated by addition of acetic acid and
gel exclusion chromatography was employed to resolve
endorphin related peptides from residual lipotropin.
The peptides were located by RIA with a endorphin
antiserum, the citraconyl groups being removed by the
exposure to acetic acid during chromatography. The
endorphin containing fraction was resolved by ion
exchange chromatography on SP-Sephadex C25 (sodium form)
in 50% acetic acid with a sodium chloride gradient (0 to
0.5M, mixer volume 1OOml). The peptides related to
endorphin again were located in the eluted fractions
by RIA.
The lipotropin fractions from the two regions of
pituitary, obtained by gel exclusion chromatography,
were further examined by HPLC (Smyth 1984) using a C18
column in 10mM HCl with an acetonitrile gradient (0 to
25% in 2 min, and 25 to 50% in 25 min). Aliquots of the
eluted fractions were dried in vacuo and the lipotropin
located by RIA.
RESULTS AND DISCUSSION
The lipotropin fractions obtained from both the anterior
pituitary and pars intermedia, after citraconylation and
trypsinisation, gave rise only to endorphin 1-31; none
of the shortened forms of endorphin endorphin 1-26
and endorphin 1-27) were formed (figure 1).
Similarly no evidence for the presence of shortened forms
of lipotropin could be detected by HPLC; only a single
immunoreactivity component was observed. It can be
concluded that lipotropin is generated in both regions of
pituitary in a form that contains the full 31 residue
sequence of endorphin. The results show that the
proteolytic processing reaction that releases the N-
terminus of lipotropin goes to completion and the lipo-
tropin is converted to endorphin before any detectable
C-terminal proteolysis takes place.
It is well known that the endorphin related peptides
that are present in the pars inter-media exhibit a high
degree of C-terminal proteolysis (Smyth and Zakarian
1980). The major peptides are the 26 and 27 residue
forms together with the corresponding N-acetyl deriva-
tives, whereas the 31 residue form of endorphin in the
pars intermedia is only a minor component. The present
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FIGURE 1. Ion exchange chromatography of
endorphin forms released by tryptic
digestion of citraconylated lipotropin from
(a) bovine pars intermedia and (b) anterior
pituitary. The peptides were chromato-
graphed as described in the text.
results show, in marked contrast, that lipotropin in
the pars intermedia and in the anterior pituitary
exhibits no C-terminal shortening of the peptide chain.
It is clear that the processing reactions that release
lipotropin (Reaction 1), and endorphin from lipotropin
(Reaction 2), take place and go to completion before
proteolysis at the C-terminus commences. It could be
that the combined rates of Reactions 1 and 2 are
several orders of magnitude greater than the rate of
Reaction 3. Alternatively the final processing step
may take place in a different cellular compartment from
that where lipotropin is formed, or it may take place
in the same compartment but under different conditions.
It seems likely, furthermore, that the enzyme that
generates lipotropin and endorphin is different from
the enzyme that is involved in C-terminal shortening
of the peptide chain.
The molecular events involved in the conversion of
lipotropin to endorphin 1-27 are seen to comprise a
series of three cleavage reactions which take place
consecutively. Thus shorter forms of lipotropin do not
POMC LPH 1-91 end 1-31 end 1-27
seem to occur to a measurable extent in the pituitary
and the conversion of lipotropin to endorphin 1-31
appears to be a mandatory step which must take place
before C-terminal proteolysis of the peptide chain can
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occur.
The results suggest that processing reactions take place
in ordered sequence, each step going to completion before
the succeeding step commences. The ordered processing
could, of course, be related to conformational restriction
of certain cleavage sites which would determine the nature
of the fragments produced; alternatively the cleavage
reactions may be catalysed by different enzymes. In
either case the possibility should be considered that
proteolytic processing reactions may be regulated
independently.
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BRIDGE PEPTIDE IS A CLEAVAGE PRODUCT OF PRO-DYNORPHIN PROCESSING IN
THE RAT ANTERIOR PITUITARY
Robert Day and Huda Akil
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ABSTRACT
Bridge peptide, the sequence of amino acids which joins
alpha-neo-endorphin and dynorphin A 1-17, was determined to exist as
a free molecule in the rat anterior pituitary. Gel filtration
chromatography revealed the presence of the free peptide as well as a
high molecular weight intermediate of 8-9 kilodaltons.
INTRODUCTION
Pro-dynorphin (PRO-DYN) is the common precursor to a series of
leucine-enkephalin extended opioid peptides, including dynorphin
(DYN) A 1-17, DYN A 1-8, DYN B 1-13 and alpha-neo-endorphin (for
review see Dores et al. 1984). These products are generated when
PRO-DYN undergoes a series of proteolytic cleavages at basic amino
acid pairs. The order in which these events occur is not well
understood. However, nucleotide sequence analysis of cloned
complementary DNA disclosing the primary sequence of PRO-DYN
(Kakidani et al. 1982) combined with knowledge of Lys-Arg as a
cleavage site permits certain predictions. One of these predictions
would be the liberation of the amino acid sequence which lies in
between alpha-neo-endorphin and DYN A 1-17, and is referred to in
this text as "bridge peptide."
The bridge peptide sequence is highly heterogeneous across species
(Civelli et al. 1985). In rat, it is composed of 23 amino acids,
while porcine and human bridge peptide are 21 and 19 amino acids,
respectively. However, the 6 amino acids which compose ethe
C-terminal of bridge peptide are conserved across species.
PRO-DYN end product immunoreactivity is known to be present in the
anterior lobe of the pituitary (cf. Khachaturian et al. 1986) and has
been characterized as existing mainly in high molecular weight
intermediates (Seizinger et al. 1984). Two intermediates have been
described, an 8 kdal molecule with alpha-neo-endorphin in its
C-terminal and a 6 kdal molecule with DYN A 1-17 in its N-terminal.
This would suggest the presence of free bridge peptide in the
anterior pituitary. This study was undertaken to verify if bridge
peptide occurred as an intact entity.
METHODS
A radioimmunoassay (RIA) to bridge peptide was developed. Porcine
bridge peptide synthesized by Dr. Richard Houghten (Scripps Clinic,
La Jolla, CA) was conjugated to thyroglobulin and injected s.c. to
rabbits. The labelled antigen for this RIA was iodinated (I 125) rat
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bridge peptide (rat bridge peptide was also synthesized by Dr.
Houghten). The iodination was carried out in the presence of
chloramine-T and the unreacted cold, peptide was separated from
labelled bridge peptide by HPLC. The RIA was carried out in a 300 ul
volume, consisting of 2 parts - 150 mM PO buffer (pH 7.2) with 0.1%
BSA, 0.9% NaCl, 0.06% triton and 0.01% sodium azide; 1 part -
methanol: 0.1 N HCl (1:1, v/v). The assay was incubated 24 hrs at
4°C and bound labelled antigen was separated from free labelled
antigen by the addition of 100 ul of 0.5% bovine gamma globulins and
500 ul of 20% polyethylene glycol. Under these conditions the
antibody was used at a final dilution of 1/18,000. The limit of
sensitivity, defined here as the amount of unlabelled antigen
required to displace 10% of labelled antigen, was 30 fmoles. The
antibody was determined to be C-terminal directed.
Fifty anterior pituitaries from adult male Sprague-Dawley rats were
homogenized in 10 ml of methanol: 0.1 N HCl (1:1, v/v). The
extracts were chromatographed on Sephadex G-50, superfine column (1.5
X 90 cm) in 1% formic acid and 0.01% BSA. Two ml fractions were
collected, lyophilized and resuspended in methanol: 0.1 N HCl (1:1,
v/v). Aliquots of these fractions were analyzed for bridge peptide
immunoreactivity.
RESULTS AND DISCUSSION
Gel filtration chromatography of rat anterior pituitaries combined
with the bridge peptide RIA revealed the presence of two peaks; Peak
I and Peak II, (Table I).
TABLE I. Distribution of bridge peptide immunoreactivity (IR) in the
rat anterior pituitary after gel filtration
chromatography.
Apparent MW Bridge Peptide-IR1 % of Total
(kilodaltons) (fmoles) Bridge Peptide-IR
Peak I 8-9 864 7.0
Peak II2 2-3 11,475 93.0
1Sum of immunoreactivities measured in fractions of Peaks I and II.
2Co-migrates with rat bridge peptide.
Ninety-three percent of the bridge peptide immunoreactivity was
contained in Peak II, a Peak which co-eluted with synthetic rat
bridge peptide standard. Seven percent of the immunoreactivity was
contained in Peak I, a higher molecular weight species of 8-9 kdal.
When accounting for column recovery ( 80%) and the number of
pituitaries chromatographed, one rat anterior lobe would contain
approximately 280 fmoles of free bridge peptide. However, the total
content of bridge peptide is most likely higher, since we observed a
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high molecular weight species with bridge peptide immunoreactivity
(Peak I). It is possible that this molecule contains bridge peptide
with a blocked C-terminal, i.e. extended with DYN A 1-17. If this
were the case, the amount of immunoreactivity detected for Peak I,
would be largely underestimated since our antibody was determined to
be C-terminal directed and a C-terminal extended bridge peptide is
poorly crossreactive.
The biological effects of bridge peptide are not known and will have
to be explored. This peptide does not contain the Tyr-Gly-Gly-Phe
amino acid sequence associated with opioid function. Modulation of
opioid function, however, may still be possible. It is not known
what role bridge peptide fulfills in regards to existing in the same
precursor molecule as the leucine-enkephalin extended opiate peptides
known as dynorphins.
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ABSTRACT
Endo-oligopeptidase A known to hydrolyse the Phe5-Ser6 bond of
bradykinin and the Arg8-Arg9 bond of neurotensin has been shown to
produce, by a single cleavage, leucine5-enkephalin from small
prodynorphin derived enkephalin-containing peptides. The specificity
constants (kcat /km) obtained for the hydrolysis of bradykinin,
neurotensin arnd dynoprphin B are of the same order, suggesting that the
substrate amino acid sequence is not the only factor determining the
cleavage site of this enzyme.
INTRODUCTION
Biologically active peptides are generated from large inactive
precursor molecules by proteolytic cleavages. It has been proposed
that biologically active sequences bracketed by pairs of basic amino
acid residues are liberated by the action of a trypsin-like
endopeptidase followed by a carboxypeptidase B type exopeptidase
(Steiner et al. 1980). In this study, we provide evidence that this
pattern of sequential cleavage may not be the only mechanism for
liberating enkephalin from low molecular weight enkephalin-containing
peptides. Previous reports have described the purification and
characterization of endo-oligopeptidase A, a 75000 Dalton thiol
peptidase (Camarqo et al. 1973; Carvalho and Camargo 1081) which
hyrolyses the Phe5-Ser6 bond of bradykinin (Camargo et al. 1973), the
Arg8-Arg9 bond of neurotensin (Carmargo et al. 1983) and liberates
methionine5-enkephalin (ME) from BAM 12P by cleavage at the Met5-Arg6
position (Camargo et al. 1985). Following this latter observation, we
report here that bovine brain endo-oligopeptidase A can produce, by a
single cleavage, leucine5-enkephalin (LE) from small precursor
molecules.
MATERIALS AND METHODS
Endo-olipopeptidase A assay
Endo-oligopeptidase A used for enzyme assays was highly purified by
immunoaffinity chromatography (data not shown). Enzyme assays. were
performed in a final volume of 100 µl of 17.5 mM Tris-HCl pH 7.6
containing 7 µg of endo-oligopeptidase A (specific activity 1370
µmol/min/mg towards bradykinin), 0.35 mM dithiothreitol and 10-20 nmol
of the required peptide. Samples were incubated at 37°C and the
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reaction terminated by addition of 5 ul of concentrated H3PO4.
Aliquots from each incubation medium were analysed by reverse phase
HPLC over a
Corporation).
C18 µBondapak column (4.6 x 250 mm; Millipore
Peptides were separated by an initial 3 min isocratic
elution in 0.1% H3PO4 pH 2.7 containing 10% (v/v) acetonitrile
followed by a 15 min linear gradient of 10-50% (v/v) acetonitrile in
the 0.1% H3PO4 pH 2.7, at a flow rate of 2 ml/min. Reaction products
were monitored by optical density at 214 nm.
RESULTS
The ability of endo-oligopeptidase A to hydrolyse several
enkephalin-containing prodynorphin derived peptides was studied. With
dynorphin(DYN)-B as substrate the product formed was LE, demonstrating
that this peptide is hydrolysed at the Leu5-Arg6 bond (fig.1A; table
1). Furthermore, the amount of LE released accounted for all the LE
contained within DYN-B fig.1B. LE formation was inhibited in a
concentration dependent manner by bradykinin, indicating that the
purified endo-oligopeptidase A contained only one enzyme activity.
fig. 1. Hydrolysis of peptide substrates by purified
endo-oligopeptidase A was analysed by reverse phase HPLC
with (A) a typical chromatogram showing the production of LE
from DYN-B and (B) the formation of LE from DYN-A1-8,
-NEO , DYN-B  and - N E C
Standards : Tyr-Gly-Gly-Phe (1), LE-Arg6-Arg7 (2) LE-Arg6
(3) and LE (4).
Similar results were obtained using the prodynorphin derived peptides
DYN-A1-8, -neoendorphin(NEO) and -NEO. LE formation again accounted
for around 100 % of the total peptide LE content, except in the case
of -NE0 where this could not be measured due to the slower rate of
hydrolysis over the time course of the experiment (fig. 1B; table 1).
The complementary basic peptides produced by endo-oligopeptidase A
hydrolysis of these species eluted as single peaks on another HPLC
system described elsewhere (Camargo et al. 1985), substantiating the
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observation that cleavage occurs only at one position. In contrast,
the related peptides DYN-A1-17 and DYN-A1-13 were not detectably
cleaved by endo-oligopeptidase A. Since smaller peptides DYN-A1-6
(LE-Arg6) and LE itself were also found to be resistant to cleavage by
this enzyme, whereas the heptapeptide DYN-A1-7 was hydrolysed to
liberate Tyr-Gly-Gly-Phe, but not LE, these results indicate that in
general, the optimum for the release of LE is between 8-13 amino acid
residues and that substrate size may be important in determining both
the cleavage position and the susceptibility tc hydrolysis.
TABLE 1
Prodynorphin peptides hydrolysed by endo-oligopeptidase A
DYN A1-7 Tyr-Gly-Gly-Phe-Leu-Arg-Arg
DYN A1-8 Tyr-Gly-Gly-Phe-Leu Arg-Arg-Ile
DYNE B Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr
-NEO Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro-Lys
-NEO Tyr-Gly-Gly-Phe-Leu-Arg-Lys-Tyr-Pro
Arrows indicate the observed cleavage points. The sequences
of LE, LE-Arg6, DYN-A1-13 and DYN-Al-17, which were
resistant to hydrolysis, are not shown.
Specificity of endo-oligopeptidase A
These results indicate an optimum substrate size for catalysis by
endo-oligopeptidase A. However, the requirement for amino acids around
the subceptible bond is unclear since the enzyme can cleave the
Phe5-Ser6 bond in bradykinin (Camargo et al. 1973, the Arg8-Arg9 bond
in neurotensin (Camargo et al. 1983) and the Leu5-Arg6 bond in DYN-B,
where the amino acid residues found surrounding the cleavage sites
bear little similarity. Therefore, the hydrolysis of these peptides
was further investigated using a >20000 fold purified enzyme. As shown
in table 2 all three peptides prove good substrates for this enzyme,
with km values in the lower µM range. In addition the high specificity
constants (kcat/km) are not strikingly different between substrates,
suggesting that the primary amino acid sequence of the peptides alone
is not responsible for determining the cleavage site.
TABLE 2
Bradykinin
Neurotensin
DYN-B
Specificity of endo-oligopeptidase A
Km(µM) kcat(s
-1) kcat/Km(M-1s-1)
8.78 9.8 1.12 x 106
12.49 1.55 0.28 x 106
5.23 21.52 4.11 x 106
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Endo-oligopeptidase A catalysis of bradykinin, neurotensin
and DYN-B was stopped when less than 15 % of the substrates
had been hydrolysed and the products analysed over HPLC.
Assays were conducted in triplicate at 0.5, 1.0, 1.5, 2.0,
3.0 and 4.0 µM substrate concentrations. km and kcat values
were obtained using Lineweaver-Burk plots with initial rates
expressed as molar rates.
DISCUSSION
Recently it has been reported that the processing of dynorphin
precursors into dynorphins may occur via a single-step reaction
involving cleavage at a single arginine (Wallace et al. 1984; Devi and
Goldstein 1985) which differs from the general mechanism of
trypsin-like followed by carboxypeptidase-B like hydrolysis (Steiner
et al. 1980). Since several biologically active peptides are now known
to be released by proteolysis at cleavage sites other than dibasic
residues (Devi and Goldstein 1985; Niall et al. 1982; Kreil et al.
1980), it may be that processing does not necessarily follow the
trypsin-carboxypeptidase B-like enzyme hypothesis. In this study it
has been shown that endo-oligopeptidase A, an enzyme which displays
selectivity towards small intermediates, could be involved in this
type of processing scheme and, more particularly, in the processing of
the prodynorphin precursor.
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ABSTRACT
An endopeptidase hydrolyzing dynorphins A and B
alpha-neo-endorphin at the Arg6-Arg7 or Arg6-Lys7 bonds,
and
was partially purified from human cerebrospinal fluid and
further characterized by various biochemical techniques
including HPLC gel permeation (UltroPac TSK G3000SW) and
ion exchange (TSK DEAE-3SW) chromatography. A procedure
for quantitative analysis of the enzyme in individual CSF
samples is also described. The activity in lumbar CSF of
women in late pregnancy was significantly lower than that
in control samples.
INTRODUCTION
The endogenous opioid peptides alpha-neo-endorphin,
dynorphin A (Dyn A) and dynorphin B (Dyn B) derive from a
common precursor polypeptide, proenkephalin B. As with
other neurotransmitters or neuromodulators their actions
are likely to be under enzymatic control. Several pepti-
dases capable of converting dynorphins have been reported
(e.g. Devi and Goldstein 1984; Mizuno and Matsuo 1984).
We recently reported an endopeptidase in human cerebro-
spinal fluid (CSF) capable of releasing the N-terminal
hexapeptide Leu-enkephalin-Arg6 from dynorphin A (Nyberg
et al. 1985). The enzyme, identified as a serine pro-
tease, cleaves at pairs of consecutive basic amino acid
residues and showed close similarity with an endopepti-
dase previously purified from yeast (Mizuno and Matsuo
1984). Here we describe further biochemical characteri-
zation of this activity and a procedure for its quantita-
tion in individual CSF samples.
MATERIALS AND METHODS
Materials. Reference peptides were from sources previous-
ly noted (Nyberg et al. 1985). Labelling of dynorphin B
with 125I was performed as described (Christensson-
Nylander et al. 1985). The chromatographic material
(SP-Sephadex) was purchased from Pharmacia Fine Chemicals
(Uppsala, Sweden). The peptidase inhibitors bestatin and
phosphoramidon were from Sigma and captopril from Squibb
(Princeton, NJ, U.S.A.). All other chemicals and solvents
were of analytical reagent grade from commercial sources.
Enzyme preparation. The dynorphin converting endopepti-
dase was purified from pooled human CSF by ion exchange
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TABLE 1. Conversion of proenkephalin B derived peptides
by the purified CSF endopeptidase1.
Peptide Structure Release of Leu-
enkephalin-Arg6
(pmol/min)
Dyn A Tyr-Gly-Gly-Phe-Leu-Arg-Arg- 12.3
-Ile-Arg-Pro-Lys-Leu-Lys-Trp-
-Asp-Asn-Gln
Dyn A 4.1
(1-8)
Dyn B Tyr-Gly-Gly-Phe-Leu-Arg-Arg- 10.1
-Gln-Phe-Lys-Val-Val-Thr
Alpha- Tyr-Gly-Gly-Phe-Leu-Arg-Lys- 7.4
neo-end. -Tyr-Pro-Lys
1Peptides (10 uM) were incubated in triplicates with the
CSF enzyme (1 mg/ml) and aliquots were removed at
different times and analyzed by RIA for the hexapeptide
peptide product. For other details see text.
chromatography, hydrophobic interaction chromatography,
and molecular sieving (Nyberg et al. 1985).
High performance liquid chromatography (HPLC). The HPLC
system (LKB Produkter AB, Bromma Sweden) was used for gel
permeation (TSK G3000SW, 7.5 x 600 mm), ion exchange
(TSK DEAE-3SW, 7.5 x 150 mm) and reversed phase (Spheri-
sorb C-18, 5u, 4.6 x 250 mm) chromatography. Eluted frac-
tions were collected and analyzed for enzyme activity.
All columns were calibrated with peptide and protein
standards.
Enzyme assay. All incubations were performed in Eppendorf
tubes at 37°C. Enzyme fractions or pure CSF (20 ul) were
incubated with a mixture of 125I-labelled (about 5000
cpm) and unlabelled (40 pmol) dynorphin B in a final
volume of 40 ul Tris-HCl (20 mM, pH 7.8) in the presence
of 100 uM bestatin, 10 uM captopril, and 20 uM phosphor-
amidon. The reaction was terminated by dilution with 1.5
ml cold pyridine(0.018 M)-formate(0.1 M) buffer (pH 3.2)
before product separation on SP-Sephadex minicolumns. The
generated enkephalyl hexapeptide was eluted with 0.35 M
pyridine-formate buffer (pH 4.4) and collected for count-
ing. In assays of individual CSF samples incubations (in
triplicates) were allowed to proceed for 60 min. Product
formation was also monitored by radioimmunoassay (RIA)
(Nyberg et al. 1985).
RESULTS
Fig. 1A illustrates the the UV-profile and the pattern of
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chromatography ofFIGURE 1. (A) HPLC gel permeation
a crude CSF sample (200 ul). The column was eluted
with 40 mM ammonium acetate (pH 7.0) and fractions
of 0.5 ml were collected at a flow rate of 30 ml/h.
(B) HPLC ion exchange chromatography of peak 2
material. Gradient, 0.05-0.25 M NaCl in 20 mM Tris-
HCl (pH 7.2); fraction size, 1 ml; flow rate, 60
ml/h. (C) RP-HPLC reaction mixtures of the CSF
enzyme and Dyn A, Dyn B or alpha-neo-endorphin. The
column was eluted at a flow rate of 1 ml/min with a
40 min linear gradient of acetonitrile (15-45%)
containing trifluoroacetic acid (0.04%).
dynorphin converting activity obtained after HPLC gel
filtration of a crude CSF sample. As earlier shown
(Nyberq et al. 1985)) the enzyme activity was resolved
in two major peaks, one eluting ahead of albumin (> 68
kdaltons) and the other at a position corresponding to
40 kdaltons (peak 2). In this study, material correspond-
ing to peak 2 was subjected to further characterization.
On HPLC ion exchange chromatography (Fig. 1B), peak 2
separated into two distinct fractions. The major fraction
eluted as a comparatively basic protein, thus showing
similar properties as those of the yeast enzyme (Mizuno
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and Matsuo 1984). This enzyme fraction was capable of
releasing the N-terminal fragment, Leu-enkephalin-Arg6,
from Dyn A, Dyn B and alpha-neo-endorphin, as shown in
Fig. 1C, as well as from Dyn A (1-8). The enkephalyl
hexapeptide appeared as a major product in all experi-
ments. The formation of this fragment was confirmed by
amino acid analysis. Studies performed with RIA amounts
of substrate indicated a different rate of conversion of
the various proenkephalin B products (Table 1). Dyn A and
Dyn B were converted at a higher rate than alpha-neo-
endorphin and Dyn A (1-8). A KM-value of 0.45 mM for con-
version of Dyn B was estimated for the purified enzyme.
The enzyme could be analyzed in less than 100 ul CSF
samples. Values obtained by product quantitation with RIA
parallelled those obtained by the labelled substrate
procedure, which was used here. The enzyme activity was
analyzed in lumbar CSF of normal women of fertile age and
of women in late pregnancy. Mean levels in the pregnant
group (6.7 units, n = 12) were significantly lower (p <
0.01) than those in the nonpregnant subjects (11.7 units,
n = 10, one unit was defined as the release of 1 pmol
Leu-enkephalin-Arg6 per ml CSF and min).
DISCUSSION
The enzyme described here acts on the proenkephalin B
family of opioid peptides with specificity towards con-
secutive pairs of basic amino acid residues. The enzyme
more efficiently converted Dyn A than e.g. its (1-8)
fragment suggesting that the sequences beyond the local
cleavage site are important. We have therefore named it a
dynorphin converting enzyme. The lower levels found in
CSF of pregnant women is of interest since they corre-
late negatively to the increased levels of opioid pep-
tides observed in this group (Lyrenäs et al. to be pub-
lished). It should be noted that the product, Leu-enke-
phalin-Arg , maintains opioid activity but with differ-
ent receptor preference. Therefore, this enzyme may not
only terminate the action of dynorphin peptides but also
generate a fragment with different activity profile.
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PRESENCE OF ENKEPHALIN PRECURSOR IN MOLLUSCAN NEURAL TISSUE EXTRACT
Barry Mixon, Sunita Kuruvilla, George B. Stefano and
Michael K. Leung
Departments of Chemistry and Biological Sciences
State University of New York/Old Westbury
Old Westbury, NY 11568, U.S.A.
ABSTRACT
Mytilus pedal ganglia extract was treated sequentially with TPCK-
trypsin and carboxypeptidase B. The treated sample and an untreated
sample were purified separately with Sep-Pak C18 and subjected to
HPLC. Fractions with Rt's corresponding to the Met-, Leu-enkephalin
and Met-enkephalin-Arg6-Phe7 were assayed for enkephalin activities
by displacement studies using pedal ganglia membrane and 3H-DAMA.
The data showed the activities in the regions of Met-, Leu-
enkephalin and Met-enkephalin-Arg6-Phe7 of the treated sample
increased over that of the untreated sample by 2.3, 2.5 and 1.6
folds respectively. These results provided strong evidence for the
presence of enkephalin precursor material in Mytilus.
INTRODUCTION
Recently, we reported the isolatio and identification of Met-, Leu-
enkephalin and Met-enkephalin-Arg6-Phe7 in Mytilus pedal ganglia
(Leung and Stefano 1984; Stefano and Leung 1984). These results
demonstrated directly the presence of an enkephalinergic system in
the invertebrates. In addition, this system must be similar to the
mammalian one. Direct biochemical evidence, obtained by HPLC-RIA
technique, for the presence of enkephalin in shore crab has also
been reported by Jaros et al. (1986). Thus, the opioid system must
be developed at a very early stage of evloution.
Based upon current knowledge, all known opioid peptides are
processed from three precursors--proenkephalin, prodynorphin and
pro-opiomelanocortin. The nucleotide sequences as well as the amino
acid sequences for all three precursors had been deduced by cDNA
technique (Noda et al. 1982; Nakanishietal. 1979; Kakidani et al.
1982). Comparison of the gene and protein sequences reviewed
tremendous homology among the precursors (Horikawa et al. 1983). It
is, therefore, likely that all three precursors share a common
evolutionary origin.
Structurally, all opioid peptides in the precursors are bracketed by
a pair of basic amino acids on both the N- and C-side. This
indicated a similar processing scheme for all three opioid
precursors. Opioid peptides can be processed from their precursors
by sequential treatment with trypsin and carboxypeptidase B (Lewis
et al. 1980. The isolation and identification of Met-enkephalin-
Arg6-Phe7 in Mytilus is especially strong evidence for the presence
of proenkephalin-like precursor in this organism. This is true
since the heptapeptide represents the last seven amino acid sequence
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in the mammal proenkephalin. In this present report data will be
presented which strongly suggested the existence of opioid precursor
material in Mytilus pedal ganglia.
MATERIALS AND METHODS
Subtidal Mytilus were harvested from Long Island Sound at Northport,
N.Y. Pedal ganglia from 425 fresh animals were excissed and stored
at -160° C before use. The ganglia were homogenized with a Brinkman
Polytron Homogenizer with four 3-sec bursts in 7.5 ml of 50 mM Tris-
HCl buffer, pH 8.0; containing 0.1 M NaCl and 10 mM CaCl2. The
homogenate was centrifuged at 10,000xg for 10 min at 4° C and the
supernatant was filtered with a 0.22 um membrane. The protein
content of the supernatant was determined by Bio-Rad (Richmond, CA.)
dye assay. TPCK-Trypsin was added to an aliquot of the filtrate in
an amount equal to 1% of the protein content. This mixture was
incubated overnight at 37° C. The enzyme activity was inactivated
by heating at 80° C for 15 min. After clarification by
centrifugation, carboxypeptidase B was added in an amount equal to
2% of the protein content. It was incubated at 37° C for 4 hr and
then inactivated as described earlier.
The incubation mixture was purified by Sep-Pak C18 cartridge
(Waters). The cartridge was activated first with methanol and
water. After the sample was injected into the column, it was rinsed
with 1% acetic acid and then eluted with methanol. The eluant was
lyophilized, dissolved in water and filtered through a 0.45 um
membrane. An aliquot of the extract without enzymatic treatment was
processed in similar manner for use as the control,
Purified samples of the treated and untreated extracts were
fractionated by HPLC on a Brownlee RP-300 reverse-phase column. The
HPLC system used was a Waters model 840. The solvent system used
was consisted of 0.1% trifluoroacetic acid (TFA) as A and 80%
acetonitrile in 0.1% TFA as B. The column was initially eluted
isocratically for 5 min with 20% B and followed by linear gradient
of 20-80% B in 20 min. One-ml fractions of both samples were
collected. Fractions with Rt's coresponding to Met-, Leu-enkephalin
and Met-enkephalin-Arg6-Phe7 were subjected to displacement assay
using Mytilus pedal ganglia membrane and 3H-DAMA. The displacement
assay procedure was the same as described previously (Leung and
Stefano 1984).
RESULTS AND DISCUSSION
The chromatograms, monitored at 280 um, of the untreated and treated
samples are shown in figure 1. The untreated sample contained
numerous small peaks and several major peaks (fig. 1A). After
enzyme treatment significant changes in the peak pattern was
observed (fig 1B). As a result of the enzymatic actions some of the
major peaks were significantly reducedin size. Results from the
displacement assays are also represented in figure 1. The
displacement activities in fractions from the untreated sample are
in general significantly lower than those in the treated sample.
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The combined displacement activities found in the Met-, Leu-
enkephalin and Met-enkephalin-Arg6-Phe7 regions as compared to the
3H-DAMA standard were 35, 23 and 30% respectively. The combined
activities in these same regions in the treated sample were 81, 57
and 48%. They represented an .pa increased of 2.3, 2.5 and 1.6
folds of activities in Met-enkephalin, Leu-enkephalin and Met-
enkephalin-Arg6-Phe7, respectively, in the treated sample over that
of the untreated. These data strongly suggested the presence of
opioid precursor material in the Mytilus pedal ganglia extract.
FIGURE 1. HPLC and displacement assays of untreated (A)
and treated (B) samples of Mytilus pedal ganglia extracts.
Procedure were as described in the text. One hundred
percent displacement is 3H-DAMA bound in the presence of
10 uM levorphanol minus 3H-DAMA bound in the presence of
10 UM dextrorphan.
Evidence has been gathered which demonstrate the presence of opioid
system in the invertebrates. Great-structural and physiological
similarities also exist between the vertebrate and invertebrate
opioid peptides (review, Leung and Stefano 1986). This preliminary
report provides additional support in this area by showing the
existence of enkephalin precursor in Mytilus. Even though only
limited information is available concerning the precursor material
in Mytilus, one significant similarity with the mammalian precursors
is observed. Since the enkephalin peptides in the Mytilus precursor
can be released by trypsin and carboxypeptidase B they must be
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bracketed by basic amino acids as in the mammalian precursor.
However, it is not known if the amino acids at both ends are paired
and if more than one precursor is present in the tissue.
In conclusion, our current and earlier findings clearly demonstrated
the existence of an opioid mechanism in Mytilus. The enkephalin
peptides in Mytilus areidenticaltothose of mammals. As in the
mammals, the enkephalin peptides in Mytilus appear to exist in a
precursor form when first synthesized. The enkephalin peptides in
the Mytilus precursor are also bracketed by basic amino acids and
can be released by trypsin and carboxypeptidase B treatment. These
results suggest that the entire opioid mechanism, including the
structure of the precursor and the processing scheme, is a product
of early evolutionary development. Its importance as a signal
system is emphasized by its conservation through evolution.
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INACTIVATION OF [LEU5]-ENKEPHALIN IN THREE ISOLATED PREPARATIONS:
RELATIVE IMPORTANCE OF AMINOPEPTIDASE, ENDOPEPTIDASE-24.11 AND
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ABSTRACT
Enkephalin had been shown to be almost exclusively hydrolyzed by
three peptidases in the previous studies. In the present investiga-
tion, the relative importance of three enzymes in the inactivation of
[Leu5]-enkephalin was examined in three isolated preparations. Re-
sults showed that amastatin-sensitive aminopeptidase played the
greatest role in both guinea-pig ileum and rat vas deferens while it
played the similar role to either phosphoramidon-sensitive
endopeptidase-24.11 or captopril-sensitive peptidyl dipeptidase A in
mouse vas defer-ens.
INTRODUCTION
Three distinct enzymes, aminopeptidase, endopeptidase-24.11 ("
enkephalinase"), and peptidyl dipeptidase A (angiotensin converting
enzyme), had been shown to inactivate enkephalin in three isolated
preparations, guinea-pig ileum (Aoki et al. 1984), mouse vas deferens
(Aoki et al. 1986), and rat vas deferens (Cui et al. 1986). Addition-
ally, the enkephalin-hydrolyzing aminopeptidase, endopeptidase-24.11,
and peptidyl dipeptidase A had been reported to be inhibited almost
completely with either 100 µM of bestatin or 1 µM of amastatin, ei-
ther 1 µM of thiorphan or 1 µM of phosphoramidon, and 1 µM of
captopril, respectively (Aoki et al. 1984; Aoki et al. 1986; Cui et
al. 1986). Moreover, approximately 98% of enkephalin had been shown
to remain intact when enkephalin was incubated with an ileal membrane
fraction for 60 min at 37°C in the presence of three peptidase inhib-
itors, amastatin, captopril, and thiorphan (Hiranuma and Oka 1986).
Thus, enkephalin had been demonstrated to be almost exclusively hy-
drolyzed by three distinct enzymes. In the present investigation, the
relative importance of three enzymes in the inactivation of [Leu5]-
enkephalin was examined in three in vitro isolated preparations,
guinea-pig ileum, mouse vas deferens, and rat vas deferens.
MATERIALS AND METHODS
Chemicals
A gift, gratefully received, was captopril from Sankyo Company
(Tokyo, Japan). Amastatin, phosphoramidon and [Leu5]-enkephalin were
purchased from Peptide Institute, Inc. (Minoh, Japan).
In vitro isolated preparations
The vasa deferentia from mice or rats, and the myenteric plexus-lon-
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gitudinal muscle strip of guinea-pig ileum were prepared and set up
for electrical stimulation as described previously (Oka et al. 1982).
The % inhibition of the stimulated muscle twitch produced by
enkephalin was plotted against the log concentration of the opioid to
estimate the IC50 (concentration of the opioid peptide to produce 50%
inhibition of the twitch). When the effect of the peptidase inhibitor
on the potency of enkephalin was studied, the inhibitor was given at
least ten minutes before the enkephalin administration. The % differ-
ence shown in the tables was calculated from the formula % difference
= [(IC50 before additional treatment - IC50 after additional treat-
ment) / IC50 before additional treatment] x 100. The significance of
% differences between IC50 values of two adjacent groups was deter-
mined by the paired Student's t-test.
RESULTS AND DISCUSSION
[Leu5]-Enkephalin significantly inhibited the electrically-evoked
contractions of guinea-pig ileum. Since its IC50 value in one prepa-
ration was sometimes significantly different from that in another,
the IC50 values in the absence and the presence of the peptidase in-
hibitor were estimated in the same preparation.
TABLE 1. The greater enhanced effects of amastatin than
either phosphoramidon or captopril on the inhibitory poten-
cy of [Leu5]-enkephalin in guinea-pig ileum
Inhibitors IC50(nM) Ratio of % Difference
potency
None 220 73 1
Amastatin 55.0 13 3.82 0.31 73.3 2.0***
None 275 81 1
Phosphoramidon 227 68 1.20 0.084
16.9 1.9***
None 194 59 1
Captopril 165 43 1.18 0.093 16.4 1.7***
Each peptidase inhibitor at the final concentration of 1 µM
was given 10 min before the enkephalin administration. Each
value represents the mean S.E. of 4 experiments.
***P < 0.01.
The inhibitory potency of [Leu5]-enkephalin was significantly en-
hanced by the pretreatment of the guinea-pig ileum with either
amastatin, phosphoramidon or captopril (table 1). The magnitude of
the enhancement by amastatin was significantly higher than that by
either phosphoramidon or captopril (table 1). This shows that
amastatin-sensitive aminopeptidase plays the major role in the inac-
tivation of exogenously given enkephalin in guinea-pig ileum, being
consistent with the previous report (Geary et al. 1982).
In the mouse vas deferens, the inhibitory potency of [Leu5]-
enkephalin was also significantly enhanced by each peptidase inhibi-
tor (table 2). The magnitude of the enhancement by amastatin, howev-
er, was similar to that by either phosphoramidon or captopril in
mouse vas deferens (table 2). This shows that three enkephalin-hydro-
lyzing peptidases play the similar role in the inactivation of
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[Leu5]-enkephalin in mouse vas deferens.
TABLE 2. The similar magnitude of the enhanced effects of
three peptidase inhibitors, amastatin, phosphoramidon and
captopril, on the inhibitory potency of [Leu5]-enkephalin
in mouse vas deferens
Inhibitors IC50 (nM) Ratio of
potency
% Difference
None
Amastatin
9.54 1.5 1
4.76 0.56 2.01 0.19 47.5 4.6***
None 11.7 1.7 1
Phosphoramidon 7.19 0.98 1.63 0.061 37.7 2.5***
None 10.7 1.7 1
Captopril 5.39 0.61 1.93 0.16 45.3 4.0***
Each peptidase inhibitor at the final concentration of 1 µM
was given 10 min before the enkephalin administration. Each
value represents the mean S.E. of 8 experiments.
***P < 0.01.
TABLE 3. The highest, the intermediate, and the lowest
magnitude of the enhanced effects of amastatin (A),
phosphoramidon (P), and captopril (C), respectively, on the
inhibitory potency of [Leu5]-enkephalin in rat vas deferens
pretreated with the residual two peptidase inhibitors
Inhibitors IC5o (µM) Ratio of % Difference
potency
P + C 59.2 13 1
P + C + A 2.16 0.19 37.3 7.9 96.5 1.2***
C + A 9.45 2.1 1
C + A + P 5.43 1.6 1.99 0.15 46.6 3.9***
A + P 1.95 0.44 1
A + P + C 1.43 0.26 1.32 0.093 22.8 6.1*
The mixture of peptidase inhibitors was given 10 min before
the enkephalin administration at the final concentration of
1 µM each. Each value represents the mean S.E. of 4
experiments. *P < 0.05, ***P < 0.01.
In the rat vas deferens, the presence of the enzyme with low
enkephalin-hydrolyzing activity was sometimes difficult to de-
tect when the residual enzyme with high enkephalin-hydrolyzing ac-
tivity was not inhibited in the preliminary experiments. When the
enkephalin-hydrolyzing ability of a particular enzyme among three en-
zymes was examined, therefore, the residual two enzymes were inhib-
ited in advance. The IC50 values of [Leu
5]-enkephalin in the rat vas
deferens pretreated with three peptidase inhibitors were significant-
ly lower than those pretreated with any combination of two peptidase
inhibitors (table 3). The data in table 3 show that amastatin-sensi-
tive aminopeptidase, phosphoramidon-sensitive endopeptidase-24.11 and
captopril-sensitive peptidyl dipeptidase A play, respectively, the
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greatest, the intermediate and the least role in the inactivation of
[Leu5]-enkephalin in rat vas deferens.
Previous studies (Aoki et al. 1984; Aoki et al. 1986; Cui et al.
1986) have shown that, when three peptidase inhibitors are given in-
dividually to the bath after the enkephalin administration, the
enkephalin-induced inhibition of contractions of the isolated prepa-
ration is enhanced every time by the administration of each peptidase
inhibitor although each inhibitor by itself does not inhibit the con-
tractions at all when an opioid peptide is absent in the bath. Addi-
tionally, the observation that the inhibition produced by peptidase
inhibitors is completely reversed by naloxone, an opioid antagonist,
indicates that the inhibition must be caused by the increased amount
of the enkephalin in the vicinity of opioid receptors by the adminis-
tration of each peptidase inhibitor. Therefore, previous results
(Aoki et al. 1984; Aoki et al. 1986; Cui et al. 1986) have indicated
that three enkephalin-inactivating peptidases are all located very
close to opioid receptors and produce a significant concentration
difference of enkephalin between the surrounding organ bath and the
vicinity of opioid receptors. Additionally, these enzymes are sug-
gested not only to inactivate the exogenously given enkephalin in the
vicinity of opioid receptors but also to play important roles in the
termination of the action on opioid receptors of the enkephalin re-
leased from presynaptic nerve terminals. Interestingly, the results
in the present investigation have shown that the relative importance
of the [Leu5]-enkephalin-inactivating enzymes is dependent on the
tissue examined. The significance of the difference in the relative
importance of the inactivating enzymes from one tissue to another re-
mains to be elucidated in the present investigation.
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CHARACTERIZATION OF ENKEPHALIN DEGRADATION IN RAT PLASMA
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ABSTRACT
Approximately 80% of the hydrolysis of [leu]enkephalin in rat plasma
can be attributed to bestatin-sensitive aminopeptidase activity, and
an additional 5% is due to angiotensin converting enzyme.
Thiorphan-sensitive enkephalinase hydrolysis of [leu]enkephalin could
not be detected in plasma. On the other hand,
2-d-ala-1-[leu]enkephalin is metabolized approximately 35% by an
unidentified bestatin-sensitive enzyme and approximately 15% by
thiorphan-sensitive enkephalinase in rat plasma, while
captopril-sensitive angiotensin converting enzyme is without
measurable activity against this substrate.
INTRODUCTION
We reported previously (Martinez et al. 1985) that a very high
correlation exists in rats between the rate of [leu]enkephalin (LE)
hydrolysis in plasma and the latency to escape on the first trial in
an active avoidance task. The activity of the plasma enzyme system is
altered by shock experience, suggesting that the enzyme system may
influence behavior by regulating the concentration of
[leu]enkephalin, or its substrate, in blood and hence at a receptor.
The specific enzymes involved in this relationship are as yet
unidentified.
Data from brain tissue suggest a major role for aminopeptidases and a
dipeptidyl carboxypeptidase ("enkephalinase") in the cerebral
metabolism of endogenous and exogenously-administered enkephalin
(Schwartz et al. 1983; Hambrook et al. 1976; Hazato et al. 1983).
Studies by Hambrook et al. (1976) implicate the same enzymes in rat
plasma as well. In vitro studies with the guinea pig ileum attribute
enkephalin hydrolysis in this tissue to the combined action of
aminopeptidases, enkephalinase, and angiotensin converting enzyme
(ACE) (Aoki et al. 1984). In the isolated perfused rat lung,
aminopeptidases and ACE, but not enkephalinase, are responsible for
enkephalin metabolism (Gillespie et al. 1985). In the present study
we characterize in more detail the enzymes associated with the
hydrolysis of LE in rat plasma.
MATERIALS AND METHODS
Male Sprague-Dawley rats (300-400 gm) were anesthetized with
pentobarbital and implanted with femoral artery cannulae. In vitro
enkephalin metabolism was measured in blood samples collected two
days later through the indwelling cannulae. For this assay, plasma
was rapidly separated, incubated 5 min at 37 deg C to permit
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metabolism of endogenous enkephalin, and then combined in 115 or 230
µl aliquots with one or more of the following inhibitors: bestatin
(prepared in saline to achieve final concentrations of 5 - 1500 µM),
thiorphan (prepared in 5% N,N-dimethyl formamid in saline to achieve
final concentrations of 0.1 - 10 µM), and captopril (prepared in
saline to achieve final concentrations of 0.1 - 10 µM).
Following a 15 min incubation period, either 3H-LE (3 or 6 µM,
specific activity 43.6 Ci/mmol) or 3H-2-d-ala-1-LE (3 or 6 µ1,
specific activity 58 Ci/mmol) was added to the reaction mixture.
Aliquots of plasma were removed at several time points after label
addition; the reaction was terminated in these aliquots with two
volumes of 0.1% trifluoroacetic acid in methanol. Unmetabolized LE or
2-d-ala-1-LE was separated from its combined metabolites by thin
layer chromatography, according to the method of Ziring et al.
(1983), and quantified by liquid scintillation counting.
RESULTS
The half-life of LE in rat plasma was determined to be 2.4 min, which
is in close'agreement with the 2.5 min half-life determined by
Hambrook et al. (1976) in a vas deferens bioassay. The plasma
half-life of 2-d-ala-1-LE was between 3.5 and 7.5 hr.
The aminopeptidase inhibitor bestatin, in concentrations between 5
and 1500 µM, produced concentration-dependent decreases in the rate
of LE metabolism, to a maximum of 80% inhibition. The dipeptidyl
carboxypeptidase ("enkephalinase") inhibitor thiorphan, in
concentrations up to 10 µM, was without detectable effect on the rate
of LE hydrolysis. The combination of bestatin and thiorphan produced
no further inhibition beyond that attributable to bestatin alone. On
the other hand captopril (0.1 - 10 µM), an ACE-selective inhibitor,
when combined with bestatin (500 µM), produced an additional
concentration-dependent decrease in LE hydrolysis. The maximal
inhibition produced by this combination was approximately 25% beyond
that produced by bestatin alone. See Table 1 for summary of these
data.
A different pattern of enzyme activities was revealed when
2-d-ala-1-LE replaced LE as substrate for the reaction. Although this
substrate is reportedly insensitive to aminopeptidase degradation in
brain (Llorens et al. 1982), a concentration-dependent decrease in
2-d-ala-1-LE hydrolysis was seen in the presence of bestatin (50 -
1500 µM), to a maximum of approximately 30 - 40% inhibition (although
in one animal more than 90% inhibition was observed). Thiorphan (0.1
- 10µM) produced small concentration-dependent decreases in
hydrolysis, to a maximum of 10 - 20% inhibition. The combination of
bestatin (500 µM) and thiorphan (0.1 - 10 µM) produced no further
inhibition beyond that attributable to bestatin alone. ACE hydrolysis
of 2-d-ala-1-LE was not detectable, since captopril (0.1 - 10 µM)
produced no measurable inhibition. These data are summarized in Table
1.
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TABLE 1: Effects of Inhibitors on Enkephalin Metabolism
Substrate Inhibitor Concentration Maximum %
(Highest con- Dependent Inhibition
centration;µM) Inhibition? (Estimate)
3H-LE bestatin (1500)
thiorphan (10)
best (500) + thio (10)
best (500) + cap (10)
3H-2-d-ala-1-LE bestatin (1500)
thiorphan (10)
captopril (10)
best (500) + thio (10)
yes 80
no 0
no 80
yes 85
yes
yes
no
no
35
15
0
35
Combined inhibitor studies = bestatin (best) at a single
concentration, with thiorphan (thio) or captopril (cap) in
increasing concentrations
DISCUSSION
These data indicate that bestatin-sensitive aminopeptidase activity
accounts for approximately 80% of the [leu]enkephalin hydrolysis in
rat plasma. This is in agreement with the report by Venturelli et al.
(1985), based on the concentrations of resulting metabolites, that
aminopeptidases hydrolyze approximately 75% of the enkephalin in rat
blood. Approximately 5% of the LE in blood is metabolized by
captopril-sensitive ACE, while thiorphan-sensitive enkephalinase
activity could not be detected. This pattern of enzyme activities is
similar to that in rat lung (Gillespie et al. 1985), but different
from that in brain and guinea pig ileum (Schwartz et al. 1983;
Hambrook et al. 1976; Hazato et al. 1983; Aoki et al. 1984). The
enzyme(s) responsible for the remaining 15% of LE metabolism in blood
are as yet unidentified.
Our data also suggest an unusual pattern of enzyme activities against
the 2-d-ala-1-LE substrate. This substrate reportedly is selective
for enkephalinase and insensitive to aminopeptidase activity in brain
tissue (Llorens et al. 1982), and its hydrolysis in brain is potently
inhibited by thiorphan (Roques et al. 1983). In addition, brain
enkephalinase is not inhibited by bestatin (van Amsterdam et al.
1983). However, in our studies, only 10 - 20% of the hydrolysis of
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2-d-ala-1-LE could be attributed to a thiorphan-sensitive
enkephalinase; 30 - 40% of the hydrolysis was due to an unidentified
bestatin-sensitive enzyme, captopril-sensitive ACE activity could not
be detected, and the source of the remaining 40 - 60% of the
degradation is unknown.
Taken together, these data indicate that rat plasma has its own
unique pattern of enkephalin hydrolysis. The enzymes active in plasma
may be isoenzymes to the enzymes found in other tissues, differing
from these latter enzymes in their sensitivities to inhibitors.
Alternatively, the plasma enzymes may only appear to be different
because of differences in conformation or in the availability of a
substance that competes with, or alters the binding of,
[leu]enkephalin or the inhibitors to the enzymes.
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ABSTRACT
A membrane-bound enkephalin (ENK) -hydrolyzing amino-
peptidase (AP) was partially purified from neuroblastoma
(clone N1E-115) cell membranes; enzyme activity was
assayed by determination of the leu-enkephalin (LENK)
degradation product, tyrosine (Tyr), with HPLC. The
enzyme was extracted with Triton X-100, resolved by
anion-exchange chromatography and further purified by
gel filtration. The overall purification was about
100-fold with a yield of 43%. The apparent Mr value of
the AP by gel filtration in the presence of 0.3% Triton
X-100 was approx. 400 kDa. In the absence of detergent
the apparent Mr value was about 305 kDa. In the elution
buffers, where Triton X-100 was omitted, the peptidase
activity was lost. The enzyme had a Km of 0.13 mM and a
Vmax of 450 nmoles per mg protein per min at 25°C for
LENK and exhibited little sensitivity to bestatin (IC50:
200 µM) and puromycin (IC50: 500 µM), but it was
strongly inhibited by amastatin (IC50: 8 µM). The enzyme
is an amphiphilic membrane protein; the native primary
structure is preserved only in the 'detergent form'. It
seems to be AP N (EC 3.4.11.2) with an optimum of pH 7.2
to 7.4. We assume that this AP plays the important role
in inactivating ENKs on the neuronal level.
The ENK-degrading AP, partially purified from primary
rat brain astrocyte cell membranes, exhibited a smaller
apparent Mr value (130 kDa) and a higher sensitivity to
amastatin (IC50: 0.4 µM), bestatin (IC50: 90 nM) and
puromycin (IC50: 5 µM) than did the N1E-115 enzyme. From
these data we conclude that there are at least two
membrane-bound APs responsible for the ENK degradation
in the brain.
INTRODUCTION
In this paper we report the existence of an AP N like
enzyme in membranes of neuroblastoma cells (N1E-115) and
of a bestatin-sensitive AP in cell membranes of primary
astrocytes of 2-day old rats. In case of the neuronal
enzyme the entire AP molecule in the cell membranes of
the NlE-115 cells is extracted by the neutral detergent
Triton X-100 leading to an amphiphatic form called the
detergent form. The catalytically active site of the
enzyme can also be solubilized by proteolytic cleavage
at the hydrophilic-hydrophobic junction of the protein
chain (protease form). Both forms of the AP have been
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purified and some of its properties have been
investigated and compared. The comparison includes the
partially purified glial AP, in which a detergent and
protease form was not distinguishable.
MATERIALS AND METHODS
(Tyr-3,5-3H)-LENK (36.5 Ci/mmol) was purchased from
DuPont (NEN, Dreieich, Germany). Mono Q monobeads and
superose 6 were from Pharmacia Fine Chemicals AB
(Uppsala, Sweden). LENK, bestatin and puromycin were
from Sigma Chemical Co. (Munich, Germany). Mouse
neuroblastoma cells, clone N1E-115, were grown as
monolayers. The media were changed three times a week
and the experiments performed at the confluent stage,
usually 7 days after plating. Primary astrocytes of
2-day old rats were cultured as previously described
(Lentzen and Palenker 1983). After washing the cells
were scraped off in 10 mM dipotassium phosphate buffer,
pH 7.4, containing 1 mM EDTA with 2.8 µg aprotinin/ml
and homogenized in a Potter-Elvehjem homogenizer
(glass/Teflon). The homogenate was centrifuged at 4°C at
1000 x g for 15 min, the 1000 g supernatant at 8000 x g
for 20 min, the 8000 g supernatant at 40000 x g for 30
min. The 40000 g pellet was washed once with 10 mM
dipotassium phosphate buffer, pH 7.4, containing 1 mM
EDTA with 2.8 µg aprotinin/ml and once more in
dipotassium phosphate buffer without EDTA. The pellet
was resuspended in 10 mM dipotassium phosphate buffer
(40 mg/ml) containing 1 mM DT, 1 mM PMSF, 100 nM
pepstatin A, 0,3% Triton X-100, 20% ethylene glycol, 2.8
µg aprotinin /ml, pH 7,7, solubilized at 4°C for 1 h and
subsequently centrifuged at 4°C at 100000 x g for 1 h.
The 100000 x g supernatant was loaded on an
anion-exchange column (Mono Q, Pharmacia, Uppsala,
Sweden) and eluted with 10 mM dipotassium phosphate, 20%
ethylene glycol, 1 mM DT, 1 mM PMSF and 0.3% Triton
X-100 and an NaCl gradient from 0 to 1 M with a flow
rate of 1 ml/min. The pooled enzyme fractions of the
Mono Q chromatography were concentrated by
ultrafiltration and applied to a Superose 6 column
(Pharmacia; 1.0 x 30 cm). Protein was eluted with 10 mM
dipotassium phosphate buffer containing 0.1 M NaCl, 0.3%
Triton X-100, 20% ethylene glycol, pH 7.4, at a flow
rate of 0.5 ml/min. 40 µl of enzyme fractions were
preincubated with 40 µl dipotassium phosphate buffer, pH
7.4, for 15 min at 25° C and further incubated with
3H-LENK (20 µl) for 15 min. The incubation was stopped
with 10 µl of 1 N HCl and by deep-freezing of the
samples in liquid nitrogen. The 3H-labeled Tyr was
detected as described (Lentzen and Palenker 1983).
RESULTS AND DISCUSSION
The enzyme was purified within 10 h after homogenization
of the cells. The optimal time was 60 min for
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solubilizing the AP from the neuroblastoma cell
membranes incubated with 0.3 % Triton X-100 at 4°C.
Under these conditions 95% of the whole AP activity was
solubilized. In the supernatant after solubilization
only one activity peak was detected using anion-exchange
chromatography. At a concentration of 0.25-0.35 M NaCl
about 77% of the whole activity loaded on the column was
eluted. In the absence of detergent in the elution
buffer, the peptidase activity was lost. The relatively
naked protein molecules tend to bury their hydrophobic
regions by clustering together, forming large aggregates
under the loss of enzyme activity. The fractions from
anion-exchange chromatography were loaded after
concentrating by ultrafiltration on a gel filtration
column. The Mr value of the enzyme in the presence of
Triton X-100 was approx. 400 kDa. The following proteins
were used for calibration: thyroglobulin 669 kDa,
ferritin 440 kDa, catalase 232 kDa, aldolase 158 kDa.
After solubilization, using Triton X-100 as detergent,
the hydrophobic domain binds a micelle of detergent,
thereby increasing the molecular weight by about 95 kDa,
corresponding to approx. 150 molecules of detergent.
Therefore, the Mr value of the native enzyme after gel
filtration seems to be 305 kDa. The Michaelis constants,
Km and Vmax, for LENK as substrate was calculated by
Lineweaver-Burk analysis using substrate concentrations
from 1.8 to 800 µM. The Km and Vmax for LENK were 125 µM
and 450 nmoles per mg protein per min at 25°C. The AP
inhibitors, amastatin (IC50: 8 µM), bestatin (IC50: 200
µM) and puromycin (IC50: 500 µM) had inhibitory effects.
The enzyme is active between pH 5.9 and 8.2 with maximal
activity for LENK hydrolysis between pH 7.2 and 7.4.
These properties of the enzyme are not in accordance
with the studies about ENK-degrading APs in synaptosomal
preparations (Hui et al. 1983; Hersh 1985 ). However,
they are in agreement with the studies of Maroux et al.
(1973), Gray and Santiago (1977), Kenny and Maroux
(1982) and others on the AP N from microvilli from
intestinum and kidney of pigs and rats. Experiments of
Gros et al. (1985) suggest, that AP N is present in the
brain. If solubilization and purification of the enzyme
was made without suitable protease inhibitors or if
trypsin was added to the detergent extract, some
catalytically active fractions were isolated in the
anion-exchange chromatography, which showed activity
both in the presence and in the absence of the detergent
in the elution buffer. We selected a low-molecular
weight activity peak (66 kDa) for determination of the
kinetic parameters for the substrate LENK and for
estimation of the IC50 values for the inhibitors
bestatin and puromycin. This fraction showed a six-fold
higher affinity (Km: 25 µM) and more sensitivity against
bestatin (IC50: 0.6 µM).
Our studies with the so-called detergent- and protease
form of the enzyme demonstrate that there obviously
exists an amphiphatic integral membrane protein
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comparable to the AP N. Correspondingly this peptidase
has a lipohilic, catalytically inactive anchor in the
membrane and a hydrophilic catalytically active head
projecting into the extracellular space. The hydrophilic
head can be cut off by proteases like trypsin and can be
further fragmented dependent on the incubation time. It
was surprising that the hydrophilic part of the AP shows
a lower Km value and lower inhibitor constants than did
the detergent form of the enzyme. We suggest that this
enzyme is the membrane-bound, ENK hydrolyzing, neuronal
AP, which must be distinguished from a glial AP.
We isolated an AP from cell membranes of primary
astrocytes. Solubilization and purification of the glial
enzyme were performed as described above for the
neuronal enzyme. As in the case of the neuronal enzyme
the glial AP is an membrane protein as several
solubilization trials with different detergent
concentrations revealed. Using anion-exchange
chromatography, only one AP activity peak was eluted at
a sodium chloride concentration of 0.3 M. In contrast to
the neuronal AP the glial enzyme was catalytically
active independent on the presence or absence of Triton
X-100 in the elution buffer. The pooled Mono Q fractions
containing the AP activity were concentrated by
ultrafiltration and then further purified by gel
filtration. After calibrating the column with standard
proteins, this peptidase corresponded to a molecular
weight of approx. 130 kDa.
The enzyme had an optimum of about pH 6.7. Its affinity
to the substrate LENK with a Km of 14 µM is relatively
high. It was strongly inhibited by amastatin (IC50: 0.4
µM), bestatin (IC50: 90 nM) and puromycin (IC50: 5 µM).
Similar results for a synaptosomal bestatin-sensitive AP
were reported by Hui et al. (1983), Hersh (1985) and
Giros et al. (1986). In contrast to the neuronal enzyme,
a detergent- and protease form of the glial AP is not
distinguishable. (This work was supported by the DFG).
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Bruno Giros, Catherine Llorens-Cortes, Claude Gros
and Jean-Charles Schwartz
Unite 109 de Neurobiologie et Pharmacologie
Centre Paul Broca de l'INSERM 2 ter rue d'Alésia 75014 PARIS (FRANCE)
ABSTRACT
The tripeptide Tyr-Gly-Gly (YGG) was established as an endogenous
constituent in rat brain. Its origin from enkephalin neurons is
suggested by its regional distribution paralleling that of (Met5)-
enkephalin (YGGFM), its decrease following kainate-induced ablation
of the striato-pallidal neurons and its enhanced formation following
depolarization of pallidal slices. Enkephalinase (EC 3.4.24.11) is
selectively responsible for endogenous YGG formation in vitro and in
vivo.
INTRODUCTION
Using a sensitive RIA (Llorens-Cortes et al. 1985b) YGG, a potential
metabolite of opioid peptides (OP), was characterized as an extraneu-
ronal constituent of mouse brain (Llorens-Cortes et al. 1985a).
In this present work we have characterized YGG in rat brain regions
and explored the hypothesis that it may originate from OP by asses-
sing the effects of lesions of a known enkephalin pathway and stu-
dying its formation in depolarized slices.
MATERIALS AND METHODS
In most cases male Wistar rats were killed by decapitation, brain
regions dissected out in the cold in less than 3 min and homogenized
in 0.4 N HClO4. Experiments with slices of globus pallidus were
performed as described (Giros et al. 1986).
RIAs for YGGFM and YGG were performed as described (Gros et al. 1978;
Llorens-Cortes et al. 1985a)
RESULTS AND DISCUSSION
YGG immunoreactivity was detected in all regions of rat brain (table
1) and appears to correspond to authentic YGG as indicated by its
chromatographic patterns in various systems (namely HPLC on C18
µBondapak columns). Its levels in striatum did not differ when rats
were killed by decapitation or microwave irradiation, indicating that
it was not formed artefactually by hydrolysis of larger peptides
brought into contact with peptidases at the homogenization step.
In most brain areas YGG levels corresponded to about 10 % of YGGFM
levels (table 1). This parallel regional distribution is consistent
with the idea tnat the tripeptide constitutes a metabolic product of
enkephalins or related OP.
Ablation of proenkephalin-A-containing neurons in the striato-
pallidal pathway elicited by intrastriatal kainate was accompanied
by significant decreases in YGG in both the injected and the
projection areas (table 2).
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TABLE 1: Regional distribution of YGG and YGGFM immunoreactivities
in rat brain
REGIONS YGG YGGFM Y G G
(pmol/mg protein) YGGFM
Globus pallidus 3.50 0.40 38.2 0.38 0.09 0.01
Substantia nigra 1.71 0.25 10.0 0.80 0.17 0.03
Caudate putamen 1.01 O.11 14.8 0.16 0.07 0.01
Hypothalamus 0.47 0.03 12.7 0.70 0.04 0.01
Cerebral cortex 0.45 0.05 3.62 0.30 0.12 0.01
Hippocampus 0.29 0.02 2.40 0.28 0.12 0.02
Brainstem 0.05 0.01 0.46 0.03 0.11 0.04
Cerebellum 0.02 0.02 0.10 0.01 0.20 0.02
Means  S.E.M. of data from 5 to 18 experiments.
TABLE 2: Effect of kainic acid injections on YGG-ir and YGGFM-ir
levels in caudate-putamen and globus pallidus
ANALYSED REGION YGG LEVELS YGGFM LEVELS
(pmol/mg protein)
Caudate putamen
Control side
Injected side
Variation
Globus pallidus
Control side
1.06 O.11 19.7 0.8
0.77 0.09* 1 5 . 4 1.3=
- 27 % - 23 %
4.12 0.36 28.2 1.9
Injected side 2.09 0.21** 19.7 1 . 3
Variation - 49 % - 30 %
* P < 0.05 ; ** P < 0.01 ; *** P < 0.001 compared to control
Kainic acid (1.5 µg/1 µl), dissolved in distilled water adjusted
to pH 7.4 was microinjected into the right anterior caudate-
putamen at a rate of 0.6 µl/min. Animals were sacrificed by
decapitation 14 days later.
Means S.E.M. of data from 18 separate experiments.
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When pallidal slices were incubated in the absence (not shown) or
the presence (table 3) of bestatin, an aminopeptidase inhibitor
preventing the hydrolysis of YGG (De la Baume et al. 1983), the
tripeptide was predominantly found in the incubation medium. This
extracellular localization of YGG is consistent with data from sub-
cellular
1985a). K+-induced depolarization of the slices elicited a strong
fractionation studies in mouse brain (Llorens-Cortes et al.
elevation of YGG in the medium (in which it was identified by HPLC)
as well as in slices (in which it might be locates in the
extracellular space). The amount of YGGFM released by the K+ stimulus
(corresponding to the difference of YGGFM tissue levels at 5 mM K+
and 50 mM K+, respectively) was notably inferior to the increase of
the sum (YGGFM + YGG) recovered in the medium (table 3). This indica-
tes that released peptides other than YGGFM, i.e. presumably other OP
derived from proenkephalin A also contribute in YGG formation.
TABLE 3: Effects of a depolarizing stimulus on tissue and incubation
medium levels of YGG-ir and YGGFM-ir of pallidal slices
CONDITIONS
LEVELS IN SLICES
(pmol/mg protein)
LEVELS IN MEDIUM
(pmol/mg protein)
Y G G F M Y G G Y G G F M Y G G
5 mM K+ 23.8 0.9 1.2 0.2 0.8 0.1 2.6 0.5
50 mM K+ 17.9 0.2 2.1 0.2 2.6 0.2 10.2 0.7
Difference - 5.9 1.0 + 0.9 0.3 + 1.8 0.2 + 7.6 0.9
*P < 0.05 ; ** P < 0.01 ; *** P < 0.001 compared to 5 mM K+
Slices were preincubated for 10 min in the presence of 100 µM
bestatin), and incubated for a further 5 min with 50 mM K+, when
stated. At the end of incubations, slices were separated from
medium by a short centrifugation and peptides extracted into
HClO4 were radioimmunoassayed in both fractions.
Means SEM from 6 experiments
In the presence of Thiorphan in increasing concentrations, the K+-
induced rise in YGG was progressively abolished while the recovery of
YGGFM in the incubation medium rose to reach the amount of YGGFM
released from the slices (figure 1). The IC50 value of Thiorphan (9
nM) was consistent with its effect being se;lectively mediared by
inhibition of enkephalinase. In addition acetorphan (10 mg/kg), a
parenterally-active derivative of Thiorphan, strongly reduced YGG
levels in various brain regions (by 55-70 % after 1h), establishing
enkephalinase as the YGG forming enzyme in vivo as well as in vitro.
This peptidase selectively cleaves amide bonds comprising the amino
group of en aromatic (or hydrophobic) amino acid residue which is
consistent with the idea that OP (which all have in common the YGGF
sequence) are precursors of YGG. Also the fact that enkephalinase is
an ectoenzyme in brain (De La Baume et al. 1983) is consistent with
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the idea that YGG is formed after release of OP, derived from
proenkephalin A precursor since other OPs are poor substrates.
the
FIGURE 1: Effects of Thiorphan, en "enkephalinase" inhibitor,
on levels of YGG and YGGFM imnunoreactivities in the incubation
medium of K +-depolarized slices of rat globus pallidus.
Pallidal slices were preincubated for 10 min in the presence of
100 µM bestatin and increasing concentrations of Thiorphan and
then exposed for 5 min to 50 mM K+. After centrifugation, YGG
and YGGFM were radioimmunoasssyed in media.
In conclusion, all data were consistent with the idea that YGG repre-
sents an extracellular metabolite of endogenous OPs derived from
proenkephalin-A for which its measurement may constitute an index of
release.
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EVALUATION OF STRIATAL ENKEPHALIN RELEASE IN VIVO FROM STEADY
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ABSTRACT
The tripeptide Tyr-Gly-Gly (YGG), an extraneuronal metabolite of
opioid peptides (OP) derived from proenkephalin A is in a highly
dynamic state in mouse striatum. Inhibition of its synthesis by
Thiorphan reduced its levels with a t 1/2 of 12 min. Inhibition of
its degradation by bestatin elicited its rapid accumulation consis-
tent with a t 1/2 of enkephalins in the one-hour range. Pentobarbital
anesthesia markedly reduced its steady state level end turnover
rates.
INTRODUCTION
Using a sensitive RIA, we recently characterized YGG as an endogenous
constituent of mouse (Llorens-Cortes et al. 1985a,b) and rat brain
tissues (Giros et al. this volume). Endogenous YGG appears to be
formed extraneuronally by enkephalinase degradation of the OPs de-
rived from the proenkephalin A precursor
distribution parallels that of YGGFM, ii)
because i) its regional
its levels decrease after
ablation of these neurons iii) its extracellular localization has
been shown by subcellular fractionation and studies with brain
slices; iv) its level rises considerably as a result of depolariza-
tion of proenkephalin A neuron terminals, which are abundant in
slices from globus pallidus, and v) inhibitors of the ectoenzyme
enkephalinase inhibit YGG formation selectively.
We have presently attempted to evaluate YGG turnover in mouse stria-
tum by measuring its rates of decline and rise following inhibition
of enkephalinase and aminopeptidase respectively. To validate these
measurements under conditions of altered neuronal activity, we
assessed the effects of pentobarbital anesthesia which is known to
modify the activity of a variety of neuronal systems.
MATERIALS AND METHODS
Male Swiss mice were killed after i.c.v. administration of saline or
peptidase inhibitors. The striata were dissected out in less than 2
min, homogenized in 0.4 N HClO4 and YGG measured in extracts by a RIA
(Llorens-Cortes et al. 1985a,b).
RESULTS AND DISCUSSION
Thiorphan elicited a monoexponential decline of striatal YGG with a
fractional rate constant of 3.5 0.5 hr corresponding to a t 1/2
of 12 2 min end a turnover-rate of 18 3 pmol/mg protein/hr
(figure 1). A similar rate of decline was found with 1 mg/kg acetor-
phan a parenterally-active enkephalinase irhibitor (Lecomte et al.
1986) (not shown).
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FIGURE 1: Decline of YGG levels in mouse striatum after
administration of the enkephalinase inhibitor Thiorphan.
Mice were given saline or 100 ug of Thiorphan i.c.v. and were
killed at different times after injection. Values are means
S.E.M. of five to eight experiments.
* P < 0.05 ; ** P < 0.01 versus the respective controls.
After bestatin administration, striatal YGG increased linearly for
15-20 min and then reached a plateau at about twice its steady-state
level (figure 2).
pmol/mg protein/hr.
The initial rate of YGG accumulation was 18 3
FIGURE 2: YGG accumulation in mouse striatum after administra-
tion of the aminopeptidase inhibitor bestatin.
Amimals received saline or 150 ug of bestatin i.c.v. and were
killed at different times after injection. Values are means
S.E.M. of 5-11 experiments.
*P < 0.05 ; ** P < 0.01 versus the respective controls.
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From these two consistent estimations it may be inferred that YGGFM
release and its degradation into YGG occur at a rather high rate,
implying that the turnover of striatal enkephalins is comparable to
that of "classical" neurotransmitters. This conclusion is somewhat
unexpected since the t 1/2 of neuropeptides, although never reported
before, is often assumed to be longer due to processes of ribosomal
synthesis, maturation and axonal transport which precede their exo-
cytosis.
However the above values should be considered with caution since they
are based upon a series of assumptions that may not be verified.
Peptidase inhibition may not be complete immediately after treat-
ments and may trigger feedback control mechanisms regulating OP
release. Bestatin blocks the degradation of not only YGG but also of
OPs. Hence the fairly good agreement between the two estimations of
YGG turnover rate may be to a certain extent fortuitous. Nevertheless
the observation (Llorens-Cortes et al. 1986) that a similar value is
found for the rate of YGGFM accumulation in an extrasynaptosomal
fraction of mouse striatum following complete blockade of its metabo-
lism (by Thiorphan plus bestatin) strenghthen our conviction that
these represent reasonable estimates of the rate of enkephalin
release in vivo.
In mice treated with pentobarbital the striatal YGG levels were
found to decrease progressively, a plateau being reached after 30
min (figure 3) without significant modification of YGGFM levels (not
shown).
FIGURE 3: Steady-state levels end bestatin-induced accumula-
tion of YGG in mice anesthetized with pentobarbital.
Mice were given pentobarbital i.p. at 60 mg/kg either alone
(solid line) or with 150 ug of bestatin, administered 30 min
later i.c.v. (broken line) and were killed at various intervals
thereafter. Values are means S.E.M. of 5-15 experiments.
N.S. non significant
* P < 0.01 versus saline ; ** P < 0.01 versus pentobartital
alone.
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When this new steady-state level was reached, administration of
bestatin elicited, for the next 15 min, linear accumulation of YGG at
a rate (pmol/mg protein/hr) of 7 1 versus 18 2 in controls.
A similar effect was observed when mice were anesthetized with chlo-
ral. This decrease in steady-state YGG level during anesthesia seems
attributable to impairment of enkephalin release and of YGG formation
shown with peptidase inhibitors. Barbiturates reduce the activity of
several classes of aminergic neurons. As far as we know, this is the
first time that their effects on peptidergic neuron activity have
been reported. The drastic reduction in the activity of enkephalin
neurons, shown by the present data, might be relevant to the hyper-
algesic and anticonvulsive effects of barbiturates since enkephalins
induce opposite effects.
Hence the steady-state level of YGG appetis to constitute a useful
index of changes in enkephelin neuron activity in the brain, just as
the levels of certain extraneuronal metabolites reflect changes in
monoamine neuron activity. Measurement of this simple index offers
the great advantage of avoiding the administration of any metabolic
inhibitor. A similar experimental approach could conceivably be
applied to other classes of cerebral neuropeptides as soon as their
metabolic pathways are identified.
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ISOLATION AND CHARACTERIZATION OF ACTH-RELATED PEPTIDES
FROM PORCINE PITUITARIES
Karlheinz Voigt and Wolf Stegmaier
Institut für Klinische Pharmakologie, Freie Universität,
D-1000 Berlin 45, F.R.G.
ABSTRACT
We report on the isolation of new variants of porcine
ACTH with corticotropic activity. Two of these variants
differ in their amino acid sequence from porcine ACTH at
one position (Arg8). This implies that they cannot be
derived from the known precursor proopiomelanocortin
(POMC).
INTRODUCTION
The adrenocorticotropic hormone (ACTH) is synthesized as
part of its precursor POMC. In the pituitary intermediate
lobe ACTH 1-39 can be processed to -MSH (acetyl-
ACTH 1-13-amide) and CLIP (ACTH 18-39). None of these
peptides possesses corticotropic activity.
However, recently corticotropic active fragments of ACTH
were isolated from porcine anterior pituitaries and
identified as ACTH 1-38, ACTH 1-37, ACTH 7-39 and
ACTH 7-38 (Ekman et al. 1984).
We supposed that there could be more and yet shorter
ACTH-variants showing significant biological activities.
We will report on the isolation and sequence deter-
mination of five new ACTH-variants from porcine pitui-
taries, two of them differing in their primary structure
from the corresponding ACTH-sequence.
MATERIALS AND METHODS
Isolation of ACTH-like peptides
Fresh porcine pituitaries were obtained from a
slaughterhouse. They were extracted and prepurified as
described by Schleyer et al. (1976) and by additional gel
filtration on Fractogel TSK HW-40 (S) (Merck, F.R.G.).
The resulting fraction P-LF II D3 was further
chromatographed in a number of successive reversed phase
HPLC-systems.
The semipreparative system using an Ultrasphere ODS
column (250x10 mm, particle size 10µ, Beckman, U.S.A.)
yielded three main peaks eluting in a gradient of 0.2 %
TFA and acetonitrile. These main fractions were further
chromatographed in one or two analytical HPLC-systems
using either a 250x4.6 mm column packed with Ultrasphere
ODS 10µ and a gradient of 0.2 % TFA and acetonitrile
and/or a 250x4 mm column packed with Hypersil WP 300
butyl 5µ (Shandon, U.K.) and a gradient of 50 mM
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potassium phosphate pH 2.5 and acetonitrile. This
resulted in 6 pure fractions F1 to F6. All peptides were
detected by their UV-absorption at 210 and 280 nm.
Peptide mapping
Fractions F1 to F6 were digested by TPCK-treated trypsin
(Sigma, F.R.G.), staphylococcus aureus protease (Miles,
U.S.A.), proline specific endopeptidase (Miles, U.S.A.)
and mouse submaxilliary protease (Sigma, F.R.G.)
following slightly modified standard procedures.
The digests were subjected to reversed phase HPLC on a
250x4 mm column packed either with HD-Gel (Gynkotek,
F.R.G.) or Hypersil WP 300 butyl 5µ applying a gradient
of 0.2 % TFA and acetonitrile.
Amino acid analysis
The amino acid compositions of the desalted and
hydrolyzed peptides were determined by precolumn
derivatization with ortho-phthalaldehyde (OPA) and
mercaptoethanol. The procedure of Umagat et al. (1982)
was modified and optimized for the routine analysis of
50 pmol samples.
Sequence analysis
The pure peptides were manually sequenced following the
4-N,N-dimethylaminoazobenzene-4'-isothiocyanate (DABITC)
method of Wittmann-Liebold and Kimura (1984).
The C-termini were enzymatically sequenced using carboxy-
peptidase Y (Sigma, F.R.G.) as descibed by Allen (1981).
Biological activity and RIA
Corticotropic activity was tested by the dose dependent
secretion of corticosteron from isolated rat adrenal
cells (Sayers et al. 1971)
Radioimmunoassays using 125I-labelled tracers were per-
formed for systems specific for -MSH, CLIP and the
middle portion of the ACTH-molecule.
RESULTS AND CONCLUSIONS
The prepurified extract of porcine pituitaries was
subjected to reversed phase HPLC in a number of
successive HPLC-systems with increasing separation power.
The HPLC-systems were monitored by region specific ACTH-
radioimmunoassays and by the corticotropic activity
tested with isolated rat adrenal cells. Finally we
obtained fractions F1 to F6, all showing a strong
crossreactivity to ACTH-antisera directed against the
middle portion of ACTH.
F1 to F6 were proven to be pure by OPA amino acid
analysis . They were digested by trypsin, staphylococcus
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aureus protease, proline specific endopeptidase and mouse
submaxillary protease. The resulting peptide fragments
were separated by means of HPLC and subjected to amino
acid analysis and manual microsequencing.
FIGURE 1. Schematic representation of the amino
acid sequences of pACTH 1-39 and its variants
F1 to F6.
The results are shown in figure 1. The amino acid
sequence of  F1 relates to ACTH 7-31 with the uncertainty
of Asx in ACTH position 29. F3, F5 and F6 proved to be
identical to ACTH 1-31, ACTH 7-35 and ACTH 7-38,
respectively. The latter variant has been already
described by Ekman et al. (1984).
F2 and F4 are ACTH-fragments with close sequence
homologies but differ from the above mentioned variants
by an exchange of Thr for Arg8 , thus resembling
(Thr8-)ACTH 7-31 and (Thr8-)ACTH 1-31.
Our peptides F1 to F6 exhibited a corticotropic activity
of about 2 to 25 % compared to porcine ACTH 1-39.
These by now unknown ACTH-variants could be generated
from ACTH by truncating it C-terminally in an unspecific
manner. In contrast the N-terminal cleavage site between
His6 and Phe7 seems to be very specific since no other
N-terminally truncated ACTH-variants have been isolated
(Ekman et al. 1984). To our knowledge such a specifity
has not been attributed to one of the known proteases.
The occurrence of the two (Thr8-)ACTH-variants points to
the existence of a gene differing from the known POMC-
gene.
Both genes could occur together in one animal or in a
subpopulation of animals lacking the ordinary POMC-gene
and having instead the gene for the ACTH-variants.
Oates and Herbert (1984) and Gossard et al. (1986) found
only one porcine POMC-gene. Boileau et al. (1983)
isolated two POMC mRNA species which coded for two
different N-terminal POMC-sequences but they did not show
differences in the ACTH-coding region.
The mutation at position 8 of the ACTH molecule might be
of functional relevance because the partial sequence
about it is crucial for the biological activity of a
number of POMC derived peptides (ACTH, - M S H , -MSH,
-MSH).
281
REFERENCES
Allen, G. Methods in Molecular Biology. Amsterdam,
Elsevier, 1981. 41 pp.
Boileau, G., Gossard, F., Seidah, N.G., and Chretien, M.
Can J Cell Biol, 61:333-339, 1983.
Ekman, R., Noren, H., Hakanson, R., and Jörnvall, H.
Regulatory Peptides, 8:305-314, 1984.
Gossard, F.J., Chang, A.C.Y., and Cohen, S.N.
Biochim Biophys Acta, 866:68-74, 1986.
Oates, E., and Herbert, E.
J Biol Chem, 259:7421-7425, 1984.
Sayers, G., Swallow, R.L., and Giordano, N.D.
Endocrinology, 88:1063-1068, 1971
Schleyer, M., Voigt, K.H., and Pfeiffer, E.F.
Horm Metab Res, 8:175-181, 1976.
Umagat, H., Kucera, P., and Wen, L.F.
J Chromatogr, 239:463-474, 1982.
Wittmann-Liebold, B., and Kimura, L.-F.
In: Walker, J.M., ed. Methods in Molecular Biology,
Vol. I. Clifton N.J.: Humana Press, 1984. pp. 221-242.
ACKNOWLEDGEMENTS
This work was supported by the Deutsche Forschungs-
gemeinschaft (SFB 87/B2; Vo 253/6-1).
282
A MEMBRANE BOUND SUBSTANCE P DEGRADING ENDOPEPTIDASE
FROM RAT BRAIN
Andreas Bergmann and Karl Bauer
Institut für Biochemie und Molekularbiologie D-1000
Berlin 10, Franklinstra e 29, F.R.G.
ABSTRACT
From rat brain, a membrane bound substance P-degrading
endopeptidase (SPE) was purified 1580 fold to near
homogeneity. After extraction with 1OmM CHAPS, the enzyme
preparation was subjected to ion exchange chromatography
on DEAE-cellulose, adsorption chromatography on hydroxy-
apatite, gelfiltration through Ultrogel AcA 44 and FPLC
on Mono Q. This enzyme of 70000 molecular weight is
optimally active at pH 7.5. Metal chelators( EDTA and EGTA)
and sulfhydryl modifying reagents (N-ethylmaleimide and
p-chloromercuriphenylsulfonic acid) are strongly inhibi-
tory while the serine-protease inhibitor diisopropyl-
fluorophosphate does not effect the enzyme activity.
The enzyme is strongly inhibited by bacitracin but not
by phosphoramidon and captopril. Degradation of substance P
is strongly inhibited by neurotensin, somatostatin, ACTH
1-39, and less effectively by LHRH but not by Leucine-
enkephalin. Substance P is preferentially hydrolyzed at the
Gln6-Phe7 peptide bond but fragmentation at the Pro4-Gln5,
Gln5-Gln6,Phe7-Phe8 and Glyg-Leu1O bonds was also observed.
INTRODUCTION
The mechanism involved in the inactivation of the
putative neurotransmitter substance P are unknown. A
number of peptidases capable of degrading substance P have
been identified (Akopyan et al. 1979, Chrètien et al. 1980,
Leeet al. 1983, Matsas etal. 1983, Skidgelet al. 1984,
Yokosawaetal. 1983), but their functions for the
inactivation of synaptically released substance P
remain unclear. We previously reported that substance P
is hydrolyzed by a bacitracin sensitive enzyme localized
on neuronal cells in primary culture (Horsthemke etal.
19841 and now report on the purification of a membrane
bound and bacitracin sensitive substance P degrading
endopeptidase from rat brain.
MATERIALS AND METHODS
Enzyme assay: The enzyme solution was diluted with buffer
A (25mM K-diethylmalonate, pH 7.5, containing 0.04% NaN3)
and supplemented with 1OOpM diisopropylfluorophosphate
(DFP) and 1OOµM bestatin (final volume=19µl). After prein-
cubation at 35°C for 15 minutes the reaction was started
by addition of O.1µCi (3H)-Phe8-substance P (1µl;24.5Ci/
mmol). At given time intervals 10µl of the reaction
mixture was spotted on silica gel plates (Merck, F.R.G.).
The plates were developed in ethyl acetate:pyridine:acetic
acid:H20 (125:100:20:60). Theamount of degraded substance P
was determined as described (Horsthemke etal. 1984).
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Enzyme purification: All steps were performed at 4°C.
Frozen rat brains (1OOg) were thawed and homogenized in
380ml buffer B (5mM NaP04, pH7.5 containing 1mM DTE and
O.O4%NaN3). The homogenate was centrifuged for 1h at
1OOOOOg. The resulting pellet was rehomogenized in buffer
B (380ml) and washed again for additional 5 times. The
last homogenate was adjusted to 1OmM CHAPS (Sigma) and
stirred for lh. The membrane extract obtained by cen-
trifugation at 1OOOOOg for 1h was then fractionated by
ion exchange chromatography on DE-52 cellulose (equi-
librated in buffer B) using a linear NaCl gradient
(0-250mM). The substance P degrading activity eluting
at 4.5 to 8.5 mSi conductivity was pooled and applied
to a hydroxyapatite column, equilibrated in buffer B.
After washing with 50mM NaP04, two substance P degrading
activities were desorbed in a linear gradient from 50
to 180mM NaP04. The enzyme eluting at higher NaP04-
concentrations (6-9mSi conductivity) was pooled, concen-
trated by ultrafiltration (Amicon PM 10 membrane) and
subjected to gel filtration through Ultrogel AcA 44.
The substance P degrading endopeptidase eluting with a
molecular weight of approx. 70000 was clearly separated
from another substance P degrading activity of low
molecular weight and was further purified over FPLC on
Mono Q (Pharmacia) . The enzyme eluted as a single peak
at approx. 120mM NaCl. After rechromatography on Mono Q
this enzyme preparation was used for all further
investigations.
RESULTS AND DISCUSSION
Although the enzyme assay contained 100pM DFP to
inhibit the degradation of substance P by dipeptidyl-
aminopeptidase IV and other serine-proteases, several
substance P degrading activities could be separated by
the purification procedure described. By this procedure
the substance P degrading endopetidase was purified
1580 fold to yield an enzymatically homogenous-enzyme
preparation.
The SPE was found to be strongly inhibited by metal-
chelating compounds such as EDTA and EGTA and also by
the -SH reactive reagents N-ethylmaleimide (NEM) or
p-chloromercuriphenylsulfonic acid (pCMBS) but not by
DFP, an inhibitor of serine-proteases (tab.1). SPE is
strongly inhibited by bacitracin, a general inhibitor
of various peptidases which also inhibits the substance
P degrading activity associated with neuronal cells in
primary culture (Horsthemke et al. 1984). These results
suggest that SPE is different from the substance P
degrading activity described by Leeet al. (1981) which
is not inhibited by 1mM Bacitracin. SPE is obviously
also different from other peptidases known to hydrolyze
substance P and other peptides (e.g. Leu-Enkephalin),
namely angiotensin converting enzyme and endopeptidase
24.11, since it is not inhibited by captopril and also not
by phosphoramidon, the known inhibitors of these enzymes.
284
Test substance concentration %inhibition
EDTA
EGTA
NEM
pCMBS
DFP
Captopril
Phosphoramidon
Bacitracin
I
1mM
1mM
100µM
100µM
100µM
1OµM
1OµM
100µM
93
70
96
100
0
0
0
72
Substance P
Neurotensin
Somatostatin
ACTH 1-39
LHRH
Leu-enkephalin
TABLE 1.
1OOµM 83
100µM 92
100µM 85
100µM 81
1OOµM 24
1OOµM 0
Test substances (2µl, 10-fold concentrated in
buffer A) were mixed with 17µl of buffer A
containing 1µl enzyme. Except when peptides
were tested, the mixture was preincubated for
15 min at 35°C. The reaction was started by
adding O.1µCi (1µl) (3H)-substance P and stopped
after incubation for 15 min at 35°C by spotting
1µl aliquots on silica gel plates. The amount
of substance P degraded was determined as
described under "materials and methods".
In agreement with these results, the degradation of
(3Hl-substance P was not effected by addition of un-
labeled Leu-enkephalin. In contrast, the degradation of
the radiolabeled tracer was strongly inhibited not only
by unlabeled substance P but also by neurotensin,
somatostatin and ACTH 1-39 while LHRH was considerably
less effective. These results strongly indicate that
SPE is not a substance P-specific enzyme but a more
general peptidase which also hydrolyzes other peptides
by recognizing only certain structural elements of
their substrates. This notion is supported by the
observation that SPE catalyzes the hydrolysis of
substance P at various peptide bonds. Identification
of the enzymatically formed fragments by HPLC on a
µBondapak C18-column and amino acid analysis clearly
demonstrated that substance P is preferentially hydro-
lyzed by SPE at the Gln6-Phe7 bond additionally also at
Pro4-Gln5,Gln5-Gln6, Phe7-Phe8 and Gly9-Met10 peptide
bonds.
Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2
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The present studies clearly demonstrated that SPE is
distinctly different from the substance P degrading
activities described so far and furthermore suggest
that this bacitracin-sensitive endopeptidase is a good
candidate likely to be important in the synaptic
inactivation of substance P and/or other neuropeptides.
However, since the physiological function of neuro-
peptide degrading enzymes appears to be primarily
determined by their specific localisation, only
immunocytochemical investigations at the electron-
microscope level will finally answer the question as
to the physiological function of this enzyme.
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IN SITU HYBRIDIZATION VERSUS NORTHERN ANALYSIS:
WORKING TOWARDS THE CORRELATION OF TWO QUANTITATIVE TECHNIQUES FOR
OPIOID AND VASOPRESSIN mRNAs IN THE RAT HYPOTHALAMUS AND PITUITARY
Thomas G. Sherman and Stanley J. Watson
Mental Health Research Institute
University of Michigan
205 Washtenaw Place
Ann Arbor, MI 48109-0720
ABSTRACT
Several physical and technical aspects of in situ hybridization are
examined to help ascertain to what extent the total specific mRNA
population of interest in a tissue section is actually detected using
complementary RNA probes. Two experimental paradigms, Rot curve
hybridization analysis and varying the tissue section thickness,
indicate that complementary RNA (cRNA) probe hybridization to a
specific mRNA in a tissue section can be made saturable, but remains
so only for those mRNAs within a limited distance from the surface of
the section. Direct comparison with Northern analysis, however,
shows that in situ hybridization still gives comparable relative
quantitative results for mRNA levels changing due to physiological
stimulation.
INTRODUCTION
The application of in situ hybridization for the autoradiographic
identification of cellular mRNAs has gained general acceptance as a
useful tool in studies of the anatomical localization of specific
gene products. If this qualitative information could be extended to
either the absolute or relative quantitation of specific mRNA
transcripts, then in situ hybridization could be an even more useful
tool for the regulation of gene expression in tissues possessing
extreme cellular heterogeneity, such as the brain. Towards this end,
several technical aspects of in situ hybridization, including probe
hybridization kinetics, tissue section thickness, probe length and
photographic emulsion preparation are being further characterized in
hopes that such an understanding will aid in the application of in
situ hybridization as a quantitative method. In this brief
manuscript, we will discuss the application of [32P]-labeled cRNA
probes, generated with the pSP6 vector system (Promega Biotec), for
in situ hybridization studies of pro-opiomelanocortin (POMC) mRNA in
the intermediate lobe of the rat pituitary, or a [32P]-labeled
synthetic oligonucleotide complementary to rat vasopressin mRNA in
the rat magnocellular hypothalamus.
MATERIALS AND METHODS
Many of the in situ hybridization methods presented in this
manuscript have been extensively described elsewhere (Brahic and
Haase 1978; Cox et al. 1984; Lewis et al. 1985; Sherman et al. in
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press; Watson et al. in press; Watson et al. 1985). Northern gel
analysis was conducted as previously described by Sherman et al.
(1986).
RESULTS AND DISCUSSION
The kinetics of cRNA hybridization to mRNA immobilized in a tissue
section, as is the case with in situ hybridization, more closely
approximates the situation existing with Northern or dot-blot
analyses than with classical solution-phase hybridization. The laws
of nucleic acid hybridization kinetics tell us that the rate of
duplex formation of excess cRNA probe to its complementary mRNA in an
immobile phase should follow pseudo first-order kinetics as described
by equation 1 (Young and Anderson 1985):
H = Do (1 - e
-kRoT) Equation 1
where H is the amount of duplex RNA formed, [Do] is the initial
amount of mRNA in the immobile phase, [Ro] is the initial amount of
cRNA probe in the mobile phase, T is time and k is a constant
possessing the units of 1/(sec-moles/liter). Practical application
of this equation takes the form of the so-called Rot curve, where
percent or amount of hybridization is plotted against the product of
probe concentration and time of hybridization (Ro x t = Rot). That
this can be shown to hold approximately true for in situ
hybridization is shown in figure 1, in which varying concentrations
of a mouse POMC cRNA probe are hybridized for varying lengths of time
against rat POMC mRNA in the intermediate lobe of the pituitary.
Figure 1. Rot curve for POMC cRNA hybridization to rat
pituitary intermediate lobe. To each 10 micron section was added
250,000 to 5,000,000 dpms of [32P]-labeled cRNA probe (800
nucleotides). Hybridizations were conducted for 2 to 7 days.
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In its simplest terms, figure 1 demonstrates that the extent of
[32P]-cRNA:mRNA duplex formed increases with time or [32P]-cRNA
concentration, and that with sufficient amount of either or both of
these, the hybridization is saturable.
While it is good to know that in situ hybridization follows orderly
kinetics, and is, to a limited extent, predictable, the situation is
more complicated than it appears. It is more accurate to conclude
from figure 1 that the POMC mRNA accessible by the cRNA probe is
saturable; for recent preliminary experiments suggest that only the
POMC mRNA localized in the top 2-4 microns of the tissue section is
available for hybridization. Probe hybridization to pituitary
sections ranging in thickness from 4.5 to 20 microns resulted in
specific signals all lying within the same (relatively large)
standard error. Thicker sections clearly did not give appreciably
greater signal than much thinner sections. That this results from an
effective limit of probe penetrance is a likely explanation.
Although in situ hybridization, as of this stage, remains non-
quantitative in absolute terms, it still may be useful for relative
quantitation studies where many uncharacterized sampling problems
essentially cancel each other out of the results. Even Northern gel
analysis remains at this level, since neither the efficiencies of RNA
transfer from gel to membrane nor the hybridization to these
immobilized RNAs are quantitative.
Figure 2. Correlation between Northern and in situ hybridiza
tion quantitation of salt-loading induced increases in vasopressin
mRNA in the supraoptic and paraventricular nuclei. The Northern gel
data is published in Sherman et al. (1986). The in situ data rep
resents average values from 2-4 sections for each nuclei. *p 0.005.
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The analysis is effective, nonetheless, because each sample suffers
the same disadvantages experienced by all samples. This situation
may, in some situations, be true for in situ hybridization analysis
also. Figure 2 depicts the results of an experiment comparing the
relative quantitation of vasopressin mRNA in hypothalamic
magnocellular nuclei by either Northern gel or in situ hybridization
using the same synthetic oligonucleotide probe (Sherman et al. 1986).
The induction of cytoplasmic vasopressin mRNA occurring with chronic
salt-loading, as detected by Northern gel analysis, is similarly
detected by in situ hybridization. Both Northern hybridization bands
and in situ positive nuclei were quantitated with a digital image
analysis system using [32P] autoradiographic standards. At a first
approximation, therefore, it appears the two results give comparable
results. A similar comparison was made in the quantitation of POMC
mRNA in the intermediate lobe of the pituitary during chronic
haloperidol treatment (Kelsey et al. 1986). Clearly, however, there
remains the question of tissue section sampling as a source of great
error with in situ hybridization, which is not a problem with
Northern analysis.
In conclusion, we have shown that in situ hybridization follows
orderly hybridization kinetics, and can be a useful tool for the
relative quantitation of cellular mRNAs in some circumstances. We
feel, that with additional characterization and optimization
(including the development of good autoradiographic standards), the
capability of accurate, absolute, quantitation exists.
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IMMUNOHISTOCHEMICAL EVIDENCE FOR SUBPOPULATIONS OF
DYNORPHINERGIC NEURONS
Bruce Quinn and Eckard Weber
Institute for Advanced Biomedical Research
Oregon Health Sciences University
Portland, OR 97201
ABSTRACT
Biochemical studies have shown that the dynorphin precur-
sor can generate at least seven opioid peptides. We
report here a study of dynorphin products analyzed on
adjacent semithin sections of rat brain, showing evidence
for differential peptide localization among magnocellular
neurons. In the oxytocinergic nucleus of the anterior
commissure, staining was strong for dynorphin B but very
weak for other prodynorphin markers; in the supraoptic
nucleus, a discrete subset of dynorphin neurons were posi-
tive for leu-enkephalin.
INTRODUCTION
Several recent studies have suggested regional hetero-
geneity in the immunohistochemical localization of pro-
ducts from the POMC (Bloch et al. 1979; McGinty and Bloom
1983) and proenkephalin precursors (Williams and Dockray
1983.) Heterogeneity of hypothalamic magnocellular
neurons has been reported for oxytocin/CRF expression
(Sawchenko et al. 1984) and for vasopressin in the supra-
optic nucleus (Richards et al. 1985.) When studied by
RIA, the processing of the dynorphin precursor varies
markedly among brain regions (Weber et al. 1982b); how-
ever, immunohistochemical heterogeneity has not been
reported. Therefore, we have examined hypothalamic magno-
cellular dynorphin neurons for differential immunohisto-
chemical staining of prodynorphin products.
MATERIALS AND METHODS
Male Sprague-Dawley rats were colchicine-treated (50 ug
icv) 48 hrs before perfusion with 4% paraformaldehyde,
and brains were immersed 24 hrs in 20% sucrose/3% PEG MW
400 before freezing in Cl2F2 Me (chilled in a liquid
nitrogen bath). Serial sections were cut at 1-2 u in a
-25° C cryostat. Sections were stained as previously
described at 1:400-1:800 (Weber and Barchas 1983) and
visualized with fluoroscein-labeled second antibodies.
Antisera were raised in our laboratory and characterized
previously: dynorphin A (Dyn A R2-4), Dyn A(1-8) (R2-2),
Dyn B (R2-4), alpha-neo-endorphin (a-NEp R2-4), leu-
enkephalin (L-Enk R1-3) and met-enkephalin-arg-gly-leu
(MERGL R2-2). In each case staining was blocked by pre-
incubation with 10-20 uM of the homologous peptide, but
not by the other peptides.
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Dyn B Dyn A Dyn A(1-8) a - NEp
Figure 1. Serial sections, nucleus of the anterior
commissure.
RESULTS AND DISCUSSION
We have previously colocalized oxytocin and Dyn B in the
nucleus of the anterior commissure (ACN; Quinn and Weber
1985.) As shown in figure 1, there was only weak stain-
ing in these cells for Dyn A, Dyn A(1-8), and a-NEp.
Blocking controls suggest relative C-terminal specificity
for these antisera. McGinty (1985) has reported cortical
neurons staining with Dyn B(R2-4); after pretreatment
with cholinesterase, other Dyn antisera produced staining
in her preparations (J. McGinty pers. comm.) Dyn B
(R2-4) may thus recognize its epitope in perikarya where
other Dyn products are uncleaved.
In the paraventricular nucleus (PVN), the four Dyn anti-
sera produced staining differing somewhat in intensity
but consistent across PVN magnocellular neurons for each
antiserum. In contrast, in the supraoptic nucleus (SON),
isolated groups of neurons had sharply reduced staining
for a-NEp, despite consistent staining with the other
antisera (figure 2.) The same weak/strong aNEp cells
could be followed on several adjacent sections, and this
finding was similar in all animals studied. This result
could reflect either differential processing of a-NEp
among SON neurons, or possibly, different absolute precur-
sor expression, to which this antisera may have been more
sensitive. In support of the former hypothesis, dilution
of Dyn A(1-8) antiserum to extinction (1:6400) never
produced a pattern similar to a-NEp (data not shown.)
a - NEp Dyn A(1-8) a - NEp
Figure 2. Serial sections, supraoptic nucleus
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Dyn A (1-8) Leu - Enk
Figure 3. Adjacent sections, supraoptic nucleus.
In the SON, isolated Dyn-positive neurons stained
brightly for Leu-Enk, against a background of other Dyn
neurons with no detectable Leu-Enk staining (figure 3);
the majority of SON Dyn occurs in vasopressin neurons
(Watson et al. 1982a; our obs.) Consistent with earlier
work (Weber et al. 1982a; Watson et al. 1982b; Williams
and Dockray 1983) we saw no MERGL staining in this study
in the SON. Production of Leu-Enk from Dyn has been
shown by RIA/lesion studies by Zamir et al. (1984.) We
saw only scattered Leu-Enk-positive neurons in this
nucleus, and in only about half of these colchicine-
treated animals. However, in noncolchicine-treated rats,
Martin and Voigt (1982) have reported a subset of Leu-Enk
positive terminals in the vasopressin fibers of the
neurohypophysis, while all vasopressin terminals were
Leu-Enk positive after trypsin pretreatment. Our results
further support a process for Leu-Enk production in a
specific subset of the vasopressin/dynorphin pathway.
Heterogeneity of neuropeptide expression in the magno-
cellular system has been documented several times. Oxy-
tocin neurons express CRF in the ACN, sometimes in the
PVN, and occasionally in the SON (Sawchenko et al. 1984.)
All ACN, but only rare SON oxytocin neurons contain Dyn
(Quinn and Weber 1985.) Interestingly, in the mapping of
several antisera to regions of the brainspecific precur-
sor 1B236 Bloom et al. (1985) reported similar staining
in almost all brain regions except the magnocellular sys-
tem, where only the C-terminal immunogen (P7) was reac-
tive; this finding resembles our observation for Dyn in
the ACN. McCabe et al. (1986) found evidence of SON sub-
groups with differential vasopressin mRNA response, eval-
uated in situ under dehydration stress. Opioid peptides
are thought of as co-transmitters with potential modula-
tory effects on terminals at sites of release (Pittman
et. al. 1983.) Possibly, the subgroups reported here
allow release of oxytocin/vasopressin with alternate com-
plements of opioids, if these subgroups have distinct
afferent pathways such as for norepinephrine (Sladek and
Zimmerman 1982.) Alternatively, these opioid subgroups
could reflect functional groups of oxytocin/vasopressin
neurons selectively colocalized with yet-undescribed
neuropeptides.
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CO-EXISTENCE OF PRODYNORPHIN - OPIOID PEPTIDES AND SUBSTANCE P IN
PRIMARY SENSORY AFFERENTS OF GUINEA-PIGS
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Dept. of Anatomy
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ABSTRACT
Light microscopic immunoenzymatic and immunofluorescence
histochemistry revealed co-existence of opiofd peptfdes with
substance P in primary sensory neurons of all segmental dorsal root
and trigainal ganglia of guinea-pig. Sensory opioid peptides
appeared to be exclusively processed from prodynorphin and include
[leu]enkephalin, neoendorphlns, and dynorphin A. We suggest the
presence of presynaptfc opfoid autoreceptors in prlmary sensory
afferences.
INTRODUCTION
It is a widespread concept that enkephalins in terminals of the
dorsal horn presynaptically inhibit the release of substance P (SP)
from spinal endings of primary sensory afferences although the
neuroanatomical evidence for such a synaptic circuitry is missing
(Basbaum and Fields 1984; Jessel 1983; Kosterlitz and NcKnight 1981).
It was concluded that there is no primary sensory origin of spinal
opfoid peptfdes (Botticelli et al. 1981; Vincent et al. 1984).
Contrary to this view are immunohistochemical investigations with
cultured mouse dorsal root ganglia demonstrating a few dynorphin-
immunoreactive (ir) ganglfonic cells (Sweetnam et al. 1982). Also in
neonatal rats very few enkephalfn ir small ganglfonic cells were
found (Senba et al. 1982). First morphological evidence for a general
opfofdergic primary sensory pathway in adult animals was obtained in
an immunohistochemical study with guinea-pigs (Weihe et al. 1985a).
Measurements by radioimmunoassay indicated the presence of low
amounts of ir dynorphin and ir -neoendorphin in human spinal ganglia
(Przewlocki 1983). The main focus of this study was to investigate
the posslble co-existence of opioid peptides, apparently exclusively
derived from prodynorphin (Weihe et al. 1985a), with substance P in
primary sensory afferences.
MATERIALS AND METHODS
Six male guinea-pigs of 200-250 g were deeply anaesthetized with
Nembutal (i.p.) and fixed by perfusing 500 ml Bouin's solution
retrogradcly through the distal abdominal aorta. Both trigeminal
ganglia, the entire spinal cord and the medulla, the segmental
cervical, thoracfc and lumbosacral ganglia, peripheral somatic
nerves, somatic (e.g. skin) and visceral (e.g. heart) tissues were
dehydrated in propan-2-ol, and embedded in paraplast. 4-6 µ thick
serial sections were Incubated with the primary antisera at room
temperature. Several rabbit polyclonal primary antisera directed
against a variety of proenkephrlin-opiofd peptides ([Met]enkephalin,
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heptapeptide, octapeptide, BAM 12P, metorphamide), against various
prodynorphin-opioid peptides i.e. dynorphln A (1-8), dynorphin A
(1-17), dynorphln B, /ß-neoendorphin, and against [Leu]enkephalin
were used as previously described (Weihe et al. 1985a). Additional
polyclonal antisera were against dynorphln A (1-179, -neoendorphin
(Millan et al. 19869, amidorphin (Seizinger et al. 19859. A
monoclonal antlbody against enkephalln which was found to stain the
pentapeptides non-differentially (Cuello et al. 19849 but not
dynorphln and neoendorphins or larger molecular forms of
proenkephalin- or prodynorphin-opiolid peptides was also used. SP was
immunoreacted with commercial monoclonal antlbody NCl/34HL.
Specifities of antisera were tested by preincubating them at 37°C for
2 hours or more with 100 nmol homologous or heterologous peptides per
ml working dilutions. Biotlnylated species-specific secondary
antisera and Streptavidin- peroxldase-complexes were used in 1:50
respectively 1:200 dilutions. The diaminobentidine reaction was as
described (Weihe et al. 1985a). Co-existence and co-distribution of
ir material was preferentially determined using paired consecutive
sections alternately stained immunoenzymatically with the antibody
against SP vs. the various antisera against different opioid
peptides. In order to assess co-ex istence on Identical sections the
monoclonal SP antlbody and the different polyclonal and monoclonal
antisera against opioid peptldes were applied slmultaneously and
visualized by consecutive immunofluorescence double-staining using
either Fluorescein-Streptavidin or Texas-Red-Streptavidin.
RESULTS AND DISCUSSION
Out of all opioid antisera Investigated that against [Leu]enkephalin
produced the strongest immunoreactions in numerous small and some
medium-sized dorsal root and trigeminal ganglionic cells and their
processes even In dilutions up to 1:80000. Our novel preabsorption
studies Indicated that It was less specific In immunohistochemistry
than it could be expected from previous radioimmunoassay data (Weber
et al. 19839. It crossreacted completely with C-terminal extenstons
of [Leu]enkephalin including the neoendorphfns and with dynorphln A
(1-13) and (1-17). There was less crossreaction with [Met]enkephalin,
the hepta- and the octapeptide. BAM 12 P had a lower blocking potency
than the shorter fragments. Contrary to the immunohistochemically
relatively unspecific [leu]enkephalin antiserum those against
dynorphln A (1-17) and -neoendorphln were highly specific and
neither crossreacted with proenkephalin peptides nor with
[Leu]enkephalin, dynorphln A (1-6), (1-7), (1-8), (1-13) but were
fully preabsorbed with low concentrations (1-10 nmol) of homologous
peptides. Equivocal results were obtained with higher molecular
weight forms containing the dynorphin A (1-179 or neoendorphin
sequences. In spite of the partial crossreactivity of the
[Leu]enkephalin antiserum with [Met]enkephalin containing
proenkephalin-sequencer we argue that the ir material In sensory
ganglia visualized with this antiserum does not appear to be
proenkephalln-derived because none of the numerous antisera against
proenkaphalin-peptides revealed ir material In sensory ganglia. Since
the monoclonal antibody against enkephalln was found to stain sensory
gangllonlc cells and fibers we conclude that the pentapeptlde
[Leu]enkephalin itself is processed which is in progress to be
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substantiated by other methods as used for the identification of
putative sensory opioid peptides in skin, heart and peripheral nerves
(Weihe et al. 1983; 1985a,b).
Out of the antisera against prodynorphin opioid peptides we selected
the most effective (against [leu]enkephalin, dynorphin A 1-17 and
-neoendorphin) for the evaluation of co-existence. Both, the
immunoenzymatic and the immunofluorescence detection demonstrated
co-existence of ir opioid peptides with ir SP in all segmental dorsal
root and trigeminal ganglia. It appeared that a major population of
small ganglionic cells which contained ir opioid peptides exhibited
also SP immunoreactivity. Opioid-antisera did not crossreact with SP
and the SP antibody was not preabsorbed with any of the opioid
peptides. There was a substantial population of non-opioid but SP ir
ganglionic cells. Preliminary morphometric data indicate that the
cell diameters of the non-opioid SP ir cells are large. Assessment of
the variations in the number of ir cells depending on the segmental
level of ganglia or even on a non-random distribution pattern within
individual ganglia (Price 1985) are needed for precise quantification
of opioidergic SP-ergic primary sensory neurons. The co-existence of
opioid- and SP-ir material in primary sensory ganglionic cells and
their juxtaperikaryal processes was paralleled by co-distribution in
small diameter fibers (C, A ) of dorsal horn, dorsal roots, Litsauer
tract, peripheral somatic and visceral nerves, and of vascular and
non-vascular nerves of many somatic (e.g. skin) and visceral (e.g.
heart) tissues. Preliminary data indicate that the ir opioid material
not unexpectedly was also co-existing with calcitonin gene related
peptide (CGRP), a recently identified co-transmitter candidate of SP
in primary sensory neurons (Skofitsch and Jacobowitz 19859. Further
co-existence patterns of opioid and non-opioid peptides can be
expected based on the current knowledge of the neurochemistry of
primary sensory neurons (Jessel 1983).
We suggest that the well known presynaptic opioid receptors on spinal
endings of primary sensory afferences are, at least in part,
autoreceptors and not heteroreceptors as generally believed.
Interestingly opioid receptors seem to be present also on perikarya
of sensory ganglionic cells (Ninkovic and Hunt 1985; Werz and
Macdonald 1984) which may be the target of opioidergic fibers
occasionally observed in this study surrounding non-opioidergic
sensory ganglionic cells. Primary sensory opioid peptides, to our
opinion, are exclusively processed from prodynorphin and include
[leu]enkephalin. All may inhibit the release of co-transmitters like
SP or other peptides (e.g. CGRP) or non-peptide substances not only
centrally but also peripherally (Dale's principle) by acting on
mainly kappa, but also some delta, presynaptic autoreceptors, and
perhaps, also on postsynaptic heteroreceptors. Experimental evidence
for opioid receptors being functionally important in mechanisms of
reflex vasodilation and extravasation has been obtained recently
(Smith and Buchan 1984). The main function of primary sensory
prodynorphin opioid peptides (Weihe 1985; Weihe et al. 1985a) may be
antinociceptive as suggested for spinal segmental or
ascending/descending opioid systems (Cruz and Basbaua 1985; Han and
Xie 1984; Herman and Goldstein 1984; Jessel 1983; Kosterlitz and
McKnight 1981; Millan et al. 1986). It will be interesting to see
whether there are also trophic functions of sensory opioid peptides.
297
REFERENCES
Basbaum, A.I., and Fields, H.L. Ann Rev NeurosciI 7:309-38, 1984.
Botticelli, L.J., Cox, B.M., and Goldstein, A. Proc Natl Acad Sci,
78(12):7783-7786, 1981.
Cruz, L., and Basbaum, A.I., J Co Neural 240:331-348, 1985.
Cuello, A.C., Milstein, C., Couture, R., Wright, B., Priestley, J.V.,
and Jarvis J. J Histochem Cytochem, 32(9):947-957, 1984.
Han, J., and Xie, G., Pain, 18:367-376, 1984.
Herman, B.H., and Goldstein, A. J Pharmacol Exp Therapeutics,
232(1):27-32, 1984.
Jessell, T.M. In: Krüger, D.T., Brownstein, M.J., and Martin, J.B.
eds. Brain Pe tides. J. Wiley & Sons, NY., Chichester, Brisbane,
1983. pp 316-331.
Kosterlitz, H.W., and McKnight, A.T. In: Autrum, H., Ottoson, D.,
Perl, E.R., and Schmidt, R.F., ed. Progress in Sensory Physiology,
Springer Berlin-Heidelberg, 1981. pp. 31-95
Millan, M.J., Millan, M.H., Czlonkowski, A., Höllt, V., Pilcher,
C.W.T., Herz, A. and Colpaert, F.C. J Neurosci, 6(4):899-906, 1986.
Ninkovic, M., Hunt, S.P. Neurosci Lett, 53:133-237, 1985.
Price, J. J Neurosci, 5(8):2051-2059, 1985.
Przewlocki, R., Gramsch, C., Pasi, A., and Herz, A. Brain Res,
280:95-103, 1983.
Seiringer, B.R., Liebisch, D.C., Gramsch, C., Herz, A., Weber, E.,
Evans, C.J., Esch, F.S., Böhlen P. Nature, 313(5997):57-59, 1985.
Senba, E., Shfosaka, S., Hara, Y., Inagaki, S., Sakanaka, M.,
Takatsuki, K., Kawai, Y., and Tohyatna, M. J Comp Neurol, 208~54-66,
1982.
Skofitsch, G., and Jacobowitz, D.M. Peptides, 6:747-754, 1985.
Smith, T.W., and Buchan, P. Neuropeptides, 5:217-220
Sweetnam, P.M., Neale, J.H., Barker, J.L., and Goldstein A. Proc Natl
Acad Sci USA, 79:6742-6746, 1982
Vincent, S.R., Dalsgaard, C.-J., Schultzberg, M., Hökfelt, T.,
Christensson, I., Terenius L. Neurosci, 11(4):973-987, 1984.
Weber, E., Evans, C.J., Barchas, J.D. TINS August 1983, 333-336.
Weihe, E. Neurosci Lett, Suppl 22: p5, 1985.
Weihe, E., McKnight, A.T., Corbett, A.D., Hartschuh, W., Reinecke, M.,
and Kosterlitz, H.W. Life Sci 33(1):711-714, 1983
Weihe, E., Hartshuh,W., and Weber, E. Neurosci Lett, 58:347-352,
1985a.
Weihe, E., McKnight, A.T., Corbett, A.D., and Kosterlitz, H.W.
Neuropeptides,   5:453-456, 1985b.
Werz, M.A., and Macdonald, R.L. Neuropeptides, 5:253-256, 1984.
ACKNOWLEDGEMENTS
For the donation of antisera we would like to thank E. Weber, Oregon
(antisera against [leu]enkephalin, -neoendorphin, heptapeptide,
octapeptide, BAM 12P, metorphamide); A. Goldstein, Stanford (antisera
against dynorphin A and B); A. Herz and co-workers C. Gramsch, B.
Seiringer and D.C. Liebisch, Munich (antisera against /&neo-
endorphin, dynorphin A 1-17, heptapeptide). Immunochemical reagents
were from Amersham. Peptides from Peninsula, CRB and Bachem,
commercial antisera from Serotec, Seralab, Immunonuclear, CRB. The
study was supported by "Stifterverband der Deutschen Wissenschaft",
"Freunde der Universität Mainz", and Schering AG, Berlin.
298
DISTRIBUTION OF ENKEPHALIN-LIKE IMMUNOREACTIVITY IN THE FELINE HEART;
ITS INTERRELATION WITH SUBSTANCE P- AND
VASOACTIVE INTESTINAL POLYPEPTIDE-LIKE
IMMUNOREACTIVE NERVE FIBERS
Sadaaki Maeda, Junji Nakamae, Hiroyuki Ichikawa*,
Satoshi Wakisaka*, Michio Akai* and Reizo Inoki
Department of Pharmacology and Oral Anatomy I*,
Osaka University Faculty of Dentistry,
1-8, Yamadaoka, Suita, Osaka, 565 JAPAN.
ABSTRACT
Distribution of enkephalin (Enk)-like immunoreactivity in the feline
heart was investigated by indirect immunofluorescence method. Enk-like
immunoreactive (Enk-IR) nerve fibers and cells predominated in the
atria but were rare in the ventricles. Enk-IR cells were mainly
distributed near sinoatrial (SA) node and between aorta and pulmonary
artery. These cells were usually grouped in clusters near blood
vessels or cardiac ganglia. Some Enk-IR cells appeared to extend their
processes to other Enk-IR cells, cardiac ganglia, blood vessels and
rarely cardiac muscles in the atria. Furthermore, substance P (SP)-
and vasoactive intestinal polypeptide (VIP)-IR nerve fibers were
closely associated with some Enk-IR cells. Moreover, the distribution
and morphological profiles of Enk-IR cells were very similar to those
of catecholamine (CA)-containing cells.
INTRODUCTION
Recent radioimmunological and immunohistochemical studies have
revealed the wide, but uneven distribution of several neuropeptides in
the central and peripheral nervous system. In the heart, the
occurrences of neuropeptides were reported by several investigators
using radioimmunoassay or immunohistochemical method. Biochemical
studies of Lang et al. (1983) detected the existence of methionine
(Met)- and leucine (Leu)-Enk-like immunoreactivity in guinea pig
heart. Weihe et al. (1983) characterized opioid peptides in guinea pig
heart. Lundberg et al. (1983) reported that Enk-IR nerve fibers were
localized in vagal nerve. Little is known, however, on the detailed
distribution of Enk-like immunoreactivity in the heart. In this study,
we elucidated the distribution of Enk-like immunoreactivity in the
feline heart and examined the interrelation between Enk-IR cells and
SP- or VIP-IR nerve fibers. Furthermore, we presented the possible
coexistence of Enk and CA in the heart.
MATERIALS AND METHODS
Immunohistochemistry: Young cats, weighing 2.5-3.0 kg, were used in
this study. Animals were anesthetized and perfused through the left
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cardiac ventricle with ice-cold Zamboni fixative. Whole heart was
carefully removed, separated cardiac atria under dissecting microscope
and stored in the same fixative at 4°C overnight. Specimens were then
frozen in isopentane cooled by the liquid nitrogen and serial frozen
sections were cut at the thickness of 20-30 um with a cryostat.
Indirect immunofluorescence method was applied to the sections.
Sections were first incubated either with rabbit anti Met-Enk serum
Ucb, diluted 1:1600), rabbit anti Leu-Enk serum (Ucb, 1:1600),
monoclonal rat anti SP serum (Sera Lab, 1;1000) or rabbit anti VIP
serum (INC, 1:1000) at room temperature overnight in a humid
atomosphere. After rinsing several times, sections were then incubated
in FITC-conjugated anti rabbit IgG (Miles, 1:1000), or FITC-conjugated
anti rat IgG (Cappel, 1:1000) for 60 min at 37°C. For double
immunostaining of Enk and SP, sections were first incubated with the
mixture of rabbit anti Enk serum (final dilution 1:1600) and rat
monoclonal anti SP serum (final dilution 1:1000) at room temperature
overnight, rinsed several times and then incubated with the mixture of
RITC-conjugated anti rabbit IgG (Cappel, final dilution 1:1000) and
FITC-conjugated anti rat IgG (final dilution 1:1000). Sections were
viewed with fluorescence microscope using appropriate exciting filter.
After photography, sections were stained with hematoxylen-eosin to
determine the structure of the tissue.
Catecholamine histochemistry: For demonstration of CA, glyoxylic acid-
induced fluorescence method of Imai et al. (1982) was applied. Cats
were killed by bleeding and hearts were removed immediately. Cardiac
atria were cut into small pieces and fixed in FA-GLU-PA-GA-S solution
(4% paraformaldehyde, 0.5% glutaraldehyde, 0.2% picric acid, 2%
glyoxylic acid and 15% sucrose in 0.1M phosphate buffer, pH 7.3) for 2
hours at 4°C. The specimens were then frozen and cut at the thickness
of 20- 30 um with a cryostat. Sections were immersed in FA-GA-S
solution (4% paraformaldehyde, 2% glyoxylic acid and 15% sucrose in
0.1M phosphate buffer, pH 7.3), air-dried for 60 min at 45°C, sealed
with xylene and viewed with fluorescence microscope.
RESULTS
As the distribution of Met-Enk-IR and Leu-Enk-IR structures was very
similar, we simply described as "Enk-IR." Enk-IR structures
predominated in the atria but were rare in the ventricles. In the
atria, many Enk-IR cells were localized near SA node and between aorta
and pulmonary artery. Enk-IR cells were also distributed between
coronary sinus and pulmonary vein and near inferior vena cava. Several
thin Enk-IR nerve fibers with varicosities were observed in the atria1
muscles (fig. 1), along the blood vessels and near the ganglionic
cells. Enk-IR cells were distributed in clusters or, in some cases, in
single cells. Many Enk-IR cells were localized at the walls of small
blood vessels (fig. 2) and near the ganglia (fig. 3). Some Enk-IR
cells were observed to extend their processes toward other Enk-IR
cells, blood vessels, ganglionic cells and rarely cardiac muscles.
Double immunostaining sections revealed that many SP-IR nerve fibers
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FIGURES. 1-3: Immunofluorescence micrographs of Enk-like
immunoreactivity.
FIGURE 1: Thin varicose Met-Enk-IR nerve fibers are
observed in the atria1 muscles (M) near SA node.
FIGURE 2: Several Leu-Enk-IR cells are localized at the
walls of small blood vessels (BV) between aorta and
pulmonary artery. FIGURE 3: Met-Enk-IR cells are present
over the ganglion near SA node.
FIGURE 4: Histofluorescence micrograph between aorta and
pulmonary artery. Several CA-containing cells are observed
near the blood vessels. Some CA-containing cells extend
their processes.
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with varicosities were observed around the Enk-IR cells. Adjacent
sections incubated with anti VIP serum showed that many varicose VIP-
IR nerve fibers formed dense network over the Enk-IR cells. The
distribution and morphological profiles of CA-containing cells were
very similar to those of Enk-IR cells (fig. 4). Moreover, CA-
containing nerve fibers were observed in close association with some
CA-containing cells.
DISCUSSION
Our study demonstrated the detailed distribution of Enk-IR structures
in the feline heart. Enk-IR nerve fibers with varicosities were
present in cardiac muscles, at the walls of blood vessels and near the
ganglionic cells. Some Enk-IR cells were observed to extend their
processes to the ganglionic cells, blood vessels and rarely cardiac
muscles. These findings suggest that Enk may directly control the
cardiac functions. Recently Laurent et al; (1985) reported that Enk
had a direct positive inotropic effect on cultured cardiac myocytes.
Our present findings support their results. Moreover, our immuno-
histochemical evidences that SP- and VIP-IR nerve fibers were closely
associated with Enk-IR cells suggest that SP and VIP may regulate the
effects of Enk in the heart. It was reported that Enk coexisted with
CA in the chromaffin cells of adrenal gland and Enk might regulate the
release of CA from the chromaffin cells. Although the coexistence of
Enk and CA was not investigated in this study, it was shown that the
distribution and morphological profiles of CA-containing cells were
very similar to those of Enk-IR cells. Thus, our observation suggests
that in the heart Enk-IR cells may also contain CA and regulate the
release of CA.
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ABSTRACT
A predominantly microvascular localization of aminopeptidase M (APM)
was established both by immunohistochemistry and biochemical studies
of isolated microvessels. In addition a high relative specific
activity of APM was evidenced in fractions enriched in synaptic
membranes.
INTRODUCTION
APM (EC 3.4.11.2) which is sensitive to bestatin but relatively
insensitive to puromycin has recently been identified in rat cere-
bral membranes (Schwartz et al. 1984 ; Gros et al. 1985). Its major
role in the inactivation of endogenous enkephalins released from
brain slices was demonstrated by the protecting effects of several
inhibitors including antibodies directed against the active site of
APM (Giros et al. 1986). Since the KM values of enkephalins for APM
and another cerebral aminopeptidase more sensitive to puromycin do
not greatly differ, the preferential role of APM is likely to re-
flect topological rather than catalytic differences. We have there-
fore studied the localisation of APM in rat brain by immunohisto-
chemical and subcellular fractionation methods.
MATERIAIS AND METHODS
Polyclonal antibodies (Ab) directed against an homogeneous prepara-
tion of rat kidney APM were obtained in rabbits (Gros et al. 1985).
Monoclonal Ab against "enkephalinase" (EC 3.4.24.11) were obtained
after injecting to mice a preparation of rat kidney brush borders.
The recognition of "enkephalinase" was assessed by immunoprecipita-
tion of the enzyme activity (in preparation).
Immunolocalizations were established by incubating unfixed frontal
sections of rat brain (or isolated microvessels) with either polyclo-
nal anti APM Ab followed by antirabbit immunoglobulins (labelled
with [125I] or peroxidase) or [125I] monoclonal anti-enkephelinase Ab.
Subcellular fractions were prepared and named according to Gray and
Whittaker (1962).
Aminopeptidase activity was measured using 40 nM [3H] (Met5)enkepha-
lin as substrate. Incubations were for 10 min at 37°C in the presence
of 1 µM Thiorphan and 20 µM puromycin, [3H]Tyr being isolated by
polystyrene bead column chromatography. APM activity was evaluated as
the difference between values obtained in the presence and absence of
APM antibodies.
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RESULTS AND DISCUSSION
Immunostaining of rat brain sections (figure 1) indicates a rather
uniform localization of APM within the brain parenchyma which con-
trasts with the highly heterogeneous localization of enkephalinase,
the other major enkephalin-degrading peptidase.
In agreement, assay of APM activity in homogenates from several brain
regions revealed a rather uniform distribution of the enzyme activity
which represented approximately 1 % of the total aminopeptidase
activity (not shown).
FIGURE 1: Autoradiography of APM (upper picture) and enkepha-
linase (lower pictures) immunoreactivities in frontaI sections
of rat brain.
The [125I] Labelled enkephalinase Ab was obtained as described
(H. POllard, P. Ronco, P. Verroust and J-C. Schwartz
-
submitted).
am : amygdala ; Cg : cingulate cortex ; Ch : choroid plexus ;
cp : caudate putamen ; GP : globus pallidus ; hip :
hippocampus ; SN : subtantia nigra
304
However a strong APM immunoreactivity was detected in the walls of
vessels in all studied cerebral areas as well as within choroid
plexuses such as those of the lateral ventricles (figures 1 and 2).
FIGURE 2: Immunoperoxidase staining of APM in a frontal
section of rat brain (left) and in isolated microvessels
(right).
Ch : choroid plexus ; v : vessel
The microvascular localisation of APM was confirmed after isolation
of cortical microvessels by a sieving procedure. On this relatively
pure fraction a dense immunostaining of all vascular elements was
observed (figure 2). After solubilization of the isolated micro-
vessels with Triton X-ICC, APM activity was clearly identified by
establishing the potencies of various inhibitors.
APM antibodies inhibited about 80 % of the eminopeptidase activity of
this fraction at a dilution (1/50,000) similar to that required to
inhibit purified APM. Also the IC50 values of bestatin (2 µM), amas-
tatin (5 µM) and puromycin (78 µM) were similar on the two
preparations.
This major microvascular localization of APM suggests that the
enzyme may participate in the inactivation of neuropeptides regula-
ting the permeability and tone of cerebral vessels. Together with its
presence in choroid plexuses, it also suggests that it participates
in the enzymatic "blood-brain barrier" which prevents the access of
circulating regulatory peptides into the CSF and brain extracellular
fluids.
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FIGURE 3: Subcellular distribution of APM into fractions from
rat cerebral cortex.
Fractions were obtained after two different density gradient
centrifugatiohs end designated according to Gray and Whittaker
(1962). The relative specific activity (RSA) is the ratio
percent of enzyme activity over percent of recovered proteins.
In primary subcellular fractions from cortical homogenates, a major
portion (78 %) of APM was found to sediment with the heavy P1 frac-
tion containing microvessels whereas 7 % and 10 % sedimented with
the P2 and P3 fractions respectively and no significant APM activity
would be detected in soluble form. However upon density gradient
analysis of the shocked synaptosomal fraction a clear enrichment (by
about 5-fold as compared to the homogenate) was found in those
subfractions containing synaptic membranes (figure 3). However it
is difficult to exclude a contamination of these fractions by ele-
ments of the predominant vascular pool in brain.
In conclusion this study indicates a dual localization of APM in
rat brain. The synaptic localization would be more consistent than
the microvascular one with the major participation of APM in neuronal
enkephalin inactivation.
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ABSTRACT
The content and extent of processing of gamma-3-MSH and B-endorphin
were determined in the anterior (AL) and intermediate (IL) lobes of
three monkey pituitaries. The peptides existed in equimolar amounts
in each lobe. The processing of gamma-3-MSH paralleled that of
B-endorphin in each lobe; the primary products in AL were
B-lipotropin and a 9K form of gamma MSH, whereas in IL the
predominant products were N-acetyl-B-endorphin and gamma-3-MSH.
INRODUCTION
Gamma-3-melanocyte stimulating hormone (MSH) is a 27-residue peptide
found in the N-terminal region of proopiomelanocortin (POMC),
containing the MSH core sequence His-Phe-Arg-Trp (Nakanishi et al.
1979). There are two major cleavage sites in the N-terminal domain
of POMC, which potentially generate the extreme N-terminal peptide,
gamma-3-MSH, and joining peptide, which is the segment found between
gamma MSH and ACTH. Gamma-3-MSH thus can be found associated with
joining peptide (molecular weight 8-10K, depending on the extent of
glycosylation), the N-terminal fragment of POMC (molecular weight
10-12K), or alone (molecular weight 3-4K). Bovine and human (but not
rat) gamma-3 MSH have an additional cleavage site that potentially
generates the C-amidated II-residue peptide, gamma-1-MSH (Ling et al.
1979).
Gamma-3-MSH has been shown to exist in several forms in bovine
(Tanaka et al. 1980; Shibasaki et al. 1980a, 1980b) and rat (Pedersen
et al. 1982) AL and IL, as well as being present in whole human
pituitary extract (Tanaka et al. 1980). To date, however, the nature
of gamma-3-MSH in monkey pituitary has not been studied. In the
present investigation we examined the content and degree of
processing of gamma-3-MSH in monkey AL and IL, and compared these to
the corresponding parameters for B-endorphin.
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MATERIALS AND METHODS
Pituitaries
Three post-menopausal Rhesus monkeys (Macaca mulatta) were
anesthetized and sacrificed. The pituitaries were immediately
removed, placed on wet ice, and dissected into the AL and the IL.
The IL was trimmed as closely as possible, but due to the anatomy of
monkey pituitary, a clear separation between anterior/posterior and
intermediate pituitary was not feasible, hence the IL had
contaminating fragments of both anterior and posterior lobes. After
dissection, the pituitaries were frozen on dry ice and stored at
-70°C.
Extraction
The peptides were extracted from the pituitaries into acetone/0.1N
HCl (3:1). The extract was dried by lyophilization, and the residue
resuspended in 1.0% formic acid. For column chromatography, the
formic acid extract was used. For radioimmunoassay, aliquots of
formic acid extracts were dried and resuspended in the appropriate
assay buffer.
Radioimmunoassays
human B-MSH, human B-endorphin, and ACTH, <10-6.
B-endorphin and N-acetylated B-endorphin were assayed by previously
established radioimmunoassays (Cahill et al. 1983a, Akil et al.
1981a). Gamma-3-MSH was measured using an assay recently developed.
Samples were diluted in a 50 mM sodium phosphate buffer, pH 7.6
containing 0.12M NaCl, 0.004M EDTA, 0.016% NaN3, 1.6% normal rabbit
serum, and 0.1% polylysine. The assay was run at disequilibrium
conditions for 72 hours at 4°C; the antiserum, raised in rabbits
using synthetic bovine gamma-3-MSH conjugated to bovine serum albumin
with bis-diazatized benzidine as an antigen, was used at a final
dilution of 1/25000. The radioactive trace was human gamma-3-MSH,
iodinated by the chloramine T method (Hunter and Greenwood, 1962).
Separation of free from bound material was by the second antibody
method, using sheep-anti-rabbit gamma-globulin. This assay has an
intrassay CV of 9.2%, and an interassay CV of 5.0%. It has a useable
range of 6-300 fmoles/tube, with an IC of 40 fmoles/tube. On a
molar basis, its crossreactivity profile is: gamma-3-MSH = 1;
Lys-gamma-1-MSH, <10-3; gamma-1-MSH and gamma-2-MSH, <10-4; a-MSH,
Column Chromatography
Samples were applied to a sephadex G-50 column (1.5 x 90 cm) that had
been precalibrated with molecular weight standards. Aliquots of each
fraction were dried, resuspended in the appropriate buffer, and
assayed for B-endorphin and gamma-3-MSH immunoreactivity. The
fractions with immunoreactivity in the void volume of this column
were pooled, and rechromotagraphed on a sephadex G-100 column (1.5 x
90 cm) to separate larger-sized fragments. The percentage of the
total immunoreactivity found in each peak was calculated for each
peptide.
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RESULTS AND DISCUSSION
As shown in table 1, the immunoreactive gamma-3-MSH and B-endorphin
concentrations were not significantly different fcr each pituitary
lobe. In addition, much of the B-endorphin immunoreactivity in
intermediate lobe was N-acetylated, whereas very little was in
anterior lobe, similar to previous findings in rat pituitary (Akil et
al. 1981b).
TABLE 1. Gamma-3-MSH and B-endorphin Content of Monkey
Pituitary Lobes
Lobe Peptide Content (pmoles/mg tissue)
gamma-3-MSH B-endorphin N-acetyl-B-endorphin
anterior 120 33 91 26 5 3
intermediate 69 20 98 46 6 2 52
The size distribution for B-endorphin and gamma-3-MSH
immunoreactivity in each lobe are shown in table 2.
TABLE 2. Percent of Total B-endorphin and gamma-3-MSH Found In
Each Peak
PEAK
(3-5K)
II III
(9-11K) (15-20K) (Void)
Anterior lobe
gamma-3-MSH 22 10% 60 7% 18 3 % 1 1%
B-endorphin 37 15% 54 17% 3 % 1 1%8
Intermediate lobe
gamma-3-MSH 48 12% 35 6% 16 11% l l%
B-endorphin 65 15% 29 14% 5 3 % 2 1 %
Peak I corresponds to 3-5 kdaltons, representing B-endorphin or
gamma-3-MSH. Peak II is 9-11 kdaltons, and contains B-lipotropin or
(tentatively) glycosylated gamma-3-MSH plus joining peptide. Peak
III is 15-20 kdaltons, and in the case of gamma-3-MSH
immunoreactivity probably represents the entire 16K N-terminal POMC
fragment; the remaining 15K C-terminal piece may be the peak measured
by the B-endorphin assay. Peak IV is the void volume of the G-100
column, presumably representing intact POMC. The processing for each
peptide is quite similar, with a tendency toward the presence of
smaller fragments in both lobes. The AL manifests predominately
B-lipotropin-sized material when B-endorphin-immunoreactivity is
measured, although a significant portion of the immunoreactivity is
B-Endorphin-sized, as has been previously reported (Cahill et al.
1983b). Gamma-3-MSH-immunoreactivity in AL is found in a similar
sized fraction which is tentatively gamma-3-MSH extended with joining
peptide. The IL shows a pattern of smaller, more processed material
309
(B-endorphin or gamma-3-MSH-sized), and the B-endorphin is
N-acetylated.
These findings are in agreement with previous studies on lower
animals. Pedersen et al. (1982) demonstrated that gamma-3-MSH exists
in 6K and 11K forms in rat AL and IL; the smaller form predominates
in IL, whereas the larger form is more predominant in AL. Similar
findings were reported by Shibasaki et al. (1980a) from their studies
on bovine AL and IL. Fractions of 15K, 8K, and 4.5K daltons have
been shown to have gamma-3-MSH immunoreactivity in bovine whole
pituitary, but in humans the predominant form of gamma-3-MSH
immunoreactivity is 9K daltons (Tanaka et al. 1980). The presence of
gamma-3-MSH immunoreactivity in 16K, 9K, and 4K fractions observed in
monkey pituitary is consistent with these previous reports in other
species.
In summary, we have shown that gamma-3-MSH immunoreactivity is
detectable in monkey AL and IL, is present in equimolar amounts with
B-endorphin, and is processed into primarily 4K and 9K fragments,
paralleling the processing of B-endorphin. The smaller fragment
predominates in IL, while the 9K fraction is the primary product in
AL, similar to the way B-endorphin is handled by the pituitary lobes.
We are currently developing an assay for gamma-1-MSH to determine if
gamma-MSH in monkey pituitary is processed to this smaller form.
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ABSTRACT
This study examines the multiple opioid receptor subtypes present in
the pituitary-adrenal axis of several species using in vitro
autoradiography. The monkey neural lobe was found to contain all
three subtypes with a preponderance of kappa sites, while the rat and
bovine neurohypophyses contained only kappa sites. In the adrenal,
opioid receptor sites were found exclusively in the medulla and
varied with species. Monkey adrenal contained predominantly delta
sites with a relatively small number of kappa sites present, while
bovine adrenal medulla had predominantly kappa sites and only a
relatively small proportion of delta receptor sites. No specific
opioid receptor binding could be detected in the rat adrenal. These
results emphasize the importance of species-differences in
understanding the role of opioids in neuroendocrine regulation.
INTRODUCTION
Several lines of evidence suggest that the endogenous opioid systems
may modulate the release of pituitary hormones. Acute administration
of mu opiates, for instance, has been reported to increase the
release of ACTH, growth hormone, and prolactin while decreasing the
release of luetinizing hormone and thyroid stimulating hormone
(Martin et al. 1975, Bruni et al. 1977, Cicero et al. 1977). Kappa
agonists, on the other hand, have been reported to antagonize the
antidiuretic action of vasopressin (Leander, 1983) and modulate the
release of oxytocin (Bicknell et al. 1985, Samson et al. 1985).
While the neuroendocrine effects of the endogenous opioids are well
established, the opioid receptor subtypes mediating these actions and
their anatomical localization is not clear. To clarify this issue
futher, this study has examined the opioid receptor subtypes found in
the pituitary-adrenal axis across several species using in vitro
receptor autoradiography.
MATERIALS AND METHODS
Pituitaries and adrenals of rats, monkeys, and cows were frozen,
sectioned on a Bright cryostat (25 um) and thaw-mounted on precleaned
and subbed microscope slides. The tissue sections were then dried
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overnight at 4°C under reduced pressure in a glass desiccator and
stored in a -80°C freezer. Immediately prior to using the tissue,
the slide-mounted sections were gradually brought up to room
temperature and incubated with various opioid ligands in 50 mM Tris
buffer (pH 7.5 at 25°C). The tritiated opioids used were DAGO
(Tyr-D-Ala-Gly-MePhe-Gly-ol, 57.5 Ci/mmol 20.0 - 0.6 nM) to label mu
sites, DPDPE (D-Pen2, D-Pen5-enkephalin, 29 Ci/mmol, 30.0-0.9 nM) to
label delta sites, and (-)bremazocine (41.4 Ci/mmol, 10.0 - 0.3 nM)
to label kappa sites. As bremazocine does not selectively bind to
kappa receptors, all [3H]bremazocine binding was conducted in the
presence of IGO nM DAGO and DPDPE in order to block the mu and delta
sites. The slides were incubated for 60 minutes, drained, and washed
in four consecutive 250 ml, 50 mM Tris washes (pH 7.6, 4°C). Slides
incubated with [3H]DAG0 and [3H]DPDPE were given four 30 second
washes, while those incubated with [3H]bremazocine were given four 4
minute washes. Following the Tris washes, all slides were rinsed (2
seconds) in a 250 ml wash of distilled water (4°C) and quickly dried
with a portable hair dryer set to cool. Nonspecific binding was
evaluated by treating a parallel set of slides with the same
concentration of [3H]ligand with a 1 uM final concentration of
unlabelled competitor: levorphanol to displace [3H]DAG0, DSLET
(Tyr-D-Ser-Gly-Phe-Leu-Thr) to displace [3H]DPDPE, and UM 1071 (MR
2034) to displace [3H]bremazocine. Slides were then arranged in
X-ray cassettes and apposed to tritium-sensitive LKB Ultrofilm for
179 days.
RESULTS AND DISCUSSION
Marked species differences were observed in the distribution of the
opioid receptor subtypes in the pituitary and adrenal. In the
pituitary, opioid receptor binding was found only in the neural lobe,
but the subtypes present varied with species (table 1).
TABLE 1. MULTIPLE OPIOID RECEPTOR SUBTYPES IN PITUITARY AND
A D R E N A L
I. Pituitary (Neural Lobe)
Rat Monkey Bovine
Kappa ++ +++ +++
M u --- + ---
Delta --- ++ ---
II. Adrenal
Kappa --- + +++
M u --- --- +
Delta --- +++ +
(+++ = dense, ++ = moderate, and + = light labelling)
Rat Monkey Bovine
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More specifically, the monkey neurohypophysis contained all three
opioid receptor subtypes with a preponderance of kappa sites, while
the rat and bovine pituitaries contained only kappa receptor sites.
The lack of opioid receptors in the anterior lobe would suggest that
the endogenous opioids do not act directly on the pituitary to
moderate hormonal release, but most likely have their effects on the
hypothalamus itself. While debate in the literature has centered
around whether the opioid receptors present in the neural lobe are on
pituicytes (Lightman et al. 1983, Bunn et al. 1985) or nerve
terminals (Falke and Martin 1985), their localization within the
neurohypophysis provides an anatomical basis for the modulation of
neural lobe hormones, such as, vasopressin and oxytocin.
In the adrenal gland, both kappa and delta receptors were observed in
the monkey and bovine medulla (table 1). The animals differed,
however, in the relative proportions of these sites in the medulla.
In the bovine adrenal, kappa sites were prominent with a relatively
small proportion of mu and delta sites present, while in the monkey,
delta sites were predominant, with a small proportion of kappa sites
present. In contrast, no opioid receptor binding was observed in the
rat adrenal owing, most likely, to the relative paucity of opioid
receptor sites in this tissue. Illustrative examples of opioid
receptor autoradiography in the monkey pituitary and adrenal are
present below in figure 1.
FIGURE 1. Darkfield autoradiograms of opioid receptors in the
monkey pituitary (A) and adrenal (B). Note the labelling of
kappa sites in the neural lobe of the pituitary and the delta
sites in the adrenal medulla. Abbreviations include AL =
anterior lobe, Ctx = cortex, Med = medulla and NL = neural
lobe.
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These results emphasize the importance of considering
species-differences in understanding the role of opioid receptors in
neuroendocrine regulation. In the adrenal, for instance, where the
predominant receptor subtype varies with species, different opioid
receptor subtypes may serve the same function in different animals.
If catecholamine (CA) release is the functional endpoint, kappa
receptors may be important in modulating CA release in bovine adrenal
medulla (Dumont and Lemaire 1985), while delta receptors may mediate
these actions in the monkey adrenal.
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ABSTRACT
The selective µ and ligands [3H]DAGO and [3H]DPDPE have been used
to investigate the distribution of specific opioid subtypes in the
rat small intestine by in vitro autoradiography. There was a
greater density of [3H]DPDPE binding at regions of the villi and
crypts than [3H]DAGO binding. These results suggest that the opioid
receptors located in these regions are predominantly of the
subtype.
INTRODUCTION
It has been suggested that opioid peptides are important in
regulating the transport of water and electrolytes across the rat
small intestine (Warhurst et al. 1983). Recently, using in vitro
autoradiography, we have demonstrated dense [3H]naloxone and [3H]
dihydromorphine binding in proximal and distal regions of the rat
small intestine (Dashwood et al. 1985). In the present autoradio-
graphic study we have used [3H]DAG0 and [3H]DPDPE in order to
determine which opioid receptor subtype is most prominent in the
villi and crypt regions of the small intestine of the rat.
MATERIALS AND METHODS
Radioligand binding studies
Sprague Dawley rats (male, 150-200 g) were obtained from Charles
River. All radiolabelled ligands were obtained from Amersham.
DAGO, (D-Ala2-Mephe4-Glyol5)-enkephalin and DPDPE, (D-Peu2,D-Peu5)-
enkephalin were obtained from Cambridge Research Biochemicals (UK).
Rats were stunned and decapitated and the whole brain, minus
cerebellum, was removed. Tissue was homogenised (Polytron Setting
5, 20 sec) in 50 vols Tris-HCl buffer (50 mM pH 7.7 at 25°C) and
centrifuged for 20 min at 40,000 g. The resultant pellet was
resuspended in 100 vols Tris buffer, incubated at 37°C for 45 min
and centrifuged. The final pellet was suspended in 100 vols Tris
buffer and used immediately. The membrane suspension was incubated
for 45 min at 25°C in the presence of [3H]ligand and either drug or
buffer. The reaction was terminated by filtration under reduced
pressure through Whatman GF/B filters and washed with buffer.
Specific binding was that component displaced by 10 µM diprenor-
phine. Displacement data were analysed using the ALLFIT computer
programme (DeLean et al. 1978). Saturation data were analysed using
the Ligand programme (Munson and Rodbard, 1980).
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In vitro autoradiography
Serial 20 µM longitudinal frozen sections of the rat proximal small
intestine were taken and thaw mounted onto gelatinised microscope
slides. These sections were then incubated in 4 nM [3H]naloxone,
[3H]DPDPE and [3H]DAGO (Amersham). Alternate sections were
incubated in the presence of 1 µM unlabelled naloxone in order to
determine the degree of binding to non-specific sites. The
incubation conditions used were those described by Gillan and
Kosterlitz (1982). After washing in buffer and drying, the sections
were placed in 24 x 30 cm X-ray cassettes and apposed to LKB [3H]
Ultrofilm for 4-6 weeks at 4°C. Tritium standard scales (American
Radiolabelled Chemicals Inc.) were included in each cassette. At
the end of the exposure period the film was processed and areas of
high [3H]ligand binding were evident as accumulation of silver
grains on the film. Photographs of autoradiographs were taken
where appropriate and preliminary densitometric measurements were
carried out on a Cambridge Quantimet 970 image analysis system.
RESULTS
Radioligand binding studies
Saturation analysis of [3H]opioid binding revealed that both DAGO
and DPDPE bound to one class of site with KDS of 1.7 0.5 (n=4) and
1.6 0.6 (n=0.4) nM respectively. Unlabelled DPDPE was a potent
and selective inhibitor of [3H]DPDPE. Whereas, as expected, DAGO
potently and selectively interacted with the [3H]DAGO binding site.
Naloxone interacted with both sites but with some selectivity for
the [3H]DAGO binding site. Data on the selective antagonist ICI
174,864 is shown for comparison (Table 1). Thus, it can be
concluded that, under the conditions used in the autoradiographic
studies, DPDPE will label exclusively sites whereas DAGO will
label exclusively µ sites. Naloxone, at the concentration used,
although labelling a mixture of µ and sites will interact
primarily with the µ population.
µ site = [3H]DAGO
KI (nM)
site = [3H]DPDPE
DPDPE 780 40 (n=4) 1.3 0.4 (n=5)
DAGO 1.7 0.3 (n=4) 570 80 (n=4)
Naloxone 1.8 0.4 (n=3) 14.3 0.5 (n=3)
ICI 174,864 > 10,000 (n=4) 62 14 (n=4)
TABLE 1: Inhibition of [3H]opioid binding
Autoradiography
On development of the autoradiographs there was a striking degree of
[3H]naloxone binding to the villi and crypts as reported previously
(Dashwood et al. 1985). From the raw autoradiographic data the
degree of [3H]DPDPE binding to the intestine was far greater than
[3H]DAGO binding indicating that a higher population of opioid
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receptors are present than µ receptors. In all cases [3H]ligand
was displaced when incubated with 1 µM naloxone (see Figure 1).
Preliminary densitometric analysis was carried out whereby
measurements of the grey levels of the autoradiographs were compared
to densities of the tritium standard scales included with each
cassette. These measurements showed that the rank order of opiate
ligand binding to villi and crypt regions of the rat small intestine
was [3H]DPDPE > [3H]naloxone > [3H]DAGO where:
DPDPE = 225 fmol/mg protein
naloxone = 65 fmol/mg protein
D A G O = <34 fmol/mg protein
FIGURE 1. Binding of [3H]naloxone, [3H]DPDPE and [3H]DAGO to
longitudinal sections of rat small intestine (left). All
[3H]ligands were displaced when incubated in the presence of
1 µM unlabelled naloxone (right). Scale bar = 500 µm.
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DISCUSSION
Opiates are known to exert profound effects on fluid and electrolyte
transport across the epithelium of the small intestine (Dobbins
et al. 1980; Hughes et al. 1982; Turnberg 1983). The possible
location of the opioid receptors involved in the regulation of fluid
transport has emerged from the demonstration of dense [3H]naloxone
and [3H]dihydromorphine binding to the villi and crypt regions of
the rat intestinal mucosa using an in vitro autoradiographic
technique (Dashwood et al. 1985).
In the present study we have used [3H]DAGO and [3H]DPDPE, specific
ligands for the µ and opioid receptors respectively in order to
determine which subtypes are located in the villi and crypt regions
of the rat small intestine. The results indicate a greater binding
of [3H]DPDPE (at least eight times greater) to the villi and crypts
compared to [3H]DAGO binding. These data are consistent with a
previous study which suggested that the effects of opiates on
intestinal fluid movement are mediated by the specific opiate
receptor (Kachur et al. 1980). Recently we have demonstrated a
marked increase in opioid receptor density in the villi and crypts
of rat small intestine with streptozotocin-induced diabetes mellitus
when compared to normal rats (Dashwood and Thompson 1986).
Although the functional significance of the identification of opioid
receptors in the small intestine awaits clarification it is
suggested tentatively that the intestinal opioid receptors are
capable of adaptation in certain pathological conditions.
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ABSTRACT
Our experiments focused on the examination of the distribution of mu
opioid receptor binding sites in normal human brain using the highly
selective ligand [3H]DAG0, in both membrane binding assay and in
vitro receptor autoradiography. Mu opioid binding sites are very
discretely distributed in human brain with high densities of sites
found in the posterior amygdala, caudate, putamen, hypothalamus and
certain cortical areas. Moreover the autoradiographic distribution
of [3H]DAG0 binding sites clearly reveals the discrete lamination
(layers I and III-IV) of mu sites in cortical areas.
INTRODUCTION
Various investigators have reported on the presence of opioid recep-
tor binding sites in human brain. For example, the gross regional
distribution of mu and delta receptor subtypes and the predominance
of kappa receptors have been shown (Kuhar et al.1973; Bonnet et al.
1981; Pfeiffer et al.1982). However, the characterization of these
various opioid receptor types has not been studied in detail. As a
first series of experiments, we investigated the distribution of mu
opioid receptors in normal human brain using a highly selective
ligand [3H]D-Ala2, (Me)Phe4, Gly-ol5 enkephalin (DAGO; Peterson et al.
1983) in both membrane binding assays and in vitro receptor auto-
radiography.
MATERIALS AND METHODS
Membrane binding assays were performed using normal human brains
obtained at autopsy, frozen on dry ice and then kept at -80°C until
used (Quirion 1985). Subsequently, punches (500-750 mg) were taken
from various areas, homogenized in 50 mM Tris.HCl buffer, pH 7.4 at
4°C using a Brickman polytron (setting 5, 20 s). The homogenate was
then centrifuged for 15 min at 49,000 x g. The supernatant was
discarded and the pellet resuspended in buffer and homogenized as
above. This preparation was then incubated at 37°C for 40 min and
centrifuged for 15 min at 49,000 x g. The final pellet was washed
twice with buffer and resuspended in buffer to a final concentration
of 0.8 - 1 mg protein/ml (Lowry et al.1951). For binding assays, 0.1
ml of membrane preparation was added to 0.85 ml of 50 mM Tris.HCl
buffer, pH 7.4 at 25°C, with various concentrations of [3H]DAGQ (44.7
Ci/mmol, New England Nuclear) ranging between 0.05 - 1 nM in 0.05 ml,
to a total incubation volume of 1,0 ml. After 60 min, incubations
were terminated by rapid filtration through Whatman GF/B filter
strips followed by 3 x 5 ml rinses using cold incubation buffer.
Filter strips were pre-soaked in 0.05% polyethyleinine to reduce
binding to filters. Specific binding was calculated as the dif-
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ference in radioactivity bound in presence and absence of 5 µM
cyclazocine. Binding was quantitated by counting filters in 6.0 ml
Scinti-Verse II (Fisher Scientific Ltd., Canada) scintillation
cocktail.
For receptor autoradiography, human brain slide-mounted sections were
prepared as described before (Quirion 1985). Sections were then in-
cubated for 60 min at room temperature in 50 mM Tris.HCl, pH 7.4 con-
taining 1 nM [3H]DAG0. Specific binding was determined as above. At
the end of incubation, slides were rinsed for 5 min in cold incuba-
tion buffer, dipped in cold distilled water to remove salts, dried
and then juxtaposed tightly against tritium-sensitive film (Ultro-
film, LKB Instruments). After 12 weeks, films were developed as
previously described (Quirion et al.1981).
RESULTS AND DISCUSSION
As shown in table 1, mu opioid binding sites are discretely distrib-
uted in human brain. More specifically, high densities of binding
sites are found in the posterior amygdala, caudate, putamen, various
thalamic and hypothalamic nuclei (table 1). Much lower densities are
present in various brainstem nuclei including the pontine, hypoglos-
sal and trigeminal nuclei (table 1). In the cortex, Brodmann's areas
#30, 24, 23, 22, 21, 20, 17, 9, 6 and 4 (in descending order) are
especially enriched in mu opioid binding sites (table 1).
Preliminary autoradiographic data support results obtained in mem-
brane binding assay. As shown in figure 1, high densities of
[3H]DAG0 binding sites are seen in the caudate, putamen, ventral
pallidum-substantia innominata area and cortical layers I and IV.
Much lower densities are found in the globus pallidus, internal
capsule and claustrum (figure 1).
The distribution of mu sites in human brain reported here using a
highly selective ligand correlates fairly well with previous results
obtained using less selective probes (Kuhar et al.1973; Pfeiffer et
al.1982; Bonnet et al.1981). In all these studies, it was found that
the amygdala, hypothalamus, thalamus, caudate and putamen were en-
riched in mu sites. Additionally, we provided preliminary data on
the distribution of these sites in multiple cortical areas and brain-
stem.
The autoradiographic distribution of mu sites in human brain is also
most interesting. As observed in rat brain (Goodman et al.1981;
Quirion et al.19831, high densities of sites are found in caudate,
putamen and certain cortical layers. However, it appears that the
"patchy" distribution of mu sites in the striatum is less apparent in
human brain. The possible significance of this observation remains
to be established. We are currently studying the comparative
distribution of other opioid binding sites (delta and kappa) in
normal and pathological human brain.
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Table 1. Distribution of [3H]DAG0 binding sites in different
regions of the human brain using membrane assay.
Region Kd (nM)
1.1Caudate
Posterior amygdala
Hippocampus
Hypothalamus
Putamen
Thalamus
Substantia nigra
Internal capsule
Cortex - Brodmann area
9
44
24
8
6
22
20
24
4
23
31
21
17
30
39
19
18
Cerebellum
Pontine nucleus
Bmax (fmol/mg protein)
32.3
1.0 53.8
1.1 19.1
4.2 49.3
2.2 25.2
1.1 30.5
2.2 11.1
0.4 7.8
0.4 35.2
0.6 26.2
0.9 36.1
0.2 24.7
0.5 37.5
0.4 32.3
0.5 46.7
0.2 25.3
1.3 39.9
0.9 78.9
0.3 27.1
0.5 42.6
1.0 25.6
0.6 30.0
0.6 28.9
0.3 12.6
0.4 11.4
8.1 46.8
1.0 23.6
Data represent mean of 2-3 experiments using 6 different
concentrations of ligand. All data were analyzed by
computerized linear regression analysis (Bio-Soft, Elsevier,
Cambridge, England).
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Figure 1. Photomicrograph of the autoradiographic distribution
of [3H]DAG0 opioid binding sites in human brain. Abbreviations
used: C, caudate; CL, claustrum; GP, globus pallidus; P,
putamen; SI, substantia inominata, I and IV, layers I and IV of
the cortex.
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ABSTRACT
Injection of apomorphine into the nucleus accumbens of rats elicits
hypermotility, presumably by activating postsynaptically located dopa-
mine receptor systems. This behavioral response is inhibited by local
treatment with CCK-8 or endorphin. The action of both peptides is
antagonized by intra-accumbal treatment with naloxone. These findings
suggest that endogenous opioids are implicated in certain neuroleptic-
like effects of CCK-8 and that in the nucleus accumbens a functional
interaction exists between CCK-8, endogenous opioids and dopaminergic
systems.
INTRODUCTION
The influence of peptides related to endorphin and cholecystokinin
(CCK) on behaviors of rodents suggest that these peptides induce ef-
fects that can also be elicited by neuroleptic drugs (De Wied et al.
1978; Van Ree et al. 1980; Zetler 1983; Van Ree et al. 1983).
Clinical studies have revealed that treatment with these peptides
results in an antipsychotic effect in a number of schizophrenic
patients (Van Ree et al. 1986; Nair et al. 1986). Since brain dopa-
mine has been implicated in the antipsychotic action of neuroleptics,
extensive studies have been performed to investigate the interaction
between these peptides and dopaminergic systems in the brain. One
approach to study this interaction is to determine the behavioral
effect of dopaminergic drugs micro-injected into restricted brain
areas, and to investigate whether known or purported antipsychotic
substances interfere with this behavioral effect. Following this ap-
proach and focussing on the nucleus accumbens area, that contains
terminals of the dopaminergic mesolimbic pathway, we have found that
relatively small doses of apomorphine induce hypomotility in rats.
This behavioral response that may be mediated by presynaptically lo-
cated dopamine receptor systems, can be blocked by local pretreatment
with neuroleptic drugs (e.g. haloperidol and sulpiride) and peptides
related to endorphin and cholecystokinin (Van Ree et al. 1982,
1983, 1984). The active peptides in this respect are the opioid
endorphin and the non-opioid -acetyl endorphin, des-Tyr1 endor-
phin and desenkephalin endorphin and both sulphated and desulphated
CCK-8. When higher doses of apomorphine are injected into the nucleus
accumbens, the rats show hypermotility, a behavioral response pro-
bably mediated by postsynaptically located dopamine receptor systems.
This response is antagonized by pretreatment with endorphin and
sulphated CCK-8 (CCK-8-S) but not by the non-opioid type endorphins
and desulphated CCK-8 (CCK-8-DS) (Van Ree et al. 1983, 1984; Van Ree
and Gaffori 1983). Since the effect of endorphin can be blocked by
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naloxone and is not mimicked by the non-opioid related peptides
acetyl endorphin and des-Tyr1 endorphin), the effect is likely
mediated by opioid receptor systems. Interestingly this action of
endorphin is unique in that other opioid peptides, like enkephalins
and and endorphin, are not active in this respect (Van Ree and
Gaffori 1983). Evidence has been presented that CCK-8-S counteracts
opioid-induced analgesia (Faris et al. 1983), suggesting an inter-
action between CCK-8-S and endogenous opioids. The present experiments
were designated to investigate whether opioid receptor systems are
involved in the antagonizing action of CCK-8-S on the apomorphine-
induced hypermotility following injection into the nucleus accumbens.
MATERIALS AND METHODS
Male Wistar rats weighing 130 - 140 g were equipped with a stainless
steel cannula at each side of the brain. The cannulae were aimed at the
nucleus accumbens (for details see Van Ree et al. 1982, 1983). At
least 7 days after the operation, the rats were three times injected
bilaterally with 1 µl. Groups of rats received placebo, CCK-8-S (10
ng) or endorphin (10 ng), after 30 min placebo or naloxone (2 µg)
and 10 min later placebo or apomorphine (10 µg). Twenty minutes after
the last injection the rats were placed in a small open field, a per-
spex circular test cage, the bottom of which was divided into 4 equal
sections. Motor activity was measured for 3 min by counting the number
of sections explored. After experimentation the sites of injection
were evaluated histologically. Data of rats outside the nucleus accum-
bens were discarded from the analysis. Group means and standard errors
were calculated and the statistical significance was determined using
ANOVA and subsequently Newman-Keuls analysis. The peptides were
donated by Organon International B.V., Oss, The Netherlands and nalo-
xone by Endo, New York, U.S.A. Drugs and peptides were dissolved in
saline just prior to experimentation.
RESULTS AND DISCUSSION
Injection of apomorphine (10 µg) into the nucleus accumbens resulted
in hypermotility (table I). This behavioral effect was completely
antagonized by local pretreatment with either CCK-8-S or endorphin.
As already mentioned desulphated CCK-8 and non-opioid peptides related
to endorphin e.g. acetyl endorphin are inactive in this respect
(Van Ree et al. 1983, 1984). Thus, small changes (i.e. desulphation
and acetylation) in the peptide structure lead to inactivation with
respect to this action of the peptides. Interestingly, both sulphated
and desulphated CCK-8 and both the opioid and non-opioid type endor-
phins interfere with another dopaminergic system in the nucleus accum-
bens, which can be activated by small doses of apomorphine (Van Ree
et al. 1983, 1984). Desulphation and acetylation thus result in more
selectively acting peptides in this case. Whether these enzymatic
processes occur before or after the release of the peptides, thus
intra- or extraneuronally, is unknown, although the present knowledge
favors intraneuronal processing.
The opioid antagonist naloxone antagonized the inhibitory effect of
both CCK-8-S and endorphin on apomorphine-induced hypermotility
(table I). Naloxone did not interfere with the apomorphine response
per sé (Van Ree et al. 1984). The apomorphine-induced hypermotility
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TABLE I
Effect of naloxone on the antagonistic action of CCK-8-S and
endorphin on apomorphine-induced hypermotility following
injection into the nucleus accumbens
Treatment Motor activity
scores
(mean SEM)
- 60' - 30' - 20'
placebo placebo placebo 15.2 0.4 (28)
placebo placebo apomorphine  10 µg 23.1 0.6* (27)
CCK-8-S 10 ng placebo apomorphine 10 µg 15.5 0.7+ (23)
CCK-8-S 10 ng naloxone 2 µg apomorphine 10 µg 22.6 1.7° (10)
YE 10 ng placebo apomorphine 10 µg 14.8 0.7+ (14)
Y E 10 ng naloxone 2 µg apomorphine  10 µg 23.9 1.2° ( 7)
( ) number of observations
ANOVA: F (5,103) = 32.48 (p < O.OO1), Newman-Keuls:
* different from placebo, placebo, placebo (p < 0.05),
+ different from placebo, placebo, apomorphine (p < 0.05),
° different from peptide, placebo, apomorphine (p < 0.05).
is thought to be mediated by activation of postsynaptically located
dopamine receptor systems. Thus, CCK-8-S and endorphin may act in
this brain area as a dopamine antagonist. Indeed the dopamine anta-
gonist haloperidol blocked the hypermotility induced by apomorphine
following injections into the nucleus accumbens, but the effect of
haloperidol (100 pg) was not affected by similar treatment with nalo-
xone. It may therefore be postulated that activation of opioid recep-
tor systems or release of endogenous opioids is involved in the effect
of CCK-8-S on the apomorphine-induced hypermotility. Candidates in
this respect are endorphin receptors or endorphin respectively,
since endorphin in contrast to other opioid peptides mimics this
effect of CCK-8-S. Endogenous opioids may be involved in some, but
not all interactions between CCK-8-S and dopaminergic systems in the
nucleus accumbens. In fact, the CCK-8-S-induced inhibition of the
hypomotility elicited by small doses of apomorphine is not affected
by local treatment with naloxone. CCK-8-S may thus have multiple ac-
tions on the function of dopaminergic neurons in the nucleus accum-
bens, and in one or some of these actions endogenous opioids are con-
cerned. The functional interaction between CCK-8, endogenous opioids
and dopaminergic systems may contribute to further elucidate the anti-
psychotic action of certain endogenous peptides.
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ABSTRACT
In order to study the role of methionine enkephalin (met-enkephalin)
in cardiovascular system, interaction between clonidine and met-
enkephalin on the rate of sympathetic nerve discharge was investi-
gated. In anesthetized rabbits multiunit renal nerve activity (RNA)
was monitored after the treatment of met-enkephalin alone or met-
enkephalin plus clonidine pretreatment. Met-enkephalin suppressed
RNA, and reduced heart rate and blood pressure. Treatment of met-
enkephalin after clonidine (2 to 20 µg/kg) increased the duration of
RNA suppression. The data suggests that the cardiodepressive action
of met-enkephalin is mediated by the stimulation of central presyn-
aptic adrenergic receptor as proposed for clonidine.
INTRODUCTION
Met-enkephalin has profound effects on the cardiovascular system in
addition to diverse other physiological actions (Evans et al. 1986;
Simon and Hiller 1978). Met-enkephalin decreased blood pressure and
heart rate in parallel with the suppression of sympathetic nerve
activity in anesthetized intact rabbits (Rhee et al. 1985), although
the response to the peptide in conscious animal may be different
(Yukimura et al. 1981). This cardiodepressive effects of the pep-
tide was blocked by naloxone, but not by naloxone methobromide,
which is a quaternary analog of naloxone. The cardiovascular action
of the peptide was also partially blocked by phentolamine, a non-
specific alpha-adrenergic receptor blocker (Eulie and Rhee 1984).
It is understood that met-enkephalin effect is mediated by opioid
receptors and alpha adrenergic system is involved in the hypotensive
action of met-enkephalin, but the exact nature of interaction
between the peptide and clonidine is not clear. Therefore, the main
object of this research was to establish potential synergistic or
additive interaction of the two drugs.
MATERIALS AND METHODS
In pentobarbital (30 mg/kg i.v.) anesthetized rabbits, the right
femoral artery and vein were cannulated for the measurement of
arterial pressure and subsequent delivery of drugs. The rabbits
were allowed to respire spontaneously through a tracheostomy.
Arterial blood pressure was monitored by a Statham P23 pressure
transducer coupled to a pressure processor amplifier (Gould Instru-
ments, Cleveland, OH, model 13-4615-52) which computes the systolic,
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mean, diastolic, and pulse pressures. Heart rate (HR) was monitored
by a Gould Biotec ECG amplifier (model 13-4615-65).
After the basic surgery, the animals were placed on their right side
and the kidney was exposed retroperitoneally. A branch of the left
renal nerve was carefully dissected from the surrounding connective
tissue, cleaned and suspended on a bipolar electrode as reported
Rhee et al. (1985). Multiunit renal nerve activity (RNA) was moni-
tored, and integrated for a given time before analysis. All of the
above parameters were recorded on a Gould 16-channel electrostatic
recorder (model ES 1,000). Renal blood flow was determined electro-
magnetically.
Animals were given met-enkephalin (Sigma Chemical Co., St. Louis,
MO) in bolus doses of 3, 10, and 30 µg/kg in ascending order with a
5-min interval between doses. After establishing the control dose-
response curve of met-enkephalin, the same dose-response test was
repeated 10 min after pretreatment with 1, 2, 5, 10, and 20 µg/kg of
clonidine. The mean values for arterial pressure, HR and RNA were
calculated and time for half-maximal recovery (T50) of systolic
blood pressure was also determined. Each datum point was analyzed
by unpaired student t test and significant difference was considered
as P is lesser than .05.
RESULTS AND DISCUSSION
In anesthetized rabbits an intravenous injection of met-enkephalin
decreased systolic, mean and diastolic blood pressure in the peptide
dose dependently, which confirms our previous reports (Rhee et al.
1985; Eulie and Rhee 1984). However, pulse pressure was slightly
increased in many experiments as shown in fig. 1. Heart rate and
renal nerve activity (RNA) were reduced by the peptide so that
integrated RNA per min was also significantly reduced. Renal blood
flow was reduced by the treatment of met-enkephalin from the control
26 ml/min for a kidney to 21 ml/min. It is not clear whether this
effect on renal blood flow is secondary to its primary effect on
blood pressure or its potential direct effect on renal blood ves-
sel. Clonidine initially increased blood pressure which was fol-
lowed by a gradual but a profound reduction in blood pressure and
heart rate in the drug dose-dependent manner. Clonidine also sup-
pressed RNA in a manner similar to met-enkephalin, which usually
manifested at the time of initial increase in blood pressure by
clonidine. Simultaneous administration of clonidine and met-
enkephalin produced an additive action in duration of RNA suppres-
sion. Clonidine also increased the time that is required 50% recov-
ery from the maximal reduction of blood pressure (T50). But it was
not always possible to see clonidine additively interact with met-
enkephalin in the reduction of blood pressure or heart rate due to
presumable interference with baroreflex and other physiological
compensating mechanisms (fig. 2).
Antihypertensive effect of clonidine is known to be mediated by the
stimulation of central adrenergic receptors which will decrease
peripheral sympathetic outflow. The similarity between the action
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of the two drugs, particularly at low doses of clonidine (e.g.,
under 5 µg/kg) suggests the mechanism of met-enkephalin on cardio-
vascular action indeed involves central stimulation of recep-
tors. It is also supported by the fact that adrenergic blocker such
as phentolamine antagonized cardiovascular effects of met-enkephalin
instead of potentiating the effects (EuLie and Rhee 1984).
Figure 1. Effects of met-enkephalin (ME) on cardiac
parameters in intact anesthetized rabbit. Animal was
prepared as in "methods" and ME (300 µg/kg) was loaded
at the first bar in a volume of .25 ml of saline and
flushed with saline as shown at the second bar. RNA,
SP, MP, DP, PP and BPfa indicate renal nerve activity,
systolic, mean, diastolic and pulse pressures, and
femoral arterial blood pressure, respectively. Note
that there is no unit in integration of RNA.
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Figure 2. Interaction between clonidine and met-
enkephalin on mean blood pressure in anesthetized
rabbits. Animals were prepared as in fig. 1 and met-
enkephalin was given 10 min after the treatment of
clonidine. Vertical bars indicate S.E. and numbers
indicate the number of animal used.
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BETA-ENDORPHIN MODULATES THE INHIBITORY ACTION OF CORTICOTROPIN-
RELEASING FACTOR ON LUTEINIZINC HORMONE SECRETION
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ABSTRACT
(2 nmole, icv),
nmole, icv), a mu1
effect of CRF on LH.
opiate receptor antagonist, also reversed the
ip),
Either kappa (Mr1456 and Mr2266) (10 mg/kg,
or delta (ICI 154,129) (10nmole, icv) opiate receptor
antagonists did not significantly modify the’inhibitory effect of CRF
on circulating LH levels. These results suggest that central END
participates in the inhibitory action of CRF on LH secretion.
The present study investigates the possible role of endogenous opioid
peptides in mediating the inhibitory effect of corticotropin-
releasing factor (CRF) on circulating Iuteinizing hormone (LH) . The
centraI injection of an antiserum against endorphin END)
reversed CRF-induced LH decrease in castrated male rats, while
antisera raised against DYN-A or M-Enk were inactive. END-(6-31)
a END antagonist, and beta-funaltrexamine (4.8
INTRODUCTION
Endogenous opioid peptides (EOP) exert a tonic inhibitory effect on
luteinizing hormone (LH) secretion. They modulate the hypothalamic
secretion of gonadotropin-releasing hormone (GnRH), and participate
in the negative feedback action of gonadal steroids on hypothalamic-
pituitary function (Cicero et al. 1979; Van Vugt et al. 1982).
Recently, the central injection of corticotropin-releasing factor
(CRF) has been shown to decrease plasma LH levels in castrated rats
Rivier and Vale 1984; Ono et al. 1984). The action of CRF on LH
secretion is  independent from the stimulation of the pituitary-
adrenal axis, and appears to be due to an effect of CRF on the
mechanisms that control GnRH secretion (Rivier and Vale 1985).
Interestingly, the coexistence of CRF and EOP has been described in
the arcuate-ventromedial hypothalamus (Watson et al. 1982; Millan et
al. 1986), thus suggesting a possible functional interaction in
between these pathways into these brain areas, particularly rich of
GnRH neurons. The aim of the present study was to evaluate whether
the inhibitory action of CRF on LH secretion involves EOP activation.
Passive immunoneutralization of the three most important brain EOP
(beta-endorphin, END; dynorphin-A, DYN-A; methionine-enkephalin, M-
Enk) and specific antagonists for the main opiate receptor subtypes
(mu/epsilon, kappa, delta) were used to antagonize the action of CRF
on circulating LH.
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MATERIALS AND METHODS
Male Sprague-Dawley rats (220-240 g) were used. One week before the
bioassay, rats were castrated and a permanent cannula was implanted
into lateral ventricle of the brain. The implantation of a jugular
catheter was done 24 hours before the experiments. Ovine CRF (2
nmole) (Rivier et al. 1983) was dissolved in water and injected icv
(5µl) In groups of 6-8 rats antiserum raised against END or DYN-
A or M-Enk was injected icv (5 µI) two hours before the CRF
administration. In another set of experiments the following opiate
receptor antagonists were administered centrally: END(6-31), a
END antagonist (2 nmole) (gift of Dr. C.H. Li, San Francisco, CA);
beta-funaltrexamine ( -FNA) (4.8 nmole) (Res. Biochem. Inc., Wayland,
MA), a long acting irreversible mu1 receptor antagonist; ICI 154,129
(10 nmole) (gift of Dr. P. Sacerdote, Bethesda, MD), a delta antag-
onist. Two different kappa opiate receptors antagonists were
injected intraperitoneally: Mr1456 MS and Mr2266 BS (10 mg/kg BW)
(gift of Drs. Plauth and Elich, Boerhinger Ingelheim, Ingelheim an
Rhein, FRG). Blood samples were collected before and every 30
minutes following CRF injection. Plasma LH levels were measured by
radioimmunoassay, using materials provided by NIADDK (Bethesda, MD).
The assay sensitivity was 10 pg; the inter- and intrassay
coefficients of variation were 6% and 3.5% respectively.
Statistical analysis of the results was performed using the one-side
multiple comparison test of Dunnett and the multiple range test of
Duncan.
RESULTS AND DISCUSSION
The central injection of CRF significantly decreased plasma LH levels
in castrated male rats from 6.8 + 0.7 ng/ml to 3.4 + 0.3 ng/ml (M +
SEM) (P < 0.01). The inhibitory effect of CRF on LH secretion was
measurable over a 60 minute period following the administration of
the peptide (4.6 + 0.7 ng/ml, P < 0.019, reaching the nadir values
after 180 minutes. The central injection of an antiserum raised
against END completely reversed the inhibitory effect of CRF (fig.
1). In END immunoneutralized rats, plasma LH levels were in the
same range as control rats. By contrast, in rats injected with DYN-A
or M-Enk antiserum the inhibitory effect of CRF on LH was not
significantly modified (fig. 1). These results showed that CRF
interact centrally with END in modulating LH decrease. In support
of this hypothesis, we have observed that the central injection of
END(6-31) or FNA also reversed the decrease of LH levels induced by
icv injection of CRF (fig. 1). However, in rats pretreated with
FNA a slight CRF-induced LH decrease was still evident (fig. 1), thus
suggesting a secondary role of mu1 receptor subtype regulating LH
secretion. Kappa (Mr1452 or M-2266) and delta (ICI 154,129) opiate
receptor antagonists did not significantly influence the LH decrease
following CRF injection (fig. 1). These results suggest that CRF
decreases plasma LH levels by stimulating the inhibitory action of
END on GnRH neurons. Moreover, these results agree with the
observation that END is the main EOP involved in the control of LH
secretion. The use of a specific antiserum to END (Schultz et al.
1981; Forman et al. 1983) or of mu/epsilon opiate receptor
antagonists (Petraglia et al. 1984; Panerai et al. 1985) have
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indicated a major role of END pathway in tonically inhibiting LH
secretion. These results may also explain recent reports showing
that either a CRF antagonist (Rivier et al. 1986) or naloxone (Hulse
et al. 1982; Brisky et al. 1984) completely reversed stress-induced
LH decrease in rats. It is possible that stress activates
hypothalamic CRF/ MND pathways, leading to a decrease in GnRH as
well as LH secretion. It is therefore possible that the
antireproductive actions of stress activation of pituitary-adrenal
axis may be explained not only by a pituitary (Suter and Schwartz
1985) or gonadal (Sapolsky 1985) action, but also by the central
activation of CRF/ END pathways. In conclusion these results show
that CRF and END interact to modulate LH secretion.
Figure 1: Effect of various antisera (AS) raised against END,
DYN or M-Enk or of antagonists for the different opiate receptor
subtypes on CRF-mediated LH inhibition. *P < 0,01 vs. control rats
(NRS, normaI rabbit serum).
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LEUMORPHIN IS A POTENT INHIBITOR OF VASOPRESSIN SECRETION
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ABSTRACT
The effects of intracerebroventricular (i.c.v.) injection of leumor-
phin on the vasopressin secretion induced by angiotensin II or
dehydration were studied in conscious unrestrained rats. The vaso-
pressin secretion induced by angiotensin II (100 pmol) was signifi-
cantly inhibited by the simultaneous injection of leumorphin (6 pmol-
600 pmol) in a dose-dependent manner. In 72-hour water-deprived
rats, the i.c.v. injection of leumorphin (60 pmol or 600 pmol)
significantly suppressed the vasopressin secretion dose-dependently.
These results suggest that leumorphin is involved in the regulation
of the vasopressin secretion.
INTRODUCTION
Leumorphin is a proenkephalin B-derived 29-amino acid polypeptide
containing leucine-enkephalin sequence at its N-terminus (Kakidani et
al. 1982, Suda et al. 1983). Using a specific radioimmunoassay (RIA)
for leumorphin coupled with high performance liquid chromatography,
we demonstrated the presence of leumorphin in the pituitary and brain
(Nakao et al. 1983, Suda et al. 1984) and parallel distribution of
leumorphin and dynorphin in the brain (Suda et al. 1985). We also
reported that leumorphin acts as an agonist at the type opioid
receptor (Suda et al. 1983) and that intracerebroventricular (i.c.v.)
injection of leumorphin inhibits water drinking induced by water
deprivation or angiotensin II (AII) in rats, suggesting its involve-
ment in water and electrolyte balance (Imura et al. 1985, Imura et
al. 1986). In addition, dynorphin derived from the same precursor as
that of leumorphin, is known to co-exist with vasopressin (AVP) in
magnocellular neurons in the supraoptic and paraventricular nuclei
(Watson et al. 1982). In this study, to further elucidate the
involvement of leumorphin in fluid balance, we have examined the
effect of i.c.v. injection of leumorphin on the AVP secretion in
conscious unrestrained rats.
MATERIALS AND METHODS
Peptides
Synthetic angiotensin II (AII) was purchased from Protein Research
Foundation, Osaka, Japan. Human leumorphin was synthesized by a
conventional solid phase method (Yamamoto et al. 1983). These
peptides were dissolved in physiological saline solution for intra-
cerebroventricular (i.c.v.) injection at a volume of 5 µl.
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Experimental animals
Male Wistar rats, weighing 200-230 g, were housed in a temperature-
controled room (25 1°C) with a 12-hour light-dark cycle (light on
7:00 A.M.). The rats were fed standard rat biscuits and given free
access to food and water. They were anesthetized with sodium pento-
barbital (Nembutal, Abbott Laboratories, Chicag, 50 mg/kg, intra-
peritoneal) and a stainless steel cannula was implanted stereo-
taxically into the left lateral ventricle as reported elsewhere
(Ikeda and Matsushita 1980). Four days later, a jugular catheter was
positioned into the superior vena cava under the pentobarbital
anesthesia. The experiments were performed after a 3-day recovery
period. At the end of experiments, 5 µl of 1 % Evans blue solution
was injected through the cannula to confirm that the placement of the
cannula was appropriate.
Effect of leumorphin on AII-stimulated AVP secretion
Rats were simultaneously injected i.c.v. with AI1 (100 pmol) and
leumorphin (0, 6 pmol, 60 pmol or 600 pmol). Blood (250 µ1) samples
were taken from the jugular catheter four times, just before the
injection and 1.5, 5 and 10 minutes after the injection.
Effect of leumorphin on dehydration-induced AVP secretion
After 72-hour water-deprivation, the effect of i.c.v. injection of
leumorphin (0, 60 pmol or 600 pmol) on the AVP secretion was exam-
ined. Blood (250 µl) samples were drawn from the jugular catheter at
0, 1.5, 5 and 10 min. An equal volume of physiological saline
(250 µ1) was injected intravenously just after the blood sampling.
Radioimmunoassay (RIA)
Blood samples were collected into polypropylene tubes containing
Na2EDTA (1 mg/ml). Plasma was separated immediately and stored at
TABLE 1. Effect of i.c.v. injection of leumorphin on AVP
secretion induced by AII
No. of
Treatment Dose
Time after i.c.v. injection
rats before 1.5 min 5 min 10 min
AII 100 pmol 7 3.1 16.6††† 8 . 9 † † † 6.1 †
±0.4 ±1.2 ±0.7 ±0.5
Leumorphin§  6 pmol 4 4.7 13.3† † 6.0 5.1
±0.7 ±1.6* ±1.2* ±0.7
60 pmol 6 3.3 6.8 3.5 3.4
±0.4 ±1.2** ±0.4** ±0.4**
600 pmol 7 3.4 4.0 3.4 3.4
±0.4 ±0.6** ±0.4** ±0.4**
Values are means ± S E . § AII as given simultaneouly.
(pg/ml)
* P(0.05, ** P(0.01 vs AII (Duncan's multiple range test).
†P<0.05, ††P<0.01, †††P<0.001 vs before injection
(paired t test).
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-20°C. The plasma vasopressin concentration was measured by RIA
(Yamada et al. 1986).
Statistical analysis
The data were analyzed by paired t test or Duncan's multiple range
test following one way analysis of variance.
RESULTS AND DISCUSSION
I.c.v. injection of AII (100 pmol) stimulated the AVP secretion from
the posterior pituitary in conscious unrestrained rats. This AVP
secretion was significantly inhibited by the simultaneous i.c.v.
injection of leumorphin (6 pmol-600 pmol) in a dose dependent manner
(table 1). The plasma AVP concentration was markedly elevated in 72-
hour water-deprived rats. As shown in table 2, the i.c.v. injection
of leumorphin (60 pmol or 600 pmol) also suppressed the dehydration-
induced AVP secretion dose-dependently.
The present study has demonstrated that leumorphin possesses a potent
inhibitory action on the AVP secretion in conscious unrestrained
rats. This observation is consistent with the inhibitory effects of
i.c.v. administration of endogenous opioid peptides such as endor-
phin and enkephalins on the AVP secretion (Van Wimersma Greidanus et
al. 1979, Summy-Long et al. 1981). In the present study, a rela-
tively small dose of leumorphin (6 pmol) significantly inhibited the
AVP secretion, when compared with those of endorphin and enke-
phalins (Van Wimersma Greidanus et al.1979, Summy-Long J.Y. et al.
1981). This potent inhibitory effect of leumorphin on the AVP secre-
tion corresponds to our previous findings that leumorphin inhibits
water drinking induced by i.c.v. injection of AII or water depriva-
tion much more effectively than neo-endorphin or leucine-enkephalin
(Imura et al. 1985, Imura et al. 1986).
The potent inhibitory effect of leumorphin on the AVP secretion
together with its potent antidipsogenic action indicates that leumor-
phin plays a regulatory role in fluid homeostasis in the central
nervous system.
TABLE 2. Effect of i.c.v. injection of leumorphin on AVP
secretion induced by 72-hour water deprivation
No. of
Treatment Dose
Time after i.c.v. injection
rats before 1.5 min 5 min 10 min
Leumorphin 0 5 13.8 - 14.2 -
1.5 2
60 pmol 5 15.4 14.8 9.5 7.9
2.0 3.4 1.9* 2.2
600 pmol 5 14.0 6.7 4.8 5.7
1.5 1.2 0.5** 1.3
(pg/ml)
Values are means SE.
* P<0.05, ** P(0.01 vs Leumorphin 0
(Duncan's multiple range test).
P<0.05, P<0.01 vs before injection (paired t test).
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THE EFFECT OF 17-ALPHA-ESTRADIOL, A POSSIBLE ENDOGENOUS OPIATE
ANTAGONIST, ON D-ALA2-MET5-ENKEPHALINAMIDE-INDUCED
BLOOD PRESSURE RESPONSES IN CONSCIOUS, UNRESTRAINED RATS
A. Chandra and W. R. Dixon
Department of Pharmacology and Toxicology
School of Pharmacy, University of Kansas, Lawrence, KS 66045
ABSTRACT
D-ala2-met5-enkephalinamide (DAME) produced a dose-related increase
in the mean arterial blood pressure of conscious, unrestrained
rats. Intravenous injection of DAME (0.5, 1, 2, and 4 mg/kg)
resulted in mean systemic arterial blood pressures of 138±2, 146±5,
141±4, 156±5 mmHg, respectively. 17-alpha-estradiol and its
derivatives are known to be inactive in target tissues responsive
to estrogenic hormones such as 17-beta-estradiol. However, LaBella
et al. (1978) found after testing a large number of steroid
hormones and their metabolites that only 17-alpha-estradiol
significantly inhibited binding of 3H-naloxone, an opiate
antagonist, in rat-brain homogenates. The present study was
designed to determine whether 17-alpha-estradiol could antagonize
the cardiovascular responses elicited by intravenous injections of
DAME. Intravenous infusion of 17-alpha-estradiol (1.5 mg/kg) every
2 hours for 24 hours (total infusion time was 2 minutes for each
infusion) did not change the mean systemic arterial blood pressure
(94±5 mmHg) compared to the blood pressure prior to infusion of 17-
alpha-estradiol (99±7 mmHg). Intravenous infusion of 17-alpha-
estradiol (1.5 mg/kg) 10 minutes prior to DAME (1 mg/kg, i.v.)
resulted in a blood pressure of 106±9 mmHg, which is significantly
less than the blood pressure of 146±5 mmHg seen with DAME (1 mg/kg,
i.v.) alone. Intravenous injection of DAME (1 mg/kg) 8 hours after
the last infusion of 17-alpha-estradiol produced an increase in
mean systemic arterial blood pressure of 136±8 mmHg. These results
indicate that 17-alpha-estradiol may function as an opiate
antagonist.
INTRODUCTION
Pinsky et al. (1975) studied the role of endogenous sex steroids in
morphine antinociception. They showed that morphine was ineffec-
tive in relieving the stress of mild pain in gonadectomized rats.
However, adrenalectomy alone enhanced morphine antinociception.
The authors suggested that mild pain may mobilize an endogenous
steroid of gonadal origin which acts to reduce the nociception
response and that the adrenals may release a substance that
antagonizes the effects of both the antinociceptive steroid and
morphine. LaBella et al. (1978) showed that a large number of
steroids of the estrane, androstane, pregnane, and etianic-acid
series, including their sulfate and glucuronide conjugates, were
inactive in an opiate radioreceptor assay (displacement of 3H-
naloxone). In their experiments, only 17-alpha-OH estrogens showed
significant affinity for displacement of 3H-naloxone in rat-brain
homogenates.
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The present study investigated the possibility that the 17-alpha-
estradiol (a potent competitor for binding of 3H-naloxone and other
opiate drugs--such as morphine, methionine-enkephalin, and leucine-
enkephalin--to brain membranes or brain slices [see LaBella 1985])
may function as an opiate antagonist and may antagonize the cardio-
vascular responses elicited by d-ala2-met5-enkephalinamide in
conscious, unrestrained rats.
MATERIALS AND METHODS
Male Sprague-Dawley rats weighing 300-350 gm were used in the
study. Under ether anesthesia, the femoral artery and vein were
catheterized with PE-50 tubing in order that blood pressure might
be measured and drugs injected. The PE-50 tubing was guided
through subcutaneous fat on the back and was exited from the
neck. A heparin solution (285 units/ml) was injected into the
tubing to prevent blood clotting. The PE-50 tubing was then
connected to a 21-gauge needle connected to a three-way stopcock
fastened to a transducer, which in turn was connected to a Model 7
Grass Polygraph used to record blood pressure. 17-alpha-estradiol
was dissolved in vehicle (propylene glycol/absolute ethanol/glacial
acetic acid/ascorbic acid; 95/5/0.6/0.01; v/v/v/w). D-ala2-met5-
enkephalinamide (DAME) was dissolved in 0.9% normal saline. Three
groups of animals were used in these experiments.
(1) Rats were given intravenous injections of various doses
of DAME (0.5, 1, 2, and 4 mg/kg).
(2) An intravenous infusion of 17-alpha-estradiol
(1.5 mg/kg) was given every 2 hours for 24 hours (total
infusion time, 2 minutes for each infusion). One hour
after the last infu-sion, a bolus injection of 17-
alpha-estradiol (1.5 mg/kg, i.v.) was given 10 minutes
prior to DAME (1 mg/kg, i.v.). Eight hours later, the
injection of DAME (1 mg/kg, i.v.) was repeated.
(3) An intravenous infusion of vehicle was given at the
rate of 0.1 ml every 2 hours for 24 hours (total
infusion time, 2 minutes per infusion). One hour after
the last infusion, a bolus injection of vehicle
(0.1 ml, i.v.) was given 10 minutes prior to DAME
(1 mg/kg, i.v.). Eight hours later, the injection of
DAME (1 mg/kg, i.v.) was repeated.
Statistical evaluation of the data was performed by ANOVA and by
the Student Newman-Keul test for multiple comparisons of means
(Zar 1974).
RESULTS AND DISCUSSION
Intravenous injection of d-ala2-met5-enkephalinamide (DAME,
primarily a delta-receptor agonist) at 0.5, 1, 2, and 4 mg/kg
caused a dose-related increase in mean arterial blood pressure
(fig. 1) with a duration of 0.98±0.14, 2.25±0.42, 1.90±0.72, and
9.17±0.79 minutes, respectively. However, the heart exhibited
bradycardia (165±15, 150±16, 146±14, 135±15). 17-alpha-estradiol
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has been found not to have biological activity in target tissues
responsive to estrogenic hormones, such as 17-beta-estradiol
(Ruediger et al. 1983; Foy and Teyler 1983; Pert et al. 1973).
It was also shown that in a family of steroids, only 17-alpha-
estradiol was effective in displacing 3H-naloxone in rat-brain
homogenates (LaBella et al. 1978, 1985). This observation is
consistent with the idea that 17-alpha-estradiol might have opioid
antagonist properties. Intravenous infusion of 17-alpha-estradiol,
1.5 mg/kg (infused every 2 hours for 24 hours; total infusion time
of 2 minutes for each infusion), did not significantly alter blood
pressure and heart rate in the conscious rat (fig. 2). One hour
after the last infusion of 17-alpha-estradiol (1.5 mg/kg, i.v.), a
bolus injection of 17-alpha-estradiol (1.5 mg/kg, i.v.) was given
10 minutes prior to DAME (1 mg/kg, i.v.). The hypertension
produced by DAME was significantly inhibited. Eight hours later,
the injection of DAME (1 mg/kg, i.v.) produced a mean arterial
blood pressure of 136±9 mmHg, which was significantly higher than
the blood pressure response to DAME (106±9 mmHg) given 10 minutes
after 17-alpha-estradiol (fig. 3). An interesting observation was
that a bolus injection of 17-alpha-estradiol alone could sig-
nificantly decrease the mean arterial blood pressure response
(78±5 mmHg) with a duration of 6.00±0.41 minutes. This is in
contrast to the lack of effect of the same dose of 17-alpha-
estradiol infused over two minutes. Moreover, 17-alpha-estradiol
produced sedation after the infusion of the steroid or after a
bolus injection. It has been reported that the gonadal steroid
progesterone and the mineralocorticoid deoxycorticosterone, as well
as several of their metabolites, caused sedation and anesthesia in
the rat (Atkinson et al. 1965). Recently, Majewska et al. (1986)
found that reduced metabolites of progesterone and deoxycortico-
sterone are potent modulators of the GABA-receptor complex in crude
synapto-somal membranes from rat brain and that these metabolites
interact with the receptor complex in a manner similar to that of
the barbiturates. In our results, 17-alpha-estradiol antagonized
the hypertension resulting from intravenous injections of DAME,
suggesting that 17-alpha-estradiol may function as an endogenous
opioid antagonist.
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FIGURE 1. The effect of intravenous injection of d-ala2-met5-enkephalinamide (DAME)
on the blood pressure of conscious, unrestrained rats.
**P < 0.01 compared to the saline injection. n-=-number of animals.
FIGURE 2. The effect of intravenous infusion of 17-alpha-estradiol. 1.5mg/kg
(infused every 2 hours for 24 hours; total infusion time, 2 min. for each in usion)f
on the blood pressure and heart rate response of conscious. unrestrained rats. There
was no significant difference in the blood pressure and heart rate during the 24-hours.
FIGURE 3. The effect of intravenous infusion of 17-alpha-estradiol, 1.5mg/kg (infused
every 2 hours for 24 hours; total infusion time. 2 min. for each Infusion) on the mean
blood pressure response to DAME (1mg/kg. i.v.) of conscious, unrestrained rats.
**P < 0.01 compared to control. n = number of animals.
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STRESS-INDUCED-ANTINOCICEPTION AND MORPHINE SENSITIVITY
IN MICE FOLLOWING CHRONIC TREATMENT WITH ANABOLIC/
ANDROGENIC STEROIDS
David A. Cowan, Susan Friend, Alan Gibson,
Michael Ginsburg, and Stephen L. Hart
Drug Control Centre, and Department of Pharmacology,
Kings College London (KQC), Manresa Road, Londn SW3 6LX UK.
ABSTRACT
In male mice treated chronically with anabolic/androgenic teroids,
morphine produced changes in exploratory behaviour similar to those
normally associated with anxiolytic drugs. In addition, steroid
treatment attenuated opioid-mediated stress-induced antinociception.
INTRODUCTION
It has been recognised for some time that opioid drugs disturb norm-
al endocrine function (Meites 1980). In the case of male gonadal
hormones, opioid agonists reduce circulating levels of testosterone
by inhibiting the release of hypothalamic LHRH (Cicero 1980). Conv-
ersely, administration of opioid antagonists elevates plasma LH and
testosterone. These findings, together with the detection of opioid-
containing neurones in the hypothalamus, have led to the proposal
that endogenous opioids are involved in the negative feedback contr-
ol of LHRH release exerted by circulating testosterone (Cicero et al.
1982). It follows that administration of male sex hormones might
influence endogenous opioid function in brain. In this paper, we
report that chronic treatment of mice with anabolic/androgenic ster-
oids alters some behavioural responses to opioids.
MATERIALS AND METHODS
Male mice (LACA strain ; 20 - 25 g) were used throughout. Steroids
were given by weekly i.m. injections as slow-release preparations
in ethyl oleate. Controls received appropriate volumes of ethyl
oleate alone.
Antinociception
Testosterone, methyl-testosterone, or methenolone (each 0.4 mg/Kg)
were given for 4 weeks. 3 - 4 days after each steroid injection
morphine-induced antinociception (20 mg/Kg, i.p.) was assessed on
a hot-plate (54°C).
Motor activity
Methyl-testosterone or methenolone (5, 10, and 20 mg/Kg) were given
for 6 weeks. On the seventh week, motor activity was assessed 24 hr
before and 30 min after 20 mg/Kg morphine i.p. Animals were injected
with saline or morphine 30 min prior to being placed in an activity
cage. After a 10 min settling in period X - Y motor activity was
counted for 10 min.
Exploratory behaviour
Methyl-testosterone or methenolone (5 mg/Kg) were given for 6 weeks.
On the seventh week, exploratory behaviour was assessed 24 hr before
and 30 min after 20 mg/Kg morphine i.p. Animals were given saline
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or morphine 30 min before being placed in a box maze (Davies and
Wallace 1976). After a 1 min settling in period exploratory behav-
iour was counted for 3 min. Parameters measured were, dipping (push-
ing head down hole in middle of box section), rearing (placing both
front paws on dividing walls), and crossing (moving from one box
section to the next).
Stress-induced antinociception (SIA)
Methyl-testosterone or methenolone (1 and 5 mg/Kg) were given for 6
weeks. On the seventh week, SIA was assessed by recording reaction
time on a hot-plate (54°C) before and 2 min after a 3 min swim at
20°C (Hart et al. 1983).
RESULTS
Antinociception
In naive mice, morphine increased hot-plate reaction time by 35 sec.
In control mice, treated with ethyl oleate, there was a gradual decr-
ease in morphine-induced antinociception such that, by the fourth
week, there was no significant increase in reaction time; this was
presumably due to tolerance induced by the weekly exposure to morphi-
ne for the antinociceptive test. A similar pattern was shown by mice
treated with the steroids, there being no significant difference
among the groups.
Motor activity
In control mice, morphine increased motor activity from 192 ± 10 to
252 ± 15 counts/10 min (mean ± s.e.). Methyl-testosterone treatment
per se did not affect motor activity, but it abolished the stimulato-
ry effect of morphine. A similar, but less pronounced, inhibition of
morphine-induced motor activity was observed in methenolone treated
mice.
Exploratory behaviour
The results from these experiments are shown in figure 1. In control
mice, morphine reduced the number of dips, but did not affect rearing
or crossing. Morphine also reduced the number of dips in mice trea-
ted with methyl-testosterone or methenolone. Further, in methyl-
testosterone treated mice, morphine reduced the number of rears,
while in methenolone treated mice morphine increased the number of
crossings.
SIA
These results are given in table 1. In ethyl oleate treated mice
the initial median reaction time on the hot-plate (T1) was 12 sec;
after a 3 min swim the reaction time (T2) was increased by 9 sec.
Treatment with methyl-testosterone or methenolone did not alter
the initial reaction time; however, in methyl-testosterone trea-
ted mice (5 mg/Kg) the increased reaction time following a swim
was attenuated. Methenolone (5 mg/Kg) also reduced the prolongat-
ion of reaction time after a swim, but in this case the reduction
was just outside the levels of significance (0.01>P>0.05).
DISCUSSION
The results clearly indicate that chronic administration of
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FIGURE 1. Histogram showing (mean ± s.e.) exploratory
behaviour of mice on a box maze for 3 min. Open columns -
mice given 6 weekly injections as indicated (steroids at
5 mg/Kg) ; hatched columns - same mice 30 min after 20 mg/Kg
morphine. * P<0.05
anabolic/androgenic steroids alters the behavioural responses of mice
to opioids. Two results are of particular interest. First, on the
box maze morphine increased the number of crossings in mice treated
with methenolone. Few drugs have been shown to have this effect, and
the common property of those that do seems to be anxiolytic activity
(J. K. Davies personal communication). The difference in morphine
activity in methyl-testosterone and methenolone treated mice on the
box maze may be a reflection of the different anabolic/androgenic
ratios of the two steroids. Secondly, methyl-testosterone and to a
lesser extent methenolone decreased SIA in a model which is known
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Median Reaction Times
Saline
Ethyl Oleate
Methyl Testosterone 1mg/Kg
5mg/Kg
Methenolone 1mg/Kg
5mg/Kg
T 2 - T 1
(12) T 1 +10
(12) 12 +9
(6) 12 +9
(12) 11 +2.5*
(12) 9.5 +12
(12) 12.5 +6.5
TABLE 1. Median reaction times (sec) of mice on a hot-
plate. T1 was measured after 6 weekly injections of the
treatment indicated. T2 was measured 2 min after a 3 min
swim. The increased reaction time (T2 - T1) represents SIA.
Numbers in parentheses give number of mice.
* P<0.05
to involve the release of endogenous opioids (Hart et al. 1983).
Thus, steroid administration not only influences responses to exoge-
nous opioids but also behavioural activity resulting from endogenous
opioid function. Both these observations may have relevance to one
group of individuals known to take regular doses of anabolic ster-
oids; that is athletes involved in strength-related events (Goldman
1984). In such athletes, the interaction between male sex hormones
and opioids may be of importance during competition since both stre-
ss and exercise are potent stimuli for endogenous opioid release
(Gibson et al. 1979 ; Gambert et al. 1981).
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OPIOIDS AND E-RECEPTORS INTERACTION: FURTHER STUDIES IN
CULTURED CELLS
Angelo Reggiani, Angelo Carenzi and Davide Della Bella
Zambon Farmaceutici Research Laboratories
Via Lillo Del Duca 10, 20091 Bresso-Milan, Italy
ABSTRACT
In the present paper a further evidence of a functional link between
opioids and ß-receptor system in cultured rat C6 cells is presented.
We showed that C6 cell exposure to Desmethylimipramine (DMI) causes
expression of opioid receptors and loss of ß-receptors. We now
show that C6 cells exposure to DMI causes an increase of intracel-
lular levels of opioid peptides and an increase of aminopeptidase
activity. In addition, the presence of the aminopeptidase inhibitor
bestatin during cell exposure inhibits DMI-induced R-receptor loss.
These results indicate that cell exposure to DMI causes the full
expression of the opioid peptide system. This effect could be
related to changes of ß-receptor system.
INTRODUCTION
It has been recently found that C6 cell exposure to DMI causes
expression of cell membrane opioid receptors (Tocque et al. 1984)
and we have recently found that this effect was associated to the
loss of R-receptors (Reggiani et al. in preparation). We also found
that the simultaneous presence of opioids during DMI-exposure
prevents ß-receptors down regulation and a similar modulation
can be demonstrated on isoproterenol (ISO) induced desensitization
in DMI-exposed cells. All these results suggest that, besides the
actual mechanism of inducing ß-receptors loss opioids could operate
to preserve ß-receptor function. In order to investigate whether
DMI-induced opioid receptors appearance was associated to a wider
influence on opioid peptide system experiments were carried out
to study the effect of cell exposure to DMI on the intracellular
synthesis of opioids and on their metabolic degradation. Further-
more, the effect of peptidase inhibitors on DMI induced loss of
ß-receptors was tested in the attempt to verify whether peptidase
inhibitors could mimic the exogenous opioid agonist action.
MATERIALS AND METHODS
Confluent monolayers of rat C6 glioma cells between passage 47th
to 75th were used. Cells were grown in a humidified atmosphere
5% CO2 - 95% air, using EMEM supplemented with 10% FBS and anti-
biotics as growth medium. 3H-DHA and 3H-DHM bindings were estimated
as previously described by Fishman et al. (1981) and by Albouz
et al. (1982) respectively. CAMP levels were measured on acid
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extracts from cell suspension by using the RIA method of binding
protein as recommended by Amersham. Met-Enkephalin (ME) content
was measured on acid extracts from cell suspension by using rabbit
antibody from Amersham (code RPM-1561) and 10 nM 3H-ME as radio-
active tracer. The hydrolysis of 3H-Leu-Enkephalin (3H-Le) by
cultured C6 cells was estimated as follows: at the end of the
proper treatment cells were challenged for their ability to hydro-
lyze peprides by exposing cultures for 30 min to 20 nM LE containing
10.000 cpm 3H-LE. At the end, the medium was collected, boiled
for 3 min and aliquots were applied for TLC separation by comparison
with the proper standard mixtures.
RESULTS AND DISCUSSION
The influence of cell exposure to DMI on the intracellular content
of opioid peptides was investigated by measuring ME content as
probe of the opioid peptide concentration. As shown in table 1
naive cells have an intracellular level of ME comparable to the
lowest estimate in whole brain and in other cultured cell lines
(Gilbert et al. 1982, Glaser et al. 1982, Miller et al. 1978,
Yang et al. 1977, Hughes et al. 1977). 24 hrs of cell exposure
to different concentrations of DMI increased peptide content up
to 5-6 times as much, suggesting that DMI exposure would trigger
the expression of opioid peptides synthesis.
TABLE 1. Effect of C6 cell-exposure to different concentra-
tions of DMI on the intracellular content of ME.
TREATMENT
(24 hrsl [M]
ME-CONTENT
(fmol/mg protein)
Vehicle 277 31
DMI 5 . 10-5 1784 110 *
DMI 5 . 10-6 1055 97 *
DMI 5 . 10-7 630 78 *
* P < 0.05 vs vehicle treated cells
Kesults are the mean ± SE of 3 determinations in duplicate.
C6 exposure to DMI also influenced cell associated neuropeptidase
activity as indicated by the results reported in table 2. According
to these experiments, both in vehicle and in DMI treated cells
most, if all, the neuropeptidase activity was due to an aminopepti-
dase since the major fragment formed was 3H-Tyrosine (3H-T).
However, after cell exposure to DMI, the aminopeptidase activity
was increased as indicated by the time dependent decrease in the
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amount of intact 3H-LE recovered after cell challenge associated
to the time dependent increase of 3H-T formed.
TABLE 2. Influence of cell exposure to DMI (5 . 10-5M) on cell
associated neuropeptidase activity versus exogenous 3H-LE.
TREATMENT
TIME OF EXPOSURE RECOVERY AFTER CHALLENGE
(hrs) 3H-LE (cpm) 3H-T(cpm)
Vehicle 8 6549 2663
16 6263 2606
24 6423 2680
DMI 8 5345 3090
16 4969 4270
24 3770 5015
At the end of the treatment cells were challen ed for 30 min
with 20 nM LE containing 10.000 cpm of intact 3H-LE.
Among the neuropeptidase profile of the various peptidase inhibitors
tested, only bestatin was found effective in interfering on DMI
induced R-receptors loss of density and function. Table 3 summarizes
the effects of bestatin on DMI induced decline of either O-receptors
density or ISO stimulated CAMP accumulation in intact cells. In
both cases the aminopeptidase inhibitor protected against DMI
induced effects suggesting that the newly synthesized peptides
mimic the action of exogenous peptides on ß-receptors system.
TABLE 3. Effect of bestatin on DMI induced decrease of R-re-
ceptors density and ISO-stimulated CAMP accumulation in in-
tact C6 cells.
TREATMENT CAMP a)
(24 hrs) (pmol/mg protein)
3H-DHA BOUND Bmax
(fmol/mg protein)
Vehicle 2157 169 255 41
DMI 957 181 * 123 23 *
DMI+bestatin 1691 171 ns 221 35 ns
Bestatin 2258 183 ns 241 47 ns
* P < 0.05 vs vehicle ns: not significant vs vehicle
a) CAMP after 10 min of challenge with ISO 10-6M
DMI concentration was 50 µM, bestatin was 1O µM
Results are the mean ± SE of 3 determinations in duplicate.
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At the present time it is not known which is the actual biochemical
mechanism involved in the reported effects of cell exposure to
DMI. However, all these results could suggest that a common
mechanism would activate opioid receptors' appearance, opioid
peptide synthesis and aminopeptidase activity. Since the inhibition
of endogenous opioid peptide degradation by bestatin prevents DMI
induced B-receptor loss it can be speculated that the opioid system
activation could be related to specific changes in B-receptor
function.
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MU/DELTA OPIOID SITE SELECTIVITY OF SOME ANTIDEPRESSANTS
Ellen E. Codd and Richard F. Walker
Department of Reproductive and Developmental Toxicology
Smith Kline and French Laboratories
1500 Spring Garden Street
Philadelphia, PA 19101, USA
ABSTRACT
Since pain and depression are influenced by opioids and
antidepressants, it was of Interest to explore their interaction
with common CNS receptors. A method for binding site selectivity
was used to evaluate antidepressant specificities in inhibiting mu
versus delta opioid binding. With the very specific opioid probes
used, DAGO and DPDPE, a wide range of antidepressant selectivities
was found. These may represent different modes of interaction
between mu and delta opioid sites and antidepressant compounds.
INTRODUCTION
Chronic pain and depression are frequently associated, but the
mechanisms underlying the efficacy of antidepressants in the
management of pain syndromes are not clearly understood. The
effectiveness of these drugs in pain relief may be secondary to
their antidepressant activity, or may result from their own
intrinsic analgesic activity. Since certain antidepressants inhibit
opioid binding in vitro (Biegon and Samuel 1980; Somoza et al. 1981;
Baraldi et al. 1983; Isenberg and Cicero 1984), it was of interest
to examine the mu/delta opioid specificity of the interaction. The
site selectivity method (Bárány 1973, Terenius and Wahlström 1976)
was used to circumvent the potentially confounding effects of
al losteric interactions between µ and opioid binding sites
(Vaught et al. 1981, 1982; Rothman and Westfall 1982a and b).
MATERIALS AND METHODS
Male Sprague-Dawley rats (2-3 months of age) were decapitated and
their brains removed. The forebrains were homogenized in 50 mM
Tris-HCl (pH 7.4 at 25°C) in a teflon-glass homogenizer. The
homogenate was centrifuged at 27,000 x g for 15 min and the pellet
resuspended in Tris buffer (100 ml buffer/g brain tissue). One ml
of this crude membrane fraction was used per assay tube; the final
assay volume was 1.1 ml. Incubations (25°C, 1 hr) were terminated
by filtration over Whatman GF/B filters with a Brandel cell
harvester. Tubes and filters were rinsed 3 X 4 ml buffer.
Radioactivity was counted in Protosol/Econofluor (New England
Nuclear).
The experimental design was based on the site selectively method
(Barany 1973; Terenius and Wahlström 1976). DAGO and DPDPE were
used as indicator ligands for µ and opioid binding sites
respectively. In each of two test solutions, both ligands were
present at about their Kd values (previously determined to be:
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DAGO, 0.4 nM; DPDPE 1.8 nM). In one solution DAGO was in the
tritiated form, while DPDPE was radiolabeled in the other. A range
of concentrations of the antidepressants examined was incubated in a
series of tubes under each test condition. Controls for
nonsaturable binding contained nonradlolabeled indicator ligand at a
concentration of 0.1 µM. Binding of the indicator ligand in the
presence of antidepressant was calculated as a percent of that
observed when no test drug was present. The results were graphed
according to Bárány (1973) and Terenius and Wahlström (1976).
Tritiated DAGO and DPDPE were from New England Nuclear, while the
nonradiolabeled peptides were from Peninsula Labs. Imipramine and
desipramine were from Sigma. Other antidepressants were kindly
donated: fluoxetine by Eli Lilly, mianserin by Organon,
amitriptyline by Merck, chlorimipramine by CIBA-GEIGY and
nomifensine by Hoechst.
RESULTS
Previous work has demonstrated the excellent specificity of DAGO and
DPDPE for µ and opioid binding sites, respectively (Mosberg et
al. 1983; Paterson et al. 1984). In the present study, nonradio-
labeled DAGO and DPDPE were also highly selective for the sites
labeled by their tritiated analogs (fig. 1). DAGO inhibited only 5%
of 3H-DPDPE binding at a concentration which blocked 85% of
3H-DAGO binding, while DPDPE prevented 98% of 3H-DPDPE binding
at a concentration which blocked only 5% of 3H-DAGO binding.
FIGURE 1. Relative inhibition of 3H-DAGO and 3H-DPDPE
binding by nonradioableled DAGO and DPDPE (1 nM - 0.1 mM).
Each point shown represents the mean of triplicate
determinations of specific binding.
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The mu/delta site selectivity of several antidepressants was
evaluated in this test system and a range of selectivities was
observed (fig. 2). Amitriptyline and mianserin competed equally well
for DAGO and DPDPE binding sites; the graph of their inhibition data
fell on the diagonal, indicating no preference for mu versus delta
opioid binding sites. In contrast, fluoxetine had a 10-fold
selectivity for sites labeled by the delta site ligand, DPDPE since
its data points fell well above the diagonal. The other
antidepressants tested Including imipramine, nomifensine,
chlorimipramine and desipramine, had greater selectivities for mu
binding sites since their competition data points were below the
diagonal line (fig. 2). Thus, although all the antidepressants
tested inhibited opioid binding in the range of concentrations
tested, the drugs varied greatly in their preference for mu versus
delta binding sites.
FIGURE 2. Relative inhibition of 3H-DAGO and 3H-DPDPE
binding by some antidepressants. - fluoxetine. 1- 300 PM,
- amitrptyline, 1 - 1000 µM; - mianserin 6 - 100 PM;
- nomifensine, 10 - 1000 µM; - chlorimipramine, 30 -
1000 µM; - imipramine, 0.1 - 1000 PM; - desipramine.
0.1 - 1000 µM. The values shown are the means of triplicate
determinations of specific binding.
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DISCUSSION
Modulatory interactions between mu and delta ligands have been
demonstrated in analgesic responses (Vaught and Takemori 1979; Lee
et al. 1980; Vaught et al. 1982) and receptor binding (Vaught et al.
1981; Rothman and Westfall 1982a and b). Because of the proposed
allosteric interactions between mu and delta opioid binding sites
(Rothman and Westfall 1982a,b; Vaught et al. 1982). the site selec-
tivity method was chosen to investigate antidepressant preference
for opioid receptor subtypes. Because the molecular constituents of
the test solutions used in this method are identical, their effects
on the receptors will be identical (Terenius and Wahlström 1976).
Under such conditions, DAGO and DPDPE exhibited a high specificity
for their respective binding sites (fig. 1). An almost 100-fold
concentration range exists for each ligand within which there is
virtually no overlap in ligand binding between sites. Since the
Kd of each ligand is well within that concentration range, the
site selectively method is a powerful analytical tool when DAGO and
DPDPE are used as the indicator ligands at their Kd concentrations.
A range of selectivities was found among the antidepressants
tested. Patterns of selectivity included delta preferring
(fluoxetine), mu preferring (desipramine, imipramine, chlor-
imipramine, nomifensine) and unselective (amitriptyline,
mianserin). A similar range of preferences was observed by Isenberg
and Cicero (1984) using dihydromorphine and DADL as mu and delta
ligands. respectively. Presumably the use of more selective
indicator ligands in the present study yielded greater
discrimination of the selectivities of compounds tested.
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ABSTRACT
Effects of varying concentrations of ethanol on the conformations
of DAGO, a D-specific opioid ligand were monitored by FT-IR
spectroscopy. The binding of 3H-labeled DAGO (u-agonist) and
DSLET ( agonist) to opioid receptors in the presence of varying
concentrations of alcohol was also determined. The results
indicate that the conformational features of the ligands are
altered and conformational factors may play a role in
ligand-receptor interaction.
INTRODUCTION
The concept of multiple receptors for the opioid ligands was
originally proposed by Portoghese (1965). However, this concept
was more widely accepted only after Martin et al. (1976) proposed
that there are at least 3 types of opioid receptors, i.e., µ,
and from their pharmacological experiments. Later Lord et al.
(1977) put forth evidence for a fourth type of receptor,
Presently, there are several methods that differentiate the various
receptor types (Paterson et al. 1984). Hiller et al. 1981 proposed
that alcohol selectively inhibits binding to receptors, as
&receptors are more strongly influenced by the alcohol-induced
membrane fluidity changes than are the µ-receptors. They further
stated that it is likely that alcohol affects the receptor rather
than the peptides (ligands). As drug-receptor interaction involves
rigid stereochemical and structural requirements, and in view of
the importance of the conformational features for drug-receptor
interaction, we have previously investigated the effects of ethanol
on the secondary structural features of Met5-enkephalinamide
(Rapaka et al. 1986). We proposed that conformational features of
the ligand may also play a role in drug-receptor interaction. We
have presently extended these studies to both µ and specific
opioid peptide ligands.
MATERIALS AND METHODS
DAGO (Tyr-D-Ala-Gly-N-Me-Phe-Gly-ol) and DSLET (Tyr-D-Ser-Gly-Phe-
Leu-Thr-OH) were purchased from Bachem Inc., Switzerland.
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3H DAGO was purchased from Amersham, Boston, MA, and 3H DSLET
was purchased from New England Nuclear Corporation. FT-IR
Spectroscopy was performed as reported by Rapaka et al. (1986).
Rat brain membrane preparation was prepared as reported by Bhargava
and Das (1986).
RESULTS AND DISCUSSION
FT-IR spectra of DAGO were obtained at room temperature with 0%.
2%, and 5% (v/v) ethanol in water. The background subtracted
spectra are presented in figure 1. In water, DAGO manifests a
doublet amide I band with an intense band at 1651 cm-l and a less
intense band at 1636 cm-1 with a shoulder around 1670-1680
cm-1. From the conformational dependence of IR amide bands
(Renugopalakrishnan et al. 1986; Byler et al. 1986), the intense
band at 1651 cm-1 is assigned to either -helical or "unordered"
structure, the 1636 cm-1 band to ß-sheet structure, and the broad
shoulder at 1670-1680 cm-1 to ß-turn structure. The occurrence
of helical structure seems less likely, due to the short peptide
backbone of DAGO. Hence, DAGO is expected, based on IR studies, to
exist in a conformational equilibrium involving ß-turn, ß-sheet,
and "unordered structures. In 2% aqueous ethanol, the pattern of
IR bands remains unchanged but the intensities of the bands are
slightly diminished. At higher concentrations of ethanol, i. e.,
5% (v/v), the resolution-enhanced amide I region is simplified by
the occurrence of two bands, an intense band at 1635 cm-1 and a
less intense band at 1660 cm-l. Although the spectrum is
simplified, further studies are required to clarify the details of
assignment. In order to correlate the ethanol-induced changes in
conformation with receptor binding parameters, binding of the
tritiated ligands to receptors in the rat brain membrane
preparation was studied. The effect of alcohol on binding of the
tritiated ligands to the rat brain membrane preparation is
presented in table 1.
TABLE 1
Effects of Varying Concentrations of Alcohol on the Binding
of 3H-Labeled Opioid Peptides to Opioid Receptors.
Alcohol Specific Binding
Concentration 3H DAGO
% v/v % Control
Specific Binding
of 3H DSLET
% Control
Control 100 100
1 63.1 89.6
2 59.0 83.0
3 54.6 70.8
5 43.1 48.5
In our earlier studies (Rapaka et al. 1986), we investigated the
conformational changes of Met5-enkephalinamide upon the addition
of different concentrations of ethyl alcohol to an aqueous solution
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of Met5-enkephalinamide. Met5-enkephalinamide is an ideal
molecule for these studies, as it exists in both ß-turn and ß-sheet
conformations. FT-IR is ideally suited to follow the
conformational transitions as changes in both ß-turn and ß-sheet
conformations can be monitored simultaneously and the technique is
simple and fast. Hence, in our continuing studies FT-IR was the
method of choice.
Schiller and colleagues (Schiller and DiMaio 1980; DiMaio and
Schiller 1980; DiMaio et al. 1982), from their studies on cyclic
enkephalin analogs and the corresponding linear analogs, proposed
that the opioid receptor subtypes differ in their conformational
requirements of the ligand. Later several groups proposed that
indeed the conformational features such as the ß-turns, ß-sheets,
or other extended structures may play a role in receptor subtype
recognition (for a review see Rapaka et al. 1985). Ethanol is
Figure. 1. Resolution-enhanced FT-IR spectra in the
amide I region of DAGO in water (3 mM) at room
temperature and in the presence of ethanol. (A) without
ethanol; (B) with 5% ethanol.
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known to induce conformational changes in polypeptides and proteins
(Mishra and Ahluwalia 1983; Conio et al. 1970). Although Hiller et
al. (1981) believe that alcohol may not affect the peptide, but
rather the receptor, it appears likely that the effect may be
primarily on the ligand. The ligands are usually small molecules
and, especially, the enkephalins and their analogs are only
pentapeptides and are known to exist in a conformational
equilibrium. The FT-IR results indicate that both DAGO and
Met5-enkephalinamide exist in a conformational equilibrium
involving ß-turns and ß-sheets. Addition of alcohol destabilizes
these structures. Binding studies indicate that binding to both µ-
and ligands is inhibited in the presence of alcohol. We believe,
the inhibition of binding by alcohol is not specific to ligands
only. Finally, it is also possible that alcohol may induce
conformational changes in both the ligand and the receptor. Hence,
the inhibition of binding may be due to loss of conformational
features of the ligand or the receptor or both. Further studies
are in progress.
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ABSTRACT
Rats were given a daily opportunity to consume a
sweetened ethanol solution (ES) or water until they took
about 2.0 g/kg of pure ethanol (E) during 1.5 hr/day.
Then, rats were given one of a number of opioids before
an opportunity to drink. Some opioids, e.g., morphine
(MOR), methadone, and fentanyl, at small doses, increase
ES-intake; some decrease intakes, e.g., naloxone (NX) and
MR 2266. Diprenorphine, a mixed agonist-antagonist
having no analgesic potential and blocking other opioids'
analgesia, increases ES-intake across a wide range of
doses beginning with 0.003 mg/kg.
INTRODUCTION
From older studies of a time when people could legally
buy opium as well as alcohol (Seigel 1985), to studies of
E's metabolism (Davis and Walsh 1970, Cohen and Collins
1970) and modern studies of
Hiller et al. 1981, Tabakoff 1981), a relationship
receptor-dynamics (e.g.,
between processes of opioids and E have been proposed.
Not all E's effects are mediated by way of opioid
receptors, since naloxone (NX) has limited or no effects
on many E-induced events (Severs 1970). E has, however,
many effects and endogenous opioids are multifaceted. It
is unknown, however, whether or not all effects of E are
unrelated to opioid-mechanisms. Since, there are no
known E-receptors, E may achieve its ability to sustain
its own use by way of opioid-mechanisms. If this is the
case, at least some opioids should increase and NX should
decrease E-intake. Large doses of morphine (MOR),
however, decreased E-intake (Sinclair 1974) and NX
reduces intake of many ingesta including ESs (Reid 1985).
So, these early studies of opioids' effects on E-intake
did not support the idea that opioids had specific
effects on taking ES.
A problem with testing drugs' effects on E-intake is that
rats do not readily take meaningful amounts of ESs across
the brief time that relevant doses of drugs might be
effective. To overcome this, a sweetened ES was used and
it was found that rats eventually take, over days,
substantial amounts of E during brief daily opportunities
to do so. After rats were taking considerable ES, small
doses of MOR (e.g., 2 mg/kg) were tested and they
produced marked increments in E-intake. Studies of the
small-dose-MOR-effect indicate that (a) the increment in
intake is not related to flavoring of ES, (b) it does not
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tolerate, and (c) it is not dependent on variables such
as housing conditions, age, or sex of the subjects
(Hubbell et al. 1985, Reid et al. 1986). ES-intake was
also shown to be more sensitive to NX than water-intake.
So, the basic theoretical requirement of an agonist
increasing and an antagonist decreasing E-intake was met.
Also, benzodiazepines and a barbiturate did not produce
similar effects and a dopamine receptor antagonist did
not modify the intake of an ES (Mudar et al. 1986).
These initial results led us to test other opioids and
some of those tests are reported here.
MATERIALS AND METHOD
Male, Sprague-Dawley rats were placed on a daily regimen
for more than 21 days before testing. The daily regimen
involved water-deprivation until the time of presentation
of ES and water for 1.5 hr/day (food was always
available). ES was 5 g sucrose, 12 g pure E and water
added to yield 100 g of solution. Across days, rats
gained weight as those given unlimited water. So, these
healthy rats can take or not take ES. At first, rats
take very little, but, across days they take more and
more until they take about 2.0 g/kg of E during the 1.5
hr-period (an amount often producing visible
drunkenness).
After stable intakes are achieved, rats were given
placebo, and then the next day, an opioid. Subsequent to
a test of one dose, a number of days intervened and then
another placebo and dose were tested. Rats were given a
limited number of doses before being retired to avoid
carryover-effects; although in direct tests for
carryover, we have yet to observe any as long as 2 days
intervened between tests. Each dose was tested with 10
or more rats. Injections were given subcutaneously, 15
min before a test. Doses range from very small to those
large enough to interfere with drinking of any kind.
Consequently, the largest doses of all opioids are
expected to reduce intakes.
A number of indices of rats' intake of E are possible,
e.g., (a) preference ratio, i.e., the amount of ES
taken/total fluid-intake, or (b) g of pure E taken/kg of
body weight (g/kg). Since these two measures were highly
correlated, only g/kg are reported in detail here, but
preference ratios are mentioned when they give a
different perspective. The mean difference between
intake under placebo and a dose is determined and
dependent t-tests calculated.
RESULTS AND DISCUSSION
Small doses of MOR as well as small doses of methadone
and fentanyl increase intake of ES. With large doses of
MOR, preference ratios are often increased since large
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doses reduce intake of water more than ES. These agents
can be analgesics and are readily self-administered. Not
all opioid analgesics, however, increase E-intake, e.g.,
ethylketocyclazocine (EKC) did not, except in a narrow
range of doses. Also, levorphanol and dextrorphan both
increase E-intake at small doses. NX reduces E-intake.
When MOR and NX are given concurrently, the resultant E-
intake is as if NX alone was given. MR2266, in doses
similar to NX. decreases intake.
Diprenorphine is not an analgesic and blocks other
opioids' analgesia. Diprenorphine, however, increments
pressing for rewarding brain stimulation and establishes
a conditioned place preference, both of which are indices
of an opioids' ability to induce positive affect (Beaman
et al. 1984, Pollerberg et al. 1983). Diprenorphine
across a wide range of doses increases E-intake and, if
anything, reduces water-intake. When diprenorphine and
NX are given concurrently, the effect is that of NX.
FIGURE 1. Mean difference scores are depicted (drug-placebo),
so a positive score indicates the dose produced that increment
in g/kg of E-intake. Only the value for 0.2 mg/kg for levor-
phanol tartrate (LEV) and 0.2 and 2.0 mg/kg dextrorphan tar-
trate (DEX) represent reliable (p < 0.05) differences. Only
the value for 0.1 for (-)Ethylketocyclazocine (EKC) is reliably
different than placebo-scores of all the values plotted in the
top-right panel. Doses greater than 0.3 mg/kg of NX HCl represents
reliable decreases in E-intake. All values representing dipren-
orphine's effects, except the smallest (0.001 mg/kg) and the
largest dose (10 mg/kg), are statistically significant. Doses
are represented as the salt, except for diprenorphine and EKC.
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When diprenorphine and MOR are given concurrently, the
increase in E-intake is greater than when either is given
alone. Diprenorphine increases intakes of unflavored ES
(Reid et al. 1986). It is clear, small doses of some
opioids produce marked increments in E-intake. The
pattern of different opioids' effects indicate that the
ability to increment E-intake is not related to opioids'
analgesic potential: some analgesics produce decreases
in intake and others little or no effect. Diprenorphine,
an antagonist with respect to analgesia, produces
increases. A pattern that seems to relate to opioids'
enhancement of drinking ES is the pattern of opioids'
effects on pressing for rewarding brain stimulation. In
general, the doses of opioids that increase pressing also
increase E-intake.
These data lead to the conclusion that an opioid-
mechanism could be involved in E's ability to sustain its
own intake and involved in promoting "excessive" E-
intake. Perhaps, it is the same mechanism that is
involved with increasing pressing for rewarding brain
stimulation. The receptor for which diprenorphine is an
agonist, which is also sensitive to NX's antagonism,
seems particularly germane.
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ABSTRACT
Intracerebroventricular injection of (+)-naloxone
shortened pentobarbital-induced sleeping times in rats.
It does not appear that opiate receptors regulate the
duration of narcosis.
INTRODUCTION
The role of opiate receptors and the endogenous opioid
peptides in the production of general anesthesia is
unclear. Intracerebroventricular administration of
racemic (+)-naloxone dose-relatedly shortened the duration
of sleeping time induced by pentobarbital, halothane and
ketamine in rats. The fact that equivalent molar doses of
naltrexone, a more potent opiate antagonist, had no
antianesthetic effect suggested that naloxone's activity
was unrelated to an opiate receptor mechanism (Kraynack
and Gintautas 1982). Naloxone exhibits biopharmacological
effects unrelated to opiate receptor activity. Parallel
experiments with the inactive enantiomer, (+)-naloxone,
may provide additional evidence concerning the opioid
agonism theory of anesthesia.
This study was designed to investigate the modification of
narcosis in laboratory animals by the inactive enantiomer
of naloxone, (+)-naloxone. The effects of centrally
administered (+)-naloxone on the duration of sleeping time
(ST) has been determined in rats anesthetized with
pentobarbital.
METHODS AND MATERIALS
Male Sprague-Dawley rats (Harlan Sprague-Dawley,
Indianapolis, Indiana) weighing 125-150 g, were given an
intraperitoneal injection of sodium pentobarbital (50
mg/kg). Immediately after the loss of righting reflex
(LRR), groups of rats received an intracerebro-
ventricular (ICV) injection of 120 or 240 ug of
(+)-naloxone according to a method described previously
(Kraynack and Gintautas 1982). Control ST were determined
in rats receiving 0.9 percent saline ICV. A total volume
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of 12 or 24 microliters of the test drug or 0.9 percent
saline was injected into the right lateral ventricle of
the brain. The (+)-naloxone was dissolved in 0.9 percent
saline for injection. There were 10 rats per treatment
group. Awakening was defined as regaining the righting
reflex (RRR). Sleeping time (ST), defined as the period
between LRR and RRR, was recorded for all experimental
groups.
Data were expressed as the mean ± SEM. Bonferroni (DUNN)
t- test was used to evaluate pairwise differences of
naloxone induced changes. Critical differences was set at
alpha = 0.05. Significant differences between values was
assumed when p<0.05.
RESULTS
There was no statistically significant difference between
mean sleeping times of saline treated rats receiving 12 or
24 ul injections. The data were pooled
for comparisons. The mean sleeping time induced with
pentobarbital (ICV saline treatment) in this study
demonstrated no statistically significant differences from
that previously reported by us (pairwise differences
p<0.05; t-test).
Intracerebroventricular administration of (+)-naloxone
shortened the ST duration of rats anesthetized with
pentobarbital. A dose-related shortening of ST was not
observed. Sleeping time was shortened by 17 and 21
percent in rats receiving 120 or 240 ug ICV of
(+)-naloxone (table 1).
Treatment group
Saline
(+)-naloxone
120 ug
240 ug
Mean Sleeping Time (ST)
(min ± SEM)
140.9 ± 3.7
116.3 ± 6.9*
111.0 ± 12*
*Significantly different from control at 0.05
level
Thirty and forty percent of the rats in the groups treat-
ed with 120 or 240 ug, respectively, of (+)-naloxone
died. These animals exhibited gasping respiratory move-
ments accompanied by cyanosis, defecation and micturition.
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DISCUSSION
The present study clearly demonstrates that centrally
administered (+)-naloxone shortens ST induced by
pentobarbital. Enantiomeric specificity was not observed.
As shown by Ijima et al. (1978), (+)-naloxone has no more
than 1/1.000 - 1/10,000th the activity of (-)-naloxone as
an opiate receptor antagonist in severe1 in vitro systems.
Our studies revealed that siqnificantly higher doses of
(+)-naloxone, and (+)-naloxone are needed to shorten ST,
than would be expected if the drugs acted strictly as
opiate receptor antagonists. In addition, naltrexone, a
more potent narcotic antagonist, has no antianesthetic
effect in rats anesthetized with pentobarbital, halothane
or ketamine. In accordance with our data, is the fact
that barbiturates do not modify the stereo-specific opioid
receptor binding of 3H-naloxone (Pert and Snyder 1973).
The mechanism of naloxone's antianesthetic action remains
obscure, but we may conclude that narcosis (as measured by
the righting reflex), the predominant effect of general
anesthetics, is not related to pharmacologic competition
for opiate receptors. Clearly, pentobarbital does not
mediate its effect on the righting reflex (i.e., narcosis)
through pharmacologic antagonism of a receptor sharing
comparable affinities for naloxone, naltrexone and
morphine. Furthermore, Way et al. (1984) found no
evidence that anesthetics act by increasing endogenous
opioid peptide activity and concluded that analgesia
associated with general anesthesia is not mediated by
beta-endorphin; nor, as suggested by Shingu et al. (1981)
do general anesthetics alter sensitivity or facilitate
opioid peptide actions on nociceptive neurons. These
findings concur with those of Deady et al. (1981) who
concluded that the righting reflex is depressed through a
mechanism separate from that responsible for analgesia.
Consequently, these in vivo findings enhance our under-
standing of the many inconsistant and often contradictory
results reported concerning naloxone antagonism when
different indices (narcosis, analgesia, cardiorespiratory
effect) are used. The inference that these effects of
general anesthesia share a common mechanism mediated by
opiate receptors appears unwarranted.
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ABSTRACT
Centrally problematic in the study of drugs of abuse is
the addictive process itself. Addictive drugs affect do-
paminergic nigrostriatal and mesolimbic neuronal circui-
try during brain reward. These findings show that co-
caine produces a decrease in dopamine release from rat
striatum and prevents the surge of dopamine release which
occurs post-mortem. The results suggest that dopaminer-
gic control over striatal neuronal membrane may be impor-
tant in neurochemical mechanisms underlying brain reward.
INTRODUCTION
Cocaine's commonality with opiates is "abuse potential."
A neuronal reward circuitry in brain exists (Olds and
Milner 1954) and activation of this circuitry is neces-
sary for reinforcement (Wise 1982). Psychomotor stimu-
lants and opiates both appear to have their effect in
the nigrostriatal and mesolimbic areas of the descending
reward fibers of the medial forebrain bundle (Corbett
and Wise 1980;Wise 1981). Whereas opiates affect the
level of cell bodies, stimulants affect terminals of the
dopaminergic nerve fibers (Wise 1984).
The critical response for the rewarding property of co-
caine is an action at the dopaminergic synapse. Cocaine
actually prolongs the activity of dopamine by presynap-
tic reuptake inhibition, an action shared by amphetamine
(Fuxe et al. 1967). Although amphetamine has been shown
to augment dopamine release (Broderick et al. 1983),
there have been no previous in vivo studies on the dopa-
minergic release mechanisms of cocaine. The present
study serves to further elucidate the relationships be-
tween cocaine, striatal dopaminergic presynaptic mechan-
isms and brain reward.
METHODS
The effect of cocaine (20 mg/kg SC) on dopamine release
from striata of male, Sprague-Dawley rats was studied by
semiderivative electroanalyses, an in vivo electrochemi-- -
cal methodology. Chloral hydrate, anesthetized rats
(body temperature maintained at 37° C) underwent stereo-
taxic surgery for positioning of a teflon-coated working
graphite electrode (150-175µ) (stearate modification)
(Blaha and Lane 1983) in anterior striatum. A Ag/AgCl
reference electrode and stainless steel auxiliary elec-
trode was placed in contact with the rat cortex. Semi-
derivative voltammograms were recorded every ten minutes.
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Potentials were applied between -200 and +500 mv, at a
scan rate of 10 mv sec-1. In calibration experiments,
the electrochemical response increased linearly with el-
evated concentrations of dopamine without interference
from serotonin, other amines, associated metabolites and
ascorbic acid.
RESULTS AND DISCUSSION
The results show that cocaine, at a dose sufficient to
produce euphoria, caused a decreased dopamine release
from rat striatum. The dopamine signal returned to nor-
mal within the hour period studied. These results are
consistent with the known half-life of cocaine (Nayak et
al. 1976).
FIGURE 1. A line graph showing the time course
characteristics of the effect of cocaine (20
mg/kg SC) on dopamine release from rat stria-
turn. The x axis represents time (in minutes)
before and after the administration of cocaine.
The y axis represents dopamine release as per-
cent of control. The percent of controls were
calculated by averaging the first four scans
and dividing all values by that average. This
was done for each animal. The results were
considered statistically significant (p<0.05)
if the data points were outside the 95% con-
fidence limits of the control.
Other addicting drugs, such as morphine and enkephalina-
mides, also decrease dopamine release from rat striatum
(Broderick et al. 1983; Broderick et al. 1984;Broderick
1985). Post-mortem studies of rat striatal dopamine re-
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lease after cocaine treatment show that cocaine caused an
inhibition of the significantly increased surge of dopa-
mine release which occurs at death (Phebus et al. 1986;
Broderick 1986).
FIGURE 2. Semiderivative voltammograms showing
post-mortem differences between dopamine re-
lease in cocaine treated (left voltammogram)
and untreated animals (right voltammogram).
The x axes represent increasing oxidation po-
tentials in volts;
rent in nA sec-1.
the y axes represent cur-
The electrochemical signal
for dopamine (1) represents dopamine release
pre-mortem. The electrochemical signals for
dopamine (2,3,4,5) represent dopamine release
post-mortem, (ten minute intervals), in a co-
caine treated animal. In contrast, the right
voltammogram represents dopamine release ten
minutes post-mortem in an untreated animal.
The signal is increased approximately six-
fold over that dopamine release indicated by
voltammogram (1) pre-mortem.
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Taken together with previous studies which show that co-
caine inhibits reuptake (Fuxe et al. 1967), these find-
ings lend explanation to a report showing unchanged stri-
atal dopamine concentrations after cocaine (Lasley et al.
1985). In aqreement with others (Rice et al. 1985),
these studies show that in vivo electrochemistry primar-
ily estimates release. Finally, the results suqqest
that control of dopaminergic function, perhaps across
membrane (Sershen et al. 1984), may be as important in
brain reward mechanisms than is augmentation of dopamin-
ergic function.
REFERENCES
Blaha, C.D., and Lane, R.F. Brain Res Bull, 10:861-864,
1983.
Broderick, P.A. Life Sci, 36:2269-2275, 1985.
Broderick, P.A. The Hastings Center Report, in prepara-
tion, 1986.
Broderick, P.A., Blaha, C.D., and Lane, R.F. Brain Res,
269:378-381, 1983.
Broderick, P.A., Gardner, E.L.. and Van Praaq, H.M.
Biol Psychiat, 19(1):45-54, 1984.
Corbett, D., and Wise, R.A. Brain Res, 185:1-15, 1980.
Fuxe, K., Hamberger, B., and Malmfors, T. Eur J Pharma-
col, 1:334-341, 1967.
Lasley, S.M., Emmett-Oglesby, M.W., and Lane, J.D. Soc
Neurosci Abstr, 11(Part 2):1208, 1985.
Nayak, P.K., Misra, A.L., and Mule, S.J. J Pharmacol Exp
Therap, 196(3):556-569, 1976.
Olds, J., and Milner, P. J Comp Physiol Psychol, 47:419-
427, 1954.
Phebus, L.A., Perry, K.W., Clemens, J.A., and Fuller, R.W.
Life Sci, 38:2247-2453, 1986.
Rice, M.E., Oke, A.F., Bradberry, C.W.,
Brain Res, 340:151-155, 1985.
Sershen, H., Reith, M.E.A., Hashim, A.,
and Adams, R.N.
and Lajtha, A.
Eur J Pharmacol, 102:175-178, 1984.
Wise, R.A. Behav Brain Sci, 5:39-53, 1982.
Wise, R.A. Brain Res, 213:190-194, 1981.
Wise, R.A. Neuralmechanisms of the reinforcing action
of cocaine. In Grabowski, J., ed. Cocaine: 1984. Nation-
al Institute on Drug Abuse Research Monograph 50. DHHS
Pub. No. (ADM) 84-1326. Washington, D.C.: Supt. of
Docs. U.S. Govt. Print. Off., 1984. pp. 15-33.
ACKNOWLEDGEMENTS
Supported in part by a grant from the Upjohn CO. Please
address reprint requests to the author: Dr. P.A. Broderick Dept. of
Pharmacology, City University of NY Medical School, Covent Ave. at
138th Street, New York, New York 10031
370
CENTRAL CLUCACON ANTAGONIZES MORPHINE- AND STRESS-
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ABSTRACT
Previously, we have demonstrated that glucagon antagonizes morphine-
induced antinociception in the rat (Malcolm et al. 1985). In the present
studies we have shown that central injection of glucagon antagonizes
morphine- and stress-induced antinociception in the mouse. Since stress-
induced antinociception is mediated by the activation of endogenous opioid
systems, these findings provide the first evidence for glucagon’s ability to
antagonize endogenous opioid actions.
INTRODUCTION
Clucagon and its receptor have been identified within the mammalian central
nervous system (CNS)(Tager et al. 1980, Hoosein and Curd 1984). However,
with the exception of reports indicating that intracerebroventricular (icv)
injections of glucagon elevate circulating levels of somatostatin (Abe et al.
1978) and glucose (Marubashi et al. 1985), very little is known about the
physiological and pharmacological actions of glucagon in the CNS.
We have previously reported that central injection of glucagon antagonizes
morphine-induced bradycardia and antinociception in the rat (Malcolm et al.
1986) suggesting that glucagon may functionally interact with endogenous
opioid systems. This interpretation is supported by the observations that (1)
glucagon and opioid receptors share many similarities in neuroanatomical
distribution (Akil and Watson 1983, Hoosein and Curd 1984) and (2) other
brain-gut peptides (e.g. ACTH, somatostatin, cholecystokinin) have been
shown to possess some anti-opioid properties (Terenius 1975, 1976, Faris et al.
1983, ltoh et al. 1982). In the present studies we sought to determine whether
central injection of glucagon antagonizes opioid actions in another species,
the mouse, and furthermore to determine whether central glucagon can
modulate the action of endogenous opioid systems. Since endogenous opioid
systems are thought to mediate immobilization stress-induced
antinociception, we chose to test glucagon’s ability to antagonize stress-
induced antinociception as a means to assess glucagon’s effects on endogenous
opioid actions.
MATERIALS AND METHODS
All studies were carried out using male mice (ICR, CD-l strain) weighing
approximately 30 g and having free access to food and water. Central (icv)
injections of drugs were performed in conscious mice according to the method
of Haley and McCormick (1957). Immobilization stress was induced by
restraining animals for 30 minutes in a restraining apparatus for mice (Amir
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et al. 1981). Animals were injected icv with either saline (control) or
glucagon (1 or 10  µg, n=5-10; Eli Lilly and Co., Indianapolis, IN) just prior to
subcutaneous (SC) injection of morphine sulfate (5 mg/kg, n=8; Merck and Co.,
Inc., West Point, PA) or immobilization. Thirty minutes after morphine or 30
min after the onset of immobilization stress, animals were placed on a hot
plate (52°C) and jump/escape latencies were recorded. Maxiumum time
allowed for an animal to remain on the hot plate was 90 seconds.
Data were analyzed using analysis of variance followed by Duncan’s Multiple
Range test for comparison. The level of statistical significance was chosen at
p < 0.05.
RESULTS AND DISCUSSION
Compared to control nociceptive response latencies (29.3±11 sec), morphine
administration elevated jump/escape latencies 2-fold (65.1±11 sec) by 5
minutes post-injection (fig. 1). Pretreatment with 10 but not 1 µg glucagon
icv significantly attenuated morphine-induced antinociception at 15 and 30
minutes by 66% and 68%, respectively. Mice not treated with morphine (fig.
1, saline/saline group) exhibited a progressive decrease in nociceptive
response latencies when tested over time, and this decrement most likely
reflects the normal learning curve for these animals. These findings in the
mouse confirm our previous observations in the rat and support the hypothesis
that central glucagon antagonizes morphine actions and furthermore indicate
that glucagon’s anti-opioid effects occur across species.
SALINE + SALINE
SALINE + MORPHINE
GLUCAGON ( 1 µg , ICV ) + MORPHINE
GLUCAGON ( 10 µg , ICV) + MORPHINE
Figure 1. Effects of icv injection of glucagon on morphine-
induced antinociception in the mouse. Clucagon at 10 µg but
not 1 µg icv, significantly (p<0.05) attenuated morphine-induced
antinociception at 15 and 30 min as compared to the saline plus
morphine-treated group (n=5-10).
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Thirty minutes of immobilization elevated nociceptive response latencies 2.3-
fold from 32.6±6 to 76.6±8 sec. (fig. 2). Pretreatment with 1 but not 10 µg
glucagon icv completely prevented the stress-induced antinociception (fig.
2). In both studies, glucagon treatment (1 and 10 µg, icv) alone did not alter
baseline nociceptive response latencies at the times tested. This suggests
that glucagon’s antagonism of these opioid effects is not due to a direct
lowering of the threshold to pain but rather may represent a functional
antagonism between glucagon and the opioids. Since glucagon receptors have
been localized in areas of the brainstem (Hoosein and Curd 1984) known to be
involved in the regulation of pain transmission, it is possible that glucagon’s
antagonism of opioid-induced antinociception may be mediated through
glucagon receptors at these brainstem sites.
Figure 2. Effects of icv injection of glucagon on stress-induced
antinociception in the mouse. Clucagon at 1 µg but not 10 µg,
icv, completely prevented the stress-induced antinociception at
30 minutes post-injection. Clucagon treatment alone (1 and 10
µg, icv) did not alter baseline nociceptive response latencies at
the times tested.
In summary, these data confirm our previous findings in another species and
more importantly demonstrate that central glucagon blocks stress-induced
ant inociception. Since stress-induced antinociception is mediated by the
activation of endogenous opioid systems, these findings provide the first
evidence for glucagon’s ability to antagonize endogenous opioid actions.
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ENDORPHINS CONTRIBUTE TO THE LOSS OF GLUCOSE HOMESTASIS IN
ANAPHYLACTIC SHOCK
Shimon Amir
Neuroscience Center
The Weizmann Institute of Science
Rehovot, Israel
ABSTRACT
Central injection of naloxone attenuated the development of hyper-
glycemia following induction of non-fatal anaphylaxis in mice, but it
failed to reverse the hyperglycemia in this model. In contrast, cen-
tral TRH both blocked as well as reversed the hyperglycemic response.
These results suggest a possible role for central endorphin mecha-
nisms in the hyperglycemic response to anaphylactic shock in mice.
Further, they demonstrate a novel action of TRH to block shock-in-
duced hyperglycemia. This antihyperglycemic action of TRH is inde-
pendent of opiate mechanisms.
INTRODUCTION
Endorphins have been implicated in the cardiovascular depression of
circulatory shock because treatment with the opiate antagonist nalo-
xone reversed the hypotension and improved survival in several exper-
imental shock states, including endotoxic, hemorrhagic, spinal, and
anaphylactic shock (Holaday 1983). More recent studies have shown
that endorphins may also contribute to the glucose dishomeostasis
which characterizes shock since naloxone was found to block the hy-
perglycemic response to endotoxin administration (Amir and Harel
1983) or hemorrhage (Bereiter et al. 1983). The involvement of en-
dorphins in the hyperglycemic response to shock was further investi-
gated in the present study by evaluating the effect of central or
systemic naloxone on the plasma glucose responses to non-fatal ana-
phylaxis in mice. In addition, the effect of the physiologic opiate
antagonist thyrotropin-releasing hormone (TRH) on the plasma glucose
responses to anaphylaxis was investigated. TRH was found in earlier
studies to block fatal anaphylaxis in mice (Amir et al. 1984) and to
antagonize opiate-induced hyperglycemia in this species (Amir 1985).
MATERIALS AND METHODS
Subjects were normally fed male ICR mice, 28-30 g. Anaphylaxis was
induced by subcutaneous (SC) injection of the histamine releaser com-
pound 48/80 (C 48/80 [Sigma] 4 mg/kg in 0.2 ml saline). Naloxone
(Endo) and TRH (Sigma) were dissolved in sdline and injected intra-
cerebroventricularly (ICV) or intravenously (IV) one min before or 15
min after C 48/80. The ICV injections were made according to the
method of Haley and McCormick (1957) using a Hamilton microsyringe
bearnig a 27 gauge needle 2.5 mm long. Animals were sacrificed by
decapitation at different times after C 48/80 administration. The
trunk blood was collected and centrifuged to obtain plasma. Plasma
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glucose concentrations were detenmined by the glucose oxidase method
using a Bekckman glucose analyzer.
RESULTS AND DISCUSSION
Induction of anaphylaxis by SC challenge with 4 mg/kg C 48/80 result-
ed in a rapid and sustained increase in the levels of circulating
glucose (fig. 1). This hyperglycemia was attenuated by 10 ug nalo-
xone given ICV one min before C 48/80. In contrast, naloxone in-
creased the plasma glucose of shocked mice when given IV (100 ug) one
min before C 48/80 (fig. 2).
FIGURE 1. Effect of ICV naloxone or TRH pretreatment on
plasma glucose of C 48/80-treated mice. The symbols and
vertical lines represent means ± SEM of plasma glucose con-
centrations. Asterisks indicate significant difference
from C 48/80 alone (p<0.05 t tests).
As with naloxone, ICV pretreatment with 10 ug TRH strongly blocked C
48/80-induced hyparglycemia (fig. 1). However, TRH also blocked the
hyperglycemic response when given IV (100 ug, fig. 2).
Finally TRH (1 ug ICV), but not naloxone (1 ug ICV), reversed the hy-
perglycemic response to C 48/80 when given 5 min after induction of
shock (fig. 3).
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FIGURE 2. Effect of IV naloxone or TRH prtreatment on
plasna glucose of C 48/80-treated mice. See legend to fig.
1 for details.
The results with naloxone suggest that activation of edorphin mecha-
nisnms in the CNS may contribute to the loss of glucose homeostasis
and development of hyperglycemia following induction of anaphylactic
shock in mice. Morever, failure of systemic naloxone to mimic the
central action of the drug on hyperglycemia further suggests that en-
dorphins may affect central and peripheral glucoregulatory mechanisms
differentially. In contrast to naloxone TRH not only blocked C
48/80-induced hyperglycemia but also rapidly reversed it. This sug-
gests that the antihyperglycemic action of TRH is independent of en-
dorphin mechanisms. Thus, while naloxone probably affects the devel-
opment of hyperglycemia following C 48/80 by antagonizing a central
opiate receptor-mediated action of endorphins to stimulate glucose
production (Van Loon and Appel 1981), TRH may act in the CNS to phys-
iologically oppose the hyperglycemia by stimulating insulin secretion
and enhancing glucose uptake. This possibility is consistent with
recent finding that TRH lowers the plasma glucose of normoglycemic
mice by a parasympathetic-mediated insulin-dependent mechanism (Amir
et al. 1985).
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FIGURE 3. Action of ICV naloxone or TRH to reverse C
48/80-induced hyperglycemia. See legend to fig. 1 for de-
tails.
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EFFECTS OF OPIOID ANALGESICS ON LOCAL CEREBRAL GLUCOSE UTILIZATION
Edythe London, Richard Fanelli, Margit Szikszay and Donald Jasinski
Addiction Research Center, National Institute on Drug Abuse
Baltimore, MD 21224, U.S.A
ABSTRACT
The autoradiographic 2-deoxy-D-[1-[4C]glucose ([14-C]DG) method
was used to map the effects of morphine, oxymorphone and nalbuphine
on local cerebral glucose utilization (LCGU), an index of local
brain function. The mu agonists (morphine, oxymorphone) decreased
LCGU in thalamic nuclei, including some which have been implicated
in somatosensory processing. Nalbuphine did not produce these
effects, but stimulated LCGU in nuclei of the spinal trigeminal
tract. The findings suggest that different supraspinal mechanisms
mediate the actions of mu vs. kappa opioids, and that the [14-C]DG
procedure is helpful in elucidating the anatomical areas involved.
INTRODUCTION
Opioid analgesics vary in their spectrum of side effects and abuse
potential. The differences may reflect varying activities at opioid
receptor subtypes. Oxymorphone is a relatively pure mu agonist,
morphine has mu and kappa agonist properties, and nalbuphine is a
partial agonist at ka a receptors with minimal sigma agonist and mu
antagonist properties (Jaffe and Martin 1985). The purpose of this
study was to compare the distributions of the in vivo effects of
these drugs on rates of LCGU, an index of local cerebral function.
Studies of LCGU have been used to elucidate the in vivo metabolic
responses to drugs of various classes, including dopaminergic agents
(McCulloch 19821, cholinomimetics (Dam et al. 1982), and GABA-
mimetics (Palacios et al. 1982).
MATERIALS AND METHODS
Male Fischer-344 rats, 3 mo of age (Charles River Breeding Labora-
tories) were acclimated to a vivarium (25°C, 12h:12h light:dark
cycle) at the Addiction Research Center for about 4 weeks before the
drug studies. [14-C]DG, specific activity 59 mCi/mmol, Amersham
Corp.) was rechromatographed to ascertain purity. Oxymorphone HCl
and nalbuphine HCl were supplied by DuPont Pharmaceuticals; morphine
sulfate was obtained from Mallincbrodt. Inc.
The rats were fasted overnight before being prepared with
indwelling, femoral venous and arterial catheters under light
halothane anesthesia. After surgery, they were placed in a sound-
insulated box where they were allowed to recover from surgery for
about 3 h before drug treatments.
Opioids were administered S.C. 15 min before the radiotracer.
Control animals received S.C. injections of 0.9 % NaCl. Effects on
arterial blood gases and pH were assessed at several times.
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LCGU was determined after injection of [14-C]DG (125 µCi/kg body
weight, i.v.) as previously described (Sokoloff et al. 1977).
arterial blood samples were collected for assesment of plasma
glucose and [14-C]DG. Animals were killed by a pentobarbital
overdose 45 min after the [14-C]DG injection, and brains were
rapidly removed and frozen in 2-methylbutane at -5O°C.
Frozen 20 µM cryostatic sections were cut from the brains at -18 to
-20°C thaw-mounted onto glass coverslips, and exposed to x-ray film
(Kodak SB5) for one week in a cassette containing [14-C]methyl-
methacrylate standards. Brain radioactivity was determined by
quantitative autoradiography using a Leitz microscope and the
MPV-DADS scanning microdensitometry system (E. Leitz, Inc.). Brain
structures were identified using standard rat brain atlases. LCGU
was calculated from brain and plasma radioactivities and plasma
glucose concentrations using an operational equation (Sokoloff et
al. 1977).
RESULTS
Morphine and oxymorphone, but not nalbuphine decreased the pH of
arterial blood (mean pH ± SEM: control, 7.403 ± .006; morphine,
7.336 ± .013; oxymorphone, 7.336 ± .009; nalbuphine, 7.391 ± .008).
Oxymorphone significantly increased arterial blood PaCO2 and
greased PaCO2 51 min after the drug administration (PaCO2,
PaO2: control, 32.8 ± 0.9, 94.0 ± 2.0; oxymorphone 38.0 ± 1.4,
080. ± 4.0). At this time, morphine produced similar changes in
blood-gases (35.9 ± 2.8, 82.0 ± 3.0), but to a smaller degree which
did not reach statictical significance.
Drug effects on LCGU were examined in 62 brain regions, and
significant differences from control were obtained in twelve of the
regions (Table I). Morphine and oxymorphone decreased LCGU in
several thalamic nuclei and in the dorsal tegmental nucleus and the
median eminence. Nalbuphine stimulated LCGU in the spinal nuclei of
the trigeminal nerve, and in the globus pallidus.
DISCUSSION
The results support the view that opioid systems are involved in
several distinct analgesic mechanisms that are mediated by different
subpopulations of opioid receptors. The LCGU decrements in thalamic
nuclei induced by the mu agonists are consistent with mu receptor
localizations and with the hypothesis that these opioids can produce
analgesia not only by activating descending inhibitory pathways but
also by inhibiting ascending somatosensory pathways at a supraspinal
level. There are especially high concentrations of mu receptors in
midline and ventral thalamic nuclei (Goodman et al. 1980). In
contrast, the kappa system has been localized to other brain areas,
including the striatum, hypothalamus, and trigeminal sensory nuclei
(Goodman and Snyder 1982; Watson et al. 1982). Nalbuphine's effect
on LCGU in sensory nuclei of the spinal trigeminal tract is
consistent with an active inhibition of pain pathways originating at
a spinal level (Dubner and Bennett 1983).
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The findings indicate that the [14-C]DG method can be used to
delineate CNS areas mediating the effects of opioid analgesics,
distinguishing between effects of ligands for various opioid
receptor subtypes.
79 ± 2.3* 107 ± 6.3
62 ± 1.3* 83 ± 5.3
63 ± 1.3* 90 ± 5.7
58 ± 1.8* 81 ± 3.9
79 ± 2.8* 114 ± 7.7
37 ± 1.7* 51 ± 3.2
70 ± 3.2* 84 ± 7.8
52 ± 3.3 63 ± 4.6*
43 ± 2.3 61 ± 6.6*
46 ± 3.4 64 ± 4.6*
TABLE 1. EFFECTS OF OPIOID AGONISTS ON GLUCOSE UTILIZATION
Saline Morphine Nalbuphine
Control 8 mg/kg 16 mg/kg
95 ± 8.9 69 ± 3.4* 94 ± 6.6Paratenial Nucleus
Central Medial Nucleus
Ventrolateral Nucleus
Ventroposterior Nucleus
Medial Part
Lateral Part
Interanteromedial Nucleus
Median Eminence
Dorsal Tegmental Nucleus
Spinal Trigeminal Nerve
Oral Part
Interpositus Part
Caudal Part
Globus Pallidus
86 ± 7.4
74 ± 6.1
100 ± 8.8
46 ± 3.1
90 ± 5.6
51 ± 2.9
49 ± 3.3
52 ± 2.7
41 ± 3.9
104 ± 7.5
79 ± 8.3
43 ± 1.9 53 ± 3.2*
min).
Each value represents the mean ± SEM for 6 rats (µmol/100 g/
Values obtained in rats treated with 0.4 mg/kg oxymorphone
were similar to those from morphine-treated rats.
*Significant from control by one-way analysis of variance and
Duncan's multiple range test, p <0.05.
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EFFECTS OF MORPHINE AND CALCIUM ANTAGONISTS
ON PLASMA GLUCOSE IN MALE RATS
Margit Szikszay*, Frederick R. Snyder and Edythe D. London
Neuropharmacology Laboratory, Addiction Research Center,
National Institute on Drug Abuse, Baltimore, Maryland 21224, U.S.A.
*Department of Physiology, University Medical School
Szeged, Hungary
ABSTRACT
Subcutaneous administration of morphine sulfate (4-16 mg/kg) did
not significantly alter the plasma glucose concentration in fasted
adult male Fischer-344 rats. All rats treated with calcium channel
antagonists, verapamil or diltiazem (10 mg/kg, with or without
morphine), showed marked and significant hyperglycemia, persisting
at high levels throughout the 2 h experiment.
INTRODUCTION
Calcium channel antagonists reduce calcium influx through voltage-
dependent calcium channels (for reviews see Chaffman and Brogden
1985; Schramm and Towart 1985). Opioids also inhibit Ca2+ influx
in a naloxone-reversible manner (for reviews see Ross and Cardenas
1979; Chapmand and Way 1980), suggesting that opioids might interact
with calcium channel antagonists in affecting various physiological
parameters. In this regard, calcium antagonists potentiate morphine
induced antinociception and hypothermia in rats (Benedek and
Szikszay 1984), but attenuate the respiratory depressant effect of
morphine (Szikszay et al. 1986). The major objective of the present
work was to determine if calcium antagonists and morphine interact
to alter plasma glucose levels in rats.
MATERIALS AND METHODS
Seventy seven male 3-4 month old Fischer-344 rats were fasted for
approximately 15 h prior to surgery, and then were prepared with a
femoral arterial catheter under halothane anesthesia. They were
partially immobilized as described previously (London et al. 1981),
so that results would be pertinent to future studies of cerebral
glucose utilization. Three hours later, arterial blood samples were
taken from awake rats 5 min before and at 0.25, 0.5, 1 and 2 h after
drug treatments to assess plasma glucose concentrations by a Beckman
Glucose Analyzer 2.
Morphine sulfate, verapamil HCl and diltiazem HCl were dissolved in
0.9% NaCl. Morphine sulfate was administered at 4, 6, 8 and 16
mg/kg, and calcium antagonists were given at 10 mg/kg, expressed as
the salts. All doses of morphine were tested with verapamil, but
only 4 mg/kg was tested with diltiazem. Drugs were injected S.C.
either alone or in combination (5-6 rats/group). Effects of the
treatments were assessed by a two-way (diltiazem) or three-way
(verapamil) analysis of variance with repeated measures over time.
Post-hoc comparisons were performed using Tukey's w-procedure.
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RESULTS AND DISCUSSION
At all doses tested, morphine did not significantly alter the plasma
glucose concentration as compared to values in saline-treated rats
[main effect of morphine (4,43); F = 0.61. Although a hyperglycemic
effect of morphine has been recognized for many years, most of the
previous experiments were performed in cats and dogs (Borison et
al. 1962; Feldberg and Shaligram 1972). In rodents, some studies
have shown altered glucoregulation in response to morphine,
depending upon the strain, gender and dose. For example, Simon et
al. (1981) did not show significant effects of 4 or 8 mg/kg morphine
on blood glucose in female mice. In immature (120-140 g) female
Sprague-Dawley rats, 30 mg/kg morphine increased the glucose level
by about 40% (Muller et al. 19671, and in male non-fasted,
anesthetized Wistar rats, 20 mg/kg morphine increased plasma glucose
by about 50% (Nakaki 1981). The dosages of morphine used in our
experiments were much smaller and apparently were not sufficient to
cause hyperglycemia in awake male Fischer-344 rats.
FIGURE 1. Effects of different morphine doses and verapamil
on plasma glucose levels. Measurements were taken before (0)
and at four times after the S.C. injection of 0.9% NaCl
10 mg/kg verapamil morphine alone and in combination
with verapamil . Abscissae: time in hours. Ordinate:
mean deviation from the baseline values (114.3 ± 4.1 mg/dl).
*Significant p<0.05 (verapamil vs. morphine + verapamill.
In contrast, rats treated with verapamil, alone or in combination
with morphine, showed marked and significant elevations of arterial
plasma glucose levels [main effect of verapamil (1,43); F = 2141.
Moreover, there were significant interactions of verapamil not only
with time but also with dose of morphine (Fig 1). The highest
plasma glucose levels were observed in verapamil-treated rats after
the lower doses of morphine; whereas rats treated with 16 mg/kg of
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morphine + verapamil had approximately the same plasma glucose level
as rats treated with verapamil
interaction: (4,43); F = 5.81.
alone [morphine by verapamil
Plasma glucose levels rose more
sharply during the first hour and tended to level off or increase
at a lower rate during the second hour after treatment [verapamil by
time interaction: (3,129); F = 20.21. The significant three-way
interaction of morphine by verapamil by time (12,129; F =3.5)
reflected the difference between verapamil alone as compared to
verapamil in combination with the three lower doses of morphine at
2 h only. Diltiazem alone or in combination with 4 mg/kg morphine
produced a level of hyperglycemia similar to that obtained with
verapamil (52-60 mg/dl over baseline, data not shown).
Although verapamil inhibits both calcium entry and uptake in the
pancreatic beta cells and glucose-induced insulin release in vitro
(Malaisse et. 19771, effects of calcium channel antagonists on
blood glucose concentrations in vivo have been inconsistent. For
example, nifedipine produced hyperglycemia and increased blood
glucagon levels in human subjects (Charles et al. 1981), but
verapamil (0.5 mg/kg, i.p.) did not alter blood glucose in rats
(Luyckx and Lefebvre 1976). Our results indicate that a much higher
dose of verapamil or diltiazem can produce hyperglycemia in rats,
suggesting an overall hyperglycemic effect of calcium antagonists.
The authors thank Dr. Ronald K. Browne of Marion Laboratories, Inc.
for supplying diltiazem.
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DYNAMIC CHANGES IN THE LEVELS OF STRIATAL PROENKEPHALIN mRNA
AND LARGE MOLECULAR WEIGHT ENKEPHALIN CONTAINING PEPTIDES
FOLLOWING ELECTROACUPUNCTURE
Xang Tsou, Min Zheng and Xiao-Hong Ding
Shanghai Institute of Materia Medica, Academia Sinica
Shanghai, 200031, China
ABSTRACT
Electroacupuncture has been shown to increase met- and leu-enkephalin
contents in rat striatum and hypothalamus. Its mechanism was further
studied by measuring the levels of the large molecular weight enke-
phalin containing peptides (LECP), processed intermediates, free
leu-enkephalin as well as proenkephalin mRNA in the striatum of rats
decapitated at different times after the termination of 30 min
electroacupuncture. A prominent increase of leu-enkephalin was seen
in rats decapitated immediately after electroacupuncture. This
increase returned to control level at 0.5 h. The levels of LECP and
intermediates began to elevate at 1 h after electroacupuncture,
reached a plateau at 8 h and lasted for 96 h. A second phase of
smaller but longer lasting increase of leu-enkephalin appeared at
8-96 h. The proenkephalin mRNA amount measured by dot-blot procedure
increased 3-5 folds starting at 1 h and lasting for at least 48 h.
INTRODUCTION
It has been shown that acupuncture increases the contents of met-
and leu-enkephalin immunoreactivities in the striatum and the hypo-
thalamus (Tsou et al. 1980). This effect was attenuated by icv
administration of the protein synthesis inhibitor cycloheximide
suggesting that acupuncture accelerates enkephalin synthesis (Wu et
al. 1980). In order to gain some insight into this mechanism, we
followed the levels of the enkephalin precursors, the processed
intermediates and leu-enkephalin in the rat striatum simultaneously
after electroacupuncture for 96 h. To answer if it also involves
gene transcription, the proenkephalin mRNA was quantitated by dot-
blot procedure at various times after electroacupuncture.
MATERIALS AND METHODS
Electroacupuncture
Rats weighing 200-250 g were restrained in lucite containers. One
stainless steel electrode was implanted in the sciatic nerve region
of each hind limb. The electrodes were connected to a therapeutic
acupuncture stimulator, which produces intermittent high and low
frequency biphasic waves. The rats were stimulated for 30 min with
pulses just above the threshold of slight vocalization.
Chromatographic fractionation and enzymatic digestion
The striata of 10 rats from the same group were pooled and homogeni-
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zed in a 10 times volume of 1 M acetic acid.
centrifuged for 20 min at 10,000 rpm, 4°C.
The homogenate was
The supernatant was
fractionated on a Sephadex G 75 column. From each collecting tube
1 ml of eluates was lyophilized. The lyophilized material was
resuspended and incubated first with TPCK treated trypsin solution
and then with carboxypeptidase B. The enzymes were subsequently
inactivated in a 90°C water bath for 20 min. Radioimmunoassay was
carried out as described (Tsou et al. 1930).
Proenkephalin mRNA quantitation
RNA was extracted and purified according to Feramisco et al (1982).
A 918 base pair cDNA complementary to the proenkephalin mRNA sequence
of human pheochromocytoma was a gift of Professor E. Herbert. This
cDNA was cloned into the Pst 1 site of pBR 322 (Comb et al. 1982 and
propagated in E. coli RRI. The cDNA probe was labelled with 32P)
MT? by nick-translation to a final specific activity of 1-5x108
cpm/µg. Equivalent amount (20 µg) of RNA from each sample was used
for dot-blot assay on a nitrocellulose filter paper, which was then
washed and exposed on to a X-ray film at -7O°C. The autoradiograms
were scanned with a Shimadzu CG-930 scanning densitometer.
RESULTS AND DISCUSSION
When the rat striatal eluates from the Sephadex G 75 column were
monitored at 254 µM, two peaks of absorption were observed. Radio-
immunoassay of leu-enkephalin content in each collecting tube
revealed immunoreactivities only in those tubes containing small
molecular size peptides. This peak of immunoreactivites coincided
with the second peak of UV absorption. In the tubes containing
higher molecular weight peptides and proteins, leu-enkephalin immuno-
reactivities only appeared after trypsin and carboxypeptidase B
digestion. Therefore the eluates from tube No. 3-24 (corresponding
to the first peak of UV absorption) were pooled as the total amount
of the enkephalin precursors, from tube No. 25-48 as the intermedia-
tes and from tube No. 49-68 (corresponding to the second peak of UV
absorption) as the free leu-enkephalin. A composite figure (figure
1) could be drawn with changes of precursors, intermediates and free
leu-enkephalin levels in the rat striatum after the termination of
30 min electroacupuncture. A prominent increase of leu-enkephalin
content appeared immediately (0 h) after electroacupuncture. This
rapid increase declined quickly to the control level at 0.5 h.
During this initial period no change in the levels of precursors and
intermediates was found. At 1 h after the termination of electro-
acupuncture, there were elevations of both the precursor and
intermediates levels, which rose steadily until reaching a plateau
at about 8 h and lasted for at least 96 h. A second phase of smaller
hut longer lasting increase of leu-enkephalin appeared at 8 h and
lasted for more than 96 h. These results suggest that a huge amount
of enkephalin is released during acupuncture. The high level of
leu-enkephalin represents the released and the newly formed but still
unreleasable forms. The quick decline of leu-enkephalin was due to
rapid degradation of the released form. Although during this initial
period no change was found with the precursor and the intermediate ,
the rate of biosynthesis and processing might have already increased
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FIGURE 1. Changes in the levels of enkephalin
precursors, processed intermediates and leu-
enkephalin after electroacupuncture. Each column
represents the content in the extract of pooled
striata of 10 rats.
so that their levels could remain unchanged. After the cessation
of electroacupuncture for about 1 h, the rate of enkephalin
utilization might slow down leading to an increase in the levels of
enkephalin precursors and processed intermediates. Their elevation
would eventually lead to a second phase of smaller but longer lasting
increase of leu-enkephalin.
Proenkephalin mRNA was quantitatad by hybridization with a human
proenkephalin cDNA probe using dot-blot procedure. A 3-5 fold
increase of proenkephalin mRNA level in the striatum could be  detect-
cd as early as 1 h after the termination of 30 min electroacupuncture.
This proenkephalin mRNA induction continued for at least 48 h (fig
2).
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FIGURE 2. Temporal effect of electroacupuncture
on rat striatal proenkephalin mRNA level.
C: conrol; 0.5, 1,2, 16, 48 and 96 are the
time intervals (h) between the termination of
electroacupuncture and the sacrifice of the
animals.
Since no change in the proenkephalin mRNA level was observed in the
first hour after electroacupuncture, the initial rapid enkephalin
increase in the striatun is most likely due to accelerated trans-
lation of the mRNA and post-translational processing of the precursor.
It is also postulated that the large release of enkephalin during
electroacupuncture may lead to a depletion of the releasable form.
'This depletion in turn brings about an enhanced transcription of the
proenkephalin gene. Such a mechanism may play an important part to
compensate the depletion by electroacupuncture.
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ABSTRACT
Dopaminergic denervation by 6-hydroxydopamine (6-OHDA) increased
proenkephalin-A gene expression in the striatum as evidenced by
increases in the levels of Met5-enkephalin (ME), precursor and
preproenkephalin mRNA (PE-mRNA). This and other lines of evidence
support the hypothesis that nigrostriatal dopamine input is inhibi-
tory to striatal enkephalin neurons and that the removal of this
inhibitory influence leads to an acceleration of ME biosynthesis.
These findings suggest that the enkephalin system may be associated
with the progression of adaptive changes subsequent to dopaminergic
dysfunction in basal ganglia.
INTRODUCTION
Enkephalins are found in high concentrations in the same forebrain
structures which contain high levels of dopamine (Atweh and Kuhar,
1977; Hong et al. 1977; Johnson et al. 1980). Treatments that
alter dopaminergic transmission also alter the enkephalin system, for
example, chronic dopamine receptor blockade with haloperidol leads to
an increase in ME biosynthesis (Hong et al. 1978; Tang et al. 1983;
Sabol et al. 1983; Hong et al. 1985; Mocchetti et al. 1985; Sivam
et al. 1986). In addition, unilateral substantia nigra lesions also
increase the ME level in the ipsilateral striatum (Thal et al.
1983). Parkinson's disease and Lesch-Nyhan syndrome are two clinical
disorders in which dopamine deficiency has been found to be the major
component. Therefore, elucidation of the interrelationship between
enkephalin and dopamine in basal ganglia function is important
and the present work addresses this issue.
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METHODS
Adult Sprague-Dawley rats received 6-OHDA (200 µg, free base) intra-
cisternally in a volume of 25 µl. Behavioral evaluation to assess
dopaminergic supersensitivity following 6-OHDA lesions was made by
measuring locomotor activity. Animals were decapitated, brains were
removed, the striata and hippocampi were dissected out and used for
biochemical determinations.
Dopamine, dihydroxyphenylacetic acid (DOPAC) and homovanillic acid
(HVA) were determined utilizing the reverse phase high-performance
liquid chromatography (HPLC) procedure. The content of ME (native
ME) was determined by radioimmunoassay (RIA) as described earlier
(Hong et al. 1978). Precursor content as reflected by the cryptic
ME level was determined following sequential digestion of the
tissue proteins with trypsin and carboxypeptidase-B (Sivam et al.
1986). Dynorphin-A (1-8)-like immunoreactivity was determined by
RIA.
Total RNA was isolated from striatal tissues following the method
described by Chirgwin et al. (1979). Northern blot and dot-blot ana-
lyses were carried out using a nick-translated 32P cDNA probe from
rat brain (Yoshikawa et al. 1984). The blots were subjected to
autoradiography followed by densitometry. The data were evaluated
for significance by analysis of variance. Post hoc comparisons bet-
ween group means were made with Fisher’s Least Significant Test.
RESULTS AND DISCUSSION
Rats lesioned with 6-OHDA exhibited an enhanced locomotor response
(table 1) to LY-171555, a D2-dopamine receptor agonist. These data
Table 1. Locomotor responses to dopamine agonist in rats
lesioned with 6-OHDA.
Drug Activity Counts
Treatment (counts/150 min)
Unlesioned control Saline 884 ± 92
Unlesioned control LY-171555 2954 ± 757*
6-OHDA lesion Saline 876 ± 176
6-DHDA lesion LY-171555 31403 ± 2000*
LY-171555 (0.3 mg/kg), a D2 agonist. There are at least 8 rats in
each group. p<0.05 compared to the respective saline group.
document a functional supersensitivity of dopamine receptors and con-
firm previous observations (Breese et al. 1985a,b). The 6-OHDA-
induced lesion reduced dopamine (>90%) in striatum; the dopamine
metabolite DOPAC and HVA were also markedly reduced. These data
clearly indicate the effectiveness of 6-OHDA treatment to destroy
dopaminergic fibers.
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Table 2. Effect of 6-OHDA-induced lesions on various biochemical
parameters in the striatum.
Proenkephalin-A systemb
Native ME 1.34 ± 0.07 (12) 1.99 ± 0.17* (13)
Cryptic ME 0.19 ± 0.02 (12) 0.31 ± 0.02* (12)
PE-mRNA 100 ± 0 (4)
Parameters
Dopamine systema
Dopamine
DDPAC
HVA
Treatment
control 6-OHDA lesion
41.8 ± 1.8 (8) 3.2 ± 0.6 (8)
5.8 ± 0.4 (8) 0.7 ± 0.1* (8)
2.2 ± 0.2 (8) 0.5 ± 0.1* (8)
157 ± 5* (4)
Dynorphin systemC
Dynorphin-A (1-8) 20.6 ± 1.43 (12) 21.3 ± 1.53 (12)
* p<0.01 compared to respective control group. Values are mean ± SE
of the indicated number of samples given in parentheses. a) Dopamine
and its metabolites were estimated by HPLC; b) ME was estimated by
radioimmunoassay and PE-mRNA was quantitated by RNA-cDNA hybridiza-
tion; c) dynorphin-A (1-8) was measured by radioimmunoassay.
The 6-OHDA lesioned group had elevated levels of ME in the striatum
as compared to levels observed in unlesioned controls (table 2).
Dynorphin-A (1-8) content was also evaluated, but no significant
change was observed between the groups. The hippocampal content of
ME or dynorphin-A (1-8) was not altered by the 6-DHDA treatments.
These results indicate regional specificity and selectivity with
regard to the increase in ME as a result of 6-DHDA-induced lesions.
In order to investigate the mechanism of this increase, the
proenkephalin content as reflected by the cryptic ME content, as well
as the PE-mRNA abundance, was assessed in the striatum. It was
found that both precursor content and PE-mRNA abundance were
increased after 6-DHDA-induced lesions (table 2).
These data provide evidence that dopaminergic denervation by 6-OHDA
administration increases major biosynthetic indices of ME in the
basal ganglia, suggesting increased transcription and/or translation
processes for this peptide. These results are consistent with other
lines of evidence (see Introduction) that dopamine can modulate the
enkephalinergic neurons in the striatum. These studies support the
hypothesis that dopaminergic neurons are inhibitory to ME-containing
neurons in the striatum and that the removal of this control results
in disinhibition of enkephalinergic neurons (Tang et al. 1983; Thal
et al. 1985; Hong et al. 1985) which, in turn, leads to enhanced
synthesis of ME. The adaptive changes in the enkephalin system
resulting from the dopamine deficiency may have relevance to clinical
syndromes with dopamine deficiency.
391
REFERENCES
Atweh, S.F. and M.J. Kuhar. Brain Res, 134: 393-405, 1977.
Breese, G.R., Baumeister, A., NapiK T.C., Frye, G.D. and Mueller,
R.A. J Pharmacol Exp Ther, 235: 287-295, 1985a.
Breese, G.R., Napier, T.C. and Mueller, R.A.. J Pharmacol Exp
Ther,  234: 447-455, 1985b.
Chirgwin, J.M., Przybyla, A.E., MacDonald, R.J. and Rulter, W.J.
Biochemistry, 18: 5294-5299, 1979.
Hong, J.S., Yang, H.Y.T.,
383-386, 1977.
Fratta, W. and Costa, E. Brain Res, 134:
Hong, J.S., Yang, H.Y.T., Fratta, W. and Costa, E. J Pharmacol
Exp Ther, 205: 141-147, 1978.
Hong, J.S., Yoshikawa, K., Kanamatsu, T. and Sabol, S.L. Fed Proc,
44: 2535-2539, 1985.
Johnson, R.P., Sar, M. and Stumpt, W.E. Brain Res, 194: 566-571,
1980.
Mocchetti, I., Schwartz, J.P. and Costa, E. Mol Pharmacol, 28:
86-91, 1985.
Sivam, S.P., Strunk, C., Smith, D.R. and Hong, J.S. Mol Pharmacol,
In press, 1986.
Tang, F., Costa, E. and Schwartz, J.P. Proc Natl Acad Sci (USA),
80: 3841-3844, 1983.
Thal, L.J., Sharpless, N.S., Hirschhorn, I.D., Horowitz, S.G. and
Makman, M.H. Biochem Pharmacol, 32: 3297-3301, 1983.
Sabol, S.L., Yoshikawa, and Hong. J.S. Biochem Biophys Res
Comm, 113: 391-399, 1983.
Yoshikawa, K., Williams, C. and Sabol, S.L. J Biol Chem, 259:
14301-14308, 1984.
392
INCREASED ENKEPHALIN GENE EXPRESSION IN THE HIPPOCAMPUS
FOLLOWING SEIZURES
Jeffrey D. White and Christine M. Gall*
Division of Endocrinology, Health Sciences Center
SUNY, Stony Brook, NY 11794
*Department of Anatomy and Neurobiology
University of California, Irvine, CA 92717
ABSTRACT
Bilateral, recurrent seizures were induced in adult male rats by a
unilateral, electrolytic lesion of the dentate gyrus hilus. This
treatment led to a bilateral depletion of enkephalin-like
immunoreactivity in the hippocampal mossy fibers by 12 hours (h)
post-lesion, a rebound above normal levels by 24 h, a further rise by
4 days then a fall to control values by 10 days post-lesion. The
mRNA for preproenkephalin was elevated in the granule cells by 3h
post-lesion, reached a maximal 24-fold rise by 30 h then fell again
to control values by 4-10 days post-lesion.
INTRODUCTION
The mossy fiber axons of the rat hippocampus have been shown to
contain the opioid neuropeptides enkephalin and dynorphin (Gall et
al. 1981, McGinty et al. 1983). This topographic and exclusively
ipsilateral projection from dentate gyrus granule cells to CA3
pyramidal cells represents a principal relay in the circuit of
excitatory connections within the hippocampal formation. In contrast
to enkephalin's typically observed inhibitory actions, in hippocampus
enkephalin has been demonstrated to lead to a net excitation of
pyramidal cells either through inhibition of inhibitory neurons
(Zieglgansberger et al. 1979) or by changing somatic dendritic
coupling (Lynch et al. 1981). Several previous studies have
demonsytrated that enkephalin-like immunoreactivity or
preproenkephalin mRNA change in the hippocampus in response to a
variety of seizure-producing stimuli (Gall et al. 1986; Hong et al.
1980; Hong et al. 1985 a,b). Similarly, we have demonstrated that
enkephalin peptide biosynthesis is stimulated 14-fold following a
unilateral electrolytic lesion of the dentate gyrus hilus and that
this rise in peptide biosynthesis is preceeded by a rise in the
content of preproenkephalin mRNA (White et al. 1986). In the present
study we wished to monitor the time course over which enkephalin-like
immunoreactivity and preproenkephalin mRNA change in the granule
cells following the seizure-producing hilus lesion.
MATERIALS AND METHODS
Materials
Male Sprague-Dawley rats (200-250 gm) were used for these studies.
Reagents for nucleotic acid techniques were generally from Sigma and
Fisher. [ ] 32P-CTP (300 - 600 Ci/mmol) was from Amersham or ICN.
GeneScreen Plus membrane was from New England Nuclear.
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Surgical procedures
Experimental animals were anesthetized and a lesion was placed in the
right dentate gyrus hilus using an insulated steel wire and an anodal
current of 0.8mA for 8 sec. as described (White et al. 1986).
Control (sham lesion) animals received identical surgical procedures
without current. Behavioral seizures were rated using the scale of
Racine (1972) and only those animals displaying scale 4-5 seizures
were used for the study.
Immunohistochemistry
Coronal sections through the hippocampus were processed for
enkephalin-like immunoreactivity by the peroxidase antiperoxidase
technique as described elsewhere (Gall et al. 1981).
Tissue Harvest and Nucleic acid techniques
At designated intervals following the lesion, the rats were
sacrificed by decapitation, the hippocampus contralateral to the
lesion was dissected free and divided longitudinally into region CA3
and CAl/dentate gyrus. The latter samples were used for RNA
measurement.
Total nucleic acid was prepared by extraction in urea/SDS followed by
phenol/chloroform extraction and ethanol precipitation. Total RNA
was obtained by treating these samples with RNase-free DNase,
phenol/chloroform extraction, and ethanol precipitation. Identical
concentrations of RNA was electrophoresed on denaturng agarose gels,
transferred to nylon membrane and hybridized with 32P-labeled cRNA
probe to rat preproenkephalin mRNA. Following washing, the blot was
apposed to X-ray film. The resulting autoradiographs were scanned
densitometrically for quantitation. Details are given in White et
al. (1986).
RESULTS AND DISCUSSION
In previous studies, we have demonstrated that a unilateral lesion of
the hilus leads to the generation of bilateral,
electrophysiologically identified episodes of epileptiform activity
which are initiated approximately 1-2 hours post-lesion and that
recur for 12 hours thereafter (Gall et al. 1986). Additionally, we
have demonstrated that this seizure-producing paradigm leads to a
dramatic increase in enkephalin biosynthesis in the granule cells.
Thus, 24 hours post-lesion, there is a 14-fold increase in enkephalin
peptide biosynthesis, as measured by the technique of in vivo
radiolabeling, and a similar rise in preproenkephalin mRNA (White et
al. 1986). Preliminary studies suggested that enkephalin levels
gradually returned to normal levels and the present studies were
initiated to verify and extend these initial observations.
Figure 1 illustrates the changes in the intensity of
immunohistochemical staining for enkephalin-like immunoreactivity in
intact, contralateral mossy fibers at various times post-lesion. As
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the figure indicates, enkephalin levels are low in control animals
(a) but fall rapidly to non-detectable levels by 12-hours post-lesion
(b). By 24 hours post-lesion the staining has attained supranormal
levels and enkephalin-like immunoreactivity increases further by 2-4
days post-lesion (c). However, by 10 days post-lesion the staining
has returned to control values.
FIGURE 1: Enkephalin-like immunoreactivity in the mossy fibers of
region CA3 of a control animal (a) and, rats sacrificed at
12-hours (b), 2 days (c) and 1 month (d) post-lesion. Side
contralateral to lesion is shown.
Preproenkephalin mRNA levels
The above described changes in enkephalin-like immunoreactivity were
accompanied by a similar change in the content of preproenkephalin
mRNA in the dentate gyrus granule cells following the hilus lesion.
As shown in figure 2, preproenkephalin mRNA was elevated in the
granule cells as early as 3 hours post-lesion (2-fold above control),
reaching a peak by approximately 30 hours post-lesion (24-fold) then
declining to near baseline levels by 10 days post-lesion.
FIGURE 2: Preproenkephalin mRNA in the granule cells: The
autoradiogram of the Northern blot analysis of preproenkephalin
mRNA content in animals sacrificed at the indicated post-lesion
intervals is shown above. C=control, h=hours, d=days.
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The present experiments have demonstrated that enkephalin gene
expression is rapidly influenced by the consequences of the hilus
lesion. These changes appear to be relatively transient in that
enkephalin peptide and preproenkephalin mRNA levels return to control
values by 10 days following the cessation of seizures. It is worth
noting that the hilus lesion-induced changes in enkephalin gene
expression are not accompanied by changes in the relative amounts of
the several Met-enkephalin containing peptides present in the mossy
fibers. That is, despite the large increase in enkephalin peptide
biosynthesis induced by the seizures, the ratio of Met-enkephalin,
Met-enkephalin-ArgGlyLeu, Met-enkephalin-ArgPhe, and BAM 18P does not
change, suggesting a tight physiological control of the
post-translational processing of proenkephalin (White et al. 1986).
The rapid and dramatic increase in enkephalin biosynthesis within
identified hippocampal neurons in response to seizure activity makes
the hilus lesion a promising paradigm for the elucidation of
mechanisms which regulate enkephalin gene expression in brain. Given
the well-known anatomy, physiology and putative neurotransmitter
makeup of hippocampal circuitry, it will now be possible to evaluate
the separate roles played by peptide release and depletion of
cellular storage pools, neuronal excitation per se and the activation
of specific post-synaptic receptors in the regulation of enkephalin
gene expression.
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REGULATION OF PROOPIOMELANOCORTIN (POMC) mRNA LEVELS
IN PRIMARY PITUITARY CULTURES
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ABSTRACT
The effect of a variety of neurotransmitters and of cor-
ticotropin releasing factor (CRF) upon levels of mRNA
coding for proopiomelanocortin (POMC) was studied in
primary cultures of rat pituitary. Total nucleic acid was
extracted from cells, fixed on nitrocellulose and hybri-
dized to a single-stranded ( 32P-labeled DNA complementary
to 150 bases of mouse POMC mRNA. After two days incuba-
tion with CRF (10 M), the levels of POMC mRNA in both
the anterior (AL) and the intermediate lobe (IL) cells
increased by about 100%. A similar increase in the IL
cells was seen after incubation with the ß-adrenergic
agonist isoprenalin (10-6M). In contrast, dopamine (10-6
M) and GABA (10-6 M) decreased POMC mRNA levels in the IL
cells to about 50% of control levels without affecting
POMC mRNA levels in the AL cells.
lobes, POMC mRNA was decreased by the Ca2+-channel
In both pituitary
blocker D600 (10
-5M) and increased by forskolin (10-6M).
This indicates that both CAMP and Ca2+ ions play an im-
portant role as intracellular messengers for the control
of POMC gene expression in normal melanotrope and corti-
cotrope cells.
INTRODUCTION
The proopiomelanocortin (POMC) gene is expressed in both
the melanotrope cells of the intermediate (IL) and the
corticotrope cells of the anterior (AL) lobe of the pi-
tuitary. Processing of the peptide precursor, however, is
different in the two structures. In addition, there exist
major differences in the regulation of the release of
POMC-derived peptides from the two pituitary lobes. Thus,
the secretion of POMC peptides from corticotrope cells is
stimulated by CRF and inhibited by glucocorticoids. The
secretion from the melanotrope cells of IL is under inhi-
bitory control of dopamine (DA) and aminobutyric acid
(GABA) (Demeneix et al. 1986). In contrast to CRF, which
stimulates both melanotrope and corticotrope cells (Vale
et al. 1983, Proulx-Ferland et al. 1982), DA and GABA
only interact with IL cells. There is accumulating evi-
dence that these factors not only modulate peptide secre-
tion but also induce a readjustment of peptide biosynthe-
sis. Recently, we and others have shown that POMC gene
expression at the mRNA level can be modulated by pro-
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longed treatment with glucacorticoids, CRF and dopaminer-
gic drugs in vivo (Birnberg et al. 1983, Bruhn et al.
1984, Höllt and Haarmann 1984, Höllt et al. 1982, Chen et
al. 1983) (for a review see Civelli et al. 1984). How-
ever, from these in vivo results it is difficult to in-
terpret whether these drugs act directly at the level of
pituitary cells to change POMC mRNA levels or indirectly
by altering factors released by the hypothalamus. There-
fore, we measured the effect of various drugs on primary
cultures of IL and AL of rat pituitary.
MATERIALS AND METHODS
Cells were cultured as previously described (Loeffler et
al. 1985). Briefly, intermediate (IL) and anterior pitui-
tary lobes (AL) from 30 male Sprague-Dawley rats (200 g)
were dispersed and washed with phosphate-buffered saline
(PBS) supplemented with kanamycin (50 µg/ml), 0.1% colla-
genase, 0.2% dispase II, 0.1% hyaluronidase, 0.05% DNase
I and 1% bovine serum albumin (BSA). Dispersion was com-
pleted after shaking for 1 h at 37°C. IL and AL cells
were plated on 24 and 48 dishes (Costar), respectively,
in BM 86 WISSLER medium (Boehringer, Mannheim, F.R.G.)
supplemented with 10% foetal calf serum. After two days
of culture, cells were kept in serum-free medium to which
drugs were added during two additional days. The cultured
cells were lysed in 300 µl of 20 mM HEPES, 1 mM EDTA and
1% SDS and the total nucleic acids (TNAs) were extracted
with phenol-chloroform. The TNAs were bound to
nitrocellulose filters according to the dot-blot
technique of White and Bancroft (1982). For
hybridization, a single-stranded cDNA complementary to
150 nucleotides of mouse POMC mRNA was used. The mouse
POMC DNA originally cloned in pBR 322 (a generous gift
from Dr. J. Roberts, New York) (Roberts et al. 1979) was
subcloned in M13 mp8 vector. A single-stranded M13 recom-
binant containing the message-sense insert was used as a
template for the synthesis of a cDNA with high specific
activity (109 cmp/µg DNA). Relative POMC mRNA levels are
expressed as percentage of control.
RESULTS
Treatment of c e l l s for two days with dopamine (10-6 M)
and GABA (10-6 M) resulted in a marked decrease in POMC
mRNA levels in the IL, but not in the AL cells of the pi-
tuitary (Fig. 1). Isoprenaline (10-6 M), a B-receptor
agonist, increased the POMC mRNA levels in the IL cells
by about 100% (its effect on the AL cells has not been
measured). CRF (10-8 M) doubled POMC mRNA levels in both
IL and AL (Fig. 1).
The Ca++ channel blocker D600 (10
-5 M) reduced the POMC
messenger in both pituitary lobe cells (Fig. 2) by about
50%, whereas forskolin (10-5 M), an agent which stimu-
lates the adenylate cyclase, increased the POMC mRNA
levels in AL and IL by more than 100% (Fig. 2).
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Fig. 1: After two initial days of culture, IL and
AL cells were treated for 48 h in serum-free me-
dium with various drugs in the presence of 1‰
ascorbic acid. Dopamine (10-6 M) (DA), GABA
(10-6 M), CRF (10-8 M) and isoprenalin (10-6 M)
(Isop.) were used. Data are given as percentage of
control. Significance of differences are assessed
with Student's t test (*when p < 0.05).
Fig. 1 Fig. 2
Fig. 2: IL and AL cells were treated for 48 h in
serum-free medium with Ca++ channel antago-
nist D600 (10
-5 M) or with the adenylate cyclase
activation forskolin (10-6 M) (FK). Data are given
as percentage of control. Significance of differ-
ences are assessed with Student's t test (*when
p < 0.05).
DISCUSSION
The results of this study showed that in primary cultu-
res of rat pituitary, various neurotransmitters directly
modulate the gene expression of POMC at the mRNA level.
This regulation can be different in the distinct pituita-
ry lobes; thus, dopamine and GABA decrease POMC mRNA in
the IL but not in AL cells. However, for CRF a similar
increase in the POMC mRNA levels in both AL and IL has
been found (Fig. 1). In earlier experiments, we found a
marked decrease in the levels of POMC-mRNA in the IL of
rats which had been chronically infused with low doses of
CRF (Höllt and Haarmann 1984). Thus, it appears that CRF
induces changes in the activity of unknown transmitters
in vivo, which counteract its own up-regulating effect on
POMC mRNA in the IL. In both lobes, CAMP appears to play
a major role as second messenger for the changes in POMC
gene expression at the mRNA level. Indeed, forskolin,
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which elevates intracellular CAMP by activating the ade-
nylate cyclase, increases POMC mRNA levels. Moreover,
isoprenalin, a ß-receptor agonist, increases CAMP levels
and enhances POMC mRNA in the IL. Similarly, CRF, which
increases CAMP levels in both lobes, increases POMC mRNA
levels. The direct involvement of CAMP in the POMC mRNA
enhancing effect of CRF was recently demonstrated in
AtT20 cells (Reisine et al. 1985). Besides CAMP, Ca
2+
appears to have an important function in the control of
POMC gene expression in both lobes, since the Ca2+-anta-
gonist D600 inhibited POMC mRNA levels. It may be that
GABA exerts its effect on IL cells by decreasing their
electrical activity and thus causing a decrease in Ca
entry (Demeneix et al. 1986, Taraskewich and Douglas
1982).
 In conclusion, we have shown that a variety of substances
(dopamine, GABA, CRF, ß-adrenergic agonist) directly in-
teract with melanotrope or corticotrope cells to modulate
POMC gene expression. These effects appear to be mediated
by CAMP and/or Ca2+ ions.
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REGULATION OF HYPOTHALAMIC ß-ENDORPHIN AND DYNORPHIN RELEASE
BY CORTICOTROPIN-RELEASING FACTOR (CRF)
Osborne F.X. Almeida, Kostas E. Nikolarakis and Albert Herz
Department of Neuropharmacology
Max-Planck-Institut für Psychiatric
D-8033 Martinsired. F.R.G.
ABSTRACT
Synthetic rat-human corticotropin releasing-factor (CRF), in
doses between 10-12M and 10-8M, significantly stimulates the
release of immunoreactive ß-endorphin and dynorphin-A from
rat hypothalamic slices superfused in vitro: With prolonged
exposure to CRF, there is a reduction in the release of both
opioids which can be reversed by the addition of naloxone.
The latter result indicates the involvement of autoregula-
tory mechanisms in the control of opioid neuronal function.
INTRODUCTION
The opioid peptide ß-endorphin is found in both the pitui-
tary and hypothalamus (Rossier et al. 1977). While several
studies have shown that corticotropin releasing factor (CRF)
is one important modulator of pituitary ß-endorphin (Bruhn
et al. 1984; Höllt and Haarmann 1984; Vale et al, 1980), the
role of CRF in regulating hypothalamic ß-endorphin has been
only speculated upon (Nikolarakis et al. 1986; Sirinathis-
inghji 1985). The studies described here were done to test
the effects of CRF upon hypothalamic ß-endorphin release.
In addition, CRF effects upon the release of dynorphin-A
(dynorphin) were also investigated. Dynorphin is found in
pituitary and brain (Höllt et al. 1980), but there is no in-
formation available as to whether its secretion is modulated
by CRF.
MATERIALS AND METHODS
Hypothalami were obtained from adult male Wistar rats,
sliced (250 µM) and superfused, in pairs, with Medium 199
(100 ul.min-1) in chambers maintained at 37°C. Superfusates
were collected every 10 min., snap-frozen and later assayed
for ß-endorphin and dynorphin immunoreactivities. CRF was
added to the superfusion medium at concentrations ranging
from 10-18 M to 10-8M . In separate experiments, naloxone
(10-6M) was added to the slices together with CRF (10-8M).
RESULTS AND DISCUSSION
CRF was found to significantly stimulate the release of ß-
endorphin and dynorphin from rat hypothalamic slices in-
vitro, when presented at doses of 10-12M to 10-8M. The data
therefore support earlier speculations about the stimulatory
effects of CRF upon hypothalamic ß-endorphin (Nikolarakis et
al. 1986; Sirinathisinghiji 1985) and provide evidence that
CRF also stimulates the release of dynorphin, an opioid
derived from a precursor different to the one from which
ß-endorphin is derived.
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Fig. 1. Time course of ß-endor-
phin release after superfusion
with CRF 10-8M. Basal release
rates were in the range of 3-5
fmol•100µl-l.10 min-1.
Figure 1 shows the ß-endorphin response to CRF; the pattern
of response for dynorphin was similar, except that stimula-
tion of release occured some 30-40 min. later. Of particu-
lar interest in fig. 1 is the decline in the amount of opi-
oid released upon continued exposure to CRF. This feature
suggested to us that CRF stimulates the release of opioids
which may then act presynaptically to turn off their own
release (reminiscent of the way neurotransmitters limit
their own release). Indeed, when the opiate receptor antago-
nist naloxone was superfused together with CRF the attenua-
tion of opioid peptide release was not observed. Furthermore,
there was a tendency for opioid release to increase when
naloxone was presented on its own: and these effects persist
in the presence of tetrodotoxin (TTX, 10-6M), suggesting
them to be presynaptic events. Current studies are focussed
on finding the type of ligand(s) involved in this inhibition
of opioid peptide release.
We conclude that: (1) CRF can stimulate the release of ß-
endorhin and dynorphin from the rat hypothalamus; (2) pro-
longed exposure to CRF leads to an attenuation of opioid
peptide release; and (3) naloxone prevents the loss of
response to CRF, demonstrating the involvement of autoregu-
latory mechanisms in the control of opioid peptide neurones.
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INHIBITION OF LH RELEASE BY CRF MAY BE PARTIALLY MEDIATED
THROUGH HYPOTHALAMIC ß-ENDORPHIN RELEASE
Kostas E. Nikolarakis, Osborne F.X. Almeida and Albert Herz
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Max-Planck-Institut für Psychiatric
D-8033 Martinsried, F.R.G.
ABSTRACT
Corticotropin releasing factor (CRF) given i.c.v. at doses
of 0.02-2 nmol, significantly inhibited luteinising hormone
(LH) secretion in castrate male rats. The luteinising horm-
one releasing hormone (LHRH) release from hypothalamic
slices Superfused in vitro with CRF (10-12M - 10-8Ml was
markedly reduced. In rats that had been infused with nalox-
one 2 days prior to testing with 0.2 nmol CRF, the effect
of the CRF was significantly reduced. Together, these find-
ings indicate that CRF inhibits LH secretion by inhibiting
LHRH release from the hypothalamus, and that the latter
action involves endogenous opioid peptides.
INTRODUCTION
Injections of corticotropin-releasing factor (CRF) into the
mesencephalic central gray area of the brain inhibits sexu-
al receptivity in the female rat (Sirinathsinghji 1985),
and its injection into the third ventricle reduces serum
luteinising hormone (LH) concentrations (Rivier and Vale
1984). Since opioids inhibit LH secretion (see Millan and
Herz 1985) and CRF modulates ß-endorphin levels in the
pituitary (Bruhn et al. 1984; Höllt and Haarmann 1984) and
hypothalamus (Almeida et al. this volume), an involvement
of opioids in the CRF inhibition of LH has been postulated
(Sirinathsinghji 1985; Nikolarakis et al. 1986). In view of
our recent data, showing CRF stimulating the release of ß-
endorphin and dynorphin from the hypothalamus (Almeida et
al. this volume), the possibility that hypothalamic, rather
than pituitary, opioids might mediate the CRF action arises.
MATERIAL AND METHODS
1. In vivo experiment:
Adult male Wistar rats were implanted with i.c.v.
stainless steel guide cannulae. 5 days later they were
bilaterally castrated and had a cannula placed into a
jugular vein. Some rats were also implanted with osmo-
tic minipumps containing naloxone (released at a rate
of 9.6 mg/kg/day), starting 48h prior to, and during,
treatment with CRF. CRF was applied i.c.v. 5 days
after castration in doses ranging from 0.02 to 2 nmols.
Blood was withdrawn at various time intervals via the
jugular cannula and the serum was assayed for LH con-
centrations.
2. In vitro experiment:
Hypothalami were dissected from normal adult male
Wistar rats following decapitation, and superfused as
described elsewere (Nikolarakis et al. 1986). CRF was
403
added in the superfusion medium at concentrations rang-
ing from 10-12 to 10-8M. Ten minute pools of superfu-
sate were collected and assayed for LHRH.
RESULTS AND DISCUSSION
CRF at all doses tested (0.02, 0.2 and 2 nmoles) produced
significant reductions in serum LH levels within 30 min of
i.c.v. administration. LH levels remained significantly
lower in rats receiving 0.2 or 2 nmoles for up to 6 hours,
whereas LH secretion was not significantly different 2 hours
after treatment with the lowest dose. In the presence of the
opioid antauonist naloxone the CRF (0.2 nmol) inhibition of
LH was significantly reduced (fig. 1).
Fig. 1. Serum LH
levels after CRF in
castrates pretreated
with either water or
naloxone via osmotic
mini-pumps. LH levels
in untreated castrates
shown for comparison.
Furthermore, rats treated with naloxone showed a faster
recovery of LH levels than did the animals that received
CRF alone. In our in vitro experiments basal LHRH release
was suppressed in a dose dependent way after CRF applica-
tion (fig. 2).
Our findings are in accordance with a previous report
(Rivier and Vale 1984) showing that centrally administered
CRF is a potent inhibitor of LH secretion in recently cas-
trated male rats. Although naloxone could block the CRF in-
hibition of lordosis behaviour in the rat (Sirinathsinghji
1985) , suggesting an opioid involvement, the application of
a different antagonist, naltrexone, did not affect the CRF
inhibition of LH (Rivier and Vale 1984), leading the latter
authors to question an involvement of opioids. Our results,
showing that chronic opiate blockade leads to a reduced
inhibition at LH by CRF, indicates an opioid involvement in
this CRF action. CRF probably inhibits LH by reducing the
release of hypothalamic LHRH. The inhibitory actions of CRF
within the hypothalamic neuronal pathways affecting LHRH
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Fig. 2. Dose-response inhibition of LHRH release
from hypothalamic slices in vitro.
release could include the release of opioids. In fact, we
have found that CRF increases both ß-endorphin and dynorphin
release from hypothalamic slices (Almeida et al. this vol-
ume.
In conclusion, we suggest that CRF inhibits LHRH and
secretion by stimulating the release of opioids such
ß-endorphin and dynorphin from hypothalamic sites.
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ABSTRACT
Injection of a complete Freunds adjuvant-saline emulsion into the
hindpaw of the rat induces a peripheral inflammatory process
accompanied by pronounced increase (3 fold) in spinal cord dynorphin
content. A marked increase (-9 fold) in the mRNA coding for the
preprodynorphin precursor accompanies the increase in peptide. The
parallel elevations of the mRNA and peptide product suggest that an
increased activity of dynorphin neurons occurs in spinal cord in
response to altered afferent input due to the peripheral inflammatory
process.
INTRODUCTION
Chronic inflammatory states, as exemplified by the adjuvant-induced
arthritis model, have been associated with an increase in spinal cord
met5-enkephalin content (Cesselin et al. 1980) and more recently
dynorphin (Millan et al. 1985, 1986). Using a peripheral, more acute
inflammation model we have found that spinal dynorphin is subject
to a rapid elevation in its content (Iadarola et al. 1985). The
increase is specific to the spinal segments innervating the inflamed
limb and peaks between 5-8 days. A basic problem in interpreting
these data revolves around whether an elevated peptide content re-
flects an increase or decrease in peptide utilization. We have
measured the content of preprodynorphin mRNA in spinal cord tissue
during the peripheral inflammation. Our results indicate that the
dynorphin peptide increase is accompanied by a pronounced increase in
preprodynorphin mRNA accumulation.
MATERIALS AND METHODS
Inflammation of one hind paw was induced by intraplantar injection
(100 ug) of a saline-Freunds adjuvant (Calbiochem) emulsion in 350 g
male Sprague Dawley rats. Treated rats were killed by decapitation
after 5 days of inflammation; a group of non-treated rats was killed
at the same time. The whole spinal cord was removed from the spinal
canal by injection of saline at the sacral vertebral level (De Sousa
& Horrocks 1979). The dorsal lumbar spinal cord was dissected and
frozen on dry ice until use. RNA was prepared as described by
Chirgwin et al. (1979) using homogenzation in guanidine thiocyanate
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and centrifugation of RNA through cesium chloride. Dynorphin peptides
were assayed in the guanidine thiocyanate supernatants from the above
RNA preparation as described by Naranjo et al. (1986); the specific-
ity of the antibody is described in Iadarola et al. (1986).
Northern blots were prepared with poly A+ enriched RNA and were
hybridized with plasmids pBgBa and pBaBa labeled with 32P-dCTP and
-dATP to a specific activity of 1-3 x 105 cpm/ng. The two plasmids
each contain 800-900 base pairs of genomic DNA from the major exon
and represent, respectively, the protein coding and non-coding re-
gions of rat preprodynorphin mRNA (Civelli et al. 1985). After
autoradiography the blots were washed (Byrd et al. 1986; Milner and
Sutcliffe 1983) and probed again with a cDNA to the rat ß-actin
message (Nudel et al. 1983) in order to standardize each lane for
slight variation in the amount of poly A+ RNA applied. Both
autoradiograms were scanned with a laser densitometer and the data
are expressed as a ratio of the dynorphin densitometric signal to the
ß-actin signal.
RESULTS
A single hybridization band was observed after agarose gel electro-
phoresis conducted under denaturing conditions (Tang et al. 1983).
This indicates that no heterogeneity in message size (Civelli et al.
1985) occurs in dorsal spinal cord preprodynorphin mRNA in the
inflamed condition compared to control (Fiagure 1). At 5 davs of
inflammation a marked elevation of preprodynorphin mRNA is evident.
The RNA blot was hybridized
with labeled dynorphin DNA
probes. Dorsal spinal cord
RNA was extracted at day 5
of inflammation (treated) and
processed in parallel with
untreated rats (control). The
increased density of the band
from the inflamed condition
is apparent. There appears to
be some nonspecific binding
or tailing into the nearby
band of 18 S rRNA; this was
not included in the densito-
metric analysis.
Figure 1
Increase in preprodynorphin mRNA
after inflammation
This same blot was rehybridized with a rat ß-actin cDNA (not shown).
Normalization of densitometric scan from the dynorphin blot with that
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from the ß-actin blot showed that about a 9 fold increase in dynor-
phin mRNA had occurred in the inflamed condition (Figure 2).
Measurement of dynorphin A 1-8 content from the guanidine thiocyanate
supernatent from this experiment and several other similar RNA prep-
arations showed that the mRNA increase was accompanied by approxi-
mately a 3 fold increase in this dynorphin peptide (Figure 2).
The peptide content
of several guanidine
thiocyanate RNA
preparations was
analyzed (Naranjo et
al. 1 9 8 6 )  f o r
dynorphin A 1-8
content (left side).
The histograms at
the right show the
ratio of dynorphin
mRNA to ß-actin
mRNA based on the
areas under the re-
spective peaks after
densitometric scan-
ning. The ß-actin
cDNA probe was used
to standardize the
lanes for the amount
of poly A+ RNA ap-
plied.
FIGURE 2
Comparison of increase in dynorphin
A 1-8 peptide and dynorphin mRNA
after inflammation
DISCUSSION
The data presented here show that a peripheral inflammation induces
an increase in dynorphin mRNA content and dynorphin A 1-8 immuno-
reactivity. These observations are consistent with the idea that
the increase in peptide occurs as a result of an activation of
dynorphin gene transcription in neurons located in dorsal lumbar
spinal cord. Since mRNA transcription and translation generally
occur in the neuronal cell body, our data also minimize the possibil-
ity that the dynorphin peptide increase arises from alternative
neuronal sources such as the dorsal root ganglia (Botticelli et al.
1981, Basbaum et al. 1986) or a supraspinal nucleus.
The data suggest that spinal cord dynorphin-containing neurons are in
an altered state of activity produced by the afferent input arising
from the inflamed limb. The concurrent elevation of both mRNA and
peptide product support the idea of an increase in peptide synthesis
and utilization. However, the precise mechanism whereby the increase
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in mRNA occurs (for review see Schwartz and Costa 1986) and whether
peptide release is increased requires further examination.
In conclusion, the data presented suggest an enhanced activity of
spinal cord dynorphin neurons during a peripheral inflammation and
indicates the participation of these neurons in the sensory process-
ing or modulation of pain at the spinal level.
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DIFFERENTIAL EFFECTS OF SELECTIVE BRAIN LESIONS ON HYPOTHALAMIC
AND PITUITARY IR-DYNORPHIN
Santi Spampinato, Sanzio Candeletti, Emanuela Cavicchini,
Patrizia Romualdi, Ester Speroni and Sergio Ferri
Institute of Pharmacology, University of Bologna, Irnerio 48
40126 Bologna, Italy.
ABSTRACT
Selective radiofrequency and neurotoxic lesions of the serotonergic
pathways caused in the rat a significant reduction of ir-dynorphin A
and Bin the hypothalamus but not at pituitary level. These data con-
firm that dynorphin-related peptides are regulated independently in
these areas.
INTRODUCTION
Several studies support the view that differential neural and endo-
crine factors participate in the regulation of immunoreactive dynor-
phin (ir-DYN) at hypothalamic and pituitary level (Höllt et al.1981,
Spampinato et al. 1986a. Spampinato et al. 1986b). Thus, it seems
reasonable to hypothesize that hypothalamic and pituitary ir-DYN pools
may be influenced by aminergic neurons, since biogenic amines act as
neurotransmitters in these areas. Millan et al. (1984) reported that
noradrenergic neurons regulate ir-DYN in the neurointermediate lobe
of the pituitary. However, little is known about possible interac-
tions between the dynorphinergic and serotonergic systems. To ascer-
tain this possibility we examined the changes of hypothalamic and pi-
tuitary ir-DYN A and B following neurotoxic and radiofrequency lesions
of serotonergic neurons.
MATERIALS AND METHODS
Neurotoxic lesions
Male Sprague-Dawley rats (220-250 g) bearing chronic intracerebroven-
tricular (icv) cannulae received 5,7 dihydroxytryptamine creatinine
sulphate (5,7 DHT, 200 µg/rat, icv) combined with desipramine (25
mg/kg, i.p., 60 min prior to 5,7 DHT).
Lesions of the medial and dorsal raphe nuclei
Male Sprague-Dawley rats (220-250 g) were anaesthetized and placed in
a stereotaxic apparatus. Radiofrequency lesions were performed by
nickel-chrome electrodes, according to the Pellegrino et al. (1979)
stereotaxic atlas and pilot studies. The coordinates adopted for the
medial raphe nucleus were: antero-posterior (AP) -6.3 mm, lateral (L)
1.3 mm, depth (D) -8.6 mm at an angle of 8°; for the dorsal raphe nu-
cleus were: AP -6.2 mm, L 0.8 mm, D -6.3 mm, at an angle of 7°.
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Sham lesions were performed in an identical manner with unactivated
electrodes. Histological examinations were made in all lesioned ani-
mals to ascertain the correct position and size of lesions.
Preparation and processing of tissue extracts
Two weeks after lesions rats were killed by decapitation. Hypothalamic
and pituitary tissues were processed and ir-DYN A and B measured by
radioimmunoassay as extensively reported (Spampinato et al.l986a, Cone
and Goldstein 1982).
RESULTS AND DISCUSSION
As shown in table 1, ir-DYN A and B were significantly reduced in the
hypothalamus after the 5,7 DHT treatment, while there was no change
in the pituitary gland. This neurotoxin causes a prolonged reduction
of serotonin in whole brain, including the hypothalamic area, as a
consequence of the destruction of serotonergic neural terminals
(Baumgarten et al. 1977). It is likely therefore, that the reduction
of serotonin levels in the hypothalamus might affect in some way the
dynorphinergic system.
Table 1
Effect of 5,7 DHT treatment on hypothalamic and pituitary
content of ir-DYN A and ir-DYN B.
Area examined
ir-DYN A ir-DYN B
Treatment (fmol/µg protein) (fmol/µg protein)
Hypothalamus Control 0.44±0.09 1.81±O.11
Treated 0.27±0.04** 1.25±0.13**
Anterior pituitary Control 1.70±0.11 7.51±0.76
lobe Treated 2.44±0.29 9.05±1.42
Neurointermediate Control 9.30±0.96 47.04±4.09
pituitary lobe Treated 11.56±1.81 51.14±5.76
Each group consisted of 8-10 rats.
** p < 0.05 vs control rats of the same group (Student's two-tailed
t-test).
After destruction of dorsal and medial raphe nuclei, from which origi-
nates the major serotonergic input to the hypothalamus (Van de Kar and
Lorens 1979). a decrease of ir-DYN A and ir-DYN B occurred in this
area (table 2). On the contrary, the levels of both peptides remained
unmodified in the pituitary gland (table 2). Thus, these results are
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in agreement with those reported above and, taken together, give evi-
dence of an influence of the serotonergic system on hypothalamic dy-
norphins.
This hypothesis is further supported by the well known interactions
between other opioid peptides and the serotonergic neurons at hypotha-
lamic level (Spampinato et al. 1979).
Table 2
Effect of medial and dorsal raphe nuclei lesions on hypotha-
lamic and pituitary content of ir-DYN A and ir-DYN B.
Area examined
ir-DYN A ir-DYN B
Treatment (fmol/µg protein) (fmol/µg protein)
Hypothalamus Control 0.40±0.08 1.98±0.17
Lesioned 0.26±0.05** 1.47±0.27**
Anterior pituitary Control 1.34±0.05 8.79±0.39
lobe Lesioned 1.28±O.08 9.53±0.84
Neurointermediate Control 10.01±1.37 64.08±1.60
pituitary lobe Lesioned 8.64±1.54 63.22±3.25
Each group consisted of 8-10 rats.
** p < 0.05 vs control rats of the same group (Student's two-tailed
t-test).
The existence of a differential regulation of dynorphin-related pep-
tides by the serotonergic system is consistent with a recent paper of
Majeed et al. (1985), who found a decrease of duodenal, but not hypo-
thalamic, ir-DYN after an acute treatment with drugs known to activate
the serotonergic system. However, the discrepancy with our findings
as regards hypothalamic ir-DYN, may be related to the fact that we
achieved a chronic and marked depletion of brain serotonin.
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MODULATION OF ß-ENDORPHIN SECRETION FROM MOUSE PITUITARY TUMOR
CELLS BY CALMODULIN INHIBITOR W7
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ABSTRACT
The involvement of calmodulin in the secretion of ß-endorphin from
the mouse anterior pituitary tumor cell line, AtT-20, was
investigated. The calmodulin inhibitor W7 potentiated secretion
produced by 8-BrcAMP, and induced a secretory response to arginine
vasopressin, which did not elevate ß-endorphin levels when added
alone. Release of hormone in response to CRF was not affected.
Calmodulin phosphodiesterase inhibitor 8-MeOMeMIX produced a dose-
dependent increase in 8-BrcAMP stimulation, suggesting that
inhibition of cAMP degradation is the mechanism of enhancement of
8-BrcAMP-induced secretion in the presence of W7.
INTRODUCTION
The mouse anterior pituitary tumor cell line AtT-20 secretes ACTH
and R-endorphin in response to a variety of receptor-mediated
events and to cAMP analogues (Reisine et al. 1982; Axelrod and
Reisine 1984). The participation of the adenylate cyclase/protein
kinase A pathway AtT-20 cells share with corticotrophs and other
endocrine cells in the anterior pituitary (Bilezikjian and Vale
1983; Brazeau et al. 1982; Labrie et al. 1982; Aguilera et al.
1983). It has recently been demonstrated that Ca2+-channel
antagonists are capable of elevating cAMP levels and CAMP-dependent
responses in the presence of growth hormone releasing factor and
forskolin in somatotrophs and GH4 cells respectively (Barinaga et
al. 1985; Waterman et al. 1985). This Ca2+-dependent modulation of
cAMP processes suggests a Ca2+ -sensitive component in either the
biosynthesis or degradation of the cyclic nucleotide. As there is
evidence that the calmodulin (CaM)-dependent phosphodiesterase can
contribute to decreasing cAMP levels (Miot et al. 1984; Erneux et
al. 1985), and Murakami et al. (1985) have demonstrated the
involvement of CaM in ACTH secretion in anterior pituitary
(Murakami et al. 1985), experiments were conducted with a CaM
inhibitor and an inhibitor of the CaM-dependent phosphodiesterase
to investigate any contribution this system might have in AtT-20
cell secretion.
MATERIALS AND METHODS
Release Experiments
AtT-20 cells were plated in 24 well Primaria plates (Falcon) at an
initial density of 1 x 105 cells/ml/well in Dulbecco's Modified
Eagle Medium (DMEM, Gibco) with 10% fetal calf serum (HiClone), and
grown at 37°C in 5% CO2. Incubations with regulators were
conducted three or four days after plating in 0.1% bovine serum
albumin (BSA, Sigma) in DMEM. 414
CaM inhibitor W7 (6-aminohexyl-5-chloronapthalene-1-sulfonamide,
Sigma) and CaM-dependent phosphodiesterase inhibitor 8-MeOMeMIX (1-
methyl-3-isobutyl-8-methoxy methylxanthine (a gift from Dr. Jack
Wells, Vanderbilt University, Nashville) were dissolved in ethanol
and DMSO respectively, diluted in DMEM and added 15 minutes before
the secretagogues. Corticotropin releasing factor (CRF,
Penninsula) arginine vasopressin (AVP, Sigma) and 8-BrcAMP (8 bromo
adenosine 3':5'-cyclic monophosphate, Sigma) were introduced to the
wells and the incubation continued for a further three hours at
37°C. The medium was then removed and stored at -20°C or assayed
immediately.
RIA
The ß-endorphin immunoreactivity (B-End I.R.) was assayed using
Sugar antisera (a gift of Dr. Richard Allen). The antibody
recognizes the mid portion of ß-endorphin and has a titre of
1:2,000.
Aliquots of medium were incubated with antibody and 125I-labelled
ß-endorphin overnight in 200 ul PBS, 0.1% BSA, 0.1% Triton X-LOO at
4°C and antibody-bound label was precipitated the next day with 500
ul 2% goat antirabbit gamma globulin, 0.2% normal rabbit serum
(both from Breit Laboratories) in 1.2 M ammonium sulphate in 10 mM
sodium phosphate buffer, pH 7.2, at 4°C. Tubes were centrifuged in
a Beckman J6B centrifuge and pellets were counted on a Micromedic
Apex 10/600 gamma counter.
RESULTS
AVP.
CaM inhibitor W7 at 10 uM did not affect basal secretion, and no
effect on CRF-stimulated secretion was observed (fig. la), however,
the response to 8-BrcAMP was considerably enhanced, and the
addition of W7 appeared to increase R-End I.R. in the presence of
FIGURE 1a. Incubation of AtT-20 cells with regulators
of secretion in the presence (closed bars) and absence
(open bars) of 10 uM W7 and conducted as described in
materials and methods. Concentrations of compounds
were as follows: CRF, 30 nM; 8-BrcAMP, 500 uM; AVP,
100 nM. Bars show the mean and standard deviation of
at least two experiments conducted in triplicate.
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FIGURE 1b. Dose-response curve of W7 in the presence
(closed bars) and absence (open bars) of 500 uM 8-Br
CAMP. Each point represents the mean and standard
deviatio of a representative experiment conducted in
triplicate.
Figure lb shows the dose-related increase in ß-end I.R. in response
to W7 in the presence of 500 uM 8-BrcAMP. The increase over
control is particularly marked at 30 uM W7, which represents the
ID50 for this inhibitor when tested in intact cells (Hidaka and
Tanaka 1985).
The capacity of 8-MeOMeMIX to potentiate 8-BrcAMP secretion is
shown in figure 2. No increase is apparent at 2 uM, the reported
ID50 for this compound (Miot et al. 1984); only at 30 uM and 100 uM
8-MeOMeMIX is an increase over 8-BrcAMP alone apparent.
FIGURE 2. Dose-response curve of 8-MeOMeMIX in the
presence (closed bars) and absence (open bars) of 500
uM 8-BrcAMP. The experiments were conducted twice
with similar results. The values shown are the means
and standard deviations from a representative
experiment conducted in triplicate.
DISCUSSION
The data presented here suggests the involvement of an
inhibitory calmodulin function, perhaps at the level of cAMP
degradation, in AtT-20 cells.
Murakami et al. (1985) found that in pituitary halves, W7
inhibited CRF-stimulated secretion at 100 uM, a concentration
which potentiated 8-BrcAMP-stimulated secretion in AtT-20 cells
in the experiments described in figure 2. This difference could
be due to an altered signal transduction mechanism in AtT-20's
or to the difference in secretagogues used. In the above paper
a small increase in both ACTH release and cAMP levels in
response to CRF was observed at 10 uM W7.
In the absence of direct measurement of CAMP levels, the role of
a calmodulin dependent phosphodiesterase can only be inferred by
the data presented here. In thyroid and astrocytoma cells this
type of phosphodiesterase activity is associated with capacity
of muscarinic agonists to attenuate increases in cAMP (Miot et
al. 1983; Miot et al. 1984; Meeker and Harden 1982), and occurs
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concomitantly with phosphatidylinositol turnover (Masters et al.
1984). Although the contribution of this system in AtT-20 cells
has not been described, the basal activity of the CaM
phosphodiesterase may indicate that this activity could be
increased in response to a receptor mediated event.
It is clear from the data presented here and elsewhere that
further work is needed to clarify the effects observed when cAMP
and CAMP-mediated functions are elevated by calcium-channel
blockers, calmodulin inhibitors and calmodulin-sensitive
phosphodiesterase inhibitors.
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ABSTRACT
Release of immuno-reactive metenkephalin has been demonstrated from
slices of rat amygdala in vitro. This release was calcium dependent
and the amount released was related to the concentration of
potassium ions in the releasing stimulus. The effect of drugs such
as clonidine, an alpha 2 adrenoceptor agonist, and idazoxan, an
antagonist, on this release was measured. Neither drug had a
significant effect on the amount of ir-metenkephalin released. Thus
although release of noradrenaline can be affected by opioids it seems
that release of endogenous opioids is not affected by drugs which
interact with noradrenaline.
INTRODUCTION
Several groups of workers have studied the stimulated release of ir-
metenkephalin (ir-ME) from slices of rat brain taken from various
regions e.g. Henderson et al. (1978) corpus striatum, Iversen et al.
(1978) qlobus pallidus, Bayon et al (1978) qlobus pallidus, Richter
et al. (1980) corpus striatum, Lindberg and Dahl (1981) corpus
striatum and Del Rio et al, (1983) corpus striatum and periaqueductal
grey. The majority of the groups have confined their studies to
areas which are relatively rich in their content of enkephalins. In
this study we have investigated an area of the brain which has a
lower content of enkephalins (Hong et al.1977) but which shows a
high level of alpha-2 adrenoceptor agonist binding (Unnerstall et al,
(1984), and we have examined the effects of drugs active at alpha-2
adrenoceptor sites on the potassium stimulated release of ir-
metenkephalin in order to examine if these drugs can have any effects
on enkephalin release. There have been reports of interaction
between alpha-2 agonist druqs and opioid induced changes in neuronal
function (Aghajanian 1978). and also in behavioural studies (Tsenq
et al. 1975), but the exact nature of the sites of interaction of
these two groups of drugs is still not clear.
MATERIALS AND METHODS
Adult male Wistar rats (200-300 g body wt.) were decapitated and the
brains removed onto ice. The amygdalae were dissected out, and
tissue slices (1.0x0.4x0.4mm) were prepared on a McIlwain tissue
chopper. The slices were placed in superfusion chambers and super-
fused with an oxygenated physiological saline solution (PSS) pH7.2
containing (mM) NaCl 118, KCl 5, KH2P04 1.2, MgSO4 1.0, CaCl2 0.75,
NaHCO3 25, glucose 11, ascorbic acid 1.0. In addition 1g/l bovine
serum albumen and 50mg/l bacitracin were included to reduce peptide
breakdown. The slices were superfused for ten minutes to
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equilibrate at a rate of 0.5ml/min. Four eight minute fractions
were then collected with the first four minutes of the third
fraction beinq exposed to PSS containing an elevated potassium ion
concentration (balanced bv a reduction in sodium ion concentration).
Normally this elevated K+-concentration was 35mM. At the end of
each experiment the tissue was removed from the chambers and
processed for radioimmunoassay as described by Morris & Livingston
(1984). The fractions were extracted on Sep-Pak disposable ODS
columns and also processed for radioimmunoassay. The radioimmuno-
assay used an antibody to the sulphoxide form of metenkephalin which
was generously provided by the group working at St. Bartholomew's
Hospital, London. This antibody was highly specific and showed
negligible cross-reactivity, and a sensitivity down to 1 femtomole
per assay tube (Clement-Jones et al.1980). The amounts of ir-ME
released were calculated as a fractional release of the total
present in the tissue at the start of the release period for each
fraction.
RESULTS
Preliminary experiments showed that the ir-metenkephalin released
produced parallel displacement curves in the radioimmunoassay with
authentic metenkephalin and that the PSS and raised K+ had no
intrinsic effects on the radioimmunoassay. The recovery of ir-ME,
calculated by adding a known amount of ME to the PSS, was 35%.
Basal release was 5-20 pq/min representing about 0.1-0.2% of tissue
stores. The amount of ir-ME released was dependent on the K+
concentration used, 25mM K+ produced only a slight rise in release,
35mK+ raised release to about 0.8%, 45mM K+ raised release to about
1.2% and 55mM K+ raised it to about 2%. The release of ir-ME was
also dependent on the presence of Ca++ions and omission of Ca++ ions
completely abolished 35mM K+ stimulated release (Fig. 1). 35mM K+ was
chosen as the release stimulus for the subsequent experiments. In
the presence of 1 µm clonidine, the alpha-2 adrenoceptor agonist, from
the start of perfusion there was no significant change in 35mM K+
stimulated release of ir-ME. similarly in the presence of 1 µm
idazoxan (RX781094), the alpha-2 adrenoceptor antagonist, there was
no significant change (Fig. 2).
DISCUSSION
The recovery rates of ir-ME found in these experiments are similar to
those obtained by Iversen et al.(1978) and Bayon et al.(1978),
however some workers (Richter et al.1979) have found higher
recoveries using faster perfusion rates. It would appear that
recovery rates do vary with the experimental conditions used. The
values for basal release of 0.1-0.2% agree well with most of the
other reports (Iversen et al.1978, Sawynok et al.1980, Lindberg and
Dahl 1981). Similarly,
response to K+
the degree of increase in release in
stimulation was comparable with the other reports
although comparison is difficult because of the variety of values for
K+ utilised in the different studies. The concentrations of
clonidine and idazoxan used were sufficient to produce significant
effects in studies using stimulated [3H] noradrenaline release from
rat amygdala under similar experimental conditions, but at these
levels had no effect on ir-ME release. These findings are in accord
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FIGURE 1.
Effect of K+ concentration and _presence of Ca++ ions on
release of ir-ME from rat amygdala. Each example represents
a single experiment.
with our earlier report (Morris & Livingston 1986) that adminis-
tration of clonidine to rats did not affect ir-ME levels in this
region. Thus we would conclude that although opioids may affect
noradrenaline release and there are reports of alpha-2 adrenerqic
modulation of the effects of chronic opioid administration, there is
no evidence that alpha-2 adrenergic active drugs can effecf the
release of endogenous metenkephalin from the rat amygdala in vitro.
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ABSTRACT
Chronic localized pain increased the level of the opioid peptides,
dynorphin (DYN), neoendorphin (ANEO), Met-enkephalin (MET) and
Met5-enkephalin-Arg6-Gly7-Leu8 (MEAGL), in the lumbar enlargement of
the rat spinal cord. It was accompanied with a reduction of the
spontaneuos and K+-stimulated release of ANEO and MEAGL from spinal
cord slices in vitro and a decreased release of ANEO from the spinal
cord in vivo. The results indicate that the reduction in the activity
of endogenous opioid peptide systems might occur in the spinal cord
of rats subjected to chronic pain.
INTRODUCTION
Chronic localized pain, as well as chronic polyarthritis increase the
level of opioid peptides derived from prodynorphin (Przewlocki et al.
1984, Millan et al. 1985) and proenkephalin (Cesselin et al. 1980,
Faccini et al. 1984, Przewlocki et al. 1984) in rats. these changes
occur mostly in the lumbar enlargement of the spinal cord. They are
accompanied with an increase in the analgesic potency of various
opioid agonists and opioid peptides when applied directly into the
spinal cord (Przewlocki et al. 1984). The obtained results indicate
that supersensitivity of opioid receptors develops in rats subjected
to chronic pain. Furthermore, the above observation posed a question
whether chronic pain was associated with the enhancement or decrease
of the activity of spinal opioid peptide systems. Therefore we
studied an in vitro and in vivo release of opioid peptides from the
spinal cord of rats subjected to prolonged localized pain. In
addition, we evaluated the activity of enkephalin convertase, an
enzyme thought to be responsible for the enkephalin synthesis in the
nervous system (Strittmatter et al. 1984).
MATERIALS AND METHODS
Male Wistar rats (250-300 g) were intradermally injected with 0.1 ml
of Freund's adjuvant into the hind limb sole in order to induce a
chronic local inflammation. Three weeks after inoculation the rats
were killed by decapitation and their spinal cord was immediately
dissected and divided, and the tissue was processed to estimate
immunoreactive DYN, ANEO, MET and MEAGL by specific RIAs as described
previously (Przewlocki et al. 1983). For the in vitro release the
tissue from dorsal halves of the lumbar enlargement was sliced (300
µm) with MC Ilwain tissue chopper. Slices weighing about 100 mg were
transferred to 1.5 ml superfusion chambers filled with a Ca2+-free
medium. After 20 min of washing the slices were continously super-
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fused (flow rate 0.25 ml/min, temp 30°C with Krebs-bicarbonate
solution modified according to Chavkin et al. (1983). Fractions (1 ml)
were collected and ANEO and MEAGL were measured by RIAs. The in vivo
release was performed according to the techniques described by Yaksh
and Tyce (1980). To determine the stimulated release 30 and 57 mM K+
and 20 µM capsaicin were used in respective solutions. Aliquots
(usually 250 µl) of the collected frations were used directly for
RIAs. The enkephalin convertase activity, as well as the 3H-
guanidinoethylmercaptosuccinic acid (GEMSA - an inhibitor of enke-
phalin convertase) binding to the enzyme were assessed according to
Strittmatter et al. (1984).
RESULTS
As is shown in tab. 1, a chronic localized pain induced an increase
in the level of DYN, ANEO, MET and MEAGL locally in the lumbar (but
not cervical or thoracic) part of the spinal cord.
TABLE 1. The influence of chronic localized pain (CP) on
the levels (pmol/g) of opioid peptides in lumbar spinal
cord of rats
DYN ANEO MEAGL NET
C P 55.8±5.5* 26.5±1.8* 139.0±13.0* 551.5±62.6
p* <0.05
control 26.1±2.3 12.8±1.3 93.6±3.6 401.2±34.0
FIGURE 1. In vitro release of ANEO (A) and MEAGL (B) from the
spinal cord of rats subjected to chronic pain. Control
chronic pain
No changes in the peptide level were observed when tested in
different brain structures (hypothalamus, thalamus, cortex). An
increase in the -endorphin content was noticeable in the anterior,
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but not intermediate part of the pituitary (not shown). Increased
levels of the peptides were accompanied with a slight increase in the
basal in vitro release of ANEO and MEAGL from the dorsal part of the
lumbar spinal cord. The stimulated release (57 mM K+) was not
significantly different when both groups of rats were compared (fig.
1). When the release was calculated as per cent of the tissue
content, it showed that the basal and K+-stimulated release was
significantly lower in rats subjected to chronic pain (0.16 ± 0.01 vs
0.1 ± 0.01, and 0.34 ± 0.04 vs 0.15 ± 0.02 in controls and rats with
chronic pain, respectively). The release of ANEO was further examined
using an in vivo superfusion technique. The results are shown in fig.
2. As can be seen, in viva basal and stimulated release (30 mM K+ or
20 µM capsaicin) of ANEO was significantly lower in rats subjected to
chronic pain.
The activity of enkephalin convertase, an enkephalin synthetizing
enzyme was not significantly changed though a slight decrease in the
binding affinity of the enzyme inhibitor 3H-GEMSA occurred in the
lumbar spinal cord of rats subjected to chronic pain (KD = 4.46 ± 0.1
vs KD = 6.17 ± 0.2, respectively).
FIGURE 2. In vivo release of ANEO from the spinal cord of rats
subjected to chronic pain. Control chronic pain
DISCUSSION
The present results demonstrate that chronic localized pain induces
changes in the level and release of opioid peptides from the spinal
cord. An elevated level of the peptides in the lumbar part of the
spinal cord was accompanied with a decrease in the release of
peptides derived from prodynorphin and proenkephalin in both in vitro
and in vivo studies. Similar results were currently obtained by
Cesselin et al. (1984), who examined release of Met-enkephalin in
polyarthritic rats. It appears that prolonged painful stimuli most
probably induced a decrease in the opioid peptide release, which
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leads to their accumulation in neuronal terminals and, in conseque-
nce, decreases the availability of the peptides at a synaptic cleft.
This might further induce supersensitivity of opioid receptors;
actually, this phenomenon was demonstrated in our laboratory in rats
subjected to chronic localized pain (Przewlocki et al. 1984), as well
as in polyarthritic rats (Kayser and Guilbad 1983). Similar phenomena
might also occur in man, since some authors reported reduction in the
opioid peptide content in the cerebra-spinal fluid of patients
suffering from chronic pain (Almay et al. 1978).
In conclusion, our results indicate that both prodynorphin and
proenkephalin systems in the rat spinal cord adapt themselves to
chronic painful stimuli by reducing the system activity, which in
consequence, may result in their insufficiency in physiological
mechanisms of pain control.
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ABSTRACT
The acute effects of a Gaba-mimetic drug, sodium Valproate, are
studied on brain enkephalin contents in rat brain. Valproate
administered at both 300 and 600 mg/kg doses induces an increase of
enkephalin levels in striatum, hypothalamus, brain stem and cortex.
No effect is seen in the hypophysis.
INTRODUCTION
When relations between monoaminergic and enkephalinergic systems are
extensively studied, the interactions between opioidergic and
Gabaergic systems present an interesting development of opiate
physiology. Both anatomical evidences (Aronin et coll 1984) and
pharmacological arguments (De Feudis 1984) underly the concept of a
Gaba/enkephalin link. Some studies were realized about the effects
of Gaba-mimetic drugs on opiates. Roughly, administration of a Gaba
A agonist is generally followed by a reduction of opioid 'levels
(Duka and coll 1980) or release (Bourgoin and coll 1982). In
opposition, the Gaba-B mimetic drugs as Baclofen enhance enkephalin
release from brain rat slices (Sawynok and Labella 1981).
Sodium Valproate (VPA) is an extensively used anti-epileptic drug,
enhancing Gaba levels by blocking the degradation enzymes of this
neuro-transmitter (Johnston and Slater 1982). We studied the acute
effect of this drug on Mat-Enkephalin and Leu-Enkephalin levels in
five areas of rat brain. VPA was administered at doses eliciting an
anti-epileptic effect on kindled seizures in rat (Tulloch and coll
1982)
MATERIEL AND METHODS
Three groups of 7 albinos male rats (300g +/- 20) from Iffa Credo
were used for the experiments. Animals of each group were
administered I.P. respectively by two doses of 300 and 600 q/kg of
VPA (Depakine, Labaz laboratories, France), and 0.5 ml of
distillated water (drug vehicle). The rats were killed by
decapitation, without anaesthesia, between 10:00 and 12:00 am, to
avoid a possible effect of circadian ryhtms.
Both tissue samples preparation and RIA procedure was carried out as
previously described (Cupo and Jarry 1985). ME antibodies exhibit
following properties: IC50 = 9.1 pM and cross-reactive factor (f)
with analog peptides always greater than 175. LE antibodies were
obtained by an original method (Cupo and coll to be published) and
present the following characteristics: IC50 = 23 pM and f > 80 in
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all cases.
RESULTS
Injection of VRA at anti-epileptic doses is followed by an increase
of both LE (table 1) or ME (table 2). This effect is significant at
a 600 mg/kg dose for LE levels and significant for the 2 doses for
ME levels. Note the lack of effect in the hypophysis.
TABLE 1. Acute effect of sodium valproate on Leucine-enkephalin
levels in five areas of rat brain. Two doses were injected
intra-peritonealy: 300 and 600 mg/kg. Animals were sacrified 30
minutes after injection. Results are given in picomole of wet
tissue (+ or - sem). St= striatum, Ht=Hypothalamus,
Hph=Hypophysis, Br.St.=Brain stem, and Cx=cortex.
Groups St. Ht. Hph. Br St. Cx
Controls 0.033 0.033 0.26 0.013 0.0023
(0.004) (0.003) (0.012) (0.001) (0.001)
VPA 300 0.038 0.039 0.25 0.012 0.005
mg/kg (0.004) (0.006) (0.016) (0.012) (0.002)
VPA 600 0.065 0.068 0.23 0.029 0.005
mg/kg (0.010) (0.021) (0.016) (0.005) (0.004)
*** *** *** **
Statistical analysis: variance analysis. ***, p<0.001;
**,p<0.01; *, p<0.05.
When administration of two doses of VPA induces an increase of
enkephalinergic system activity in four brain areas, the lack of
this effect in hypophysis suggests that, in 30 minutes, VPA presents
store of a neuro-neuronal action than a neuro-endocrine one. In this
point of view, if the effect of VPA per se on enkephalinergic
neurons must not be discarded, there are many evidences that there
is a close correlation between plasmatic concentrations of VPA and
synaptic Gaba levels (Iadarola and Gale 1981). The nature of the
effect of VPA on ehkephalinergic systems seems to mimic the effects
of Baclofen and suggests a preferential implication of Gaba B
receptors (Sawynok and Labela 1981).
The small delay between the injection of VPA and the sacrifice of
the animals is a good argument for an increase of enkephalin levels
in relation to an increase in pro-enkephalin consumption more than
to an increase of pro-enkephalin processing. Preliminary results on
octapeptide (an other peptide derived from pro-enkephalih) show that
the same doses of VRA induce a reduction of octapeptide levels
suggesting a precursor consumption and/or a differential maturation
of the pro-ehkephalin related peptides (Vion-Dury and coll to be
published)
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This work raises an important question: are the therapeutic or
adverse effects of VPA partially related to enkephalinergic pathway
activation ? When action of opioid peptides or agonists on epilepsy
is very complex and very discussed (Frenk 1983), it is probable that
the anti-epileptic action of VPA is mainly related to an increase of
Gaba-ergic transmission (Johnston and Slaters 1982).
TABLE 2. Acute effect of sodium valproate on
Methionine-Enkephalin levels in the same areas of rat brain.
For legend, see table 1.
Groups St. Ht. Hph. Br.St. Cx
Controls 0.58 0.52 2.49 0.19 0.033
(0.06) (0.016) (0.42) (0.016) (0.003)
VPA 300 0.82 0.77 2.51 0.24 0.041
mg (0.11) (0.08) (0.34) (0.03) (0.003)
** ** *
VPA 600 0.80 0.76 2.37 0.33 0.051
mg (0.13) (0.11) (0.48) (0.04) (0.004)
*** **
Yet VPA (as others Gaba-mimetic drugs) exhibits also important
analgesic properties at lower doses than those used for the
anti-epileptic treatment (Mesdjian and coll 1983) Some preliminary
dosages show that VPA a 100mg/kg (analgesic doses), induces an
increase of opioid peptides in striatum(Vion-Dury and coll to be
published). In this point of view, it must be noted that Mesdjian
and coll (1983) suggested an non implication of opioidergic
transmission because the effect of VPA was not reversed by naloxone.
They conclude that the effects of VPA was related to an increase of
Gabaergic transmission. But, if it is assumed that 1) weak doses of
VPA induce an increase of enkephalinergic transmission, and 2) the
synaptic organization of Gaba/enkephalin link is underlyed by a
parallel circuitry (Andree and coll 1983), the lack of the effect of
naloxone can be easily explained: the naloxone antagonism of
enkephalin effect would be masked by Gaba-mimetic action of VPA on
pain pathways.
Increase of enkephalinergic transmission after VPA treatment might
also explain the apparition of a tolerance and dependence to
analgesic action of both morphine and Gaba agonists in mice
receiving injections of THIP(Andree and coll 1983). If the action of
VPA on enkephalinergic pathways is underlyed by a preferential
activation of Gaba-B receptors, our results might also explain the
syndrome of a Baclofen overdose, which mimics the syndrome of opiate
overdose (De Feudis 1984).
So, from these data, it is possible to try to complete the schema
proposed by Andrée and coll (fig 1) and to suggest the hypothesis of
a parallel organization of Gaba-ergic and enképhalinergic pathways
with a fine modulation of enkephalinergic activity by Gaba-ergic
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system involving several
Bourgoin and coll (1981).
Gaba-ergic receptors as suggested by
FIGURE 1: Possible organization of the relations between Gabaergic
and enkephalinergic systems (from Andree and coll 1983): Commentary
in the text
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ABSTRACT
The opioid heptapeptide, [Met]enkephalin-Arg6-Phe7 was measured in
CSF of women at term pregnancy and during the luteal phase by RIA.
Levels turned out to be significantly increased in pregnant women.
These results are in agreement with an earlier paper in which we re-
ported increased levels of receptorassayed opioid peptides deriving
from proenkephaln A in CSF of women in term pregnancy compared to
levels in nonpregnant, nonpuerperal women.
INTRODUCTION
C-terminal extensions of the pentapeptides [Met]enkephalin and [Leu]-
enkephalin (so called ECPs) were in fact isolated from brain and
peripheral tissues a few years prior to the sequencing of the opioid
peptide precursors proenkephalin A and proenkephalin B. One of these
C-terminally extended peptides, [Met]enkephalin-Arg6-Phe7, was de-
scribed by Stern et al. 1980. On a molar basis, Rossier et al. (1980)
found this heptapeptide eight times more analgesic than [Met]enkepha-
lin in the tail flick test. In a previous study we reported elevated
levels of so-called FII endorphins both in term pregnancy and in
early puerperium compared to levels in nonpregnant, nonpuerperal wo-
men. We suggested these elevated FII endorphins to derive from the
[Met]enkephalin precursor (Lyrenäs et al. 1986). In the present study
we measured CSF levels of [Met]enkephalin-Arg6-Phe7 by RIA in indivi-
dual pregnant women and in nonpregnant women during the luteal phase
of the menstrual cycle.
MATERIAL AND METHODS
The study included CSF from two groups of women:
1. This group comprised of 12 pregnant women who underwent elective
cesarean section at term due to pelvic disproportion. The operations
were performed during spinal anesthesia and five ml samples of CSF
were removed prior to administration of the anesthetic drug. CSF
levels of [Met]enkephalin-Arg6-Phe7 were measured by RIA.
2. A control group composed of eight nonpregnant nonpuerperal healthy
female volunteers; CSF samples were collected during the luteal phase
of the menstrual cycle. Lumbar punctures were performed at the level
of L:3-L:4 with the same technique as used in group 1. CSF levels of
[Met]enkephalin-Arg6-Phe7 were estimated by RIA.
CSF samples were taken in ice cold polyethylene tubes prepared with
EDTA, immediately frozen and kept at -70°C until analyzed.
Materials: Peptide standards used in this study were obtained from
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sources previously noted (Nyberg et al. 1983). Reversed phase silica
gel cartridges (SepPak C-18) were purchased from Waters Associates
(Milford, Mass., U.S.A.). All other chemicals and solvents were of
analytical reagent grade from commercial sources.
Sample work up: Prior to RIA, the thawed CSF sample (two ml) was sub-
jected to SepPak separation. Before sample application, the car-
tridge was washed consecutively with 10 ml methanol containing 0.04 %
trifluoroacetic acid (TFA), 10 ml methanol and 10 ml water. The CSF
sample was applied in a volume of two ml and the cartridge washed
with 2.5 ml of water. Elution was carried out with aqueous mixtures
of TFA (0.04 %) and increasing concentrations of methanol. The hepta-
peptide-containing fraction was eluted with 60 % methanol and evapo-
rated. The dried fractions were redissolved in 100 µl 1M acetic acid
and incubated for 30 min. at 37°C with 1 % H2O2. All samples were
evaporated a second time before RIA analvsis.
The radioimmunoassay for [Met]enkephalin-Arg6-Phe7 was based on the
charcoal adsorption technique and conducted in conformity with those
described for other peptides (Christenson-Nylander et al: 1985). The
antibodies were raised against the heptapeptide sulfoxide
([Met]-O-enkephalin-Arg6-Phe7) and the iodinated oxidized peptide was
used as tracer. The detection limit of the RIA was around
20 fmol/tube. Crossreaction with [Met]enkephalin and other
proenkephalin A or B derived peptides was less than 0.1 %. Runs with
the synthetic heptapeptide added to artificial CSF at a concentration
of 50 fmol/ml indicated a recovery of approximately 70 % of the ex-
traction procedure.
High performance liquid chromatography (HPLC): A HPLC system (LKB,
Bromma, Sweden) was used for identification of the measured peptide.
Pooled aliquots of the assayed fractions were analyzed in a single
run. The column (Spherisorb C-18, 5 µ, 4.5 x 250 mm) was eluted
with a 40 min. linear gradient of acetonitrile (10-45 %) contain-
ing TFA (0.04 %). Fractions of 0.5 ml were collected at a flow rate
of 0.5 ml/min. and evaporated prior to RIA analysis.
RESULTS
fmol/ml. The difference is statistically significant (p < 0.05;
Student's t-test). HPLC identification showed that the major part
of RIA activity eluted like the standard (figure 2). Minor activity
eluting with higher retention time was also observed.
Figure 1 shows the levels of radioimmunoassayable CSF [Met]-O-enke-
phalin-Arg6-Phe7 in groups 1 and 2. The mean level (SD) in term preg-
nancy was 32.8 (12.0) fmol/ml and in the luteal phase 22.4 (7.1)
DISCUSSION
The complexity of the proenkephalin systems is considerable, and a
whole family of enkephalin peptides can be identified in human CSF
(Nyberg et al. 1986). We have earlier used a receptorassay to
identify so-called Fraction II opioid peptides, which mainly derive
from proenkephalin A. In CSF from women at term pregnancy and in the
early puerperium, fraction II levels were increased (Lyrenäs et al.
1986). One major component in Fraction II is [Met]enkephalin-Arg6-Phe7
(Nyberg et al. 1983). The present study using a specific RIA for this
peptide, confirmed the elevation of enkephalin peptides at term preg-
nancy. Assuming this elevation to reflect increased activity,
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FIGURE 1. CSF levels of [Met]enkephalin-Arg6-Phe7 in
term pregnancy and during the luteal phase measured
by RIA. Antibodies used in the RIA were raised using
the heptapeptide sulfoxide.
FIGURE 2. High performance liquid chromatography of
[Met]enkephalin-Arg6-Phe7 sulfoxide immunoreactivity.
Calibration runs were performed with synthetic stan-
dards as indicated by arrows (ENK = enkephalin).
Further details are given in the text.
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enkephalin pathways appear to be under higher tonic activity in late
pregnancy and the early puerperium than in non-pregnant, non-puer-
peral women. Similar information is available with regard to plasma
levels, i.e. the hormonal secretion of -endorphin and [Met]enke-
phalin in late pregnancy and early puerperium (Pancheri et al. 1985).
The general elevation of endorphin activity in late pregnancy and
early puerperium may be considered a primary reaction subserving
a protective role or be a secondary reaction to the stress involved.
Further studies will be needed to distinguish between these possi-
bilities and to elucidate the basic mechanisms.
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ABSTRACT
We have been using rat spinal cord-dorsal root ganglion primary
cocultures (SC-DG) as a model system for exploring K receptor regula-
tion. During the first 10 days in culture, the total number of opi-
ate receptors increased markedly, reaching a Bmax of 180 fmoles/mg
protein for K sites and a Bmax of 50 fmoles/mg protein for µ sites.
Following this period of development, the K and µ receptor number did
not change significantly. No detectable sites were observed at any
time of culture. The binding of [3H]diprenorphine to K sites was
found to be saturable, of high affinity and stereospecific. After
chronic agonist treatment of cultured cells, K receptors did not
down-regulate, whereas more than 50% of the µ receptor sites did.
Following chronic antagonist treatment, µ receptors were markedly
up-regulated (260% of control), while K sites exhibited a weaker up-
regulation response (160% of control). These data demonstrate that K
opiate receptors are expressed at high concentrations in SC-DC cul-
tures andthatcontraryto µ receptors in spinal cord and receptors
in NG10815 cells, K binding sites are less susceptible to modulation
following chronic agonist or antagonist treatment. This suggests
that K receptors may be regulated by different control mechanisms.
INTRODUCTION
Exposure of cells to agonists or antagonists often results in a
change in the concentration of their surface receptors.
Up-regulation of µ and opiate receptors in rat brain has been
induced by chronic administration of antagonists (Tempel et al.
1985). Ample documentation of µ and receptor down-regulation has
been provided by agonist treatment of aggregated fetal brain cells
(Lenoir et al. 1984) and of cultured. NG10815 cells (Law et al. 1983).
On the other hand, very little is known about the regulation of K
opiate receptors in nervous tissue. We have been using SC-DG cul-
tures as a model system for exploring K receptor regulation since
spinal cord has been proved to be a rich source of K sites (Attali et
al. 1982).
METHODS
SC-DG cultures were prepared according to Ransom et al. (1977). After
2 weeks in culture, the cells were treated for the time indicated.
Cells were washed 3 times with PBS and incubated 15 min at O°C in 100
mM NaCl and 50mH Tris-HCl (pH=7.4). Cells were homogenized and cen-
trifuged for 30 min at 27,500xg, pellets resuspended in 100mM NaCl,
50mM Tris-HCl (pH=7.4) and incubated for 15 min at 37°C to allow
bound drug to dissociate from the receptor. The membranes were fur-
ther washed twice in 50mM Tris-HCl (pH=7.4) and resuspended in the
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same buffer for binding assay. In control untreated cells, equal
concentrations of the same agonists or antagonists were added to cul-
ture dishes immediately before cell harvesting. K binding sites were
laballed by [3H] diprenorphine (30 min, 37°C) in the presence of DAGO
(0.1µM)  and DADL (0.1µM) to suppress the contribution of µ and
sites. [3H] DAGO and [3H]DSTLE were used for labeling (30 min, 37°C)
µ and receptor sites, respectively. Non-specific binding was
determined in the presence of 10 µM diprenorphine.
RESULTS
sites were found to be saturable and of high affinity
(Kd=O.85±0.15nM, n=11 and Kd=2.4±0.5nM, n=3, respectively).
No detectable µ, or K sites were observed on day of plating.
During the first 10 days in vitro, the total number of opiate recep-
tors increased markedly, reaching a Bmax of 180±44 fmoles/mg protein
(n=11) for K sites and a Bmax of 50±6 fmoles/mg protein (n=3) for µ
sites. Following this period of development, the K and µ receptor
number did not change significantly. Interestingly, no detectable
sites were observed at any time of culture (up to 4 weeks in vitro).
The binding of [3H] diprenorphine to K sites and that of [3H]DAGO to µ
FIGURE 1. Pharmacology of K opiate binding sites in SC-DG
culturess. The pharmacological profile of various ligands
was assessed by competition experiments. K receptors in
membranes of 2 weeks old SC-DG cultures were labeled by
[3H]diprenorphine (1.5nM) in the presence of DAGO (0.1µM)
and DADL (0.1µM). The data correspond to a typical experi-
ment replicated two to three times with similar values.
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Treatment
TABLE 1. Regulation of opiate receptors upon chronic agonist or
antagonist treatment
Etorphine 1 µM, 1 day 47±2**** 96±7 0±0****
Etorphine 1 µM, 3 days N D 80±1 *
U50488 10 µM, 1 day N D 95±11
Naloxone 10 µM, 5 days 261±17*** 1 6 4 ± 3 * * * *
30±11 **
123±3 * * *
Regulation of µ and receptors was assayed in 2 week old
SC-DG cultures and that of sites in NG108-15 cells.
Results are expressed as percent of control binding to
untreated paired cultures. Values were deduced from satu-
ration experiments; the control binding values for µ, a n d
receptors are 48±3, 187±36 and 435±21 fmoles/mg protein,
respectively (n=3). Significance of data was calculated by
the unpaired student t test (*p<0.05, **p<0.02, ***p<0.01,
****p<0.001). ND (not determined).
Displacement experiments revealed that the binding to K sites was
stereospecific since MR 2034 and levorphanol were potent competitors,
while their respective inactive enantianers, MR2035 and dextrorphan
were ineffective (figure 1A). K selective ligands such as MR2034,
ethylketocyclazocine and tifluadom were able to compete with
[3H]diprenorphine binding at low concentrations, whereas µ or
ligands were shown to be very weak displacers (figure 1B). The
affinity of the K agonist U50488 decreased significantly in the pres-
ence of 100µM GTP and 100mM NaCl (data not shown). Following chronic
exposure to the non-selective opiate agonist etorphine (1µM, 24h), K
receptors did not down-regulate, whereas under the same experimental
conditions, 53% of µ sites down-regulated (table 1). The same
results were obtained by using the K selective agonist U50488 (10 µM,
24h). In contrast, we found that in NG10815 cells which contain pre-
dominantly sites, one day treatment with 1 µM etorphine or 10 µM
U50488, a concentration with also occupies receptors induced
receptor down-regulation by more than 90% and 70%, respectively.
Prolonging the time of agonist exposure(etmphine 1 µM, 3 days), we
observed a weak but significant down-regulation of receptors which
amounted now to 20% (table 1). Followinq chronic antagonist treat-
ment (naloxone 10 µM, 5 days), µ receptors strongly up-regulated
(261% of control), while sites exhibited a weaker up-regulation
(164% of control). Similar experiments performed in NG108-15 cells
showed that receptors slightly up-regulated (125% of control).
SC-DG CELLS NG108-15 CELLS
(% of control) (% of control)
DISCUSSION
In agreement with previous studies showing that the adult spinal cord
contains high amounts of receptors (Attali et al. 1982; Czlonkowski
et al. 1983), our data now demonstrate that after neuronal differen-
tiation in vitro, opiate receptors are expressed at high concentra-
tions (more than 70% of total receptors) in SC-DC cultures. The
opioid nature of these binding sites is demonstrated by the satur-
ability, high affinity and stereospecificity of ligand binding. The
properties of the binding sites is revealed by the pharmacological
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profile of various compounds in competition experiments. selective
ligands were good displacers, while µ and ligands were relatively
ineffective. The regulation of K agonist binding (U50488) in cul-
tured cells by GTP and Na+ correlates well with previous studies
showing a similar regulation in adult rat spinal cord (Kelly et al.
1982), which suggests a possible couplinq of K receptors to adenylate
cyclase (see also Attali and Vogel this volume). Our data concerning
K receptor regulation reveal striking differences with µ and recep-
tors. Contrary to µ receptors in SC-DG cells or receptors in
NG10815 cells, K receptors were not down-regulated upon chronic expo-
sure of SC-DG cultures to etorphine or U50488. Only after 3 days of
agonist exposure, a slight down-regulation of K sites is observed
(20%). This lack of apparent down-regulation for K receptors sug-
gests that the regulation upon chronic activation might occur at a
different level such as post-receptor binding regulatory compnents
(Attali and Vogel this volume). Upon chronic antagonist treatment, K
receptor regulation, exhibited again a different feature when cm-
pared to µ receptors. However, although K sites displayed a weaker
up-regulation, the significant increase in K opiate binding might be
the result of several mechanisms. These may include either increased
receptor synthesis, lowered degradation, unmasking of active receptor
molecules, or even conversion of newly synthesized non-binding recep-
tors to active receptors. It is interesting to note that antagonist-
induced µ receptor up-regulation in fetal mouse spinal cord-ganglion
explants does not require the synthesis of new receptor molecules
(Tempel et al. 1986). Taken together, these data reveal that con-
trary to µ or receptirs, K binding sites are less susceptible to
modulation upon chronic agonist or antagonist treatment, suggesting
that they are regulated by different control mechanisms.
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ABSTRACT
There is considerable variation in the potency of opioids across
different animal models of antinociceptive activity. In the less
sensitive tests the partial agonist analgesics behave as antagonists.
The activity of opioids in antinociceptive tests appears to be
dependent on both the intensity of the noxious stimulus and the
intrinsic activity of the drug.
INTRODUCTION
It has long been recognised that the potencies of analgesic agents
exhibit considerable variation between different animal models. For
example, the ED50 for morphine in the hot plate test has been
reported to be 30 times greater than in the abdominal constriction
model (Ward and Takemori 1983). In addition, several drugs (eg.
nalorphine) which display potent antfnociceptive activity in the
abdominal constriction test are inactive in tests employing heat as
the noxious stimulus (Tyers 1980). It has been suggested that the
neural pathways involved in the transmission of heat and non-heat
stimuli may possess different types of opioid receptor, and that
drugs which are ineffective against heat stimuli act predominantly at
k-sites.
However, this hypothesis does not explain why the potencies of drugs
such as morphine vary between tests. Neither does it explain the
observation made by several groups (Zimet et al. 1986. Sewell and
Spencer 1976, Luttinger 1985) that heat tests can be made to detect
the agonist-antagonist analgesics by lowering the temperature of the
stimulus.
The present study was designed in an attempt to clarify the relative
contribution of receptor selectivity, intrinsic activity and test
methodology to the analgesic efficacy of opioids.
METHODS
Dose responses to each of the test drugs were performed on 4
analgesic tests employing different noxious stimuli : 55° hot plate
(mouse), acetic acid induced abdominal constriction (mouse), paw
pressure (rat) and tail flick (rat). The animals used were either
female mice of the Alderley Park strain weighing 18-20g or newly
weaned female Alderley Park strain rats weighing 40-60g. In all
studies the test drug was administered subcutaneously 30 minutes
prior to test.
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Mouse hot plate
Reaction times of mice placed on a hot plate maintained at 55°C were
determined. Any drugs devoid of activity were tested as antagonists
of the k-agonist tifluadom. In this situation dose responses to
tifluadom were performed in the presence and absence of a constant
dose of antagonist. Groups of at least 6 mice were used in all hot
plate studies.
Acetic acid induced abdominal constriction
Acetic acid (0.4 ml) was administered intraperitoneally 30 minutes
after the test drug. Animals were left for 2 minutes before counting
the cumulative number of responses over the next 15 minute period. A
minimum group size of 10 was employed. In the first part of the
study the acetic acid concentration was 0.4%, but in later
experiments 0.25% and 0.6% concentrations were also used.
Paw pressure
Thresholds for each hind paw were measured using a modified
"Analgesimeter" (Ugo Basile, Milan) with the endpoint being taken as
the first struggle or vocalisation by the rat.
Tail flick
The method used was essentially the same as that described by D'Amour
and Smith (1941). The rat's tail was placed over a focussed light
beam and the latency to flick recorded. A cut-off time of 20 seconds
was imposed. In both rat studies at least 10 animals were used per
group.
RESULTS AND DISCUSSION
The activity of each of the drugs varied according to the test
situation (table 1) with only the full agonists and high intrinsic
activity partial agonists displaying full dose response curves across
the complete range of tests. U50488H produced a flattened dose
response curve on the hot plate test but complete dose responses on
the rat paw pressure and tail flick tests and the mouse abdominal
constriction test. The lower intrinsic activity partial agonists
xorphanol, nalbuphine, bremazocine, levallorphan and nalorphlne were
effective only on the abdominal constriction test.
The potencies of the drugs varied across the range of tests making it
possible to rank the assays in order of decreasing sensitivity as
follows: abdominal constriction > tail flick = paw pressure > hot
plate. These findings prompt the suggestion that each model provides
a different noxious stimulus intensity with hot plate providing the
highest and abdominal constriction test the lowest. If, by
increasing the stimulus intensity, the apparent number of "spare"
receptors is reduced, then it is possible to explain the current
observations. In the hot plate test, which provides the highest
stimulus intensity as reflected by the low potencies of the test
drugs. only the full agonists fentanyl and tifluadom and the high
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intrinsic activity partial agonist morphine have sufficient efficacy
to generate a full dose response. U50488H is less efficacious and
this is reflected by a flattened dose response on the hot plate test
although full dose responses were produced against the other lower
intensity stimuli. The low intrinsic activity partial agonists have
sufficient efficacy to be effective against only the lowest
stimulus.
TABLE 1 Antinociceptive potencies of a range of opiolds
If this explanation is correct, the lower efficacy drugs should
antagonise the effects of agonists acting at receptors for which the
partial agonists have affinity. This hypothesis was tested by
determining the effects of nalorphine, levallorphan and bremazocine
on the dose response to tifluadom in the hot plate test. The
tifluadom dose response was shifted to the right in a parallel manner
in the presence of each of these partial agonists (results not shown)
thus providing support for the hypothesis.
These findings do not support the suggestion of Tyers (1980) that
µ-agonists are equipotent against heat and non-heat stimuli whereas
k-agonists are less effective against heat. In the light of the
current findings it is obvious that µ and k-drugs with sufficient
efficacy are equally effective against heat and non-heat stimuli as
demonstrated by their similar potencies in the paw pressure and tail
flick assays, employing mechanical and thermal stimuli respectively.
The most likely explanation for this discrepancy is that many drugs
regarded as k-agonists are, in fact, partial agonists (Miller et al.
1985). The current data suggest that it is the efficacy of the drug
rather than its receptor selectivity which determines its profile
against different noxious stimuli.
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TABLE 2 Effect of acetic acid concentration on potency
Further support for the hypothesis is provided by the second part of
the current study which examined the effects of changing the stimulus
intensity within one assay - the mouse abdominal constriction test
(table 2). Responses to the µ- and k-agonists, morphine and
tifluadom were not significantly influenced by the acetic acid
concentration. In contrast the k-partial agonists xorphanol,
nalorphine and levallorphan, and the p-partial agonist nalbuphine
exhibited lower potency and flattened dose response curves when
tested against the higher acetic acid concentrations.
In conculsion, antinociceptive tests exhibit a wide range of
sensitivity to opioids. Some models such as the hot plate assay are
only sensitive to high doses of full agonists, whilst partial
agonists display antagonist properties. The more sensitive assays
such as the abdominal constriction test appear to have a high
receptor reserve in the abdominal constriction model. These findings
highlight the need for caution when comparing data from different
tests, or even from the same test performed under slightly different
conditions.
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ABSTRACT
Possible involvement of cerebral delta opioid receptors in
antinociceptive processes was studied in a test utilizing heat as the
noxious thermal stimulus. The investigation focused on selective
agonists and antagonists for mu and delta opioid receptors. Morphine
and [D-Ala2,NMPhe4,Gly-ol]enkephalin (DAGO) were used as agonists for
the mu receptorwhile [D-Pen2,D-Pen5]enkephalin (DPDPE) was the agonist
for the delta receptor. Two approaches were employed: first, the
intracerebroventricular (i.c.v.) analgesic activity of the agonists was
determined in the absence, and in the presence of graded i.c.v. doses of
the selective delta antagonist, ICI 174,864 (N, N diallyl-Tyr-Aib-Aib-
Phe-Leu-OH)(where Aib is alpha-aminoisobutyric acid); second, acute
tolerance to morphine was produced and the possible presence of acute
cross-tolerance between subcutaneous (s.c.) morphine and the delta
agonist investigated. ICI 174,864 antagonized the analgesia produced
by DPDPE, but not that resulting from morphine or DAGO. biorphine
pretreatment resulted in the development of acute tolerance to i.c.v.
morphine, and acute cross-tolerance to i.c.v. DAGO, but not to i.c.v.
DPDPE. These results provide evidence that both cerebral delta and mu
opioid receptors are responsible for the mediation of analgesia in tests
utilizing heat as the nociceptive stimulus.
INTRODUCTION
Traditional views regarding the involvement of supraspinal opioid
receptorsintests ofanalgesiawhere heat is employed as the nociceptive
stimulus have focused on the exclusive involvement of mu, rather than
delta and kappa, receptors (Audigier et al. 1980; Chaillet et al. 1984;
Changetal. 1982). While the analgesic effects of i.c.v. kappa agonists
are generally difficult to detect, both mu and delta agonists produce
effective analgesia by this route (Porreca et al. 1984). Thus, it is of
interest to determine whether even highly delta selective agonists such
as DPDPE (Mosberg et al. 1983) produce supraspinal analgesia in thermal
tests by activation of mu receptors, or whether cerebral delta receptors
are also involved in this effect. The present investigation attempts to
determine the possible involvement of cerebral delta opioid receptors in
thermal analgesic tests using direct antagonism with the highly
selective delta antagonist, ICI 174,864 (Cotton et al. 1984) as well as
the determination of possible cross-tolerance between morphine and the
selective delta agonist, DPDPE.
MATERIALS AND METHODS
Analgesic assay: Male, ICR mice (20-25 g) were tested forthelatencytoa
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rapid flick of the tail following immersion into warm (55°C) water. The
mice then received graded i.c.v. doses of agonist and distilled water, or
agonist and antagonist. The i.c.v. injection was made following the
induction oflightether anesthesia by an incision in the scalp, location
of bregma and injection directly into the lateral ventricle using a
microliter syringe in a volume of 5 µl. Twenty min after the i.c.v.
injection, a time determined to be close to the peak analgesic effect of
the agonists, the mice were retested for the latency to tail-flick. A
cut-off time of 15 sec was employed in order to minimize damage to the
tail. Post-drug latency was comparedtotheindividual pre-drug latency
and percent analgesia determined.
Acute tolerance: The procedure used was that described by Vaught and
Takemori (1979). Mice received a single S.C. injection of morphine
sulfate (100 mg/kg) or water 5 hr prior to testing. The morphine
pretreatmentnolongerhadanyagonisteffectatthis time. Graded doses
of morphine, DAGO and DPDPE were then given i.c.v. andtestingtook place
after 10 min.
RESULTS
Co-administration of ICI 174,864 (at 1 or 3 µg, i.c.v.) with i.c.v. DPDPE
resulted in a dose-related antagonism of the analgesic effect (fig. 1).
In contrast, ICI 174,864 (3 µg) failedtoantagonizethemorphine (fig.1)
or DAGO (not shown) dose-response lines.
Figure 1. Analgesic dose-response lines for i.c.v. morphine
(circles) or DPDPE (squares) in the absence (closed symbols) or presence
of ICI 174,864 (open symbols) at 1 or 3 µg (DPDPE) or 3 µg (morphine).
Pretreatment with morphine (100 mg/kg, S.C. at -5 hr) did not result in
any analgesic effect following the i.c.v. administration of water. The
i.c.v. morphine dose-response line was displaced to the right by a factor
of 6.6, indicating the developmentofacutemorphine tolerance (table 1).
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In contrast, the i.c.v. DPDPE dose-response line was not affected (table
1), indicating a lack of i.c.v. acute cross-tolerance between morphine
and the selective delta agonist.
TABLE 1. Analgesic A50 (and 95% C.L.'s)(µg/mouse) for 3 agonists
given intracerebroventricularly to control or morphine pretreated mice
(100 mg/kg, S.C. at -5 hr) in the warm-water tail-withdrawal test.
Agonist
Potency
Control Morphine-pretreated
Morphine 0.25 (0.107 - 0.598) 1.65 (0.79 - 3.47) 6.6
DPDPE 5.71 (3.13 - 10.43) 7.84 (4.53 - 13.56) 1.37
DPLPE 6.77 (0.01 -2.8-16.4) 7.68 (5.17 - 11.41) 1.13
DISCUSSION
The present study has investigated the possible involvement of delta
opioid receptors in the inhibition of responses to a noxious thermal
stimulus. Both mu (morphine, DAGO) and delta (DPDPE) agonists produced
full dose-response effects after i.c.v. administration, suggesting that
both mu and delta receptorsmightbe responsible forthemediation of this
effect. Previous studies, however, have suggested that all supraspinal
analgesia determined in tests utilizing heat as the noxious stimulus
relied on the sole activation of mu opioid receptors (Audigier et al.
1980; Chailletetal 1484; Chang etal. 1982). Ward and Takemori (1983)
found that the naloxone pA2 value against [D-Ala
2, D-Leu5]enkephalin
(DADLE) was slightly lower than that against morphine. Additionally,
those investigators found that the i.c.v. analgesic effects of DADLE were
antagonized by beta-funaltrexamine (beta-FNA)(Takemori et al. 1981),
leading to the suggestion of involvement of both i.c.v. mu and delta
opioid receptors in the tail-flick test. Our results using DPDPE, a
highly selective delta agonist (Mosberg et al. 1983) together with ICI
174,864, a highly selective delta antagonist (Cotton et al. 1984),
support this conclusion.
The co-administration of ICI 174,864 with DPDPE produced a dose-related
antagonism of i.c.v. DPDPE, but not morphine or DAGO, analgesia.
Administration of ICI 174,864 alone, at the doses studied, didnotaffect
the tail-flick response. Differential antagonism has historically been
taken as the strongest evidence fortheinvolvementofmultiple receptors
inapharmacological effect. Thus, the present results strongly suggest
that both cerebral mu (morphine, DAGO) and delta (DPDPE) receptors
mediate analgesia in this test.
Determination of the possible presence or absence of acute cross-
tolerance between morphine and DPDPE was also employed as a second
approach in an attempttoconfirmthe results oftheexperiments using the
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delta antagonist. While the presence of cross-tolerance suggests
either activity at a common receptor or some common post-receptor
pathway, the absence of cross-tolerance is reasonable evidence of
activity of separate receptor types. Acute pretreatment with a bolus
injection of morphine resulted in the development of acute tolerance as
shown by the rightward displacementofthe i.c.v. morphine dose-response
line. Similarly, morphine pretreatment displaced the i.c.v. DAGO dose-
response line to the right demonstrating acute cross-tolerance. In
contrast, however, the i.c.v. DPDPE dose-responselinewas not affected.
The lack of i.c.v. cross-tolerance between DPDPE and morphine, while not
establishing activity at separate receptors, supports the concept of
involvement of two receptors in this effect.
The finding of a lack of i.c.v. acute cross-tolerance between DPDPE and
morphine, when taken together with the antagonism of DPDPE, but not
morphine or DAGO analgesia by ICI 174,864, provides strong and direct
evidence of involvement of both cerebral delta, and mu opioid receptors
in this analgesic test. This concept has been previously suggested on
the basis of a lack of i.c.v. inhibition of gastrointestinal transit by
DPDPE, butnotby mu agonists (Porreca et al. 1984). The involvement of
kappa receptors in this thermally-initiated endpoint seems unlikely as
kappa agonists do not produce reliable effects after i.c.v.
administration. Thus, it appears thatbothmu and delta receptors in the
brain participate in this analgesic effect; the identification of the
spinal opioid receptors in this effect remains to be investigated.
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ABSTRACT
BAM-18, a new endogenous opioid containing 18 amino acid residues,
was tested in 3 behavioral paradigms. Tail-flick analgesia, a
spinally mediated response, hot-plate analgesia, a centrally mediated
response, and open-field locomotor activity. Rats were
stereotaxically implanted with a unilateral cannula aimed at the
lateral ventricle. Following recovery, each animal was tested in one
of the paradigms after receiving an intraventricular injection of
BAM-18, morphine or the Ringer's vehicle. BAM-18 produced
significant tail-flick analgesia only at doses (50 ug) 50 times
higher than those needed with morphine (1 ug). BAM-18 produced an
extended hyperalgesia at lower doses (5 ug) that was also seen
transiently at the high dose. The analgesia but not the hyperalgesia
was reversed by naloxone (10 mg/kg, s.c.). BAM-18 produced
significant naloxone-reversible hot-plate analgesia, but again it was
less potent than morphine (50 ug for BAM-18 vs. 5 ug for morphine).
There was no evidence of hyperalgesia in this paradigm. Locomotor
activity, following 50 ug of BAM-18, resembled control injections for
the first 18 minutes, then became reduced in a manner similar to
morphine (5 ug). This reduction in activity was completely reversed
by naloxone. These data suggest that BAM-18 is indeed an opioid
molecule but is at least 10 times less potent at altering behavior
than morphine.
INTRODUCTION
BAM-18 is a new endogenous opioid molecule of 18 amino acid residues
which has recently been isolated from bovine adrenal medulla (Evans
et al. 1985). BAM-18 is a derivative of the pro-enkephalin A
molecule (Pittius et al. 1984), and is found in high concentrations
in many areas of the central nervous system including striatum,
hypothalamus, pons/medulla and spinal cord (Evans et al. 1985). We
have found that BAM-18 binds with high affinity to both u and k
receptors (ki-0.29 nM and 0.75 nM, respectively) and might therefore
be expected to exhibit potent analgesic activity. After central
administration of BAM-18 or morphine, we tested rats in 2 analgesia
paradigms, tail-flick which is a spinally mediated response and
hot-plate which is centrally mediated (Jensen and Yaksh 1985), and
also assessed drug effect on spontaneous locomotor activity. All
observed behavioral changes after BAM-18 administration were tested
for naloxone reversibility.
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MATERIALS AND METHODS
Seventy male Sprague-Dawley rats (Charles Rivers, Portage, Michigan)
were unilaterally implanted with a 24 gauge stainless steel injection
cannula aimed at the lateral ventricle (-1.0 mm from bregma, +1.7 mm
from midline and -3.0 mm from dura). Following recovery, the animals
were placed in one of the following experimental paradigms.
Experiment 1.
Animals were placed in the tail-flick restrainer and allowed to
acclimate for 30 minutes. The tip of the tail was blackened to
reduce variability of heat absorbtion. The intensity of the heat
lamp was adjusted for each animal to yield a mean baseline tail-flick
latency of 7-9 seconds. Following 3 baseline readings, BAM-18 or
morphine, dissolved in 20 ul of modified Ringer's solution, or
Ringer's alone, was administered through the cannula and tail-flick
latencies were performed every 2 minutes for a total of 30 minutes.
Naloxone reversibility was determined by administration of naloxone
(10 mg/kg, s.c.) 15 minutes before icv BAM-18 or Ringer's injections.
Experiment 2.
The hot-plate testing apparatus consisted of a Corning hot-plate
covered with a 0.25 inch aluminum plate for even heat distribution,
and a plexiglass open-ended box on the plate. The temperature was
maintained at 45° C and monitored continually with a YSI thermistor
thermometer. Animals were allowed to habituate to the apparatus on a
cold plate. Testing was performed by lowering the animal, by its
tail, onto the hot-plate. When the hind paws touched the plate,
timing began and was terminated when the animal licked a hind paw.
Three readings were taken and averaged to yield the pre-drug
baseline. BAM-18 or morphine, dissolved in 20 ul of Ringer's
solution, or Ringer's alone was administered through the cannula, and
latencies were performed every 5 minutes for a total of 30 minutes.
Naloxone reversibility was determined by administration of naloxone
(10 mg/kg, s.c.) 15 minutes before icv BAM-18 or Ringer's injections.
Experiment 3.
Spontaneous locomotor activity was recorded in an Opto-Verimex-Minor
activity monitor (Columbus Instruments). Animals were injected with
BAM-18 or morphine dissolved in 20 ul of Ringer's solution or
Ringer's alone, as in previous experiments, and placed in the animal
activity monitor. Locomotor activity was recorded every 6 minutes
for a total of 60 minutes. Naloxone reversibility was assessed by
administration of naloxone (10 mg/kg, s.c.) 15 minutes prior to icv
BAM-18 or Ringer's solution injection.
RESULTS
BAM-18 produced a significant analgesic response in the tail-flick
paradigm (figure la) similar to that seen with morphine. However,
the dose of BAM-18 required was 50 times that needed with morphine
(50 ug and 1 ug respectively). At lower doses of BAM-18 (5 ug), and
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transiently at higher doses, a hyperalgesic response was
observed. The analgesia but not the hyperalgesia was reversed by
naloxone (10 mg/kg, s.c.)(figure 1b), unmasking the hyperalgesia at
the 50 ug dose. A significant analgesia was also observed with
BAM-18 in the hot-plate paradigm (figure 2a). The dose required was
vs. controls)
FIGURE 1. a. Mean tail-flick latency (sec) after
intraventricular administration of 2 doses of BAM-18.
b. Mean tail-flick latency (sec) after pretreatment
with naloxone (10 mg/kg, s.c.) and icv administration
of either BAM-18 or Ringer's solution. Scores
represent change from baseline (drug score - baseline
score). Bars are S.E.M.'s. (* p < 0.05, F-test,
administration of BAM-18. b. Mean hot-plate latency
(sec) after pretreatment with naloxone (10 mg/kg,
s.c.) and icv administration of either BAM-18 or
Ringer's solution. Scores represent change from
baseline (drug score - baseline score). Bars are
S.E.M.'s. (* p < 0.05, F-test, vs. control)
10 times greater than an analgesic dose of morphine (50 ug BAM-18, 5
ug morphine). The BAM-18-induced analgesia was completely reversed
by naloxone (10 mg/kg, s.c.)(figure 2b). BAM-18 was 50 times less
potent than morphine in producing analgesia in the tail-flick test (a
spinally mediated response) and 10 times less potent in the hot-plate
test (a centrally mediated response). These data suggest that the
degradation of BAM-18 plays a significant roll in determining its
potency in the production of analgesia. BAM-18 (50 ug) did not
affect locomotor activity during the first 18 minutes following
injection (figure 3a). During the later time frames, BAM-18 caused a
reduction in spontaneous activity similar to that seen with morphine,
albeit at a larger dose than morphine (5 ug). The reduction in
spontaneous activity caused by BAM-18 was completely reversed by
naloxone (10 mg/kg s.c.)(figure 3b). Occasionally, seizure-like
activity was seen with the 50 ug dose of BAM-18. The seizures were
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of three types, wet-dog shakes, head and fore-paw shakes, and
barrel-rolling. The barrel-rolling behavior was observed in one
animal even after naloxone. Non-naloxone reversible barrel-rolling
activity is routinely seen with 100 ug intraventricular injections of
Dynorphin (1-13) (Herman et al. 1980) which has some sequence
homology with BAM-18.
icv administration of BAM-18. b. Mean open-field
locomotor activity after pretreatment with naloxone (10
mg/kg, s.c.) and icv administration of either BAM-18 or
FIGURE 3: a. Mean open-field locomotor activity after
Ringer's solution. Bars are S.E.M.'s. (* p < 0.05,
F-test, vs. control)
In conclusion, BAM-18, when administered centrally, is capable of
producing analgesia in 2 different behavioral tests. However, it is
consistantly less potent than morphine. Reliable analgesia has been
achieved with as little as 0.5 ug ivc in the tail-flick paradigm
(McGregor et al. 1978) whereas in the present work a dose of 50 ug
BAM-18 was required. Similarily, BAM-18 reduces spontaneous activity
but, again, at a larger dose than is required for morphine. A
hyperalgesia in the tail-flick paradigm was observed at low doses of
BAM-18 and was unmasked by naloxone at higher doses. All observed
effects of BAM-18 (except the hyperalgesia) were reversed by
naloxone.
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ABSTRACT
The icv administration of potassium chloride a few min
before the icv injection of opioids, antagonized the
supraspinal analgesia induced by these substances in the
mouse. The antagonistic effect of a single injection of
KCl lasted for 3 to 4 days and was accompanied by
opposite changes in 3H-DADLE binding to mesencephal ic
(decrease) and spinal cord (increase) membranes.
INTRODUCTION
Potassium ion has usually been considered as an inert
agent on properties of the opioid receptor in vitro (Pert
and Snyder 1974). However, electrophysiological studies
have recently shown that op io ids cause hyperpolarization
of neurons by opening certain potassium channels in the
neural membrane. This action of opioids was reduced by
increasing the extraneuronal concentration of ion
(Willians et al. 1982). On the basis of these findings,
the influence of icv administration of KCl on the
analgesia induced by opioids at supraspinal level in the
mouse was investigated.
MATERIALS AND METHODS
Pept ides were obtained from Bachem (Bubendorf,
Switzerland). Tritiated dihydromorphine (DMH) and
D-Ala2,D-Leu5-enkephal in (DADLE) were purchased from
A m e r s h a m  C o r p o r a t i o n  a n d  N e w  E n g l a n d  N u c l e a r
respectively. Albino male mouse CFLP. 22-27 g were used
throughout. Analgesia was evaluated by the tail-flick
method in a water bath at 52° C. and expressed as a
percent of the maximum possible effect after setting a
cut off time of 10s. Binding experiments were carried out
on crude P2 fractions at 25°C for 30 min in 2 ml of 50mM
TRIS buffer pH 7.7 in the presence of several
concentrations of labeled 1 igands. Samples were filtered
through Whatman GF/B filters and counted in a
scintillation counter Beckman LS-5801.
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RESULTS
KCl or NaC (0.1-1 µmole/mouse,icv) given 30 min before
the icv administration of opioids, did not modify the
analgesia induced by morphine and related alkaloids
(normorphine, levorphanol...), which agrees with previous
reports (Chapman and Way 1980). Similarly, the ions did
not alter the analgesic properties of DTLET and
morphiceptin. However, potassium but not sodium (1
µmole/mouse), clearly diminished in a dose-dependent and
non-competitive manner the analgesia induced by several
opioid peptides of different receptor selectivities
(table 1): µ, FK 33-824; , DADLE, DPLPE. In mice
pretreated with KCl icv 0.3, 0.5 and 1 µmole/mouse, DADLE
only reached 85, 60 and 20% of the maximum analgesic
effect. KCl treatment also reduced the analgesia elicited
by endogenous opioid peptides derived from the
Proenkephalin precursor. In contrast, the analgesic
action of ß-endorphin remained practically unchanged.
TABLE 1. Effect of KCl and NaCl on the analgesia induced
by opioids in the mouse
Opioid
test time NaCl KCl
min ED50 ED50 slope
Morphine 30 3.00 0.26
DADLE 15 0.10 0.02
DPLPE 15 20.9 3.10
DTLET 15 1.14 0.17
FK 33-824 30 0.0027 0.0003
Morphiceptin 5 6.91 0.75
Met-ENK-Arg-Phe 5 37.1 4.20
Adrenorphin 15 28.1 2.53
Peptide E 30 1.51 0.72
ß-endorphin 30 0.042 0.004
3.30 0.22 0.90
> 30* 0.24
>200* 0.54
1.44 1.15 1.15
0.15 0.09* 0.51
7.22 0.60 1.06
>300* nd
> 100* nd
> 10* nd
0.070 0.006 0.80
Salts (1µmole/mouse) were given icv 30min prior
to the opioids. Groups of 8 to 12 animals were
used. Slopes and ED50 were computed from the
Hill transformation of experimental data. ED5Os
are in nmoles/mouse. * Statistically different
from the group treated with NaCl, Student's t
test;p<0.05. Abbreviations,nd:non determinated;
DPLPE: (D-Pen2, L-Pen5)-enkephalin; DTLET:
(D-Thr2, Leu5)-enkephalin-Thr6; FK 33-824:
(D-Ala2, N-Me-Phe4, Met-(o)5-ol)-enkephalin.
The antagonistic effect of a single icv injection of KCl
(1 nmole/mouse) was found to be of a remarkable long
duration. The analgesia was still diminished 3 days later
and after a slow recovery phase the animals showed a
normal response to opioids on the 5th day (table 2).
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TABLE 2. Time-course of KCl antagonism on opioid-induced
supraspinal analgesia
Ratio Na/K
Opioid Dose Day: 1 2 3 4 5
Morphine 3.0 0.86 0.89 1.12 1.15 0.88
DADLE 0.1 5.80* 3.20* 2.26* 1.67* 1.20
FK 33-824 0.003 2.80* 2.34* 2.14* 1.75* 1.37
Salts <1µmole/mouse,icv) were given once on day
1, 30 min prior to the opioids. Opioids were
administered icv at ED50 (nmole/mouse) and the
analgesic effect studied daily for 5
consecutive days. Ratios between the percent of
the maximum analgesic effect induced by opioids
in groups of mice (n=10) pretreated either with
NaCl or KCl are shown. * Statistically
different from the group treated with NaCl,
Student's t test; p<0.05.
TABLE 3. Time-course of KCl effect on 3H-DADLE binding
Ratio Na/K
Structure Day: 1 2 3 4 5
Mesencephalon Kd 1.00 1.11 1.02 1.03 1.10
Bmax 0.95 1.53* 1.35* 1.12 1.11
Spinal cord Kd 1.05 1.00 0.95 0.95 0.98
Bmax 1.03 0.75* 0.80* 0.96 1.10
Salts (1µmole/mouse.icv) were given once a day
1. Groups of mice were killed 30 min after the
salt injection on day 1 and at the intervals
above indicated. Ratios between parameters
obtained from NaCl and KCl treated mice are
shown. The experiment was repeated four times. Kd
and Bmax for 3H-DADLE specific binding to
mesencephalic and spinal cord membranes are
respectively: 3.2 0.2 nM, 115 5 fmoIe/mg
protein and 1.9 0.1 nM, 56 3 fmole/mg protein.
* Statistically different from 1, Student's t
test; p<0.05.
The specific binding of 3H-DHM and 3H-DADLE to mouse
brain and spinal cord membranes was also monitored during
the 5 days after the single icv injection of the salts
(1 µmole/mouse). No change was shown when the whole brain
was studied. However, in KCl treated mice, 3H-DADLE
specific binding decreased in mesencephalon and increased
in spinal cord. These changes were evident 24 h after the
KCl injection and slowly returned to the initial values
on day 4 (table 3). In contrast, 3H-DHM binding to these
structures remained unchanged.
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DISCUSSION
The apparent selectivity of the antagonism induced by KCl
on the opioid analgesia and the changes found in the
number of opioid receptors labeled by DADLE, agree with
the proposed involvement of, multiple receptors in the
supraspinal analgesia induced by opioids (Höllt et al.
1985). Assuming that hypothesis, the "potassium-
sensitive" opioids would induce at least a part of the
analgesic effect after binding to a receptor(s) whose
function is susceptible of being reduced by that ion. The
'potassium-sensitive' receptor appears not to be the one
preferred by either the opiate alkaloids, morphiceptin or
DTLET to promote analgesia. Interestingly, DTLET and its
analog DSLET seem to induce analgesia through the
morphine receptor (Chaillet et al. 1984). On the other
hand, it has been shown that morphine- and ß-endorphin-
induced analgesia can be modulated without altering the
antinociceptive properties of the ligand DADLE or the µ
ligand FK 33-824 (Tulunay et al. 1981). In the present
study, it was evidenced the antagonism by KCl of DADLE-
and FK 33-824-evoked analgesia but not of morphine, thus
confirming the possibility of modulating the analgesic
effects of FK 33-824 and morphine independently. Of
interest is a recent report describing the existence of
an additional type of binding site to which µ- and
d-selective enkephalin analogs display their highest
affinities (Lutz et al. 1985). We find particularly
interesting the antagonism by KCl of the analgesia
elicited by the Proenkephalin-derived peptides. This
result might indicate that a common mechanism underlies
the effect of that family of endogenous opioids. Although
further work is required to identify the opioid receptor
whose function is decreased by potassium as well as the
processes responsible for that antagonism, these results
suggest a regulatory role for that ion on the function of
the opioid receptor in vivo.
REFERENCES
Chaillet, P., Coulaud, A., Zajac, J.M., Fournie-Zaluski,
M.C., Coustentin, J. and Roques, B.P. Eur J Pharmacol,
101:83-90, 1984.
Chapman, D.B. and Way, E.L. In:George, R., Okun, R. and Cho,
A.K. ed. Annual Review of Pharmacology and Toxicology.
Vol. XX. Palo Alto, Annual Reviews Inc., 1980. pp 553-579.
Höllt,V., Sánchez-Blázquez, P. and Garzón, J. Phil Trans
R Soc Lond, B308:299-310, 1985.
Lutz, R.A., Cruciani, R.A., Munson, P.J. and Rodbar, D. Life
Sci, 36:2233-2238, 1985.
Pert, C.B. and Snyder, S.H. Mol Pharmacol, 10:868-879, 1974.
Tulunay, F.C., Jen, M.F., Chang, J.K., Loh, H.H. and Lee, N.M.
J Pharmacol expt Ther, 219:296-299, 1981.
Willians, J.T., Egan, T.M. and North, R.A. Nature, 299:74-77,
1972.
453
INCREASE IN MET-ERKEPHALIN LEVEL AND ANTINOCICEPTIVE EFFECTS
INDUCED BY KELATORPHAN IN THE RAT SPINAL CORD.
Marie-Claude Fournié-Zaluski*, Sylvie Bourgoin**
François Cesselin**, Michel Hamon**, Daniel Le Bafs*** ,
Antony H. Dickenson and Bernard P. Roques .
* Chimie Organique, U 266 INSERM, UA 498 CNRS, Faculté
de Pharmacie, 4 Av. de l'Observatoire, 75006 Paris, France.
** U 288 INSERM, CHU Pitié-Salpérière, 75013 Paris,
*** U 161 INSERM, Centre Paul Broca, 75014 Paris,
**** University College, London.
ABSTRACT
Kelatorphan, a mixed inhibitor of “enkephalinases” is used for
demonstrating the implication of endogenous enkephalins in
nociceptive transmission at the spinal level.
INTRODUCTION
The high levels of enkephalins in the superficial dorsal horn of
spinal cord, together with dense opiate receptor binding sites, may
be related to a role in the modulation of nociceptive transmission
at the spinal level. However, demonstration of this putative role is
prevented by the rapid degradation of enkephalins by three
peptidases : enkephalinase, aminopeptidase M and a dipeptidylamino-
peptidase whose specific role is not clearly established. Mixed
inhibitors of these three enzymes were developed and kelatorphan is
the first of a new series of compounds exhibiting high analgesic
properties by both i.c.v. and i.v. routes (Fournié-Zaluski et al.
1985). Consequently, kelatorphan was also studied for its ability to
protect endogenous enkephalins (Bourgoin et al. 1986) and to depress
the responses of nociceptive neurons in the spinal cord (Dickenson
et al. 1986).
RESULTS AND DISCUSSION
Effect of kelatorphan on the in vitro outflow of endogenous
met-enkephalin from rat spinal cord slices. Superfusion of dorsal
horn slices with 2 and 20 µM kelatorphan, produces an increase of
82% and 175% in the spontaneous and 130% and 230% in the K+evoked
outflow of enkephalin. The association of bestatin (20 µM) and
thiorphan (1 µM) is inactive on the spontaneous release.
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Effect of kelatorphan on the in vivo release of met-enkephalin like
material (MELM) from the rat spinal cord. The subarachnoidal space
of anesthetized rats was perfused with artificial CSF, with or
without, the various inhibitors. As shown in table 1, kelatorphan
increases both the spontaneous outflow of MELM and the outflow
evoked by K+ depolarization or by a noxious treatment.
TABLE 1. Comparison of the effect of kelatorphan and the
association bestatin + thiorphan on the in vivo release
of MELM from the rat spinal cord.
Treatment Control Th(1µM)+B(20 µM) Kelatorphan(20µM)
None 4.33 ± 0.4 9.47 ± 0.66 10.82 ± 1.38
K+ (40mM) ±10.97 1.59* 23.65 ± 3.29*
Muzzle pinching10.10 ± 1.26* 19.82 ± 2.42* 22.28 ± 4.60”
* P < 0.05.
Inhibition of nociceptive neurones in rat spinal cord. The
inhibitors were applied at the indicated concentrations onto the
surface of the dorsal horn of anaesthetized rats and the neurons
were recorded and characterized by their responses to electrical
stimulation of A and C fibres. As observed in figure 1, the effect
of kelatorphan was significant with a dose as low as 2.5 µg and the
inhibition of C fibres was clearly dose dependent. The maximal
effects were seen with 25 and 50 µg.
FIGURE 1. Inhibition of the A evoked activity and
C-fibre responses by bestatin, thiorphan and kelatorphan.
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The A fibre responses were only significantly altered by the highest
doses. The effects of kelatorphan were greater than those produced
by the same doses of bestatin and thiorphan and were reversed by
naloxone.
Analgesic effects of kelatorphan on hot plate and tail flick tests.
The properties of kelatorphan were also studied on the tail flick
test, a spinal model of analgesia and on the hot plate test, which
is considered as a supraspinal model. As shown in table 2,
kelatorphan induces high analgesic responses on the jump latency
time but also on both the licking, and the tail flick tests for the
highest doses. All these effects are reversed by naloxone.
TABLE 2. Effects of kelatorphan on analgesic tests in
mice.
Hot plate test Tail flick test(s) c)
Licking time(s) a) Jump latency time(s) b)
control 5 ±0.3
10 µg 4.3±O.3 (NS)
40 µg 6.1±0.7 (NS)
80 µg 8.4±0.8 *
114 µg 8.6±_0.9 **
200 µg 9.2±1.3 ***
50±5 7.3±0.3
82±8 ** NT
123±16 *** 7.6±0.5 (NS)
188±1O *** 7.9±0.6 (NS)
200±16 *** 11.9±0.6 ***
206±15 *** 12.2±0.6 ***
a) cut off time, 30 s ; b) cut off time, 240 s ; c) cut
off time, 24 s.
CONCLUSION
The experiments performed in both CNS and spinal cord clearly
indicated that the use of mixed inhibitors of "enkephalinase" are
the most efficient method for the in vivo study of physiological
properties of enkephalin.
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ABSTRACT
Intrathecal injection of subanalgesic doses of morphine (7.5 nmol) and dynorphin-A-(1-13)
(1.25 nmol) in combination resulted in a marked analgesic effect as assessed by tail flick
latency in the rat. The analgesic effect of the composite of dynorphin/morphine was
dose-dependent in serial dilutions and not accompanied by any signs of motor dysfunc-
tion. Synergism between dynorphin and morphine can also be demonstrated without
motor dysfunction, when dynorphin is injected together intrathecally with a serial
increasing dosages of morphine. Metenkephalin showed an analogous synergistic effect
with dynorphin and also morphine in the spinal cord, although dynorphin (and also
metenkephalin) antagonized morphine analgesia by the intraventricular route. The
underlying mechanism of the interactions among different classes of opioid ligands at
different levels of the central nervous system deserves further study.
INTRODUCTION
The analgesic effect of dynorphin upon intrathecal injection has been well documented
(Han and Xie 1982, Piercey et al. 1982, Przewlocki et al. 1983); but large dose of intrathe-
cal dynorphin often causes motor paralysis of hind limbs, which might interfere with the
tail flick analgesic test. Intraventricular injection of dynorphin and also metenkephalin
have been proved to have an inhibitory effect on morphine or beta-endorphin analgesia
(Lee et al. 1980, Friedman et al. 1981). So it would be interesting to compare the interac-
tion of dynorphin, metenkephalin, and morphine in the spinal cord and the brain. This
may provide important clues about the pain modulatory effects of different types of opioid
ligands and their interactions.
METHODS
Rats, 200-250 gm in body weight were used. Intrathecal injections were given via PE-10
catheter within 24-48 hours after its implantation into the spinal subarachnoid space
(Yaksh and Rudy 1976). Intraventricular injections (ICV) were given to the lateral ven-
tricles through a stainless steel cannula inserted along an appropriate guide anchored to
the skull. Tail flick latencies (TFL) were assessed (Jen and Han 1979) prior to drug
administration and thereafter; the percent change of pain threshold was determined by
taking the pre-drug level as 100 %. Statistical significances between groups were assessed
by Student’s t-test.
RESULTS
I. Synergistic effect between dynorphin and morphine given intrathecally:
Different groups of rats, 8 to 11 in each group, were given 1.25 nmol of dynorphin-A-(1-13)
or 7.5 nmol of morphine separately or in combination at a total volume of 10 µl. The
combined effect was much stronger than the mathematical additive effect of the two com-
ponents, which were both not significantly different from the saline control (fig. 1).
The combination of morphine and dynorphin gave rise to a marked increase in TFL over
100 % of the basal level 10 min after injection, which was maintained at a height
between 104±15 % and 119±7 % for the whole observation period of 80 minutes (fig. 2).
The effect was also dose-related upon serial dilution. None of the rats showed any signs
of motor dysfunction when they were allowed to move freely out of the holders.
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FIGURE 1. Analgesic effect of dynorphin-A-(1-13)
1.25 nmol, morphine 7.5 nmol and both drugs in
combination. *** Indicates p <0.001 compared to
either dynorphin or morphine alone.
FIGURE 2. Dose-response effect of seriall dilutions of
intrathecal dynorphine/morphine composite.
Numerals in parentheses indicate number of
animals.
Similar synergistic effect between dynorphin and morphine could also be observed when
dynorphin was given on top of serial increasing dosages of morphine of 2, 4, 8, 16, and 32
nmol, given in succession every 10 min (fig. 3). Again, none of these animals showed any
signs of motor dysfunction.
FIGURE 3. Synergistic effect between
dynorphin and serial increasing dosages
of morphine given intrathecally.
II. Synergistic effect between metenkephalin and morphine or dynorphin given intrathe-
tally:
Analogous synergistic effect was observed between metenkephalin and serial increasing
dosages of morphine or dynorphin given intrathecally (fig. 4 and 5). Subanalgesic dose of
metenkephalin (100 nmol) was effective in potentiating morphine analgesia across various
dose ranges of morphine or dynorphin.
FIGURE 4. Synergistic effect between metenkephalin FIGURE 5. Synergistic effect between metenkephalin
and serial increasing dosages of morphine given and serial increasing dosages of dynorphin given
intrathecally. intrathecally.
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III. Antagonism of morphine analgesia by dynorphin given intraventricularly:
Different groups of rats, 6-11 in each group, were given ICV injection of normal saline 8
µl, dynorphin-A-(1-13) 20 nmol or morphine 30, 60, and 120 nmol respectively. Saline and
dynorphin did not cause any significant change in basal pain threshold. However, mor-
phine, at different dose levels, produced a dose-dependent increase of 19±12, 75±18, and
139±7 % of basal pain threshold.
When dynorphin 10 and 20 nmol was given ICV together with 120 nmol of morphine in
another 2 groups of rats, the analgesic effect of morphine was attenuated. A reduction of
88 % was noticed with 20 nmol of dynorphin and was statistically very significant (p <
0.01) from the group given morphine alone (fig. 6).
FIGURE 6. The effect of ICV injection of
various doses of dynorphin-A-(1-13) and
morphine in combination.
When dynorphin 20 nmol was given 30 min after 120 nmol of morphine was injected ICV,
a drastic suppression of the analgesic effect of morphine was noticed within 20 min (68 %
reversal, p < 0.001, as shown in fig. 7). Similar suppressibe effect was noticed when dynor-
phin 20 nmol was injected ICV together with 30, 60, and 120 nmol of morphine given in
serial succession to rats (fig. 8). The differences in analgesic effect between the group
given morphine and dynorphin in combination and the group given saline plus morphine
were statistically significant or very significant across all dosages of morphine.
FIGURE 7. The effect of ICV injection of
dynorphin-A-(1-13) on morphine anal-
gesia. M, morphine 120 nmol; D,
dynorphin-A-(1-13) 20 nmol; NS, normal
saline.
FIGURE 8. Antagonistic effect of dynor-
phin on increasing dosages of morphine
given intraventricularly.
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DISCUSSION
Our data clearly showed that a subanalgesic dose of dynorphin-A-(1-13) produced a
marked potentiation on morphine analgesia whereas none of the animals had any sign of
motor dysfunction. Thus different effects of dynorphin-A on sensory and motor function
may occur depending on the dose: a small amount. of exogenously applied or endogenously
released (Han and Xie 1984) dynorphin-A primarily affects nociception. Motor activities
are impaired only when a relatively large dose is administered or huge amount of dynor-
phin is released in case or cord injury (Faden et al. 1983). The supposition that
dynorphin-A in spinal cord may be more involved in sensory rather than in motor func-
tion seems to be in line with the findings that the dynorphin-A content in the dorsal spi-
nal cord is much higher than in the ventral cord (Botticelli et al. 1981).
Synergism between different classes of opioid ligands dynorphin, metenkephalin, and mor-
phine at the spinal level implies that they may act’ synergistically in the spinal cord and
are important modulators of pain at that level. These findings strongly suggest that
dynorphin-A-(1-13), morphine and metenkephalin are acting on different receptor popula-
tions or different binding sites of the receptor, resulting in a synergistic effect. Another
interesting finding in our study is the sharp contrast between brain and spinal cord for
dynorphin/morphine interaction. While dynorphin-A-(1-13) potentiated morphine anal-
gesia in the spinal cord, it antagonizied morphine analgesia in the brain. This
phenomenon was first reported in mice (Friedman et al. 1981, Tulunay et al. 1981) and is
here confirmed in the rat. The same was true for the interaction between metenkephalin
and morphine. The underlying mechanism of the intriguing interactions among different
classes of opioid ligands at different levels of the central nervous system deserves further
study.
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SIMILAR ACTIONS OF KAPPA AND MU AGONISTS ON SPINAL NOCICEPTIVE
REFLEXES IN RATS AND THEIR REVERSIBILITY BY NALOXONE
Chris G. Parsons, David C. West* and P. Max Headley
Dept. of Physiology, The Medical School, Bristol BS8 1TD, UK
* Dept. of Physiology, University College, Cardiff CF1 1XL, UK
ABSTRACT
The mu agonist fentanyl and the kappa agonists U-50,488 and tifluadom
were tested intravenously in electrophysiological experiments on
spinal nociceptive reflexes in anaesthetised, spinalised rats.
Responses of single motoneurones to thermal and mechanical stimuli
were reduced to a similar degree by both mu and kappa agonists and
these effects were reversed by low doses of naloxone.
INTRODUCTION
Most studies addressing the role of opiate receptor subtypes in the
modulation of spinal nociceptive responses have used behavioural
tests. Interestingly, systemic kappa agonists have been reported to
be relatively ineffective against reflexes to thermal noxious stimuli
in tail flick and hotplate tests, whilst having clear effects against
reflexes to mechanical and visceral noxious stimuli (Tyers 1980,
Upton et al. 1982, Ward and Takemori 1983). Several reports from
Yaksh and his coworkers have indicated that this is also the case
when kappa agonists are administered intrathecally, whereas mu
agonists are effective against reflexes to thermal as well as to
mechanical and other noxious stimuli (see Yaksh and Noueihed 1985).
Other workers have reported that kappa opiates show less difference
in effectiveness between thermal and non-thermal nociceptive tests
using either systemic (VonVoigtlander et al. 1983) or intrathecal
administration (Przewlocki et al. 1983).
We have been using an electrophysiological correlate of these
behavioural studies so as to be able to record the responsiveness of
single motoneurones to intravenously administered mu and kappa
ligands. We have selected agonists on the basis that they show
receptor selectivity, that they are suitable for systemic
administration and that they are rapidly metabolised. We have used
fentanyl as a mu agonist (see Magnan et al. 1982) and U-50,488
(VonVoigtlander et al. 1983) and tifluadom (Römer et al. 1982) for
kappa receptors. We have used the opiate antagonist naloxone to test
the opioid receptor specificity of the observed agonist effects.
MATERIALS AND METHODS
Experiments were performed on alpha-chloralose anaesthetised,
spinalised rats. Using silver wire electrodes, recordings were made
from the axons of single motoneurones in fine ventral root filaments.
The motoneurones were excited by natural peripheral stimuli which
were electronically controlled for duration, repetition rate and
constancy of intensity. The opioids were tested for selectivity
against responses to alternating thermal and mechanical noxious
stimuli. Particular care was taken to adjust the stimulus intensities
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so as to elicit similar action potential discharge rates in response
to the different stimuli. Analysis was of the total number of spikes
evoked by the stimulus.
All drugs were given intravenously in these spinalised preparations,
both so as to expose the whole polysynaptic pathway to the
motoneurone to even concentrations of the drug and so as to allow
direct comparison with doses used in behavioural tests. Doses were
augmented logarithmically; normally until the cumulative dose was
sufficient to reduce the response to less than 25% of the control
mean count of spikes per response. Tests were only considered
acceptable if the response recovered by more than 50% of the
reduction. More than one drug was tested on nearly all cells.
RESULTS
As predicted, fentanyl reduced thermal and mechanical nociceptive
responses to a similar degree. In fact at 2 ug/kg on 23 motoneurones
in 19 rats the thermal and mechanical nociceptive responses were
reduced to means of 44% (±7 SEM) and 51% (±8) of control
respectively. The kappa agonists U-50,488 and tifluadom showed a
similar lack of selectivity when tested against alternating thermal
and mechanical responses in 14 and 10 rats respectively. For example,
at 2 mg/kg, U-50,488 reduced noxious heat responses of 23 cells to a
mean of 45% (±7) and noxious pinch responses to 54% (±7). Tifluadom
was more potent than U-50,488, 0.2 mg/kg being sufficient to reduce
noxious heat responses of 10 cells to a mean of 47% (±12) and noxious
pinch responses to 30% (±10) of control values. Such non-selectivity
by the kappa agonists was however dependent on the neuronal firing
rates during the two stimuli; this is illustrated in figure 1. The
left side shows an apparently 'selective' reduction of the mechanical
response by U-50,488. The right side shows that when firing rates
of alternating responses of the same cell were matched by reducing
the heat stimulus, this selectivity was no longer apparent.
FIGURE 1. Responses of a motoneurone to noxious heat and
pinch alternated in a regular 3 minute cycle. Alpha-
chloralose anaesthetised, spinalised rat.
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When tested in opiate naive rats, the opiate antagonist naloxone (0.1
to 10 mg/kg) had no effect on the responses of motoneurones to
noxious heat or pinch stimuli. We were unable to distinguish between
the effects of mu and kappa agonists with naloxone at 0.1 mg/kg i.v.
since this dose effectively reversed the actions of fentanyl,
U-50,488 and tifluadom. Thus, in 7 cells, naloxone at 0.1 mg/kg
reversed the depression of heat responses by U-50,488 (1-16 mg/kg)
from a mean of 16% (±7 SEM) to 81%(±12) of control. An example of
such a result is illustrated in figure 2.
FIGURE 2. Responses of a motoneurone to noxious pinch
stimuli applied every 3 minutes. The squares indicate
responses to pinch during a test with U-50,488 and show the
subsequent time course of recovery. The diamonds illustrate
superimposed data from a subsequent, similar test on the
same cell. In this case reduction of the pinch response by
U-50,488 was rapidly reversed by a low dose of intravenous
naloxone. Alpha-chloralose aneasthetised, spinalised rat.
DISCUSSION
Our electrophysiological experiments have shown that the kappa
agonists U-50,488 and tifluadom reduce thermally-evoked reflexes to
just as great a degree as mechanically-evoked reflexes. This non-
selectivity contrasts with the results of most of the behavioural
tests which have utilised spinal administration of opioids. This
contrast between electrophysiological and behavioural tests can best
be explained by two factors. Firstly, in our experiments great care
was taken to adjust stimulus intensities so as to match the responses
in terms of motoneuronal firing rate. The relative strength of
reflexes in behavioural tests cannot be assessed in terms of neuronal
firing rate and therefore cannot be matched in the same way. Figure 1
illustrates that the apparently selective depression by U-50,488 of a
motoneuronal response to noxious pinch was entirely dependent on the
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relative stimulus intensities. It is thus clear that stimulus
intensity is a crucial factor in the assessment of the
antinociceptive effects of opioids.
The second factor is the different receptor access by a drug between
systemic and intrathecal or epidural administration. For most opioid
drugs, the diffusion from intrathecal or epidural sites into the cord
has not been assessed. For fentanyl it is apparently very poor, for
the effective dose intrathecally can exceed the effective systemic
dose (Durant and Yaksh 1986, Yaksh et al. 1986). In the absence of
specific data for the kappa agonists it is thus possible that the
relative ineffectiveness of topically administered kappa agonists in
thermally-evoked reflexes is due largely to inadequate penetration of
the cord to the appropriate opioid receptor sites. Systemically
administered kappa agonists certainly can reduce such reflexes by an
action restricted, via spinal transection, to the spinal cord.
The reversal of kappa opioid mediated effects by low doses of
naloxone illustrates the problem of using this antagonist in attempts
to distinguish between mu and kappa mediated effects in vivo.
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OPIOID ANALGESIA IN THE MOUSE: EVIDENCE FOR MULTIPLE
RECEPTORS USING ß-FNA
Pilar Sánchez-Blázquez and Javier Garzón
Department of Neuropharmacology, Cajal Institute
28006 Madrid, Spain
ABSTRACT
The icv injection of morphine or DADLE ED50 a few min
before the alkylating agent ß-FNA resulted in complete
protection of their respective analgesic effects when
evaluated 24h later, although a 1 ittle cross-protection
could be observed. The analgesia evoked by DADLE was
partially protected using higher doses of morphine before
R-FNA. However, higher doses of DADLE did not protect the
analgesia induced by morphine. On the other hand, the
antagonistic action of KCl on opioid analgesia was found
to be dependent on the opioid utilized to protect the
opioid receptor against the effect of R-FNA. These
results are discussed in terms of multiple receptors
mediating opioid analgesia at supraspinal level in the
mouse.
INTRODUCTION
Frequently it has been assumed that opioids induce their
antinociceptive effect at the supraspinal level after
binding to the µ class of opioid receptor. However,
several laboratories have evoked the mediation of
multiple receptors in that phenomenon (see Höllt et al.
1985). With respect to that concept, we have recently
reported (Garzón and Sánchez-Blázquez, this volume) that
a single icv injection of KCl antagonized the supraspinal
analgesia elicited by certain opioids. In the present
study, we have investigated further the issue by
analyzing the analgesic effect of different opioids on
mice previously exposed to the effect of ß-FNA in the
presence of various protecting opioids. Moreover, the
antagonistic action of KCl on those animals treated with
ß-FNA was studied.
MATERIALS AND METHODS
Albino male mouse CFLP, 22-27 g were used throughout.
Opioids were obtained from commercial sources.
ß-funaltrexamine from N.I.D.A.. Analgesia was evaluated
by the tail flick test using a water bath at 52° C as
noxious stimulus. Latencies were measured both before and
after any given treatment and analgesia expressed as a
percent of the maximum possible effect after setting a
cut off time of 10s.
465
RESULTS AND DISCUSSION
The ß-fumarate methylester of nal tre xone (ß-FNA) given
icv 0.2 nmole/mouse, antagonized the analgesia induced 24
h later by icv injection of morphine or DADLE ED50s (fig
1). Morphine or DADLE ED50s given a few min prior to
ß-FNA produced a good protect ion of their respective
analgesic effect, but little cross-protection could be
observed. This result agrees with the proposed
multiplicity of opioid receptor mediating analgesia at
supraspinal level (see Höllt et al. 1985). Therefore,
these two opioids at ED50 seem to mainly act on each
selective receptor in order to induce analgesia. Although
higher doses of morphine induced a good protection of
DADLE ED50 analgesic effect, in contrast, DADLE at ED90
did not improve the analgesic action of morphine ED50 24h
after the ß-FNA challenge. Thus indicating a low
cross-binding of that opioid peptide to the morphine
receptor. The µ ligand FK 33-824 and the ligand DTLET
protected to a similar extent the analgesia elicited by
morphine and DADLE ED50s (fig 1). This result suggests
that both enkephal in derivatives might have access to
morphine and DADLE analgesic receptors.
As previously described (Garzón and Sánchez-Blázquez,
this volume) a single icv injection of KCl, but not NaCl,
(1 µmole/mouse) reduced the analgesic activity of DADLE
and FK 33-824 in naive mice (table 1). That treatment did
not alter significantly the analgesia evoked by either
morphine or DTLET, confirming that this pept ide induces
analgesia through the same receptor used by the alkaloid
(Chaillet et al. 1984). In mice treated with morphine
ED90, 30 min before ß-FNA, it could be observed that the
analgesia induced by these four opioids was much less
sensitive to KCl. The 13-FNA mainly blocked the
"potassium-sensitive" opioid receptors. Conversely, with
DADLE ED90 given 15 min be fore ß-FNA, the analgesic
effect of those opioids 24h later was now reduced by KCl
administration. Thus, it is 1 ikely that opioids
displaying a better affinity to the morphine receptor
will induce analgesia insensitive to KCl antagonism. On
the other hand, a simultaneous binding to both receptors
will result in a slight decrease of analgesic potency
which will be difficult to detect experimentally. That
might be the case for DTLET. Therefore, the possibility
of the "potassium-sensitive" receptor being an additional
type of binding site to which µ- and d-selective
enkephalin derivatives display a high affinity appears to
be very attractive (Lutz et al. 1985).
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FIGURE 1. Protection against the antagonistic
effect of 13-FNA on the supraspinal analgesia
elicited by opioids in the mouse.
Protecting opioids at doses inducing various
degrees of analgesia were administered 30 min
(morphine and FK 33-824) or 15 min (DADLE and
DTLET) be fore R-FNA respectively. Analgesia
induced by morphine and DADLE ED50s was
evaluated 24h later. All substances were
injected icv in a final volume of 4 µl. Values
are the MEAN SEM of percent of maximum
analgesic effect from various groups each of 10
mice. Student’s t test was applied for
statistical analysis. a and b refer to saline
and ß-FNA treated groups respectively.
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TABLE 1. Effect of ß-FNA and KCl administration on the
analgesia elicited by opioids in the mouse
ß-FNA
Control Morphine ED90 DADLE ED90
test
Opioid dose time - + + +KCl
Morphine 27.0 30 90 14 87 4 76 6 74 5 50 4 25 3*
DADLE 1.7 15 89 5 33 2* 55 4 45 3 80 5 33 3*
FK 33-824 0.03 30 90 3 43 2* 71 6 65 6 90 3 39 3*
DTLET 1.5 15 61 3 50 Z 45 4 46 3 58 3 29 2*
Morphine and DADLE ED9Os (27 and 1.7
nmole/mouse) were given 30 or 15 min before
ß-FNA (0.2 nmole/mouse) respectively. Opioid
doses are in nmole/mouse. Analgesia was
evaluated 24h after ß-FNA. KCl (1 umole/mouse)
was administered 24h after ß-FNA and 30min
before the opioids. All substances were
injected icv in a final volume of 4 µl. Values
are the MEAN SEM of percent of maximum
analgesic effect from various groups each of 10
mice. * Statistically different from the group
not receiving KCl. Student’s t test; p<0.05.
Abbreviations:
DADLE : (D-Ala2, D-Leu5)-enkephalin.
DTLET : (D-Thr2, Leu5)-enkephalin-Thr6.
FK 33-824: (D-Ala2, N-Me-Phe4, Met-(o)5-ol)-
enkephalin.
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HYPERALGESIA PRODUCED BY INTRATHECAL OPIOID ANTAGONISTS DEPENDS ON
RECEPTOR SELECTIVITY AND NOXIOUS STIMULUS
C.W.T. Pilcher and Julia L. Browne
Department of Pharmacoloqy
Faculty of Medicine
P.O. Box 24923 - Safat
KUWAIT 13110
ABSTRACT
Opioid antagonists selective for , k- and µ-receptor subtypes were
administered intrathecally in rats prior to determination of response
thresholds to noxious heat, pressure and chemical visceral stimula-
tion. All antagonists induced hyperalqesia differentially with two or
more stimuli but and µ-blockade failed to alter writhing activity.
Thus, the extent of involvement of an opioid receptor subtype in
antinociception depends on the type of noxious stimulation.
INTRODUCTION
The multiplicity of endogenous opioid systems is reflected in the
fact that there are at least three families of endogenous opioid
peptides (EOPs) and at least three different opioid receptors are
widely recoqnised (Höllt et al. 1983). Among the questions raised by
this complexity are: does any one EOP modulate pain processes and are
they mediated by a specific receptor? If EOPs have physiological
roles in antinociception and these are expressed through activation
of specific receptors, antagonists selective for those receptors
should produce altered nociceptive responding. Previously we studied
opiate antagonists in rats never before exposed to exogenous opioids
and showed that systemic administration of k-selective agents induced
hyperalqesia to pressure without affecting nociceptive heat thresh-
olds, whereas naloxone was equipotent in producing hyperalqesia with
both stimuli (Pilcher and Browne 1983). In the CNS the recognised
receptor subtypes are differentially distributed; k-agonists are
ineffective analgesics when given intracerebrally (Wood et al. 1981)
but they are active on intrathecal injection, as are and µ-opioids
(Przewlocki et al. 1983). Since it appears that spinal populations of
, k- and µ- receptors participate in modulation of pain we have now
extended our studies to examine the effects of their antagonists
applied directly to the spinal cord. For selective antagonism at
k- and µ-receptors ICI 174,864 (Traynor et al. 1985), Mr 1452 (Merz
personal commun.) and naloxone (Vonvoiqtlander et al. 1983) were used
respectively.
MATERIALS AND METHODS
Male hooded rats were used. They were housed at about 22°C in a
light-dark cycle with lights on 06.00 - 18.00 h. Food and water were
freely available. On attaining a body weight of 300-350 g they were
implanted with a polyethylene cannula in the subarachnoid lumbar sac
according to Schmauss and Yaksh (1984). Injections of drugs and
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analgesic tests were carried out 48 h after surgery. Drugs were
injected in a volume of 10 µl followed by a flush with 10 µl isotonic
saline over a period of 45 sec. Naloxone hydrochloride and ICI
174,864 (Allyl2-Tyr-Aib-Aib-Phe-Leu-OH) were dissolved in isotonic
saline. Mr 1452 ((-)-N(3-Furylmethyl)- -normetazocine methanesulph-
onate) was first dissolved in distilled water and diluted 1:10 with
isotonic saline. Doses are expressed as the weights of the salts.
Analgesic Testing
Analgesic testing was carried out between 09.00 and 12.00 h. In the
paw pinch and tail immersion tests baseline (control) thresholds were
obtained 15 min before drug injections.
Paw pinch Initial nociceptive pressure thresholds of non-inflamed
hind paws were determined using an 'Analqesy-Meter' (Uqo Basile,
Milan).
Tail immersion Tail imnersion tests were carried out at 50 (±0.2)°C.
Latencies to the nociceptive response, a flicking or withdrawing of
the tail from the water, were determined.
Writhing test The number of writhing responses made during the 5 min
immediately following an intraperitoneal injection of 4% sodium
chloride was determined.
In all tests results were expressed as a percentage of the control
value. Statistical analyses were performed using analysis of variance
and post hoc t-tests.
RESULTS
All three antagonists produced their maximal effects in the tail
inmersion and paw pressure tests within 1-4 min after cessation of
injections. ICI 174,864 produced a significant reduction in paw pres-
sure thresholds (p<0.01), which was maximal at 25% with 0.1 µg after
only 1 min. The dose-response curve was almost flat over the range
examined (0.01-1.0 µg) and doses above 2.0 µg caused hind limb flac-
cidity followed by severe rigidity. In the tail immersion test ICI
174,864 produced a significantly greater reduction in threshold (37%)
than with pressure (p<0.01). In contrast to these hyperalgesic
effects with heat and pressure, at 0.1 µg this antagonist had no
effect on writhing scores.
The hyperalgesia induced by Mr 1452 was maximal at 1.0 µq and that
obtained with pressure (49%) was significantly greater (p<0.01) than
with heat (33%). This antagonist increased writhing responses by 18%
but the effect was not significant. The hyperalqesic effect of Mr
1452 was greater than that of either of the other two antagonists
with pressure and visoeral stimulation. Naloxone also gave peak
effects at 1.0 µg and was most effective in the tail immersion test,
when latencies were reduced by 70%. Naloxone produced significantly
greater (p<0.01) reductions in tail flick latencies than the other
antagonists. Marked hyperalqesia was also seen with the pressure
stimulus (42%) and a weak, insignificant effect occurred in the
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writhing test. Thus the order of hyperalgesic effectiveness of recep-
tor blockade in the three tests was: tail imüersion, p > > k; paw
pressure, k > µ > ; writhing, k > µ > = 0.
FIGURE 1. Hypóralqesic effects of opioid antagonists selec-
tive for , k- and µ-receptors with different stimuli. P=
paw pressure: H=heat; W=writhing. (n=5-8)
DISCUSSION
The results reported herein demonstrate that opioid antagonists
administered to the spinal cord of opioid-naive rats produce hyperal-
gesia to different kinds of noxious stimuli. This heightened sensit-
ivity is interpreted as resulting from prevention of antinociceptive
modulation by endogenous ligands. It is also clear that the magnitude
of the hyperalqesia depended not only on the antagonist's selectivity
for a receptor subtype, but also on the nature of the noxious
stimulus. Moreover, the time-course of an antagonist's action in the
same animal was not identical for all stimuli. These differences in
time-courses and effectiveness support two related notions: i) that
neural systems concerned with nociception are distinguishable on the
basis of their receptor subtype, ii) that the extent to which spinal
, k- and µ- receptors participate in modulation of pain processing
depends on the qualitative nature of the stimulus. The present
findings support our earlier work in which, using systemic administr-
ation of naloxone and the k-antagonists Mr 1452 and Mr 2266, it was
shown that the latter are 10 to 15-fold more potent in producing
hyperalgesia with pressure than heat.
In general, the above results are compatible with those of studies
using selective agonists. Martin et al. (1976) first showed that
the prototypic k-agonist, ethylketocyclazocine, was twice as potent
as morphine, the p-prototype, in suppressing the mild pressure-evoked
flexor reflex in spinal dogs. It was later reported that k-agonists
were analgesic against noxious visceral stimulation and pressure but
not heat, whereas µ-agonists were effective against all three
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stimuli (Tyers 1980). When administered intrathecally, µ- and k-
agonists inhibited responses in the writhing test but agonists were
ineffective (Schmauss and Yaksh 1984). In the hot plate and tail
flick tests µ- and but not k-agonists were analgesic. If these
differential analgesic actions of exogenous agonists reflect reliably
the physiological activation of receptors by their respective endog-
enous liqands, then the corollary, that selective antagonists will
produce hyperalqesia differentially, should hold true. The results
presented here support this proposition.
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IN VIVO STUDIES ON DELTA OPIOID RECEPTORS
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ABSTRACT
[D-Pen2, D-Pen5]enkephalin (DPDPE), a selective agonist at
delta opioid receptors, causes excessive vertical rearing
when given icv to rats or s.c. to mice. Tolerance devel-
ops to this behaviour. Rats do not rear excessively when
injected icv with the following prototype agonists at
opioid receptors: OAGO, dynorphin A, U-50488H or SK&F
10047. The incidence of OPDPE-induced rearing is reduced
when rats are pretreated S.C. with ICI 174864 (a selective
antagonist at delta opioid receptors) (A50=0.09 mg/kg) but
not by ICI 178173 (an inactive analogue of ICI 174864);
this finding suggests that delta binding sites mediate the
behaviour. Pretreatment with naloxone attenuates rearing
but the antagonism is unimpressive over the dose range
tested (0.05-1 mg/kg, s.c.). Low doses of haloperidol
(A50=0.05 mg/kg, s.c.) antagonize the rearing. Dopamine
may therefore mediate the behaviour through delta receptor
modulation of dopamine release. The practical gain from
this study is as follows: a simple, discriminating test is
now available for evaluating novel delta agonists and
antagonists in vivo.
INTRODUCTION
[D-Pen2, D-Pen5]enkephalin (DPDPE) (Mosberg et al. 1983) is
a selective agonist and ICI 174864 (Cotton et al. 1984) is
a selective antagonist at delta opioid receptors. Initial
experiments in vivo (Cowan et al. 1985) have shown that
the icv administration of DPDPE to rats causes a marked
increase in vertical rearing. This behaviour was studied
in the present work as a possible in vivo index of delta
agonist activity.
We used the following approaches to clarify the pharmacol-
ogical basis of DPDPE-induced rearing: (a) interaction
studies between DPDPE and ICI 174864, ICI 178173, naloxone
and haloperidol, respectively! (b) tolerance experiments
involving multiple icv injections of DPDPE, and (c) com-
parative behavioural studies with agonists selective for
mu (DAGO), kappa (dynorphin A, U-50488H) and sigma (SK&F
10047) opioid binding sites, respectively.
MATERIALS AND METHODS
Male albino Sprague Dawley rats (180-200 g; n=4-8) were
each stereotaxically implanted with an icv cannula. Five
days later, the animals were placed singly in perspex
boxes (25 cm long; 20 cm wide; 30 cm high) for an hour
then challenged with test agent (5 µl icv). Animals were
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observed and scored for behavioural changes for a period
of 50 min after agonist administration. Potential antag-
onists were given s.c. 5 min before a standard dose of
DPDPE (20 µg).
Female mice (20-25 g; ICI strain; n=6) were injected S.C.
with DPDPE (3-30 mg/kg) and observed regularly over the
following hour. The number of rears displayed by each
mouse was counted at +1O min for 1 min.
In a tolerance study! DPDPE (20 µg) [Group 1] or saline
[Group 2] was given icv to rats twice daily (at 9 a.m.
and 5 p.m.). Animals in Group 1 were tested for 50 min
in observation boxes after the 1st, 7th and 13th (final)
injection. Animals in Group 2 were similarly challenged
(with 20 µg of DPDPE) after the 7th and 13th injection.
The following compounds were used: [D-Ala2, MePhe5, Gly-ol5]
enkephalin (DAGO), DPDPE and dynorphin A (all from Penin-
sula); ICI 174864 (Diallyl-Tyr-Aib-Aib-Phe-Leu-OH, Aib is
aminoisobutyric acid; ICI); ICI 178173 (Diallyl-Tyr-Aib
-D-Ala-Phe-Leu-OMe; ICI); naloxone hydrochloride (Endo);
N-allylnormetazocine (SK&F 10047; Sterling Winthrop) and
trans-(±)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)
cyclohexyll-benzeneacetamide methanesulphonate (U-50488H;
Upjohn).
RESULTS
In rats, the DPDPE dose-response relation for rearing was
curvilinear with the 20 µg dose being most effective (fig.
1). Behavioural depression was associated with 50 µg of
DPDPE; lower doses caused increased yawning, licking of
penis, sniffing and biting/licking (forepaws, wood chips
and faecal pellets). Behavioural activation was essen-
tially over by +50 min. After s.c. injection to mice,
DPDPE provoked increased rearing (table 1), grooming and
restlessness for about 30 min.
FIGURE 1. Curvilinear dose-response curve for
DPDPE-induced rearing in rats.
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TABLE 1. DPDPE-induced rearing in mice.
Dose Rears during 10th min
(mg/kg, s.c.) (mean ± s.e.)
Saline 7.33 ± 1.17
3 10.83 ± 0.83*
10 14.33 ± 1.17**
30 13.17 ± 2.24*
*P<0.05; **P<0.01 (Dunnett's test).
TABLE 2. Antagonism of DPDPE-induced rearing in rats.
Test agent *A50 (mg/kg, s.c.)
Haloperidol 0,053 (0.022-0.13)
ICI 174864 0.087 (0.031-0.24)
ICI 178173 Inactive at 1 mg/kg
Naloxone Flat dose-response curve
*Tallarida and Murray (1981).
ICI 174864 caused an unusual behaviour in rats - hindleg
stretching. When the animals were given ICI 174864 (0.01,
0.10 and 1 mg/kg, s.c.) 5 min before the standard dose of
DPDPE (20 µg), rearing was antagonized in a dose-dependent
manner (table 2). ICI 178173 (an inactive analogue of ICI
174864) (1 mg/kg, s.c.) did not antagonize DPDPE-induced
rearing. Pretreatment with naloxone (0.05-1 mg/kg, s.c.)
attenuated rearing but the antagonism (35% at 1 mg/kg)
was unimpressive.
Tolerance developed to DPDPE-induced rearing by the 7th
injection (49±8 rears from 91±12 rears) and had fully
developed by the 13th injection (25±16 rears). Control
(saline-injected) rats reared excessively when challenged
with DPDPE (20 µg) on the 7th and 13th injections.
When rats were injected icv with DAGO (0.125 and 0.50 µg),
dynorphin A (0.50 and 10 µg), U-50488H (7.5 and 100 µg)
and SK&F 10047 (5 and 50 µg) increased rearing was not
observed.
DISCUSSION
Early behavioural experiments with [D-Ala2, Met5]enkephalin
(amide) [DALA] revealed that this opioid peptide, when
injected into the nucleus accumbens (Pert and Sivit 1977)
or ventral tegmental area (Broekkamp et al. 1979) of rats,
increases locomotor activity and vertical rearing. These
brain areas, part of the mesolimbic dopamine system, play
an important role in regulating exploratory and locomotor
behaviours. Kalivas et al. (1983) have recently summar-
ized evidence that favours enkephalinergic modulation of
the mesolimbic dopamine system.
DPDPE, the selective delta agonist (Mosberg et al. 1983),
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is behaviourally active when given icv to rats, and evokes
a rich array of signs that are reminiscent of those des-
cribed for amphetamine and apomorphine. Perhaps the most
notable behaviour is repetitive vertical rearing, which
can also be observed in mice after s.c. DPDPE. This beh-
aviour has been the focus of the present communication.
Our results with ICI 174864, ICI 178173, naloxone and
haloperidol lead to the conclusion that DPDPE-induced
rearing is controlled by delta receptor modulation of
dopamine release. Future studies with newly available
dopamine receptor antagonists will no doubt sharpen our
views on the dopaminergic basis of DPDPE-induced rearing.
Follow-up experiments with ICI 174864 should be started
so as to unravel the in vivo pharmacology of this inter-
esting agent. For example, a high dose of naloxone (10
mg/kg) (Haber et al. 1978) attenuates amphetamine-induced
rearing in rats (Gupta and Gregory 1967; Bryan and Ellison
1975). What can we expect with low doses of ICI 174864 in
this paradigm?
Two practical gains result from our study. First,
DPDPE-like compounds can be discrimin-
ated from agents with less selectivity for delta binding
sites, e.g, DALA (Kalivas et al. 1983), as well as proto-
type agonists at mu, kappa and sigma recognition sites.
Second, DPDPE-induced rearing provides a simple in vivo
endpoint against which the next generation of potential
delta antagonists may be tested and compared.
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EFFECTS OF NALOXONE AND NEUROTENSIN ON EXCESSIVE GROOMING BEHAVIOR
OF RATS INDUCED BY BOMBESIN, -ENDORPHIN AND ACTH
Tj.B. van Wimersma Greidanus
Rudolf Magnus Institute for Pharmacology,
Medical Faculty, University of Utrecht,
Vondellaan 6, 3521 GD Utrecht, The Netherlands
ABSTRACT
Bombesin, endorphin and ACTH-(1-24) induce excessive grooming be-
havior in rats. Whereas ACTH increases the frequency of all compo-
nents of grooming behavior (head washing, bodily grooming and paw
licking), the most pronounced element of bombesin- and endorphin-
induced excessive grooming is scratching. Naloxone counteracts
peptide-induced grooming and in particular excessive scratching is
reduced by this opiate antagonist. Also neurotensin suppresses
peptide-induced grooming behavior and in particular scratching. It is
concluded that the element scratching is the component of grooming
behavior which is mainly displayed by activation of opiate receptors
and that neurotensin is able to interfere with opiate receptor medi-
ated behavior.
INTRODUCTION
ACTH and MSH are the first peptides reported to induce excessive
grooming (Ferrari 1958; Ferrari et al. 1963). Later also other pep-
tides appeared to be active in this respect. Neurohypophyseal hormones
(Delanoy et al. 1978; Rees et al. 1976; Drago et al. 1986), prolac-
tin (Drago and Bohus 1981; Drago et al. 1981), substance P (Katz
1979), bombesin (Gmerek and Cowan 1983; Katz 1980; Kulkosky et al.
1982; Van Wimersma Greidanus et al. 1985a), dynorphin and endorphin
(Aloyo et al. 1983) have recently been shown to induce excessive
grooming behavior. Interestingly, the various grooming-inducing pep-
tides have been reported to induce structurally different grooming
bouts. ACTH and related peptides produce excessive grooming, which is
as far as the composition of the grooming behavior is concerned, com-
parable to normally occurring grooming behavior (Gispen and Isaacson
1981; Van Wimersma Greidanus et al. 1985a, 1986), whereas grooming
induced by endorphin and bombesin is characterized by the predomi-
nant display of scratching (Gispen and Isaacson 1981; Gmerek and
Cowan 1983; Van Wimersma Greidanus et al. 1985a). Naloxone, halo-
peridol and neurotensin have been shown to suppress the excessive
grooming induced by ACTH (Van Wimersma Greidanus and Rinkel 1983;
Van Wimersma Greidanus et al. 1986) and by bombesin (Van Wimersma
Greidanus et al. 1985b), and it has been suggested that opioid and
dopaminergic systems are involved in peptide-induced excessive
grooming (Wiegant et al. 1977a, 1977b; Spruijt et al. 1986; Cools
et al. 1978; Dunn et al. 1981; Gispen and Wiegant 1976). The pre-
sent study deals with the nature of the excessive grooming induced by
ACTH, endorphin and bombesin and with the effects of neurotensin
and naloxone on thus induced excessive grooming. In particular the
suppressive effects of neurotensin and naloxone on the various com-
ponents of the excessive grooming are discussed.
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MATERIAL AND METHODS
Male rats (150 g) of an inbred Wistar strain, equipped with a canula
in the right lateral ventricle, were used. Bombesin was intracerebro-
ventricularly (i.c.v.) injected in doses grading from 10 ng, 30 ng to
100 ng, endorphin in doses of 10 ng, 30 ng, 100 ng, 300 ng, 1 µg
and 3 µg, whereas ACTH was administered in a dose of 1 µg. Pretreat-
ment with naloxone was performed at 20 min prior to the i.c.v. in-
jection of peptides, using a dose of 1 mg /kg. Pretreatment with
neurotensin was performed immediately before peptide administration
in a dose of 1 µg i.c.v. For observation of grooming behavior rats
were placed into perspex boxes (26 x 20 x 13 cm). Using a 15 sec
sampling time, the display of grooming elements (head washing: H;
bodily grooming: B; sexual (= anogenital) grooming: A; paw licking:
P; scratching: S) was recorded for a period of 50 min, starting 10
min after peptide administration and placing of the animals into the
observation boxes.
RESULTS AND DISCUSSION
Bombesin induces a dose dependent increase of grooming behavior, with
scratching as the most pronounced element. Even administration of the
relatively low dose of 10 ng results in excessive grooming and in
particular excessive scratching. Naloxone suppresses significantly
the excessive grooming induced by bombesin. This suppression of bom-
besin-induced excessive grooming by naloxone is mainly due to a re-
duction in scratching and, to a lesser extent, bodily grooming. As a
result of this differential suppression of the various elements of
bombesin-induced excessive grooming by naloxone, a strong shift in
the relative distribution of grooming elements occurs in bombesin-
treated rats following pretreatment with this opiate antagonist. From
these results it is concluded that excessive scratching as induced by
bombesin is the component of grooming behavior which is mainly dis-
played by activation of opiate receptor systems, Neurotensin also
suppresses bombesin-induced excessive grooming, mainly by reducing
the element scratching. Consequently neurotensin induces a change in
the relative distribution of grooming elements displayed by bombesin-
treated rats, which is more or less similar as the one induced by
naloxone. Thus, it is tempting to assume that neurotensin interferes
with opiate receptor systems, at least with one of the behavioral
results of such a system, i.e. scratching.
Administration of endorphin induces excessive grooming behavior as
well. However, the endorphin induced excessive grooming is less
pronounced and the frequency of grooming is quite lower than observed
following similar doses of bombesin. Doses of endorphin exceeding
200 ng are even less powerful than doses of 30 ng and 100 ng and a
dose of 3 µg does not exert excessive grooming at all during the ob-
servation period of 50 min. Time course studies reveal that this bell-
shaped dose-response curve for the grooming inducing effect of
endorphin is due to the endorphin induced immobility of the animals
during the first half of the observation period. Doses of 30 ng and
100 ng endorphin induce excessive grooming with scratching as one
of the predominant elements. This confirms the idea that excessive
scratching is mainly due to activation of opiate receptor systems.
Both naloxone and neurotensin suppress the endorphin induced ex-
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cessive grooming, mainly by reduction of the element scratching. This
differential suppression of the various components of endorphin-
induced excessive grooming by naloxone and neurotensin again results
in a shift in the relative distribution of the various grooming ele-
ments.
Administration of ACTH results in excessive grooming behavior in which
all elements are more or less equally involved. In this respect ACTH-
induced excessive grooming differs markedly from the excessive grooming
behavior displayed by rats treated with bombesin or endorphin. Inte-
restingly both naloxone and neurotensin suppress ACTH-induced excessive
grooming without affecting the relative distribution of the various
grooming elements.
From these data it is concluded that different neuroanatomical and/
or neurophysiological systems in the brain are involved in excessive
grooming induced by bombesin, endorphin or ACTH. In addition it
appears that scratching is the behavioral element which is mainly
displayed by activation of opiate receptor systems. Moreover, it seems
likely that neurotensin interferes with opiate receptors.
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FOR KAINIC ACID-INDUCED WET DOG SHAKES.
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ABSTRACT
Kainic acid (KA) caused an initial decrease and a subse-
quent rebound in hippocampal enkephalin (ENK) in rats
exhibiting wet dog shakes (WDS) without behavioral con-
vulsions. Antibody to methionine-enkephalin but not
dynorphin A(1-8) injected into lateral ventricles attenu-
ated KA-induced WDS, as did naloxone. Granule-cell
destroying injections of colchicine into ventral but not
dorsal hippocampus caused a 60% reduction of hippocampal
ENK and a complete elimination of KA-induced WDS. These
studies suggest that release of granule cell ENK, which
is 3 times more concentrated in ventral than dorsal hip-
pocampus, plays an important role in KA-induced WDS.
INTRODUCTION
In the hippocampal formation, opioid peptides of the ENK
family are contained in: a) projections from lateral
entorhinal cortex to dentate gyrus and Amman's horn, b)
dentate granule cells, and c) scattered neurons
throughout hippocampus (Gall et al. 1981).
Concentrations of ENK are several times higher in ventral
than in dorsal hippocampus (Hong and Schmid 1981). The
dynorphin (DYN) family of opioid peptides is contained in
dentate granule cells (McGinty et al. 1983).
Concentrations of DYN A(1-8) in ventral hippocampus are
twice those in dorsal hippocampus (Kanamatsu et al., in
press). KA causes an initial seizure-associated deple-
tion of hippocampal ENK and DYN and a subsequent rebound
at 48 hr that corresponds to changes in ENK and DYN immu-
nostaining of the mossy fiber axons of the dentate
granule cells (Kanamatsu et al. in press). The purpose
of the present studies was to determine whether ENK or
DYN contained in dentate granule cells is important for
KA-induced WDS or behavioral convulsions. Studies were
designed to determine : a) whether KA-induced changes in
hippocampal ENK or DYN are associated with WDS as well as
with seizures, and b) whether the effects of icv injec-
tions of antibody to methionine enkephalin (ME) or DYN,
sc injections of naloxone, or intrahippocampal injections
of colchicine that destroy dentate granule cells
(Goldschmidt and Steward 1981) have an effect on
KA-induced WDS or seizure behavior.
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METHODS
Male Fischer-344 rats between 12 and 15 weeks of age were
used in these studies. KA was administered SC (8 mg/kg),
and rats were observed for WDS and limbic seizures (rear-
ing, clonus, hypersalivation, and falling) for 2.5 hr.
At this time, rats were anesthetized with pentobarbital
(50 mg/kg) to prevent seizure-related mortality. Data
were analyzed with analysis of variance significant
main effects were followed with post hoc Fisher's LSD
tests.
Study I. Rats (n=4) were injected with KA and were
with a radioimmunoassay described previously (Hong et al.
1978) in hippocampal tissue that had been frozen at -70
Stydy II. Rats (n=40, 10/group) were injected with 0,
2.5, 5.0, and 10.0 mg/kg of naloxone (NAL) SC 5 min prior
to injection of KA.
Study III.
body to ME, DYN A(1-8),
Rats (n-38) were injected with 20 ul of anti-
or normal rabbit serum into the
lateral ventricles 6 min prior to injection of KA. The
ME antiserum crossreactivity was: ME, 100%; leucine
enkephalin (LE), 0.47%; DYN A (1-8) < 0.06; ME
-Arg-Phe (MEAP), < 4.0% and B-endorphin (BE), < 0.2%.
The DYN A (1-8) antiserum crossreactivity was: DYN A
(1-81, 100%; DYN A (1-13), 0.02%; DYN A (1-17), 0.01%;
ME, 0.005%; and LE, 0.005%. For the ME antiserum, the
IC-50 was 644 fmoles, and for antiserum to DYN A (1-8),
it was 25.5 fmoles.
Study IV. Rats (n=86) were bilaterally injected with
colchicine (COL) (2.5 µg/site) into dorsal and ventral
hippocampus, dorsal hippocampus alone, or ventral hippo-
campus alone. After a 2 week recovery period, rats were
injected with KA and killed 48 hr later. Rats (n-40)
injected with COL into the dorsal or ventral hippocampus
alone were killed by perfusion with 4% formalin, and
brains were processed for cresyl violet and Luxol fast
blue staining. Rats injected with COL into dorsal and
ventral hippocampus were perfused with 1.2% sodium sul-
fide followed by 4% paraformaldehyde (n-19) for Timms
staining of zinc and immunocytochemical staining of ME
and DYN or were killed by decapitation for radioimmunoas-
say of ME and DYN (n-27):
RESULTS
Study I. Rats included in data analysis were those that
exhibited WDS but not behavioral convulsions following
systemic injection of KA. Those killed 1-2 hr post
injection had an averaae of 45 WDS and those killed 48
post injection had an average of 55 WDS across the 2.5 hr
observation period. Hippocampal ME was decreased by 23%
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at the early time point and was increased by 40% at the
later time point. DYN was initially decreased by 50% and
returned to baseline at 48 hr.
Study II. NAL caused a dose and time-dependent decrease
in KA-induced WDS. The maximal effect (59% reduction)
was achieved with a dose of 5.0 mg/kg. This effect was
observed from the onset of WDS 30 min post KA injection
to approximately 90 min post injection.
Study III. Pretreatment with antibody to ME but not
A (1-8) caused a
DYN
30% reduction in KA-induced WDS when
compared to rats receiving only control serum.
Study IV. COL injections into ventral hippocampus alone
or combined injections into dorsal and ventral hippo-
campus caused a virtually complete elimination of
KA-induced WDS. COL injections into dorsal hippocampus
did not attenuate KA-induced WDS. None of the injections
had an effect on the onset or topography of behavioral
convulsions. COL caused a 60% depletion of ME and a 100%
depletion of DYN in dorsal and ventral hippocampus. ME
in ventral hippocampus is approximately 3.7 times that in
dorsal hippocampus; therefore the absolute reduction of
ME in ventral hippocampus was greater than that in dorsal
hippocampus. COL blocked the KA-induced increase in hip-
pocampal ME observed in saline-injected controls. Timms
and Nissl staining combined with immunostaining for ME
and DYN revealed severe (>75%) destruction of granule
cells and their mossy fiber axons.
DISCUSSION
Several lines of evidence suggest that release of ENK
within the hippocampal formation plays an important role
in KA-induced WDS. WDS follow KA-induced epileptiform
bursting of hippocampal neurons (Lothman and Collins
1981); electrical stimulation of dentate granule cells
sufficient to cause a population spike also leads to WDS
(Damiano and Connor 1984). Lesions of the CA3 region of
hippocampus attenuate electrically-induced (Damiano and
Connor, 1984) and KA-induced WDS (Isaacson and Lanthorn
1981). These studies suggest that release of a
transmitter from granule cells onto CA3 pyramidal neurons
plays an important role in KA- or electrically-induced
WDS. Injections of ENK into the lateral ventricles cause
naloxone-reversible WDS (Drust and Connor 1983), suggest-
ing that this behavior involves actions at an opiate
receptor. The granule cells of the dentate gyrus contain
two families of opioid peptides, ENK and DYN (See Intro-
duction) either of which could play an important role in
the initiation of KA-induced WDS.
In these studies, we found that SC injections of KA that
lead to WDS but not behavioral seizures cause initial
depletions of ME and DYN and 48 hr later a rebound in ME.
We also found that pretreatment with NAL attenuated
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KA-induced WDS. These results suggest that release of an
opioid peptide, possibly ME or DYN could play a role in
KA-induced WDS. Therefore, we injected antibody to ME or
DYN A(1-8) into the lateral ventricles prior to SC injec-
tion of KA and found that antibody to ME but not DYN
attenuated KA-induced WDS. Selective COL lesions of the
dentate granule cells of the hippocampal formation were
performed to determine whether ME contained in these neu-
rons was important for KA-induced WDS. We found that COL
lesions of ventral but not dorsal hippocampus were suffi-
cient to eliminate KA-induced WDS. Because systemic KA
causes greater increases in metabolic activity in ventral
than in dorsal hippocampus (Lothman and Collins 1981), we
propose that release of ENK from dentate granule cells in
ventral hippocampus onto neurons of the CA3 region plays
an important role in the generation of KA-induced WDS but
does not appear to be essential for subsequent behavioral
convulsions. [5-T32-ES-07126]
REFERENCES
Damiano, B.P. and Connor, J. D. Brain Research, 308:
383-386, 1984.
Drust, E. G. and Connor, J. D.
458-459, 1983.
J Pharmacol Exp Ther, 224:
Gall, C., Brecha, N., Karten, H. J., and Chang, K.-J.
J Comp Neurol, 198:335-350, 1981.
Isaacson, R. L. and Lanthorn, T. H. Federation Proc, 40:
1508-1512, 1981.
Goldschmidt, R. B. and Steward, O. Proc Natl Acad Sci
USA, 77(5):3047-3051, 1981.
Hong, J. S., Yang, H.-Y.T., Fratta, W., and Costa, E. J.
Pharmacol Ther, 205:141-147. 1978.
Hong, J. S., an Schmid, R. Brain Research, 205:415-418,
1981.
Kanamatsu, T., Obie, J., Grimes, L., McGinty, J. F.,
Yoshikawa, K., Sabol, S., and Hong, J. S. J Neuro-
science, (in press).
Lanthorn, T., Isaacson, R.L. Life Sci, 27:171-178, 1978.
Lothman E.W. and Collins, R.C. Brain Research, 218:
299-318, 1981.
McGinty, J. F., Henriksen. S.J., Goldstein, A.,
Terenius, L.; and Bloom, F. E. Proc Natl Acad Sci
USA, 80:589-593, 1983.
484
OPIATE RECEPTOR BINDING AND BEHAVIORAL EFFECTS OF
MORPHINE IN RHA/VERH AND RLA/VERH RATS
D. Lazega, P. Driscoll*, H.-R. Frischknecht,
B. Siegfreid and P.G. Waser
Inst. of Pharmacology, Univ. of Zurich
Gloriastrasse 32, 8006 Zurich, Switzerland
*Inst. of Anatomy, Univ. of Lausanne
1005 Lausanne, Switzerland
A B S T R A C T
Large baseline differences were found in open field activity and rearing
behavior between 2 psychogenetically selected rat lines, as well as differences
in the effects of peripherally administered morphine (2,4 and 10 mg/kg) on
those behaviors and on body temperature. The 2 lines also showed different
capacities of tritiated DACO binding to preparations of striatal membranes.
INTRODUCTION
Roman high-avoidance (RHA/Verh) rats are selectec and bred for the rapid
acquisition of two-way active avoidance, whereas Roman low-avoidance
(RLA/Verh) rats are selected and bred for the non-acquisition of that
response. Considerable literature has accumulated documenting
neurochemical correlates of behavior in these rats, and profound differences
exist between them in baseline activity and in stress situations, in which
RHA/Verh rats become hyperactive and RLA/Verh rats tend to ‘freeze’
(Driscoll and Battig 1982, Driscoll 1986). Genetic differences in opioid
peptide systems, in relation to known differences in behavior, have been
extensively studied in several species (e.g. Neil et al. 1986, Frischknecht et al.
1986), and it is likely that genetically related behavioral modification, through
selective breeding, can also lead secondarily to opiate changes. We have
therefore compared the effects of morphine on open field behavior, nocieption
and body temperature in RHA/Verh and RLA/Verh rats, and also compared
both lines in regard to opioid receptor binding to preparations of crude
membranes of striatum and hippocampus.
MATERIALS AND METHODS
28 male RHA/Verh (mean body weight 340 g) and 28 male RLA/Verh rats
(332 g) were divided into groups of 7 and injected i.p. with either saline or
morphine (2,4 or 10 mg/kg). 30 min later, the numbers of squares crossed and
rearing behavior were monitored, individually, during 5 min in an open field
(60 x 60x 30 cm, divided into 9 equal squares). 40 min after injection, the
nocieptive response was measured with a tail-flick apparatus. The intensity
of the heat beam was adjusted to obtain baseline response latencies of about 2
sec. A cut-off time of 15 sec was used to prevent tail damage. Rectal body
temperature was measured 90 min after injection with a telethermometer
probe. Statistical analyses were performed by 2-way ANOVAs followed by
Duncan’s multiple range test.
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The brains of other groups of RHA/Verh and RLA/Verh male rats of the
same age were removed, following decapitation, and striata and hippocampi
were extracted and weighed. 4 strata were pooled for each replication. The
tissue was homogenized in Tris buffer (pH 7.4 at 2°C), centrifuged at
39,000g for 15 min, the pellet suspended in Tris buffer and incubated at 37°C
for 45 min and centrifuged again.
buffer at 25°C.
The resulting pellet was suspended in Tris
For the assay, .8 ml final homogenate was added to .1 ml of
the labeled ligand solution and .1 ml of Tris buffer of cold displacer ligand
solution. The final tissue concentration was 5.5 mg fresh tissue/ml,
corresponding to .43 mg protein/ml. The mixture was incubated for 2.5 hr at
25°C, filtered through a Whatman GF/B filter disc and washed 3 times with
5 ml ice-cold Tris buffer. The filters were dried and, after the addition of
10 ml scintillation cocktail (toulene: Triton X-100 at 2:1, and Butyl-PBD
5g/l3), were cou
(D-Ala2, MePhe4, Gly-ol5) enkephalin (
ted at an efficiency of 42-45%. The ligands used were H-
tritiated DAGO) for mu-binding
determination, and 3H-(D-Ala2, D-Leu5) enkephalin (tritiated DADLE),
added with cold DACO (7nM/nM DADLE) for delta binding. Cold DAGO was
added to suppress the mu-fraction of tritiated DADLE binding. Non-specific
binding was defined as the bound radioactivity in the presence of cold
etorphine at a constant ratio of 1000x the concentration of labeled ligand.
Scatchard analyses (striatum only) were performed by the use of LIGAND
program (Dr. Munson, NIH, Bethesda, MD, USA).
RESULTS
In regard to both open field activity and rearing, it was found that RHA/Verh
rats were more active than RLA/Verh rats (p< .001). Perhaps as a result of
the large baseline (NaCI injection) differences, morphine administration did
not significantly decrease behavior in RLA/Verh rats, while most dosages
significantly diminished both horizontal and vertical activities in RHA/Verh
rats. The analysis of tail-flick response latencies showed no significant
genetic differences, only a pronounced drug effect (p< .0001). A significant
TABLE 1
Effects of morphine on open field behavior, nociception and
body temperature in RHA/Verh and RLA/Verh rats (Results are
expressed as the mean 2 s.e.m.; n=7 per treatment group)
Number of Number of Tail-flick Body
Squares Rearings Latency Temperature
crossed (sec) (°C)
RHA NaCl 63.3±6.2 43.4±5.4 1.88±0.40 37.85±0.14
2mg/kg 46.3±7.8 28.4±4.4 4.28±1.88 38.35±0.13
4mg/kg 40.0±12.1 21.6±4.6 10.10±2.15 38.72±0.21
10mg/kg 33.8±8.2 9.0±2.2 15.00±0.00 39.14±0.14
RLA NaCl 19.7±5.2 11.8±3.2 2.48±0.67 37.74±0.16
2mg/kg 14.0±4.9 11.6±1.9 7.91±1.92 37.98±0.16
4mg/kg 17.7±4.0 8.3±2.2 9.09±1.82 38.02±0.17
10mg/kg 6.6±3.1 23.1±1.8 13.46±1.54 37.52±0.29
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antinociception was found in RHA/Verh rats with 4mg/kg, but already at
2mg/kg in RLA/Verh rats. In addition, a significant increase in body
temperature after morphine, as compared to the NaCl controls, was found
only in RHA/Verh rats (4mg/kg: p< .005, 10mg/kg: p< .001).
The 2 lines also differed significantly in tritiated DAGO binding to
preparations of striatal membranes. As visualized in figure 1 A, the binding
capacities differed significantly, Bmax being 1.72x greater in RHA/Verh
than in RLA/Verh rats. The affinities did not differ (Student-t-test). No
difference was found in tritiated DADLE binding to the same preparation
(figure 1B). Curve-fitting by LIGAND program revealed a single binding site
saturated by tritiated DAGO and 2 binding sites saturated by tritiated
DADLE. In addition to table 2, the second binding site of tritiated DADLE
was characterized by a Kd of 7.1±2.5 and 4.9±2.1 and a Bmax of 11.9±1.0 and
11.6±0.9 for RHA/Verh and RLA/Verh rats, respectively. The meaning of
this
FIGURE 1
Scatchard plot of specific binding of tritiated DAGO (A)
and tritiated DADLE (6) to preparations of striatal memb-
ranes of RHA/Verh (o) and RLA/Verh ( ) rats. Each point
represents the mean of a triplicate incubation. Concen-
tration ranges of labeled ligands were 0.3-12nM for tri-
tiated DAGO and 0.3-17nM for tritiated DADLE. The thin
lines in figure IA represent the 95%-condidence limits (±2
sigma) of the means.
TABLE 2
Binding results of tritiated DAGO and tritiated DADLE to
preparations of striatal membranes of RHA/Verh and RLA/Verh
rats, expressed as mean value (± s.e.m.) of 3 separate
experiments. 4 striata were pooled for each experiment. Kd
is expressed as nM and Bmax as fmol/mg of tissue.
3 H - D A G 0 3H-DADLE
Kd Bmax Kd Bmax mu/delta
RHA 0.39±0.40 9.6±0.44 0.06±0.14 4.19±0.4.3 2.3
RLA 0.36±0.08 5.56±0.35 1.02±0.24 4.62±0.77 1.2
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second binding site is not yet known. The first fraction of the Scatchard was
therefore considered to define delta binding. Single-point binding of tritiated
DAGO (5nM) and tritiated DADLE (1.5 nM) to preparations of hippocampal
membranes from RHA/Verh and RLA/Verh rats did not differ significantly.
DISCUSSlON
The genetic differences seen here in regard to the behavioral and
thermoregulatory effects of morphine, as well as in the striatal mu-receptor
binding capacities, provide valuable information which not only adds to the
steadily increasing state of knowledge regarding this type psychogenetic
selection, but also which indicates some potentially interesting directions for
future research. First of all, opioids are believed to exert a neuromodulatory
role, particularly in regard to the striatum and locomotor behavior, where
they have long been known to participate in the regulation of dopaminergic
and cholinergic transmission (Cheney et al. 1974, Frischknecht et al. 1986).
Morphine also affects the production and metabolism of brain serotonin
(Perez-Cruet et al. 1975). All 3 of these neurotransmitter systems (as well as
locomotor activity) are known to differ in RHA/Verh and RLA/Verh rats in
that the former have a more active striatal dopamine metabolism, a more
active serotonergic system in several brain areas, and have lower levels of
hippocampal and, possibly, striatal choline acetyltransferase activity than do
the latter (Driscoll and Battig 1982, Driscoll 1986, Scatton et al. unpublished
results). Therefore, a more detailed analysis of endogenous opioid peptides, as
well as additional opioid receptors and regions, would definitely be of interest
in these lines of rats.
Secondly, the mu opiate receptor, particularly in the striatum, appears to be
involved in the initiation of acute opiate dependence (Eisenberg 1985, Neil et
al. 1986) and, as genetic background appears to be important with respect to
predisposition to dependence (Jacob and Ramabadran 1981). The finding in
the present study that the Bmax of mu binding differs by almost 2 to 1
between RHA/Verh and RLA/Verh rats would seem to make a comparsion of
these 2 rat lines, in regard to opiate dependence studies, an undertaking of the
utmost interest, with clinical implications.
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ABSTRACT
Two experiments were performed to explore 1) the
sexual behavior of male obese cafeteria rats, 2) a
possible role of endogenous opiates in the regulation
of their sexual behavior. In obese cafeteria rats the
proportion of ejaculators and the number of
ejaculations per hour were significantly lower
compared to controls. Naltrexone provoked an increase
in the number of ejaculations/h both in control and
cafeteria rats due to an induction of copulatory
behavior in sexually inactive rats. Thus nutritional
obesity provokes an impairment of sexual behavior and
an injection of naltrexone (2.5 mg/Kg IP) lifts this
inhibition in a similar way as in inactive, control
rats.
INTRODUCTION
Two kinds of obesity in rodents, the genetic obesity
of Zucker fa/fa rats and the obesity nutritionally
induced by a choice of highly palatable foods, include
hyperphagias ; both these hyperphagias are suppressed
by opiate antagonists, naloxone or naltrexone
(Margules et al. 1978, Mandenoff et al. 1982). It is
known that opiate antagonists enhance sexual behavior
in non obese rats (Hetta 1977, Myers and Baum 1979) ;
agonists inhibit it and antagonists lift this
inhibition (Gessa et al. 1979, Hetta 1977, McIntosh et
al. 1979, Mumford and Kumar 1979, Myerson and Terenius
1977, Pellegrini et al. 1978). Therefore we made the
hypothesis that the decrease in sexual performances
could be linked to a hyperendorphinism in nutritional
obesity as well as in genetic obesity. In genetic
obesity a sexual impairment is documented (Edmonds and
Withyachumnarnkul 1980), and it has been recently
discovered that sexuality and fertility are restored
by an injection of naloxone (personal communication :
J. Walter, D. Margules). However no information is
available concerning the sexual behavior during
nutritional obesity. The present work has two aims :
to evaluate sexual behavior in cafeteria obese rats
and to determine the effect of an opiate antagonist,
naltrexone, on this behavior.
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MATERIALS AND METHODS
Animals
56 male Wistar rats weighing between 200 and 250g were
housed in groups of 4. They were maintained at 24°C
with a 12 hour light/dark cycle.They were distributed
in two groups : a group "control" (n=28) received
ordinary laboratory chow (Extra Labo M25) ad lib; a
group "cafeteria" (n=28) was given 4 palatable foods
in addition to chow. The 4 supplementary items were
changed each day on a weekly rotation. The animals
were weighed regularly. At week 9 the mean body weight
of "cafeteria" rats was 514.25±6.09g vs 438.69±5.22g
for the controls (mean ± sem < 0.001). The first
sexual behavior test was then performed. One week
later control and cafeteria rats were divided in two
subgroups: one IP injected with NaCl (1 ml/Kg of body
weight), the other with naltrexone (NTX 2.5 mg/Kg),
The sexual behavior tests were conducted 30 mn after
the injections.
Sexual behavior tests
The tests were carried out during light period
(between 02.00 and 06.00 pm) over one hour. 3 males
were placed in a cage. Ten minutes later four 3 month
old female rats, made sexually receptive by an IN
injection of oestradiol benzoate (10µg/rat) 48 hours
and 24 hours prior, were introduced. During the sexual
test, some rats were sexually active while others were
inactive. The parameters observed were:-intromission
latency (latency of the occurence of the first
intromission after the introduction of the females in
the cage) ; -pre-ejaculatory latency (latency from the
first intromission to ejaculation), - refractory
period (post-ejaculatory period between an ejaculation
and the next intromission) - number of ejaculations
per hour (Nb ejac/h).
Statistical Analysis
The proportions of sexually active and inactive
control and cafeteria rats were compared by X2 test.
The parameters studied in control and cafeteria rats
were compared with the Student T test. Effects of
naltrexone on the different parameters were analyzed
with the T paired test.
RESULTS
Table 1 shows that at week nine the proportion of
active cafeteria rats is significantly smaller than
that of active control rats (*P< 0.01). The number
of ejaculations/h in the cafeteria group is smaller
than in the control group (** P< 0.025).
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Table 1 Control Cafeteria
Active n
%
Inact n
%
Act + Inact n
Nb ejac/h
(mean + sem)
14 5
50% 17.8%*
14 23
50% 82.2%
28 28
1.96±0.42 0.67±.31*”
When the active cafeteria rats are considered alone,
the number of ejaculations/h and the parameters
characterizing the sexual behavior are not
significantly different from those of the active
control rats ("control" (n=14) vs “cafeteria” (n=5):
intromission latency 12.33±2.15 vs 10.22±3.02, pre
ejaculatory latency 19.71±4.37 vs 18.4±4.50,
refractory period 4.38±0.71 vs 5.0±0.71, expressed in
minutes + sem,
3.8±0.667.
intromission frequency 3.92±0.33 vs -
Tabie 2 shows that naltrexone increases the percentage
of active rats both in cafeteria and control qroups,
though this increase is not statistically siqnifi -
cant. Naltrexone significantly increases the global
number of ejaculations in both groups. But if the
sexually active rats are considered alone the number
of ejaculations is not significantly increased by
naltrexone (4.57±0.97 for controls and 5±1.41 for
cafeteria), nor are any of the other parameters
studied.
Table 2
Control Cafeteria
NaCl NTX NaCl NTX
Active 7
% 50% 78.6%
2 5
14.3% 35.7%
Inact 7 3 12
% 50% 21.4% 85.7% 6493%
Act+Inact n 14 14 14 14
Nb ejac/h 1.92±2.2 3.5±2.17**0.5±1.29 1.28±1.98*
 (mean+sem)
NTX vs NaCl *P< 0.05, ** P < 0.025
DISCUSSION
The first finding was quite expected: a nine week
cafeteria diet inhibits the sexual behavior since out
of 28 rats only 5 ejaculate during a one hour sexual
test. Thus an impairment of sexual behavior occurs in
various types of obesity, both genetic and
nutritional, suggesting an effect of obesity itself.
The results concerning the involvement of the opiate
system in such an impairment are less clearcut. In
control rats naltrexone does not modify sexual
behavior of active rats, but does induce sexual
activity in inactive rats. This result is quite
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consistent with those of the literature : it has been
reported that in sexually active rats, small or medium
doses of opiate antagonists do not modify the sexual
behavior (Gessa et al. 1979, McIntosh et al. 1979,
Myerson and Terenius 1977), while high doses
facilitate it (McIntosh et al. 1977, Myers and Baum
1979). In inactive rats high (McIntosh et al. 1979)
and even low doses (Gessa et al. 1979) induced
mounting and ejaculations. In inactive cafeteria rats,
naltrexone increases sexual performances, however the
amplitude of such an increase is not significantly
different from that observed in control rats. The dose
of 2.5 mg/Kg of naltrexone used to test an eventual
hypersensitivity to opiate antagonists in sexual
behavior of cafeteria rats could appear to be high
since we previously showed that a dose as low as 0.5
mq/Kg is efficient for suppressing hyperphaqia induced
by cafeteria diet without modifying food intake in
chow fed rats (Mandenoff et al. 1982). However 0.5
mq/Kq of naltrexone did not provoke any change in
sexual performances either in cafeteria or in control
rats (unpublished results). Thus there is no
experimental evidence that in terms of sexual behavior
cafeteria rats are more sensitive to naltrexone than
control rats. In conclusion, like genetic obesity,
nutritional obesity provokes an impairment in sexual
behavior and an opiate abtaqonist induces the
copulatory behavior in cafeteria inactive rats as well
as in controls. Although Naltrexone lifts the
inhibition of sexual behavior induced by the cafeteria
diet, it is not proved that the impairment of sexual
behavior in cafeteria obese rats is related to an
hyperendorphinism.
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ABSTRACT
Morphine stimulates food consumption in the land snail Helix
aspersa. This stimulation of food consumption can be blocked by
naloxone, the potent opiate antagonist. In addition, this opiate-
induced food consumption exhibits tolerance by the sixth day of
treatment. This study further highlights opioid mechanisms in
relatively simple organisms and also suggests that these
mechanisms are "ancient" signal systems.
INTRODUCTION
Opioid substances have been shown to have diverse functions that
transcend their original proposed role in nociceptive/analgesic
systems. The importance of this family of compounds is
highlighted even more with their discovery in invertebrates.
Recently we have reported the isolation and identification of
Met-enkephalin, Leu-enkephalin and Met-enkephalin Arg6-Phe7 in
Mytilus pedal ganglia (Leung & Stefano 1984; Stefano and Leung
1984). The same neural tissue also has been shown to contain
opioid receptors that are similar to those reported to exist in
mammals (Kream et al. 1980; Stefano et al. 1980). As a result, it
is no longer surprising to find opiate functions in various
invertebrates. In mammals opiate mechanisms have been shown to
be involved in the regulation of normal ingestive activities
(Morley et al. 1983). Opiates have been shown to not only
stimulate food consumption but various ingestive behaviors as
well (Sanger 1981; Sanger and McCarthy 1981; Morley et al. 1983).
Naloxone, the potent opiate antagonist, can block these
morphine-induced activities (Brands et al. 1979) as well as
decrease feeding in food deprived mammals (Brown and Holtzman
1979). In an earlier study Kavaliers et al. (1984) demonstrated
that opiates could induce feeding in the slug Limaz maximus.
Thus, this study complements the earlier study in that morphine
also stimulates this activity in Helix aspersa.
MATERIALS AND METHODS
Helix aspersa were obtained from the Pacific Biomarine Company in
California. The animals were maintained in the laboratory at 21±
1°C under a 12-hr light and 12-hr dark cycle. They were housed
prior to experimentation in a large Styrofoam box containing
moistened paper towels, lettuce, carrots and rat chow. The
organisms were divided into four groups and placed in individual
1L beakers containing moistened paper toweling clinging to the
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side and bottom. For each experiment there was a minimum of five
groups of organisms. A substrate of lettuce and carrots were
pureed in a blender and poured into a 5 cm petri dish. This was
then weighed before and after a 3-hr feeding period and corrected
for evaporation. Animals receiving drug treatments were injected
through the epidermis in a region superior to the anterior
ganglionic complex. The organisms received either drug, vehicle
or no injection.
Table 1. The effects of opiates on food consumption
in the land snail Helix aspersa
OPIATE DOSE(M) %CONSUMED OPIATE DOSE(M) %CONSUMED
vehicle ---- 100 naloxine 10-7 100
morphine 10-7 100 naloxone 10-6 90
morphine 10-6 124a naloxone 10-5 50b
morphine 10-5 140b naloxone 10-4 70b
morphine 10-4 135b
etorphine 10-4 138b
Morphine 10-5 and Naloxone 10-5 95% Consumed
Animals were maintained in groups of four for a
3-hour interval. Each group consumed .7g of food.
The variation between groups was no greater than 4%
Statistical analysis was by Student's t-test, a =
P<0.05, b = P< 0.0.1 Vehicle and control values
were identical (.7g/3 hr).
Table 2. Demonstration of tolerance to morphine in
reference to its induced stimulation of food ingestion.
DAYS MORPHINE DOSE (10-6M) %CONSUMED
1 AS NOTED 125
2 AS NOTED 125
3 AS NOTED 120
4 AS NOTED 113
5 AS NOTED 99
6 10 - 5 130
Experiments were as noted in table 1. These animals
were injected with morpine 4x/day for the indicated
number of days. Statistical analysis was by Student's-
t-test, a = P<0.05, b = P< 0.01.
RESULTS
Vehicle and control organisms ate 0.7g/3 hr of the prepared food.
Morphine treated organisms exhibited a significant dose-dependent
increase in food consumption (table 1). This increase in food
consumption occurred within the first 1.5 hr following morphine
injection. Interestingly, organisms observed for 24-hr (vehicle
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and morphine treated) were found to consume the same amount of
food, indicating that the morphine groups' food consumption
decreased following the initial morphine-induced stimulation of
ingestion. Naloxone, an opiate antagonist, when administered
alone was found to decrease food ingestion in a dose dependent
manner (table 1). In addition, when co-injected with morphine it
blocked the opiate induced stimulation of food consumption.
Again, the maximal effects of naloxone occurred during the first
1.5 hr of treatment.
In another sec of experiments, organisms treated with morphine
(10 M) 4x/24 hrs) for 5 days gradually lost the morphine
induced stimulation of food consumption. However, increasing the
dose of morphine on the 6th day brought it back (table 2). This
may serve to indicate that this behavior was made tolerant to
morphine.
DISCUSSION
The present report suggests that an endogenous opioid system may
be present in Helix aspersa and that it may be involved with the
organisms feeding responses and food intake. The same type of
regulatory role of opioids in regard to food consumption has been
reported in Limax maximus by Kavaliers et al. (1984). In both
studies, naloxone was able to antagonize the opiate stimulation
of food ingestion, indicating the presence of specific opiate
receptors. In addition, in both organisms naloxone alone was able
to reduce food intake, strongly suggesting the presence of an
endogenous opioid system regulating feeding behaviors.
Interestingly, this system can be made tolerant to chronic
morphine treatments, a finding which clearly demonstrates the
cellular complexity of invertebrate opioid activities.
In general the growing body of evidence for the presence of
endogenous opioid regulatory systems in invertebrates is
increasing (for review, Leung & Stefano 1986; Stefano 1986). The
data to date suggests that opioid evolvement had an early
development and that this "old" status highlights the importance
of these particular signal molecules.
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EFFECT OF ELECTROLYTIC AND CHEMICAL VENTROMEDIAL
HYPOTHALAMIC LESIONS ON FOOD INTAKE, BODY WEIGHT, ANALGESIA
AND THE CNS OPIOID PEPTIDES IN RATS AND MICE.
Gopi A. Tejwani and Charles W. Richard III
Department of Pharmacology
College of Medicine
The Ohio State University
Columbus, Ohio 43210
ABSTRACT
The hyperphagia and obesity induced by ventromedial hypothala-
mic (VMH) electrolytic lesions in female rats were asscciatedwitha
70-94% decrease in the level of ß-endorphin (ß-E) in the hypothal-
amus and other regions of brain, but not in the pituitary. Dynorphin
(Dyn) and methionine-enkephalin (ME) levels were also decreased.
Rats with VMH lesions were less sensitive to the inhibitory effect
of naloxone on their food-intake. Mice injected with gold
thioglucose (GIG) also showed a decrease inthehypothalamiccontent
of ß-E and Dyn and exhibited 30% less analgesia compared to control
mice after cold swim stress.
INTRODUCTION
Lesions in the VMH region of brain cause hyperphagia, obesity
and several other behavioral and physiologic abnormalities
(Hetherington and Ranson 1940; Powley 1977; Bray and York 1979). In
view of the role of opioid peptides in appetite control (Morley et
al. 1983), the objectives of this study were to examine the effects
of VMH lesions on the CNS opioid peptides and correlate these
changes with specific behavioral characteristics such as food intake
and analgesia.
MATERIALS AND METHODS
Female Sprague-Hawley rats (240-260 g) were obtained from lab
Supply (Indianapolis, IN) and were maintained as described earlier
(Vaswani et al.1983). The details of the stereotaxic VMH lesioning
technique are described by Richard III, 1984. Briefly, the rats
were anesthetized with sodium pentobarbital (40 mg/kg) and were
positioned in a Kopf 1404 research stereotaxic instrument. Prophyl-
actic antibiotics (ampicillin 70/mg/kg i.m., and gentamicin, 5 mg/kg
i.m.), were administered immediately and 24 hr after surgery. The
electrode was positioned 0.2 mm posterior to bregma, ± 0.7 mm
lateral to the mid-sagittal suture and 10 mm below the surface of
the skull. Bilateral VMH lesions were produced by passing an anodal
current between the 0.5 mm uninsulated tip of an epoxy coated
stainless steel electrode (0.11 mm diameter) and a rectal cathode
for 20 sec (2 ma x 20 sec current = 40 millicoulombs). control rats
were subjected to sham operation. Sold thioglucose (GIG), 800
mg/kg, was given i.p. to female outbred CD-1 mice (Charles River),
21-25 g, to produce bilateral VMH lesions. For histological veri-
fication of the extent of VMH and GTG lesions, animals were perfused
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with 10% formaldehyde solution in saline. The brains were removed,
blocked and sectioned in 20p sections, cut at -20°C on a cryostat
and picked up on gelatin coated slides. Slides were stained with
cresyl violet and an anatomical comparison and verification of
lesion placement was done. Upon gross inspection, the median
eminence was found intact in all VMH-lesioned rats. Opioid peptides
were measured by RIA as reported previously (Tejwani et al. 1985).
Analgesia in mice was measured by using a hot plate at 55°C and the
movement of the hind limb was used as the criterion of acute
exposure. Measurement of opiate receptor (µ-receptor) birding was
done by using [15,16-3H]-etorphine, according to the method of Pert
and Snyder (1973) as modified by Bardo et al (1982) and Young et al.
(1983) .
RESULTS AND DISCUSSION
Since ithasbeenreportedthatweightgain in animals with VMH
lesions is accentuated by a high fat diet (Sawchenko et al. 1981)
rats in our study were maintained on a high fat diet (Vaswani et al.
1983).
Daily consumption of a high fat diet increased by 136% in rats
with VMH lesions (n=22, P<0.001). Fifteen days later these rats
weighed 35% more than sham operated animals (P<0.001, data not
shown) . VMH lesions in rats (n=9) significantly reduced B-E levels
in the hypothalamus (-85%), striatum (-94%), midbrain/thalamus
(-88%), medulla/pons (-97%), hippocampus (-74%) and cortex (-70%)
but not in the pituitary (fig. 1A). Dynorphin level decreased
(fig. 1B) in the hypothalamus (-54%), pituitary (-66%) and
hippocampus
(-28%). Brain ß-E cell bodies are confined to the medial basal
hypothalamus and arcuate nucleus. Destruction of cell bodies or
fibers eminating from this area would conceivably reduce brain ß-E
content. Watson et al. (1978) observed that unilateral arcuate
lesions produced a 40% decrease in D-E in the central gray area,
while Kerdelhue et al. (1982) showed that mediobasal hypothalamus
(MBH) lesioned rats had an 89% decrease in ß-E in the central gray
area. Milan et al.(1980) have found that small discrete lesions of
the arcuate nucleus produced a marked reduction in the hypothalamic
ß-E and Dyn levels. In the present study the reduction in pituitary
Dyn most probably represents a destruction of neurointermediate lobe
Dyn fibers originatihg in hypothalamus. The reduction in hippo-
campal Dyn may represent a yet unidentified hypothalamic-hippo-
campal pathway. We observed (fig. 2A) a decrease in ME level in the
hypothalamus (-37%) and hippocampus (-38%). In spite of a decrease
in the level of opioid peptides, lesioned rats were still sensitive
to the effect of naloxone, although to a lesser extent. Naloxone
decreased the food intake in rats with VMB lesions by 33%, compared
to 67% in control rats (fig. 2B).
Eleven weeks after GTG administration, mice weighed 32% more
than control (fig. 3A). GTG lesions significantly reduced hypo-
thalamic ß-E (-80%) and Dyn (-19%) but did not affect ME level.
Mice with GTG lesions had no statistically different sensitivity to
naloxone or levorphanol but showed 30% less analgesia compared to
control mice after 1.5 min of cold swim stress (fig. 3B). We
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FIGURE 1 Effect of VMH lesions on ß-endorphin1-31 (A) and
dynorphin1-13 (B) levels in female rats 12 days after electrolytic
lesions (n=9) orshamlesions (n=7).
FIGURE 2 A. Effect of VMH lesions on methionine-enkephalin
level. B. Effect of naloxone on food-intake. Rats were tested 9
days after lesioning, after 12 hr of food-deprivation. Naloxone (1
mg/kg) was given i.p. 30 min before testing. Food-intake was
measured for 1hr.
FIGURE 3 A. Effect of GTG lesions on weight gain in female CD-
1 mice. B. Analgesic response of mice with GIG lesions to 1 mg/kg,
i.p. injection of naloxone or levorphanol
analgesia (1.5 min swim in H2O at 4°C).
or stress-induced
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conclude that electrolytic or GTG lesions in VMH decrease CNS opioid
peptide levels which is reflected by an alteration in the feeding
behavior and analgesia in these animals.
Compensatory up-regulation and down-regulation of neurotrans-
mitter receptors have been shown to occur with chronic neurotrans-
mitter decreases and increases, respectively. Compensation of
initially perturbed behaviors has been postulated to occur in
parallel with changes in receptor affinity or number. In our study,
examination of 3H-etorphine receptor binding in VMH and GTG-
lesioned animals revealed no change in the opioid receptor affinity
or number in any of the brain regions where a decrease in the opioid
level was observed (data not shown).
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BOTH ADRENAL OPIOIDS AND GLUCOCORTICOIDS INVOLVED IN THE
INCORPORATION OF INFORMATION INTO MEMORY POST-STRESS
D. Jefferys and J.W. Funder
Medical Research Centre, Prince Henry's Hospital, Melbourne,
Australia 3004
Various behavioral paradigms have clearly shown that glucocorticoids
and opiates influence the acquisition and maintenance of several
behaviors in the rat. Recently, in an experimental paradigm
originally designed to screen for antidepressants (4), we have shown
that manipulation of steroid and opioid levels profoundly influence
the maintenance of an immobile floating response. This response
develops when rats are swum in a restricted space from which they
cannot escape. Rats are placed in a narrow plexiglass cylinder for
15 minutes; initially they swim vigorously, but progressively spend
more and more time relatively immobile. Normal, naive rats are
immobile for 70% of the last 5 minutes of the test period, and for a
similar percentage of a 5 minute retest period 24 hrs later.
FIGURE 1: Rat showing characteristic immobile posture.
We have shown that rats have no difficulty in acquiring the
immobility response after adrenalectomy, hypophysectomy or concurrent
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hypophysectomy and adrenalectomy (adrx-hypox). As is shown in figure
2, hypophysectomized animals showed levels of immobility similar to
intact animals on retest. In contrast, adrenalectomized rats (or
adrx-hypox) showed a significant reduction in immobility, remaining
immobile for only 28%-30% of the time.
FIGURE 2: Percent immobility during the 5 minute retest by
intact, adrenalectomized, hypophysectomized and hypophysec-
tomized-adrenalectomized rats. Columns represent mean ± SEM
values, the number of animals in each group is shown within each
column. Significant differences from control are shown. **P
<0.01.
This behavioral effect of adrenalectomy was reversed by the
glucocorticoids corticosterone or dexamethasone (DM), but not by the
mineralocorticoid deoxycorticosterone, administered within an hour- of
the initial test period. The catecholamines adrenaline and
noradrenaline were shown to be without effect. The non-specific
opiate agonist D[Ala2-Met5]enkephalinamide (DAMEA), at 5 or 50 µg,
reversed the behavioral effect, with animals remaining immobile for
68% of the retest period (3).
On the basis of these findings we suggested that maintenance of
immobility was dependent on glucocorticoids and/or adrenal opioid
peptides, and that in vivo these mechanisms may have a coordinate
effect.
To verify the specificity of the opiate effect we administered
naloxone (0.1-10 mg/kg) to adrx rats with the DAMEA, and as a control
tested the effect of equivalent doses of naloxone on the dexamethasone
reversal. With increasing doses of naloxone there was a progressive
fall in immobility on retest in both DAMEA and DM treated animals. At
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10 mg/mg naloxone, DAMEA treated animals were immobile for 31% and DM
treated animals for 36% of the retest period. We therefore tested
naloxone at similar doses in the intact animal. Over the dose range
used, naloxone lowered immobility equivalently in intact and in adrx
rats treated with DAMEA or DM; with 10 mg/kg intact animals were
immobile for only 36% of the 5 minute retest.
This inhibitory action of naloxone was seen only when it was given
within 1 hour of the initial swimming exposure. That the opioidergic
mechanisms involved in the maintenance of the immobility were within
the CNS was strongly indicated by the inability of MRZ2593, a
quaternary naloxone analogue which does not cross the blood-brain
barrier, to affect the swimming response (2).
On the basis of these studies, we proposed a model of maintenance of
immobility involving at least two opioidergic pathways, and that the
integrity of the second of these pathways is an absolute requirement
for the response to occur. In this model there are sensors for
peripheral opioids putatively outside the CNS, and sensors for adrenal
corticosteroids either central or peripheral. Both of these relay
onto a common effector which is itself central and opioidergic.
Activation of either pathway is sufficient to stimulate the common
effector and facilitate maintenance of the immobile response.
DAMEA is a relatively non-specific opiate agonist, and naloxone
though with a higher affinity for mu receptors than kappa or delta
receptors - is by definition a non-specific opiate receptor
antagonist. Accordingly we have undertaken studies to delineate the
receptor specificity of the opioidergic pathways involved in the
reversal of the effect of adrenalectomy. Equimolar doses of morphine
sulphate (mu-selective), [D-Ala2-D-Leu5]enkephalin (delta-selective)
and ketocyclazocine, dynorphin 1-8, dynorphin 1-17 and the
heptapeptide [Met5]enkephalin [Arg6-Phe7], all kappa-selective
agonists, were administered to adrenalectomized rats and the
behavioral effect observed. Reversal of the effect of adrenalectomy
occurred with ketocyclazocine,
[Arg6-Phe7],
dynorphin 1-17 and [Met5]enkephalin
but not with 10-fold higher doses of the mu- or
delta-selective ligands. The reversal of the effect of adrenalectomy
by ketocyclazocine was antagonized by MR2266, a kappa-selective
partial agonist/predominant antagonist (1).
That it is the peripheral opioidergic pathway which is kappa-selective
was shown by studies in which equivalent doses of MR2266 were without
effect in intact rats, or in adrx rats treated with DM.
Further evidence for glucocorticoids and opioids of adrenal medullary
origin being involved in the maintenance of the immobile behavior was
shown when intact animals were treated with the anti-glucocorticoid
RU38486 (3.75 mg/rat) and/or the nicotinic antagonist mecamylamine (10
mg/kg) - Administered alone, they were without effect; administered
together immobility was significantly reduced, with animals remaining
immobile for 40% of the 5 minute retest period. Under these
condititons both adrenal medullary secretion and glucocorticoid action
is blocked. RU38486 and MR2266, simultaneously administered to the
intact animal, similarly impaired maintenance of the immobile
response.
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FIGURE 3: Hypothetical model showing pathways for maintenance of
immobility.
Additional evidence in support of our hypothesis was the finding that
hypophysectomized animals given mecamylamine showed similar levels of
immobility on retest as found in adrenalectomized animals; MR2266
administered to hypophysectomized rats equivalently inhibited the
maintenance of immobility. These findings strongly support the
hypothesis that when animals are swum under conditions of moderate
stress, the immobile response which is acquired is maintained by
either glucocorticoids or adrenal medullary kappa-selective opioids,
with both of these endocrine effects being mediated through a final,
common, non-kappa selective opioidergic pathway.
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EFFECT OF CHRONIC EXERCISE ON ENDORPHIN RECEPTOR LEVELS IN RATS
Richard A. Houghten, Suzanne M. Pratt, Elizabeth A. Young,
Helen Brown and Dennis R. Spann
Department of Molecular Biology
Research Institute of Scripps Clinic
La Jolla, California 92037
ABSTRACT
A radioreceptor assay using [3H]2- endorphin (B-EP) was used to
examine binding in the brains of rats that had been exercised on a
treadmill for 5 months. The binding of [3H]2 EP to brain
homogenates gave an average Kd of 0.830 ± 0.055 nM for the controls
and 0.826 ± 0.022 nM for the runners, and respective Bmax's of 166 ±
20 pM and 159 ± 27 pM.
INTRODUCTION
There has been a great deal of press on the effects of "endorphins"
on "runners high", "exercise withdrawal syndrome", and "depression"
connected with cessation of running. It has been well documented
that exercise increases plasma endorphin levels in man (Colt et al.
1981 and Gambert et al. 1981) and that an up-regulation of opiate
receptors is known to occur when the opiate antagonist naltrexone is
chronically implanted in rats (Zukin et al. 1982). These facts
prompted us to examine the effect of chronic running on opiate
receptor behavior in rats. The results of this study are presented.
MATERIALS AND METHODS
Thirty six male Fisher 344 (Simonsen) rats weighing from 150-170 gms
were run on a treadmill. To habituate the rats to the treadmill they
were run for 3 weeks (10-20 min). Thirty of the most consistent
runners were randomly divided into 3 groups of 10, two groups were
designated as runners and one as the control. Dry ice was placed at
the back of each runway to keep the animals running. Electric shock,
initially used, was more stressful and injurous to the animals than
dry ice. The experimental groups were run daily for 22 weeks,
gradually working up to 1.4 km/hr for 60-70 min. The control group
was placed on the other half of the treadmill but not run. At the
end of the training period the animals were weighed, decapitated and
the following tissues were removed: brain, pituitary, soleus muscle
and plasma. The levels of endorphin in plasma and pituitary was
determined by RIA as described earlier (Watson et al. 1982). The
soleus muscles were assayed for the amount of citrate synthase
activity (Srere 1982) as an indicator of each rats conditioning level
(Lewis et al. 1980).
Radioreceptor assays (RRA) with [3H]2 EP were performed on brain
homogenate prepared as described previously (Ferrara et al. 1979).
The final homogenate was resuspended at a concentration of 10 mg
wet-weight of brain per ml of cold Tris buffer. Binding experiments
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were performed on 0.666 ml aliquots of membranes (0.5mg protein).
Membranes were incubated with Tris buffer or unlabeled EP (500 nM)
and then with varying amounts of [3H]2 EP (0.3 - 3.0 nM) for 60 min
at 22°C then 10 min at 0°C in an ice water bath. The incubation was
terminated by rapid filtration. Receptor-ligand interaction was
examined by Scatchard analysis (Scatchard 19491. Results were
analyzed for significance by Student's T-test.
RESULTS AND DISCUSSION
The biochemistry of the changes which occur due to chronic
physiological conditions, such as aging, stress, excessive food
intake, habitual exercise and the major chronic functional psychoses
are poorly understood. Although ill defined, there appears to be a
relationship between the central and peripheral opioid peptides
and/or their receptors in many age related disorders.
While increases in endorphin levels in plasma drop to normal in
30-60 minutes after cessation of exercise (Gambert et al. 1981), any
changes in the receptor number for endorphin would be expected to
return to normal over a period of five to seven days (Zukin et al.
1982). This decrease in receptor number, with a concomittant
periodic increase in opioid peptide level could possibly explain the
"addiction" felt by runners, and may also be one factor in a number
of compulsive behavior patterns or the general phenomenon of
addiction. Very little work has been carried out which addresses the
possibility of change in the receptor systems in chronic
physiological states.
Our research began with a working hypothesis that receptor dynamics
occur for a variety of physiological changes, and very likely occur
differently for the various opiate receptors and brain areas. These
changes may therefore effect physiological/psychological variables
such as mood, sleep, sexual behaviors, etc. to different degrees at
different times.
A convenient natural means for inducing receptor changes was needed,
and since there has been much press on the effects of the endogenous
opioid peptides (usually lumped together as "endorphins") on
"runner's high" or "addiction to running", it was decided to examine
the possible changes in the receptor behavior in chronically
exercised versus sedentary rats. The rat has long been used as a
model for physical fitness studies (Harpur 1980). The RRA for
endorphin was selected because it has been used extensively in this
laboratory (Ferrera et al. 1979). The exercise regimen used, is
known to give substantial exercise conditioning to heart and leg
muscle in the rat (Baldwin et al. 1972). When the receptor assay for
endorphin was carried out using 9 runners and 9 sedentary controls
and their Scatchard plots examined, it was found that an apparent
small decrease of receptor number for the runners (Bmax = 159 pM
versus Bmax = 166 pM) had occurred with no change in affinity of
binding (Fig. 1). The differences were consistent throughout the
nine points of the Scatchard analysis, although the individual points
reached 95% significance by Student's T test in only three instances.
While the difference in receptor number was small, the decrease for
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the runners is in the direction one might expect if an agonist
down-regulation were operative (Zukin et al. 1982). A loss of body
weight of approximately 10% was found for the running rats, the
effect of which will be examined in subsequent experiments.
Figure 1
Scatchard plot of [3H]2- endorphin binding to rat brain
homogenates of the running group (o) and the control group
(o). Each point represents the mean of values obtained from
nine animals.
Our results also indicated a substantial increase in B-endorphin
levels in plasma for runners versus controls, but no apparent
difference in levels in the whole pituitary (Table I). Since it is
known that endorphfn levels increase in some brain areas in rats
(Wardlaw and Frantz 19801, while decreasing in others (Gambert et al.
1980), the small decrease in receptor number found for the runners
versus the controls indicates that regional brain areas need to be
examined for both differences in receptor numbers and endorphin
levels. The difference in endorphin levels in anterior and
posterior pituitary versus whole pituitary also need to be examined.
These studies are in progress.
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Table I
Plasma, EP levels in Pituitary, Citrate syntase in Soleus
and Body weight.
Runners Controls
Plasma EP (fmoles/ml) 14.5 ± 3.56 2.95 ± 0.55
Pituitary EP (pmoles) 1020 ± 85 865 ± 63
Soleus-citrate syntase
(µM/g/min)
13.04 ± 0.32 5.16 ± 0.14
Body weight (g) 311.0 ± 2.95 355.3 ± 2.60
Results are presented as means ± SEM.
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INTRATHECAL MORPHINE AND BLOOD PRESSURE IN PREECLAMPSIA
Carl E. Costas, Nabil W. Doss, Shaesta G. Humayun,
Jonas Gintautas, Adel R. Abadir and Barry J. Kraynack*
Anesthesiology Research Laboratories,
Brookdale Hospital Medical Center,
Brooklyn, N.Y. 11212, U.S.A.,
*Department of Anesthesiology,
South Carolina School of Medicine,
Columbia, S.C. 29203, U.S.A.
ABSTRACT
Ten term parturients with moderate-severe preeclampsia
received intrathecal morphine for labor analgesia.
Significant reductions in blood pressure and heart rate,
which were unrelated to analgesia, were observed.
INTRODUCTION
Preeclampsia is a serious disease of pregnancy which is
associated with proteinuria, hypertension and edema.
Toxemia is responsible for up to 20% of reported fetal
and maternal deaths (Bonica 1965). For toxemic
patients, the ideal technique of analgesia for labor and
delivery does not exist. Each method has significant
disadvantages (James and Wheeler 1982). In the case of
normal parturients, it has been demonstrated that pro-
longed analgesia (8-11 hours) for labor can be achieved
with intrathecal morphine (ITM) without any adverse
effects to mother or newborn. No change in maternal
heart rate or blood pressure was observed (Abboud et al.
1982, Baraka et al. 1981).
Anesthetic management of preeclamptic patients during
the labor and delivery period remains controversial. It
was of interest to determine whether ITM afforded any
advantages as an analgesic method for parturients with
severe toxemia.
MATERIALS AND METHODS
Ten parturients (average age, 20 years), greater than 34
weeks gestation, in early labor and undergoing oxytocin
augmenation of labor were studied. Moderate to severe
preeclampsia was defined by the following criteria: 1)
systolic blood pressure >160 mm Hg or diastolic blood
pressure >100-110 mm Hg; 2) proteinuria; 3) oliguria.
Treatment consisted of intravenous hydration and con-
tinuous infusion magnesium therapy (prior to intra-
thecal morphine). Each patient received 1.0 - 1.2 mg of
morphine sulfate (preservative free) in 2.0 cc of 10%
dextrose solution via a 25 gauge spinal needle at the
L2-3 interspace while in the sitting position. After
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one minute, the patient was placed supine with the head
elevated at 30 degrees and with a left lateral tilt by
wedge. Oxygen (5 L/minute by face mask) was admin-
istered continuously. The patient's blood pressure
(systolic, diastolic, mean) and heart rate were moni-
tored continuously using an Ohio 2100 Adult Non-
invasive Blood Pressure Monitor.
Progress of labor was estimated by continuous external
cardiotocography and by hourly vaginal determination of
cervical dilation. Oxytocin augmentation was used in
each case. Pain level was evaluated by the patient
using the visual linear analog scale (Revill et al.
1976). Also, an investigator independently assessed the
intensity of pain and its relief, and time of onset
(Writer et al. 1981). These assessments were made
before ITM injection, every 15 minutes for one hour,
every 1/2 hour for the next seven hours and then every
hour until delivery. Maternal venous blood gases were
obtained before ITM injection and every 4 hours after-
wards up to 24 hours. Maternal arterial blood gases
were determined at delivery. Fetal scalp pH determin-
ations were obtained in one patient during labor. The
condition of the infants was evaluated by Apgar scores
at 1, 5, and 15 minutes, by measuring time to sustained
respirations (TSR) and determining umbilical venous
blood gases from doubly clamped cord at delivery.
Maternal vital signs were monitored for a total of 24
hours post-intrathecal injection. Anesthesia for de-
livery was provided by pudendal block (1% lidocaine).
One patient underwent caesarian section due to failure
to progress. Maternal side effects attributed to mor-
phine were rated absent, mild or severe every 60
minutes.
RESULTS AND DISCUSSION
We observed that 1.0 and 1.2 mg of morphine intra-
thecally administered provided prolonged and complete
analgesia (up to 8 hours) during oxytocin stimulated
labor in moderate and severely preeclamptic patients.
The average diastolic blood pressure and mean arterial
blood pressure were reduced 22% and 15% respectively.
Heart rate averaged a 14% decrease. These autonomic
changes and pain relief occurred within 60 minutes of
ITM injection. The decrease in blood pressure and heart
rate occurred prior to the onset of oxytocin-induced
labor. Although magnesium sulfate was used, other
antihypertensive therapy was not required. Fetal and
maternal acid-base status remained normal during labor.
Time to sustained respirations for the infants was less
than 30 seconds. Apgar scores were greater than 8 at 5
minutes in all infants. In the post-partum period (up
to 30 hours) no significant adverse effects in mother or
newborn were noted. Maternal and neonatal blood gases
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were normal at delivery. Maternal blood gases were
unchanged up to 24 hours post-partum. No respiratory
distress was observed. Several patients had loss of pin
prick and cold sensation over the neck, chest, abdomen,
legs and feet. Following ITM some patients complained
of nausea, vomiting and itching.
Although Baraka et al. (1981) and Abboud et al. (1982)
have  demonstrated the efficacy of intrathecal morphine
as an analgesic during labor, it is still considered an
experimental technique. Dosage, as well as other
factors, remain to be determined. In this small series
of preeclamptic patients, we observed satisfactory
analgesia for labor (up to 8 hours) and up to 30 hours
post-cesarian section. No significant maternal or
fetal/neonatoal side effects were seen. More important
was our observation of a temporally related decrease in
diastolic and mean blood pressures and heart rate in
preeclamptic women during labor. This decrease was
unrelated to pain relief since induction with oxytocin
had not begun.
These findings suggest that ITM may be of therapeutic
benefit to toxemic patients. Abouleish et al. (1981)
observed moderate blood pressure decrease in monkeys
receiving ITM (0.07 mg/kg). No such changes have been
observed in normal human parturients. The mechanisms by
which blood pressure and heart rate are lowered by ITM
in preeclamptic patients remains speculative. Laubie et
al. (1977) noted that morphine-like agents reduced
sympathetic tone (lowered blood pressure and heart rate)
by an action on the CNS. The clinical significance of
these preliminary findings remains unknown, but appears
promising.
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ABSTRACT
The effect of intracerebroventricular (i.c.v.) administration of
leumorphin on basal blood pressure and angiotensin II (AII)-
stimulated increase in blood pressure was examined in conscious
unrestrained rats. The i.c.v. injection of leumorphin (0.06 and
0.6 nmol) elicited significant depressor effect. The i.c.v. adminis-
tration of leumorphin with AI1 (0.1 nmol) significantly attenuated
the AII-induced pressor response and, furthermore, lowered blood
pressure below the basal level. These results suggest that leum-
orphin is involved in the central control of blood pressure.
INTRODUCTION
The possibility that opioid peptides are involved in the central
modulation of blood pressure homeostasis stems from the cardio-
suppressive effects of opiate alkaloids and is strengthened by the
neuroanatomical findings that opioid peptides are distributed in
brain regions especially in the areas involved in cardiovascular
regulation (Khachaturian et al. 1985). Several experiments of
central administration of opioid peptides suggest the integral role
of opioids in blood pressure control, but no unanimous conclusion on
their effects has been drawn, since their effects largely depend upon
the state of consciousness of the experimental animals (Yukimura et
al. 1981) or the sites of administration (Feuerstein et al. 1982).
The possible existence of leumorphin with 29 amino acids was
predicted by the nucleotide sequence of preproenkephalin B (Kakidani
et al. 1982) and we demonstrated its existence in the pituitary and
brain using radioimmunoassay coupled with gel filtration and high
performance liquid chromatography (Nakao et al. 1983, Suda et al.
1984, Suda et al. 1985). We also reported that leumorphin is a
ligand (Suda et al. 1983) and possesses potent actions on consum-
matory behaviors in rats (Imura et al. 1986). In the present study,
we examined the effects of intracerebroventricular (i.c.v.) adminis-
tration of leumorphin on blood pressure using conscious unrestrained
rats.
MATERIALS AND METHODS
Animals Thirty-seven male Slc: Wistar rats (220-270 g) were used. A
stainless steel cannula was stereotaxically implanted into the left
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lateral ventricle 1-2 weeks before the experiments. One day before
the experiment, a polyethylene catheter was placed in the abdominal
aorta through the left femoral artery. For i.c.v. injection, the
peptide dissolved in isotonic saline or saline as a vehicle was
injected (5 µl) for 10 sec. Blood pressure (mean arterial pressure)
was monitored while the animals were conscious and freely moving in
their cage as previously reported (Itoh et al. 1986).
Experiment 1. Effect on basal blood pressure Twenty-one rats were
divided into 4 groups, and rats in each group received one of the
following administrations: saline, 6 nmol of leucine-enkephalin (Leu-
enkephalin), 0.06 nmol or 0.6 nmol of leumorphin after a 30-min
stabilization period. Blood pressure following the administration
was monitored for 60 min and compared with the basal level.
Experiment 2. Effect on angiotensin II (AII)-induced pressor response
Sixteen rats were divided into 3 groups and rats in each group
received 2 i.c.v. injections with a minimal interval of 100 min:
first, the administration of 0.1 nmol of AI1 alone (control), and
second, the simultaneous administration of AI1 (0.1 nmol) and of
saline (Group I), 0.06 nmol of leumorphin (Group II) or 0.6 nmol of
leumorphin (Group III) (treated). Pressor responses to AI1 were
compared between the first and second administrations.
Peptides AII and Leu-enkephalin were purchased from Protein Research
Foundation (Osaka, Japan) and human leumorphin was synthesized by a
conventional solid phase method.
Statistical analysis Results are expressed as means ± S.E. Corre-
sponding values on the same animal were assessed by Student's paired
t-test and values among groups were compared by Duncan's test
following a one-way analysis of variance for multiple comparisons.
RESULTS
Experiment 1 The i.c.v. injection of leumorphin at the doses of
0.06 nmol and 0.6 nmol caused significant decreases in blood
pressure, while 6 nmol of Leu-enkephalin or saline had no apparent
effect on basal blood pressure (table 1). Two doses of leumorphin
manifested the same magnitude of maximal depressor effects but the
temporal profiles were different. The duration of significant
suppression of blood pressure was 2 min in 0.06 nmol of leumorphin
and 10 min in 0.6 nmol of leumorphin. There were no apparent changes
in heart rate (2.8 ± 3.5 % for Leu-enkephalin, 4.4 ± 0.6 % for 0.06-
nmol leumorphin, and 9.3 ± 2.2 for 0.6-nmol leumorphin).
Experiment 2 Hypotensive effects of leumorphin were more notable
when blood pressure was elevated by centrally administered AII. As
shown in table 2, pressor response to central AII was reduced by the
two doses of leumorphin by 60-70 %. Both doses of leumorphin even
lowered blood pressure below the basal level (-8.1 ± 3.1 mmHg for
0.06 nmol and -19.0 ± 1.8 mmHg for 0.6 nmol) and this depressor
effect persisted more than 20 min.
DISCUSSION
The present study has demonstrated potent suppressive effects of
i.c.v. administration of leumorphin on both basal blood pressure and
pressor response to centrally administered AII in conscious rats. In
our preliminary study, the depressor effects of leumorphin were
partially blocked by the preadministration of naloxone, indicating
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TABLE 1. Effects of i.c.v. injection
of Leu-enkephalin and leumorphin on basal blood pressure
in conscious unrestrained rats
Treatment Baseline
Group (mmHg)
Maximal Change
(mmHg)
Saline 127.8 ± 2.6 0.9 ± 2.9
Leu-enkephalin 6 nmol 117.5 ± 4.4 2.5 ± 1.9
Leumorphin 0.06 nmol 116.8 ± 4.2 -6.5 ± 2.7†
Leumorphin 0.6 nmol 119.1 ± 3.5 -7.2 ± 1.7†
Values are the means ± S.E.
Significantly different from saline-control:
† = P<0.01, Duncan's test.
TABLE 2. Effect of i.c.v. injection of leumorphin
on blood pressure increase induced by i.c.v. administration
of angiotensin II in conscious unrestrained rats
Treatment
group
Baseline Maximal % reduction Recovery
(mmHg)
response of maximal time
(mmHg) response(%)
§ (min)
Group I control 121.7 22.9 68.4
(Saline) ±3.0 ±2.7 2.2 ±9.9
treated 122.6 21.4 ±6.0 53.1
±2.6 ±1.6 ±6.4
Group II control 129.8 18.1 51.0
(Leumorphin ±4.5 ±1.9
0.06 nmol) treated 131.5 5.6
65.3 ±15.4
214.4† 2.1
±4.6 ±2.0* ±1.2*
Group III control 120.8 24.0 58.6
(Leumorphin ±4.0 ±2.8 ±69.2 ±9.6
0.6 nmol) treated 125.2 7.8 ±4.9† 2.5
±4.0 ±2.2*** ±1.3**
Values are the means±S.E.
§: 100 x ((Maximal response) control - (Maximal response)
treated) / (Maximal response) control.
Significantly different from control: *=P<0.05, **=P<0.05,
***=P<0.001, Student's paired t-test.
Significantly different from Group I: †=P<0.01,
Duncan's test.
that the observed effects were mediated by opioid receptors. Little
is known about the role of ligand on blood pressure regulation. In
anesthetized rats, the microinjection of agonist, U50488H into the
nucleus tractus solitarius was reported to increase blood pressure
and decrease heart rate (Carter and Lightman 1985), while
dynorphin(1-13) microinjected into the hypothalamic periventricular
nucleus was found to cause hypotension and bradycardia (Feuerstein
and Faden 1982). Our results using conscious rats further indicate
the involvement of leumorphin, agonist, on the maintenance of
blood pressure. Sites of action or mechanisms of the depressor
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effect of leumorphin cannot be ascertained from our present experi-
ment since leumorphin administered intracerebroventricularly may
affect multiple opioid sensitive circumventricular sites (Atweh and
Kuhar 1977). However, we have observed the inhibition of vasopressin
secretion induced by centrally administered AII by i.c.v. injection
of leumorphin (Yamada et al. 1986). This finding together with our
observation that leumorphin is present in the hypothalamus (Suda et
al. 1985) suggests that the depressor effect of leumorphin is in part
mediated by the inhibitory modulation of vasopressin secretion, as
observed with other opioid peptides (Summy-Long et al. 1981).
The potent inhibitory effect of leumorphin on blood pressure demon-
strated in this study and our previous works of its marked suppres-
sive actions on water intake (Imura et al. 1985) and vasopressin
secretion (Yamada et al. 1986) imply the involvement of leumorphin in
body fluid and blood pressure homeostasis.
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RELATIONSHIP BETWEEN DIHYDROETORPHINE AND CHOLINERGIC
SYSTEM IN THE INHIBITION OF RESPIRATION AND HEART RATE
C.F. Bian, S.H. Xing and W. Qin
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Xuzhou, Jiangsu 221000, China
ABSTRACT
The respiratory inhibition caused by dihydroetorpine (DHE) was fully
antagonized by pilocarpine or physostigmine, but the bradycardia was
not. When atropine (icv) was combined with DHE, the respiratory
inhibition was antagonized but the bradycardia persisted. However,
intravenous atropine antagonized both the respiratory and cardiac
inhibition caused by DHE.
Key Words : dihydroetorpine, atropine, pilocarpine, physostigmine,
respiration, heart rate
INTRODUCTION
Dihydroetorpine (DHE) is a potent analgesic agent. When given
intravenously, it causes significant respiratory and cardiac
inhibition. B-7601, a new muscarinic blockade, antagonizes the
bradycardia after DHE (Bian et al. 1985). Bethanechol, a
cholinomimetic, acts on the respiratory center, causing initial
excitation and subsequent inhibition, of which the latter can be
antagonized by atropine, but not the former (Gonsalves and Borison
1980). Considering that opioids decrease the release of Ach and
thus depress respiration (Pepeu 1973), we studied the effects of
DHE, atropine and the cholinomimetics on respiration and heart rate
to explore the relationship between DHE's inhibitory effects on
respiration, heart and cholinergic system.
MATERIALS AND METHODS
Hybrid rabbits were used; body weight was 1.8-2.5 kg and six groups
with 5-7 in each group.
Pilocarpine hydrochloride and physostigmine salicylate were
purchased from the Medical Supply Station of Shanghai, and atropine
sulfate from the Chengdou First Pharmaceutical Factory. DHE was
given by the Academy of Military Medical Sciences of China.
Respiration and ECG were recorded with RM-86 polygraph. The tidal
volume was estimated according to the amplitude of respiration.
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RESULTS AND DISCUSSION
Effects on respiration:
DHE (0.5 µg/kg, iw) inhibited rabbits’ respiration, the effect being
most apparent 5-10 min after injection. The frequency was decreased
by 70±12% or more (mean ± SD, p<0.01) with no significant change in
tidal volume and the change lasted over 40 min.
Pilocarpine (2.5 mg/kg, icv) accelerated respiration from 53±14 to
94±21 times/min (p<0.01) 10 min after its administration without
significant change in tidal volume. When DHE was given at this
point, respiration became slower but still more rapid than the
control. After physostigmine (0.3 mg/kg, iv), the respiration
increased markedly by 10 min (from 59±9 to 159±48 times/min,
p<0.01); the tidal volume was decreased from 56±29 to 33±27 ml, but
the ventilation volume remained higher than the control. When DHE
was then given, the frequency became lower (still higher than the
control) and the tidal volume matched that of the control (fig.
1). These results suggest both pilocarpine icv and physostigmine iv
stimulate the respiratory center and antagonize the respiratory
inhibition of DHE. This may be related to the possibility that DHE
could resemble morphine in that it agonizes opiate receptors and
retards the release of Ach (Pepeu 1973).
Atropine (0.1 mg/kg, icv) increased the frequency of respiration
from 51±11 to 75±37 times/min (p>0.05) 5 min after injection, with
no significant change in tidal volume. Five minutes after or before
DHE, atropine antagonized the inhibitory effect of DHE on
respiration, the changes being significant (p<0.01 and p<0.05
respectively). When a bigger dose of atropine (1 mg/kg) was given
intravenously, its antagonistic effect also appeared, but rather
slowly (30 min after injection). It is clear that atropine and DHE
are antagonistic in modifying respiration. Gonselves demonstrated
that bethanechol first stimulates and then inhibits respiration, and
proposed the possibility that there are 2 subtypes of muscarinic
cholinoreceptors in respiratory center, excitatory M1 and inhibitory
M2, of which atropine blocks the latter selectively (Gonsalves and
Borison 1980). We postulate that Ach is the excitatory transmitter
for the respiratory center, while DHE agonizes opiate receptor,
depressing the release of Ach in the CNS (Bian et al. 1985) and
blocks M2 receptor, it antagonizes the inhibitory effect of DHE on
respiration.
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TABLE 1. Antagonist effect of atropine on respiratory
inhibition of DHE in rabbits (n-6 in each group)
Group Change of respiration (%, mean±SD)
minutes after DHE
A -70±12 -72± 11 -71±10 -65±10 -62±l2
B 51±77 46±55 36±54 40±40 37±44
C -55±ll -57±17 -49±5** -38±10 -29±8
D -54±12 -53±12 -4O±20* -30±34 -23±8**
E -60±16 -61±l5 -58±9 -50±11 -39±19**
compared with group A: *p<0.05; **p<0.01
A: DHE 0.5 µg/kg, iv. B: Atropine 0.1 mg/kg, icv;
C: Atropine 0.1 mg/kg, icv 5 min after DHE iv;
D: Atropine 0.1 mg/kg, icv 5 min before DHE iv;
E: Atropine 1 mg/kg, iv 10 min after DHE iv.
Effects on heart rate:
DHE (0.5 µg/kg, iv) as well as pilocarpine (2.5 mg/kg, icv)
decreased the heart rate of rabbits from 262±26 to 187±32 beats/min
and from 268±27 to 182±12 beats/min respectively (p<0.01).
Subsequent DHE following pilocarpine further decreased the heart
rate to 167±14 beats/min, showing no significant alteration (fig
2.). The bradycardia faded gradually and the heart rate remained
slower than the control at 40 min. Physostigmine alone did not
decrease heart rate significantly (p>0.05), nor did it affect the
bradycardia following DHE significantly. The bradycardia following
pilocarpine icv is secondary to the raised blood pressure, which is
induced when pilocarpine agonizes the central M receptor, and
therefore is reflex in nature (Henry and Rachel 1982).
Atropine (0.1 mg/kg, icv) made the heart rate decrease from 276±29
to 227±4 beats/min (p<0.05). Its addition after or before DHE
showed no remarkable interaction between them. However, intravenous
atropine (1 mg/kg) antagonized DHE’s bradycardia almost
completely. In view of the fact that the bradycardia of DHE was
abated by atropine iv, but not icv, it may be inferred that atropine
blocks the M receptors in the cardiac muscles and thus nullifies the
elevated vagal tone over the heart, which is elicited by DHE through
its stimulation of the µ or receptor in the cardiovascular center
(Feldberg and Wei 1978; Xia 1985).
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Figure 1. Antagonist effect of
pilocarpine and physostigmine on
respiratory inhibition by DHE in
rabbits (n=6). D H E
0.5µg/kg,iv; pilocarpine
2.5 mg/kg,icv;
physostigmine 0.3 mg/kg, iv.
* pilocarpine or physostigmine
Figure 2. Effect of DHE
and pilocarpine (pill on
heart rate in rabbits
(each group=6)
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THE ROLE OF µ- AND OPIOID RECEPTORS ON THE
INTESTINAL PROPULSION IN RATS
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ABSTRACT
The agonist effects on intestinal transit of relatively selective
µ- and ligands, administered intraperitoneally, and their antagonism
by the preferentially µ- and antagonists naloxone and ICI 174,864
were studied in rats 5 min after a charcoal meal. The dose-response
curves of the preferential µ- ligands morphine and [D-Ala2, MePhe4,
Gly-ol5] enkephalin (DAGO) were shifted by naloxone at low doses but
not by ICI 174,864. The preferential peptide [D-Pen2, D-Pen5]
enkephalin (DPDPE) had no significant agonist activity. [D-Ala',
D-Leu5] enkephalin [DADLE) induced dose-related effects that were
weakly antagonized by ICI 174,864 and partly by low-dose naloxone.
Thus the inhibition of intestinal transit induced by opioids may
depend mainly on the interaction of the agonists at the u-receptors,
while the receptors may play only a secondary role. DADLE agonist
effects probably depend on interaction at µ-, and at non-opioid
receptors.
INTRODUCTION
Inhibition of intestinal transit in rats is a well-known opioid
effect currently attributed to local and CNS-mediated mechanisms
(Manara et al. in press). It has been reported that the CNS-mediated
antipropulsive activity of opioids depends on their interaction at
u-receptors or at µ- and receptors when respectively supraspinal
or only spinal mediations are involved (Porreca and Burks 1983;
Galligan et al. 1984; Porreca et al. 1984).
To clarify the contributions of opioid receptor types in the local
component of opioid-induced inhibition of intestinal transit, we
showed that k-receptors probably play no major role (Gambino et al.
1983; Petrillo et al. 1984; Tavani et al. 1984; Petrillo et al.
1985). In this study, in order to determine the contribution of µ-
and receptors, we investigated the effects on intestinal propulsion
of relatively selective µ- and agonists and antagonists after intra-
peritoneal injection.
MATERIALS AND METHODS
Overnight fasted male CD-COBS rats (Charles River, Italy) 180-200 g,
were tested for intestinal transit (Manara et al. in press). Five min
after a charcoal meal (Tavani et al. 1980) rats were killed and the
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distance travelled by the charcoal meal was recorded as a percentage
of the total length of the small intestine (% intestinal transit).
Drugs and peptides were dissolved in distilled water and injected
intraperitoneally (i.p.). The following drugs and peptides were used:
morphine HCl (Salars, Italy), naloxone HCl (gift from Endo Laborato-
ries, USA), N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH (ICI l74,864)(gift
from Dr. J.S. Shaw, ICI, U.K.), [D-Pen2, D-Pen5] enkephalin (pen-
insula, USA), [D-Ala2, MePhe4, Gly-ol5] enkephalin (DAGO) and [D-Ala2,
D-Leu5] enkephalin (DADLE)(Bachem, Switzerland).
RESULTS AND DISCUSSION
The two relatively selective u-agonists morphine (Magnan et al. 1982)
and DAGO (Handa et al. 1981) injected i.p. into rats at the peak
time or a plateau of the effect (5 and 1 min before charcoal respec-
tively, data not shown) induced dose-related inhibition of intestinal
transit, fitting a straight regression line (Fig. 1). The doses
reducing transit to 50% that of drug-free controls (ED50) were about
15.2 and 6.2 µg/kg for morphine and DAGO respectively. Pretreatment
with the preferential p-antagonist naloxone (Magnan et al. 1982)(50
µg/kg i.p. 6 min before charcoal) shifted the dose-response curves
to the right and the ED50 were 239 µg/kg for morphine and 153 µg/kg
for DAGO. The relatively selective antagonist ICI 174,864 (Cotton
et al. 1984; Corbett et al. 1984) at the dose of 1 mg/kg 6 min
before charcoal, did not inhibit intestinal transit (110% of controls)
and did not significantly shift the dose-response curves of the two
agonists. This leads us to conclude that both morphine and DAGO i.p.
inhibited intestinal transit in rats mainly through the u-type opioid
receptor.
The relatively selective agonist DPDPE (Mosberg et al. 1983,
Corbett et al. 1984) at doses from 60 to 2000 µg/kg i.p. 5 min
before charcoal did not reduce intestinal transit dose-dependently
(Fig. 1). A very slight agonist effect was seen at a few doses but
there was never any significant difference from controls. No stronger
agonist effects were observed when DPDPE was injected 1 or 10 min
before the meal (data not shown). Metabolic inactivation of the
peptide in our conditions cannot be excluded, although it is unlikely
as DPDPE is reported to be stable in the hamster vas deferens prepa-
tion (McKnight et al. 1985).
Conversely DADLE, which has been reported to act at sites with
cross reactivity at µ- sites (Magnan et al. 1982), injected i.p.
5 min before the meal, induced a dose-related inhibition of intestinal
transit with an ED50 of about 23 µg/kg (Fig. 1). When 50 µg/kg of
naloxone was injected 6 min before the meal, DADLE's effect was partly
antagonized, but with no dose relation. A dose of 5 mg/kg of naloxone
was necessary to antagonize the effect of 80 µg/kg of DADLE from 41%
to 69% of control value. In the presence of 1 mg/kg of ICI 174,864
i.p. 6 min before charcoal the dose-response curve of DADLE showed a
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group. All curves except naloxone + DADLE and DPDPE significantly fitted a straight line. Comparison of regres-
sion lines by analysis of variance showed that morphine vs ICI + morphine and DAGO vs ICI + DAGO were the same,
whereas DADLE vs ICI + DADLE (p<0.05), morphine vs naloxone + morphine and DAGO vs naloxone + DAGO (p<0.01).
Fig. 1 -
Overnight fasted rats were injected i.p. with water naloxone
Dose-related inhibition of the intestinal transit induced by morphine, DAGO, DPDPE and DADLE.
min before a charcoal meal, with morphine, DPDPE or DADLE 5 min before or with DAGO 1 min before the meal. Con-
(50 µg/kg) or ICI 174,864 (1 mg/kg) 6
trols received water. % intestinal transit was measured 5 min after the meal. Mean and S.E. of 5-8 rats per
very slight but statistically significant shift to the right and the
ED50 was 38.5 µg/kg. Because of the low solubility the highest dose
of ICI 174,864 in our conditions was 4 mg/kg i.p. This dose itself had
no antipropulsive effect and partly prevented the antipropulsive ef-
fects of 40 µg/kg i.p. of DADLE, reducing the inhibiting effects of
the agonist from 41% to 64% of control value. The very weak antagonism
of ICI 174,864 on DADLE-induced constipation and the slight tendency
of some doses of DPDPE to inhibit intestinal transit suggest that the
d-receptor probably plays a secondary role in the antipropulsive action
of i.p. opioids. Thus DADLE's effect might also depend on its inter-
action at u-sites and probably at some other non-opioid sites not
easily displaceable by opioid-antagonists.
In conclusion, the inhibition of intestinal transit in rats induced by
i.p. opioids appears to depend mainly on the agonists' interactions
at the p-receptor, while the receptor seems to play only a secondary
role. However more selective compounds are needed to determine the
exact role of µ- and receptors in locally elicited intestinal transit
inhibition.
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ABSTRACT
Dynorphin A (Dyn A)-related peptides have been implicated in the
pathophysiology of spinal cord injury in part because their intrathecal (i.t.)
injection causes hindlimb paralysis. The effects of paralytic doses of i.t. Dyn
A (1-13) and Dyn A (3-13) on spinal cord blood flow and cardiac output were
examined in rats using radiolabeled microspheres. Both Dyn A (1-13) and Dyn
A (3-13) significantly reduced blood flow in lumbosacral spinal cord without
altering cardiac output. Pretreatment with naloxone failed to block these
reductions in blood flow. Thus, the paralytic effects of Dyn A may result
from non-opioid actions of Dyn A to reduce spinal cord perfusion.
INTRODUCTION
Endogenous opioids have been implicated in the pathophysiology of spinal cord
injury based on evidence that the opioid antagonist naloxone improves spinal
cord blood flow (Faden et al. 1981a; Young et al. 1981) and neurological
function (Faden et al. 1981b) following experimental spinal trauma. Among
the opioids found in spinal cord, dynorphin A (Dyn A)-related peptides have
been specifically implicated as potential mediators in the pathogenesis of
spinal cord injury for several reasons: 1) trauma-induced loss of motor
function is reduced following treatment with the relatively selective opioid
receptor antagonist WIN44,441-3 (Faden et al. 1986) suggesting involvement
of an endogenous ligand such as Dyn A; 2) in contrast to other opioids, Dyn
A immunoreactivity progressively increases at the injury site following
trauma (Faden et al. 1985); and 3) Dyn A-related peptides are unique among
opioids in producing a flaccid hindlimb paralysis following intrathecal (i.t.)
injection in rats (Przewlocki et al. 1983; Faden and Jacobs 1984; Herman and
Goldstein 1985; Long et al. 1985). Dyn A may promote injury mechanisms by
altering spinal cord blood flow following trauma, and in turn, the therapeutic
actions of naloxone may result from protection against Dyn A contributions to
post-traumatic ischemia. Alternatively, the paralytic effects of i.t. Dyn A
have been shown not to involve actions at opioid receptors (Faden and Jacobs
1984; Herman and Goldstein 1985; Long et al. 1985). Consequently,
deleterious actions of Dyn A in injured spinal cord may result from the non-
opioid actions of this peptide. Therefore, the present studies were conducted
to determine 1) if i.t. Dyn A reduces spinal cord blood flow, and 2) whether
Dyn A-induced blood flow alterations involve opioid or non-opioid
mechanisms. Using radiolabeled microspheres, we examined the effects of
Dyn A (1-13) and the non-opioid fragment Dyn A (3-13) on spinal cord blood
flow. Additionally, we evaluated the ability of naloxone to block these
actions of Dyn A (1-13).
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MATERIALS AND METHODS
Male Sprague Dawley rats (300-350g) were anesthetized with ketamine
hydrochloride (100 mg/kg, i.m.). Saline-filled polyethylene catheters (PE IO)
were introduced into the spinal subarachnoid space through the atlanto-
occipital membrane and advanced to the level of the lumbar enlargement (8.5
cm). On the following day, rats were again anesthetized with ketamine (100
mg/kg, i.m.). A PE 50 catheter was advanced through the carotid artery into
the left ventricle of the heart for injection of microspheres, and a PE 50
catheter was inserted into the tail artery for mean arterial pressure
recordings and reference blood sampling.
Approximately one hour following catheterization, a 0.5 ml microsphere
suspension containing 150,000 to 250,000 microspheres labeled with either
141Ce or 86Sr was injected over a 15-20 second period, followed immediately
by a 0.5 ml heparinized saline flush delivered over 15-20 seconds. Reference
blood withdrawal was begun IO seconds prior to microsphere injection and was
continued for a total of 75 seconds (withdrawal rate of 1.0 ml/min). Two
microsphere injections (20 min preceding and 10 min following i.t. injections)
provided cardiac output (CO) and blood flow data. lntrathecal injections of
Dyn A (1-13) (25 nnmoles), Dyn A (3-13) (50 nmoles), or saline were made in a
total volume of 18 µl (including catheter flush). Following the second
microsphere injection, brains and cervical, thoracic, and lumbosacral portions
of the spinal cord were removed and weighed, and the activity of each isotope
was measured in a gamma counter. Cardiac output (ml min-1) was calculated
as total injected radioactivity times withdrawal
radioactivity in the reference blood sample.
rate divided by the
Tissue blood flow (ml min-1
100g-1) was calculated as tissue radioactivity times withdrawal rate divided
by reference blood radioactivity.
Differences between post- and pre-treatment measurements in each rat were
evaluated by analysis of variance. Significant differences among treatment
group means were determined by the least significant difference test.
RESULTS AND DISCUSSION
Dyn A (1-13) significantly reduced blood flow to the lumbosacral spinal cord
(49-66%) without altering cardiac output or blood flows to the brain or other
spinal cord regions. These reductions in spinal cord perfusion were limited to
those regions where direct exposure to the intrathecally injected Dyn A would
be expected on the basis of the measured distribution of 125I-BSA in the
spinal cord following its i.t. injection (results not shown). Naloxone
pretreatment 10 minutes prior to injection of Dyn A (1-13) failed to block the
reductions in lumbosacral blood flow. Additionally, lumbosacral blood flow
was significantly reduced by the non-opioid fragment Dyn A (3-13). Thus, the
Dyn A effects on spinal cord perfusion appear to involve non-opioid
mechanisms. Similarly, the dose-related hindlimb paralytic actions of Dyn A
(1-13) are not blocked by naloxone, and are shared by Dyn A (3-13)
(Przewlocki et al. 1983; Faden and Jacobs 1984; Herman and Goldstein 1985;
Long et al. 1985). Consequently, the paralytic actions of Dyn A may result
from non-opioid actions of Dyn A to reduce spinal cord perfusion. Assuming
that intrathecally injected Dyn A (1-13) mimics the actions of endogenous Dyn
A in injured spinal cord, it would appear likely that the therapeutic actions of
the opioid antagonist naloxone in spinal cord injury (Faden et al. 1981a; Faden
et al. 1981b; Young et al. 1981) do not result from protection against Dyn A-
induced ischemia, since these effects appear to involve non-opioid
mechanisms.
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TABLE I. (A) Cardiac outputs’ (CO) and (B) blood flows2 in brain,
cervical, thoracic, and lumbosacral spinal cord 20 min preceding (Pre) and
10 min following (Post) i.t injections of Dyn A (1-13) (25 nmoles), Dyn A
(3-13) (50 nmoles), or saline. Rats treated with naloxone (10 mg/kg, s.c.)
were injected 10 minutes prior to i.t. administration of either saline or
Dyn A (1-13) (25 nmoles). Data are presented Ias means ± S.E.M. for
groups of 8 rats. * p< 0.05, 1ml min-1, 2ml min-1 100g-1
T R E A T M E N T
SAL Dyn (1-13) Dyn(3-13) Nal/Sal Nal/Dyn
187±1.5 204±12 197±29 200±26
149±11 160±17 203±25 193±26
Brain
Pre 211±35 245±30 280±35 208±25 287±25
Post 194±23 207±18 217±26 203±28 212±19
Cervical
Pre 96±7 108±11 113± 11 107±15 118±11
Post 104±10 103±8 112±12 106±12 95±9
Thoracic
Pre 76±4 96±11 95±7 82±8 92±5
Post 80±10 83±5 79±8 83±7 57±7*
Lumbosacral
Pre 75±4 100±8 109±10 91±9 102±8
Post 82±10 51±12* 61±13* 100±14 34±11*
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ABSTRACT
The present study examined the role of endogenous opioid peptides in
the pathophysiological sequelae of fluid percussion head injury in
the cat. Two hours following injury, tissue concentrations of
dynorphin-like immunoreactive material (ir-Dyn) were significantly
elevated in specific brain regions where injury, as evidenced by
histological examination, was most severe. Changes in ir-Dyn but not
beta-endorphin-like immunoreactive material (ir-End) were signifi-
cantly correlated with a fall in regional cerebral blood flow (CBF)
that occurred 2 h following injury. Administration of the opiate
antagonist WIN44,441-3 (with enhanced activity at kappa-receptors)
stereospecifically increased cerebral blood flow to the injured
regions.
INTRODUCTION
Endogenous opioids have been implicated as secondary pathophysiolog-
ical factors in shock and trauma (Faden 1984a,b). Traumatic injury
to the central nervous system (CNS) may cause functional deficits
through the release of endogenous factors, including endogenous
opioids. We have provided evidence that the kappa-receptor/dynorphin
opioid system may play a pathophysiological role in traumatic spinal
cord injury (Faden et al. 1983; 1985a,b). Although the non-selective
opiate antagonist naloxone has been found to improve several physia-
logical variables (mean arterial pressure, brain perfusion pressure)
following fluid percussion head injury in the cat (Hayes et al.
1984), there is no information available regarding the role of
specific opioid peptides in traumatic brain injury or of the effects
of opiate antagonists on CBF. In the present study, we utilized a
fluid percussion device to induce traumatic head injury in the
anesthetized cat and measured regional concentrations of ir-Dyn and
ir-End by radioimmunoassay at 2 h after injury. Beta-endorphin was
chosen as a comparison neuropeptide because: (1) it is derived from
a different prohormone system (Li 1981); (2) it has a different
distribution in the brain from that of dynorphin (Khachaturian
et al. 1985); and (3) it has been implicated in the pathophysiolagy
of shock and trauma (Faden 1984a,b). Changes in the regional
concentration of opioid peptides were compared with changes in
regional CBF at 2 h following injury in order to gain insight into
the possible involvement of endogenaus opioid systems in the patho-
physiological sequelae of traumatic brain injury. We also examined
the effectiveness of the opiate-receptor antaganist WIN44,441-3 with
its dextrostereoisomer WIN44,441-2 (which is inactive at the opiate
receptor) on local CBF after traumatic brain injury.
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MATERIALS AND METHODS
Male and female cats (2.75 - 3.25 kg) were anesthetized with sodium
pentobarbital (30 mg/kg). Animals were then intubated, paralyzed
with pancuronium (0.6 mg/kg) and artificially ventilated with
70% N2O/30% 02. A femoral cutdown was performed far placement of
venous (drug administratian) and arterial (blood gas) catheters.
A catheter was also inserted into the left atrium far administration
of radiolabelled microspheres. A hallow injury screw was rigidly
fixed to the skull aver an 8 mm craniectomy centered over the
sagittal suture midway between lambda and bregma. Head injury was
induced by infusing a rapid epidural saline bolus, produced by the
fluid percussion device, through the central injury screw. At 2 h
past-injury (3.2 - 3.6 atmospheres [atm]), one group of animals
(n=6/group) were sacrificed, brains removed, dissected and assayed
far regional concentrations of endogenous opioids using radioinmuno-
assays as previously described (Ghazarossian et al. 1980; McIntosh
et a?. 1985; Molineaux et al. 1982). Antisera for radioimnunoassay
was generously supplied by Drs. A. Goldstein (dynorphin) and
G. Mueller (beta-endorphin). A second group of animals (n=5/group)
were assigned to treatment with an intravenous bolus of either
WIN44,441-3 (-) (0.2 mg/kg) or its dextrostereoisomer WIN44:441-2 (+)
(0.2 mg/kg) administered 1.5 min following fluid percussion injury
(3.2 -3.6 atm). Sequential measurement of regional CBF using
intra-atria1 injections of radiolabelled microspheres as previously
described (McIntosh et al. 1986) was performed 10 min prior to drug
administration, 30 min, 1 h and 2 h following drug treatment. At 2 h
following injury, animals were sacrificed for CBF measurements.
RESULTS AND DISCUSSION
Tissue concentration of ir-Dyn were significantly elevated in the
caudate nucleus (p < 0.05), frontal cortex (p < 0.05) and medulla
TABLE 1
Endogenous opioid response 2 h after head injury.
Dynorphin Beta-endorphin
(fmol/mg protein) (fmol/mg protein)
Baseline Post-injury Baseline Past-injury
Anterior Pituitary 4917 ± 704 1043 ± 539** 6938 ± 947 3393 ± 1185
Frontal Cortex 10 ± 1 17 ± 2* 13 ± 6 24 ± 16
Caudate Nucleus 301 20± 521 ± 50* 61 ± 24 93 ± 23
Parietal Cortex 55 ± 12 68 ± 5 16 ± 6 30 ± 21
Midbrain/Thalamus 60 ± 26 64 ± 6 77 ± 4 33 ± 9*
Medulla 40 ± 10 69 ± 4* 9 ± 3 18 ± 14
* = p < 0.05; ** = p < 0.01
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(p < 0.05) where injury, evidenced by histological examination, was
most severe. Tissue concentrations of ir-End were not significantly
altered following injury (table 1). A significant fall in whole
brain and regional CBF to caudate nucleus, frontal cortex and pons
(p < 0.05) was observed in WIN (+) animals at 2 h post-injury
(table 2). The change in ir-Dyn but not ir-End was correlated with
the fall in regional CBF that was observed. In addition, WIN (-)
caused a significant increase in CBF to frontal cortex, caudate
nucleus, midbrain/thalamus and medulla.
TABLE 2
The effects of WIN(-) an cerebral blood flaw (ml/100 g/min
± S.E.M.).
10 min 30 min 1 h 2 h
Region Baseline Post-drug Post-drug Post-drug Post-drug
Frontal Cortex 60 ± 14 59 ± 15 82 ± 10 94 ± 18* 93 ± 12*
Caudate Nucleus 55 ± 15 54 ± 8 72 ± 15 77 ± 10 84 ± 10*
Parietal Cortex 34 ± 7 33 ± 1 41 ± 8 41 ± 6 46 ± 7
Midbrain/
Thalamus 41 ± 10 44 ± 11 52 ± 13 60 ± 13 65 ± 10*
Medulla 38 ± 8 47 ± 11 44 ± 10 46 ± 12 54 ± 8*
Whole Brain 46 ± 4 42 ± 4 49 ± 8 53 ± 9 56 ± 7
The effects of WIN(+) on cerebral blood flow (ml/100 g/min
± S.E.H.).
10 min 30 min 1 h 2 h
Region Baseline Post-drug Post-drug Post-drug Post-drug
Frontal Cortex 59 ± 8 55 ± 15 54 ± 15
Caudate Nucleus 69 ± 17 67 ± 18 64 ± 17
Parietal Cortex 43 ± 18 39 ± 11 39 ± 8
Midbrain/
Thalamus 57 ± 16 54 ± 18 47 ± 10
Medulla 46 ± 10 45 ± 14 40 ± 15
Whole Brain 54 ± 6 40 ± 13 44 ± 10
* = p < 0.05 when ompared to baseline values.
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52 ± 12 43 ± 10*
61 ± 14 49 ± 16*
36 ± 7 32 ± 7
49 ± 4 34 ± 9*
34 ± 8 33 ± 10
42 ± 9 37 ± 5*
Our results suggest that tissue concentrations of dynorphin but not
beta-endorphin are elevated in brain regions where the fall in CBF is
most pronounced following injury. This fall in CBF observed at 2 h
post-injury could be reversed by administration of the opiate antago-
nist WIN (-), which has enhanced activity at kappa-receptors (Michne
et al. 1978), but not WIN (+) (table 2). The lack of effect shown by
the dextro-stereoisomer in this model implies that the efficacy of
WIN (-) is mediated through an action at opiate receptors. These
results are consistent with the hypothesis that dynorphin, acting
through specific opiate receptors, may contribute to the pathophysi-
ology of secondary brain injury following head trauma. In addition,
it appears that opiate antagonists with increased activity at kappa-
receptor sites may be effective in the treatment of reduced cerebral
blood flow often associated with acute head injury.
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ABSTRACT
Cats were treated using a blinded protocol with either the
dextrorotary or levorotary form of WIN 44,441-3 injected
subcutaneously six hours after middle cerebral artery occlusion,
followed by continuous subcutaneous infusion. The levorotary form
acutely improved neurologic function in 90% of animals, whereas the
dextrorotary form had no effect. Survival rate and infarct size were
the same in both groups. These results further implicate the kappa
receptor in the pathophysiology of cerebral ischemia.
INTRODUCTION
The results of our previous work indicate that endogenous opioid
peptides may contribute to the pathophysiology of neurological
deficits caused by cerebral ischemia. In humans, the opiate
antagonist, naloxone, reversed neurological deficits secondary to
cerebral ischemia, whereas morphine exacerbated them; in both
situations, there was no change in vital signs or level of
consciousness (Baskin and Hosobuchi 1981). The neurological deficits
produced by unilateral carotid ligation in gerbils were reversed by
the intraperitoneal administration of naloxone (Hosobuchi et al.
1982). In baboons, naloxone partially reversed and morphine
exacerbated ischemic neurological deficits resulting from focal
cerebral ischemia; the effect was not due to a change in systemic
parameters (Baskin et al.1982, Baskin et al. 1984, Zabramski et al.
1984). In cats with focal ischemia, naloxone and naltrexone improved
neurologic function and prolonged survival (Baskin et al. 1986);
dynorphin 1-13 also prolonged survival, suggesting that the kappa
receptor is involved in this phenomenon (Baskin et al. 1984). This
study was designed to further elucidate the role of the kappa
receptor in focal cerebral ischemia by using the relatively selective
kappa antagonist, WIN 44,441-3 to treat cats with experimentally
induced focal cerebral ischemia.
MATERIALS AND METHODS
20 adult male cats were randomly assigned in blinded fashion to one
of two groups, and were treated with the dextrorotary or levorotary
form of WIN 44,441-3. The cats were sedated with ketamine, and
anesthesia was induced by a mixture of halothane, nitrous oxide, and
oxygen, administered by mask. The trachea was then intubated, but
the cat was allowed to breathe spontaneously. One million units of
penicillin G was then administered intramuscularly. Transorbital
occlusion of the right middle cerebral artery (MCA) was performed
using the technique described in cats by O'Brien and Waltz (1973).
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In all cases, the MCA was occluded proximal to the take-off of the
lenticulostriate arteries.
An incision was made in the mid-lumbar region and a subcutaneous
pocket was created for the later placement of an osmotic pump
designed to deliver drug solution at a constant volume. The cat was
allowed to awaken, and was examined 6 hours following MCA occlusion.
Neurological function was assessed independently by two individuals
who were unaware of the experimental protocol. Sensory and motor
function, level of consciousness, and pupillary reaction were graded
using an 18-point scale (Baskin et al. 1986).
Cats then received an intraperitoneal injection of 10 mg/kg of the
dextrorotary or levorotary form of WIN 44,441-3. A repeat
neurological assessment was performed 20 mintues later. The cat was
then sedated and an ALZET osmotic pump was implanted sterilely in the
subcutaneous pocket in the lumbar region to deliver either the
dextrorotary or levorotary isomer at 0.5 mg/kg/Hr. The investigators
were blinded as to which treatment was being administred, but the
pumps were coded in such a way that each cat received the same drug
in both the acute injection and the chronic infusion phases of the
study.
Neurological assessments were performed daily for as long as the cats
were alive, or until 7 days after occlusion, at which time all were
sacrificed. One million units of penicillin G was administered
intramuscularly daily along with subcutaneous injections of lactated
Ringer's solution calculated to provide adequate daily fluid
maintenance. Once a cat began to eat or drink, subcutaneous fluids
were discontinued. If a cat was found dead, a craniectomy was
performed, the brain removed, and a coronal section made at the level
of the optic chiasm. At the end of 7 days, all surviving cats were
sacrificed, the brains removed, and slices prepared. The slices were
incubated in a 2% solution of 2,3,5-triphenyltetrazolium chloride
(TTC) for 25 minutes according to the method of Han et al.(1983). A
TTC solution has been used extensively to demonstrate the presence
and extent of acute myocardial infarcts (Ramkisson 1966), and gives a
vivid indication of cerebral infarction in the acute stage. The
reaction product of TTC and viable tissue is a deep red fonnazan that
stains normal gray matter, whereas normal white matter stains with
less intensity. Infarcted tissue does not stain.
Color slides were then made of the stained brain slices. A
neuropathologist who was unaware of the experimental protocol made
tracings of the entire affected hemisphere and infarcted area from
projected images of the slide, A digitizing pad was used to
calculate the percentage of infarcted tissue relative to the entire
hemisphere for both sections in each cat; this defined the infarct
size.
The Wilcoxon signed rank analysis was performed to compare
neurological scores obtained before the acute drug injection with
those obtained 20 minutes after injection. A Kruskall-Wallis
analysis was performed to compare neurological scores before and
after injection between groups. A two-way analysis of variance was
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used to compare infarct size in all groups of cats. Kaplan-Meier
survival curves were constructed, and Gehan's statistic was used to
compare survival rates among groups.
RESULTS
Following acute administration, the levorotary form of WIN 44,441-3
produced statistically significant improvement in motor function in
all animals tested, whereas the dextrorotary form had no effect
(Figure 1).
FIGURE 1
Median Motor Function in Cats Tested 6 Hrs. After
Middle Cerebral Artery Occlusion
(-) WIN 44,441-3 (+) WIN 44,441-3
BEFORE INJECTION 2 2
(25/75th Percentiles) 2/3 2/3
AFTER INJECTION 4 2
(25/75th Percentiles) 4/5 2/3
There was no effect of either drug on sensory function, level of
consciousness, or pupillary reaction to light. There were no
statistically significant differences in survival rates or size of
infarction between the detrorotary or levorotary groups.
DISCUSSION
Evidence for the involvement of the kappa receptor in central nervous
system dysfunction is increasing. Tang (1985) has shown that the
kappa agonist U50,488 can improve survival and hyperactivity
associated with global cerebral ischemia in the rat. Tortella et al.
(1986) have demonstrated that U50,488 can increase our seizure
threshold either secondary to electroshock or drugs with convulsant
activities. Faden and Jacobs (1985) have shown that WIN 44,441-3 can
improve motor function in unanesthestized rabbits with spinal cord
ischemia secondary to temporary occlusion of the abdominal aorta.
In our previous work, we have shown that a variety of opioid
compounds can influence either neurologic function and/or survival in
experimental focal cerebral ischemia. Indeed, it is possible to see
a dissociation of these effects: diprenorphine improved neurologic
function without altering survival (Baskin et al. 1986), whereas
dynorphin 1-13 improved survival without changing the neurologic
deficit (Baskin et al.1984). The fact that such dissociation exists
suggests that naloxone and other compounds that alter both survival
and function may do so at either different receptor subtypes or
perhaps in several different as yet unidentified ways.
We selected WIN 44,441-3 for these experiments because of our recent
experience with dynorphin 1-13 and the dramatic improvement in
survival associated with its use in focal cerebral ischemia (Baskin
533
et al. 1984). As there is much evidence that dynorphin 1-13 binds
mainly at the kappa receptor, and that WIN 44,441-3 has significant
antagonist properties at the kappa receptor (Michne et al. 1978), we
chose this compound for testing.
Our results clearly show biologic significance of the effect of WIN
44.441-3 on neurologic function in cerebral ischemia, as only the
levorotary form produced the change. The lack of an effect on
survival may be due to an inadequate dose for this to occur, or
because of a differentially selective effect on neurologic function
alone. While WIN 44,441-3 does bind at the mu, delta, and kappa
receptor subtypes, its relatively selective kappa antagonist activity
(Michne et al.1978) provides additional supportive evidence for the
role of the kappa receptor in cerebral ischemia. Further studv of
the compound in focal cerebral ischemia including dose-response
testing is in progress.
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ABSTRACT
Increasing doses of naloxone hydrochloride (100-1000 nmol) were micro-
injected unilaterally into the rat amygdala and the behavioral, neuro-
pathological and electrographic responses were studied. Microinject-
ions of low doses of naloxone (100-250 nmol) produced staring, gusta-
tory automatisms and wet shakes whereas higher doses additionaly re-
sulted in motor limbic seizures and status epilepticus. The electro-
encephalogram showed a sequence of alterations characterised by high
voltage fast activity, spiking, bursts of polyspiking, electrographic
seizures and postictal depression which first appeared in the amygda-
la and rapidly spread to hippocampal and cortical areas. The neuropa-
thological analysis of frontal forebrain sections by means of light
microscopy revealed seizure-related brain damage in amygdala, olfacto-
ry cortex, thalamus, hippocampal formation, substantia nigra and neo-
cortex. Diazepam, 10 mg/kg i.p., when given prior to the microinjec-
tion of naloxone into the amygdala, abolished the epileptogenic and
neurotoxic effects of the drug. The results suggest that naloxone,
when microinjected into rat amygdala elicits electrographic and motor
limbic seizures followed by seizure-related brain damage.
INTRODUCTION
There is a fairly large body of evidence to suggest that derangements
in the function of endogenous opioid mechanisms in the brain may play
a role in experimental, and human epilepsy. Opiates and opioid pepti-
des can modulate the threshold for experimentally induced seizures in
a way which depends upon the art of convulsions, the route of drug ap-
plication and the species used (Frenk 1983). Intracerebroventricular
application of high doses of morphine produce electrographic and
behavioral manifestation of limbic seizure activity (Frenk 1983).
Interestingly, the opiate antagonist naloxone, when given systemical-
ly in high doses causes generalised clonic convulsions which resemble
stage 5 kindled seizures and result in prominent increase of 2-deoxy-
glucose metabolism in several limbic forebrain structures (Chugani et
al. 1984). The amygdaloid complex has been shown to play a pivotal
role in activating epileptic limbic circuits (Watson et al. 1983).
Recently we reported that intraamygdaloid microinjection of morphine
results in motor limbic seizures and brain damage (Turski et al.
1983a). The present study provides an electroencephalographic, behav-
ioral and morphological analysis of the effects produced by applica-
tion of the opiate antagonist naloxone into the amygdaloid complex
of the rat.
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MATERIALS AND METHODS
For intraamygdaloid injections adult male Wistar rats weighing 200-
220 g were used. Naloxone hydrochloride was supplied by Endo Labs
Inc (Garden City, N.Y., USA) was dissolved in saline and adminis-
tered at doses of 100-1000 nmol into the amygdala. Diazepam (Polfa,
Kutno, Poland) was suspended in a 3% solution of Tween 81 (Loba,
Vienna, Austria) and given i.p. in the dose of 10 mg/kg 15 min prior
to intraamygdaloid injection of naloxone, 1000 nmol. The methods for
stereotactic implantation, the electroencephalographic registration
and the morphological examination of the brains are described else-
where (Turski et al. 1985).
RESULTS
Microinjection of low doses of naloxone hydrochloride, 100 nmol (n=4),
into the amygdala presented no abnormal behavior. Higher doses, 250-
1000 nmol, produced hyperactivity, gustatory automatisms and occasion-
ally scratching or myoclonic movements of fore- or hindlimbs and wet
shakes. This pattern of behavior persisted up to 30-40 min in animals
FIGURE 1. The evolution of electrographic activity elicited
by unilateral injection of naloxone hydrochloride (NAL), 500
nmol, into the rat amygdala. (a) Pre-drug control recordings.
(b-f) High voltage fast activity, spiking and bursts of poly-
spiking represent electrographic patterns registered in the
amygdala 3-20 min after the injection of NAL. (g-i) Electro-
graphic seizures dominate the EEG patterns within 20-90 min
after NAL. (j-l) Progressive normalisation of electrographic
activity is observed 2-12 h after the injection of NAL. (m)
The EEG returns to the pre-drug pattern by 12-24 h post-in-
jection. AMG, amygdala; CX, cortex.
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receiving 250 nmol (n=6) of naloxone. With higher doses, 500 and 1000
nmol, the behavioral alterations increased and built up into seizures
and status epilepticus. The ED50 (effective dose) of naloxone for
generation of motor limbic seizures is 359.5 nmol (259.3-498.4)(n=24).
Motor limbic seizures commenced after a mean delay of 17.2 - 2.2 min†
following 1000 nmol (n=6) and 43.0 - 12.5 min (n=5) following 500 nmol†
of naloxone, recurred every 3-10 min and lasted up to 2-3 h following
the intraamygdaloid injection of the drug. After the intraamygdaloid
injection of 500-1000 nmol of naloxone the electrographic background
activity in the amygdala was replaced with high voltage fast activity
which progressed in high voltage spiking and bursts of polyspiking
(Fig. Ic-e), and developed into electrographic seizures. Ictal periods
lasted for 1-3 min, recurred every 3-5 min and were followed by per-
iods of depression of the electrographic activity (Fig. 1g,i). Within
24-48 h the electroencephalographic activity slowly returned to the
pre-drug pattern (Fig. 1m). Examination of frontal forebrain sections
with light microscopy 2-15 days after microinjection of naloxone, 500
and 1000 nmol, revealed widespread damage in amygdala, hippocampus,
thalamus, olfactory cortex, substantia nigra and neocortex. The dam-
age to the amygdala was most severe in the region immediately sur-
rounding the injection cannula tip and entended into adjacent regions
i.e. pyriform cortex, entorhinal cortex and claustrum. With short-
lasting survival times (48-72 h) the damage consisted of prominent
edema of the tissue as well as darkened and shrunken neurons. At lon-
ger survival time (10-15 days) the morphological structure of the
amygdala undervent severe breakdown with loss of most neurons. The
damage in the thalamus was limited to dorsomedial, reuniens, rhombo-
ideus and paraventricular nuclei. Neuronal destruction in the hippo-
campus affected CA1 subfield of the intermediate and rostral hippo-
campus. The CA3 and CA4 subfields were affected considerably less.
The damage in the substantia nigra extended into most caudal portions
of the pars reticulata, whereas pars compacta was affected only very
rarely. The most injured parts of the neocortex included areas loca-
ted dorsally to the rhinal sulcus and cingulate cortex. Pretreatment
with diazepam, 10 mg/kg, completely blocked the behavioral, electro-
graphic and morphological alterations produced by intraamygdaloid in-
jection of naloxone, 1000 nmol (n=5).
DISCUSSION
Our results demonstrate potent epileptogenic and brain damaging prop-
erties of naloxone when injected into the amygdala of rats. High do-
ses of naloxone have been reported to cause generalized clonic convul-
sions when given systemically (Chugani et al. 1984, Dingledine et al.
1978) whereas lower doses block epileptogenic properties of opiates
(Frenk 1983). Two possible explanations for the convulsant action of
naloxone in the amygdala exist. The first one implies that naloxone
blocks an endogenous anticonvulsant system which is mediated by endo-
genous opioids (Frenk 1983). In fact, anticonvulsant action of morphi-
ne and enkephalins has been reported in animal models of reflex epile-
psy and against pentylenetetrazol- and fluorothyl-induced seizures
(Frenk 1983; Frey 1986). The second proposal explaining convulsant
action of naloxone implies that the drug behaves as a aminobutyrate
(GABA)-antagonist. It is known that the opiate antagonist displaces
GABA from its binding sites in rat cerebral membranes and facilitates
bicuculline induced seizures (Dingledine et al. 1978, Sagratella and
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Massoti 1982). Since antagonism at the GABA-receptor could also be
demonstrated for morphine, it seems tempting to speculate that both,
the opiate as well as the opiate antagonist might act in the amygdala
at the same site to initiate generalised limbic seizures, namely the
GABA receptor. Studies with intraamygdaloid injections of the GABA
antagonists bicuculline and picrotoxin demonstrate that both drugs
induce motor limbic seizures and brain damage closely resembling those
seen after morphine or naloxone (Turski et al. 1983a; 1985). Diazepam,
a compound which enhances GABA-mediated synaptic inhibition in the
brain (Haefely et al.1981) abolished the epileptogenic and brain da-
maging potential of naloxone. This finding however is not indicative
of a specific GABA antagonistic action of naloxone, since the benzodi-
azepine also protects against convulsions produced by systemic or in-
traamygdaloid injections of kainic acid and cholinomimetics (Ben-Ari
et al. 1980; Olney et al. 1983; Turski et al. 1983b).
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ABSTRACT
Dynorphin A (1-13) acutely elevated the seizure threshold (ST) to the
convulsant flurothyl, and this action was not blocked by naloxone. Increases
in ST were also observed following i.c.v. injections of the non-opioid fragment
dynorphin A (3-13). Pretreatment with dynorphin A (1-13), but not dynorphin
A (3-13), non-competitively blocked the anticonvulsant effect of the µ
selective opioid DAGO. Furthermore, pretreatment with dynorphin A (1-13)
antagonized the antagonist properties of naloxone or ICI 154,129 in this
seizure model. Thus, in addition to its non-opioid anticonvulsant effects,
dynorphin A (1-13) exhibits unique antagonist actions which appear to be
specific for the active opioid fragment.
INTRODUCTION
Dynorphin A (1-13). the endogenous ligand for opioid binding sites, exhibits
activity in receptor binding assays, in vitro bioassays, and in vivo analgesia
systems. It has also been shown that dynorphin A (1-13) demonstrates opioid
antagonist effects in opiate naive and tolerant rats (Lee and Smith 1984).
Hence, under the appropriate conditions, dynorphin A (1-13) appears to possess
mixed agonist/antagonist properties.
Recently, using the flurothyl seizure test as an in vivo model to differentiate
multiple opioid receptor systems (Cowan et al. 1979; Tortella et al. 1985), we
demonstrated that FNA, another agonist with µ antagonist properties
(Ward et al. 1982), attenuates the antagonist properties of naloxone or ICI
154,129. Therefore, considering the possible similarities between FNA and
dynorphin A as opioids possessing mixed agonist and antagonist properties, the
present studies were aimed at establishing the pharmacological profile of
dynorphin A (1-13) in this in vivo model. For these studies, we used the µ
selective agonist DAGO (Handa et al.
agonist DADL (D-Ala2-D-Leu5-enkephalin) (Tortella et al. 1985), peptide
1981) and the mixed µ receptor
ligands possessing potent µ (DAGO; Robles et al. 1986) and (DADL; Tortella
et al. 1985) receptor-mediated anticonvusant profiles in the rat flurothyl test.
MATERIALS AND METHODS
Male Sprague-Dawley rats (225-300 g) obtained from Zivic Miller laboratories
(Allison Park, PA) were used. Three to five days prior to testing, rats were
anesthetized with ketamine HCL (100 mg/kg, i.p.) and stereotaxically
prepared with i.c.v. cannulae aimed at the right lateral ventricle. Three to
five days following surgery, the rats (n=8-10 per group) were randomly
assigned to treatment groups for testing. The effects of dynorphin A (1-13)
(3.9-15.6 nmol, i.c.v.) or dynorphin A (3-13) (15.6 nmol, i.c.v) on flurothyl ST
were determined at various times postinjection. Additional rats were
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pretreated with naloxone (1 or 10 mg/kg, s.c.) 10 min prior to an i.c.v.
challenge of dynorphin A (1-13) (15.6 nmol) and exposed to flurothyl 15 min
later. In separate experiments, the µ antagonist actions of dynorphin A (1-13
or 3-13) (15.6 nmol; -2hr pretreatment) were determined in DAGO (0.275-4.4
nmol, i.c.v.) treated animals. Additionally, antagonist-interaction studies
were conducted in naive rats pretreated at -2 hr with dynorphin A (1-13) (15.6,
nmol), subsequently injected with ICI 154,129 (50 nmol, i.c.v.) or naloxone (290
nmol, i.c.v) 10 min prior to receiving an i.c.v. injection of DADL (35 nmol) and
tested 20 min later in the rat flurothyl test.
To determine flurothyl ST’s, rats were exposed to the volatile convulsant
flurothyl and tested as previously described (Tortella et al. 1985). All i.c.v
injections were given in a maximum volume of 7.5 µl (including a 2.5 µl
flush). All the control groups received i.c.v. injections of saline at the
appropriate treatment times.
RESULTS AND DISCUSSION
Mean ST’s for all the control groups ranged from 340 to 370 seconds. The
administration of dynorphin A (1-13) (fig. 1A) caused a significant dose- and
time-dependent increase in ST. At the highest dose tested (15.6 nmol), ST’s
were increased 140 + 11 % of control. Peak effect occurred 15-30 min
postinjection, with a duration of action of 60 min. The anticonvulsant action
of dynorphin A (1-13) was not antagonized by naloxone (fig. 16). Moreover,
dynorphin A (3-13) (15.6 nmol) was as effective as dynorphin A (1-13) as an
anticonvulsant in this seizure model (data not shown). Collectively, these
data clearly indicate that the actions of dynorphin A to increase the ST to
flurothyl do not require the active opioid fragment, suggesting that a non-
opioid mechanism of action is responsible for dynorphin’s anticonvulsant
effect in rats.
FIGURE 1. A. Dose- and time-dependent anticonvulsant effect of
dynorphin A (1-13). B. Failure of naloxone to antagonize dynorphin A
(1-13). *p<0.05, compared to saline control (Student’s test).
The µ antagonist actions of dynorphin A (1-13) are seen in table 1. In rats
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pretreated with dynorphin A (1-73)(15.6 nmol), but not (3-13)(15.6 nmol), the
ability of DAGO to increase the threshold to flurothyl seizures was completely
antagonized. Although not shown, dynorphin pretreatment shifted the DAGO
anticonvulsant dose-response curve to the right and decreased its maximal effect,
indicating a non-competitive antagonism. The results of these experiments
demonstrate a µ selective antagonist action of dynorphin A which, unlike the non-
opioid actions of dynorphin A, is dependent upon the intact opioid fragment.
TABLE 1. Dynorphin A (1-13) antagonism of the anticonvulsant effects of DAGO.
Antagonist Dose Range of DAGO Maximal increase in ST
(nmol, i.c.v.) (% of Control)
Saline 0.275-2.2 164 ± 11
Dyn A (1-13) 0.275-4.4 115 ± 5
Dyn A (3-13) 0.275-2.2 158 ±12
FIGURE 2. Dynorphin A (1-13)
blockade of the 6 antagonist
actions of naloxone or ICI
154,129 on DADL-induced
increases in seizure threshold.
All rats were injected with
DADL in combination with
Qther substances as the
indicated dosed (substcripts).
*p<0.05, compared to control,
+p<0.05, compared to the 35
nmol DADL group (Dunnett’s
test). #p<0.05, compared to
lCI50 + DADL and NLX290 +
DADL groups (Student’s test).
The effect of dynorphin A (1-13) to diminish the ability of either naloxone or ICI
154,129 to antagonize the anticonvulsant actions of DADL (Tortella et al. 1985) is
shown in figure 2. In the absence of dynorphin A (1-13), pretreatment with i.c.v.
naloxone (290 nmol) or ICI 154,129 (50 nmol) antagonized the anticonvulsant ef-
fect of DADL (157±13 %) to 106±6 % and 120±8 % of control, respectively. How-
ever, in the presence of dynorphin A (1-13), which alone had no effect on DADL
anticonvulsant activity (151±9 %), the DADL-induced increase in ST was only
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partially antagonized by naloxone (132±6 %) and no longer antagonized by ICI
154,129 (166±9 %). Since the doses of naloxone and ICI 154,129 used here have
been previously shown to selectively antagonize opioid receptor activity in this
seizure model (Tortella et al. 1984; Tortella et al. 1985), we conclude that under
the appropriate conditions of pretreatment time and dose, dynorphin A (1-13) is
capable of antagonizing the selective antagonist actions of naloxone and ICI
154,129 in the rat flurothyl test.
In addition to the agonist properites of dynorphin A (1-13), the in vivo pattern of
results described in the present report are suggestive of three different actions
for this opioid ligand: 1) an anticonvulsant action which is clearly non-opioid, 2) µ
antagonist activity and 3) the ability to antagonize the actions of antagonists
(ICI 154,129 or naloxone), but not the agonist properties of DADL.
Interestingly, a remarkably similar pattern of results has been observed with the
agonist/irreversible µ antagonist FNA (D’Amato and Holaday 1984; Tortella et
al. 1985). Given the noncompetitive nature of the µ antagonist properties of
dynorphin A reported here, it seems possible that irreversible µ receptor blockade
may be a prerequisite for the types of antagonist interactions observed in the
present report. In this regard, dynorphin A and FNA may share a common
mechanism of action at an opioid receptor complex.
Obviously, several mechanisms can be proposed to explain the interactions
observed between dynorphin A and FNA and the antagonists. These include
act ions upon second messenger systems, altered metabolism, or simple
pharmacological interactions of the various ligands at individual µ and
receptors (Holaday et al. 1986). Alternatively, since several investigators have
performed in vivo, in vitro and binding studies indicating that µ and receptor
sites are isverconvertible (Bowen et al. 1981), and may interact through non-
competative molecular mechanisms (see Holaday et al. 1986), we and others have
postulated that a functional coupling (possibly via allosterism) of opioid binding
sites on a common receptor macromolecule may account for these interactions.
Regardless of the mechanisms involved, this consistent pattern of interactions
observed with dynorphin A in the present report, and elsewhere with FNA (see
above), may have important significance relevant to the concept of multiple
opioid receptors. At least in the case of dynorphin A, an endogenous neuropeptide
ligand, the results reported in this study strongly support the hypothesis proposed
by Lee and Smith (1984) suggesting that dynorphin may function in the CNS
primarily as a modulator of opioid receptor systems.
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ABSTRACT
Graded seizure responses to suprathreshold cerebral
electroshock in mice were modified by drugs acting at mu-
and at delta-opioid receptors. Morphine exerts a
proconvulsant effect at a non-mu opioid receptor and may
exert a simultaneous anticonvulsant effect at a mu-opioid
receptor. Delta-opioid receptor blockade increases
seizure severity, suggesting a predominantly
anticonvulsant nature of the delta-opioid system in the
seizure model tested here.
INTRODUCTION
Dua et al. (1985) demonstrated that blockade of central
delta-opioid receptors can attenuate
electroencephalographic seizures initiated by mu-opioid
receptor stimulation in rats. In contrast, Tortella and
Long (1985) had earlier reported on a putative endogenous
delta-opioid agonist which can diminish flurothyl-
provoked seizures. We have therefore examined for this
study the effects of mu- and delta-opioid receptor
agonists and antagonists on the severity of electroshock
seizure (ECS) activity in mice, to determine whether
modulation of seizure activity might be a general
property of such opioid agents.
MATERIALS AND METHODS
Electrical stimulation and seizure response measurement.
ECS was produced in Swiss-Webster albino mice by passing
60-Hz sinusoidal constant current (generator output
impedance > 50 k ohms) for 200 msecs via electrode jelly-
coated pinnae through spring-loaded metal clips. We
determined from pilot experiments in untreated mice that
a stimulus strength of 5.6 mA root mean square could
produce full seizure activity while even slightly higher
currents often produced immediate death. With 5.6 mA
strength all untreated mice displayed a gradeable
continuum of motorobehavioral responses which permitted
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us to guantitate seizure response severity in treated and
untreated animals on a scale of from 0 to 5, as follows:
0 = no observable seizure activity: 1 = mouse stunned,
immobile, may subsequently run, Straub tail; 2 = brief
(<2 sec) clonic seizure, stunned, runs and becomes
hyperactive; 3 = sustained (>2 sec) clonic seizure,
stunned: 4 = brief tonic seizure, stunned, running, all
often accompanied by brief clonic activity; 5 = sustained
tonic-clonic seizure, stunned, running, followed by
postictal depression and, occasionally, death. The
seizure severity grade for each mouse was multiplied by
total response duration (from initial application of
current until cessation of seizure activity) to obtain a
Seizure Index (SI) score. Animals which died during
seizure were assigned the mean of the two highest SI
scores for surviving animals in the same treatment group.
Effects of drugs were examined on mean SI scores for each
group.
Drugs and administration. Mice were pretreated with
morphine sulfate (MOR; BDH, at 0, 8, 32 or 128 mg/kg
intraperitoneally (ip) administered 20 min prior to
electroshock), naloxone hydrochloride (NIX; Endo, at 0,
0.16, 0.64, 1.0 or 2.56 mg/kg ip administered 10 min
prior to electroshock) and ICI 154,129 (I/l; at 0, 6 or
24 mg/kg ip administered 30 min prior to electroshock).
All drugs were dissolved in saline and injected in
volumes of 10.0 ml/kg ip.
Statistical procedures. Differences between treatment
groups were evaluated by analysis of variance (ANOVA)
followed by Duncan's test for multiple comparisons.
Linear regression was done by the method of least
squares.
RESULTS
Reproducibility and reliability of SI measurement. There
were no statistical differences between SI values
obtained by two different observers who evaluated SI in
different groups of saline-treated (control) mice in
separate experiments. Statistical inferences concerning
the effects of MOR 8 mg/kg on SI were identical between
the two experimenters and identical for tests done at
different times in separate experiments.
The effects of pretreatment with opioid drugs on SI.
These results are summarized in Table 1. NLX 1.0 mg/kg
ip by itself did not alter SI but the combination of NLX
with MOR, in a fixed molecular NLX:MOR ratio of
approximately 1:50, produced significantly greater SI
scores than did MOR alone at 32 and 128 mg/kg. The
NLX/MOR combination with MOR at 8 mg/kg produced SI
scores numerically greater than those with MOR alone at
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mainly from in vitro opioid receptor kinetics data
(Kosterlitz and Watt 1968; Lord et al. 1977) and was
aimed at maintaining essentially complete blockade of mu-
opioid receptors at all doses of MOR used in combination
with NLX. Differences between SI scores with MOR alone
and with the given combinations of MOR and NLX were
plotted against the dose of MOR over the range from 0 to
128 mg/kg. The data resulted in a straight line of best
fit (forced through origin) with slope = 2.5, r = 0.65
and p<0.001, to indicate the slope as being significantly
different from zero. Administration of I/l 6 mg/kg by
itself provoked Severity Index scores significantly
greater than those from untreated mice. SI in mice
treated with a combination of I/l and MOR was always
numerically greater, by at least 117 SI points, than with
MOR by itself at corresponding doses. Differences for
these comparisons were statistically significant with MOR
at 8 and at 128 mg/kg.
TABLE 1
Effects of Pretreatment with
Opioid Drugs on Seizure Index
8 mg/kg. The chosen NLX:MOR ratio of 1:50 was arrived at
PRETREATMENT
GRP MOR NLX I/1
A 0 0 0
B 0 1.0 0
C 0 0 6
D 8 0 0
E 8 0.16 0
F 8 0 6
G 32 0 0
H 32 0.64 0
J 32 0 6
K 128 0 0
L 128 2.56 0
M 128 0 24
SEIZURE
INDEX
mean ± S.E.
99 ± 26
129 ± 30
338 ± 8
219 ± 11
305 ± 57
405 ± 49
128 ± 16
508 ± 30
245 ± 49
85 ± 19
330 ± 55
312 ± 83
For all groups n=6, except A and D where
n=12. Mean SI for Grp A is significantly
different (p<0.05; ANOVA) from C, D, E,F, H,
J, L. M; B from C, E, F, H, L, M; C from A,
B, D, G, H; D from A, C, F, H, K; E from A,
B, H, K; F from A, B, D, K; G from C, E, F,
H, L, M; H from all except F; J from A, F, H,
K; K from C, D, E, F, H, J, L, M; L from A,
B, G, H, K; M from A, B, G, H, K.
545
DISCUSSION
The approximated linear relationship between dose of
morphine and seizure severity in the presence of a fixed
mu-opioid receptor-blocking NLX:MOR ratio supports the
possibility that morphine exerts a proconvulsant action
at a non-mu opioid receptor. The significant
proconvulsant effect of morphine, which with doses
greater than 8 mg/kg was unmasked only in the presence of
naloxone, suggests the existence of a mu-receptor related
anticonvulsant mechanism. This mechanism becomes evident
only after blockade of mu-opioid receptors and not with
morphine administration alone. Our results suggest also
the existence of an anticonvulsant delta-opioid receptor
which is tonically activated by endogenous delta-opioid
ligand(s), a concept supported here by the significantly
proconvulsant effect of I/l, a relatively specific delta-
opioid antagonist (Gormley et al. 1982), by itself at 6
mg/kg. This is consistent with the work of Tortella et
al. (1984) and Tortella and Long (1985) who maintain that
delta-opioid agonism can be anticonvulsant. Thus,
depending upon the particular seizure model being tested
(Dua et al. 1985), the central delta-opioid receptor
system may support both anticonvulsant and proconvulsant
mechanisms.
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ABSTRACT
Microinjection of morphine hydrochloride into the substantia nigra
pars reticulata, bilaterally, converts non-convulsant dose of pilocar-
pine hydrochloride, 100 mg/kg, into a convulsant one. The ED50 of
morphine for the generation of seizures after pilocarpine, 100 mg/kg,
is 3.8 nmol (2.5-5.8). Electrographic and behavioral monitoring both
show a pattern of convulsant activity similar to those produced by pi-
locarpine in doses exceeding 350 mg/kg. Morphological analysis of
frontal forebrain sections reveals epilepsy-related damage to the hip-
pocampus, thalamus, olfactory cortex, substantia nigra, neocortex and
amygdala. The proconvulsant action of morphine in the substantia nig-
ra is reversed by co-administration of naloxone hydrochloride. The
results show that the threshold for limbic seizures may be modulated
by opiates in the substantia nigra.
INTRODUCTION
The basal ganglia are concerned with the propagation of motor seizures
and in the generation of seizure activity in the limbic system. Cli-
nical observations in man and lesion studies in primates established
that substantia nigra governs the spread of seizures elicited from the
motor cortex (Hayashi 1952). The substantia nigra undergoes irrever-
sible degeneration in rodents subjected to status epilepticus (Turski
et al. 1986). Aminobutyrate (GABA), substance P and dynorphin are
tentatively suggested to subserve neurotransmitter role in the stria-
tonigral pathway (Fallon and Loughlin 1985). An excitatory amino acid,
L-glutamate and/or L-aspartate, are the most likely transmitter candi-
dates of corticonigral pathway (Fallon and Loughlin 1985). Manipula-
ting GABAergic functions in the substantia nigra (SN) modulates the
threshold for limbic seizures (Turski et al. 1986). Blockade of exci-
tatory amino acid- or substance P-mediated excitation in the SN raises
the threshold for seizures (Gale 1985). It remains uncertain whether
opiates in the SN modify the threshold for limbic seizures. Morphine
(MF) potentiates the convulsant action of systemically administered
kainic acid and pilocarpine and facilitates the rate of development of
amygdala kindling (Fuller and Olney 1979; Turski et al. 1985; Stone et
al. 1982). The morphological substrate of this action is largely un-
known, although preliminary observations indicate that the concentrat-
ion of opioid peptides changes in the SN in the course of amygdala kin-
dling (Iadarola et al. 1986). The SN is essential for the motor regu-
latory function of opiates. There is electromyographic evidence that
MF elicits increase in the muscle tone when microinjected into the SN
pars reticulata in rats (Turski et al. 1983). Application of opiate
receptor antagonist naloxone into the SN blocks the muscle rigidity
produced by systemic morphine (Turski et al. 1982). These experiments
furnish corroborative evidence for the role of nigral opiates in the
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control of spinal motor functions. The purpose of this study is to in-
vestigate the function of opiates in the SN in the motor expression of
pilocarpine-induced seizures. Seizures produced by pilocarpine in rats
provide a useful animal model of temporal lobe epilepsy which permits
studying mechanisms of initiation of and pathways operative in the pro-
pagation of convulsive activity in the brain (Turski et al. 1986).
MATERIALS AND METHODS
Male Wistar rats, 230-250 g in weight, were subject to stereotaxic sur-
gery for the implantation of stainless-steel guide cannulae directed to-
wards the SN (AP 1.61; L ± 1.9; V -2.6)(Turski et al. 1986). After
a 5-day recovery period microinjections into the SN were performed bila-
terally in unanesthetised rats. The drugs were delivered in a volume
of 0.5 µ1 (0.1 µl/min). Morphine hydrochloride (MF)(Polfa) was admini-
stered into the SN in doses of 1, 2, 5 and 10 nmol, while naloxone hyd-
rochloride (NAL)(Endo) was microinjected into the SN in the dose of 10
nmol, 15 min prior to i.p. injection of pilocarpine hydrochloride (Sig-
ma), 100 mg/kg. Methylscopolamine nitrate (Sigma), 1 mg/kg, was admini-
stered S.C. 30 min prior to the injection of pilocarpine. MF, NAL, pi-
locarpine and methylscopolamine were dissolved in saline. In all expe-
riments the animals were used once only. For depth recordings, bipolar
twisted electrodes were positioned in the dorsal hippocampus. Surface
recordings were led from screws positioned bilaterally over the occipi-
tal cortex. The brains were processed for morphological examination by
light microscopy 1-3 and 5-15 days after the administration of pilocarp-
ine. The methods for histological processing of the tissue were similar
to those described elsewhere (Turski et al. 1986).
RESULTS
Microinjection of MF into the SN pars reticulata, bilaterally, incre-
ased the severity of behavioral and EEG alterations produced by pilo-
carpine, 100 mg/kg, in a dose-dependent manner. None of four rats in-
jected with MF, 1 nmol, presented motor limbic seizures or status epi-
lepticus after pilocarpine, 100 mg/kg. Two of seven rats injected
with 2 nmol of MF developed motor limbic seizures, while microinject-
ion of 5 nmol resulted in seizures and status epilepticus in six out
of eight rats. Seven out of eight animals receiving MF, 10 nmol, dis-
FIGURE 1. Schematic reconstruction of the injection sites
of morphine (MF) in the substantia nigra of the rat. MF, 10
nmol was microinjected bilaterally into the substantia nigra
15 min prior to the i.p. administration of pilocarpine, 100
mg/kg. Dark squares represent sites from which microinject-
ions of MF convert non-convulsant dose of pilocarpine, 100 mg/
kg, into a convulsant one. Open squares represent sites from
which microinjections of MF do not affect the action of pilo-
carpine, 100 mg/kg.
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FIGURE 2. Electrographic recordings demonstrating the ef-
fect of morphine hydrochloride (MF) on the convulsant action
of pilocarpine (PILO) in rats. MF, 10 nmol, was microinjec-
ted bilaterally into the SN pars reticulata 15 min prior to
systemic administration of PILO, 100 mg/kg. (a) Pre-drug
control recordings. (b-d) Unchanged records 7-15 min after
microinjection of MF into the SN. (e-o) Electrographic recor-
dings to illustrate the alterations registered during 3 min -
18 h after the administration of PILO in rats given MF into
the SN. HPC, hippocampus; CX, cortex.
played severe status epilepticus (Fig. 1). The ED50 (effective
dose) for MF, as a factor triggering seizures in rats treated with pi-
locarpine, 100 mg/kg (n=27), was 3.8 nmol (2.5-5.8). The proconvuls-
ant effect of MF, 10 nmol, was blocked by NAL, 10 nmol, when co-injec-
ted into the SN (n=4) prior to pilocarpine, 100 mg/kg. The range of
EEG changes produced by pilocarpine, 100 mg/kg, in rats pretreated
with microinjection of saline into the SN is described elsewhere (Tur-
ski et al. 1986). The nature of EEG changes induced by pilocarpine,
100 mg/kg, in MF, 10 nmol, pretreated rats is best illustrated in Fig.
2. The electrographic activity produced by pilocarpine, 100 mg/kg, in
rats pretreated intranigrally with MF, 10 nmol, resembles the build-up
and EEG components of seizures produced by pilocarpine, 380 mg/kg (Tur-
ski et al. 1986). The pattern and topography of the damage to the fore-
brain produced by pilocarpine, 100 mg/kg, in rats pretreated with MF,
10 nmol, in the SN resemble those found in the brains of animals treat-
ed with pilocarpine, 380 mg/kg (Turski et al. 1986). Extensive morpho-
logical alterations were found throughout the hippocampus (subfields CA
1 and CA 4), thalamus (mediadorsal lateral, reuniens, rhomboideus, pa-
ratenial and paraventricular nuclei), olfactory cortex, amygdala, neo-
cortex and substantia nigra pars reticulata.
DISCUSSION
A deep controversy surrounds the function of endogenous opioids in the
pathogenesis of seizure disorders. The present report on proconvul-
sant action of MF in the SN pars reticulata in pilocarpine-model of
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limbic seizures in rats provides further proof for differential ac-
tions of opiates in the complex neuronal networks regulating the sei-
zure threshold of the forebrain. Evidence is presented that the ac-
tion of MF in the SN is opiate specific since naloxone reverses anti-
convulsant action of the drug. This finding is in apparent contrast
however with anticonvulsant action of intranigral morphine against max-
imal electroshock (MES)-induced seizures in rats. Garant and Gale
(1985) showed that very high doses of MF sulphate when injected into
the SN protect rats from tonic hindlimb extension in the MES-test.
This action of MF was blocked by systemic naloxone. Surprisingly, an-
ticonvulsant action of MF in the SN in the MES fits well protective
effect of the opiate against MES when administered systemically (Czu-
czwar and Frey 1986). Similarly, proconvulsant effect of intranigral
MF in pilocarpine-induced seizures reflects perfectly the proconvulsant
action of systemic MF in this model of convulsions (Turski et al. 1985).
Several mechanisms have been proposed as explanation of the pro- and
anticonvulsant action of MF in different experimental situations (Frenk
1983). It seems likely that SN may be proposed as a site at which opia-
tes are operative in the propagation and generation of seizures. The
apparent disparity between proconvulsant action of MF in the SN in an
animal model of limbic seizures and potent anticonvulsant action of the
drug in MES-induced convulsions probably reflects basic differences be-
tween pathways and neurotransmitters determining the spread of seizures
in these two models of epileptogenesis. Alternatively, selective inter-
actions with precise neuronal networks differentially involved in regu-
lation of the seizure threshold may well provide a basis for different-
ial response to intranigral MF in various epilepsy models. The emerg-
ing picture of the function of opiates in the SN in the modulating of
the seizure threshold is further complicated by multiplicity of opiate
receptors in this brain region. Further studies are therefore urgently
required to dissect out the contribution these receptors make to the
epileptogenesis.
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ABSTRACT
Amplitude changes of event-related sensory potentials (SEP's) present
objective measurements for the evaluation of pain perception in
man.
Alfentanil, an opioid with dominant binding to the mu-receptor
was given in graded doses (5-, 10- µg/kg) to volunteers. Nalbuphine,
an opioid with reported kappa-agonist activity, was given in graded
doses (100-, 500-, 1000- µg/kg) to another group i.v. Both groups
were also exposed  to progressively  increased electrical stimulations
(mA) in order to determine tolerance threshold before and after
drug administration. In the alfentanil group (n=5) there was a
dose- related decrease of the amplitude of the early N20-peak.
The late N100-peak was not, however, affected. This correlated
closely  (r=0.87) with a naloxone-reversible increase of tolerance
to electrical current. In the nalbuphine group (n=15), there was
a dose-related, naloxone non-reversible reduction of amplitude
of the late N1OO-peak which showed a good correlation (r=0.9) with
an increase in current threshold. As the early evoked potentials
are primarily generated in the pontine-thalamic region, it is sug-
gested that the mode of action of alfentanil resembles that of
a blockade of sensory impulses. The latter takes place before impul-
ses are transmitted to more rostrally located CNS structures which
are responsible for pain identification. The late evoked potential
affected by nalbuphine indicates an activity on thalamo-cortical
projection sites which are involved in subjects’ cognitive activi-
ties. Kappa-ligands, therefore, seem to exert a different mode
of action than mu-opioids. which results in a modulation of the
negative emotional response associated with pain, rather than an
attenuation of pain impulses.
INTRODUCTION
Monitoring of somatosenory-evoked potentials (SEP's) has gained
accep- tance as a suitable tool for the objective measurement of
efficacy of analgesics in man (Buchsbaum et al.1981; Chapman et
al.1982). As central analgesics differ in regard to their interac-
tion with opioid receptor sites, the study was undertaken in order
to evaluate the possible mode of action of alfentanil, a predominant
mu-opioid,
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and that of nalbuphine, an agonist-antagonist which mediates analge-
sia through kappa-receptor interaction (Schmidt et al.1985).
MATERIALS AND METHODS
After institutional approval and informed consent, twenty adult
male volunteers, aged 38-45 years, were studied. Unilateral right
meadian nerve SEP's were obtained from Ag/AgCl surface electrodes
fixed with collodion to the contralateral sensory cortex site (FpZ-
C3', ground right arm strap). Stimulation was of square wave nature
with a duration of 0.2 ms, at a rate of 5/s, a stimuli repetition
of 1024, and a current twice above motor threshold (supramaximal).
At a sampling rate of 256 KHz, and a filter setting between 5-800
Hz, potentials were averaged over a period of 150 ms (Neurotrec,
Interspec Medical, Wisconsin, USA). The cortical wave forms were
assayed in regard of early (less than 50 ms) and late (more than
70 ms) major deflection changes in terms of base to peak amplitude
(µV), compared to control, and identified as either N(=negative)
or P(=positive) polarity. Alfentanil was administered as a slow
bolus of 5 µg/kg, followed by 10 µg/kg 20 min later. 5 min there-
after, naloxone was given (5 µg/kg) i.v. SEP's were derived at
peak drug activity 1 min after injection. Nalbuphine was given
in graded doses (100-, 500-, 1000- µg/kg) every 15 min. Prior to
the next dose, SEP's were derived. After the last injection, naloxone
(5 µg/kg) was given. In addition, subjective pain was evaluated
by determination of tolerance threshold to progressively increased
stimulations from an electrical current (mA), applied to the median
nerve before and after each dose.
RESULTS AND DISCUSSION
Compared to control, alfentanil induced a dose-related decrease
in the amplitude of the early N20-, however, not of the late N100-
wave. This effect correlated closely (r=0.87) with a concomitant
increase in tolerance to electrical current threshold (table 1). The
opioid antagonist naloxone reversed the effects of early amplitude
suppression and the concomitant increase of tolerance to current
threshold.
TABLE 1.
The effect of increasing doses of alfentanil on early
and late SEP changes and the corresponding increase
of tolerance to electrical stimulation (mean +/-SD).
dose µg/kg
(mA)
control
5
10
naloxone
N 20(µV) N 100(µV) tolerance
1.5 +/-0.6 1.9 +/-0.9 13.2
1.2 +/-0.6 1.9 +/-1.4 18.5
0.6 +/-0.5 1.9 +/-1.4 24.8
0.9 +/-0.8 2.4 +/-2.2 11.9
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Nalbuphine induced a dose-related suppression of the amplitude
of the late N100-peak which showed a good correlation (r=0.90)
to an increase of threshold to painful stimuli. This effect could
not be reversed by naloxone (table 2).
TABLE 2.
The effect of increasing doses of nalbuphine on early
and late amplitude changes of median nerve SEP's and the
corresponding increase of tolerance to electrical current
(mean +/-SD).
dose(µg/kg) N 20(µV) N 100(µV) tolerance
control 1.5 +/-1.8 1.4 +/-1.1 13.8
100 1.6 +/-1.4 1.4 +/-0.9 18.2
500 1.3 +/-1.1 1.2 +/-0.8 21.7
1000 1.7 +/-2.3 1.1 +/-0.6 23.5
naloxone 1.3 +/-1.1 1.0 +/-0.8 23.5
The peaks of the evoked potentials are the result of stimuli, which,
along their way through the CNS, generate an excitatory response
in different anatomical structures (Buchsbaum et al.1981). Thus,
a possible funtional deficit as induced by an analgesic is reflected
in the generated SEP. By means of identifying the peaks which pre-
sent drug-induced changes, the possible site(s) of action may be
localized (fig.1).
FIG.1
Representative example of increasing doses of nalbuphine
on late evoked potentials. Note, there is a dose-related
depression of Peak 4 (N100-peak).
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In addition, by the use of an antagonist, an identification of
the type of receptor mediating the observed neurophysiological
changes is possible.
Early evoked potentials appearing less than 50 ms post stimuli
are generated in the pontine-thalamic region (Allison et al.1980).
This suggests that any change in the early peak (N20) is initiated
in these structures.Since the mu-specific opioid alentanil depres-
ses early evoked potentials in a dose-related fashion, the main
mechanism seems to be that of a blockade of sensory impulses in
subcortical structures. As a result, less activity will reach the
more rostrally located CNS structures which are responsible for
the identification of incoming impulses. The net effect is that
of a loss of pain sensations. One possible subcortical structure
involved in the identification of pain is the pallidum, a part
of the limbic system and the alleged psychomotoric center for pain
sensations and associated conflict feelings (Hassler 1970). As
a result of mu-opioid activity, limbic structures are deprived
from incoming impulses and so the pain is not felt as an aggreva-
tion. Mu-receptor sites seem to play an important part in mediating
this effect.
The suppression of amplitude of the late evoked potential (N100)
by nalbuphine, which was not naloxone-reversible, suggests a recep-
tor site which is not of mu, but rather of kappa nature (Schmidt
et al.1985). Late-evoked potentials are generated in more rostrally
located thalamo-cortical projection sites, where the subjects'
cognitive capabilities are situated (Chapman et al.1982). The
agonist-antagonist, therefore, seems to exert its analgesic activity
mainly through a modulation of impulses coming from the extralemnis-
cal sensory pathway. These neurophysiological findings are in line
with displacement and autoradiographic studies demonstrating a
predominance of kappa-binding sites in the deep layers of the corti-
cal projection sites (Maurer et al.1963; Goodman and Snyder 1984).
Nalbuphine, contrary to the mu-opoid alfentanil, although inducing
a centrally mediated effect, is functionally different than the
pure agonist. This difference is reflected mainly in the supression
of the late and not the early SEP, an effect which is not reversible
by naloxone. Thus, an attenuation of the endless discomfort
ted with pain is induced. A blockade of pain impulses as
with alfentanil is not present.
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ABSTRACT
The effects of transcutaneous electrical nerve stimulation on plasma
and cerebrospinal fluid (CSF) levels of B-Endorphin (B-EP) were
studied in 6 groups of pain-free patients. Different modes of TENS
were applied for 20 minutes. Regardless of mode and/or frequency of
the stimulation plasma and/or CSF B-EP levels were significantly
increased. Plasma and CSF responses were not correlated suggesting
that TENS activates different opiatergic pathways at central and
peripheral level.
INTRODUCTION
The efficacy of antalgic stimulations are known from thousands.
However, one of their mechanism of action has been elucidated only
after the discovery of the endogenous opioid systems in our species.
Chinese Acupuncture (Mayer et al. 1977; Facchinetti et al. 1981).
electrical acupuncture (Clement-Jones et al. 1980; Nappi et al.
1982), transcutaneous electrical nerve stimulation (TENS) (Facchinet-
ti et al. 1984) all are believed to induce analgesia through an
activation of peptides related to Proopiomelanocortin (POMC) such as
B-endorphin (B-EP). Substantial differences seems to exist between
the various kind of stimulation.
A concomitant release of B-EP and ACTH in peripheral plasma is detec-
table after electroacupunture (Abbate et al. 1980; Nappi et al.1982)
and stress situations (Guillemin et al.1977), while only B-EP is
increased upon traditional Chinese acupuncture (Facchinetti et
al.1981). As far as TENS is concerned, both opioid and non-opioid
mechanisms have been hypothesized depending on frequency of stimula-
tion (Sjolund and Eriksson 1979; Cheng and Pomeranz 1979). Anyway,
either low frequency (LoF) TENS or high frequency (HiF) TENS are
accompanied by a significant increase of pain threshold (Facchinetti
et al.1984). In this study we compared the effect of TENS application
on the changes of plasma and CSF B-EP in pain free patients.
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MATERIALS AND METHODS
Subjects
Six groups of eight patients entered the study.They were pain-free
patients (aged 46-83 ys ; 65.4 on average) undergoing transurethral
resection of benign prostatic hyperplasia,performed in local perid-
ural anesthesia. No premeditation was given and any drug treatment
was stopped for at least two weeks. TENS electrodes were applied
paravertebrally, at Th 12-L 2 level ( 2.29 cm of surface). The
different kinds of stimulation (lasting 20 min) were reported in the
table. TENS units were EPIX model kindly supplied by EMPI Inc (Min-
neapolis/MN). Ten ml heparinized blood and 5 ml CSF samples were
collected either before or at the end of treatment.Plasma and CSF
samples were added of Trasylol and then stored at -20 C until
assays.
M O D E F R E Q U E N C Y
(Hertz)
Multimod 80-100
Continous 2-10
Continous 80-100
Continous 2-10
Burst (2Hz) 85
Burst (2Hz) 2-4
I N T E N S I T Y W A V E CSF BEP
( m A ) (% M ± SE)
50-99 Changing 40.7 ± 18.8
10-30 square,250µsec 71.6 ± 16.2
50-99 52.8 ± 22.5
50-99 54.0 ± 27.7
50-99 109.2 ± 29.2
10-30 13.4 ± 10
Table 1: Details on the different TENS used and effects on
CSF B-EP as % on basal value.
Hormone Assays
Silicic acid extracts of plasma samples and 2 ml freeze-dried CSF
samples were reconstituted to 0.5 ml with 0.1 M Acetic Acid, 0.01%
BSA and applied on Sephadex G-75 column (1.5 x 45 cm) eluted through
the same solution. According to the retention coefficient of cold B-
EP (0.81), a 18 ml fraction was collected, freeze-dried, redissolved
in 0.12 M phosphate buffer, 0.1% BSA, pH 7.4 and submitted to Radioi-
mmunoassay (RIA) as previously described in detail (Facchinetti et
al.l984). Cortisol was measured in plasma samples through a commercia-
lly available RIA Kit (Radim-Italy).
RESULTS AND DISCUSSION
Both plasma and CSF B-EP levels were increased by TENS, with the
exception of burst LoF-LoI stimulation which should be considered
like a placebo. Regardless of mode of stimulation (Bursted, Continous,
Multimod) there is no difference in the B-EP changes in either CSF or
plasma (table 1). Similarly, regardless of the frequency of stimula-
tion, plasma and CSF B-EP levels were increased by at least 40% in
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respect to basal values (fig.1). Interestingly, similar data were
obtained in plasma by Hughes et al.(1984). Thus these data are oppo-
site to the hypothesis that LoF-HiI TENS would induce analgesia
through an opiate mediation, while HiF-LoI analgesia is supported by a
Figure 1: CSF and plasma B-EP changes after different kinds
of TENS (M±SE).
non-opiate mechanism (Sjolund and Eriksson 1979; Cheng and Pomeranz
1979).
It should be pointed out that few studies reported the direct meas-
urement of endogenous opioids and the hypotesis was build only on
indirect evidences, i.e. the antagonism of analgesia through nalo-
xone. However, as reviewed by Sawynok et al. (1979), naloxone rever-
sal is not a sufficient criterion since different subclasses of
opiate receptors exist and it is still unknown if just one of them
mediate analgesia (Panerai et al.1984). Moreover, many studies were
not performed in healthy controls, but in chronic pain patients (
Abraham et al.1981) where an impairment of endogenous opioid system
has been demonstrated (Genazzani et al.1984). Accordingly, we pre-
viously reported that patients affected by malignant diseases were
unable to release B-EP into CSF upon bursted HiF TENS (Facchinetti et
al. 1985). Like electroacupuncture (Nappi et al. 1982), the TENS
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induced plasma B-EP increase is accompained by a concomitant release
of cortisol levels in many cases, indicating the anterior pituitary
cleavage of POMC in this condition.If this is depending on corticot-
rophin-releasing hormone release from the hypothalamus or to a direct
effect on the pituitary remain to be clarified. However, despite TENS
increases both plasma and CSF B-EP levels, there is no correlation
between the two phenomena.Indeed, there are cases with a poor respo-
nse in CSF (less than 20%) and an important release in plasma(more
than 100%) and viceversa. In conclusion regardless of mode and/or
frequency of the stimulation plasma and/or CSF B-EP levels were
significantly increased. Plasma and CSF responses were not correlated
suggesting that TENS activates different opiatergic pathways at cen-
tral and peripheral level.
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SUMMARY
Total opioid binding and levels of the three major types of
opioid binding sites were measured in homogenates of various
limbic structures from post-mortem brains of Alzheimer's
Disease (AD) patients and age-matched control individuais.
AD brains showed an increase in kappa binding in ail six
areas of the limbic system examined, with the putamen and
caudate regions showing significant increases of 114% and
53%, respectively. In addition, the AD putamen showed a
significantly higher level of total binding (85% increase).
The amygdala of AD patients exhibited significantly lower
levels of mu and delta binding (41% and 55% decrease, respec-
tively).
INTRODUCTION
Deterioration of cognitive function in AD has been imputed in
part to neurochemical deficiencies and pathological changes
in limbic regions of the brain, an area involved in the
complex processes of memory storage and recali. We have
previously reported (Hiller et al. 1973) that in the human
brain, most areas containing high leveis of opioid receptors
lie within or are closely associated with the limblc system.
The possible involvement of the endogenous opioid system in
memory storage and physiological amnesia has been indicated
in several studies. The similarity between the anatomical
distribution of opioid receptors and pathoiogical markers of
AD and the putative role of the opioid system in cognitive
functions prompted us to undertake a study comparing opioid
receptor populations in various limbic structures obtained at
autopsy from AD patients and age matched individuais unaffec-
ted by this disease.
MATERIALS AND METHODS
Brain tissue samples, obtained at autopsy less than 24 hours
after death, from control individuals and AD patients were
stored at -70°C until processed into crude membrane prepara-
tions (Lin and Simon 1978). The regions dissected for this
study, using standard anatomical landmarks, were : caudate,
frontal cortex, amygdala, temporal cortex, putamen and hippo-
campus. Brain samples were examined for the presence of
pathology by Drs. D.J. Selkoe (Harvard Medical School. Bos-
ton, MA) J. Pearson (New York University Medical Center, New
York, N.Y.) and J. Uirich (Basel University, Basel, Switzer-
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land), from whom these post mortem brain samples were ob-
tained.
Binding assays were carried out essentially as previously
described (Hiller et al. 1973) at 25° for one hour in the
presence and absence of a 1000-fold excess of naloxone. Mu
site binding was measured with 3H-D-Ala2 MePhe4-Gly-ol5-
enkephalin (3H-DAGO, 2 nM, 49 Ci/mmol, Amersham, Des Plaines,
IL). To assess delta site binding, 3H-D-Ala2-D-Leu5 enkepha-
lin (3H-DADLE, 2 nM, 43 Ci/mmol, New England Nuclear, Boston,
MA) was used. 3H-bremazocine (2 nM 32 Ci/nmol, New England
Nuclear, Boston, MA) possessing almost equal affinity for mu,
delta and kappa binding sites, was used to assess total
binding levels. Selective binding to kappa sites was deter-
mined using 2 nM 3H-bremazoclne in the presence of 100 nM
each of unlabeled DAGO (Reckitt and Coleman, Hull, England)
and DADLE (Peninsula Lab., Inc., San Carlos, CA). AnalySiS Of
data was carried out using the Mann-Whitney U test.
RESULTS AND DISCUSSION
Binding studies were carried out on samples from twelve
autopsied brains, seven from AD patients (ages 58-68 years)
and five from control individuals (ages 54-60 years). The
presence of the characteristic neuropathological changes,
consisting of neurofibrillary tangles and neurotic plaques
in AD samples were found as well as the absence of anomalies
in control samples. In those cases where the number of indi-
vidual determinations of binding site levels differs from the
number Of autopsied cases. the amount of material recerved
was insufficient to carry out the assay. Results from equili-
brium binding studies indicated that, in some regions of the
brain of AD patients, statzistically significant differences
from control samples were observable. A summary of results
from AD and control samples is presented in tabie 1.
Total opioid receptor binding, as determined by the binding
of 3H-bremazocine, was increased in the AD putamen over
control samples by 85% (p<0.02). Assessment of mu opioid
binding sites with 3-DAGO demonstrated a 41% decrease in AD
amygdaia (p<0.06). Delta opioid binding, as determined by 3H-
DADLE binding was decreased in the AD amygdaia by 55%
(P<0.03). In addition, delta opioid binding was reduced in
AD temporal cortex by 41%. This change from control level,
however, was not significant (p<0.09). Kappa opioid binding
was assessed by the binding of 3H-bremazocine in the presence
of saturating concentrations of DAGO and DADLE. In all six
areas of the AD limbic system kappa binding was increased
(12% to 114%) over levels seen in control samples. Of these
six areas the caudate and the putamen showed statistically
significant increases of 53% (p<0.03) and 114%.
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TABLE 1
Opioid receptor binding in limbic areas of control (C)
and Alzheimer's Disease (AD) brains
fMoles/as protein
3H-DAGO 3H-DADLE 3H-BREM
BLOCKED
Caudate(C)
±S.E.
(N)
Caudate(AD)
±S.E.
(N)
P
15.45
1.17
(4)
14.40
1.95
(4)
N.S.
20.02
1.66
(5)
25.29
6.00
(7)
N.S.
Frontal Cortex(C) 17.50 24.66
±S.E. 2.10 3.74
(N) (5) (5)
Frontal Cortex(AD) 24.93 27.16
±S.E. 5.61 4.84
(N) (7) (7)
P N.S. N.S.
Amygdala(C) 25.74
±S.E. 3.45
(N) (5)
Amygdala(AD) 15.14
±S.E. 4.77
(N) (7)
P <0.06
30.48
6.90
(5)
13.69
4.31
(7)
<0.03
Temporal Cortex(C) 26.40
±S.E. 5.51
(N) (4)
Temporal Cortex(AD)20.41
±S.E. 4.21
(N) (7)
P N.S.
37.90
8.18
(4)
22.33
3.60
(7)
<0.09
P u t a m e n 9.63
±S.E. 3.37
(N) (3)
Putamen(AD) 14.77
±S.E. 2.63
(N) (7)
P N.S.
13.60
2.69
(3)
16.04
3.04
(7)
N.S.
Hippocampus(C) 4.20
±S.E. 0.02
(N) (3)
Hippocampus(AD) 4.18
±S.E. 1.04
(N) (6)
P N.S.
6.83
0.54
(3)
8.72
2.31
(6)
N.S.
49.36
6.70
(5)
75.59
8.71
(7)
<0.03
60.94
11.08
(5)
94.64
15.08
(7)
N.S.
117.50
27.83
(5)
131.53
23.60
(7)
N.S.
92.47
26.74
(3)
113.45
27.29
(4)
N.S.
27.97
5.49
(3)
59.84
7.12
(7)
<0.05
39.53
2.97
(3)
64.18
11.52
(4)
N.S.
3H-BREM
124.40
7.84
(5)
155.20
17.28
(7)
N.S.
152.80
17.59
(5)
208.37
21.17
(7)
N.S.
239.20
18.29
(5)
191.41
31.58
(7)
N.S.
188.65
36.02
(4)
171.44
23.41
(4)
N.S.
66.23
8.16
(3)
122.66
8.84
(7)
<0.02
77.83
7.26
(3)
93.52
26.89
(6)
N.S.
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(p<0.02), respectrveiy. if total kappa binding in all control
and AD brain areas is compared, an increase in total kappa
binding of 35% is noted in the AD group with a highly signi-
ficant p value of <0.01.
The simplest explanation for our observation of lowered le-
vels of mu and delta binding is that the manifestation of
AD involves cellular patterns of pathology that affect those
cells bearing mu and delta type opioid receptors. However,
other possible explanations do exist. One that seems quite
plausible is "homospecific up- or down-reguiation" in which
certain ligands can modulate the number or affinity of their
own receptors. For example, chronic exposure of HG108-15
cells to opiate agonists leads to a down-regulation of opioid
binding (Chang et al. 1982). In contrast, chronic exposure
of rats to opiate antagonists caused a 140% increase in 3H-
etorphine binding in limbic regions (Zukin et al. 1982).
This last phenomenon may be explained by a mechanism which
up-regulates the receptors by chronic displacement of endoge-
nous opioid ligands. It is possible that our observed in-
crease in kappa receptor binding may be due to an up-regula-
tion caused by a decrease of dynorphin content in the AD
limbic system. Support for this theory may be derived from
the report (Pongdhana et al. 1985) showing that intraperito-
neal injection of ketamine increased the dynorphin content of
rat brain cortex while decreasing it in the septal area.
Simultaneously, the binding affinity of the kappa ligand,
ethylketocyciarocine, was decreased in the cortex but in-
creased in the septal area. Dynorphin content of the human
caudate and putamen is among the highest in human brain
(Gramsh et al. 1982).
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ABSTRACT
The role of multiple opioid receptor types in
mediating the motivational properties of opioid
agonists and antagonists was investigated by means
of a place-preference conditioning procedure.
Mu-agonists produced positive reinforcing effects
in drug-naive animals whereas kappa agonists and
the opioid antagonist, naloxone, were aversive.
Chronic infusion of naloxone during conditioning,
at a dose sufficient to block mu- but not
kappa-receptors, antagonized the effects of both
morphine and naloxone. This treatment did not alter
the aversion produced by the kappa agonist, U69593.
These data demonstrate that opioid reinforcement
results from an activation of mu-receptors whereas
aversive effects are produced by either an anta-
gonist action at this receptor or an activation of
kappa receptors. Such results indicate that mu and
kappa opioid systems differentially modulate
motivational processes.
INTRODUCTION
There is now substantial evidence to indicate the
existence of multiple opioid receptor types within
the mammalian CNS (Lord et al. 1977; Martin et al.
1976). However, despite extensive study, the role
of these various receptor types in the regulation
of motivational processes remains ill-defined. In
the present study, a place preference conditioning
procedure was utilized to characterize the
motivational properties of opioids and examine the
role of mu (µ)- and kappa ( )-receptors in mediat-
ing their reinforcing and/or aversive effects. Con-
ditioning produced by the µ-agonist, morphine; the
K-agonist, U69593; and the opioid antagonist,
naloxone (NLX) were evaluated in drug-naive animals
and those chronically treated with NLX at a dose
which selectively blocks mu-receptors. Evidence is
presented to indicate that µ- and - opioid systems
exert opposite effects upon motivational processes.
MATERIAL AND METHODS
Subjects were male Sprague-Dawley rats weighing
120-160g. One day prior to the commencement of
563
experiments, rats were implanted, under light ether
anethesia, with osmotic minipumps (Alzet Model
2001) containing either the opioid antagonist, NLX,
at a dose (0.55 mg/kg/hr) sufficient to block µ-
but not K-receptors (Millan et al. submitted) or
distilled water. Using a place-preference condi-
tioning procedure (Mucha et al. 1982), separate
groups of implanted and drug-naive (control) rats
were administered (s.c.) various doses of morphine,
U69593, or NLX. Each rat received alternate day
injections of drug or vehicle for 6 days. Following
drug injections, rats were immediately confined to
a visually and texturally distinct environment i.e.
black box with smooth black floor for either 60 min
(morphine and U69593) or 30 min (NLX). Following
injections of vehicle, rats were confined to a
different environment, i.e. white box with rough
white floor. The order of injections and drug-
paired environments were counterbalanced within
groups. On day 7, preference for a particular place
was determined by allowing uninjected rats free
access to both environments and measuring the time
spent in each. Analyses of variance and the
Student- Newman Keuls test were used to determine
the statistical significance of results (Zarr
1974).
RESULTS AND DISCUSSION
Figure la demonstrates that, in control rats,
morphine was positively reinforcing as indicated by
a significant preference for the drug-paired place.
However, in rats chronically treated with NLX, at a
dose which selectively blocks B-receptors, the
reinforcinq effect of morphine (3.0 mg/kg) was
abolished. These results suggest that the
reinforcing properties of opioid agonists results
specifically from an activation of the µ-opioid
receptor.
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FIGURE 1: Motivational properties of µ- and
receptor agonists in control and chronic NLX-
treated rats. Each point represents the condi-
tioning score (mean ± S.E.M.) of 8-10 rats.
**p < 0.001: significant difference between
control and NLX-treated rats.
In contrast to morphine, U69593 produced dose-re-
lated aversions for the drug-paired place (figure
lb). If the aversion resulted from an agonist ac-
tion at k-receptors, selective p-receptor blockade
should be ineffective in altering its motivational
properties. As shown in figure lb, 0.16 mg/kg
U69593 was aversive in both control and NLX-treated
rats. Taken together, these data indicate that
µ-and opioid systems have opposing motivational
effects: activation of the former is reinforcing
while activation of the latter is aversive.
Previous studies using the place conditioning pro-
cedure (Bechera and Van der Kooy 1985, Mucha et al.
1982) have demonstrated that NLX is aversive in
drug-naive animals. As the reinforcing effect of
morphine is mediated by an activation of µ- recep-
tors, we hypothesized that the aversive property of
NLX results specifically from an antagonism of this
receptor. Therefore, chronic p-receptor blockade
during training should mask the b-antagonist acti-
vity of acute NLX, resulting in an attenuation of
its aversive effects. The results shown in figure 2
confirm this prediction. Administration of NLX (5.0
mg/kg) was highly aversive in control animals.
Mu-receptor blockade abolished this effect. These
data indicate the aversive properties of NLX result
from antagonist effects at the µ-opioid receptor.
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FIGURE 2: Effect of b-receptor blockade on the
aversive properties of NLX. Each point
represents the mean ± S.E.M. of 10 rats (**P <
0.001).
In conclusion, these studies demonstrate that opio-
ids with agonist actions at the µ-receptor function
as positive reinforcers whereas agonists are
aversive. Such results suggest the existence of
opposing opioid systems which regulate motivation.
Moreover, these data reveal that contrasting mecha-
nisms underlie the aversive effects of NLX as com-
pared to agonists.
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ABSTRACT
Preference conditioning models were applied to the
study of the motivational properties of opiate with-
drawal. Conditioned place and taste aversions were
produced by a single injection of an opiate antagonist
in rats implanted with a morphine but not a placebo
pellet. The hypothesis that withdrawal-produced jump-
ing reflects the aversive properties of withdrawal was
not confirmed. The use of central and peripheral
administration of antagonists suggest that the aversive
effects reflect antagonist activity in the brain.
INTRODUCTION
Although threats of drug intake reduction or of with-
drawal are powerful stimuli for activating drug seeking
behaviors in humans, the motivational properties of
withdrawal have received little attention in the
experimental literature on opiate physical dependence.
The best examined models are contractures in the
isolated opiate-treated guinea pig ileum (Schulz and
Herz 1976), and "wet dog shakes", body weight loss and
jumping or escape attempts in opiate-treated rodents
(Blasig et al. 1973, Wei et al. 1973). However, only
in the case of jumping has there been any attempt to
relate a withdrawal sign to the discomfort described by
withdrawing addicts; withdrawal-produced jumping is
said to be similar to behavior elicited by electric
shock and can be modified by variables believed to be
motivational (Siegel et al. 1975).
Previous work suggested that taste (Pilcher and
Stolerman 1976) and place preference conditioning pro-
cedures (Mucha et al. 1982) could be used to directly
assess motivational properties of opiate withdrawal,
but no attempt has been made to systematically extend
these findings. Accordingly, we describe here progress
on studies designed 1) to establish efficient models of
withdrawal aversiveness in rodents, 2) to test the
hypothesis that withdrawal jumping reflects withdrawal
aversiveness and 3) to determine the general location
of the receptors involved in the aversions.
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MATERIALS AND METHODS
Male Sprague-Dawley rats obtained from St. Constant,
Quebec, were used. Conditions of housing, testing, and
general experimental design were outlined previously
(Mucha and Herz 1986, Mucha and Iversen 1984), except
that the composition of the flavors for the taste
conditioning here comprised a) 92.7 mM NaCl, and 9.36
mM MSG and b) 1.13 mM citric acid and 0.71 mM
saccharine. All subjects were implanted using halothane
with a morphine (containing 75 mg morphine base) or
placebo pellet. Where necessary, a cannula was
implanted stereotaxically in the lateral ventricle.
Drug administration was SC (approximately 1 ml/kg) or
ICV through the cannula (4 µl). Peripheral doses of
antagonists were expressed as free base.
Withdrawal aversiveness was assessed by measuring the
preference of the subject for a cue paired with a
single administration of an opiate antagonist as
opposed to a different cue paired with the
corresponding vehicle administration. With place
training, animals were injected first with antagonist
or vehicle and then placed for 1 h into one of the two
place-training boxes and 7-24 h later injected with
vehicle or antagonist and placed into the other box.
For the taste training, rats were given 3 mls of the
appropriate flavor to drink after water deprivation
overnight and then given the necessary injection.
Unless otherwise stated, training was carried out on
the 5th and 6th day after pellet implantation; testing
was always one day after training. Place testing
involved giving individual rats access for 15 min to a
rectangular box with the two sets of training boxes
(cues) separated by a neutral grid platform. Taste
testing involved one day ad lib access to the two
flavors. Other assessment of withdrawal signs was
carried out after the antagonist administration during
the place training sessions. For the first 0.5 h after
injection rats were observed for diarrhea, jumping,
writhing and head or body shakes.
The place conditioning score was the time on the side
of the test box where withdrawal was experienced
(administration of antagonist) minus time on the
control side. The taste score comprised the amount
consumed of antagonist-paired flavor minus the amount
consumed that paired with vehicle, expressed as a
percent of total intake. An effect was considered
significant with a p<.05.
RESULTS AND DISCUSSION
As assessed with taste conditioning using a low
training dose (0.015 mg/kg) in animals trained at
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different times after implantation with morphine
pellets, naloxone was most potent when the training was
4-8 days after pellet implantation. Mean serum
morphine levels measured (Kim and Kats 1984) in tail
vein blood of 6 rats run in parallel were 126.0 ± 15.2
ng/kg on the 4th and 70.9 ± 19.0 ng/ml on the 9th day
after implantation but fell sharply thereafter (Day 11:
18.0 ± 10.1 ng/ml). On Day 14 naloxone produced almost
no effects (X = +17.3 ± 24%, n = 8) in contrast to
significant conditioning on Day 7 (X = -55.3 ± 16,4%,
n = 11).
Dose response curves were measured during the above-
mentioned period of peak naloxone sensitivity (fig. 1)
and revealed maximal aversions with 0.05 mg/kg in
pellet animals; however, even 1.5 mg/kg failed to
produce significant aversions in placebo rats. As seen
in fig. 2, potent aversive effects in pellet animals
were not limited to the use of naloxone nor the SC
route; corresponding significant aversive effects were
not seen in placebo controls (not shown). Given the
different conditions and the dose ranges where the
drugs were effective, it was concluded that the potent
aversive effects of opiate antagonists in morphine
pellet-implanted animals are probably due to their
antagonistic action and therefore reflect the aversive
properties of opiate withdrawal.
FIGURE 1 Taste conditioning scores in rats (ns =
8-10) implanted for 5 days with a morphine or
placebo pellet.
In addition, the jumping response and the aversive
state produced by withdrawal were contrasted over
different conditions of antagonist administration.
With SC naltrexone, the aversion paralleled jumping,
but in rats trained with ICV quaternary-naltrexone it
did not (fig. 2). Accordingly, we could not support
the hypothesis that presence of aversive effects was
reflected in jumping. Also, none of the other signs of
withdrawal showed a good correlation with the place
aversions (not shown).
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FIGURE 2 Place conditioning scores and jumping
measured in the same animals after naltrexone
given SC (left) or quaternary naltrexone ICV
(right). Implantation: circles, pellet; squares,
placebo.
It should be noted that quaternary naltrexone does not
readily cross the blood brain barrier but produced
clear place aversions when given centrally (fig. 2).
Therefore, it is likely that the receptors responsible
for the withdrawal-related aversive effects are
somewhere in the brain.
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MORPHINE WITHDRAWAL IN GUINEA-PIG ILEUM IS CONFINED TO ONE
ELECTROPHYSIOLOGICALLY DEFINED CLASS OF MYENTERIC NEURONE.
Stephen M. Johnson, Marcello Costa and John B. Furness
Addiction Research Laboratory
Centre for Neuroscience and Depts. of Physiology
and Anatomy
Flinders University of South Australia
Bedford Park 5042 Australia
ABSTRACT
Intracellular microelectrodes were used to record changes in
myenteric neurones underlying morphine dependence in the guinea-pig
ileum. Of the two electrophysiologically defined classes of
neurones (S and AH), only a proportion of S-neurones were involved
in the naloxone-induced withdrawal responses. Withdrawal caused
direct depolarization and discharge of action potentials in S-
neurones and also resulted in synaptic activation of neurones of
this class. Both fast and slow synaptically mediated
depolarizations were evoked by naloxone. The experiments suggest
that morphine withdrawal is expressed in quite specific neuronal
circuits in the myenteric plexus.
INTRODUCTION
The analysis of opiate dependence in the guinea-pig myenteric
plexus has been based largely on studies of the nerve-mediated
contraction of the longitudinal muscle evoked in morphine-
pretreated tissues by naloxone. The naloxone-induced contraction
is due predominantly to activation of cholinergic motor neurones
since it is depressed by tetrodotoxin and atropine (Collier et al.
1981). The residual non-cholinergic component of the contraction
may be due in part to the release of substance P (Gintzler 1980;
Tsou et al. 1985). The present study aimed to analyse the changes
underlying morphine dependence more directly by using intracellular
microelectrodes to record from myenteric neurones.
MATERIALS AND METHODS
Guinea-pigs were pretreated either by injections three times daily
with increasing doses of morphine (10 - 100 mg/kg s.c.) for 3-5
days, or by subcutaneous implantation of a pellet containing a
mixture of morphine base (120 mg) and morphine hydrochloride (30
mg) for 7 days. Longitudinal smooth muscle-myenteric plexus (LSM-
MP) preparations from the treated animals were set up in
physiological saline solution (PSS) containing 1 µM morphine in
order to maintain continuous exposure to morphine in vitro (Schulz
and Herz 1976). These preparations responded to naloxone (1 µM)
with a powerful nerve-mediated contraction of the longitudinal
muscle, the characteristic index of morphine dependence in the
guinea-pig ileum (Schulz and Herz 1976; Collier et al. 1981).
Control preparations, from untreated guinea-pigs, were unaffected
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by naloxone.
Similar LSM-MP preparations were mounted in a tissue chamber for
intracellular recording from myenteric neurones. In addition to
morphine (1 µm), the PSS perfusing the preparations contained
hyoscine (1 µm) and nicardipine (3 µm) to prevent contractions of
the longitudinal muscle during intracellular recording from
myenteric neurones.
Intracellular recordings were made from both S and AH neurones
(Hirst et al. 1974). Neurones in which electrical stimulation of
fibre tracts evoked fast cholinergic excitatory postsynaptic
potentials (e.p.s.p.'s) were classified as S-neurones. AH neurones
received no fast synaptic input and were defined by the long
lasting (2 - 30 sec) after-hyperpolarization accompanying an
action potential evoked in the soma. After a stable impalement of
a neurone had been obtained, naloxone (1 m) was added to the
perfusate to displace morphine from its receptors so that
electrophysiological changes associated with withdrawal could be
recorded.
RESULTS AND DISCUSSION
1) S-neurones
Intracellular recordings were obtained from 53 S-neurones and 40
AH-neurones in LSM-MP preparations from 51 morphine-pretreated
guinea-pigs.
50% of S-neurones in morphine-dependent LSM-MP preparations showed
changes in their properties during naloxone-induced withdrawal.
Naloxone did not alter the electrophysiological properties of S-
neurones in control tissues. The most frequent withdrawal response
was a membrane depolarization (12.1 ± 1.2 mV; mean ± S.E.M.)
observed in 40% of neurones. The change in membrane potential,
which was sustained throughout the 5-10 minute perfusion with
naloxone, was associated with a slight but not statistically
significant increase in input resistance (120 ± 30 M cf. 101 ±
22 M ; means ± S.E.M.). Twenty per cent of S-neurones responded
with a depolarization which was accompanied by discharge of action
potentials (0.5 - 10 Hz).
In 12% of S-neurones, naloxone evoked fast depolarizations which
were similar in amplitude (5 - 20 mV) and time course (20 - 50
msec) to the fast cholinergic e.p.s.p. These fast depolarizations
dissapeared after synaptic transmission was blocked by raising the
concentration of Mg++ in the PSS from 1.7 mM to 10 or 20 mM, or by
lowering the concentration of Ca++ from 2.5 mM to 0.5 mM, or by a
combination of reduced Ca++ and raised Mg++. This observation
suggested that the withdrawal response was initiated by excitation
of a cholinergic interneurone synapsing with the impaled S-
neurone. The activation of interneurones during withdrawal was
further suggested by the observation that the naloxone-induced slow
depolarization was also reduced in some cells after synaptic
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transmission blockade. Naloxone-induced withdrawal may therefore
involve activation of not only the final motor neurones (leading to
contraction of the longitudinal muscle) but also of cholinergic
interneurones and interneurones producing slow
depolarizations in S-neurones (Johnson et al. 1980).
synaptic
In a small proportion (6%) of neurones naloxone evoked action
potentials which were not associated with any change in the
underlying membrane potential or with fast e.p.s.p.'s. The
discharge of action potentials persisted after synaptic
transmission blockade. These neurones therefore represent those in
which withdrawal responses are initiated.
FIGURE 1. Possible arrangement of myenteric S-
neurones involved in naloxone-induced withdrawal
responses. During withdrawal the impaled neurone
receives synaptic input from cholinergic interneurones
(Ach) and from interneurones which release trans-
mitter(s) producing slow depolarizations. Excitation of
final motor neurones, either directly or by synaptic
activation, leads to contraction of the muscle by
release of Ach and substance P (SP) (not necessarily
from the same motor neurone). The axon of the impaled
neurone has been interrupted in the diagram to denote
that it is not identified as a motor neurone by the
intracellular recording technique.
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2) AH-neurones
In contrast to its effects on S-neurones, naloxone did not alter
the membrane potential or evoke action potential discharge in AH-
neurones of morphine-dependent LSM-MP preparations. Furthermore,
naloxone did not alter the input resistance, soma action potential
configuration or the slow hyperpolarization following a soma spike.
The specificity of the withdrawal responses for S-neurones and
their  restriction to only a proportion of those neurones suggests
that morphine withdrawal may occur in quite specific circuits in
the myenteric plexus. Fig. 1 shows the possible arrangement of
neurones participating in the withdrawal responses. The further
characterization of these neurones will provide a better
understanding of the cellular basis of morphine dependence.
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ENKEPHALINASE INHIBITORS ATTENUATE NALOXONE-PRECIPITATED
WITHDRAWAL SYNDROME
M.R. Dzoljic
Department of Pharmacology, Faculty of Medicine,
Erasmus University Rotterdam, P.O.Box 1738,
3000 Rotterdam, The Netherlands
ABSTRACT
Enkephalinase inhibitors phosphoramidon, thiorphan or phelorphan
suppressed naloxone-precipitated withdrawal symptoms in acute and
chronic morphine dependent mice and rats. It is suggested that
decreased biotransformation of the endogenous opioid peptides might
compensate the relative shortage of exogenous opiates during
withdrawal in opiate dependent subjects and could be a new and
promising way to attenuate the severity of abstinential syndrome.
INTRODUCTION
Exogenous administration of opioid peptides
withdrawal in animals (Blasig and Herz
suppress the opiate
1976) and man (Wen and Ho
1982). Similarly, blockade of biodegradation of endogenous opioid
peptides by the unspecific peptidase inhibitors aprotonin and
bacitracin or by the relatively specific enkephalinase inhibitor
phosphoramidon, suppressed the severity of the opiate withdrawal syn-
drome in rats and nitrous oxide convulsant withdrawal in mice,
respectively (Pinsky et al. 1982, Dzoljic et al. 1984). These data
indicate that enhancing of endogenous opioid peptides, by decreasing
a biotransformation of these substances, might have an attenuating
effect on the narcotic withdrawal syndrome, similar to the exogenous-
ly administered opioid peptides or opiates.
In order to study the role of endogenous opioid peptides in morphine
addicted animals we examined the effect of relatively specific
enkephalinase inhibitors, phosphoramidon, thiorphan or phelorphan,
on the withdrawal syndrome in acute or chronic morphine dependent
in mice and rats.
METHODS AND MATERIALS
Rats. Male wistar rats (200-225 g) were used in experiments. A steel
cannula for intracerebroventricular (i.c.v.) administration of
artificial cerebrospinal fluid (CSF) or enkephalinase inhibitors
was implanted stereotaxically into the left lateral ventricle.
Chronic morphine dependence was induced by subcutaneously (s.c.)
implanted pellets (75 mg morphine), according to the method described
by Blasig et al. (1973).
Mice. Adult male mice of B10A strain were used. Administration of CSF
or enkephalinase inhibitors was carried out by means of a stainless
guide cannula stereotaxically implanted in the left lateral ventricle.
Acute morphine dependence was induced by a single s.c. injection of
morphine sulphate (32 mg/kg). In order to observe the withdrawal
syndrome, two hours later mice were injected intraperitoneally (i.p.)
with naloxone hydrochloride (16 mg/kg). In general, the experimental
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model of Kosersky et al. (1974) for acute withdrawal jumping in mice
was followed.
Chronic morphine dependence was induced by two daily s.c. injections
of morphine sulphate with a starting dose of 50 mg/kg and increasing
daily by 25 mg/kg to reach a final dose of 200 mg/kg on the fifth day.
On the 8th day a last morphine injection of 225 mg/kg was given,
followed by naloxone 16 mg/kg i.p. (Takemori and Sprague 1978).
Drugs. Phosphoramidon (Cambridge Research Biochemical, New York).
thiorphan (CRB, Cambridge) and phelorphan (donated by the Division
of Pharmaceutical Chemistry, University of Amsterdam) were dissolved
in CSF before i.c.v. administration. Naloxone hydrochloride (Endo
Lab.) and morphine sulphate (Chemiefarma NV, Maarsen) were dissolved
in saline.
Statistical analysis. The significance of the differences in the
different group means are evaluated by the Mann-Whitney U test.
Significance was accepted at P<0.05.
RESULTS
Phosphoramidon (50-200 µg i.c.v.) suppressed, in a dose-dependent
manner, the naloxone precipitated withdrawal jumping but potentiated
forelimb shakes in both acute and chronic dependent mice. Both
thiorphan and equimolar doses of phelorphan decreased the severity
of the naloxone-precipitated withdrawal syndrome in rats (table 1).
However, some symptoms remained unchanged or even potentiated
(table 1).
DISCUSSION
The essential observation in this study is that enkephalinase
inhibitors, phosphoramidon, thiorphan or phelorphan attenuate the
severity of morphine withdrawal syndrome in mice and rat. However,
some of the withdrawal symptoms were either not altered or even
potentiated. For example, phosphoramidon suppressed withdrawal
jumping in the mice, while forelimb shakes were potentiated. The
failure of phosphoramidon to inhibit the forelimb tremor is not clear.
The withdrawal syndrome is a complex behavioural pattern, mediated by
a balance of many transmitter systems in various brain regions.
Unequal distribution of i.c.v. administered phosphoramidon and other
enkephalinase inhibitors might be a reason that various opiate with-
drawal symptoms were unequally affected. Furthermore, a comparison of
the effects of equimolar concentrations of thiorphan and phelorphan
shows that phelorphan has a less prominent antiwithdrawal effect than
thiorphan. These differences might be due to the unequal penetration
into the various brain regions or to the unequal capacity to inhibit
the biodegradation of the enkephalins. It is of interest to note
that some sexual manifestation during naloxone-precipitated
withdrawal were potentiated by administration of thiorphan or
phelorphan (penile licking, erection, ejaculation). It supports the
idea that sexual response might be potentiated by any condition
activating the endogenous opioid system (Henry 1982), including the
enkephalinase inhibitors (this study). The decrease or abolition of
the abstinential diarrhea by i.c.v. administered enkephalinase
inhibitors is in accordance with suggestion that opioid peptides
might regulate the intestinal transit by a central mechanism
(Galligan and Burks 1982).
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Incidence of the withdrawal signs (counted signs)
CSF THIORPHAN PHELORPHAN
2 ul 40 ug/2 ul i.c.v. 62 ug/2 ul i.c.v.
WITHDRAWAL SIGNS (n=9) (n=9) (n=8)
teeth chattering 5.6 ± 2.4
wet dog shakes 10.5 ± 1.7
grooming 4.0 ± O.7
scratching 0.2 ± O.1
penile licking 5.5 ± O.4
writhing 2.3 ± 0.5
rearing 9.5 ± 2.1
digging 31. ± 5.3
head hiding 27.1 ± 5.7
chewing 69.1 ± 11.0
paw tremor 1.8 ± O.5
head shakes 1.7 ± O.3
stretching 13.2 ± 3.1
1.9 ± 0.6*
10.0 ± 1.7
3.2 ± 0.9
0.4 ± 0.2
8.7 ± 1.0*
6.8 ± 1.4
4.0 ± 0.9”
1.2 ± 0.8”
32.9 ± 8.0*
2.2 ± 0.8
3.0 ± 1.8
8.9 ± 2.4
6.7 ± 1.8
12.5 ± 1.5
5.3 ± 1.2
0.9 ± 0.5*
9.2 ± 1.5*
0.6 ± 0.3*
8.7 ± 2.0
11.1 ± 4.0*
5.6 ± 2.4
33.8 ± 10.0*
5.0 ± 0.5*
3.9 ± 1.1*
3.0 ± 1.0*
Presence of the withdrawal signs (checked signs)
erection
ejaculation
diarrhea
Straub tail
3/9 3/9 8/8*
9/9 2/9*
7/8*
*
8/9 3/9* *
Table 1. The effects (mean ± SEM) of equimolar dose of
the enkephalinase inhibitors thiorphan or phelorphan on
naloxone-precipitated (4 mg/kg, i.p.) withdrawal symptoms in
chronic morphine dependent rats. The control group received
artificial cerebrospinal fluid (CSF) instead of an
enkephalinase inhibitor. Observation period: 30 min after
naloxone administration. *Means significant difference
compared to control (P<0.05). Note that enkephalinase inhi-
bitors attenuated some of the withdrawal signs.
Concluding, the saturation of the opiate receptors by enkephalins,
following administration of enkephalinase inhibitors, alleviates the
several symptoms of morphine withdrawal syndrome in mice and rat.
Although not all withdrawal symptoms were alleviated by enkephalinase
inhibitors, it seems that the potentiation of the functional activity
of endogenous opioid peptides could be a promising tool in future for
treatment of opiate dependence.
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PRESYNAPTIC ALPHA2 ADRENORECEPTOR FUNCTION IN DEPENDENT RATS BEFORE
AND AFTER MORPHINE WITHDRAWAL
H.C. Moises, C.B. Smith, R.N. Spengler and P.J. Hollingsworth
Departments of Physiology and Pharmacology
University of Michigan, Ann Arbor, Michigan 48109
ABSTRACT
Changes in the number of alpha2 adrenoreceptors in the hippocampus,
as measured by the specific binding of 3H-clonidine, were compared
to changes in presynaptic alpha2 adrenoreceptor function in elec-
trically stimulated hippocampal slices. In dependent rats the spe-
cific binding of 3H-clonidine was reduced significantly. At 32 h
after withdrawal binding began to return toward normal values, and
at 72 h after withdrawal was significantly greater than that seen
in saline-treated rats. In hippocampal slice experiments sensitiv-
ity to clonidine was significantly decreased in morphine-dependent
animals and returned toward normal values after withdrawal. At 72
h after withdrawal, the sensitivity to clonidine of the presynaptic
alpha2 adrenoreceptor remained depressed although receptor density
as measured in the binding studies was increased. This study sug-
gests that the changes in the function of presynaptic alpha2
adrenoreceptors might be important in the development of dependence
upon morphine.
INTRODUCTION
Acute administration of morphine stimulates markedly the turnover
of catecholamines in the brains of rats (Garcia-Sevilla et al.
1978) and mice (Smith et al. 1972). Tolerance develops to this ef-
fect of morphine, and after withdrawal, norepinephrine (NE)
turnover is decreased in the brains of dependent mice (Rosenman and
Smith, 1972). Neuronal release of NE is regulated in part by the
presynaptic alpha2 adrenoreceptor. Several investigators have re-
ported that chronic treatment with morphine decreases the number of
alpha2 adrenoreceptors in specific areas of the rat brain as mea-
sured by the binding of 3H-clonidine, an agonist at alpha2
adrenoreceptors (Smith et al. 1983, Vincentini et al. 1983). The
purpose of the present study was to determine whether changes in
3H-clonidine binding to hippocampal membranes that occur after
chronic morphine treatment and during withdrawal result in corre-
sponding alterations in presynaptic alpha2 adrenoreceptor mediated
inhibition of stimulation-evoked NE release from hippocampal
slices.
METHODS
Male Sprague-Dawley rats (220-240 g) were injected i.p. every 8 h
with saline or with morphine sulfate as follows (day,
mg/kg/injection): 1-3, 10; 4-6, 20; 7-9, 40; 10-12, 70; and 13-14,
100. Hippocampi were isolated from 6 rats (220-240 g). Specific
binding of 3H-clonidine to hippocampal membranes was measured as
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described previously (Smith et al. 1983). The non-linear regres-
sion analysis program, LIGAND ( Menson and Rodbard 1980) was used
to develop the final values for KD and Bmax For the electrically
stimulated brain slice experiments two sections, 0.5 mm thick, were
made perpendicular to the longitudinal axis of each hippocampus.
The slices were incubated with 3H-NE, 300 nM, for 15 min, washed
twice with fresh Krebs buffer and transferred to superfusion cham-
bers. Each slice was superfused at a rate of 0.5 ml per minute for
a 30 min equilibration period prior to the onset of field stimula-
tion. Field stimulation consisted of trains of square-wave pulses
(100 mA, 2 msec duration) at 4 Hz for 2 min periods. There were
nine stimulation periods at 16 min intervals in each experiment.
Two of each set of four slices were stimulated but did not receive
any drug. For the other 2 slices drugs were introduced into the
superfusion buffer immediately after the second (the baseline re-
sponse period) and each subsequent period of stimulation. Drug
concentrations were increased by approximately 3-fold increments in
order to construct complete concentration-effect curves. Each
slice was equilibrated in the presence of each drug concentration
for a period of 13.5 min after which the slice was stimulated for
an additional 2 min. Aliquots of the superfusate (2 ml) were col-
lected at 4 min intervals. Immediately after the last aliquot of
superfusate was collected, the tissue slice was removed from the
superfusion chamber, blotted and weighed. Release of 3H-NE was ex-
pressed as the amount of labelled amine in each aliquot given as a
percentage of the amount of labelled amine in the tissue im-
mediately before collection of that aliquot. The stimulation-
evoked release was calculated as the difference between the total
release during the period of stimulation less the estimated basal
release. EC 50’s were calculated by probit analysis.
RESULTS
After treatment of rats with morphine for 14 days, the specific
binding of 3H-clonidine was reduced significantly. Eight h after
the last injection of morphine, the Bmax for 
3H-clonidine was de-
creased by 26.3 % (TABLE 1) . At this time the rats were dependent
but did not show signs of withdrawal. Thirty-two h after the last
morphine injection the Bmax had returned only slightly toward con-
trol values. At this time the rats were at the peak of the with-
drawal syndrome. Seventy-two h after the last morphine injection,
no signs of withdrawal were noted. At this time there was a marked
(45.8%) increase above normal control values in the specific bind-
ing of 3H-clonidine.
Prolonged treatment of rats with morphine caused a decrease in the
sensitivity to clonidine of presynaptic alpha2 adrenoreceptors in
the electrically stimulated hippocampal slice preparation. Eight h
after the last injection of morphine the clonidine concentration-
effect curve was shifted to the right (FIGURE 1) and the EC50
for clonidine was increased from a control value of 3.4 ± 0.8 nM
to a value of 26.3 ± 9.8 nM in the dependent rats. Thirty-two h
after the last morphine injection the clonidine concentration-
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TABLE 1. Specific binding of 3H-clonidine to hippocampal
membranes isolated from rats treated with morphine or af-
ter withdrawal from morphine.
Treatmenta Bmax
 b % Change
K D
C n
Duration in Bmax
Control 96.5 ± 2.6 0 3.71 ± 0.54 12
1 Day 83.5 ± 4.9d -13.5 3.31 ± 0.35 4
14 Days
8 hr 71.1 3.2f± -26.3 3.36 ± 0.69 7
32 hr 78.3 ± 4.5e -18.9 2.64 ± 0.41 5
72 hr 140.7 ± 7.5g +45.8 3.22 ± 0.25 6
a Chronically treated animals were sacrificed at 8, 32 or
72 h after the last injection of morphine. b fmoles/mg
protein. c nM. Values represent the mean of n
observations ± the
d P < .05, e P< .0005, f P < .0001, g P < .00001.
standard error of the mean.
FIGURE 1. Effects of clonidine upon electrically evoked
release of 3H-NE from hippocampal slices from dependent
rats before and after morphine withdrawal. Abscissa:
con entration of clonidine.
of 3H-NE release
Ordinate: percent inhibition
. Open circles: controls; solid squares,
8 h after the last injection; open squares, 32 h after
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withdrawal; open triangles, 72 h after withdrawal. Each
point represents the mean of 5-9 values. Vertical bars,
standard error of the mean.
effect curve was shifted back toward the left. At that time the
EC50 for clonidine was 8.1 ± 2.2 nM. Seventy-two h after the last
morphine injection there was no further change in the clonidine
concentration-effect curve, and the EC50 for clonidine was 12.9 ±
3.4 nM.
DISCUSSION
Both the density and function of alpha2 adrenoreceptors in the
brain change when rats are made dependent upon morphine and after
withdrawal of dependent rats from morphine. Although Hamburg and
Tallman (1981) reported an increase in the density of alpha2
adrenoreceptors in cerebral cortex from rats implanted with mor-
phine pellets for 4 days, the present study and previous studies
(Smith et al. 1983, Vincentini et al. 1983) indicate that the maxi-
mum number of specific binding sites for 3H-clonidine is decreased
in morphine-dependent rats. This decrease in binding is well-cor-
related with a decrease in the sensitivity to clonidine of
presynaptic alpha2 adrenoreceptors in electrically stimulated
hippocampal slices. Seventy-two h after withdrawal from morphine
the sensitivity to clonidine of presynaptic alpha2 adrenoreceptors
in the hippocampus remains depressed although there is a marked
increase in the number of specific binding sites for 3H-clonidine.
This observation suggests that during withdrawal an increase in the
number of postsynaptic alpha2 adrenoreceptors occurs in the
hippocampls. The finding of changes in alpha2 adrenoreceptor
number and sensitivity in the hippocampus of morphine-dependent
rats suggests that alterations in central presynaptic alpha2
adrenoreceptor function might be have an important role in opioid
dependence.
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THE EFFECT OF CHRONIC MET-ENK ON VARIOUS DOPAMINE
SYSTEMS IN THE RAT
Kathy A. Steece, Frank A. DeLeon-Jones, John M. Lee,
and Ronald F. Ritzmann.
Neurobiology Laboratories, West Side VA Hospital,
University of Illinois, Health Sciences Center,
Research & Development (151), P.O. Box 8195
Chicago, Illinois, USA
ABSTRACT
Morphine and enkephalins act preferentially via different
receptors, mu and delta, respectively. Chronic administration of
morphine or methionine enkephalin results in development of
physical dependence. Data from our laboratory suggests that
there are some differences in the effect of these two opioids
with regards to certain neurochemical systems.
INTRODUCTION
Several types of opioid receptors have been demonstrated.  Among
these are the mu (µ) and delta (6) receptors which interact with
morphine and enkephalins, respectively. Distinctions between
these 2 classes of receptors have been clearly defined on the
basis of pharmacological differences, localization studies, and
peripheral bioassays (for review see Paterson et al. 1 9 8 3 ) .
There is a dense population of µ as well as 6 receptors in the
striatum and hypothalamus. Here neuroregulatory interactions
occur with various neurotransmitter systems. Both µ and
receptor agonists can elicit alterations in dopaminergic
transmission in these areas. The relationship between
catecholamines and responses induced by opioids have been
investigated extensively to determine whether amines play an
important role in the adaptive mechanism(s) of physical
dependence. Chronic administration of either morphine or
enkephalin peptides results in development of physical
dependence. Continuous exposure to morphine has been
demonstrated to result in an increased sensitivity of striatal
and hypothalamic dopamine (DA) systems as measured by apomorphine
(APO)-induced stereotypy and hypothermia, respectively (Ritzmann
et al. 1983). Changes in the high affinity component of D2-DA
receptor binding for agonists in these brain regions were found
to correlate with these APO-induced behavioral/physiological
parameters in morphine-dependent rats (Ritzmann et al. 1983). It
remains to be determined whether various opioid receptors are
regulated by or linked to different molecular processes.
Therefore, the many differences in characteristics of µ and
receptors leads one to question whether the mechamism(s) of
adaptation during chronic exposure to morphine and enkephalins
are similar. Thus, using a method which produces physical
dependence, the effect of chronic methionine enkephalin
administration on striatal and hypothalamic dopamine systems was
investigated.
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MATERIALS AND METHODS
Male Wistar rats, (Fredricks Cancer Center) weighing between 200-
300 grams were housed in a controlled environment (temperature 23
± 2°C; light 0800 to 1800 hours). Animals were anesthetized with
Equithesin (2.7 cc/kg; Jen Sail) and a stainless steel cannula
was implanted into the lateral ventricle of the brain.
Methionine5-enkephalin (met-enk) was administered into the
ventricle at a rate of 10 µg/µl/hr for 5 days via an osmotic
mini-pump (Tm, Alzet; model 2001). Control animals received 0.9%
sterile saline in place of a met-enk solution and underwent the
same procedures as the met-enk treated animals. A mini-pump was
connected to a cannula via polyethylene tubing. Withdrawal was
initiated by disconnecting the tubing and sealing off the
cannula. Rectal measurements of body temperature were monitored
every 2 hours for the first 8 hours and at the 24 hour time
point. Twenty four hours after initiation of withdrawal, animals
were either tested for behavioral/physiological responses to the
dopamine agonist apomorphine (0.5 mg/kg, i.p.) or sacrificed for
binding studies. In animals receiving an APO injection, behavior
was monitored at 5 minute intervals for 30 minutes post-injection
and rated according to the following scale: a score of 0 -
normal behavior; 1 - increased locomotor behavior; 2 - rearing
and head bobbing (non-continuously); 3 - rearing and head bobbing
(continuously); 4 - stereotyped sniffing continously; 5 - licking
and gnawing behavior. An animal was considered stereotypic if a
score of at least 4 was obtained. Rectal temperatures were
monitored in these animals prior to and 30 minutes after APO
injection. Animals for DA binding assays were sacrificed by
decapitation at the 24 hour time point. Hypothalamus and striata
were dissected out for determination of specific D2-DA receptor
binding. Binding assays were performed as previously described
(Ritzmann et al. 1983). Parametric data was analyzed by t-tests.
Values are expressed as means ± SEM. Non-parametric data was
analyzed using Fisher's Exact Probability Test. Binding data was
analyzed by the computer program LIGAND (Munson and Rodbard
1980).
RESULTS AND DISCUSSION
Chronic 5 day exposure to met-enk resulted in a marked degree of
physical dependence as evidenced by a significant (p<0.01) degree
of withdrawal hypothermia up to 8 hours after initiation of
withdrawal. The maximum temperature change occured in the
peptide treated animals at the 4 hour time point (-0.69 ± 0.14°C
met-enk group; 0.09 ± 0.07°C control group). Temperatures
returned to control levels in the met-enk group 24 hours post-
withdrawal. Animals dependent on met-enk were more sensitive
than controls to the hypothermic response to APO 24 hours after
initiation of withdrawal. This was evident by a temperature
change of -0.67 ± 0.22°C in the met-enk treated animals compared
to a change of -0.08 ± 0.18°C in control animals (Fig. 1). This
increased sensitivity to APO-induced hypothermia is similar to
that observed in animals physically dependent on morphine
(Ritzmann et al. 1983). In contrast, met-enk treatment groups
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exhibited a response to APO-induced stereotypy that was not
statistically different from their controls (0% stereotypic, met-
enk group; 12% stereotypic, control group; Fig. 1). This is
unlike the effect produced by chronic morphine treatment which
results in an increased sensitivity to APO-induced stereotypy
(Ritzmann et al. 1983). Chronic morphine exposure produces an
increase in percentage of receptors and/or increase in affinity
of D2-DA receptors in the high affinity state in both
hypothalamus and striatum for DA (Ritzmann et al. 1983).
Similarly, 5 day met-enk treatment increased the affinity in the
hypothalamus of the high affinity component for DA compared to
controls <KD - 10.0nM control group; KD - 0.008nM, met-enk group;
Table 1). This increased affinity of hypothalamic DA receptors
correlates positively with the increased sensitivity to APO-
induced hypothermia observed in these animals. In contrast to
morphine treatment (Ritzmann et al. 1983), the high affinity
striatal D2-DA receptor binding was not different in control
versus met-enk treated animals (KD - 53nM, control group; KD - 46
nM, met-enk; Table 1). Again this corresponds with the lack of
change in response to APO-induced stereotypy seen in these
animals compared to controls. There was no change in receptor
binding capacity (Bmax) in either striatal or hypothalamic D2-DA
agonist binding with chronic met-enk similar to that observed
previously with chronic morphine (data not shown). Although met-
enk preferentially interacts with receptors it also interacts
with µ receptors at higher concentrations. Recently Pasternak
and Wood (1986) have postulated the existence of 3 receptor types
that bind morphine and enkephalins selectively: µl, which has
very high affinity (<1 nM) for both morphine and enkephalins; µ2,
a site which preferentially binds morphine far more potently than
enkephalins; and which selectively binds enkephalins. The
hypothalamus has been demonstrated to contain a high
concentration of µ1 receptors and these have been linked to
effects on DA turnover in this region (Pasternak and Wood 1986).
On the other hand, the striatum contains high concentrations of
µ2 and receptors which have been demonstrated to effect DA
turnover in this area (Pasternak and Wood 1986). Therefore, met-
enk may be affecting the DA system in the hypothalamus via µl
receptors and via receptors initially in the striatum.
However, desensitization or down-regulation of but not µ
receptors can occur during chronic exposure to opioid peptides in
various cell cultures and brain slice preparations (for review
see Zukin and Temple 1986). Therefore the possibility exists
that the effect on DA turnover by 6 receptors during chronic
opioid exposure is different than that produced by either µ1 or
µ2 receptors. Recent data from our laboratory suggests that this
phenomena of opioid receptor down-regulation does indeed occur in
vivo in the striatum during 5 day met-enk exposure (Steece et al.
1986). Hence, such an adaptive mechanism of 6 receptors in the
striatum could conceivably account for the overall lack of effect
of chronic met-enk on the DA system in the striatum.
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FIGURE 1. The effect of 5 day met-enk treatment on
APO-induced hypothermia and stereotypy 24 hours after
initiation of withdrawal. (n > 12; *p<0.05)
EFFECT OF MET-ENK ON THE AFFINITY (KD) OF D2-DA RECEPTORS
Treatment Striatum Hypothalamus
Control 46.0 10.0
Met-Enk 53.0 0.008
TABLE 1. The effect of 5 day met-enk treatment on the
high affinity component of D2-DA receptors in the striatum
and hypothalamus. Each group represents at least four
determinations. Data is KD expressed in nM.
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EFFECTS OF PRIOR EXPOSURE TO MORPHINE ON THE OPIOID INHIBITION
OF THE STIMULATED RELEASE OF [3H]NOREPINEPHRINE
FROM GUINEA PIG CORTEX SLICES
Linda L. Werling, Stephen R. Brown and Brian M. Cox
Department of Pharmacology, Uniformed Services University
Bethesda, Maryland 20814, U.S.A.
ABSTRACT
The potassium stimulated release of [3H]norepinephrine ([3H]NE) from
terminal fields of locus coeruleus projections can be inhibited in a
dose-dependent manner by mu and kappa selective opioids. Chronic
exposure to morphine for six days decreases the maximum achievable
depression by the mu selective agonist Tyr-D-Ala2-Gly-Me(Phe)-Gly-ol
(DAGO) , but has no effect on the degree of inhibition produced by the
kappa selective opioid U50,488H.
INTRODUCTION
Opioids inhibit release of several neurotransmitters in the central
nervous system, presumably by interactions with receptors located
presynaptically on the nerve terminals. There are reports of the
opioid inhibition of the release of dopamine and acetylcholine
(Mulder et al. 1984), and of norepinephrine (Monte1 et al. 1974;
Hagan and Hughes, 1984). In the rodent, cell bodies of the locus
coeruleus project to several areas of the brain, including the cortex
(Ungerstedt 1971). Locus coeruleus neurons are hyperpolarized by
the application of opioids in electrophysiological studies using
slices of brain tissue from the rat (Williams and North 1984) and
the guinea pig (Pepper and Henderson 1980). The terminal fields of
these noradrenergic fibers contain opioid receptors, as shown
autoradiographically (Lewis et al. 1983) and in binding studies
(Werling et al. 1985). We therefore investigated the possible
opioid regulation of the release of [3H]NE by the mu selective
agonist DAGO and the kappa selective agonist U50,488H in naive guinea
pigs compared to those implanted with osmotic pumps which delivered
chronic morphine to the animals for six days.
METHODS
Male Hartley guinea pigs (300 - 600 g) were subcutaneously implanted
with Alzet osmotic pumps (Alza Corp., Palo Alto, CA) containing
either 0.9% saline or morphine-HCl at the appropriate concentration
to deliver 100 µg/hr. After 6 days, animals were sacrificed, their
brains removed to ice, and the cortices dissected. The cortices were
chopped in two planes into 250 µm slices on a Sorvall TC2 tissue
slicer (DuPont Instruments, Newtown, CT), then suspended in oxy-
genated modified Krebs Ringers (MKR) solution (127 mM NaCl, 5 mM KCl,
1.3 mM NaH2P04, 1.2 mM MgS04, 2.5 mM CaCl2, 15 mM HEPES, 10 mM
Glucose). Subsequently, all steps of the preparation and experiment
were performed in a warm room which was maintained at a constant
temperature of 37°C. The tissues were washed 3 times in MKR (20 ml/
half cortex), resuspended in MKR and incubated for 15 min with 15 nM
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[3H]NE (New England Nuclear, Boston, MA). The tissues were then
washed twice for 5 min each in MKR, and once for 5 min in MKR con-
taining 1 µM each desiprimine and yohimbine. All subsequent steps
were carried out in buffer containing these drugs to prevent feedback
inhibition of release through presynaptic alpha receptors and re-
uptake of released [3H]NE. The tissue slices were resuspended in MKR
and distributed onto a series of nylon mesh baskets attached to
Costar (Cambridge, MA) multi-well plastic culture plate lids. The
baskets rested in the wells which contain 2 ml each MKR. To change
treatment, the lids were lifted from one plate of wells to the next,
which contained buffer with or without drug as appropriate. In all
cases, MKR had been pregassed with 95 % O2/5% CO2 and pipetted into
the wells immediately before tranferring the baskets. In this way,
24 different conditions could be examined simultaneously in
quadruplicate by employing 4 plates of 24 baskets each. Preliminary
experiments established that a stable baseline release was achieved
by 10 min incubation time in wells. After this initial 10 min
incubation, baskets were transferred to another set of wells
containing MKR, this time containing drug as appropriate, for 10
min. The tissues were then stimulated to release [3H]NE by trans-
ferring the baskets to wells containing 20 mM potassium plus or
minus drug as appropriate for 10 min. Finally, tissue was
transferred to wells containing 0.2 N HCl for 45 min to extract the
remainder of the loaded [3H]NE. All releasates were sampled and
counted, and fractional release calculated according to the total
amount of radioactivity in the tissue samples during the release
interval.
RESULTS
Both mu and kappa selective opioids produced a dose-related depres-
sion of stimulated [3H]NE release. The maximum inhibition produced
by DAGO was 60% in animals which received saline containing pumps,
and that produced by U50,488H was about 85% (Fig 1). The inhibition
Of release produced by the mu agonist DAGO was more readily
reversible by naloxone than the inhibition produced by the kappa
agonist U50,488H, consistent with their action through mu and kappa
receptors, respectively. However, at doses of agonist greater than
500 nM, the inhibition produced by either agonist could not be
completely reversed. In the absence of any added agonist, naloxone
did not produce an increase in control resting or stimulated release
at doses between 1 and 1000 nM.
In the cortices of animals chronically treated with morphine, the
maximum achievable depression by DAGO was about 40%, but that by
U50,488H was unchanged at 85% (Fig 1). The shape of the DAGO dose
response curve was changed in the morphine tolerant tissues relative
to that in controls. Whereas in cortex from naive animals, DAGO
produced a broad displacement over the concentration range 0.05 - 500
nM in chronic morphine treated animals, lower concentrations showed
similar potency in inhibiting the release of [3H]NE while higher
doses produced relatively little additional depression. At
concentrations of 5.0 nM and above, means of values representing per
cent control release from tissues of saline treated (n = 6) animals
were significantly different from those from chronic morphine treated
(n = 3) animals as determined by a two-tailed T test (p < 0.05). The
T statistic employed a pooled variance estimate derived from a two
way analysis of variance. As in the control animals, in the absence
of added agonist, naloxone failed to increase resting or stimulated
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Fig. 1 Inhibition of the stimulated release of [3H]NE by
DAGO (A) and U50,488H (B) in chronic morphine treated
and saline treated guinea pigs. Data are expressed
as percent of release of [3H]NE elicited by 20 mM K+ in
the absence of any added agonist. Control release from
the cortices of morphine tolerant animals was approx-
imately 70% that of naive animals. Data are means from
three morphine treated and three naive animals.
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[3H]NE release in tissue from chronic morphine treated animals. Thus
the overall effect of the chronic treatment was a reduction in the
maximum effect of the mu agonist, while the inhibition of [3H]NE
release by the kappa agonist was not changed significantly.
DISCUSSION
The data presented suggest that both mu and kappa opioid receptors
may be involved in the regulation of release of norepinephrine in the
cortex of the guinea pig. These observations are consistent with
electrophysiological studies on neurons of the locus coeruleus and
receptor binding studies. Presumably opioid peptides within the
brain are available to interact with the receptors which modulate
this release. However, naloxone was not able to increase either
resting or stimulated release, suggesting that the release of
norepinephrine from the cortex is not under tonic suppression by
these opioids. In the morphine dependent state, the regulation of
release of this neurotransmitter by opioids which work through
interaction with mu type receptors is apparently altered. DAGO
produces a lower maximum inhibition of release in the morphine
tolerant animal. However, the ability of kappa opioids to inhibit
release remains relatively unaffected. This result is not unexpected
since morphine exerts its effects primarily through mu opioid
receptors. Further characterization of the effects of opioids on
release of catacholamines in the dependent state may help to
elucidate adaptive mechanisms of tolerance and dependence.
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TOLERANCE TO OPIOIOS IN SINGLE LOCUS COERULES NEURONS OF THE RAT
Macdonald J. Christie, John T. Williams and R. Alan North
Neuropharmacology Laboratory
M.I.T.(56-245), Cambridge, MA 02139, U.S.A.
ABSTRACT
Chronic treatment of rats with morphine caused tolerance to the
membrane hyperpolarizing action of morphine in single locus coeruleus
neurons in vitro. Tolerance was less pronounced for
Try-D-Ala-Gly-MePhe-Gly-ol (DAGO) than for normorphine. No changes
were found in affinity of naloxone for µ-receptors on these neurons,
nor in the properties of the potassium conductance increase caused by
µ-receptor activation. These results suggest that the mechanisms
underlying tolerance involve either a reduction of the number of µ-
receptors on each cell, or a reduced coupling of µ-receptors to
potassium channels.
INTRODUCTION
Opioid inhibition of firing of locus coeruleus (LC) neurons is due to
membrane hyperpolarization (Williams et al. 1982). This
hyperpolarization results from increase in conductance to
potassium ions and is brought about by activation of p-receptors
(Williams et al. 1982; Williams and North 1984). -Adrenoceptor
agonists also hyperpolarize LC neurons by increasing the same
potassium conductance as that which is activated by µ-receptor
agonists (North and Williams 1985). The mechanisms underlying the
development of opioid tolerance could involve adaptations of µ-
receptor binding sites, the coupling of binding sites to potassium
channels, potassium channels themselves, or subsequent processes.
Some of these possibilities were investigated in the present study by
measuring the potassium conductance increased by µ-receptor and
-adrenoceptor agonists in LC neurons from rats chronically treated
with morphine.
METHODS
Rats were treated with morphine by subcutaneous implantation of
morphine-containing pellets (75 mg base) on alternate days for 7 days
(1,3,5 and then 7 pellets/day). Intracellular recordings were made
as previously described (North and Williams 1985) from the LC of
rats killed 2 to 4 days after the last implantation. Slices of pons
containing the LC were submerged in a continuously flowing
artificial cerebrospinal fluid at 37°C to which drugs could be added.
Membrane current was measured by single electrode voltage clamp
technique (Axoclamp II)(North and Williams 1985). All data are
presented as mean ± SEM. The unpaired Student t-test was used.
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RESULTS
Membrane properties of LC neurons from animals chronically treated
with morphine were not distinguishable from controls. Both fired
action potentials spontaneously with amplitudes close to 80 mV, which
arose from a threshold potential of -55 mV and had durations of about
1.5 ms. Steady-state conductances were plotted directly on an X/Y
recorder by applying a ramp potential change (-130 to -45 mV, at 1
mV/s). Cells from both control and treated animals had similar
steady-state current/voltage (I/V) relationships. Between -90 and
-60 mV the I/V plot was linear (resting conductance denoted Grest,
table 1). At potentials negative to -90 mV the slope of the I/V
relation was increased (inward rectification).
Control Morphine-treated
Grest (nS) 8.34 ± 0.51 (38) 7.59 ± 0.54 (27)
G op (nS) 3.35 ± 0.28 (38) 2.79 ± 0.24 (27)
Iop (pA) 286 ± 19.3 (38) 242 ± 20.0 (27)
Iop/I 1.16 ± 0.05 (14) 1.10 ± 0.05 (11)
TABLE 1. Membrane properties of LC neurons following chronic
treatment with morphine. Grest is resting conductance between
-60 and -90 mV. Gop is maximal additional opioid conductance
at same potential range. Iop is maximal opioid current at
-60 mV. I is maximal current induced by UK14304 or
noradrenaline at -60 mV. Number of cells in parentheses.
No significant differences were found.
The increase in conductance induced by maximal concentrations of DAGO
(3 µM) or Met-enkephalin (ME, 30 µM) was determined both by measuring
the outward current induced by superfusion of the agonist while
holding the membrane potential at -60 mV, and by constructing steady-
state I/V plots in the absence and presence of DAGO (3 µM) or ME (30
µM) and then subtracting the resting conductance (table 1) from that
found in the presence of agonist over the same potential range (-60
to -90 mV). The increase in conductance and outward current induced
by DAGO (3 µM) or ME (30 µM) was not different from that induced by
maximal concentrations of agonists (noradrenaline in the presence
of cocaine (10 µM) or 5-bromo-6-(2-imidazolin-2-ylamino)-quinoxaline
(UK14304, 1 µM)). I (table 1) was the same in cells from control
and morphine-treated rats.
The EC50 for DAGO was shifted to the right two-fold in the morphine-
treated group although the maximal outward current induced by DAGO
was not significantly affected (figure 1). In control tissues, the
maximum outward current induced by normorphine (30 µM) was similar to
that produced by DAGO. In contrast, the maximum response evoked by
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normorphine in cells from morphine-treated rats was only 55 ± 2%
(figure 1) of that produced by DAGO, and the EC50 was shifted to the
right two-fold (figure 1). The degree of tolerance to normorphine
ranged from about six-fold at the foot of the concentration-response
curve to infinite at about 55% of the maximum response (figure 1).
Such reductions in the maximal response to normorphine were observed
for up to 6 h after removal of tissue from the animal.
FIGURE 1. Maximum outward currents induced by superfusion of
DAGO and normorphine following chronic morphine treatment are
expressed as percentage of maximum possible current for the
same cell. EC50 for DAGO were: control 91 ± 17 nM (8);
treated 167 ± 26 nM (11)(p < 0.05). EC50's for normorphine
were: control 0.91 ± 0.23 µM (8); treated 1.9 ± 0.17 µM (7)
(p < 0.005).
Naloxone was without effect on the membrane current of neurons for
either control or morphine-treated animals. Concentration-respone
relations for DAGO or ME were constructed in the presence of
increasing concentrations of naloxone in both control and treated
tissues. Chronic morphine treatment had no effect on the naloxone
pA2 (control 8.8 ± 0.1 (10): treated 8.7 ± 0.1 (8); Schild analysis
or method of Kosterlitz and Watt 1968).
DISCUSSION
The present results demonstrate that chronic treatment of rats with
morphine induces opioid tolerance in single LC neurones when their
properties are later measured in vitro with an intracellular
electrode. These results are consistent with extracellular
recordings of LC neurons both in vivo and in vitro (Aghajanian 1978;
Andrade et al. 1983).
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Because no significant effects of treatment were observed on the
properties of the potassium conductance, nor on the ability of
maximal concentrations of full µ-or -agonists to increase potassium
conductance, it can be concluded that the mechanisms underlying
tolerance do not directly involve the potassium channel which is
activated by µ- and -receptors. More likely, the mechanisms
underlying tolerance development occur between p-receptor and
potassium channel.
Two conclusions can be drawn from the effects of naloxone on LC
neurones following chronic morphine treatment. Firstly, consistent
with extracellular recordings from LC slice preparations (Andrade et
al. 1983), there was no change in membrane conductance or potential
following application of naloxone to tissue from treated animals.
With extracellular recording from LC neurones in vivo, a meagre
increase in firing rate was observed (Aghajanian 1978). This
discrepancy could result from the presence of circulating morphine,
or from increased activity of excitatory afferents to the LC during
in vivo experiments. Secondly, no change was observed in the
affinity of naloxone for µ-receptors.
The observation that tolerance to normorphine is more pronounced than
that to DAGO following chronic treatment is consistent with the
interpretation that the site of adaptation resides between k-receptor
occupancy and potassium channel activation. This interpretation is
based on two findings. First, full activation of potassium channels
in normal LC neurons occurs with low fractional occupancy of µ-
receptors by full agonists (Williams and North 1984), i.e. the tissue
posesses considerable receptor reserve. Second, normorphine must
occupy a greater fraction of µ-receptors than DAGO to elicit an
equivalent response; ie. it posesses lower intrinsic efficacy (Miller
et al, 1986). Thus, in control tissue both normorphine and DAGO are
capable of eliciting the same maximal response since there is
considerable receptor reserve. However, in treated tissue
normorphine is no longer capable of eliciting the same maximal
response as DAGO because fewer receptor sites are present, or because
coupling of receptor to channel has become less efficacious. In
either case the net result is a decrease in the µ-receptor reserve of
LC neurons following chronic morphine treatment.
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EFFECT OF MATERNALLY ADMINISTERED OPIATES ON THE DEVELOPMENT OF
THE ENDORPHIN SYSTEM IN THE OFFSPRING
Christina Gianoulakis
Department of Psychiatry, McGill University, Douglas Hospital
Research Centre, 6875 LaSalle Blvd., Verdun, Quebec, Canada
ABSTRACT
Pregnant rats received subcutaneous implantation of either
morphine or placebo pellets at various stages of gestation.
Untreated animals served as basic controls. The effect of
morphine treatment on the growth of the offspring as well as on
the ontogeny of endorphin in the pituitary gland and the hypo-
thalamus was investigated. Results obtained indicated that
pregnant rats treated with morphine from day 1 of pregnancy to day
21 presented complete resorption. Subcutaneous implantation of a
morphine pellet on days 11, 13 and 19 of gestation allowed
pregnancy to term, however the post-natal mortality rate was very
high. Implantation of a morphine pellet on days 9 and 13 of
gestation allowed pregnancy to term and after birth the withdrawal
reaction of the offspring was mild and the mortality rate was low.
At early stages of development there were differences in the
pituitary and hypothalamic endorphin content between the
offspring of the morphine treated animals and the offspring of the
control animals, but by day 22 no significant differences among
the various groups were noticed.
INTRODUCTION
Prenatal exposure to morphine has been shown to induce a number of
morphological and behavioural changes (Kirby and Holtzman 1982;
Lichtblau et al. 1984). Since prenatal exposure to opiates alters
the responsivity of mature rats to noxious stimuli e.g. hot plate,
inducing a decreased analgesic response (Lichtblau et al. 1984),
opiates may alter the development and function of the endogenous
opiate system (opiate peptides and opiate receptors) in the
pituitary gland and specific areas of the brain. Thus the
objective of the present studies was to investigate the effect of
exposure to morphine in utero on the ontogeny of the endorphin
related peptides in the pituitary gland and hypothalamus.
MATERIALS AND METHODS
Female Sprague Dawley rats at the stage of late proestrous were
placed individually into breeding cages with experienced male
breeders (Sprague Dawley). The following morning the presence of
sperms in the vagina was tested. If sperms were detected in the
vagina this was considered as day 1 of pregnancy. The pregnant
animals were divided into three major groups. Animals of group I
received subcutaneous (s.c.) implantation of morphine pellets (75
mg morphine base) at the following stages of gestation: (a) on
days 1, 4, 7, 10, 13, 16 and 19; (b) on days 11, 13 and 19; and
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(c) on days 9 and 13 of gestation. Animals of group II received
s.c. implantation of placebo pellets while animals of group III
received no treatment and served as basic controls. All animals
were given water and food ad lib. Following birth the offspring
were counted and weighed. On day 2 of post-natal life the number
of offspring per litter were limited to eight. The offspring were
weighed and sacrificed on days 1, 4, 8, 14 and 22 post-natally.
The pituitary and hypothalamus were dissected free and extracted
by sonication in 0.2 N HCL with protease inhibitors (Gianoulakis
and Gupta 1986). The extracts were stored at -75°C for estimation
of the total content of immunoreactive endorphin. Some animals
receiving a morphine or a placebo pellet on days 9 and 13 as well
as some untreated control animals, were sacrificed on days 19 and
20 of gestation. The pituitary and hypothalamus were dissected
and extracted as described previously. For the estimation of the
total endorphin like inununoreactivity EPLIR) in the
peripheral circulation trunk blood was collected at the time of
sacrifice, centrifuged and the serum was stored at -75°C till the
time of radioimmunoassay. The content of EPLIR in the tissue
extracts and the unextracted serum was estimated by
radioimmunoassay using a specific antiserum to endorphin at
1:30,000 final dilution (Gianoulakis et al. 1981). The
specificity of the antiserum was directed to the C-terminal
portion of endorphin (Gianoulakis et al. 1981).
RESULTS
In general, prenatal exposure to morphine increased the rate of
mortality of the offspring. Animals receiving morphine treatment
from day 1 of pregnancy and throughout the whole gestation period
presented complete resorption. In fact, the process of resorption
took place at the early stages of pregnancy as was shown by the
changes in body weight. Subcutaneous implantation of a morphine
pellet on days 11, 13 and 19 allowed pregnancy to term, however,
the mortality rate was very high ( 66%). Implantation of a
morphine pellet on days 9 and 13 of pregnancy allowed pregnancy to
term and after birth the withdrawal reaction of the offspring was
mild, and the mortality rate was low ( 10%). Offspring of
morphine treated animals had lower body weight at the time of
birth, however at later stages of development no significant
difference was observed among the various groups. On days 19 and
20 of gestation as well as on day 4 post-natally, the content of
EPLIR in the pituitary gland was lower in the offspring exposed
to morphine in utero. No significant difference was noticed in
the other stages of development (figure 1). The pattern of
ontogeny of endorphin was similar in the pituitary of the three
treatment groups, showing a sharp increase between days 1 to 4, a
smaller increase between days 4 to 8 and a sharp increase between
days 14 to 22. On days 19 and 20 pre-natally and day 1 post-
natally, a lower content of EPLIR was found in the hypothalami
of the animals exposed to morphine in utero, while on day 4 post-
natally a higher content of EPLIR was noticed in the hypothalami
of the offspring of both the morphine and the placebo treated
animals (figure 1). No significant difference in the content of
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EPLIR in the hypothalamus was noticed at the other stages of
development investigated. Likewise to the pituitary gland, a
similar pattern of the ontogeny of endorphin in the hypothalamus
was presented by the offspring of all treatment groups, showing a
small rate of increase between days 4 to 8 followed by a sharp
increase between days 8 to 14 and 14 to 22. On day 1 post-natally
the content of EPLIR in the serum of the offspring exposed to
morphine in utero was significantly higher than in the offspring
of the control groups. No significant difference was noticed in
the serum EPLIR content at the other stages of development among
the various groups.
FIGURE 1. Content of endorphin-like immunoreactivity
in the pituitary gland (A) and hypothalamus (B) at
various stages of pre-natal and post-natal development.
Ex = Expanded scale. *Significantly different from
controls p < 0.05
DISCUSSION
The present results clearly indicate that pre-natal exposure to
morphine may induce pre-natal death and increase the post-natal
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mortality. The high incidence of post-natal mortality may be
attributed to the withdrawal reaction of the offspring following
birth, however, the cause of the pre-natal mortality is not clear.
Since offspring of animals receiving s.c. morphine pellets on days
9 and 13 showed mild withdrawal reaction and high survival rate,
they were used for estimation of tissue and serum EPLIR content.
Though a lower content of EPLIR was observed on pre-natal days
19 and 20 in the morphine exposed offspring at later stages of
post-natal development no significant differences were noticed
among the offspring of the three treatment groups. These
observations indicate that the effect of pre-natal exposure to
morphine on the EPLIR content in both the pituitary gland and
the hypothalamus is transient and complete recovery to control
levels occurs at early post-natal life (day 8). Similar changes
in the hypothalamic endorphin content were noticed in the
offspring of both the placebo and the morphine treated animals,
suggesting that the changes observed in the content of EPLIR may
be partially due to the stress of ether exposure and surgery.
Furthermore, both the pituitary and the hypothalamus showed a
slower rate of increase in the total content of EPLIR between
days 4 and 8, the period of development known as the stress non
responsive period (Childs et al. 1982). The higher content of
serum EPLIR on day 1 of development observed in the offspring
exposed to morphine in utero, may be attributed to the withdrawal
reaction following birth.
In summary, prenatal exposure to morphine alters the content of
EPLIR in the pituitary and hypothalamus pre-natally and at early
stages of post-natal life with complete recovery to control levels
by day 8 post-natally. However, though no significant difference
is present in the total pituitary and hypothalamic EPLIR
content, the ability of the endorphin system to respond to
stress may have been modified by prenatal exposure to morphine.
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SUPPRESSION OF IMMUNOLOGICAL FUNCTIONS IN MORPHINE ADDICTED MICE
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ABSTRACT
Lymphocytes isolated from morphine addictedmice show a number of
impaired immunological functions. They include Con A stimulated
mitogensis, NK cell activity, plaque forming cell activity and
delayed-type of hypersensitivity. In addition, the met-enkepalin and
endorphin level in the lymph nodes of addicted mice were also
depressed.
INTRODUCTION
The role of the opioid peptides in modulating immune response has
received much attention since Wybran et al. (1979) first
demonstrated the existence of opiate receptors in human blood
lymphocytes. Since then, the action of the opioid peptides,
particularly the enkephalins and endorphin, in stimulating a
variety of immune response has been documented (Fischer and Falke
1984). Chronic opiate addicts are known to have higher rates of
infection (Brown et al. 1974). In human as well as in animal
studies, it has been shown that lymphocytes isolated from addicted
subjects have depressedmitogenic activity (Brownetal. 1974, Ho
and Leung 1979). As chronic addiction can also depressed the level
of enkephalin and endorphin (Clement-Jones et al. 1979, Ho et al.
1980), it is notunreasonableto expect that there may be a causal
relationship between the lower level of circulating opioid peptides
and the depressed immune status of the addict. The present study
aims to 1) establish if other immunological parameters, besides
mitogensis, can be depressed by addiction and 2) to determine
whether a depressed immune response is correlated with a lower level
of opioid peptides in the lymphoid tissues.
MATERIALS AND METHODS
Addiction of animals: Inbred female Balb/c mice weighing between 25
to 30 gm were used in this study. The mice were randomly divided
into three groups; untreated, saline-treated and morphine addicted.
Addiction tomorphine was inducedby two daily injections of 1 ml
saline containing morphine-HCl for three weeks. The dose used ranged
from 10 to 50 mg/kg/day. As 30 mg/kg/day turned out to give the
Optimal result, this dose was used for most of the experiments. The
development of addiction was confirmed by behavioral criteria. The
body weight of the animals remained constant throughout the entire
experimental period and there was no sign of malnutrition.
Assay of immune functions: Con A stimulated mitogensis was performed
according to Ng et al. (1978). Endogenous and activated natural
killer (NK) cell activity wasmeasured by the release of Cr-51 0n
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prelabeled YAC-1 cells. Plaque forming cell (PFC) activity was
determined by the formation of plaques on lyzed sheep red blood
cells after the addition of complement. Delayed-type of
hypersensitivity was measured by the swelling of the foot pad when
animals previously sensitized to sheep red blood cells were
challenged with a dose of the antigen. Unless specified otherwise,
lymphocytes isolated from the spleen were used in these studies.
Radioinmunoassay and enzyme assay: The level of met-enkephalin and
endorphin in the lymph nodes were determined by RIA according to
Clement-Jones et al. (1980) and Guillemin et al. (1977). Met-
enkephalin degrading activity of lymph node membranes was determined
by the rate of disappearance of met-enkephalin in the assay mixture.
HPLC was used to separate met-enkephalin from contaminants and by-
products.
RESULTS AND DISCUSSION
In this study we have used four imnune function tests to determine
the effect of addiction on immunity. The results are presented in
table 1 and 2 and fig. 1. In the Con A stimulation test, the
mitogenic activity of lymphocytes isolated from addicted mice was
significantly depressed. In order to prove that this effect was
mediated by morphine, the antagonist, naloxone, was coadministered.
As indicated in table 1, mitogenic activity was suppressed to a
significantly lower level when animals were treated in this manner.
TABLE 1 Effect of Addiction on Con A Stimulated Mitogensis
Treatment H-3 Thymidine Uptake
(x 10-3 cpm/105 cells)
% of Untreated
Control
Untreated 140 ± 2.8 100
Saline treated 140 ± 5.0 100
Morphine addicted 73 ± 7.0 52
Naloxone 131 ± 9.5 93
Morphine/nax 114 ± 4.5 81
The dose of morphine and naloxone used was 50 mg/kg/day. In the
naloxone experiment, it was given immediately before morphine.
Spleen cells were used in this study.
The suppressive effect of addiction on mitogensis was determined to
be dependent on the dose of morphine used (data not shown). At a
daily dose of 10 mg/kg, there was no significant suppression of
activity. Only when the dose was increased to 30 mg/kg/day did the
effect on mitogensis become noticeable. Other than dose, the organ
from which the lymphocytes were isolated may also influence the
results. Thus, cells isolated from the spleen were in general less
suppressed than those isolated from the lymph nodes. This may be due
to a difference in the response of the lymphoid tissue to
neuroendocrine control (to be discussed later).
As in the case of Con A stimulated mitogensis, addiction also
suppressed both NK and PFC activities (table 2). In the delayed-type
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of hypersensitivity assay, addicted animals had a slower and less
active response in general. Maximum swelling of the footpads was
delayed by one day on the average and the degree of inflammation was
never as severe as the controls (fig. 1).
Table 2. Effect of Addiction on Natural Killer Cell and Plague
Forming Cell Activities
Treatment
NK Activity (% Cr-51 released)
Endogenous Activated
PFC per
10 Cells
Untreated 19 45 354
Saline-treated 20 (105) 41 (91) 364(102)
Addicted 14 (73) 25 (55) 77(22)
NK activity of animals was preactivated by injection of C. parvum
(350 ug/mouse) 4 days prior to measurement. Similar results were
obtained from at least 3 independent trails. Values in parethesis
are % of untreated control.
Fig. 1. Effect of Addiction
on Delayed-Type of Hyper-
sensitivity.
The mechanism of how opiate addiction can suppress immune response
may be related to the inhibition of endogenous opioid peptide level.
In both animal and human studies, it is known that chronic addiction
can decrease the level of enkephalin and endorphin (Clement-Jones
et al. 1979, Ho et al. 1980). Since these peptides can activate
lymphocyte response (Wybran 1985), it is not unreasonable to
speculate that factors which can reduce the level of opioid peptides
would also have a negative influence on the immune system. To
assess this, we have measured the level of met-enkephalin and
endorphin in the lymph nodes of addicted and control animals. As
indicated in table 3, the concentration of both peptides were
significantly reduced in the addicted group.
Presumably, this would not be due to a higher level of degrading
enzyme activity since membranes isolated from lymph nodes of
addicted mice hydrolyzed met-enkephalin at the same rate as that of
the controls. Further work is in progress to evaluate the role of
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the opioid peptides in modulating immune responses.
Table 3 Effect of Addiction on Opioid Peptide Level and Met-
Enkepalin Degrading Activity of the Lymph Nodes
Treatment E P Met-ENK Met-ENK Degrad.Act.
Untreated 120 ± 6 1.82 ± 0.43 8.92 ± 4.75
Saline-treated 105 ± 22 1.75 ± 0.03 8.82 ± 3.68
Addicted 29 ± 11* 1.33 ± 0.22* 9.48 ± 2.74
EP was measured as ng/mg protein, met-ENK as ng/mg wet weight
and met-ENK degrading activity as nmol/min/mg protein.
* A high level of significance of difference compared with
control (p<0.01).
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ABSTRACT
Morphine UDP-glucuronyltransferase activity was demonstrated in the
brain of mice from recombinant inbred strains of the BXD series. The
formation rate of morphine-3-glucuronide was about 4 fold higher in
the progenitor DBA as compared to the C57BL strain.
INTRODUCTION
Morphine is still the mainstay in the treatment of chronic severe
pain. When used as an oral medication its effects vary between pa-
tients. To a large extent this is due to wide interindividual varia-
tion in the presystemic elimination of this drug (Säwe et al. 1985).
The possibility that also the formation of active morphine metaboli-
tes may contribute to the pharmacological effects and its variation
has previously been put forward (Joel et al. 1985, Osborne et al.
1986). A genetic difference in the quantitative metabolism as well
as a difference in metabolic pattern would be compatible with a va-
riation in effect. Whereas the major metabolite morphine-3-glucuro-
nide (M3G) is inactive, the morphine-6-glucuronide (M6G) (Shimomura
et al. 1971), and morphine-6-sulphate (M6S) (Mori et al. 1972) have
been demonstrated to possess analgesic activity in mice. However,
these metabolites represent minor metabolic pathways of morphine.
The present study was designed to investigate if there is a measu-
rable morphine UDP-glucuronyltransferase activity (UDP-GT) in the
mouse brain and if the enzyme activity i affected by one or several
genes.
MATERIALS AND METHODS
Microsomes from the whole male mouse brain were isolated by standard
procedures. The glucuronidation assay was performed according to Pa-
cifici et al. (1982). The morphine metabolites were analyzed by high
performance liquid chromatography according to Svensson et al. (1982).
The reproducibility of the whole assay was 11% determined as coef-
ficient of variation from 5 repeated assays of the same sample. The
detection limit of M3G in the incubate was 2 ng. The genetical model
used was the BXD series of recombinant inbred (RI) strains and the
two progenitor strains C57BL/6J and DBA/2J.
RESULTS
The morphine UDP-GT activity was measurable in the brain microsomes
from the progenitor strains as well as in the brain of all the RI-
strains. The reaction was linear with protein up to a concentration
of 3 mg per ml incubate (fig 1). The reaction proceeded linearly
with time from 1 to at least 4 hours (fig 1). The rate of glucuroni-
dation was 4 times higher in the DBA than in the C57BL mice (p<0.001).
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The variation between individuals was also larger in the DBA strain;
6.8 ± 4.01 pmol/mgxmin (n=10) versus 1.8 ± 0.681 pmol/mgxmin (n=9)
in the C57BL strain. The morphine UDP-GT activity in the different
RI-strains is shown in fig 2. Each bar represents one strain and the
mean of four animals. As is seen in the figure, the activity profile
from one experiment to another was not fully reproducible. The values
of the RI-strains were within the range of the two progenitor strain
values.
FIGURE 1.
Morphine UDP-GT acti-
vity in brain of DBA
and C57BL mouse
strains, at different
protein concentra-
tions (upper panel)
and the time course
of morphine-3-glucu-
ronide (M3G) forma-
tion (lower panel).
Standard incubations
(100 ul final volu-
me) were carried out
at 37°C for 2 hours,
0,2 mg protein in
TRIS-buffer pH = 7.4
with 8.3mM Mg Cl2,
3mM morphine and
15mM uridine diphos-
phoglucuronic acid
(UDPGA).
1 Mean ± standard deviation
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FIGURE 2.  Morphine UDP-glucuronyltransferase activity in mouse
brain. The profile of 13 RI-strains is shown. The averages of
two experiments each including two animals are shown as black
cuts in the histogram. The activities of the progenitor strains
were determined in 10 (DBA) or 9 (C57BL) male individuals. Mean
values and standard error of the mean for these are indicated
to the right. (Details in fig 1.)
DISCUSSION
Morphine UDP-GT activity was measurable in brain microsomes from all
strains tested. The activity differed by a factor of 4 in the two
progenitor strains indicated a strong genetic influence. However,
the distribution of morphine UDP-GT activity among the RI-strains
does not allow us to easily interpret the mode of inheritance. One
explanation might be that there is a family of morphine UDP-GT en-
zyme forms (Mackenzie et al. 1985), of which more than one contribu-
tes to the variation in our results. Environmental factors may al-
so influence the activity. We did not attempt to monitor the crow-
ding conditions in the cages which may bear importance for the brain
metabolism. Such factors may effect certain pain mechanisms as sug-
gested by Rodgers and Hendrie (1983). They showed that social con-
flict in male mice is a potent biologically relevant stimulus in the
activation of endogenous naloxone-sensitive pain mechanisms. These
authors also found that social status is an important determinant of
nociceptive response to such experience. Indeed the DBA strains that
had a higher and more variable activity "seemed" more aggressive
than the other progenitor strain.
The hypothesis that different metabolic routes of morphine could be
responsible for the analgesic effect and side effects has not been
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fully investigated. The other pathways of morphine metabolism, as the
formation of morphine-ethereal sulphate and normorphine are currently
investigated in our laboratory. Although these metabolites are formed
in minor amounts they may contribute quantitatively to the side ef-
fects by virtue of their high potency. In the light of the recent evi-
dence of biosynthesis of morphine in the mammalian body (Donnerer et
al. 1986) more information is neededd about the metabolism of this
drug and its relation to the pharmacological effects.
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OPIOID REGULATION OF PHOSPHOINOSITIDE TURNOVER. M.E. Abood, N.M.
Lee. H.H. Loh, Depts. of Pharmacology and Psychiatry, University
of California, San Francisco, CA 94143, USA.
Since a number of studies indicate the involvement of Ca++ in
the action of opioids, as well as a role for G proteins, the
regulation of phosphoinositide (PI) turnover may be a possible
second messenger system for opioids in the brain. This possibil-
ity was addressed by measuring PI turnover in rat brain cerebral
cortical slices. In the presence of 10 µM etorphine, a small (23
- 83%) but significant (p< .01, n = 9) increase in all three
products of PI hydrolysis was observed. It is worth noting that
with smaller sample numbers (n = 5), it was difficult to
demonstrate a significant increase in PI turnover in response to
etorphine. However, with smaple numbers of n = 9 or more the
increase was always statistically significant. Etorphine at 1 µM
produced a 10% increase in phosphoinositides. The etorphine
effect was a specific opioid effect, as it was reversible with 20
µM naloxone. This data indicate another second messenger system
in the rat brain through which opioids may act.
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OPIOID REGULATION OF PHOSPHOINOSITIDE TURNOVER. M.E. Abood, N.M.
Lee, H.H. Loh, Dept of Pharmacology, UCSF, San Francisco, CA
94143, USA
Since a number of studies indicate the involvement of
calcium in the action of opioids, as well as a role for G
proteins, the regulation of phosphoinositide (PI) turnover may be
a possible second messenger system for opioids in the brain.
This possibility was addressed by measuring PI turnover in rat
brain cerebral cortical slices. In the presence of 10 µM
etorphine, no significant increase in the three products of PI
hydrolysis was observed (n = 15). It is worth nothing that with
smaller sample numbers (n = 5), it was difficult to demonstrate
reproducible effects on PI turnover in response to etorphine.
The effect of etorphine on PI turnover in the midbrain was also
examined.
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SYNAPTOSOMAL MEMBRANES CONTAIN A MEMBRANCE-BOUND FORM OF
ENDOPEPTIDASE 24.15 THAT GENERATES LEU- AND MET-
ENKEPHALIN FROM LARGER PEPTIDES. G.R. Acker, C.J.
Molineaus and M. Orlowski. Dept. of Pharmacol., Mount
Sinai Sch. of Med. New York, NY 10029.
There is evidence that enkephalins are derived not
only from proenkephalin, but also from prodynorphin. A
soluble metalloendopeptidase (SMEP) (EC 3.4.24.15) from
rat brain was previously shown to cleave dynormphin
A-(1-8) (D8); and -neo-Enaorpnin and -nE) to
Leu enkephalin (LE) (Chu and orlowski, Endocrinol.,
116: 1418-1425, 1985). We have found that a membrane-
bound form of this enzyme accounts for 20-25% of the
total activity. The specific activity of this
membrane-bound form was higher in synaptosomal
m e m b r a n e s  t h a n  t h a t  o f  e n d o p e p t i o a s e - 2 4 . 1 1
("enkephalinase"). Purified synaptosomal membranes were
incubated with the prodynorphin-derived peptides D8, -
and -nE, and the proenkephalin-derived Met-enkephalin-
Arg-Gly-Leu (ME-RGL), in the presence of bestatin,
captopril and N-01-(R,S)-carboxy-2-phenylethyl]-Phe-
p-AB, specific inhibitors of aminopeptioase,
engiotensin-converting enzyme (EC 3.4.-15.1) and
memberane-bound MEP (EC 3.4.24.11), respectively. After
3 h, the rate of enkephalin generation was greater than
70% from ME-RGL, D8, -nE. A slower rate of conversion
was observed for -nE, consistent with the turnover
rate constants found for the purified SMEP (above
ref.). Addition of N-[1-(R,S)-carboxy-2-phenyletny1]-
Ala-Ala-Phe-p-AB, an active site-directed inhibitor of
endopeptidase-24.15 innibited LE and ME formation by
8 0 % indicating the involvement of this enzyme in the
observed conversions. These results demonstrate that
synaptosomes contain a membrane-bound form of
enaopeptidase-24.15 that efficiently generates
enkephalin from proenkephailn and prodynorphin sources.
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EFFECTS OF MONOSODIUM GLUTAMATE ON THE LEVELS OF BETA-ENDORPHIN
IMMUNOREACTIVE MATERIAL IN RAT DORSAL AND VENTRAL CAUDAL MEDULLA.
N. E. Alessi and H. Khachaturian, Mental Health Research Institute, University of
Michigan, Ann Arbor, Michigan 48109, U.S.A.
Neuronal perikarya containing beta-endorphin immunoreactivity (BE-IR) are found in
two regions of the brain, the hyopthalamic arcuate nucleus and nucleus tractus
solitarius (NTS) in the dorsal caudal medulla (Khachaturian et al., Trends Neurosci.
8:111, 1985). BE-IR is also found in fibers in both the dorsal caudal medulla (DCM) and
ventral caudal medulla (VCM). The exact origin of these fibers, i.e. arcuate versus NTS
is currently not known. Biochemical studies which have characterized BE-IR in medulla
have used either the entire caudal medulla or the DCM (Alessi and Quinlan, Peptides. 6
Suppl 2:137, 1985; Dores et al., Brain Res, In press). In order to clarify the
contributions of the arcuate versus NTS to total BE-IR in caudal medulla, we have used
monosodium glutamate (MSG) lesions which selectively damage the arcuate neurons.
Neonatal male Sprague-Sawley rats were injected with MSG (4 mg/gm body weight) on
postnatal days P2, P4, P6, and P8. Control animals were injected with 0.9% saline. At
100 days of age, the animals were decapitated and the brain stem rapidly frozen in
powdered dry ice. The caudal medulla was cut at the central canal into DCM and VCM.
Levels of BE-IR was determined with a BE RIA using antiserum Brenda (Drs. Watson
and Akil). In the saline injection group BE-IR in the DCM and VCM was 7.53 ± 0.99
(mean ± SEM) and 4.23 ± 0.44, respectively, with BE-IR being significantly higher in the
DCM (paired t-test. p < 0.025). MSG treatment resulted in a decrease in BE-IR in DCM
(3.51 ± 0.53). but not in VCM (3.38 ± 0.67) (n.s.). A comparison of the DCM in the
saline versus MSG groups demonstrates a significant drop in the BE-IR levels with MSG
(p<0.005). A similar comparison of the VCM demonstrates no significant change (p<
0.375). The extent of cell damage in the arcuate nucleus and NTS was also
determined immunohistochemically using a 16K antiserum. MSG and control rats were
treated with colchicine prior to sacrifice. The preliminary results indicate a significant cell
loss in the arcuate nucleus (approximately half of control), whereas no perikaryal loss
was apparent in the NTS. The results of this study suggest that a significant portion of
the BE-IR identified in the DCM oriainates from cells in the arcuate nucleus which might
be affected by MSG. Furthermore: since no significant drop in BE-IR was noted in the
VCM, BE fibers in this region of the medulla may originate either from NTS or portions of
the arcuate nucleus not affected by MSG.
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HIGH EXTRACELLULAR K+ ION AND THE DOPAMINE (DA) AGONIST
BROMOCRIPTINE INHIBIT ENDORPHINS SECRETION FROM PERIFUSED RAT
NEUROINTERMEDIATE (NIL) PITUITARY CELLS IN A VERY DIFFERENT
MANNER. Richard G. Allen and Julianne Stack. Departments of
Medicine and Physiology, Oregon Health Sciences University,
Portland, Oregon 97201, U.S.A.
The secretion of endorphins derived from the pro-hormone
pro-opiomelanocortin (POMC) is tonically inhibited by the
neurotransmitter dopamine in vivo. It has been demonstrated
that ion fluxes, voltage dependent ion channels and membrane
potentials contribute to the mechanism(s) of release of
neuropeptides from secretory vesicles. We measured the effects
of potassium, sodium and bromocriptine on endorphins release
from the NIL-cells to investigate the relationship between ion
fluxes, membrane potential and neurotransmitter actions. Male
rat NILs were enzymatically dispersed and perifused with a
continuous flow for 5 hrs. Twenty min pulses of control medium
were interrupted with 10 min pulses of experimental medium.
Control medium was a complete medium with 5.4 mM KCl and 155mM
NaCll. Experimental megiums were composed of control medium
plus additives: high K+=60.4mM KCl, high Na+=209mM NaCl,
bromocriptine(10-6M). Two min fractions were collected and
analyzed for endorphins immunoactivity. The high K+ caused
an immediate inhibition of basal release and in 10 min had
reduced secretion to 40% of the expected basal release. When
control medium was reintroduced, the secretion rate returned to
100% of the pre-inhibited rate. The high Na+ had no
significant effect on basal release, but when control medium
was reintroduced there was an immediate, transient (8 min)
increase of secretion, 407%  above the predicted basal rate.
Bromocriptine had an immediate 20-fold inhibitory effect on
secretion of endorphins that was never reversed with control
medium. The inhibitory effects of high K+ were specific for
this ion and reversible. Inhibition of secretion by
bromocriptine was much greater than high K+ and not reversible,
implying that other intracellular mechanisms may be involved in
the inhibitory effects of bromocriptine. (Supported by NIH
grant NS 19397-02).
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THE PURIFIED µ OPIOID RECEPTOR AND ITS RELATIONSHIP TO
OTHER OPIOID-RELATED BINDING SITES. E.A. Barnard, C.D.
Demoliou-Mason and Y. Wong, MRC Molecular Neurobiology
Unit, MRC Centre, Cambridge CB2 2QH, U.K.
Soluble highly active opioid receptors from rat
brain membranes have been purified by affinity
chromatography on 14- -(C-glycyl)-amido-(N-cyclopropyl-
methyl)-norcodeinone (GANC) immobilized on Affi-Gel-10,
or on D-ala2-leu5-enkephalin chloromethylketone
(DALECK) immobilized on thiol-Sepharose 4B. After
elution by opiates and a lectin affinity chromatography
step, the completely purified receptors bind opiate
agonists and antagonists with high affinity and also
opioid peptides, the latter with lower affinity. The
subtype specificity depends upon the conditions used in
the chromatography. The purified receptor from either
column shows a single protein band (apparent mol. wt.
65,000) after SDS-gel electrophoresis and silver
staining, when the affinity chromatography was in the
presence of Mg2+ and Na+. [3H]DALECK itself acts as a
u-specific affinity reagent and labels a single
polypeptide. Comparison will be made between the
receptor subunits as identified thus in the membrane
and after purification under various conditions.
Separation from other opioid subtypes in solution, and
from the initially-associated guanine-nucleotide
binding protein, can be demonstrated. Approaches
directed towards the cloning of the cDNAs encoding
these receptor subunits will also be discussed.
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E X P R E S S I O N  O F  O P I O I D  R E C E P T O R S  I N  C U L T U R E D  E M B R Y O N I C
NEURONS IS REGULATED BY COMPONENTS IN THE CULTURE MEDIUM. J.
Barq, R. Levy and R. Simantov, Department of Genetics, Weizmann Institute of
Science, Rehovot 76100, Israel.
Cultured aggregating rat brain neurons express mu, delta and kappa opioid
receptors (Lenoir, Barg and Simantov, Brain Res., 304, 285-290, 1984). A more
recent study shows that chemical depolarization alters the number and possibly
the type of receptors expressed (Simantov and Levy, Develop. Brain Res., 1986,
in press). It appears, therefore, that the profile of receptors expressed by a
given tissue, at least in culture, depends on its neurochemical activity. This
s tudy  was  unde r taken  t o  f u r t he r  ana l yze  t he  f ac to r s  t ha t  r egu la te  t he
expression of these receptors. Hindbrain, forebrain or whole brain aggregating
cell cultures were prepared from dissociated E-15 rat brain ceils and grown in
se rum con ta i n i ng  o r  se rum f r ee  med ia . 3 H-Diprenorphine was used to
determine the total number of opioid receptors, and DAGO and DPDPE, the
number of mu and delta sites, respectively. Cultures grown for only 7 days
have different receptor density and subtype profile than cultures grown for 19
days. Serum alters the receptor number, and aggregates cultured in serum free
medium have different response to depolarizing concentration of potassium ions
than serum containing cultures. Moreover, opiate antagonists have a selective
effect on the number of different receptor subtypes. These and additional data
using cultures treated with conditioned media from several cell sources indicate
that the phenotypic expression of opioid receptors in culture may be regulated
by multiple factors.
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POSSIBLE IMPLICATIONS OF PITUITARY THYROTROPIN
RELEASING HORMONE R E C E P T O R S  I N MORPHINE
TOLERANCE IN THE RAT. Hemendra N. Bhargava, Sumantra
Das, M. Bansinath and R. Prasad, Departments of Pharmacodynamics
and Pathology, University of Illinois at Chicago, Health Sciences
Center, Chicago, Il 60612, U.S.A.
The effect of chronic treatment of rats with morphine and
subsequent withdrawal  on brain and pituitary receptors  for
thyrotropin releasing hormone (TRH) was investigated. Rate were
implanted with four morphine pellets (75 mg each) during a three
day period. Placebo pellet implanted rate served as controls. Both
tolerance to and dependence on morphine developed as a result
of  this  procedure. The binding of 3H-MeTRH to membranes
prepared from whole brain minus cerebellum was unaffected in
morphine tolerant-dependent rata as demonstrated from the
unaltered Kd  and Bmax values when compared to placebo pellet
implanted animals The binding of 3H- MeTRH to five different
regions of the brain am well as pituitary were also investigated.
Binding of  3H-MeTRH to pituitary was increased during
development of morphine tolerance and naloxone preceipitated
withdrawal, whereas, binding to the different regions of brain was
unaffected under these conditions. T h e r e  w a s a decrease in
circulating levels of thyroid hormones  (T 8  a n d  T 4 ) . However,
serum TSH level remained unaltered. In contrast, 24 hour
withdrawal of morphine renulted in an increase in 3H-MeTRH
binding in pons + medulla whereas binding in other regions of
the brain as well as in pituitary was unaffected. Serum T3, T4
and TSH levels were also unaffected d u r i n g  2 4 hour
withdrawal of morphine. The results suggest that the development
of tolerance to morphine may be associated with changes in the
pituitary- thyroid axis (Supported by a grant DA-02698 from the
National Institute on Drug Abuse).
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SELECTIVE INHIBITION OF OPIOID BINDING BY FAB FRAGMENTS
FROM A MONOCLONAL ANTIBODY DIRECTED AGAINST THE OPIOID
RECEPTOR. J.M. Bidlack and W.E. O'Malley, Center for Brain
Research, University of Rochester, School of Medicine and Dentistry,
Rochester, NY 14642, U.S.A.
Fab fragments from a monoclonal antibody, OR-689.2.4, directed
against the opioid receptor selectively inhibited opioid binding to rat
and guinea pig neural membranes and to the NG108-15 neuroblastoma x
glioma cell line. In a titrable manner, the Fab fragments
noncompetitively inhibited the binding of the µ selective peptide,
[3H][D-Ala2,MePhe4,Gly-ol5]enkephalin, and the selective peptide,
[3H][D-Pen2,-Pen5]enkephalin, to  neural membranes. The Fab
fragments were competitive inhibitors of [125I-Tyr27] -endorphin binding
to neural membranes and to membranes from the NG108-15 cell line.
In contrast, opioid binding, as measured by the binding of
[3H]bremazocine to guinea pig cerebellum in the presence of µ and
blockers, was not significantly altered by the Fab fragments. The
OR-689.2.4 Fab fragments blocked the binding of [3H]bremazocine to µ
and binding sites. In addition to blocking the binding of µ and
ligands,  the Fab fragments displaced bound opioids from the
membranes. When µ sites were blocked with [D-Ala2,MePhe4,Gly-ol5]
enkephalin, the Fab fragments suppressed the binding of
[3H][D-Pen2,D-Pen5]enkephalln to the same degree as when the µ
binding site was not blocked. The Fab fragments also inhibited binding
[D-Pen2,D-Pen5]enkephalln This monoclonal antibody is directed
to the µ site regardless of whether or not the site was blocked with
.
against a 35,000 dalton protein. Since the antibody is able to inhibit µ
and binding but not  opioid binding, it appears that this 35,999
dalton protein is an integral component of µ and opioid receptors but
not  receptors.
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INTERACTIONS OF A MORPHINE (µ) RECEPTOR SPECIFIC LIGAND, [3H]Tyr-
Pro-NMePhe-D-Pro-NH2, WITH RAT BRAIN MEMBRANES. S. G. Blanchard,
P. Lee, J. S. Hong and K.-J. Chang, Molecular Biology Department,
The Wellcome Research Laboratories and N.I.E.H.S., Research
Triangle Park, NC 27709, U.S.A.
The highly u-receptor selective ligand Tyr-Pro-NMePhe-D-Pro-
NH, (PL017) was custom tritiated and its binding to rat brain
membranes was directly measured. The data were well fit by a
model assuming the existence of a single homogenous population of
binding sites. Scatchard analysis yielded values for Kd and
binding s i t e s  o f  6  nM and  . 16  pmo le /mg ,  r e spec t i ve ly .  As
expected for binding to an opiate receptor, addition of sodium,
magnesium and guanyl nucleotides to the assays resulted in a
modulation of ligand binding. In all cases tested, however, no
significant deviations of the Scatchard plots from linearity were
observed. Furthermore, displacement of 3H-PL017 by all opioid
ligands tested was monophasic, consistent with simple competitive
i n h i b i t i o n  a t  a  s i n g l e  b i n d i n g  s i t e . The IC50 values thus
obtained showed good agreement with previously published values
d e t e r m i n e d  u s i n g  l e s s  s e l e c t i v e  r a d i o l a b e l e d  l i g a n d s .  T h e
regional  distr ibution of  3H-PL017 binding to  rat  brain was
examined by in vitro autoradiography. The labeling pattern was
similar to that seen for other µ-type ligands. Because of its
high selectivity, the binding of 3H-PL017 to the µ-type receptor
can be measured directly without the need to suppress binding to
other sites. As such, 3H-PL017 should be a useful ligand for
dissecting the actions of multiple opiate receptors.
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IRREVERSIBLE BINDING OF IODO AZIDO DTLET TO RAT BRAIN DELTA
OPIOID RECEPTOR.
P. Bochet*, C. Icard-Liepkalns*, F. Pasquini+, C. Garbay-
Jaureguiberryo, B.P. Roqueso, A. Beaudet+ and J. Rossier*.
*Physiologic Nerveuse, CNRS, Gif-sur-Yvette, France ; + Institut
Neurologique de Montreal, Canada ; o INSERM, CNRS, Faculté de
Pharmacie, Paris, France.
Azido DTLET (Tyr-DThr-Gly-pN3Phe-Leu-Thr) is a photoactivable
derivative of the delta specific ligand DTLET and is itself a
potent opioid agonist. The iodination of Azido DTLET by the
chloramine T method, followed by separation over reverse phase
HPLC, yields a pure monoiodinated species, as verified by mass
spectrometry. 125I Azido DTLET displays high affinity, levorphanol
displaceable binding to rat brain membranes. The behaviour of the
ligand in inhibition experiments is very similar to that of DTLET
(Table) . I r r a d i a t i o n  w i t h  u . v .  l i g h t  ( 2 5 4  n m ) ,  f o l l o w i n g
incubation with 125I Azido DTLET, results in irreversible binding
t o  s e v e r a l  r a t  b r a i n  p r o t e i n s . SDS  po lyacry lamide  ge l
electrophoresis  shows that  one of  these proteins (apparent
molecular weight 43000) is not labeled when the incubation is
carried out in presence of a high concentration of levorphanol.
125IAzido DTLET also binds to rat brain slices (20 um thick) with
a distribution similar  to  the local isation of  delta receptors .
125IAzido DTLET has also been used to label NG 108-15 cell
membranes. The labelled proteins from both rat brain and this
opioid receptor rich cell line do not display the same patern.
Inhibition of binding by DAGO, DTLET and 127IAzido DTLET (Ki nM)
Radioactive ligand
DAGO 3.9 700 668
127IAzidoDTLET 25 1 . 4 2 . 5
136 14.9 
competing 3HDAGO 3HDTLET 125I Azido DTLET
ligand
13.8
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KAPPA OPIOID BINDING SITES ON PITUITARY ASTROCYTES.
S.J. Bunn, M.R. Hanley, and G.P. Wilkin, Dept. Biochem. Imperial College of
Sci. and Tech. London SW7, England.
Opioid binding sites in the rat pituitary are predominantly located
over the neural lobe. We have demonstrated that the majority of these
sites are of the kappa subtype, and are located on the pituitary
astrocytes, the pituicyte. This unexpected observation raises the
interesting possibility that astrocytes elsewhere in the CNS may also
possess kappa opioid binding sites. A limited study suggests however
that this is not the case. Kainic acid injection of the rat striatum
induces a marked gliosis, but a concurrent reduction in the density of
opioid binding sites. The rat striatum has only very low levels of
kappa opioid binding sites. In contrast, the guinea-pig cerebellum
ehibites a high density of these sites, located predominantly over
the molecular layer (Robson et al. 84). Such a distribution would be
consistent with a location on radial Bergman glia, a type of
cerebella astrocyte. Once again, although injections of kainic acid
produced a very considerable gliosis, there was an almost total
abolition of kappa opioid binding sites.
These and other observations suggest that the pitucicytes may be unique
among astrocytes in possessing binding sites for kappa opioid ligands.
Pituicytes also exhibit a remarkable morphological plasticity,
engaging in a dynamic interaction with the neurosecretory nerve
terminals (Hatton et al. 84). It is interesting to speculate as to the
role of this interaction in regulating neurohypophyseal secretion and
as to the possible influence of opioids upon this relationship. As a
first step in addressing these questions, and as part of a wider
interest in the actions of opioids on astrocytes, we have attempted to
establish pituicytes in tissue culture. A wide variety of culturing
procedures have been evaluated and the resulting cells identified
using immunohistochemical cell-specific markers. Monolayer cultures of
three day old rat pituitary gave rise to a number of cell types,
including a population of cells intensely expressing the astrocytic
marker glial fibrillary acidic protein. The striking stellate
morphology often displayed by these astrocytes made them easily
identifible in histologically stained preparations. Autoradiograms
produced from these cultures show that kappa directed 3H-EKC binding
was selectively localized over these cells.
It is our working hypothesis that these in vitro astrocytes are
derived from the in vivo pituicytes, an hypothesis supported by the
continuity of GFAP and kappa opioid binding site expression. We
suggest that the cultured pituicyte preparation may provide a useful
model to examine the action of kappa opioid agonists.
Robson et al 1984.
Hatton et al 1984.
Neurosci. 12, 621.
Peptides 5, 121.
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DIRECT EVIDENCE FOR THE COMPLEXATION OF A GTP-BINDING PROTEIN
WITH DELTA-OPIOID RECEPTORS. K.-J. Chang. 2. Y. Li and
S. G. Blanchard, Molecular Biology Department, The Wellcome
Research Laboratories, Research Triangle Park, NC 27709, U.S.A.
Opioid-receptors in brain are regulated by GTP and cations.
The binding affinity of opioid-agonists to receptors is decreased
by GTP and sodium ions and increased by divalent cation, Mg2+.
In neuroblastoma cells, delta-receptors are similarly regulated
by GTP and cations. Enkephalins inhibit the activity of adeny-
late cyclase in a GTP- and Na+-dependent manner. Pretreatment of
c e l l s  w i th  per tuss i s  t ox in  e l iminates  the  op i o id  inh ib i t o ry
effect  on adenylate cyclase a n d  d e c r e a s e s  t h e  a f f i n i t y  o f
agonists to delta-receptors. These ef fects  of  pertussis  toxin
are correlated with the ADP-ribosylation of  a  GTP-binding
protein. These data suggest that delta-receptors are associated
with a GTP-binding protein. In this  study, we have used an
opioid-affinity column to obtain direct evidence that suggests
the complexation of a GTP-binding protein with delta-receptors.
The solubilized receptors were assayed with 125I-labeled [D-Ala2, -
D-Leu5]enkephalin and the GTP-binding proteins were measured by
the binding activity of 35S-labeled GTP S . Delta-receptors were
solubilized from neuroblastoma cell membranes with 10 mM CHAPS
and subsequently applied to an opioid-coupled affinity column.
Nearly 90% of solubilized delta-receptors and significant amounts
of GTP-binding proteins are retained by the affinity column.
Significant activity of a GTP-binding activity was specifically
eluted by [D-Ala2,D-Leu5]enkephalin or naloxone. No significant
activity of either protein was retained and subsequently eluted
in a control column. These data suggest that a GTP-binding
protein can be adsorbed to an opioid-affinity column and subse-
quently be specifically eluted by opioid-ligands. This result
provides direct evidence that a GTP-binding protein is a part of
the delta-receptor system.
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RELATIONSHIP OF OPIATE RECEPTOR BINDING SITES AND OPIATE-INHIBITED
ADENYLATE CYCLASE IN BRAIN MEMBRANES. S.R. Childers, P. Nijssen
and J. Harris, Dept. of Pharmacology, Univ. of Florida Coll. of
Med., Gainesville, Fl 32610.
Opiate agonists inhibit adenylate cyclase in both brain and
neuroblastoma cell membranes. Adenylate cyclase appears to be
coupled to delta opiate receptors in NG108-15 cells, but the
pharmacological nature of the adenylate cyclase-linked opiate
receptor in mammalian brain has yet to be established. To
determine the relationship between high affinity multiple opiate
receptor binding sites and opiate-inhibited adenylate cyclase in
brain, we assayed adenylate cyclase in membrane preparations after
treatment with various agents which are known to block high
affinity opiate agonist binding. Incubation of membranes with
phospholipase A (500 ng/ml) inhibited 93-100% of binding of
[3H]-DAGO, [3H]-DSTLE and [3H]-EKC to mu, delta, and
kappa sites, respectively. However, adenylate cyclase in treated
membranes was still inhibited by D-Ala enk (with inhibition
blocked by naloxone); moreover, the D-Ala enk agonist dose
response curve was not affected by phospholipase treatment. To
obtain more specific receptor blockade, membranes were incubated
with irreversible opiates, then washed to remove traces of
reversibly-acting drugs; control membranes contained equal
concentrations of naloxone to control for washing. Incubation of
membranes with several irreversible opiates, including antagonists
like naloxone azine and beta-FNA, and agonists like
p-nitro-phenyl-oxymorphone, did not affect agonist dose response
curves in inhibiting adenylate cyclase, but blocked high affinity
receptor binding by 75-100%. However, incubation of membranes with
beta-CNA (10 µM), which blocked binding by 95-1OO%, shifted the
adenylate cyclase dose response curve for D-Ala enk by approx.
ten-fold. These results indicate an irreversible loss in adenylate
cyclase-linked receptors by beta-CNA, but not by other
irreversible opiates, and suggest that receptors linked to
adenylate cyclase in brain do not correspond to any of the sites
labeled with nM concentrations of [3H]-agonists.
Suppported by grant DA-02904 from the National Institute on
Drug Abuse.
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DEVELOPMENT OF A SELECTIVE MU1 OPIATE RECEPTOR BINDING ASSAY.
J.A. Clark and G.W. Pasternak, The Cotzias Laboratory of Neuro-
Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
10021, U.S.A.
Previous studies have identified a binding site of very high
affinity which bound both opiates and enkephalins with very high
aff inity. In most routine assays this binding site corresponded
to approximately 20-30% of total specific binding, precluding
detailed studies of mu1 binding. Therefore, we have developed a
simple binding assay in which greater than 75% of total specific
binding corresponds to mu1 sites. There are currently no
suitable radiolabeled mu1-selective ligands. An alternative
approach is to obtain tissue enriched in mu1 sites relative to
either mu2 or delta sites. Detailed computerized digital
subtraction autoradiograms reveal relatively high levels of mu1
and mu2 sites in the thalamus, but few delta sites. We took
advantage of the low density of delta sites in the thalamus by
using 3H[D-ala2,D-leu5]enkephalin which labels mu1 and delta
sites. The low density of delta sites relative to mu1 sites
increased the proportion of mu1 to delta binding compared to
whole brain homogenates. In this assay system, 3H[D-ala2,D-
leu5]enkephalin labels the mu1 sites with an affinity constant
(KD) of 0.4 nM and a Bmax of approximately 3 fmoles/mg tissue.
Both morphine and [D-ala2,D-leu5]enkephalin compete 3H[D-ala2,D-
leu5]enkephalin binding with IC50 values under 1 nM and
saturation studies performed in the presence and absence of
morphine reveal competitive inhibition. Other opiates and opioid
peptides also compete binding effectively. Mu1 binding in this
assay is very sensitive to sodium chloride and guanyl nucleotides
and is irreversibly inhibited by naloxonazine. N-Ethylmaleimide
at 25 µM lowers binding by greater than 50% and trypsin (1 µg/ml)
virtually abolishes binding. The development of this assay
system should provide a means of examining the mu1 binding sites
more extensively.
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Na+ and GTP have
on the kinetics of
3 similar but not identical effects
H-DPR binding: they both - and sy-
Target size analysis of the opioid receptor in NG
108-15 cells reveals that a molecular unit of 56 kDa
accounts for the binding activity determined with 3H-
diprenorphine (3H-DPR) in the presence of Na and GTP,
A UNIT WHICH IS NOT SUBSTRATE OF PERTUSSIS TOXIN MAY
MEDIATE SODIUM EFFECTS ON OPIOID RECEPTORS IN NG 108-15
CELLS. T. Costa, S. Ott and A. Herz, Department of Neu-
ropharmacology, Max-Planck-Institut für Psychiatric,
D-8033 Martinsried, F.R.G.
whereas in the absence of these agents a structure of
98 kDa is measured. This suggests that an additional
42 kDa subunit is required for opioid binding in the
absence of ions and nucleotide.
nergistically - appear to increase the proportion of a
fast-dissociating form of the receptor, but only Na+
enhances the absolute rate of association and dissocia-
tion. The slowly dissociating form is likely to repre-
sent in part a N-protein receptor complex, since in
membranes exposed to low concentrations of N-ethylma-
leimide (NEM) or obtained from cells pre- treated with
pertussis toxin (PT) the receptor exists predominantly
in a fast dissociating form and no or little GTP effect
can be detected; however, the effect of Na+ is still
present. In these membranes, as well as in those from
cells treated with cholera toxin (CT), the target size
is identical to that assessed in native membranes,
whether or not GTP is present in the binding reaction.
Conversely, in the presence of Na+, a 40% reduction of
the apparent target size is observed in+ control, PT,
CT, and NEM treated membranes. Thus, Na is the sole
agent responsible for the change in apparent target
size of the opioid receptor. We conclude that a
˜
42
kDa membrane unit, which is not substrate of bacterial
toxins, is also necessary for high affinity binding of
the opioid receptor and may mediate the effect of Na+.
Supported by the DFG, Bonn.
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DEMONSTRATION AND CHARACTERIZATION OF 3 SUBTYPES OF KAPPA
OPIOID RECEPTORS IN BOVINE ADRENAL MEDULLA MEMBRANES.
R. A. Cruciani, G. O. Pesce, P. J. Munson, and D. Rodbard,
LTPB, NICHD, NIH, Bethesda, MD 20892 USA.
Opiopeptides and their receptors are present in high concen-
tration in adrenal medulla,and may play a role in the regula-
tion of catecholamine release and chromaffin cell function.
Previous studies have shown predominance of (relative to µ and
) sites, but there has been controversy about whether these
sites represent 1, 2 or 3 classes of sites. We have used fro-
zen bovine adrenal medulla membranes in Tris.Cl pH 7.4, 37°, 30
min with 3H-etorphine (Et), 3H-ethylketocyclazocine (EKC), and
[3H]-[D-Ala2,D-Leu5]enkephalin (DADL) as tracers, displaced by
all 3 unlabeled ligands. Studies were done "unblocked" (µ,
sites), and with 100 nM DADL to block µ and s i t e s ,
and with 1, 10 and 100µM DADL to progressively block the
(or benzomorphan) site. Mathematical modeling with the LIGAND
computer program was used to analyze data from more than 100
curves, to compare models with 1 to 5 classes of sites. Results
indicate 3 subtypes of receptors . i s  s e l e c t i ve  f o r  EKC
relative to Etorphine and has binding capacity of 4 fmoles/mg
prot. is EKC-Etorphine
nonselective (Kd=1 nM), and
represents 80% of the sites
(84 fmoles/mg protein) and
can be blocked by 1 to 100
micromolar DADL. i s
Etorphine selective, with
a binding capacity of 32
fmoles/mg protein. DADL at
high concentration (100 µM)
does not block Etorphine or
MC binding to o r
Conclusion: Multiple sub-
types of kappa opioid re-
ceptors are present in bo-
vine adrenal medulla mem-
branes.
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UPREGULATION OF BRAIN KAPPA OPIATE RECEPTORS IN
SPONTANEOUSLY HYPERTENSIVE RATS.  Sumantra
Das and Hemendra N. Bhargava, Department of Pharmacodynamics,
University of Illinois at Chicago, Health Sciences Center, IL 60612,
U.S.A.
The binding of tritiated ligands for various opiate receptor
subtypes to brain membranes prepared from spontaneously
hypertensive rats and normotensive Wistar-Kyoto rats was
determined. The density (Bmax) or the apparent
dissociation constant (Kd) for the binding of the mu-ligand
(naltrexone) and delta-ligand (Tyr-D-Ser-Gly-Phe-Leu-Thr)
to brain membranes of hypertensive and normotensive rats did not
differ. However, the Bmax  for the binding of kappa-ligand
(ethylketocyclazocine) to brain membranes after the suppression of
mu- and delta-sites by 100 nM each of unlabeled D-Ala2-
MePhe4-Gly-ol5-enkephalin and D-Ala2-D-
Leu5-enkaphalin, respectively, was significantly greater in hypertensive
rats compared to normotensive rats. The Kd values for the binding
of 3H-ethylketocyclazocine (EKC) in the two groups did not differ.
The binding of 3H-EKC in brain regions was in the order:
hypothalamus> midbrain> striatum> cortex> pons + medulla. The
increase in the binding of 3H- EKC in the brain of hypertensive rats
compared to normotensive rats was due to increased binding in the
hypothalamus and cortex. These results provide for the first time
evidence for selective proliferation of kappa-opiate receptors in
the brain of hypertensive rats, and suggest that brain
kappa-opiate receptors may play an important role in the
pathophysiology of hypertension. (Supported in parts by grants
from the National Institute on Drug Abuse, DA-02598 and Chicago
Heart Association A83-30).
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PRODYNORPHIN DERIVED PEPTIDES AND mRNA IN RAT LEYDIG CELL LINES.
L. Devi, J. Douglass, R. Thompson, O.  Civelli and E. Herbert,
Institute for Advanced Biomedical Research, The Oregon Health
Sciences University, 3181 SW Sam Jackson Park Road, Portland,
OR 97201, U.S.A.
The primary structure of the rat precursor for dynorphin
peptides has recently been deduced using cDNA hybridization
technology. The precursor protein, prodynorphin, contains
several opioid peptides that have been isolated as separate
products from mammalian neural tissues. In addition,
imnunoreactive dynorphins have been found in various reprductive
tissues of rat, guinea pig and rabbit. In the rat testis, the
immunoreactive dynorphin peptides have been localized to Leydig
cells. These observations prompted us to determine the presence
of prodynorphin mRNA and dynorphin peptides in two stably
transformed rat Leydig cell lines, R2C and LC540. Prcdynorphin
transcripts were observed in poly (A+) mRNA isolated from R2C
cells but not in LC540 cells. Neither cell lines expressed the
proenkephalin gene while both cell lines expressed the
proopiomelanocortin gene. Immunoreactive dynorphin A and (Leu)
enkephalin were measured in R2C cells by radioimmunoassay. The
estimated concentration of 33fmol immunoreactive dynorphin A/mg
protein in R2C cells corresponds to a tissue concentration of
14fmol/mg protein in rat testis. Trypsin and carboxypeptidase B
treatment of the cell extract did not substantially increase the
(Leu)enkephalin immunoreactivity suggesting the absence of any
large molecular weight precursor that might have cross reacted
poorly with the dynorphin antibody. The observations that the
R2C cells contain prodynorphin transcripts and translated
products suggest that this Leydig cell line could be used to
study the dynorphin gene at the level of transcription,
translation and the processing of the propeptide.
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THE ROLE OF ENDOGENOUS OPIOID PEPTIDES IN SUDDEN INFANT DEATH
SYNDROME AND OTHER CLINICAL SITUATIONS. William L. Dewey, Edwin
C. Myer, Dale Morris and Michael Adams. Departments of
Pharmacology and Neurology, Medical College of Virginia, Virginia
Commonwealth University, Richmond, VA 23298 U.S.A.
Sudden infant death syndrome occurs in approximately two out
of every one thousand births. The cause of death is not known
but appears to be associated with respiratory malfunction. Since
opioid peptides have been shown to cause respiratory depression
and because at least one child with documented apneic spells has
been treated successfully with a narcotic antagonist, we have
investigated whether a correlation exists between endorphin
levels in CSF and/or plasma and risk for SIDS. The CSF level of
endorphin in the siblings of SIDS was 78.8 pg/ml, and children
with interrupted SIDS had levels averaging 128.9 pg/ml. The CSF
level of endorphin in children not at a high risk for SIDS
(controls) was 32.8 pg/ml. The highest control value was below
the lowest value in the high risk group. Thus no overlap existed
between the two groups. Two children with high CSF levels of
endorphin were treated with naltrexone, which resulted in
normalization of life-threatening respiratory patterns. These
results support the hypothesis that in humans endogenous opioids
in excess may result in respiratory events which, under certain
circumstances in infants, may result in SIDS. The level of
endorphin in plasma was not elevated in the high risk group.
CSF endorphins also were found to be elevated in five children
with Rett's Syndrome, and in one child with nonketotic
hyperglycemia with ongoing seizures. Two children admitted in
status epilepticus had high endorphin levels. CSF endorphins
would appear to be the result of CNS stress events and may have
many etiologic causes. (Supported in part by USPHS Grant No.
DA01647).
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EXPRESSION OF OPIOID PEPTIDE GENES IN MALE AND FEMALE
REPRODUCTIVE TISSUES. J. Douglass, B. Quinn, B. Cox, O. Civelli
and E. Herbert, Institute for Advanced Biomedical Research, The
Oregon Health Sciences University, 3181 SW Sam Jackson Park Road,
Portland, OR 97201, U.S.A.
Recent studies suggest a functional role for opioid peptides
as modulators of the hypothalamus-pituitary-qonadal axis at a
variety of levels in both males and females. We report here the
expression of all three opioid peptide genes in rat male and
female reproductive tissues. Prodynorphin mRNA is present in the
rat ovary, uterus and testis. Proenkephalin mRNA can be detected
in the epididymis and vas deferens, in addition to the ovary,
uterus and testis. POMC mRNA can be detected in the ovary,
testis and epididymis. Immunohistochemical analysis reveals that
prodynorphin derived peptides are expressed in Leydig cells in
the testis. The distribution of immunoreactive dynorphins in
reproductive tissues was also determined by RIA. Dynorphin A and
B immnoreactivity was detected in the testis, epididymis and vas
deferens of the rat, guinea pig and rabbit. These observations
suggest that opioid peptides may exert paracrine and/or autocrine
effects in mammalian reproductive tissues.
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ACTION AT THE MU RECEPTOR IS SUFFICIENT TO EXPLAIN
THE SUPRASPINAL ANALGESIC EFFECT OF OPIATES.
Fernette G. Fang. H.L. Fields, and Nancy M. Lee,
Departments of Neurology and Physiology and Langley
Porter Psychiatric Institute and Department of
Pharmacology, University of California, San
Francisco, CA 94143, U.S.A.
Mu, delta, and kappa opiate receptors have been
implicated in the production of analgesia. In order
to study the relative contributions of these
receptor types to supraspinally-mediated analgesia,
apparent pA2 values and rank order potencies were
fdetermined or intracerebroventricularly-injected
highly selective opioid agonists in the mouse using
a thermal nociceptive assay. Drugs used included
the prototypical mu agonist morphine, put tive mu
agonists DAGO [D-Ala2, N-methyl-Phe4, Gly5-ol]
enkephalin and BAM 2 P, putative delta agonists
DPDPE [D-Pen2, D-Pen5] enkephalin, DTLET [D-Thr2,
Thr6, Leu5] enkephalin, and DSLET [Tyr-D-Ser-Gly-
Phe-Leu-Thr] enkephalin, and the putative kappa
agonists U50488H [trans-3,4-dichloro-N-methyl-N[2-
(1-pyrrolidinyl)-cyclohexyl]-benzeneacetamide
methane sulfonate hydrate] and dynorphin A (1-13).
We were unable to demonstrate significant
analgesic potencies for intracerebroventricularly-
injected (i.c.v.) dynorphin A (1-13) or BAM 22P in
the absence of marked behavioral abnormalities. The
rank order potency of the remaining compounds
studied was found to be: DAGO > DTLET > DSLET >
Morphine > DPDPE > U50488H. Apparent pA2 values of
morphine, DAGO, and DPDPE in naloxone antagonism
trials did not differ significantly.
These results indicate that while both mu- and
delta-selective ligands produce potent analgesia, a
single receptor (mu) is sufficient to mediate the
supraspinal effects of opiate drugs.
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ABSENCE OF HIGH AFFINITY DELTA AND KAPPA BINDING IN RAT
PERIAQUEDUCTAL GRAY ENRICHED P2 MEMBRANE.  J.  P. Fedynyshyn, G.
Kwiat. and N. M. Lee, Department of Pharmacology, University of
California, San Francisco, CA 94143, U.S.A.
The periaqueductal gray (PAG) region of the midbrain has been
implicated in both stimulation produced and opioid induced
analgesia. In the present study the opioid binding
characteristics of the PAG were examined with an in vitro
radioligand binding technique. 2nM 3H-Ethylketocylazocine (EKG)
was used to nonselectively label µ, a n d binding sites in PAG
enriched P2 membrane. The µ selective ligand [D-Ala
2,N-Methyl
Phe4,Glyol5] enkephalin (DAGO) displaced 3H-EKC from more than
one population of binding sites with both high and low affinity.
In contrast the selective ligand [D-Pen2,D-Pen5]enkephalin
(DPDPE) and the selective ligand U50,488 displaced 3H-EKC from
a single population of binding sites with low affinity. DPDPE
and U50,488 also displaced 2 nM 3H-DAGO from a single population
of binding sites with similar low affinity. DAGO and not DPDPE
displaced 2 nM 3H-[D-Ala2,D-Leu5] enkephalin (DADLE) with high
affinity. This binding data is consistent with the presence of a
single population of µ selective high affinity binding sites in
PAG enriched P2 membrane to which ligands and ligands have
low affinity. This data is also consistent with opioid induced
supraspinal analgesia being a primarily µ opioid receptor
mediated event. This research was supported in part by National
Institute of Drug Abuse Grants DA 02643 and 1 F31 DA
05281-01(JPF).
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GASTRIC ACID SECRETORY EFFECTS SEPARATE OPIOID RECEPTOR TYPES.
D.A. Fox, E.A. Ayres and T.F. Burks, Department of Pharmacology,
University of Arizona, Tucson, AZ 85724, U.S.A.
Morphine and the endogenous opioid peptides produce variable
effects on gastric acid secretion. Part of this variability may
be due to the activation of different opioid receptor types. The
aim of the present investigation was to evaluate the effects of
central and peripheral administration of the mu selective ago-
nists DAGO and PL017, the delta selective agonist DPDPE, the
kappa selective agonist U50,488H and morphine on basal gastric
acid secretion in the rat. Gastric secretion was measured in 24
hour fasted, unanesthetized, pylorus-ligated rats. Drugs were
administered immediately after pylorus ligation either intracere-
broventricularly (ICV) through an indwelling guide cannula or
intravenously (IV) through the tail vein. Eats were sacrificed 2
hours after drug administration and stomach volume and acid were
measured. Acidity was determined by titration with 0.01M NaOH to
a pH of 7.0. ICV administration of DAGO, PL017 and morphine
produced a dose-dependent (0.3-10ug) decrease in both gastric
secretion volume and acidity. In contrast, central administra-
tion of DPDPE (100ug) or U50,488H (600ug) did not alter gastric
acid secretion. IV administration of morphine and PL017
(0.3-3mg/kg) significantly decreased gastric acid secretion.
U50,488H administered IV caused a dose-dependent (1-10mg/kg)
increase in gastric acid secretion, whereas DPDPE and DAGO did
not alter gastric secretion when given IV. The central
inhibitory effect of PL017 and the peripheral stimulatory effect
of U50,488H on gastric acid secretion were antagonized by
naloxone 3mg/kg administered subcutaneously 15 minutes prior to
the agonists. These results suggest that stimulation of central
and possibly peripheral mu receptors decreases acid secretion,
stimulation of peripheral kappa receptors increases gastric
secretion and delta opioid receptors are not involved in the
regulation of gastric acid secretion. Because of the clear
separation of gastric secretory effects observed with these
selective agonists, measurement of gastric acid secretion may be
useful as an in vivo bioassay to determine relative opioid
receptor selectivity. (Supported by AM36289 and AM33547.)
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MOLECUIAR BIOLOGY OF ENKEPHALIN CONVERTASE (CARBOXYPEPTIDASE E).
L. D. Fricker  and E. Herbert, Institute for Advanced Biomedical
Research, Oregon Health Sciences University, Portland OR 97201 USA
Enkephalin convertase (carboxypeptidase E) is the carboxypep-
tidase B-like enzyme involved in the biosynthesis of the opiate
peptides, as well as other peptide hormones and neurotransmitters.
This enzyme has been purified to homogeneity from bovine
pituitary, and a partial amino acid sequence has been determined.
Oligonucleotide probes corresponding to the amino acid sequence
have been used to isolate a cDNA clone from a bovine pituitary
cDNA library. The predicted amino acid sequence of the cDNA clone
contains several pairs of basic amino acids, and displays some
homology with carboxypeptidases A (CPA) and B (CPB). Although the
overall homology is low, all of the amino acids thought to be
essential for the catalytic activity of CPA and CPB have been
conserved in enkephalin convertase. Major differences between
enkephalin convertase and the other carboxypeptidases include an
additional 120 amino acids at the C-terminal of enkephalin
convertase, and numerous changes in amino acids near the substrate
binding sites. These changes may reflect the different
specificities of the enzymes: enkephalin convertase is very
specific for the enkephalin precursors, and does not further
degrade the enkephalin peptides. The homology between the
carboxypeptidases suggests a common evolutionary origin, which
supports the theory that the peptide processing enzymes existed
before the first opiate peptides.
The cDNA encoding enkephalin convertase hybridizes primarily to
mRNA of approximately 3.3 kb in bovine brain, pituitary, and
adrenal medulla. Restriction fragment analysis of bovine genomic
DNA indicates a single gene encodes enkephalin convertase.
Results of studies on the regulation of this gene will be
presented.
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DYNORPHIN AND ANTERIOR PITUITARY HORMONES: EFFECTS ON
PLASMA CONCENTRATIONS IN THE MALE RHESUS MONKEY.
P. M. Gilbeau, Y. Hosobuchi and N. M. Lee, Departments
of Neurological Surgery and Pharmacology, University of
California, San Francisco, CA 94143, U.S.A.
The role of dynorphin-(1-13) and dynorphin-(1-10)-
amide in the neuroendocrine control of primate anterior
pituitary hormones was studied in nonrestrained, adult
male rhesus monkeys. The effects of these opioids on
plasma concentrations of prolactin (PRL), luteinizing
hormone (LH), follicle stimulating hormone (FSH), thy-
rotropin (TSH) and growth hormone (GH) were assessed.
Dynorphin or its saline vehicle were administered and
blood was collected through an indwelling jugular cath-
eter to avoid the stress associated with these proce-
dures. Blood samples were drawn at 20 min intervals 1
hr prior to and 4 hr post administration, additional
blood samples were collected at 5 and 10 min post
administration. Opioid doses ranged from 0.1 to 120
ug/kg. Hormones were measured by RIA. Intravenous
administration of dynorphin-(1-13), 1 to 120 ug/kg,
significantly increased plasma PRL levels. Average
maximal increases of 100% to 225% occurred within 5 min
and levels remained significantly elevated for up to 2
hr. A plateau was reached following the 30 ug/kg dose.
No effect was seen with doses lower than 1 ug/kg.
Dynorphin-(1-13) had no observable effects on plasma
concentrations of LH, FSH, TSH or GH at any dose level
studied. Administration of dynorphin-(1-10)-amide
significantly increased plasma PRL concentrations.
Dose levels of 1 to 120 ug/kg produced average peak
increases from 100% to 225%, 5 to 10 min post
administration. Dynorphin-(1-10)-amide had no signifi-
cant effect on plasma concentrations of LH, FSH, TSH or
GH. The increases in PRL by dynorphin were naloxone
reversible. These results indicate a selective effect
of dynorphin on the regulatory mechanisms of PRL secre-
tion over that of other anterior pituitary hormones.
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Abstract
DIRECT ANALYSIS OF THE RELEASE OF METHIONINE-ENKEPHALIN
FROM GUINEA PIG MYENTERIC PLEXUS. A.R. Gintzler, W.C. Chan and
J. Glass. Department of Biochemistry, Downstate Medical Center, Brooklyn,
NY 11203, U.S.A.
The in vitro release of methionine-enkephalin (met-enkephalin) from 2
longitudinal muscle myenteric plexus (LMMP) strips from guinea pig ileum has
been obtained during continuous superfusion and quantitated directly using a
radioimmunoassay specific for this opioid peptide. Electrical stimulation
(5-80 Hz) produced a significant increase in the rate of release of met-
enkephalin the magnitude of which was not dependent on the frequency of
stimulation. Analysis of the release of met-enkephalin per pulse as a
function of the frequency of stimulation indicated that the release of this
opioid peptide from the myenteric plexus is inversely proportional to the
frequency of stimulation. Electrically evoked release (40 Hz) of met-
enkephalin was reduced by greater than 80% by substituting CoCl2 for CaCl2
or by pretreatment with tetrodotoxin (TTx; 1 ug/ml for 15 min. Evoked
release was also substantially reduced by pretreatment with morphine (1 uM,
1.5 min). Alternatively, pretreatment of naive LMMP strips with the opiate
antagonist (-) naloxone caused a significant increase in the rate of met-
enkephalin release in the absence of electrical stimulation. In contrast,
(+)-naloxone was devoid of any activity. These data, in combination with
indirect pharmacological experiments, strongly indicate that met-enkephalin
functions as a neurotransmitter in the enteric nervous system. Moreover,
the activity of neurons that transmit via met-enkephalin appear to be under
opioid regulation.
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INTRATHECAL DYNORPHIN (1-13) ATTENUATES WITHDRAWAL IN
MORPHINE-DEPENDENT RATS. P.G. Green and N.M. Lee. Department of
Pharmacology, University of California, San Francisco, Ca 94143,
U.S.A.
Dynorphin is an endogenous opioid peptide and studies have
suggested that it may be involved in tolerance and dependence
mechanisms (Lee and Smith, TIPS 5 108-110, 1984). Systemically
administered dynorphin has been shown to substitute for morphine
in morphine-dependent monkeys (Aceto et al., Eur. J. Pharmacol. 83
139-142, 1982). However, it is not known whether dynorphin acts
on spinal or supraspinal systems; both these have been implicated
in the development of opioid dependence (Yaksh et
al., Eur. J. Pharmacol. 42 275-284, 1977).
Male Sprague-Dawley rats (220-240g) were implanted either with
chronic catheters to permit injection of dynorphin directly into
the spinal subarachnoid space (i.t.) or cannulae for
intracerebroventricular (i.c.v) administration. At least 5 days
following surgery, rats were made tolerant to morphine by the
implantation of morphine pellets. Six hours after removal of the
pellets, rats were given either dynorphin or vehicle i.t. or
i.c.v. and assessed for withdrawal over a period of time.
The relative importance of spinal and supraspinal sites in the
modulation of opioid withdrawal could be determined by the
effectiveness of dynorphin administered i.t. and i.c.v. The data
from these experiments suggest that dynorphin is able to
attenuate morphine withdrawal signs by acting primarily at spinal
sites.
6 3 4
BRAIN OPIOID RECEPTOR REGULATION IN THE DEVELOPING ANIMAL.
J. Habas and A. Tempel2, 2Dept. of Neuroscience Albert
Einstein College of Medicine, Bronx, NY 10461, U.S.A. 1Dept. of
Medicine SUNY/Downstate Medical Center, Brooklyn, NY 11203,
U.S.A.
Chronic treatment with opiate agonists and antagonists have
been shown to induce changes in brain opioid receptor density
in adult rats. The development of these receptors and their
regulation by exogenously administered opioids in perinatal
pups has been less well characterized. We examined opioid
receptor regulation in brains of neonatal rats after chronic
agonist and antagonist treatment. Two regimens of drug treat-
ment were used: naltrexone was administered to 1) mothers prior
to conception or 2) pups of non-treated mothers starting on day
of birth. Pups (ages 1-7 days) from each treatment group were
sacrificed and brains assayed for specific opioid receptor
types. Aliquots of brain homogenate (1.0 ml, .45 mg/ml pro-
tein) were incubated with various concentrations of [3H]D-
Ala2,Gly-ol5-enkephalin (µ specific opioid) in the presence or
absence of a 1000-fold excess of levorphanol. Scatchard analy-
sis revealed a 139% increase in brain opioidy receptor density
on the day of birth in offspring of naltrexone-treated mothers.
Naltrexone administration to offspring of non-treated mothers
induced a 60% increase in brain u receptor number at day 7.
In a separate experiment, young rats were treated with morphine
sulfate (5 mg/kg). Results of [3H] etorphine (a universal
ligand) binding to brains of pups treated postnatally with
morphine sulfate revealed a 30% decrease in receptor density
after 8 days of treatment; subsequently, the number of recep-
tors increased to control levels. These data indicate that
neonatal rats exhibit the ability to regulate brain opioid
receptors and that these receptors are in a plastic state both
in utero and for the first two weeks postnatal. (This work is
supported by NIH grant No. No. NS21973).
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LIPID REQUIREMENT FOR OPIOID RECEPTOR BINDING. J.
Hasegawa, N. M.  Lee and H. H. Loh, Depts. of Pharmacology and
Psychiatry, University of California, San Francisco, San
Francisco, CA 94143, USA.
We have recently purified to homogeneity an opioid receptor
from rat brain that shows selectivity for mu-type opioid ligands
(Cho et al., Proc. Natl. Acad. Sci., 1986, in press). While
this receptor is a protein, it requires lipid for expression of
high opioid binding activity. In order to define this requir-
ment precisely, we have tested the ability of various lipid
components to reconstitute binding to the partially purified
protein. Several fatty acids were able to restore binding, with
linoleic (18:2), arachidonic acid (20:4) and linoleic (18:3) the
most potent; stearic (18:0), and oleic (18:l) were inactive.
Phospholipids were active if, and only if, they contained a)
active fatty acids; and b) acidic polar head groups. Thus
phosphatidic acid (PA) and phosphatidyl inositol (PI) containing
linoleic acid (18:2) restored opioid binding, while dioleoyl PA
and dilineoyl phosphatidylcholine (PC) did not. Confirming our
earlier findings, no lipids tested exhibited significant opioid
binding activity in the absence of the protein component.
These results indicate that mu opioids bind to a lipid-pro-
tein complex, and that both the polar head group and the fatty
acid of the lipid component are critical to this binding.
Because of the greater degree of specificity possible in a
protein, and because several lipids can combine with the protein
in an opioid binding complex, we believe that the opioid binding
site itself is on the protein; the role of the lipids, then,
would presumably be to stabilize a particular conformation of
the protein. However, we cannot rule out the possibility that
the roles of protein and lipid are reversed, with lipids binding
the opioid and proteins ordering the lipids in a specific array.
To decide between these two possibilities, it will be necessary
to label the receptor covalently with an opioid ligand.
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LUMBAR INTRATHECAL MORPHINE AFFECTS PUTATIVE PAIN
MODULATORY NEURONS IN THE RAT MEDULLA.  M.M. Heinrincher, K.
Drasner, F. Fang and H.L. Fields, Departments of Physiology,
Anesthesiology and Neurology, University of California, San
Francisco, CA 94143, U.S.A.
On- and off-cells are putative pain modulating neurons in
the rostral ventromedial medulla (RVM) of the rat. On-cell
activity increases, while that of off-cells decreases,
immediately prior to the tail flick reflex (TF) elicited by
noxious heat. We have previously shown that systemic ad-
ministration and PAG microinjection of morphine produce an
increase in activity of all off-cells and a decrease in
activity of all on-cells concomitant with inhibition of the
TF. The present experiments investigate whether spinal
opiates similarly affect the activity of on- and off-cells in
the RVM.
A lumbar intrathecal catheter was implanted under pento-
barbital anesthesia. The animals were allowed to recover for
5 to 10 days, and were then used in the electrophysiological
experiment. Activity of off- and on-cells was recorded with
a microelectrode stereotactically placed in the RVM.
Measures of spontaneous and TF-related activity were obtained
before and after intrathecal administration of 10 or 15 µg of
morphine sulfate in 5 µl of a balanced salt solution.
Intrathecally-administered morphine that inhibited the TF
(10 s cut-off) differentially affected the spontaneous
activity of on- and off-cells. Activity of all off-cells was
increased and that of all on-cells ceased following morphine.
The slowing of the off-cells and acceleration of the on-cells
in response to heat were attenuated or abolished. These
changes were reversed by naloxone (0.25-0.5 mg/kg, i.v.).
Administration of the vehicle had no effect on the activity
of these cells.
These results raise the possibility that intrathecally-
administered opiates produce analgesia in part by activation
of the sane brainstem neurons that are activated by opiates
given systemically or in the PAG.
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IMMUNOHISTOCHEMICAL LOCALIZATION OF AMINOPEPTIDASE M
IN RAT BRAIN: RELATIONSHIP OF ENZYME LOCALIZATION AND
ENKEPHALIN METABOLISM. Louis B. Hersh and Stanley Watson,
Department of Biochemistry, Universitv of Texas Health Science
Center at  Dal las,  Dal las,  Texas 75235 and the Mental  Heal th
Research Institue, University of Michigan School of Medicine, Ann
Arbor, Michigan, 48109, U.S.A.
I t  i s  c u r r e n t l y  b e l i e v e d  t h a t  t h e  p h y s i o l o g i c a l  a c t i o n  o f
synaptically released enkephalins is  te rmina ted  by  enzymat ic
degradation. Two pep t idase  ac t i v i t i es  have  been  iden t i f i ed  in
synaptic membrane preparations which could act as
“ e n k e p h a l i n a s e s ”  i n  v i v o ;  a  n e u t r a l  m e t a l l o e n d o p e p t i d a s e
(“enkephal inase”)  and an aminopept idase r e f e r r e d  t o  a s  t h e
“enkephalin degrading aminopeptidase”. Recently aminopeptidase
M  a c t i v i t y has been f o u n d  i n brain synaptic membranes
preparations. This aminopeptidase has been proposed to represent
the true enkephalin degrading aminopeptidase. If aminopeptidase
M cou ld  be  shown to  ex i s t  a t  enkepha l ine rg i c  synapses  i t s
involvment in the degradation of synaptically released enkephalins
would be more firmly established. Using a monospecific polyclonal
antibody to aminopeptidase M the localization of the enzyme in
several brain regions has been determined immunohistochemically.
The results clearly demonstrate a localization restricted to blood
v e s s e l s . The evidence that this aminopeptidase functions as an
“enkephalinase” must thus be reconciled with its localization on
blood vessels. A  mode l  wh ich  i s  sugges ted  i s  one  i n  wh ich
di f fusion of  enkephal ins away from their  receptors is a pr imary
event i n  t e r m i n a t i n g  t h e  a c t i o n  o f  e n k e p h a l i n s . D is ta l  to
enkephalin receptors several peptidases, including aminopeptidase
M, hydrolyt ical ly inact ivate enkephal ins. This action can serve
two functions. First  i t  maintains a h igh concentrat ion gradient
for diffusion of enkephalins away from the receptor, and secondly
it prevents free enkephalins from acting distal to the site of their
release.
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REGULATION OF GENE EXPRESSION OF OPIOID PEPTIDES. V. Höllt, N.
Kley, J.Ph. Loeffler and C.W. Pittius, Department of Neuropharmaco-
logy, Max-Planck-Institut für Psychiatrie, D-8033 Martinsried and
Department of Physiology, University of Munich, D-8000 München,
F.R.G.
The concentrations of messenger ribonucleic acids (mRNAs) coding
for the three opioid peptide precursors proopiomelauocortin (POMC),
proenkephalin A and prodynorphin were measured in a variety of
tissues by hybridization to cloned nucleic acid sequences comple-
mentary to the opioid precursor mRNAs. Regulation of opioid peptide
gene expression at the mRNA level was investigated in the following
sets of experiments:
1. The effects of chronic stress and/or pain on the levels of
POMC mRNA in the pituitary and on proenkephalin A and prodynorphin
mRNA in the spinal cord was studied in rats in vivo. An inductive
effect of chronic stress/pain on the POMC mRNA levels in the ante-
rior pituitary was found which could be mimicked by infusion of
corticotropin-releasing factor (CRF) and by drugs which release CRF
from the hypothalamus (e.g. morphine).
2. The influence of CRF and other secretagogues on POMC mRNA
levels was analysed in vitro using cultured rat anterior and inter-
mediate lobe cells. CRF induced an increase in POMC mRNA levels in
both pituitary lobe cells - an effect which was found to be me-
diated by cAMP. The expression of POMC mPNA levels in intermediate
lobe cells was negatively regulated by dopamine and GABA and posi-
tively by ß-receptor agonists. cAMP was found to be a critical
mediator for these effects.
3. Proenkephalin A gene expression was studied in cultured bo-
vine adrenal medullary cells. An increase in the levels of proen-
kephalin A mRNA was seen after activation of nicotinic
after treatment with depolarizing agents
receptors,
(veratridine, K+) and
after treatment with agents that stimulate the adenylatecyclase
system. These effects were inhibited by Ca2+ channel blockers in-
dicating that, besides cAMP, Ca2+ plays a major role in mediating
proenkephalin A gene expression.
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FEEDBACK INHIBITION OF CARBOXYPEPTIDASE H. V.Y.H. Hook and E.F.
LaGamma*, Laboratory of Cell Biology, NIMH, Bethesda, MD. 20892
and *Division of Developmental Neurology, Cornell University
Medical College, New York 10021, USA.
Carboxypeptidase H (CPH) is one of several processing enzymes
required for the conversion of peptide hormone and neuropeptide
precursors into the smaller active peptides. CPH removes COOH-
terminal lysine and arginine residues to result in the formation
of peptides such as (Met5)enkephalin (ME), ACTH, vasopressin, and
others. It has been refered to as 'carboxypeptidase B-like' and
'enkephalin convertase' but has now been designated 'carboxypepti-
dase H' ("H" for Hormone, Enzyme Nomenclature Committee of IUB)
to distinguish it from other carboxypeptidases. We demonstrate
in this study that CPH activity can be regulated by its products
by a feedback inhibition mechanism. CPH activity in bovine adre-
nal medulla chromaffin granules and in rat adrenal medulla homo-
genates, which contain enkephalin peptides, was inhibited by ME
with an inhibition constant, Ki, of 12.0 ± 0.8 ( ± s.e.m.) mM.
The known intragranular concentration forenkephalin peptides has
been estimated to be in the millimolar range. Therefore, CPH may
be inhibited by endogenous enkephalins as their concentration
rises. In contrast to ME, the other proenkephalin-derived pep-
tides (Leu5)enkephalin (LE), ME-Arg6-Gly7-Leu8, and ME-Arg6-Phe7
inhibited CPH with lower Ki values of 6.3 ± 0.4, 7.4 ± 0.6, and
4.4 ± 0.9, respectively. One proenkephalin precursor-molecule
contains 4 copies of the sequence ME, but contains only one copy
of each of the sequences LE, ME-Arg6-Gly7-Leu8, and ME-Arg6-Phe7.
Thus, the single copy peptides are present within the granule at
lower concentrations than ME. The difference in Ki values for
the single copy compared to the multiple copy sequences demon-
strates that CPH can be inhibited by lower concentrations of LE,
ME-Arg6-Gly7-Leu8, or ME-Arg6-Phe7 compared to ME. It appears
that the final products that result from complete processing of
proenkephalin can equivalently alter CPH activity by feedback
inhibition.
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METHAQUALONE: SPECIFIC BINDING IN CENTRAL TISSUES.
R. A. Houghten and S. M. Pratt, Scripps Clinic and Research
foundation, 10666 N. Torrey Pines Rd., La Jolla, CA 92037, U.S.A.
Tritiated analogs of methaqualone having high specific
activity were prepared for use in binding studies. Specific
binding of [3H]3-MQ (70 Ci/mmolel was found in synaptosomal
preparations of mouse, rat, and bovine brain with an apparent
dissociation constant (Kd) of 0.18-0.39 µM and a Bmax of 5.6
pmoles/mg protein. This binding was satdrable, reversible,
temperature sensitive and exhibited subcellular and regional
variations. The specific binding was inhibited by drugs that
share the pharmacological actions of methaqualone but was not
inhibited by those in unrelated classes. The ability of various
classes of opioid peptides to displace [3H]3-MQ binding will be
discussed.
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PREPROENKEPHALIN mRNA LEVELS IN TESTIS UNALTERED BY HYPO-
PHYSECTOMY. R.D. Howells, B.D. Shivers, P. Morris and S.
Udenfriend, Dept. Neuroscience, Roche Institute of Molecular
Biology, Nutley, NJ 07110, U.S.A. and The Rockefeller
University, New York, NY 10021, U.S.A.
We have reported recently that the proenkephalin gene is
expressed in rat testis (Kilpatrick et al., PNAS 82:7467-7469,
1985). Since the major physiological functions of the testis,
viz. production and release of androgens and spermatogenesis,
are dependent on luteinizing hormone and follicle-stimulating
hormone derived from the anterior pituitary gland, we have
compared the steady state levels of preproenkephalin mRNA in
hypophysectomized and sham-operated rats. Four week old rats
were hypophysectomized (n = 7) then sacrificed nine days later
with age-matched, sham-operated controls. Hypophysectomy was
verified by observing a lack of weight gain over the nine day
period and by visual inspection of the sella turcica following
sacrifice. ETestes were removed, frozen in liquid nitrogen and
total RNA was isolated following CsCl centrifugation. Steady
state levels of preproenkephalin mRNA were compared between
groups using Northern blot analysis with 32P-labeled rat
preproenkephalin cDNA as probe (Howells et al., PNAS
81:7651-7655, 1984). Hypophysectomy did not alter the levels or
the size of the mRNA in testis, which is longer by about 500
bases than preproenkephalin mRNA extracted from other tissues.
Thus, the expression of the proenkephalin gene in testis is not
influenced by gonadotropins or androgens. Currently, we are
determining the cellular localization of this mRNA in testis
using in situ hybridization and enriched cell populations
maintained in culture conditions. Knowing which cell type
expresses the proenkephalin gene should provide a better
understanding of the function of peptides derived from pro-
enkephalin in the male reproductive tract.
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AGONIST ACTION OF THE AGONIST/ANTAGONIST ANALGESIC
BUTORPBANOL ON MESOLIMBIC DOPAMINE METABOLISM IN THE
RAT. S. Iyengar, H.C. Kim and P.L. Wood, Neuroscience
Research, Research Dept., Pharmaceuticals Division,
Ciba-Geigy Corp., Summit, N.J. 07901, U.S.A.
Agonist/antagonist (Ag/Ant) analgesics have been
shown to exhibit bell-shaped dose-response curves
with regard to analgesia and nigrostriatal dopamine
metabolism (Wood et al., Life Sci. 33(1):759-762,
1983). Throughout this bell -shaped curve, these
agents act as mu and delta opioid antagonists and
demonstrate a lack of cross-tolerance between mu,
delta and ag/ant drugs. Studies with both local drug
injections as well as parenteral drug after
hemisection showed that this phenomenon was not the
result of auto-inhibition. To determine the action
of butorphanol on mesolimbic and mesocortical DA
neuronal pathways, various doses of the drug were
administered intraperitonially and dopamine
metabolism was studied by gas chromatography- mass
fragmentography. Areas studied included pyriform
cortex, prefrontal cortex, cingulate cortex,
entorhinal cortex, olfactory tubercle, nucleus
accumbens and striatum. The effect of 16 mg/kg
morphine was studied in these regions as well.
Butorphanol had no effect on the cortical regions as
well as the olfactory tubercle, even though morphine
caused potent increases in three of the cortical
regions and olfactory tubercle. Thus, this drug had no
mu opioid action in these regions. The previously
observed bell shaped dose-response curve was
reconfirmed in the striatum. However, in the nucleus
accumbens, this drug exhibited a dose-dependent
linear increase in dopamine metabolism. It thus has
an agonist effect on a mesolimbic DA pathway which
seems to be an action of this drug that is different
from that in the nigrostriatal dopamine pathway. The
receptor affinities of this action need to be
elucidated.
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ANTINOCICEPTIVE ACTIVITIES OF MORPHINE (A MU AGONIST) AND OF U
50,488 H (A KAPPA AGONIST) IN VARIOUS STRAINS OF MICE. J.J.C
Jacob, G Michaud, M.A Nicola and N. Prudhomme, Unit of Pharmaco-
logy, Pasteur Institute, F75724 Paris Cédex 15, France.
Previous studies have shown, in mice, genetic variations in
the latencies of some nociceptive reactions and in the amplitude,
duration and naloxone sensitivity of stress induced analgesias.
Differences were also found in the amounts of tritiated naloxone
or EKC bound to their brain extracts. In this work, range of doses
of two agonists, Morphine (Mo) and U 50,488 H, were studied in 4
strains (CXBH, CXBK, C3H and C57B16); doses-and times-effects
curves were drawn and ED50 calculated. With the hot plate test
(response: licking) Mo had much greater effects in two strains
(CXBH - C3H) then in the two others (CXBH - CXBK) U 50,488 H was
the most effective in a different pair of strains (C3H - C57B16)
Results were different with the tail flick test. CXBK mice were
still low responsive to Mo but C57B16 mice were than high respon-
sive. The latter strain in contrast was hardly responsive to U
50,488 H (whereas it was much more in the hot plate test). The
tail flick test was also used in spinalectomized mice (C5-C8).
Surprisingly, effects of 10 mg s.c. of Mo and of U 50,488 H were
almost similar, the pair CXBH-C3H being more responsive than the
two other strains. Assuming that Mo triggered mu receptors and U
50,488 H kappa ones, it appears that in the hot plate test, opioid
mu receptor systems (including related efferent and modulatory
pathways) would be more efficient in CXBH-C3H mice than in
C57B16-CXBK whereas kappa opioid system(s) would be more in
C3H-C57B16 than in CXBH-CXBK. When considering the tail flick
test in intact animals different mu system(s) would be involved,
at least in C57B16, a strain which would then on the contrary lack
a kappa system. The lumbo-sacral opioid system appeared to be more
developed in CXBH and C3H but no mu or kappa functional selectity
was observed; it cannot be excluded that in this latter case, the
dose used was no more selective. These observations add a new
link to previous ones.
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EFFECT OF ADRENERGIC BLOCKERS ON THE DEVELOPMENT OF
ANALGESIC TOLERANCE TO MORPHINE IN MICE. H. Kaneto
and T. Kihara. Department of Pharmacology, Faculty of
Pharmaceutical Sciences, Nagasaki University, Nagasaki
852, JAPAN.
A single dose of reserpine dose-dependently reduced
the brain content of catecholamines and antagonized
the analgesic effect of morphine. At the peak of the
effect, 24 hr after 2.5 mg/kg i.p., the brain content
of norepinephrine was lowered to 30 % of the control
Level, and the analgesic effect of morphine was also
reduced to 40 % of that in naive animals. The reduced
effect of morphine was maintained almost the same
level during 10 daily repetitions. Low dose, 0.1 mg/kg,
of reserpine neither affected the brain content of
norepinephrine nor modified the analgesic effect of
morphine. Daily treatment of animals with this low dose
of reserpine did not induce any appreciable changes in
brain norepinephrine level during 10 days, but effect-
ively blocked the development of tolerance to morphine.
Similarly, a n d blockers, phentolamine and pro-
pranolol, at the dose of 0.5, 1 and 10 mg/kg, did not
affect morphine analgesia but concomitant administra-
tion of 1 or 10 mg/kg of each blocker with 10 mg/kg
morphine suppressed the development of tolerance to
morphine analgesia. These results clearly indicate
that the suppression of the development of tolerance
to morphine analgesia is not attributed to the reduc-
tion of brain narepinephrine content by reserpine.
Maintenace of analgesic effect of morphine in reser-
pinized animals without development of tolerance
during repeated administration may support our previ-
ous finding that morphine analgesia and tolerance is
separable from each other by underlying mechanisms.
Effects of other adrenergic blockers are now under
investigation.
645
MU-1 OPIATE RECEPTOR: DO DISPLACEMENT EXPERIMENTS INDICATE
ITS EXISTENCE IN THE BRAIN? A. Kenner & Y.Sarne Department
of Physiology and Pharmacology, Tel-Aviv University,
Tel-Aviv 69-978 Israel.
Displacement from brain membranes of labeled opiate
alkaloids by low concentrations of enkephalins and of
labeled enkephalins by low concentrations of alkaloids , has
been previously explained by the existance of a common high
affinity site termed mu-l (Wolozin & Pasternak, PNAS
78,6181, 1981). An alternative interpretation of the same
results is that the trough seen in the low concentration
zone of the displacement curves represents cross binding of
mu and delta opioid ligands to delta and mu receptors,
respectively. That such cross binding takes place is
suggested by our experiments in which the same low
concentrations of [3H]-morphine bind to NG-108 membranes
which contain a pure population of delta receptors. In two
sets of experiments with brain membranes , the size of the
trough (previously interpreted as mu-l) is shown to be
dependent on the labled ligand used ; the ratio between the
size of troughs seen with [3H]-D-ala-D-leu-enkephalin
(DADLE) and [3H]-morphine varies with experimental
conditions (storage of membranes at 4°C for 72h ) and with
the ratio of mu:delta receptors (e.g. in thalamus and cortex
which are enriched in mu and delta sites, respectively).
These results cannot be explained by a common high affinity
site , but rather by binding of [3H]-DADLE to mu and of
[3H]-morphine to delta opioid receptors.
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COMPARISON OF THE INHIBITORY EFFECTS OF CORTICOTROPIN-RELESING
FACTOR (CRF) AND OPIOID PEPTIDES ON THERMAL INJURY IN RATS.
J.G. Kiang, J.Q.Z. Tian and E.T. Wei, University of California,
Berkeley, CA 94720, U.S.A.
Increased exudation of plasma proteins, as measured by Evans
Blue leakage into the innervated pawskin, can be produced by
antidromic stimulation of the saphenous nerve in the anesthetized
rat. This condition, termed neurogenic plasma extravasation
(NPE), is inhibited by opioid agonists, dynorphin (1-13), and
CRF (Europ. J. Pharmacol. 114:111, 1985). Inhibition of NPE has
been attributed to interference with the actions or release of a
putative neurotransmitter, substance P, from sensory nerve end-
ings and it has been shown by Saria (Brit. J. Pharmacol. 82:217,
1984) that administration of a substance P antagonist or deple-
tion of substance P by pretreatment of neonatal rats with
capsaicin can also reduce thermal injury to the rat's paw. In
this study, edema and protein extravasation was produced by ex-
posure of the anesthetized rat's paw to 48-58°C water for 5 min.
CRF, injected intradermally or intravenously at microgram doses,
dramatically inhibited these indices of thermal injury. By con-
trast, the effects of opioid peptides and morphine were less
clearcut. These results suggest that pharmacological modifica-
tion of the activity of sensory nerve endings may have potential
therapeutic benefit for certain forms of skin injury. Supported
in part by grant USPHS NIDA-00091.
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INCREASED MESOLIMBIC DOPAMINE METABOLISM IN THE RAT
AFTER INTRAVENTRICULAR BETA-ENDGRPHIN. H.S. Kim,
P.L. Wood and S. Ivengar. Neuroscience Research,
Research Dept., Pharmaceuticals Division, Ciba Geigy
Corp., Summit, N.J. 07901, U.S.A.
Intraventricular (ivt) injections of beta-
endorphin are known to increase nigrostriatal
dopamine metabolism in the rat (Wood et al., J.
Pharmacol. Exp. ther. 215:697-703, 1980). We now
report the effects of beta-endorphin on rat
mesolimbic dopamine metabolism in the N. accumbens
and olfactory tubercle. The levels of
dihydroxyphenylacetic acid (DOPAC) and homovanillic
acid (HVA) were measured via gas chromatography-mass
spectrometry.
Beta-endorphin (0.5 to 20 ug, ivt , 60 min)
produced potent, dose-dependent increases of DOPAC
and HVA, up to 175% and 155% of control in the N.
accumbens and olfactory tubercle, respectively. These
actions were antagonized by both naloxone (5 mg/kg,
ip) and the long acting narcotic antagonist WIN
44,441-3 (5 mg/kg, ip).
These data suggest that mesolimbic dopamine
projections also possess an opioid receptor
modulation. Selective tolerance experiments are still
required, however, to determine if the actions
reported involve a unique epsilon receptor.
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CHRONIC –ANTAGONIST TREATMENT RETARDS DEVELOPMENT OF
HYPERTENSION IN THE SPONTANENEOUSLY HYPERTENSIVE RAT
(SHR). K. Kraft, J. Diehl and K. O. Stumpe, Medizini-
sche Poliklinik, 5300 Bonn, Wilhelmstr. 35 - 37, FRG.
In general, acute application of -receptor agonists
lowers blood pressure in several species. The involve-
ment of the -receptor in the development of hyperten-
sion is still unknown. Therefore male SHR rats at 6
weeks of age and their normotensive controls (n=11 per
group) were implanted with osmotic minipumps chronical-
ly delivering the -antagonist MR 2266 (10 µg/h) or
solvent. Systolic blood pressure (SBP) was recorded
twice a week for 4 weeks. In normotensive rats develop-
ment of SBP was not affected by treatment, in SHR rats
MR 2266 significantly (p<0.01) retarded the increase of
SBP, the effect starting at 8 weeks of age (167.1 ± 3,5
vs. 178.7 ± 2.3 mm Hg (control) x±SEM). At 10 weeks of
age SBP reached 189.1 ± 3.8 and 201.6 ± 3.7 mm Hg re-
spectively. MR 2266 did not influence the body weight
development in all groups.
It is concluded that the increase of SBP in young SHR
is retarded by chronic -antagonist treatment. This in-
dicates a possible influence of -receptors in the de-
velopment of hypertension in SHR.
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THE DIFFERING PLASMA ß-ENDQRPHIN AND LEUCINE-ENKEFHALIN
CONCENTRATIONS IN NORMOTENSIVE AND HYPERTENSIVE PA-
TIENTS ARE EQUALIZED BY CLONIDINE. K. Kraft, R. Theo-
bald, K. O. Stumpe, Medizinische Poliklinik, 5300 Bonn,
Wilhelmstr. 35 - 37, FRG.
Cpiate antagonists e.g. naloxone have been shown to
block acutely the antihypertensive effect of clonidine
(C) in hypertensive (H) rats and patients, but not in
normotensive (N) controls. Thus, endogenous opioids may
participate in the antihypertensive action of C in H
patients. To determine whether there are differences in
the secretion pattern of endogenous opioids in H and N
patients, plasma ß-endorphin (ß-E) and leucine-enkepha-
lin (L-Enk) concentrations of N and mild essential H
males (n=7, 22-35 years of age) were measured hourly
from 9 p. m. to 8 a.m. after treatment with placebo or
C (2x150 µg) for 14 days. Blood pressure and heart rate
were significantly reduced after C treatment in both
groups. R-E was significantly lower in the placebo H
group than in the N group (7.7 ± 1.8 vs. 18.7 ± 1.9
pg/ml, ± SEM) from 9 p.m. to 2 a.m., but not-during
the R-E peak (2 - 8 a.m.>. In the placebo H group also
the L-Enk concentration was lower (7.8 ± 0.5 vs. 11.9
± 0.7 pg/ml). After 14 days of C, R-E concentration was
increased in the H patients (18.4 ± 2.8), but not in
the N group (19.9 ± 4.6; 9 p.m. -2a.m.) The shape of the
ß-E peak was not influenced by C in both groups. Plasma
L-Enk was significantly reduced in N patients but not
altered in the H group (9.3 ± 0.8 vs. 9.0 ± 1.3). In
conclusion, ß-E and L-Enk plasma concentrations in
young H males are reduced. Treatment with C does not
only normalize blood pressure, but also equalizes plas-
ma concentrations of ß-E and L-Enk. This indicates a
possible involvement of endogenous opioids in the main-
tenance of mild essential hypertension.
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DERMORPHIN BINDING IN RAT BRAIN AND HEART
S. A. Krumins, Department of Neurology, Uniformed
Services University of the Health Sciences, Bethesda,
MD 20814-4799, U.S.A.
Competitive inhibition of [3H]diprenorphine (DPN)
binding in rat brain by dermorphin, represented by
multiphasic plots, suggests multi-site interaction
for dermorphin. Detailed displacement studies using
selective tritiated opioid ligands revealed that
dermorphin interacts preferentially with µ receptors.
In competition with [3H][D-Ala2, MePhe4, Gly(ol)5]-
enkephalin (DAGO), dermorphin (IC50 = 2 nM) appeared
equipotent with DAGO (IC50 = 3 nM) in Tris buffer.
The µ-preferring characteristics prevailed in competi-
tion with [3H]ethylketocyclasocine (EKC) in phosphate
buffer. The displacement of [3H]EKC by dermorphin fit
a 2-site model with approximate IC50 values of 2 nM
and 1 µM. At the addition of 0.1 µM DAGO, the major
portion of [3H] EKC binding was eliminated at very low
concentrations of dermorphin (> 0.1 nM). Additional
portions of [3H] EKC binding were displaced by the
presence of 1 µM [D-Ala2, D-Leu5)enkephalin (DADLE) and
large concentrations of dermorphin (>10 µM). However,
a considerable portion of [3H]EKC binding, as indicat-
ed by the displacement with unlabeled EKC, was not
displaced by large concentrations of dermorphin, in-
dicating that dermorphin interacts very poorly, if at
all, with receptors. In competition with 3H DADLE,
dermorphin displaced the &preferring ligand according
to a 1-site model with IC50 = 75 nM, while the homo-
logous displacement by DADLE was represented by a 2-
site model with an overall IC50 value of 3.5 nM.
Dermorphin displaced [3H]diprenorphine binding in both
atria and the right ventricle but overall not as
effectively as unlabeled diprenorphine.
This work was supported by USAMRDC Grant G19228.
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IN VITRO PRODUCTION AND RELEASE OF OPIOID PEPTIDES IN THE TOOTH
PULP INDUCED BY BRADYKININ. T. Kudo, M. Kuroi and R. Inoki
Department of Pharmacology, Osaka University Faculty of Dentistry,
1-8, Yamadaoka, Suita, Osaka 565, Japan
It has been suggested in in vivo experiments that bradykinin
(BK) might be a trigger in an increase of met-enkephalin(ME)-like
peptide content in the rat incisor pulp induced by noxious stimu-
lation, and in contrast, ME-like peptides in the pulp might inhi-
bit BK release from the pulp which was noxiously stimulated in a
mode of negative feedback mechanism. In the present study, a
possible relationship between ME-like peptides and BK in the rat
incisor pulp was examined in in vitro experiments using whole
pulp, in order to clarify the suggestion mentioned above. ME-like
peptide content in the pulp was increased by BK at a concentration
of 1 nM, but not in higher concentrations, while the release of
ME-like peptides from the pulp into the incubation medium was in-
creased dose-dependently by BK(1 - 100 nM). These effects of BK
were inhibited by Des-Arg9-[Leu8]-BK, a potent BK-antagonist,
suggesting that the effects of BK were mediated through a specific
BK-receptor, Bl-receptor which might be generated de novo in the
noxiously stimulated tissue, in the pulp. On the other hand,
high K+(40 mM) did not induce any increased release of ME-like
peptides from the pulp and the BK-effects were influenced neither
in Ca++-free medium nor in the presence of ouabain(1 mM). These
results suggested that ME-like peptide releasing effect of BK was
not due to depolarization of the pulp cell membrane and was not
active. In addition, kyotorphin(10 µM), an enkephalin releaser,
the effect of which was Ca++-dependent, could not only elicit a
release of ME-like peptides from the pulp, but also a marked in-
crease of the peptide content in the pulp. However, a combination
of BK(1 µM) and kyotorphin(10 µM) attenuated the effect of BK or
kyotorphin each other. These results suggested that there might
be two kinds of mechanisms of ME-like peptide production in the
pulp, one of which was Ca++-independent and another of which was
Ca++-dependent, and those mechanisms might interfere mutually.
From these findings, a physiological role of ME-like peptides in
the pulp will be discussed.
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CHARACTERIZATION AND SOLUBILIZATION OF OPIATE RECEPTORS FROM NCB-
20 CELLS. L. Kushner, M. Eufemio, S.R. Zukin and R.S. Zukin,
Depts. of Neuroscience and Psychiatry", Albert Einstein College of
Medicine, Bronx, NY 10461, U.S.A.
The neuroblastoma x Chinese hamster brain hybrid cell line NCB-
20 is known to contain the opiate receptor and benzomorphan-
specific binding sites (West, et al., 1982). The various opiate
receptors present in this cell line have been further elucidated.
The specific binding of [3H]ethylketocyclazocine (EKC) in the
presence of 109 nM D-Ala2, NPhe4, Gly-ol5-enkephalin (OAGO) and
100 nM D-Ala2, D-Leu5-enkephalin (DADLE) revealed a linear
Scatchard plot, The receptor affinity (Kd) of 5.2 nM and density
(Bmax) of 92 fmol/mg were very similar to the values observed for
rat bain K receptors. The rank order of potency of a series of
opioids and related drugs was determined to be ketocyclazo-
cine>cyclazocine>EKC at this site, whereas phencyclidine (PCP),
TCP, and (+)SKF-10,047 do not compete for binding. The binding
site for the specific ligand [3H]TCP was characterized by a Kd
of 99.7 nM and Bmax of 8863 fmol/mg. The rank order of potency of
a series of opiates, opioid peptides, and related drugs was deter-
mined to be TCP>dexoxadrol>(-)SKF-10,047, cyclazocine>(+)SKF-
10,047>1evoxadrol>PCE, PCP at this site, whereas DAGO, DADLE, and
normorphine do noT compeTe for binding. Binding sites for the
specific ligand [3H]D-Pen2, D-Pen5-enkephalin (DPDPE) have a Kd of
6.5 nM and a Bmax of 167 fmol/mg. Specific binding could not be
obtained using the u-specific ligand DAGO. Thus, NCB-20 cell
membranes appear to have , K, and receptors (no µ receptors
are evident), and would seem to be an excellent source for the
purification of multiple opiate receptors. Solubilization of
opiate receptors from NCB-20 cell membranes was achieved using
glycerol (50%) and the zwitterionic detergent CHAPS (10 nm); a 20%
protein yield and a two-fold enrichment of receptor binding acti-
vity in the soluble protein fraction was obtained. The opioid
receptor affinity in the solubilized fraction was very similar to
that observed in membrane preparations of the cells. Thus, the
procedure appears to maintain the native conformation of the
opioid receptor.
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AUTORADIOGRAPHIC ANALYSIS OF KAPPA (3H-U-69593) AND MU
(3H-dihydromorphine) BINDING IN GUINEA PIG BRAIN SLICES
R.A. Lahti and M.M. Mickelson, CNS Diseases Research,
The Upjohn Company, Kalamazoo, Michigan 49001 USA.
Receptor binding studies have been conducted in a
series of coronal and sagittal sections from Guinea Pig
brain using the highly selective kappa ligand 3H-U-69593
(Lahti, et al., Eur. J. Pharmacol. 109: 281 (1985)) and
in closely adjacent slices using the selective mu ligand
3H-dihydromorphine. Use of the two ligands demonstrated
the clear difference in localization of kappa and mu
opioid binding.
Analysis of binding results obtained with 3H-U-69593
demostrate that kappa sites are located in specific
brain areas. Highest concentrations of kappa binding were
noted in cortical areas, nuc. accumbens, olf. tubercles,
and substantia nigra reticulata. On the other hand, mu
binding had its highest concentration of sites in the
striata, piriform cortex, amygdala, hypothalmus and the
substantia nigra.
Autoradiograms of coronal and sagittal sections will
be presented as will quantitative data on selected brain
areas.
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YOHIMBINE PRODUCES OPIOID WITHDRAWAL-LIKE REACTION IN ADDICTS.
R. R. Lannon, S. Batkl and R.T. Jones, Drug Dependence
Research Center, Dept. of Psychiatry, University of California
Medical Center, San Francisco, CA 94143, U.S.A.
Yohimbine HCI, an alpha2 adrenergic receptor antagonist, or
placebo was administered orally (0.43 mg/kg and 0.21 mg/kg) to
methadone addicts and normal volunteers to test whether opiate
addicts have dysregulated noradrenergic system homeostatic
mechanisms and, specifically, to determine whether antagonism
of the alpha2 feedback system produces an accentuated nor-
adrenergic response. Yohimbine or placebo was given 30 min
after the patients’ usual daily oral methadone dose (38 mg)
under double-blind conditions. Blood pressure, heart rate,
skin temperature, respiration, other signs and symptoms of
opiate withdrawal and changes in mood were measured. After
the high dose of yohimbine, the addicts experienced shaki-
ness, restlessness, loss of appetite, tension, chills and hot
flashes, stomach cramps, urge to urinate, twitching, muscle
cramps, sweating ng, nausea, dlarrhea, difficulty concentrating,
anxiety and irritability. Addicts had greater blood pressure
increase and skin temperature drop after yohimbine compared
to controls. The addicts characterized the symptoms as simi-
lar to opiate wfthdrawal. Clonidine, an alpha2 agonist,
suppresses noradrenerglc hyperactivity in opiate withdrawal.
Addicts, even after their usual dose of methadone, demonstrate
symptoms consistent with opiate withdrawal upon exposure to an
alpha2 antagonist. Opiate addicts and patients with affective
disorders (panic disorder, depression) may share similar
defects in locus ceruleus activity Important for malntaining
homeostasis In the noradrenerglc system.
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DOES NALOXONE ANTAGONIZE THE ANALGESIC EFFECT OF THE
PARTIAL OPIATE AGONIST BUPRENORPHINE IN MAN?
W.P. Lehmann and C. Schmauss, Max Planck Institute for
Psychiatry, Munich F.R.G
In human volunteers the thermal pain threshold was
determined by use of a Marstock thermode through which
heat was applied to the thenar of either hand. The
temperature at the thermode-skin interface was measured
by a thermocouple glued to the thermode surface and
continuously recorded by a pen recorder. Subjects mani-
pulated the stimulus temperature by turning a potentio-
meter until they experience a "slightly painful" sen-
sation which was referred as thermal pain threshold. The
partial opiate agonist buprenorphine (0.2-0.4 mg s.1.)
significantly elevated the thermal pain threshold.
Naloxone alone administered as i.v. bolus (O-1-10 mg)
did not significantly change pain threshold. Naloxone
pretreatment with 0.1 mg i.v. still completely blocked
the analgesic effect of buprenorphine but a 200 fold
higher dose was required to antagonize the established
analgesic effect of buprenorphine. The antagonism, how-
ever, was readily established when suprahigh doses of
naloxone were administerd. These data do not necessari-
ly support the concept of a "slow dissociation" of
buprenorphine from its receptor which is often referred
as reason for buprenorphines resistance to naloxone
antagonism. It is suggested that either a high receptor
occupancy or a "facilitated association" of buprenor-
phine with its opiate receptor accounts for its rela-
tive naloxone resistance.
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THE EFFECT OF ANALGESIC DOSES OF MORPHINE ON CELLULAR
A C T I V I T Y  I N  P A I N  R E L A T E D  S T R U C T U R E S :  A  2 - D E O X Y G L U C O S E
AUTORADIOGRAPHIC STUDY. R.M. Levy, M.P. Stryker, M.M.
Heinricher and H.L. fields, Deoartments of Neurological
Suroery, Neurology and Physiology, University of
California, San Francisco, CA 94143, U.S.A.
Desoite reports that morohine (MS) diffusely
decreases regional cerebral glucose metabolism (RCGM),
the effect of opioids on RCGM in behaviorally
documented analgesic states has not been investipated.
We studied RCGM using high resolution 2-deoxyglucose
(2-DG) autoradiography in rats during naloxone-
reversible MS-induced analgesia. Tail flick latency
(TF) to a noxious heat stimulus was tested in 12
ligntly anesthetized adult male rats. TF testings was
repeated 2 min after MS (5 mg/kg IV). All animals had
inital TF of 3-4 sec: after MS, TF increased to cutoff
(> 10 sec). 14C-2-DG. 100 uCi/kg IV, was then adminis-
tered and arterial glucose and radioactivity measured
at logarithmic intervals. 45 min later, rats received
2 mg/kg naloxone IV and in all cases, TF returned to
baseline. Animals were then sacrificed and standard
autoradiography was oerformed on 20 micron tissue
sections. Sections were analyzed using computer
assisted digital techniques and RCGM calculated from
tissue and plasma curves. Evaluation of RCGM after MS
administration in pain related structures. including
periaqueductal pray, nucleus reticularis paragiganto-
cellularis and nucleus raphe magnus, reveals that while
there is a trend toaward increased RCGM in these
structures. there is no statistically significant
change in RCGM as compared to non-pain related
structures and to saline treated controls. These
results suggest that, within the limits of resolution
of this technique (200 microns), these pain related
structures contain several cell oaoulations with heter-
ogeneous responses to ooiates in doses which produce
analpesia.
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REGULATION OF THE CONCENTRATION OF DYNORPHIN A (1-8) IN THE STRIATO-
NIGRAL PATHWAY BY THE DOPAMINERGIC SYSTEM. S. Li, S. P. Sivam, J. F.
McGinty* and J. S. Hong, LBNT, NIEHS, NIH, Research Triangle Park,
NC, *Dept. Anatomy, East Carolina Univ., Greenville, NC, U.S.A.
It has been reported that the dopaminergic system exerts potent
influence on the metabolism of [Met5]-enkephalin and Substance P in
the basal ganglia. Recent reports indicate that dynorphin-like im-
munoreactivity (DN-LI) is present in the striato-nigral pathway and
is found in high concentration in substantia nigra. However, the
regulation of dynorphin in this pathway is not known. The purpose
of this study was to explore the dopaminergic control of the striato-
nigral dynorphin system by measuring the levels of DN-LI after re-
peated injections of dopaminergic agonist and antagonist. Rats re-
ceived different doses of apomorphine (0.5 mg-5.0 mg/kg, s.c. twice
a day), haloperidol (1 mg/kg s.c. twice a day) or in combination
for different periods and were decapitated 16 h after the last in-
jection. Concentration of DN-LI was determined by radioimmunoassay
using a specific antiserum against dynorphin A (1-8). Seven daily
injections of apomorphine (0.5, 1.0, 2.5 and 5.0 mg/kg) caused a
dose-related increase of DN-LI in the striatum (26, 34, 63, 85% over
control at each corresponding dose). Similar increases were ob-
served in the substantia nigra (22, 52, 50 and 62% over control).
Immunocytochemical study revealed an increase in DN-LI, but not
[Met5]-enkephalin-like immunoreactivity in cell bodies located in
striatal patches. An increase in fiber staining of DN-LI in the
substantia nigra was also observed. In another experiment, rats
received 5 mg/kg of apomorphine for 1, 3, and 7 days. There was a
time-related increase in DN-LI both in the striatum (37, 50 and 85%
over control at each corresponding period) and in the substantia
nigra (32, 78 and 62%). In order to examine whether apomorphine-
elicited increase in DN-LI in the basal ganglia is mediated by the
dopaminergic receptors, haloperidol was injected alone or in com-
bination with apomorphine for 7 days. Haloperidol alone failed to
alter the striatal DN-LI, but completely blocked the apomorphine-
induced increase in DN-LI. These results suggest that dopamine
exerts potent influence on the metabolism of dynorphin in the basal
ganglia.
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CLEAVAGE OF PROENKEPHPALIN BY A CHROMAFFIN GRANULE TRYPSIN-LIKE
PROCESSING ENZYME. I.Lindberg and G. Thomas, Dept. Biochem.,
L.S.U.M.C, 1901 Perdido St., New Orleans, LA 70112, and I.A.B.R.,
Oregon Health Sciences University, 3181 S.W. Sam Jackson Park
Rd., Portland, OR 97201 USA.
Proteolytic processing enzymes with trypsin-like specificity
are required for the maturation of prohormones and neuropeptide
precursors into active peptide products. We have been interested
in the use of cDNA expression systems as a means to generate
native prohormones which can then be used to study processing
enzyme candidates. Proenkephalin was produced by infect ion of
African Green Monkey Kidney cells with vaccinia virus containing
cDNA for human proenkephalin. Intact proenkephalin secreted into
the medium was partially purified by passage over a Peptide B
affinity column followed by gel filtration chromatography. This
material was used as the substrate for the chromaff in granule
trypsin-like protease (Lindberg et al, BBRC 106, 186, 1982).
Following incubation at 37°C for varying amounts of time the
reactions were stopped by boiling, and then further incibated
with pancreatic carboxrpeptidase B (in order to remove carboxyl
terminal basic residues), Digestion products were analyzed by
radioimmunoassay using antiserum to met-enk-arg-gly-leu, an
internal sequence in proenkephalin. The production of met-enk-
arg-gly-leu-immunoreactive peptides from proenkephalin was
dependent on the length of incubation with the trypsin-like
enzyme. In addition, no immunoreactivity was observed in the
absence of additional carboxrpeptidase B digestion. Gel filtra-
tion of digestion products revealed the presence of low molecular
weight immunoreactive met-enk, leu-enk, and met-enk-arg-gly-leu
in incubated samples but not in control reactions which were
stopped immediately. HPLC identification of low molecular weight
immunoreacttve products revealed the presence of authentic met-
enk, met-enk-arg-gly-leu, and their sulfoxides. Taken together,
the results indicate that 1) the chromaffin granule protease
possesses the correct specificity to act as an enkephalin-
generating enzyme in vivo; and that 2) cDNA expression systems
represent a useful method for the production of prohormone
substrates for processing enzymes.
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PARTIAL PURIFICATION OF THE MU OPIOID RECEPTOR IRREVERSIBLY
LABELED WITH [3H] FUNALTREXAMINE. L.-Y. Liu-Chen, C. A.
Phillips, S. W. Tam, and L. G. Davis, Central Research and
Development Department and Biomedical Products Department,
E. I. du Pont de Nemours and Company, Experimental Station,
Wilmington, Delaware 19898, U.S.A.
The mu opioid receptor in bovine striatal membranes was
irrevessibly labeled with high specificity by incubation with
5 nM [3H] funaltrexamine ( FNA) at 37°C for 90 minutes in
the presence of 100 mM NaCl. The specific irreversible
binding of [3H] FNA, as defined by that blocked by 1 µM
naloxone, was approximately 60% of total irreversible binding.
The specific irreversible binding was saturable, stereo-
specific, time-, temperature-, and tissue mass-dependent. Mu
opioid ligands were much more potent than delta or kappa
ligands in inhibiting the specific irreversible labeling. SDS
polyacrylamide gel electrophoresis of solubilized membranes in
the presence of 2-mercaptoethanol yielded a major radiolabeled
broad band of MW 68-97K daltons, characteristic of a glyco-
protein band. This band was not observed in membranes labeled
in the presence of excess unLabeled naloxone or FNA. The
glycoprotein nature of the [3H] FNA-labeled opioid receptor
was confirmed by its binding to a wheat germ agglutinin
(WGA)-Sepharose column and its elution with N-acetylgluco-
samine. Following this lectin column chromatography  the mu
opioid receptor became the only protein labeled by [3H] FNA
in the absence of naloxone; no labeled protein was observed in
the presence of naloxone. WGA column eluate was digested with
pronase and the resultant mixture was subjected to high
performance liquid chromatography using C18 reverse phase
column. Three radiolabeled peptide peaks were obtained and
purified to apparent homogenity. Works are currently under
way to obtain sufficient material for sequence determination.
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CONTROL OF PROOPIOMELANOCORTIN (POMC) GENE EXPRESSION
BY CAMP AND CALCIUM. J.Ph. Loeffler, N. Kley C.W.
Pittius and V. Höllt, Department of Neuropharmadology,
Max-Planck-Institut für Psychiatrie, D-8033 Martinsried
and Department of Physiology, University of Munich,
D-8000 Miinchen, F.R.G.
The role of the second messengers CAMP and Ca++ in
the control of POMC gene expression was investigated.
Using hybridization with cloned cDNA probes, we mea-
sured POMC mRNA level in primary cultures of intermedia-
te (IL) and anterior (AL) rat pituitary cells main-
tained in serum free medium.
8 Bromo-cAMP (1 mM) but no 8 bromo-cGMP (1 mM) in-
duced a 2-fold increase in IL POMC mRNA levels. Further-
more, forskolin (1 µM) which directly stimulates the
catalytic unit of the adenylate cyclase (AC), and cho-
lera toxin (100 ng/ml) which activates the stimulatory
subunit (Ns) of the AC, induced an increase in CAMP
levels and a two-fold increase in POMC mRNA levels in
IL and AL cells after two days of treatment.
In another set of experiments, we analyzed the role
of Ca++ in POMC gene expression. When Ca++ entry was
blocked with D600 (50 µM) and nifedipine (100 nM), POMC
mRNA levels decreased to 50% of the control levels.
Similar decrease was obtained when Ca++ free medium was
used. The Ca++channel agonist BAYK 8644 (100 nM) sti-
mulated POMC gene expression and this effect was addi-
tive with forskolin. Taken together, these data suggest
that CAMP and Ca++ are implicated in the regulation of
POMC gene expression in both intermediate and anterior
cells of the rat pituitary.
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EFFECTS OF PHORBOL ESTERS ON OPIOID RECEPTOR ACTIVITY IN
NEUROBLASTOMA X GLIOMA NG108-15 HYBRID CELLS. A. K. Louie,
P. Y. Law and H. H. Loh, Departments of Pharmacology and
Psychiatry, University of California, San Francisco, CA, 94143,
U.S.A.
Incubation of neuroblastana x glioma NG108-15 hybrid cells
with the phorbol ester 12-0-tetradecanoylphorbol-13-acetate
(TPA) decreased opioid inhibition of CAMP accumulation in
intact cells. In contrast, basal and prostaglandin
E1-stimulated cAMP accumulation were unaltered by TPA
treatment. The effect on opioid inhibition was dose- and
time-dependent and TPA abolished up to 4% of opioid activity.
The potency order of phorbol esters and apparent Kact (90nM)
for TPA were consistent with phorbol esters mediating this
attenuation through the stimulation of protein kinase C. TPA
also decreased the inhibition of CAMP accumulation seen with
muscarinic and alpha2-adrenergic agonists.Scatchard analysis
of saturation binding of these membrane receptors demonstrated
that TPA decreased the number of opioid and muscarinic
receptors but not the number of alpha2-adrenergic receptors.
These data suggested that TPA attenuation of receptor activity
might be at the site of the inhibitory-nucleotide-binding
protein (Ni). When Ni was quantified by measuring the
ADP-ribosylation of its 41 kDa alpha subunit by pertussis toxin
and [32P]NAD+, TPA treatment decreased the maximal labeling
without a change in the NAD Km. In contrast, ADP-ribosylation
of the 45 kDa alpha subunit of the stimulatory-nucleotide-
binding protein (Ns) by cholera toxin was unchanged by TPA
treatment. The functioning of the remaining N. protein was
assessed by measuring their activation by guanine nucleotides.
Studies on the effects of GTP and its stable analogue GppNHp on
membrane adenylate cyclase activity were consistent with TPA
inducing a decrease in Ni activation compared to control. We
conclude that TPA attenuated opioid inhibition of adenylate
cyclase and decreases in the number of opioid receptors and Ni
proteins were identified as potential mechanisms for this
action.
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AUTORADIOGRAPHIC VISUALIZATION OF SIGMA RECEPTORS WITH
[3H]1,3 DI-O-TOLYL-GUANIDINE (DTG). S. McLean, J. F. W. Keana2
and E. Weber3, Laboratory of Neurophysiology, NIMH, Bethesda,
MD 20892, 2Dept. Chemistry, Univ. Oregon, Eugene, Oregon 97403,
and
3Institute for Advanced Biomedical Research, Oregon Health
Science University, Portland, Oregon 97201, USA.
The existence of sigma receptors, which appear to mediate
the psychotomimetic effects of certain opiates, was proposed
by Martin et al. in 1976. Recently, a new compound, DTG has
been synthesized (Weber et al., this meeting) that exhibits
selectivity and specificity for the sigma receptor.
Using receptor autoradio raphy we have investigated the neuro-
anatomical distribution of [3H]DTG binding. Biochemical studies
using slide mounted tissue sections were carried out to establish
binding conditions. Sections of guinea pig and rat brain were
incubated for 45 min at 22º C in 50mM Tris (pH 8.0) containing
1mg/ml BSA and 2nM [3H]DTC, washed (4x2min) in ice-cold 10mM
Tris(pH 7.4) with 1mg/ml BSA, blown dry and placed in x-ray
cassettes with 3H sensitive film. Blanks incubated with 10
uM haloperidol indicated specific binding of 90 percent.
[3H]DTG binding sites were heterogeneously distributed
throughout the guinea pig and rat brain. In the forebrain, dense
binding was present in the diagonal band of Broca, the paraven-
tricular nucleus of the hypothalamus, and along the border of the
medial and lateral habenula. Moderate densities were present in
olfactory and retrosplenial cortex, pyramidal and granule cell
layers of the hippocampal formation, and throughout the hypo-
thalamus, septum, zona incerta, and midline nuclei of the thalamus.
Low densities of diffuse binding were present in cortex, striatum,
and thalamus. In midbrain a high density of binding was localized
to the subcommissural organ, red nucleus and oculomotor nuclei,
a moderate density in the periaqueductal gray, and low levels
in the colliculi and substantia nigra. In the hindbrain dense
binding was found in the locus coeruleus with moderate levels
in the nucleus of the facial nerve and cerebellum.
These results demonstrate a distinct distribution of sigma
receptors that is different from that of the mu, delta, or kappa
opiate receptor subtypes.
663
INVESTIGATION OF THE INHIBITORY EFFECT OF HIGH FREQUENCY ELECTRICAL
STIMULATION ON THE GUINEA PIG ILEUM. L. R. McMartin, J. E. Olley
and W. Hope, Department of Pharmacology, Monash University, Clayton,
Victoria, Australia, 3168.
High frequency electrical stimulation (> 5Hz) of the isolated
ileum of guinea pig elicits a post-stimulation inhibition of twitch
responses at 0.1 Hz - a major component of which is considered to
be opioid (Puig et al, 1978). Experiments were performed to
investigate this inhibition. Naloxone (10 nmol/l) significantly
reduced the inhibitory response from 76.0% inhibition (s.e.m.= 4.2:
n = 61 to 51.6% (s.e.m.=1.8; n = 6) (P < 0.051. Mr 2266 [(-)2-
(3-furylmethyl)-5,9-diethyl-2'-hydroxy-6,7-benzomorphan]
(10 nmol/ll also significantly reduced the inhibition from 84.5%
(s.e.m. = 3.1; n = 5) to 36.3% (s.e.m. = 8.0; n = 5)(P < 0.05).
These data indicate a possible involvement of both µ o p i o i d
receptor ligands. The purinergic antagonist 8-phenyltheophylline
(10 µmol/l) did not significantly affect the inhibition (n = 5,
P > 0.051. Since the slow offset and resistance to washing
resembled properties of the potent endogenous ligand dynorphin,
the bathing fluid was examined for the presence of dynorphin
following 3 min high frequency stimulation. Preliminary evidence
was found for the presence of dynorphin-(1-13). dynorphin-(1-17)
and a number of other as yet unidentified inhibitory components
using reverse phase liquid chromatography techniques. Spasmogenic
activity was also found. It is suggested that the high frequency
stimulation-induced inhibition comprises several components, some
of which may be the long-acting opioid dynorphins.
REFERENCES
Puig, M.M., Gascon, P. & Musacchio, J.M. (1978). The Journal of
Pharmacology and Experimental Therapeutics, 206, 289-302.
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MIDBRAIN STIMULATION-PRODUCED ANTINOCICEPTION (SPA)
IN THE FREELY-MOVING RAT: EVIDENCE FOR MEDIATION BY
ß-ENDORPHIN(ß-EP) AND µ-OPIOID RECEPTORS:
M.J. Millan, A.Czlonkowski, M.H.Millan and A.Hers,
Cepartment of Neuropharmacology, Max-Planck-Institute
for Psychiatry, Am Klopferspitz 18a, F.R.G.
Electrical stimulation of the ventral midbrain peri-
aqueductal grey(PAG) of the rat evokes an antinocicen-
tion, in the mediation of which opioids play a role.
The particular opioid peptide and receptor type respon-
sible is, however, unknown. We have, thus, addressed this
question employing freely-moving rats.
Unilateral stimulation of the ventral PAG elicited
an antinociception strongly attenuated by a low dose
of naloxone. The locomotor effects (ipsilateral turn-
ing) were unaffected. Destruction of central ß-endor-
phinergic neurones, which project from the hypothalamus
to the PAG, greatly depleted ß-EP from brain and strong-
ly reduced SPA, but not the locomotor effects. Pharma-
cological blockade of pituitary secretion of ß-EP into
the plasma was ineffective. Chronic perfusion with a
low dose of naloxone selectively blocked the antinoci-
ception induced by a µ-agonist (morphine) but not a
agonist (U50,488). Following pump removal, morphine but
not U50,488 antinociception was enhanced, reflecting a
supersensitivity of µ-receptors. As with morphine, SPA
was reduced in the presence of naloxone and potentiated
upon its removal. Recurrent stimulation led to a toler-
ance of SPA: tolerant rats showed a reduced antinoci-
ceptive action of morphine but not U50,488.
We suggest that the antinociception against noxious
pressure and heat evoked by stimulation of the ventral
midbrain PAG is mediated by central ß-EP and µ-opioid
receptors. Whether ß-EP acts directly on µ-receptors
remains to be clarified. In addition, a possible signif-
icance of any ' '-receptor, for which ß-EP has been
postulated to be a ligand, remains open.
Supported by the Deutsche Forschungsgemeinschaft.
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KAPPA-TYPE OPIOID RECEPTOR IN HUMAN PLACENTAL MEMBRANE.
M. Niwa, *S. Ohta, **K. Kamikubo, M. Nozaki, K. Tsurumi and
***H. Fujimura. Departments of Pharmacology, *Anesthe-
siology and **3rd Internal Medicine, Gifu University School
of Medicine, Gifu 500 and ***Kyoto Pharmaceutical University
Yamashina, Kyoto 607, Japan.
We have reported that kappa opioid receptor in rat brain
possesses a different coupling mechanism from those of mu
and delta receptor between receptor binding site and GTP-
binding protein. In human placental membrane, 3H-EKC bound
to a single class of binding site (Kd:0.75nM, Bmax:60fmol),
and 3H-DHM and 3H-DADLE showed no binding activities. The
EKC binding was strongly displaced by U-50488H, dynorphin A
(1-13) and bremazocine, but not by morphine and DADLE.
These data suggest that the EKC-binding site in human
placental membrane is a homogeneouse kappa receptor.
The inhibitory effect of Gpp(NH)p in high concentration
(1mM on the EKC-binding was very weak in the presence or
absence of 100mM NaCl, in a similar manner as kappa receptor
in rat brain. The effects of SH-group brocking reagent and
pertussis toxin on the EKC-binding and post-receptor
mechanisms will be discussed.
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IN VIVO AUTORADIOGRAPHY: MATING-PRODUCED CHANGES IN
OPIATE RECEPTOR OCCUPANCY ASSESSED BY
[3H] DIPRENORPHINE AND [3H]CYCLOFOXY BINDING IN
BRAIN. N. L. Ostrowski, K. Rice and A. Pert,
Biological Psychiatry Branch, NIMH and Laboratory of
Chemistry, NIADDK, NIH, 9000 Rockville Pike, Bethesda,
MD 20892, U.S.A.
Opiate receptors are found in hypothalamic regions
that regulate neuroendocrine and reproductive functions
in rats and hamsters. Using the procedure of Seeger et
al., 1984 autoradiographic experiments were conducted
to determine whether mating (a physiological stimulus
Known to affect the hypothalamic-pituitary-gonadal
[H-P-G] axis) produced changes in opiate receptor
occupancy, an index of endogenous opioid release. Male
hamsters were selected for testing because they show
dense opiate receptor binding in the sexually dimorphic
nuclear complex of the hypothalamus and their mating
behavior is reliable, precisely timed and resistant to
disruption by the administration of opiate antagonists.
Males were injected (IV) with [3H]cyclofoxy (CF) or
[3H]diprenorphine (DP) after: a) the 5th
ejaculation of a mating session, b) exposure to a
receptive female wearing a vaginal mask, or, c)
exposure only to their home cage. Twenty min after the
injection, animals were sacrificed, their brains
removed, rapidly frozen and processed for film
autoradiography. Computer assisted densitometric
analysis of the binding showed a decrease in the
accumulation of both [3H]DP and [3H]CF in the
cingulate cortex sexually dimorphic nuclear complex
and in the anterior but not caudal striatum of brains
from mated males relative to control-mated males.
Liquid scintillation counting of adjacent brain
sections verifled high brain to cerebellar accumulation
ratios, a lack of difference in cerebellar (i.e.,
non-specific) binding among groups and the ability of
naloxone, when co-administered with the radioligands,
to completely block brain accumulation of labeled drug.
These data suggest that mating produces an Increase in
opiate receptor occupancy, presumably by releasing
endogenous opioids in discrete brain regions. This
technique may prove valuable for investigating the
neuroanatomical loci of opioid peptide-regulation of
the H-P-G axis in living animals.
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MU AND KAPPA RECEPTORS ARE COUPLED TO Ca++ TRANSPORT IN REGULATING
TEMPERATURE RESPONSE. N. P. Pillai and D. H. Ross, Molecular
Pharmacology Division, University of Texas Health Science Center,
San Antonio, TX 78284-7764, U.S.A.
The effect of opiates on body temperature has been shown to
depend on both dose and route of administration. Additionally, Mu
and Kappa agonists have recently been shown to increase and de-
crease respectively basal temperature in unrestrained rats (Geller
et al, l993). Opiates in vitro and in vivo have been shown to
alter Ca++ content, binding and transport in brain membranes.
Temperature regulation has previously been shown to be influenced
by Ca++ ion movements in the hypothalamus. We have evaluated two
opiate agonists, morphine (Mu) and U50-488H (Kappa) for their
effect on temperature and Ca++ ATPase in hypothalamus. Morphine
(15 mg/kg s.c.) produced hyperthermia (+ 1.5°C) at 2 hr. Ca++
ATPase in synaptic membranes was inhibited 24%. Hyperthermia and
enzyme inhibition were both reversed by naloxone (2-5 mg/kg).
Ca++ ATPase activity was decreased in P2 fractions of hypothalamus
(18%) and cortex (20%) (p<.05) but not cerebellum. Ca++ channel
antagonists nimodipine (1 mg/kg), verapamil (2.5 mg/kg) or dil-
tiazem (5 mg/kg) reversed hyperthermia and Ca++ ATPase inhibition.
Administration of U50-488H (3-20 mg/kg s.c.) produced a decrease
in basal temperature in unrestrained rats. This hypothermia was
accompanied by an enhancement of Ca++ ATPase in synaptosomal P2
fractions from hypothalamus but not cortex or cerebellum. Nalox-
one reversed the hypothermia and enhanced enzyme activity while
nimodipine, verapamil and diltiazem potentiated the hypothermic
effects and stimulation of enzymic activity. These results
suggest that opiate Mu and Kappa agonists may increase and de-
crease respectively
intracellular Ca++
basal temperature by a mechanism which alters
levels. Changes in Ca++ ATPase activity in the
hypothalamus together with blockade of Ca++ influx may contribute
to altered intracellular Ca++. These biochemical changes may be
differentially coupled to Mu and Kappa receptors. Supported in
part by grant from Upjohn Company.
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BINALTORPHIMINE: A HIGHLY SELECTIVE, KAPPA OPIOID RECEPTOR
ANTAGONIST. P. S. Portoghese,* A. W. Lipkowski,* and A. E.
Takemori, Departments of Medicinal Chemistry* and Pharmacology,
University of Minnesota, Minneapolis, MN 55455, U.S.A.
The concept of multiple opioid receptors has created a need
for selective antagonists for the identification of different
receptor types and for the investigation of agonist selectivity.
Although selective opioid antagonists are available for mu and
delta receptor types, the development of highly selective kappa
antagonists has been elusive. A key problem has been the ina-
bility to eliminate the mu antagonist component. Here we report
on the utilization of the "bivalent ligand" approach to designing
an extraordinarily selective kappa antagonist, binaltorphimine
(BNI), that is devoid of significant mu antagonist activity. The
chemical structure of BNI is 17,17'-bis(cyclopropylmethyl)-
6,6',7,7'-tetradehydro-4,5 4',5' -diepoxy-6,6'-(methylimino)
[7,7'-bimorphinan]-3,3',14,14'-tetrol. In the guinea pig myen-
teric plexus longitudinal muscle preparation (GPI), BNI (20 nM)
was a potent antagonist of the kappa-selective agonist, ethylke-
tazocine (EK) (IC50 ratio, 165 ± 30). No significant antagonism
of the mu-selective agonist, morphine, was observed (IC50 ratio,
1.2 ± 0.3). In the mouse vas deferens preparation, BNI (20 nM)
weakly antagonized the effect of the delta-selective antagonist,
[D-Ala2,D-Leu5]enkephalin (IC50 ratio = 4.5 ± 0.7). In mice,
BNI (20 mg/kg IV) exhibited a selectivity profile similar to that
in the GPI, with sc ED50 ratios (treated/control) for EK,
U50488H, and morphine of 5.9, 14.6, and 0.85, respectively.
These data indicate that BNI possesses no demonstrable mu antago-
nist activity and is the most highly selective kappa opioid
receptor antagonist reported. Moreover, a comparison of the / µ
selectivity ratio of BNI indicates that its kappa selectivity is
over 800-times greater than that of naltrexone. The fact that
BNI contains two opioid antagonist pharmacophores (a "bivalent
ligand") raises the possibility that its high selectivity and
potency are due to the simultaneous occupation of two vicinal
recognition sites on the kappa receptor system. The significance
of these results and the possible organization of vicinal kappa
recognition sites will be discussed. (supported by NIDA grants)
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CNS INTERACTION OF OPIOIDS AND STEROIDS IN BLOOD PRFSSURE REGULA-
TION. L.A. Reiser and E.E. Hahn, Rockefeller University, 1230
York Ave., New York, NY 10021, U.S.A.
Considerable experimental evidence has now been obtained that
endoyenous opioids are involved in the regulation of blood pres-
sure. Data from our laboratory have demonstrated that hyperten-
sive rats have higher levels of opiate receptors relative to nor-
motensive controls. This increase, which is dependent on age,
coincides with the appearance of elevated blood pressure. In oth-
er studies, we showed that opiate receptors in SHR rats exhibited
an abnormal sensitivity to salt which suggests that the impact of
sodium on blood pressure may be related to its effect on the con-
formation of the receptor. Evidence has also accumulated that a
CNS component may participate in the biochemical mechanisms by
which steroid hormones regulate blood pressure. This activity may
be mediated by specific hormones which are synthesized in situ in
localized brain regions, or alternatively by those which enter the
CNS by crossing the blood brain barrier. The discovery of an in-
terrelationship between the opioid and endocrine systems led us to
evaluate whether such an interaction in specific central sites may
participate in blood pressure regulation. In studies on the meta-
bolism of androstenedione in the CNS of rats we have shown that
19-hydroxylation of androqens greatly exceeds aromatization, and
that 19-hydroxy and 19-oxo androstenedione, both of which are hy-
pertensinoqenic agents, accumulate in quantities five times
greater than estrogens. Using a radiometric procedure we have
demonstrated that CNS production of these 19-oxygenated androyen
metabolites was greater in SHR compared to age matched WKY rats.
When naloxone or naltrexone was injected subcutaneously (0.3-1.0
mg/kg) in CD or WKY rats an increase in CNS androyen 19-
hydroxylase activity was observed. The impact of opiates on this
biotransformation was reinforced by in vitro studies in which
preincubation of
centrations ranging from 10-9 to 10-6 M inhibited the activity of
hypothalamic preparations with morphine in con-
the 19-hydroxylase. In conjunction with our report that adminis-
tration of opiate antagonists to either WKY or SHR rats increases
blood pressure, the results support the hypothesis that an in-
teraction in the brain between endoyenous opioids and 19-
oxygenated androqen metabolites may be involved in blood pressure
regulation.
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PURIFICATION OF THE HUMAN ERYTHROCYTE OPIOID RECEPTOR.
D. Rhoads, A. Rezvani, T. Cho, P. Law, H. Loh and
E. Way. Department of Pharmacology, University of
California, San Francisco, CA 94143 U.S.A.
Previous studies from this laboratory demonstrated
that opiates reduce human red blood cell deformability
by a mechanism that can be correlated with the
prevention of Ca++ efflux through inhibition of
Ca++ ATPase. Moreover, the inhibiting effect is
d o s e - d e p e n d e n t ,  s t e r e o s p e c i f i c  a n d  n a l o x o n e
reversible. The rank order of potency of various
opiates and opioids in inhibiting cell deformability
as well as their binding affinities suggest the
involvement of an opiate receptor with kappa-like
properties. In order to isolate this receptor,
erythrocyte ghosts were solubilized in 0.5% Triton
X-100 and purified by application to a wheat germ
lectin-agarose column and elution with
n-acetylglucosamine. When the eluate was applied to a
dynorphin A (1-13)-Sepharose affinity column and
eluted with nalbuphine, one major band was obtained
following SDS polyacrylamide gel electrophoresis.
Further purification by HPLC on Spherogel-TSK columns
yielded a protein peak which after two dimensional gel
electrophoresis exhibited a relative pI of 5.8 and an
apparent molecular weight of 60,000. The calculated
degree of purification was 11,250 fold which is close
to the theoretical value of 11,500. That this
apparently homogeneous material is the receptor
responsible for opioid binding and action was
substantiated by: 1) the lack of change in affinity
for 3H-diprenorphine and 3H-dynorphin(1-8) after
purification, 2) other opioids compete for the
3H-diprenorphine binding with the same affinity, and
3) cross linking 3H-dynorphin(1-8) to the isolated
material with bifunctional reagents labeled a 60,000
Dalton protein.
Supported by NIDA grant DA00037.
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HALOPERIDOL INCREASES PROENKEPHALIN MRNA LEVELS IN THE CAUDATE-
PUTAMEN OF THE RAT: A QUANTITATIVE STUDY USING IN SITU HYBRIDI-
ZATION. G.J.Romano, B.D.Shivers, R.E.Harlan, R.D.Howells* and
D.W.Pfaff. The Rockefeller University, New York, N.Y. 10021 and
*The Roche Institute for Molecular Biology, Nutley, N.J. 07110 USA
Chronic haloperidol (HAL) treatment increases the levels of
proenkephalin (PE) peptides and mRNA in the caudate-putamen (CPU)
(Tang, et al. PNAS 80:3841,1983). To determine whether this
increase in PE gene expression is exhibited by all enkephalinergic
neurons of the CPU or only by a subpopulation, we have examined
this effect on PE mRNA levels at the cellular level using in situ
hybridization. Male rats were injected ip with 2mg/kg HAL or
vehicle (VEH) daily for 2 wks,decapitated 24hr after the final
injection, and CPu were dissected and stored at -80°C.A cDNA
probe complementary to rat preproenkephalin, (Howells, et al.
PNAS 81:7651,1984), was nick-translated with [32P] or [3H] nucleo-
tides. In situ hybridization was carried out following the method
of Shivers, et al. (Meth. Enz.V124,1986). Emulsion autoradiograms
of cryostat sections hybridized with a [3H] probe were subjected
to grain counting to quantitate the autoradiographic signal.
Labelled neurons were uniformly distributed throughout the CPu.
HAL treated rats (n=6) had 3.0-fold more grains/labelled neuron
than VEH-treated rats (n=5). The total number of labelled neurons
in the CPu did not increase following HAL treatment. Film auto-
radiograms of sections which were hybridized with a [32Pl labelled
probe also showed a 3.0-fold increase in the signal from the CPu
after HAL treatment. For dot blot analysis, total RNA was isola-
ted from individual CPu tissue blocks. The autoradiographic
signal intensities of the dots from HAL-treated animals (n=7) were
2.7x greater than the dots from VEH-treated animals (n=5),
concurring with the results of northern blots.(Tang, et.al., ibid.)
These findings suggest that dopamine exerts a tonic inhibitory
effect on PE gene expression in all enkephalinergic neurons of the
CPu. The agreement between the in situ hybridization results
and dot blot analysis supports in situ hybridization as a method
for quantitative studies of gene expression in the brain.
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TEBULET, A NEW HIGHLY POTENT AND SELECTIVE LIGAND FOR OPIOID
RECEPTORS. B.P. Roques, G. Gacel, C. Seguin, V. Daugé, J. Belleney
and P. Delay-Goyet, Département de Chimie Organique, U 266 INSERM,
UA 498 CNRS, UER des Sciences Pharmaceutiques et Biologiques, 4
avenue de l'observatoire 75006 Paris, France.
Two types of compounds are commonly used for the biological and
the pharmacological characterization of 6 opioid receptors ;
DTLET, a linear hexapeptide (1) and D-Pen2-Pen5 enkephalin a
cyclic pentapeptide (2). However both ligands are not perfect,
since the former is highly potent (Ki = 1.35 ± 0.15 nM) but its
cross-reactivity with µ sites remains relatively high (Ki / Ki µ
= 0.053), whereas the latter is very selective (Ki / Ki µ =
0.0125) but displays a somewhat low affinity (Ki = 10.9 ± 1.2
nM) (3). From the proposed model (4) of selective recognition of µ
or sites and extensive conformational studies of linear and
cyclic peptides, new ligands belonging to the linear hexapeptide
series were designed in order to increase the selectivity
without loss of affinity. The must efficient compound Tebulet (5)
characterized by a constrained structure exhibits a Ki = 4.9 ±
0.6 nM and a discriminatory factor Ki / Ki µ = 0.0122. This new
proble was triticted and is now proposed as reference ligand for
studies of  receptors.
1. Zajac, J.M., Gacel, G., Petit, F., Dodey, P., Rossignol, P.
and Roques, B.P., Biochem. Biophys. Res. Commun. 111, 390-397
(1983).
2. Mosberg, H.T., Hurst, R., Hruby, V.J., Gee, K., Yamamuza,
M.J., Gillican, J.J. and Burks, J.F., Proc. Natl. Acad. Sci.
80, 5871-5874 (1983).
3. Delay-Goyet, P., Zajac, J.M., Rigaudy, P., Foucaud, B. and
Roques, B.P., FEBS Letters 183, 439-443 (1985).
4. Fournié-Zaluski, M-C., Gacel, G., Maignet, B., Prenilat, S.
and Roques, B.P., Mol. Pharmacol. 20, 484-491 (1981).
5. French Patent 80.17.523 ; US Patent 4,407,794.
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AN EXAMINATION OF THE OPIATE RECEPTOR TYPE5 LABELED
BY THE OPIATE ANTAGONIST, [3H]CYCLOFOXY: A LIGAND
SUITABLE FOR POSITRON EMMISION TOMOGRAPHY. R. B.
Rothman1, S. McLean2, V. Bykov1, A. E. Jacobson3,
R.A. Lessor3 and K. C. Rice3, 1Laboratory of
Preclinical Pharmacology, St. Elizabeths Hospital,
NIMH, Washington DC 20032. 2Laboratotory of
Neurophysiology, NIMH, Bethesda, MD, 20205.
3Laboratory of Chemistry, NIADDK, Bethesda, MD,
20205. U.S.A.
The major goal of this study was to define the
types of opiate receptors labeled in vitro by the
novel opiate antagonist [3H]cycloFOXY synthesized by
Rice and associates. The three approaches used
were: 1. quantitative 1 igand binding studies
utilizing the technique of binding surface analysis;
2. selective site-directed alkylating agents BIT
(mu-selective), FIT (delta-selective), and beta-FNA
(mu-selective) ; 3. receptor autoradiography.
Receptor binding assays were conducted using
frozen lysed-P2 preparations of rat brain. The
assay conditions were 4 to 6 hr incubations at 4° C
in 50 mM TRIS-HCl, 100 mM NaCl, pH 7.4, containing
the protease inhibitors bacitracin, bestatin,
chymostatin, and leupeptin.
Pretreatment of membranes with FIT did not
significantly reduce C[3H]cycloFOXY binding, whereas
pretreatment with BIT or FNA reduced binding by 20
and 25 % respectively. Binding surface analysis of
the interaction of DAGO and dynorphin (1-8) with
[3H]cycloFOXY binding resolved into 2 binding sites.
The Kd’s (nM) of DAGO and dynorphin were: 7.1 and
480 for DAGO, and 2912 and 141 for dynorphin.
Autoradiographic studies are in progress.
The data presently available suggests that
[3H]cycloFOXY labels mu and kappa binding sites in
rat brain.
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UNEXPECTEDLY  HIGH LEVELS OF OPIOID FEPTIDES IN RAT
BRAIN MEMBRANES. R. B. Rothman,1 J.A. Danks1 and  M.
Iadarola1. 1Laboratory of Preclinical Pharmacology,
St. Elizabeths Hospital, NIMH, Washington DC 20032,
U.S.A.
An important experimental paradigm is the
measurement of neurotransmitter receptors in vitro
following in vivo manipulations of the animal. The
possibility that observed changes reflect changes in
receptor occupancy by endogenous ligands must be
carefully ruled out.
These considerations led us to directly measure
using radioimmunassay the levels of dynorphin (1-8),
CCK-8, and MERGL in lysed P2 membranes (group I),
membranes incubated 60 min at 25º C (group II) in 50
mM TRIS-HCl at pH 7.4, and membranes incubated 60
min at 25° C in TRIS buffer containing 0.4 M NaCl
(group III).
pmol/mg protein
GROUP DYN(1-8) CCK-8 MERGL
I .253+.031 1.727±.221 .983±.081
II .108_+.009 1.015±.224 .585±.090
III .106_+.029 .179+±.007 .240±.060
Similar results were obtained when substance-P was
measured. Additional experiments indicated that
membranes rapidly degraded MERGL added to the
homogenate. Freincubation of membranes with 0.4 M
NaCl failed to increase the levels of [3H]etorphine
binding, indicating that frozen lysed-P2 membranes
do not have endogenous ligands occupying opiate
receptors. Detailed comparisons of the two binding
sites labeled by [3H]naloxone revealed changes in
binding parameters induced by preincubation with
NaCl. Additional studies are required to determine
the significance of apparently sequestered
neuropeptides in this preparation of rat brain
membranes.
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Purified mu-opioid receptor exhibits phosphatase activity. S.Roy,
N.M. Lee and H.H. Loh. Deparment of Pharmacology,University of
California, San Francisco, CA. 94143.
A mu-opioid receptor protein has been purified by this
laboratory (Cho et al., 1986). The purified receptor is a
glycoprotein with a molecular weight of 58,000 as determined by
S D S - p o l y a c r y l a m i d e  g e l  e l e c t r o p h o r e s i s .  P r e l i m i n a r y
investigations show that endogenous phosphatase-like activity is
assosciated with this protein. Further studies show that the pH
optimum for the enzymatic activity was at pH 9 with a Km= 9uM
when para-nitro phenol phosphate was used as the substrate.
Analysis of gel slices following SDS-gel electrophoresis show
that the major peak of phosphatase activity is assosciated with a
band of apparent molecular weight 60,000,which corresponds to
the molecular size of the purified mu-opioid receptor protein.
Our results also show that the enzymatic activity is activated by
Mg2+, Mn2+ and Ca2+. Further characterization of the enzymatic
activity will be presented.
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HUMAN NEUROBLASTOMA SK-N-SH CELLS: PHENOTYPIC VARIATION OF µ AND
OPIOID RECEPTORS, MUSCARINIC CHOLINERGIC RECEPTOR AND THE UPTAKE1
SYSTEM. W. Sadée1, V.C. Yu1, M.L. Richards1, F.M. Brodsky2 and
J.L. Biedler3. 1School of Pharmacy, University of California San
Francisco, CA 94143, 2Becton Dickinson Immunocytometry Systems,
Mountain View, CA 94039, and 3Memorial Sloan-Kettering Cancer
Center, New York, NY 10021, U.S.A.
Neuroblastoma cells grown in culture can undergo phenotypic
changes between epitheloid and neuroblast forms. We have
established the presence of µ and opioid receptors, muscarinic
cholinergic receptors and an effective uptake1 transport sytem for
norepinephrine in the human SK-N-SH cell line.In order to
address the question of the expression of these systems during
phenotypic modulation, phenotypically stable subclones of SK-N-SH
were used that exist either in the neuroblast state (SY-5Y), an
intermediate state (IN), or the epitheloid state (EP). While both
the neuroblast SY-5Y and the intermediate IN subclones expressed
all three systems to similar degrees,epitheloid cells were devoid
of these systems. This result documents that the coordinate
expression of multiple receptor systems correlates with the
phenotypic switch from epitheloid to neuroblast status. In
contrast there was no change of the expression of clathrin heavy
and light chain subunits with the different phenotypes. Further,
the light chain clathrin subunit was of the peripheral tissue-type
rather than the brain-type, which is consistent with the
peripheral source of neuroblastoma tissue samples. Supported by
DA 01095 from NIDA, Bethesda, MD.
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ACTIVATION OF MEDULLARY OPIOID-PEPTIDERGIC SYSTEMS BY
FORMALIN-INDUCED PERSISTENT PAIN AND ITS PHYSIOLOGICAL
ROLE. M. Satoh, M. Suqimoto, Y. Kuraishi and H.
Takaqi, Department of Pharmacology, Faculty of
Pharmaceutical Sciences, Kyoto University, Sakyo-ku,
Kyoto 606, Japan.
The nucleus reticularis gigantocellularis (NRGC)
including nucleus reticularis paragigantocellularis is
known to be an important site of analgesic actions of
opioids. Kuraishi et al. have demonstrated an increased
release of immunoreactive Met-enkephalin (iME) from the
nucleus following injection of formalin to the hind-paw
in rats. In the present experiments, we further studied
the physiological role of opioid-peptidergic system and
the content of iME in the rat NRGC. 1) Durations of
licking response were measured at periods of 0-10 min
(P-A), 10-30 min (P-B), 30-60 min (P-C) and 60-120 min
(P-D) after formalin injection into the hind-paw of the
rat. Naloxone injected systemically (using miniosmotic
pumps) or into the 4th ventricle (30 nmol/rat), but not
intrathecally (up to 300 nmol/rat), significantly
increased the duration at P-C. On the contrary,
injections of enkephalin-degrading enzyme inhibitors
(thiorphan plus bestatin; 50 µg each/rat) into the 4th
ventricle significantly suppressed the duration at P-C.
2) The region of NRGC was punched out from the freezed
slices of lower brain stem of rats. The content of iME
in the NRGC increased after treatment with thiorphan
plus bestatin. This increase was augmented by formalin
injection into the hind-paws, while treatment with
cycloheximide blocked such an augmentation. The iME
content measured after digestion of NRGC extracts with
trypsin and carboxypeptidase B was elevated by formalin
injection in rats given thiorphan plus bestatin.
These findings suggest that formalin-induced persistent
pain stimulates the biosynthesis of ME in the NRGC and
is inversely attenuated by the stimulated MEergic
system.
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THE ROLE OF SPINAL KAPPA-OPIATE RECEPTORS IN ANALGESIA.
C. Schmauss and A. Herz, Max Planck Institute for
Psychiatry, Munich, F.R.G.
Male Spraque Dawley rats were implanted with a
chronic intrathecal catheder extending into the lumbar
subarachnoid space. The antinociceptive potency of
intrathecally administered morphine and the putative
kappa-opiate receptor ligands bremazocine, Dyn 1-17,
Dyn 1-13, U50488H and trifluadom was estimated in the
tail flick (TF) and tail pressure (TP) nociceptive
tests. Morphine equipotently inhibited both TF and TP
nociceptive responses. The kappa-ligands Dyn 1-17,
Dyn 1-13, trifluadom and U50488H blocked TP but not TF
nociceptive responses at doses which did not impair
motor function. Only bremazocine was more potent in
blocking TF than TP nociceptive responses. Morphine-
tolerant rats did not exhibit tolerance to the anal-
gesic effects of U50488H and trifluadom on the TP re-
sponse, indicating that these ligands act upon a
spinal opiate receptor which is distinguishable from
the receptor through which morphine exerts its anal-
gesic effect. In line with these results is the obser-
vation that the effects of bremazocine on the TF, but
not on the TP nociceptive response, show cross-toler-
ance to morphine. These data suggest that the spinal
kappa-opiate receptor is involved in the mediation of
TP analgesia. Further support is obtained for the sug-
gestion that spinal opiate receptor subtypes differ-
entially associate with different nociceptive input.
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A MONOCLONAL ANTI-IDIOTYPIC OPIOID RECEPTOR ANTIBODY. R.Schulz1
and C. Gramsch, Department of Neuropharmacology, Max-Planck-
Institut für Psychiatrie, Martinsried; 1 Institut für Pharma-
kologie, Toxikologie und Pharmazie, Universität München, FRG.
The 3-E7 monoclonal antibody, which recognizes the N-termi-
nal sequence of endogenous opioid peptides, has been employed
to raise monoclonal antibodies against opioid receptors via an
anti-idiotypic route. Culture supernatants were screened for
immunoglobulins that interacted with F(ab)2 -fragments of the
3-E7 antibody coated to the wells. Their presence was identi-
fied by an anti-IgM-Fc -peroxidase test(ELISA). A second scree-
ning procedure involved binding to opioid receptors in rat
brain membranes, using 125I-ß-endorphin as tracer. Positive
master wells were cloned by limiting dilution. Supernatants of
posltive clones were tested in the radio receptor assay
(125I-ß- endorphin as tracer). Positive samples were then
purified by anion-exchange chromatography and the purified
material was subjected to SDS-gel electrophoresis. This
technique revealed the presence of an immunoglobulin, showing
characteristics of a reference mouse-IgM. Furthermore,
purified antibodies were submitted to affinity-chromatography
(3-E7 linked to Sepharose). The gel retained the active
principle responsible for the interaction with opioid
receptors. The highly purified antibodies were employed for
detailed receptor binding studies on rat brain membranes. The
antibody was most powerful in competing with 125I-ß-en-
gorphin, followed by 3H-D-Ala2,-D-Leu5-enkephalin and
3H-ethylketazocine; it showed a much lower competition with
3H-dihydromorphine. In contrast, the antibody failed to
interfere with the benzodiazepin 3H-flunitrazepam. The data
suggest the successful generation of a monoclonal anti-idioty-
pic antibody of the IgM-type with affinity for both the 3-E7
monoclonal antibody (antigen) and membrane-bound opioid
receptors.
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MECHANISM BY WHICH ASCORBIC ACID ABOLISHES THE ETORPHINE
INDUCED COMPENSATORY INCREASE IN INTRACELLULAR CYCLIC AMP
LEVELS IN NG108-15 HYBRID CELLS
Shail K. Sharma, Sasanka Chakraborti and Madhav Bhatia,
Department of Biochemistry,All India Institute of Medical
Sciences, New Delhi-110029, INDIA.
In NG108-15 hybrid cells ascorbic acid suppressed
the delayed etorphine induced compensatory increase in the
levels of cyclic AMP. It had however, no effect on the
early response of the cells to etrophine, as manifested in
2 transient decrease in the levels of cyclic AMP (1,2).
The mechanism of action of ascorbic acid is not understood.
In this communication we report on the following
observations. (1) The effect of ascorbic acid on transient
inhibition of adenylate cyclase activity in the homogenates
of NG hybrid cells. (2) Binding of (15,16-3H) etrophine to
monolayer cultures of NG hybrid cells in the presence or
absence of ascorbic acid. (3) Adenylate cyclase and
guanine nucleotide regulatory protein activity of homogenates
of NG hybrid cells which were grown with etrophine in the
presence or absence of ascorbic acid.
(1) Shail K. Sharma and Navin C. Khanna. Biochem. J. 208,
43-46 (1982).
(2) Navin C. Khanna and Shail K. Sharma, Life Sciences,
33, 401-404 (1983).
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BETA-ENDORPHIN ACUTELY STIMULATES SUPEROXIDE PRODUCTION BY HUMAN
POLYMORPHONUCLEAR LEUKOCYTES: COMPARISONS TO MORPHINE AND FMLP.
B. Sharp, D. Tsukayama, W.F. Keane and P.K. Peterson, Dept. of
Medicine, Hennepin County Medical Center and University of
Minnesota, Minneapolis, MN 55415, U.S.A.
We have recently shown that -endorphin ( -END), dynorphin
and morphine rapidly elicit chemiluminescense from human
polymorphonuclear leukocytes (PMN) in vitro due to the produc-
tion of superoxide (O2
- ). The present work evaluated the opiate
receptor involved in the acute PMN response to -END. Using a
f e r r i c y t o c h r o m e  C  r e d u c t i o n  a s s a y  t o  d e t e c t
significantly stimulated O2
- production by  PMN    from normal
donors (N = 5) at concentrations between 10-14-10-8M. The peak
response, 14.3 ± 1.3 (mean ± SE) nM2O2
- /mg protein, occurred at
a physiological concentration (10 . N-acetyl- -END did not
affect O2
-
abolished the stimulation by -END 10-12M, whereas (+)-naloxone
production and (-)-naloxone 10-12M completely
showed minimal inhibition (<16%). (-)-Morphine sulfate (MS)
produced a similar dose-response profile to -endorphin,
although peak PMN O2
- accumulation was significantly greater
with -endorphin (p<.O5). Unlike -endorphin, MS was ineffective
at 10 M. N-formyl-methionyl-leucyl phenylalanine (FMLP), a
peptide which stimulates PMN chemotactic activity and O2
-  produc-
tion, was tested for comparison. FMLP-stimulated O2
- accumulation
was first detectable at 10-12M; in contrast to -END and MS, the
response to FMLP increased directly with concentration. Both
(+) and (-)-naloxone were equipotent against FMLP 10-8M,
resulting in only 30% inhibition which was not significant.
H2O2, the immediate product of O2
- metabolism, was also
measured. Significant HzO2 release by PMN followed stimulation
by endorphin 10-12M. This was markedly reduced (92%) by
nitroprusside, an inhibitor of superoxide dismutase. We conclude
that: a) -endorphin acutely stimulates O2
-
 and H2C2 production
by PMN at peptide concentrations present in the systemic
circulation; b) a stereoselective, µ -like opiate receptor
mediates the action of -endorphin. Thus, stress-peptides and
exogenous opiates may modulate host defense.
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QUATERNARY OPIOID ANTAGONISTS : AN APPRAISAL, J.S. Shaw, N.J.W.
Russell and R. James, ICI Pharmaceuticals Division, Alderley Park,
Macclesfield, Cheshire. SK10 4TG, U.K.
There have been several recent reports on the action of
opioids at receptor sites outwith the blood-brain barrier. Such
studies have relied on the use of standard opioids quaternised on
the basic nitrogen which are believed to have limited access
to the CNS.
In the present study, receptor affinities have been determined
for five quaternary antagonists and their parent compounds
(naloxone, naltrexone, nalorphine and levallorphan). This has
been related to their ability to reverse µ and k agonist effects
in an abdominal constriction test modified to demonstrate
peripheral opioid actions (Bentley, Newton and Starr, Brit. J.
Pharm. 73, 325, 1981) and in conventional antinociceptive assays.
In all cases quaternisation reduced the affinity for both µ
and k-receptors and the extent of this reduction varied
considerably between compounds. Taking this into account in
subsequent in-vivo studies, N-methyl-naloxone showed no peripheral
selectivity. In contrast, the potencies of N-methyl-levallorphan,
N-allyl-levallorphan, N-methyl-nalorphine and N-methyl-naltrexone
were substantially lower (10-100 fold) in hot plate and
conventional abdominal constriction tests than could be accounted
for by loss of affinity. This indicates limited CNS penetration.
However, attempts to demonstrate peripheral antagonism with these
compounds in the Bentley, Newton and Starr test were only
successful with N-methyl-nalorphine and N-methyl-naltrexone. The
two levallorphan analogues were ineffective at doses up to 30mg/kg
S.C.
These results highlight the need for caution in the use of
quaternary opioid antagonists as research tools.
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BIPHASIC MOTIVATIONAL PROPERTIES OF PARTIAL OPIOID AGONISTS:
µ-RECEPT0RS MEDIATE THEIR REINFORCING EFFECTS. T.S. Shippenberg,
R.F. Mucha and A. Herz, Dept. of Neuroparmacoloqy, Max-Planck-
Institut für Psychiatrie, Am Klopferspitz 18a, D-8033 Martinsried,
F.R.G. and Addiction Research Foundation of Ontario, 33 Russell
Street, Ontario, Canada.
The positive reinforcing effects of opioids have been attribut-
ed to agonist actions at µ-receptors, whereas activation of
receptors may underlie their dysphoric or aversive effects. The
motivational properties of the opioid agonist-antagonist analge-
sics are little understood and the nature of their interactions
with particular opioid receptor subtypes remains ill-defined. The
present study employed a place conditioning procedure to charac-
terize the reinforcing/aversive properties of these druqs and the
receptor mechanisms mediating their effects. Rats were exposed to
one of two distinctive environments following injections of drug
or vehicle. After six such training sessions, preference for a
particular environment was assessed by allowing rats free access
to both settings and measuring the time spent on each. Pure p-ago-
nists such as morphine produced clear preferences for the drug-
paired place, while the selective -agonists, U-69593 or U-50488,
produced dose-related aversions. Of the partial agonists tested,
pentazocine was reinforcing at low doses while nalorphine was
aversive. Nalbuphine and buprenorphine produced biphasic motivati-
onal effects. Preferences were observed with low doses while
higher doses resulted in significant aversions for the drug-paired
place. Constant infusion of naloxone via minipumps during train-
ing, atadose sufficient to blocky-receptors but not -recep-
tors, antagonized the preferences induced by morphine and the par-
tial agonists, but was ineffective in modifying their aversive
properties or those of U-69593. These data strongly indicate that
the partial agonists pentazocine, nalbuphine and buprenorphine,
in addition to their purported -agonist and µ-antagonist like
actions, can function as agonists at the µ-opioid receptor and
that activation of this receptor underlies their reinforcing
effects.
Supported by Bundesgesundheit Berlin, F.R.G.
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CELLULAR LOCALIZATION OF PROENKEPHALIN mRNA-CONTAINING NEURONS IN
RAT BRAINSTEM AND SPINAL CORD. B.D. Shivers, R.E. Harlan, G.J.
Romano, *R.D. Howells and D.W. Pfaff, The Rockefeller University,
New York, NY 10021 and *Roche Institute of Molecular Biology,
Nutley, NJ 07110, U.S.A.
Previously, we reported the location of proenkephalin
mRNA-containing neurons in rat forebrain (Harlan et al., Society
for Neuroscience 11:143, 1985), and we have now extended the
description of the location of these neurons to brainstem and
spinal levels. We performed in situ hybridization on frozen,
paraformaldehyde-fixed tissue sections probed with a tritiated 435
b.p. cDNA complementary to rat proenkephalin mRNA encoding amino
acids 56-200 (Howells et al., PNAS 81:7651, 1984).Autoradiograms
were exposed 40 days. Hybridizations following RNase
pretreatment, or with probe diluent alone yielded no labeled
cells. Competition with a 25-fold excess of unlabeled probe
greatly reduced the autoradiographic signal. Sections probed with
tritiated rat pro-opiomelanocortin cRNA (gift of B. Schachter)
yielded a different labeling pattern than that observed with
proenkephalin cDNA. Labeled cells were found in the lateral
geniculate nucleus, periaqueductal gray, midbrain reticular
formation, ventral tegmental area of Tsai. inferior colliculus,
dorsal and ventral tegmental nuclei of Gudden, dorsal and ventral
parabrachial nuclei, pontine and medullary reticular formation,
some of the raphe nuclei, nucleus of the solitary tract, nucleus
of the spinal trigeminal tract, ventral and dorsal cochlear
nuclei, medial and spinal vestibular nuclei, cuneate and external
cuneate nuclei, gracile nucleus, superior olive, nucleus of the
trapezoid body, some deep cerebellar nuclei, Golgi II neurons of
the cerebellum, and most laminae of the spinal cord, especially I
and II. Generally, there was good agreement between regions shown
previously to contain immunoreactive enkephalin neurons and those
regions which we found to have neurons containing proenkephalin
mRNA; however, in many of these regions, more neurons were found
to contain proenkephalin mRNA than were shown previously to
contain immunoreactive enkephalins. The results are consistent
with the concept that opioid peptides derived from proenkephalin
participate in the integration of motor and sensory information.
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ISOLATION AND SEQUENCING OF OPIOID PEPTIDES FROM PORCINE
BRAIN EXTRACTS USING A [3H]-DAGO BINDING ASSAY TO FOLLOW
THE PURIFICATION. Mark Sonders, Bruce Campbell, Charles
Jimenez, Marjorie Shih, and Eckard Weber. Institute for
Advanced Biomedical Research, The Oregon Health Sciences
University, Portland, Oregon 97201, U.S.A.
One of the current projects in our laboratory concerns
the isolation of a putative endogenous sigma receptor
ligand using a binding assay to follow the purification
(see our presentation elsewhere in this meeting). Binding
assays have rarely been used to isolate and characterize
endogenous neurotransmitter or neuromodulator candidates
and it is therefore unclear whether the use of binding
assays to purify endogenous receptor ligands will yield
substances of physiological relevance. In order to
determine whether binding assays can be used to follow the
purification of endogenous receptor ligands yielding
physiologically meaningful compounds, we used an opioid
receptor binding assay to follow the purification of
putative opioid active peaks in chromatography fractions
from separated acid acetone extracts of 5 porcine brains
(513 g). The mu-opioid receptor-specific radioligand
[3H]-DAGO was used in the binding assay. At least eight
major peaks of [3H]-DAGO displacement activity were
observed in porcine brain extracts that had been separated
on a preparative reverse phase C-18 column. Five of the
peaks were purified to homogeneity using various reverse
phase HPLC separation systems. The homogenous peaks were
subjected to gas phase sequencing and/or amino acid
composition analysis using microanalysis methods
established in our laboratory. The five compounds were
unambiguously identified as known opioid peptides from the
proenkephalin and prodynorphin precursors.
[Met5]-enkephalin and alpha-neoendorphin represented the
largest peaks of [3H]-DAGO displacement activity. These
studies demonstrate that radioligand binding assays can be
used to follow the purification of endogenous
neurotransmitter or neuromodulator candidates and that this
method can yield physiologically meaningful endogenous
receptor ligands.
Supported by NIMH grant MH40303.
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IDENTIFICATION AND PARTIAL CHARACTERIZATION OF AN
ENDOGENOUS COMPOUND THAT COMPETITIVELY AND REVERSIBLY
INHIBITS [3H]-DTG FROM BINDING TO THE
HALOPERIDOL-SENSITIVE SIGMA RECEPTOR. Mark Sonders, Bruce
Campbell, and Eckard Weber, Institute for Advanced
Biomedical Research, The Oregon Health Sciences University,
Portland, Oregon 97201, U.S.A.
The development of [3H]-DTG as a novel, selective
ligand for the haloperidol-sensitive sigma receptor (see
our presentation elsewhere in this meeting) has enabled us
to screen brain extracts for the presence of endogenous
material that can displace [3H]-DTG from its brain
membrane binding sites. Acid extracts from whole cow
brains were purified by cation exchange chromatography.
These partially purified extracts contain a small molecular
weight compound which competitively and reversibly inhibits
the binding of [3H]-DTG to the haloperidol-sensitive
sigma receptor in guinea pig brain membrane preparations.
The substance is not a peptide. Its physicochemical
properties [chromatographic behavior in various systems,
solubility properties in polar and nonpolar solvents etc.]
will be presented. Whether or not this compound is a
physiologically relevant, endogenous ligand for the
haloperidol sensitive sigma receptor can only be determined
after the compound has been purified to homogeneity and its
chemical structure has been determined. These studies are
underway.
Supported by NIMH grant MH40303.
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EVIDENCE FOR THE EXISTENCE OF ENDOGENOUS LIGANDS FOR SIGMA
OPIOID RECEPTORS IN THE BRAIN ("SIGMAPHIN"): STUDIES FROM
BINDING ASSAYS. T.-P. Su and S. Y. Yeh, National Institute on
Drug Abuse, Addiction Research Center, Baltimore, Maryland
21224, U.S.A.
SKF-10047 was the prototypic drug for the sigma opioid
receptors which was purported to mediate the psychotomimetic
effects of certain opioids and other drugs.
receptors were later identified in tHe guinea-pig brain
Sigma opioid
homogenates in a binding assay using [3H]SKF-10047 (Su, J.
Pharmacol. Exp. Ther. 223:284, 1982). Ligand selectivities of
the sigma opioid receptors indicated that sigma opioid receptors
do not represent any other known receptor systems in the brain
and may therefore represent a new psychotomimetic pathway. The
unique ligand selectivities of the sigma opioid receptors and
the fact that its prototypic ligand SKF-10047 is psychotomimetic
in humans suggest a possibility of the existence of endogenous
ligand for this receptor. This report presents evidence that
endogenous ligands for sigma opioid receptors ("SIGMAPHIN") may
exist in the brain. Two endogenous ligands which interacted
preferentially with the sigma opioid receptors were identified
from the guinea-pig extract in a Sephadex G-50 fractionation.
These two ligands were more potent in the sigma receptor assay
than in the mu, kappa and delta receptor assays. In the
phencyclidine receptor assay, two ligands were almost
inactive. Incubation of those ligands with trypsin destroyed at
least 50% of the activities of those ligands in the sigma
receptor assay. Both ligands inhibited sigma binding in a dose
response manner. The inhibitions were competitive. The
inhibitions could be eliminated when the ligands were removed
from assay media by extensive washings. It is concluded
therefore that sigma opioid receptors are not phencyclidine
receptors and that endogenous ligands for sigma opioid receptors
may exist in the brain.
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MOOULATION BY ENKEPHALIN ANALOGS AND NEUROLEPTICS OF APO-
MORPHINE-INDUCED STEREOTYPY AND TURNING BEHAVIOR IN RATS.
J.I. Székely, I. Mate, K. Polgár and M. Till, Institute
for Drug Research, H-1325 Budapest, POB 82. HUNGARY
Some of the most characteristic behavioral effects of
classical opiates and opioid peptides are similar to those
elicitable by neuroleptics (Bloom et al., Science, 194, 630,
1976; Jacquet and Marks, idem 194, 632, 1976). Thus the ques-
tion arises whether also opioids inhit the central dopamin-
ergic tone. The neuroleptics are known to antagonize the mo-
tor effects of apomorphine (A) at specific low dose levels.
In our previous study (Sineger et al., Eur., J. Pharmacol.,
80, 359, 1982) S.C. injected morphine (M) and a potent en-
kephalin analog (2-D-Met,5-Pro-enkephalinamide, EA) only
partially inhibited the A-induced stereotypy (S) and turning
behavior (TB) in rats with unilateral nigral lesion. Never-
theless, the inhibition by EA of A-induced S was statisti-
cally significant already at subanalgesic dose levels. The
aim of the present investigations was to examine that which
brain areas might mediate the anti-A effect of opioids. As
the first step of these examinations the substances under
study were injected either i.c.v. or into the nucleus ac-
cumbens (NA) i.e. a mesolimbic region rich in dopamine. Sub-
stances examined were M a µ-selective opiate, 2-D-Ala,5-Nle-
-enkephalin sulfonic acid (ES) a delta-selective opioid, EA a
highly potent non-selective opioid peptide, furthermore,
haloperidol (H) and chlorpromazine (C). As for the inhibition
of A-induced TB the order of potency was: EA>H>M>ES C if
injecting the substances i.c.v. but EA>M>H ES C when ad-
ministering them into the NA. Examining the suppression of
A-induced S the order of potency was EA H M > E S C upon
i.c.v. administration and EA H>M ES>C upon injecting them
into the NA. The data show that certain endogenous opioids
might inhibit the brain dopamine activity via the NA.
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KYOTORPHIN AS A NEUROREGULATOR; EVIDENCE FOR ITS
BIOSYNTHESIS, RELEASE, RECEPTOR AND POST RECEPTOR
MECHANISM H. Takagi, H. Ueda and Y. Yoshihara,
Department of Pharmacology, Faculty of Pharmaceutical
Sciences, Kyoto University, - Kyoto 606, Japan
Kyotorphin (Tyr-Arg) is distributed unevenly
throughout the brain regions and concentrated in the
synaptosomes. Following studies have demonstrated
that kyotorphin produces an analgesia via a release of
met-enkephalin from the brain. In the course of
studying the mechanism of met-enkephalin release, we
found
Ca 2 +
the facilitatory effects of kyotorphin on the
entry into synaptosomes. Thus it has been
postulated that kyotorphin plays a physiologically
significant role as a neuroactive peptide. In the
present study, we reports the further evidence
indicating the role of kyotorphin as a neuroregulator.
BIOSYNTHESIS Kyotorphin is formed from tyrosine and
arginine in the brain synaptosomes. The partially
purified kyotorphin synthetase was characterized.
UPTAKE AND-RELEASE Kyotorphin was actively taken up
into P2 (crude synaptosomes). Kyotorphin preloaded
into synaptosomes was released by high KCl stimulation
in a Ca2+ dependent manner. KYOTORPHIN SPECIFIC
RECEPTOR 3H-kyotorphin specific binding activities
were obtained using the brain membrane preparations.
Leu-Arg showed a potent inhibition of the
POST RECEPTOR MECHANISM We observed the
binding.
kyotorphin-
induced mobilization of the plasma membrane-bound Ca2+
into cytosolic space, determined with the measurement
of the fluorescence of Quin-II and chlortetracycline,
and 45Ca2+ entry into synaptosomes.
induced increase of the 45Ca2+ entry
The kyotorphin-
was completely
abolished by Leu-Arg (a putative kyotorphin
antagonist). ANALGESIA Kyotorphin (i.cisternal)-
induced analgesia in mice was significantly attenuated
by co-administration of Leu-Arg.
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THE EFFECT OF HALOPERIDOL ON PRO-DYNORPHIN END PRODUCTS IN THE RAT
STRIATUM AND SUBSTANTIA NIGRA. R. Tandon, R. Day, J.E. Kelsey,
S.J. Watson and H. Akil, Mental Health Research Institute,
University of Michigan, Ann Arbor, MI 48109-0720, U.S.A.
doses of 0.25, 0.5, 1.0 or 2.0 mg/kg/day. The STR and SN were
collected and extracted in methanol:0.1N HCl (1:1 v/v). Dyn A 1-8
and Dyn A 1-17 content was measured using specific RIAs. In both
regions, Dyn A 1-8 levels increased at the lower doses of HAL
treatment (0.25 and 0.50 mg/kg), but returned to control values or
lower than control values at the higher doses of HAL. However Dyn
A 1-17 content in STR and SN progressively decreased from control
values with increasing doses of HAL. A comparison of the Dyn A
1-17:Dyn A 1-8 ratio shows an increase in the conversion of Dyn A
1-17 to Dyn A 1-8 in STR and SN in rats treated with HAL. The sum
of these observations may be explained by alterations in rates of
biosynthesis, processing and/or release of Pro-Dyn end products.
Our results demonstrate the regulation of the striatonigral
dynorphin system by dopamine. In turn, the changes in Pro-Dyn end
product ratios could subsequently modify nigrostriatal
dopaminergic function. This work was supported by the T. Raphael
Research Fund and NIMH Grant # MH39717.
While the nigro-striato-nigral loop has been extensively
studied in the context of interactions between dopamine,
acetylcholine and GABA, little is known about the role of the
recently discovered striatonigral-dynorphin pathway.
Pro-dynorphin (Pro-Dyn) perikarya are localized in the
caudate-putamen and some of these neurons are thought to be the
source of dynorphin innervation to the pars reticulata of the
substantia nigra (SN). On the other hand, dopaminergic cell
groups within the SN give rise to ascending projections to the
striatum (STR) via the nigrostriatal pathway. Pharmacological
manipulation of this system using the dopamine receptor antagonist
haloperidol (HAL) was used to examine Dyn-dopamine interactions.
Male Sprague Dawley rats were injected i.p. over 4 consecutive
days, and sacrificed on the fifth, with either saline or HAL at
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DETERMINATION OF SIZES OF THE OPIOID RECEPTORS IN THEIR
MEMBRANE ENVIRONMENT BY RADIATION INACTIVATION.
Pao-Luh Tao, Li-Ren Chang, Hsheng-Kai Lee and Horace H.
Loh. Department of Pharmacology, National Defense
Medical Center, Taipei, Taiwan, Republic of China and
Department of Pharmacology, University of California,
San Francisco, San Francisco, California 94143, U.S.A.
Opioids, like other drugs, are thought to initiate
their effects by associating with their specific
receptors. However, very little is known about the
opioid receptor as a molecular entity. The binding
components have been solubilized in detergent and
purified by different approaches, but the molecular
size of soluble opioid receptor complexes reported by
different groups varied from 23,000 to 750,000. In this
study, the technique of radiation inactivation by
gamma ray was used to investigate the apparent size of
the opioid receptor in the rat brain membranes under
different conditions. The molecular sizes of opioid
receptor complexes were egstimated as 313,000 in the
presence of [D-Ala2,D-Leu5] enkephalin, NaCl
and Gpp(NH)p; as 165,000 in the presence of NaCl only
or of both NaCl and Gpp(NH)p; as 217,000 in the
presence of Gpp(NH)p only: and as 286,000 in the
presence of MgCl2 only. A simple model has been
proposed to explain these different apparent target
sizes of opioid receptor obtained under different
conditions.
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ROLE OF THROMBOXANE A, IN THE MORPHINE INDUCED POTENTIATION OF
THE GASTROULCEROGENIC EFFECTS OF INDOMETHACIN IN RATS.
M. Tariq, N. S. Parmar and A.M. Ageel, Research Centre and
Department of Pharmacology, College of Pharmacy, King Saud Uni-
versity, P. O. Box 2457, Riyadh - 11451, Saudi Arabia.
Morphine has been shown to potentiate the ulcerogenic activity
of indomethacin in a dose dependent manner following subcutaneous
administration in rats. This potentiation is blocked partially
by anticholinergics and cimetidine and completely by naloxone
thus showing the involvement of opiate receptors in its aetiology.
We have further studied the effect of OKY-046, a specific throm-
boxane A2 synthesis inhibitor; BM 13177, a thromboxane A2 recep-
tor antagonist and sodium cromoglycate, a mast cell stabilizing
agent on the morphine induced potentiation of the gastroulcero-
genic activity of orally administered indomethacin in rats. Our
results show that thromboxane A2 is significantly involved in
this action, whereas the involvement of histamine released through
the disruption of mast cells is completely ruled out as pretreat-
ment with sodium cromoglycate does not affect the potentiating
action of morphine. It would be interesting to study as to how
thromboxane A2 is involved in the opiate receptor mediated poten-
tiation of indomethacin's ulcerogenic effect.
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THE ROLE OF µ- AND RECEPTORS IN GASTROINTESTINAL PROPULSION IN
RATS. A. Tavani, M. Sbacchi, A. La Regina, P. Petrillo, Istituto
di Ricerche Farmacologiche "Mario Negri", via Eritrea 62 - 20157
Milan, Italy.
To study the role of µ- and receptors in gastrointestinal
propulsion, overnight fasted rats received i.p. injections of
[D-Ala2, MePhe4, Gly-ol5]enkephalin (DAGO) or morphine or [D-Ala2,
D-Leu5]enkephalin (DADLE) respectively 1, 5 and 5 min before a
charcoal meal and the percentage of small intestine traversed by
charcoal was measured 5 min after the meal. The doses inhibiting
gastrointestinal transit by 50% compared to controls (ED50), ob-
tained from the dose-response curve, were 6.20, 15.19 and 23.03
µg/kg respectively for DAGO, morphine and DADLE. In the presence
of naloxone (50 µg/kg i.p. 5 min before DAGO and 1 min before mor-
phine or DADLE), the dose-response curves of DAGO and morphine were
parallel but shifted to the right of the respective curve in the
absence of the antagonist; the ED50 were respectively 153 and 239
µg/kg. Conversely, the dose-response curve of DADLE with the same
dose of naloxone was flat and doses from 15 to 1000 µg/kg of DADLE
produced about 50% of the maximal effect. In the presence of the
selective antagonist ICI 174,864 (1 mg/kg i.p. 5 min before DAGO
and 1 min before morphine or DADLE), the dose response curves of
DAGO and morphine were the same as in the absence of the antagonist.
Conversely, the dose-response curve of DADLE in presence of ICI
174,864 was different, although the antagonist shifted it only very
weakly. It thus appears that µ-receptors may be involved in the
inhibition of gastrointestinal propulsion induced by DAGO and mor-
phine and both µ- and receptors in the inhibition induced by DADLE.
The effects of the selective -compound [D-Pen2, D-Pen5] enkephalin
are discussed too.
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µ, & K OPIOID RECEPTOR DISTRIBUTION IN RAT BRAIN USING IN
VITRO LIGHT MICROSCOPY AUTORADIOGRAPHY. A. Tempel
and R. S. Zukin, Dept. of Neuroscience, Albert Einstein College
of Medicine, Bronx, NY 10461, U.S.A.
We have used quantitative in vitro autoradiography at the
level of the light microscope to determine the precise neuro-
anatomical distribution of the µ, , and  opioid receptors.
Adjacent sectons of frozen rat brain were thaw-mounted on glass
slides, incubated with radiolabelled opioid in the presence or
absence of nonlabelled ligand in order to control for nonspeci-
fic binding of the radioligand, and apposed to tritium-sensi-
tive film. The neuroanatomical pattern of µ receptors was
determined using D-Ala2,N-Me-Phe4, Gly-ol5-enkephalin (DAGO µ-
specific opioid). At the level of the anterior commissure,
discrete patches of densely-labeled opiate receptors were ob-
served, surrounded by areas of diffusely-organized receptors.
At the level of the diencephalon dense labeling of µ receptors
was seen to overlie the molecular layers of the hippocampus,
particularly the pyramidal field. Dense µ receptor labeling
was also observed in specific thalamic nuclei, layers I and
III of the neocortex and the locus coeruleus of the pons. In
contrast, receptors labeled by 3H[D-Pen2, D-Pen5]enkephalin
(DPDPE specific ligand) exhibited a diffuse distribution in the
striatum with few visible patches. In the neocortex, selected
localization was observed in layers I & II and V & VI. Nuclei
of the thalamus, hypothalamus midrain and brainstem were
notably lacking in receptors. receptors (labeled using
3H-ethylketocyclazocine in the presence of µ and blockers)
exhibited a distribution similar to that of µ receptors in the
striatum and hippocampus, but differed markedly in midbrain and
hindbrain areas. High receptor density was observed in the
midline thalamic nuclei, central gray area, substantia nigra
reticulata, interpeduncular nucleus, the locus coeruleus and
cerebellum. Thus, pronounced differences in the neuroanatomi-
cal distributions of the µ, and receptors may account in
part for the diverse pharmacological profiles, of µ, a n d
opioids. [Supported by NIH grants DA 01843 & DA 00069 (to
R.S.Z.) and NS 21973 (to A. T.)].
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STRUCTURAL REQUIREMENTS LEADING TO AGONIST AND ANTAGONIST ACTIVITY IN
4-ALKYL-4-m-(HYROXY)-PHENYLPIPERIDINES. L. Toll, J. A. Lawson, W.
Polgar, E. Uyeno, G. Frenking, G. H. Loew, Life Sciences, SRI
International, 333 Ravenswood Ave., Menlo Park, CA 94025, U.S.A.
The family of 4-(m-OH)-phenylpiperidines is a flexible fragment
of the morphine/benzomorphan fused-ring opioid family. Analogs in
this family were synthesized with varying 4-alkyl substituents,
increasing in bulk from H, through methyl and n-propyl, to
t-butyl, each with the three N-substituents, methyl, allyl, and
phenethyl. These twelve compounds were evaluated for analgetic
agonism and antagonism in mice and for binding affinities using
five 3H-labelled ligands. Energy conformation calculations on
these structures were also carried out in order to better under
stand how the 4-alkyl substituents modulate receptor binding
affinities and agonist/antagonist potency ratios through
equatorial/axial conformers. The results obtained show that the
4-alkyl-4-(m -OH)-phenylpiperidines vary as agonists with a range
of activity from weak to morphine-like and that only a few analogs
have antagonist activity. Combined results of energy conformation
calculations and in vivo and in vitro analysis suggest that
binding in a phenyl axial conformation will lead to agonist
activity, while phenyl equatorial binding will lead to antagonist
activity. Furthermore, specific interactions with 4-n-propyl and
N-phenethyl moieties can induce phenyl axial and equatorial
interactions, respectively. None of the analogs, showed fused-
ring-like N-substituent modulation of agonist/antagonist activity,
even though the 4-t-butyl analogs exist essentially completely in
the phenyl axial conformation. These compounds are the first
simple 4-alkyl substituted 4-phenylpiperidines to be reported with
a strongly preferred phenyl-axial conformation.
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IMMUNOCYTOCHEMICAL LOCALIZATION OF PRO-OPIOMELANOCORTIN
-DERIVED PEPTIDES IN THE ADULT RAT SPINAL CORD.
K. Tsou*. H. Khachaturian, H. Akil and S. J. Watson
Mental Health Research Institute, University of
Michigan, Ann Arbor, MI 48109, U. S. A. and *Shanghai
Institute of Materia Medica, Academia Sinica, Shanghai,
200031, China.
A dispersed descending pro-opiomelanocortin (POMC)
fiber system has been demonstrated by PAP immunocyto-
chemistry in the adult rat spinal cord. ( -endorphin,
ACTH, -MSH and 16K immunoreactive fibers exist in
the spinal cord from cervical down to sacral level.
Descending fibers running in parallel in the dorso-
lateral and lateral funiculus send collaterals ventro-
medially or medially to terminate in the gray matter
surrounding the central canal, where nociceptive
neurons have recently been located, in addition to
those nociceptive cells in the dorsal horn. After
spinal transection at lower thoracic level, POMC
peptide immunoreactivities disappeared below the
lesion. Moreover, no POMC cell bodies were found in
the spinal cord. Therefore, the descending fibers are
most likely of supraspinal origins.
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THE ANIMAL PHARMACOLOGY OF A NOVEL OPIOID ANALGESIC DRUG. XOHPHANOL
M.B. Tyers, A.G. Hayes, and M.J. Sheehan, Dept. Neuropharmacology, Glaxo
Group Research Ltd., Ware, Herts., England.
Xorphanol is a novel morphinan opioid drug, which has been shown to
have analgesic activity in man(1). In vitro experiments suggest
that xorphanol is a potent opioid partial agonist, with good agonist
selectivity for the -receptor. Thus in the field-stimulated,
isolated, guinea-pig ileum, it showed the low maximum agonist
activity (Emax 40%; IC20 = 0.2nM) which is typical of a partial
agonist. It was not antagonised by the µ-selective antagonist
funaltrexamine; but its dose-response curve showed a large
rightwards shift after effective -receptor antagonism with the
irreversible antagonist -chlornaltrexamine, in the presence of µ-
receptor protection(2). Xorphanol behaved as an antagonist in both
the rabbit vas deferens ( -receptors; pA2 for antagonism of
ethylketocyclazocine = 9.04) and rat vas eferens (µ-receptors; pA2
for antagonisn of D-Ala2, MePhe4, gly(ol)5 enkephalin = 8.44) which,
together with the guinea-pig ileum data , suggests partial agonist
activity at the -receptor and antagonist activity at the µ-
receptor. Xorphanol produced potent antinociceptive activity in the
mouse abdominal constriction and guinea-pig paw pressure tests (ED50
values = 0.05mg/kg S.C. and 0.035mg/kg S.C. respectively), but was
inactive in the mouse hotplate test and only weakly active in the
rat paw pressure test. This profile is characteristic of a low
efficacy -agonist(3). Xorphanol, 0.1-0.3mg/kg s.c., also showed
potent and long-lasting antinociceptive activity in the dog
toothpulp stimulation test. As expected for a partial -agonist,
xorphanol produced only low maximum respiratory depression and
inhibition of gastrointestinal motility in the mouse (Emax = 20% and
46% respectively at 3mg/kg s.c.) and produced no significant
sedation in the rotarod test in the mouse at 0.1-9mg/kg S.C. Some
short duration sedation was seen with xorphanol, 0.1-3mg/kg s.c., in
the marmoset. These animal data predict that xorphanol should be a
potent and efficacious analgesic in man, with very low side-effect
potential.
(1) Bloomfield, S S et al (1984) IUPHAR 9th International Congress
of Pharmacology, Abst. 1737P. (2) Sheehan M J et al (1985),
Br.J.Pharmac; 84, 68P. (3) Hayes A G et al (1985), Br.J.Pharmac; 86,
703P.
We would like to acknowledge H.G. Pars, Pharma.Labs.Inc., for
supplies of xorphanol mesylate.
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EVIDENCE FOR THE PRESENCE OF PRESYNAPTIC AUTO-
REGULATION OF MET-ENKEPHALIN RELEASE IN THE BRAIN AND
-EFFECTS OF KAPPA OPIOID ANTAGONISTS THEREON. H. Ueda,
N. Fukushima and H. TAKAGI Department of Pharma-
cology, Faculty of Pharmaceutical Sciences, Kyoto
University, Kyoto 606, Japan.
Presynaptic regulation of met-enkephalin release
from slices of rat midbrain, pons plus medulla
oblongata and its physiological role were studied.
Amounts of met-enkephalin released from slices were
measured by radioimmunoassay. The effects of several
subtypes of opioids on Ca2+-dependent and high K+ (30
mM)-evoked release of met-enkephalin in the presence
of tetrodotoxin (0.3 µM) were determined. The IC 20
of the high K+-evoked release by µ-type opioid
agonists, morphine and DAGO were 1.2 and 0.9 µM,
-type agonists, DTLET and DPLPE 1.5 and 0.7 µM and
-agonists, U-50488, bremazocine, dynorphin (1-17)
0.06, 0.32 and 0.15 µM, respectively. On the other
hand, opioid -antagonists (0.1-10µM) facilitated the
evoked release. Effects of -opioid anatgonists on
the nociceptive responses were observed in vivo. When
very small doses (0.2-20ng/kg s.c.) of Mr2266 were
administered into mice, it produced a significant
analgesic effect with the tail flick test when
administered intracisternally. To summarize, opioid
-type antagonist produces an analgesic effect via
blocking the autoreceptor on the nerve terminals of
met-enkephalin neurons.
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THE INVOLVEMENT OF ENHANCED Ca2+ CHANNEL ACTIVATION IN
THE NERVE TERMINALS OF MORPHINE WITHDRAWAL ABSTINENCE
IN MICE. H. Ueda, S. Tamura, M. Satoh and H. Takaqi,
Department of Pharmacology, Faculty of Pharmaceutical
Sciences, Kyoto University, Sakyo-ku, Kyoto 606, Japan
When naloxone was administered intrathecally
(i.th.) 24hr after the implantation of a morphine
pellet into mice, withdrawal jumping behavior was
precipitated and lasted for 5 min. Repeated (i.th.)
injection of naloxone produced no more jumping
behavior. The intrathecal pretreatment with IAP (5
µg) 24 hr before morphine pellet implantation
completely abolished the naloxone-precipitated
withdrawal jumping. Furthermore, intrathecal
p r e t r e a t m e n t  w i t h  s u b s t a n c e  P  a n t a g o n i s t ,
(D-Pro4,D-Trp7'9'10)-stbstance P(4-11) 5 min before
the naloxone treatment, also completely abolished the
precipitated jumping. High K+-evoked 45Ca entry into
the synaptosomes of the spinal cord of the morphine
dependent mice was enhanced by naloxone (10-4M).
Naloxone (10-4M) enhanced maitotoxin (a Ca channel
agonist)-induced 45Ca entry into the spinal
synaptosomes of dependent mice, but not of the intact
mice. Naloxone at 10-4M increased the c-AMP content
in the synaptosomes of the spinal cord of dependent
mice, but not of intact mice. Taking the previous
report that intracellular c-AMP enhances the Ca2+
entry into synaptosomes of rats, the present findings
Ca2+ channel may be activated via excessively
suggest that in the morphine abstinent state, the
formed
c-AMP and then neurotransmitter release enhanced. In
the withdrawal jumping of mice, excessive release of
substance P from the spinal cord is possibly involved.
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CHARACTERIZATION OF OPIOIO RECEPTORS IN RAT BRAIN FOLLOWING
LESIONS  OF THE NUCLEUS ACCUMBENS. E.M. Unterwald, R.S. Zukin, and
G.F. Koob*, Depts. of Neuroscience and Biochemistry, Albert
Einstein College of Medicine, Bronx, NY, 10461 and *Res. Inst.
Scripps Clinic, La Jolla, CA, 92037, U.S.A.
Autoradiographic studies have identified dense patches of mu
and kappa opioid receptors and less dense patches of delta opioid
receptors in the rat nucleus accumbens. In addition, the nucleus
accumbens is rich in dopaminergic fibers as it receives extensive
innervation from the mesolimbic dopamine tract. Anatomical and
functional relationships between the opioidergic and dopaminergic
circuitry of the brain are well established and considerable
evidence supports the concept that opioid peptides act on presyn-
aptic dopaminergic neurons to modulate dopamine release from their
axon terminals. The present study investigates the topographical
organization of opioid receptor types in the nucleus accumbens
with respect to their pre- and postsynaptic localization and their
relationship to dopaminergic nerve fibers.
Dopaminergic terminal fields in the nucleus accumbens of rats
were destroyed by unilateral injection of 6-hydroxydopamine (2µl,
8µg/µl) into the nucleus accumbens. Fourteen days after the
lesions, the fraction of each receptor type lost in the nucleus
accumbens was determined using highly specific in vitro binding
assays. Aliquots of homogenate from 6-hydroxydopamine-lesioned,
sham-lesioned, and non-lesioned nucleus accumbens (.25 ml, 0.16-
0.39 mg/ml protein) were incubated with selective [3H]-ligands in
the presence and absence of 10 µM levorphanol. The specific lig-
ands used were [3H]-D-Ala2,N-Me-Phe4.Gly-ol5-enkephalin (DAGO) for
mu receptor assays, [3H]-D-Penicillamine2,D-Penicillamine5-
enkephalin for the delta receptor assays, and [3H]-ethylketocy-
clazocine in the presence of DAGO (100nM) and D-Ala2, D-Leu5-
enkephalin (100nM) for kappa receptor assays. Results indicate
. .
substantial changes in opioid receptor binding, particularly a
dramatic loss of mu receptors, in the nucleus accumbens following
these lesions. These results suggest a neuromodulatory role for
mu opioid peptides on dopamine release in the nucleus accumbens.
(Supported in part by NIH grant DA 01843 and DA 00069 (R.S.Z.)).
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THE OPIOID RECEPTOR-GTPase-ADENYLATE CYCLASE SYSTEM IN NG108-15
CELLS: DISSOCIATION BETWEEN DESENTIZATION AND DOWN-REGULATION. L.
Vachon, T. Costa and A. Herz, Department of Neuropharmacology,
Max-Planck-Institut für Psychiatrie, D-8033 Martinsried, F.R.G.
Opioid receptor binding, low Km GTPase and adenylate cyclase
were studied in membranes derived from NG 108-15 cells pre-treated
with [D-Ala2, D-Leu5]enkephalin (DADLE) or morphine. Pre-treatment
with DADLE results in a rapid loss of responsiveness of the opioid-
dependent GTPase: this desensitization occurs as two time-dependent
processes with t 1/2 of 10 min and 8 hr. Opioid binding sites, as
assessed using [3H]diprenorphine, also decay as two time-dependent
processes upon exposure to DADLE. However, in the presence of Na+
and GTP, only the slow component is observed. The inhibition of
adenylate cyclase by opioids is also lost tine-dependently follow-
inq pre-treatment with DADLE. However, significant responsiveness
of the enzyme is still observed even after desensitization of
GFPase has occurred. While the desensitization of GTPase is due to
a pure reduction in the maximal effect of DADLE, desensitization of
adenylate cyclase occurs throuqh both a loss of maximal effect and
a decrease in the potency of DADLE. In contrast to DADLE, morphine
induces only a minimal desensitization of the opioid-GTPase-adeny-
late cyclase system, and can antagonize the fast component of the
desensitization induced by DADLE. These findings suggest that 1)
desensitization of the opioid receptor-GTPase-adenylate cyclase
system results, as a primary event, from an uncoupling between the
receptor and the nucleotide-binding regulatory protein (Ni), and
occurs before down-regulation of the receptor; and 2) the differen-
tial potencies of DADLE and morphine in desensitizing the opioid-
GTPase-adenylate cyclase system in NG 108-15 cells cannot be ac-
counted for by a mere difference in receptor affinity, but rather
appears to be related to their respective full- and partial-aqonis-
tic properties. (Supported by the Deutsche Forschunqsqemeinschaft,
Bonn, L.V. is postdoctoral fells of the Fond de la recherche en
Sante du Québec, Québec, Canada).
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METABOLISM OF [MET]ENKEPHALIN IN THE RAT SPINAL CORD: RESPONSE
TO PEPTIDASE INHIBITORS. K.I. Van Alstyne and K. Jhamandas,
Department of Pharmacology and Toxicology, Queen’s University,
Kingston, Ontario, Canada, K7L 3N6.
Enkephalin metabolism in the brain is mainly a result of the
activities of aminopeptidase and enkephalinase, and inhibition
of these enzymes by pharmacological agents leads to analgesia.
At present, little is known about the metabolism of enkephalins
by the spinal cord, a source of significant levels of enkepha-
lins and an important site of opioid analgesia. To study the
relationship between analgesia and pharmacological inhibition
of enkephalin metabolism in the same region, a system was
developed to study the metabolism of [Metlenkephalin (ME) in the
isolated rat spinal cord. The separation of ME from its putative
metabolites, tyrosine (T), tyrosine-glycine-glycine (TGG) and
des[Met]enkephalin, was performed by reverse-phase gradient
HPLC using a C18 column and 0.01 M sodium acetate (pH 4.0)
and acetonitrile as the mobile phase.Coronal slices of rat
spinal cord (400 µM) were incubated with 3H-ME for various time
intervals over a 60-min period. The radiolabelled metabolites
were separated by HPLC. The metabolism of 3H-ME by spinal cord
tissue yielded mainly 3H-T and 3H-TGG, reflecting the activities
of aminopeptidase and enkephalinase or angiotensin-converting
enzyme respectively. In the absence of peptidase inhibitors,
cervical, thoracic and lumbar regions of the cord showed similar
metabolic profiles. Metabolism of 3H-ME by dorsal and ventral
regions of the lumbar cord also yielded similar metabolic
profiles. Bestatin, an aminopeptidase inhibitor (1 x 10-7 -
2 x 10-5 M), inhibited the formation of “H-T and augmented the
formation of 3H-TGG from 3H-ME. Thiorphan, an enkephalinase
inhibitor (1 x 10-8 - 1 x 10-6 M), did not appear to inhibit
the formation of 3H-TGG from 3H-ME. This model could be useful
in making correlations between inhibition of ME metabolism and
production of analgesia by peptidase inhibitors.
(Supported by the Medical Research Council of Canada)
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INCREASE IN MORPHINE ANALGESIA BY CORTICOSTERONE: A CENTRAL EFFECT ?
C. Vidal, J.J.C. Jacob, Unit of Pharmacology, Pasteur Institute,
F 75724 Paris Cedex 15, France.
Evidence has accumulated that opioids influence the secretion
of adrenal steroids. Conversely, little is known about the modula-
tion of the opioid system by glucocorticoids. According to Holaday
et al., corticosteroids modulate opioid effects through a mecha-
nism peripheral to the neuroaxis. In a recent study, we have shown
that corticosterone (CT) potentiates the effect of enkephaline in
the hippocampus in vitro, thus indicating an interaction at a
central level. The possible behavioral correlates of such interac-
tion was investigated in the present work. Mice received either
saline or morphine hydrochloride (1 or 3 mg/kg s.c.); they were
then immediately injected intracerebroventricularly with either
CT (10-4 M or 10-5 M; 20 µl/animal) or its vehicle (ethanol 0.5%
or 2%). Groups of 16 animals were used. Licking latencies (sec)
were measured 30 min after ICV injection (hot plate test; To of
the plate 55°C). Licking latencies were as follows(vehicle was in
Exp. I and II ethanol 0.5%, in Exp. III ethanol 2%)
Exp.I Exp.II Exp.III
Vehicle 12.25 ± 0.7 15.1 ± 1.5 14.5 ± 1.4
CT 10-4 M 13 ± 1.1 11 ± 1.1 12.8 ± 1.4
16.5 ± 1.7Mo 1 mg
Mo 3 mg 17.8 ± 1.74 14.4 ± 1.1
CT 10-4 M -
+ Mo 1 mg 19.5 ± 2.45
+ Mo 3 mg 22.25 ± 2.7 18.4 ± 2.1
CT alone has no significant effect; morphine I or 3 mg/kg s.c. had
no or slight effects. The associations CT 10-4 + Mo had always
greater effects than those produced by Mo and vehicle. The diffe-
rences were hardly significant when considereing each experiment
separately but they were significant (for p < 0.05) when all
results were gathered. Further work is in progress.
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KAPPA OPIATE AGONISTS INHIBIT ADENYLATE CYCLASE AND PRODUCE
HETEROLOGOUS DESENSITIZATION IN RAT SPINAL CORD CELLS. Z. Vogel
and B. Attali, Neurobiology Department, Weizmann Institute of
Science, Rehovot 76100, Israel.
As with other receptor ligands which regulate adenylate cycl-
ase activity, opiate agonist binding in spinal cord is regulated
by GTP and Na+, suggesting a coupling to the adenylate cyclase
system. The present communication investigates the exact condit-
ions in which opiate inhibition of the spinal adenylate cyclase
can be observed. Furthermore, the opioid regulation of the enzyme
has been studied in rat spinal cord primary cultures following
chronic agonist treatment. Using crude P2 preparations of rat
spinal cord, we were able to show that µ (DAGO 10µM) and  (DADL
10µM) agonists did not affect the basal cyclase activity (3892±11
pmoles cAMP/15min/mg protein, n=3), whereas the K selective op-
iate agonist U50488 significantly and dose-dependently inhibited
this activity (30% inhibition at 10µM, p<0.02), Levorphanol at 10µM
inhibited by 20% the basal enzyme levels. The regulatory action
was stereospecific since dextrorphan was ineffective. The K sel-
ective antagonist MR2266 (10µM) fully antagonized the K agonist
response. In all cases GTP(10µM) and NaCl(100mM) were required for
the expression of the agonist inhibitory action. The inhibitory
effect of K agonists was also observed when the cyclase activity
was stimulated by forskolin (100µM). These data suggest that in
the spinal cord, opiate receptors of the Kappa type are coupled to
adenylate cyclase. Following chronic exposure to etorphine (1µM
for 4 days without wash) of rat spinal cord primary cultures, the
K agonist U50488 lost its ability to inhibit the cyclase, the bas-
al as well as the forskolin stimulated activities remaining ident-
ical to those of paired control cultures. Furthermore, this desen-
sitization process seems to be heterologous, since the 2 adrener-
gic agonist, norepinephrine, and the muscarinic agonist, carbachol,
exhibit significant lower potency for inhibiting the enzyme activ-
ity following exposure to etorphine, suggesting that the site of
tolerance induced by opiates in the spinal cord is related to post
receptor regulatory components.
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[3H]1,3-Di-O-TOLYL-GUANIDINE ([3H]-DTG) , A NOVEL,
SELECTIVE LIGAND FOR THE HAMPERIDOL SENSITIVE SIGMA
RECEPTOR. Eckard Weber. Mark Sonders, Merrit Quarum,
Sovitji Pou*, John F. W. Keana*, Institute for Advanced
Biomedical Research, The Oregon Health Sciences University,
Portland, Oregon 97201 and *Department of Chemistry,
University of Oregon, Eugene, Oregon 97403, U.S.A..
Sigma receptors are thought to mediate the
hallucinogenic effects of benzomorphan-type opiate drugs.
The characterization of the sigma receptor by biochemical
methods has been difficult because of the lack of selective
and potent ligands. During a systematic search for
potential sigma receptor active drugs we discovered that
symmetrically substituted guanidines interact with the
sjgma receptor as judged by their capability to displace
[3H](+)SKF 10,047
sites.
from guinea pjg brain membrane binding
We have synthesized a [3H]-labeled derivative of
the most potent one of these symmetrically substituted
guanidines. This compound has the following structural
formula:
Radioligand binding assay experiments have shown that this
novel, [3H]-labeled compound binds with high affinity
max = 80 pmol/gram brain tissue] in guinea pig brain
[KD = 30 nM] to a single population of binding sites [B
membrane preparations. The drug selectivity profile of the
[3H]-DTG binding site was identical to that described for
the haloperidol-sensitive sigma receptor (1,2). The
potential applications of this novel sigma receptor ligand
to the characterization of the sigma receptor in
biochemical and pharmacological experiments will be
discussed.
1.) Largent, B.L. et al., PNAS 81, 4983 (1984).
2.) Tam, S.W. and Cook, L., PNAS 81, 5618 (1984).
Supported by NIMH grant MH40303 to EW.
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EVIDENCE THAT THE MAJOR IMMUNOREACTIVE MORPHINANS IN MAMMALIAN
BRAIN ARE MORPHINE AND CODEINE. C. J. Weitz, L. I. Lowney,
R. W. Barrett and A. Goldstein, Addiction Research Foundation,
Palo Alto, CA 94304, U.S.A.
Partially purified extracts of bovine hypothalamus and rat
brain contain two major compounds recognized by antisera to
morphine and resolved by reversed-phase high pressure liquid
chromatography (HPLC). Both are found consistently in bovine
hypothalamus and rat brain, but the pattern and concentrations
are highly variable in bovine adrenal. In addition, a third minor
immunoreactive (ir) morphinan is present in hypothalamus.
Extractions and purification procedures were carried out in
sequestered glassware. A "tissueless" blank was run through the
entire system prior to each tissue work-up and shown to be free
of significant immunoreactivity on HPLC analysis.
The two major ir-morphinans in bovine hypothalamus, rat brain,
and (variably) bovine adrenal appear to be morp ine and codeine
by the following criteria: 1) co-lution with 3H-morphine and
3H-codeine in two different reversed-phase HPLC systems;
2) crossreactivity with two antimorphine antisera of contrasting
specificities; and 3) absolute crossreactivity in a quantitative
immune-removal system (bovine hypothalamus).
These results support previous work reported from our
laboratory (A Goldstein et al, Proc Natl Acad Sci USA 82: 5203,
1985) in that ir-morphinans (one of which is morphine) are
detected consistently in mammalian brain. In addition, we can
now tentatively identify our previously-reported "peak 4" as
codeine; the minor ir-morphinan in hypothalamus was reported
previously as "peak 5". These results differ from our previous
work in that “peaks 2, 3, and 6" are not detected: we have been
able to identify a source of laboratory contamination that
probably accounts for them.
Supported by DA-1199 from the National Institute on Drug
Abuse.
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CALCITONIN AND CALCITONIN GENE-RELATED PEPTIDE INDUCED MODULATION
OF CALCIUM FLUXES: CORRELATION TO ANALGESIC EFFECTS AND
MODULATION OF OPIATES. S. P. Welch, C. Cooper and W. L. Dewey,
Dept. of Pharmacology and Toxicology, Medical College of
Virginia, Richmond, VA 23298 and University of Texas Medical
Branch, Galveston, TX 77550 U.S.A.
Salmon calcitonin (CT) and Calcitonin Gene-Related Peptide
(CGRP) were evaluated for analgesic activity in the tailflick,
hotpleate, and p-phenylquinone writhing (PPQ) test in mice
following intraventricular (ivt.) administration. Both CT and
CGRP produce antinociception, however, CGRP is less potent than
CT (ED50=20ug and .36ug respectively in the PPQ test). CT
produced peak analgesic effects at 2 hr., while the maximal
effects of CGRP occurred at 1 hr. Naloxone reversed the
analgesic effects of CT in the tailflick and hot plate tests, but
not in the PPQ test. Naloxone reversed CGRP analgesic effects in
the PPQ test. At 5 min post administration ivt. both CT and CGRP
produced antagonism of subcutaneously administered (s.c.)
morphine. However, CT produced a significant 2 fold shift in the
morphine ED50, while CGRP-induced shifts were not significant,
In the electrically stimulated guinea pig ileum (GPI) assay both
CT and CGRP produced non-dose responsive, naloxone reversible
inhibition of the ileum (25 and 51% respectively). 5 min.
pretreatment of the ileum with CGRP produced an effect additive
with that of morphine, while 5 min. pretreatment with CT
antagonized morphine. However, pretreatment of the ileum for 1
hr. with CT slightly potentiated morphine. CT and CGRP both
produced time-dependent alterations in calcium uptake to whole
brain synaptosomes. Both CT and CGRP increased calcium uptake
when incubated with synaptosomes for 5 min. However both
decreased calcium uptake with 1 hr (CGRP) and 2 hr. (CT)
incubations. Both CT and CGRP appear to have intrinsic
agonist/antagonist effect which correlate well to the modulation
of calcium fluxes in the central nervous system. (Supported by
USPHS Grants DA01647 and T32DA07027).
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TREATMENT OF PAIN IN CANCER SUBJECTS BY INTRATHECAL
ADMINISTRATION OF DYNORPHIN
H.L. Wen1, Z.D. Mehali1, B.H. Ong2 and W.K.K. Ho3, 1Neurosurgical
Unit, Kwong Wah Hospital, Kowloon; 2Surgical Department, United
Christian Hospital, Kwun Tong, Kowloon; 3Department of
Biochemistry, The Chinese University of Hong Kong, Shatin, N.T.,
Hong Kong
Dynorphin, an opioid peptide originally isolated from the pig
pituitary, has been shown to have potent activity in the guinea
pig ileum bioassay. In contrast to -endorphin, this peptide
when administered intracereberally to experimental animals showed
weak to no analgesic activity. Anatomical studies have shown
that the spinal cord contains a high concentration of
inmunoreactive dynorphin and it has been rationalized that this
organ may be the primary site of action for this peptide. In
contrast to the early studies at the brain level, several groups
have shown that the intrathecal administration of dynorphin can
induce a long lasting analgesic effect in rats. In order to
evaluate the potential application of this peptide in the
treatment of pain in human subjects we have performed some
preliminary experiments by administering very small doses of this
peptide intrathecally into six cancer patients. Compared with
the injection of saline, dynorphin 1-13 was able to reduce pain
score by at least 150% between the dose of 7.5 to 60 µg. The
mean duration of relief after the administration of dynorphin 1-
13 was 4.3, 5.8, 4.5 and 5.3 hours at doses of 7.5, 15, 30 and 60
µg, respectively. The mean time of relief after saline was only
0.35 hour. Throughout the study only one to two cases of minor
side effects such as headache and dizziness were recorded.
Dynorphin 1-10 essentiallyproduced a very similar profile of
response. Thus, the structural active canponent of the dynorphin
molecule appears in this case to reside between amino acid 1 to
10.
This work was supported by a grant from the Lee Foundation of
Singapore.
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ENKEPHALIN BIOSYNTHESIS AND QENE EXPRESSION ARE INCREASED IN
HIPPOCAMPAL MOSSY FIBERS FOLLOWING SEIZURES. J.D. White, C.M.
Gall and J.F. McKelvy, Dept. of Neurobiology and Behavior , SUNY, Stony Brook, NY
11794; *Dept.of Anatomy, Univ. California, Irvine, CA 92717, USA
The biosynthesis and post-translational proccessing of proenkephalin and the level
of preproenkephalin mRNA were investigated in the mossy fiber system of the
granule cells of the hippocampus in the presence or absence of a unilateral lesion of
the hilus, a procedure which produces bilateral hippccampal seizures. In the mossy
fibers contralateral to the lesion, increases in enkephalin immunoreactivity were
detected by both immunocytochemistry and radioimmunoassay. By the technique of
in vivo radiolabeling and high performance liquid chromatographic purification of
identified radiolabeled peptides, we observed a 14-fold increase in incorporation of
radiolabeled methionine into Met5-enkephalin in lesioned vs. control animals, when
Met5-enkephalin was purified from the mossy fiber terminal fields. To examine the
post-translatinal proteolytic processing of proenkephalin, the biosynthesis of five
additional Met2-enkephalin-containing peptides was also examined. We determined
that the post-translational processing of proenkephalin did not yield exclusively
penta-, hepta- and octa-peptides but larger opioid peptides as well in both control
and lesioned animals; however, the ratio of the enkephalin peptides was not altered
following the lesion Measurement of preproenkephalin messenger RNA levels in the
granule cells by Northern analysis revealed a marked increase (24-fold) following
the lesion. These date support the hypothesis that enkephalin biosynthesis in the
granule cells is stimuleted as a consequence of seizure activity and that the mossy
fiber system offers a model system to study the modulation of opiate peptide
synthesis by neuronal activity.
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ALTERED METABOLISM OF -ENDORPHIN AND DEVIANT BIOLOGICAL ACTIVITY
OF -ENDORPHIN IN POST MORTEM BRAIN OF SCHIZOPHRENIC PATIENTS.
V.M. Wiegant, O. Gaffori, J. Verhoef, J.P.H. Burbach, G.L. Kovács
and D. De Wied, Rudolf Magnus Institute for Pharmacology, Vondel-
laan 6, 3521 GD Utrecht, The Netherlands.
The - and -endorphins ( E , E) are endogenous neuropeptides,
enzymatically generated in the brain from -endorphin ( E). In a
variety of behavioral test systems E and E produce opposite
effects, not related to their opiate like activity. The actions
of E resemble those of psychostimulant drugs, whereas E dis-
plays neuroleptic-like properties. In view of the neuroleptic-
like activity of -type endorphins, it was hypothesized that a
reduced availability of E-type activity in the brain is an
ethiological factor in psychopathologies for which neuroleptics
are beneficial, such as schizophrenia.
We have pursued this hypothesis, and investigated the concen-
tration of E, E and E in post mortem hypothalamic tissue of
schizophrenic patients with combined HPLC and RIA techniques. In
addition, we determined the activity of E fractions from brain
and pituitary tissue of such patients on the passive avoidance
response in rats. In both lines of experimentation post mortem
tissue of subjects without psychopathology was taken as control.
These results are suggestive of an altered metabolism of E in
brain tissue of schizophrenic patients, although it remains to be
established whether these alterations are consequence of ante
mortem drug treatment of the patients or are connected to the
psychopathology itself. Moreover, our results indicate that E in
schizophrenics possesses deviant biological properties.
The concentration of E and E was found to be significantly
higher in the hypothalamus of schizophrenic patients than in that
of control subjects. No difference was found in the E levels. In
the passive avoidance test, E fractions from hypothalamic or
pituitary tissue of schizophrenic patients displayed an activity
different from control and synthetic E; they were inactive or
induced the opposite response.
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ENKEPHALIN DEGRADATION IN LOCUS COERULEUS MEASURED
ELECTROPHYSIOLOGICALLY. J.T. Williams, M.J. Christie, R.A. North
and B. Roques*. Neuropharmacology Laboratory, M.I.T., Cambridge MA
02139, U.S.A. and *University Rene Descartes, Paris 75270, France.
The increase in potassium conductance caused by µ-opioid
agonists was measured by intracellular electrodes in single locus
coeruleus neurons in slices cut from rat brain. [Met5] enkephalin
(ME) was applied by superfusion for periods of 2-5 min, which was
sufficient for its effect to reach steady-state. The effect
measured was membrane hyperpolarization or, more commonly, the
outward current under voltage clamp at -60 mV holding potential.
Kelatorphan (up to 60 µM) had no effect on the LC neurons, but the
amplitude and duration of the response to ME was increased when
kelatorphan was in the superfusing solution; this potentiation was
observed in all cells. The concentration-effect curve for ME was
shifted to the left 3-30 fold by kelatorphan, the degree of shift
being dependent upon the kelatorphan concentration (2-20 µM);
further increase in kelatorphan caused no further increase in the
response to ME. The minimum effective concentration of ME was
reduced from about 300 134 to 30 nM by kelatorphan. The time
course of action of kelatorphan was studied by applying the ME for
longer periods of time (20-30 min) and during this period changing
the superfusion solution to one which contained both ME and
kelatorphan. The increase in the effect of ME occurred within 2
min and reversed 10-20 min after the kelatorphan was removed.
Outward currents evoked by Tyr-D-Ala-Gly-MePhe-Gly-ol (DAGO) and
Tyr-D-Ala-Gly-Phe-D-Leu (DADLE)(which act on the same p-receptors)
or by noradrenaline (which acts on 2 receptors but opens the same
potassium channels) were unaffected by kelatorphan. Noradrenaline
responses were potentiated 10-30 fold by cocaine (which did not
affect responses to ME); acetylcholine responses were potentiated
10-30 fold by physostigmine. The results indicate that a single
brain slice (containing 300-500 LC neurones) avidly destroys a
large proportion of ME superfusing it, that the action of
kelatorphan is readily reversible, and that the degree of
potentiation of response observed is very similar to that seen
with catecholamines and acetylcholine.
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THE ENDOGENOUS KAPPA AGONIST, DYNORPHIN(1-13) DOES
NOT ALTER NIGROSTRIATAL OR MESOLIMBIC DOPAMINE
METABOLISM IN THE RAT. P.L. Wood. H.S. Kim and S.
Iyengar. Neuroscience Research, Research Dept.,
Pharmaceuticals Division, Ciba-Geigy Corp., summit,
N.J., 07901, U.S.A.
Dopaminergic pathways in the rat brain possess
both mu and delta opioid regulatory inputs. In
contrast, previous studies with kappa agonists have
reported that these pathways appear to lack kappa
receptor regulation. We therefore examined the
actions of the endogenous kappa agonist, dynorphin(1-
13) on nigrostriatal (striatum) and mesolimbic (N.
accumbens dopamine metabolism in the rat. As a
control, plasma corticosterone levels were also
measured in all animals to assess the bioavailability
of the test drugs. This is a useful control since
serum levels of this hormone are under central mu,
delta and kappa opioid control.
While parenteral morphine elevated both plasma
corticosterone and dopamine metabolism (both striatum
and N. accumbens), neither parenteral U 50488H nor
intraventricular dynorphin(1-13) altered dopamine
metabolism. However, both kappa agonists potently
elevated plasma corticosterone levels indicating
their bioavailability to the CNS.
In summary, our data support previous reports that
mesolimbic and nigrostriatal dopaminergic neurons
lack kappa opioid regulatory inputs in the rat.
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CHARACTERIZATION OF OPIOID RECEPTOR IN HAMSTER BRAIN.
S. -W. Wu, W. -Q. Jin and Z. -Q. Chi.
Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, Shanghai 200031, China.
The distribution density of subtype of opioid re-
ceptor differs markedly in brain of different species
. The nature of opioid receptor in hamster brain has
been studied in this paper. The mu binding site was
determined with the highly selective mu ligand, 3H-
DAGO. For the delta site, 3H-DADLE was used in the
presence of unlabelled 30 nM morphine to suppress bin-
ding to the mu site. For the estimation of kappa bin-
ding, the 3H-etorphine was used in the presence of un-
labelled 30 nM morphine and 100 nM DADLE to suppress
bindings to the mu and delta sites. The non-Specific
binding was determined with 10 µM levorphanol. The
results of the experiments indicated that specific
binding of the three 3H-ligands is concentration-
dependent and saturable. Scatchard analysis showed
that the Kd and Bmax for mu binding were 1.3 nM and
17.8 pmol/g protein, respectively. For delta binding
0.88 nM and 11.6 pmol/g protein, respectively. For
kappa binding 0.52 nM and 33.8 pmol/g protein, respec-
tively. Competition binding studies indicated that
cold mu ligand, ohmefentanyl easily displaced the bin-
ding of 3H-DAGO (KI=26 pM). Relative selective
ligand, DADLE readily inhibited the binding of 3H-DADL
(KI=1.0 nM). However, selective kap
competed effectively the binding of 3H-etorphine to
a ligand, U-50488
kappa site (KI=5.9 nM). Based in our experiments, we
estimate that the hamster brain conteins 54% kappa si-
tes, 28% mu sites and 18% delta sites. These results
suggested that the binding of the high affinity to the
kappa site is predominantly presented in the hamster
brain. It markedly differs from the brain of rat or
guinea-pig.
714
STRESS-INDUCED CHANGES IN DIFFERENT MOLECULAR WEIGHT FORMS OF
DYNORPHIN PEPTIDES IN RAT BRAIN AND SPINAL CORD. G. X. Xie and
A. Goldstein, Addiction Research Foundation and Department of
Pharmacology, Stanford University, Palo Alto, CA 94304, U.S.A.
The immunoreactivities of three peptide products of the
preprodynorphin gene -- dynorphin A, dynorphin B and -neo-
endorphin -- were measured in single rat brains and spinal cords
using specific antisera after Sephadex G-50 filtration. Three
peaks of Mr about 7, 4 and 2 kDa for ir-dyn A and ir-dyn B, and
one single peak of Mr less than 2 kDa for a-neo-endorphin were
found both in the brain and in the spinal cord. The 7 kDa peak
was recognized by a specific antiserum against the carboxyl
terminus of dyn B, indicating it terminates in threonine-13 of
dyn B. The relative amounts of 7 and 4 kDa materials to 2 kDa
material were greater in spinal cord than in the brain,
suggesting a different rate of processing or release in different
regions of the central nervous system.
Swimming in 10°C cold water for 10 min produced a
naloxone-blocked increase of tail flick latency, and also caused
a striking reduction of 7 and 4 kDa dynorphins in spinal cord
but little or no change in the small M, products of the
preprodynorphin gene. The processing and release of dynorphin
peptides in the spinal cord may be accelerated by stress.
Supported by BNS-84-16617 from the National Science
Foundation.
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CONVERSION OF -ENDORPHIN TO -ENDORPHIN IN RAT PLASMA. Elizabeth A.
Young and Huda Akil, Mental Health Research Institute. University of Michigan,
Ann Arbor MI 48109 U.S.A.
With a number of stressors -endorphin is released into plasma. The rate of
disappearance of this released -endorphin is rapid, with estimates of the half
life in the 10 to 15 minute range. it is unclear if -endorphin is coverted into
any other biologically active products, nor is it clear if the rate or pathways of
degredation is changed during chronic stress. To explore these issues, we
incubated [3H] -endorphinh labelled in position 1 and 27 with plasma from
normal and chronically footshocked rats and measured the rate of conversion of
the  l abe l  f rom -endorphin size material to smaller size material. Initial
separations were done using a G-50 molecular sieving column. with subsequent
characterization and identification on BPLC. Using these methods, we see a time
dependent formation of only one radioactive peak with G-50 column sieving.
The size estimate of this peak is 16 or 17 amino acids. Since the [3H] -endorphin
was labelled on both ends of the molecule, two radiolabelled fragments should be
formed. This suggested that the molecule may be cleaved near the middle of the
molecule resulting in two fragments of similar size. To confirm this hypothesis
we used an HPLC separation of the pre-sieved fractions from the G-50 column,
and looked for the co-migration of label with either o r endorphin as well
as other unidentified peaks. We found two radioactive peaks on HPLC, one of
which co-migrated with -endorphin. and the other peak which is unidentified
currently but may well be -endorphin 18-31. Interestingly. this enzymatic
activity is induced by chronic stress so that the labelled -endorphin shows a 2-
3 fold faster conversion to this product. Whether the -endorphin remains
stable after formation is less clear. but fragments of -endorphin such as des-
tyrosine -endorphin and des-enbphalin -endorphin have been reported to
be behaviorally active. We conclude that post-release conversion of
endorphin into other biologically active fragments can occur, and that
endorphin is one of the fragments formed in plasma. Similar data have been
reported in brain synaptasomes, and a common enzyme may be present in both
tissues.
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EFFECTS OF DIFFERENTIATION ON CELLULAR AND BIOCHEMICAL PROPERTIES
OF A µ RECEPTOR CONTAINING NEUROBLASTOMA CELL LINE. V.C. Yu,
G. Hochhaus, M.L. Richards and W. Sadée. School of Pharmacy,
University of California, San Francisco, San Francisco, CA 94143,
U.S.A.
We have recently identified a human neuroblastoma cell line,
SK-N-SH, that expresses µ and opioid receptors.
Morphologically, SK-N-SH cells appear to consist of two distinct
cell types (epithelial-like and neuroblast-like) that can be
interconverted to one another. SH-SY5Y is a thrice-cloned cell
line of SK-N-SH which displays an essentially homogenous
population of neuroblast-like cells and can be grown to high cell
density. The SH-SYSY clone, like the parent SK-N-SH cells,
expresses both µ and opioid receptors, muscarinic cholinergic
receptors, and a catechol uptake1 system. The cells can be
stimulated to release inositol triphosphate by acetycholine but
not by opioids, bradykinin, ATP and Sub P. Six days treatment of
SH-SY5Y cells with either nerve growth factor (50 ng/ml), dBcAMP
(1 mM) or retinoic acid (20 µM) induces differentiation of the
cells marked by extensive neurite outgrowth. The various receptor
systems were differentially affected by the agents used to induce
neuronal maturation on receptor expression and the cellular
properties. Most strikingly, nerve growth factor and retinoic
acid increased the opioid receptor density (on calculated per mg
protein) by as much as two-fold, while dBcAMP decreased it by
approximately 40%. The effects of the differentiating agents were
less pronounced on the ACh receptor, while retinoic acid
selectively increased the uptake system by three-fold. Supported
by DA 01095 from NIDA, Bethesda, MD.
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NEONATAL TYR-MIF- ALTERS NOCICEPTIVE EFFECTS OF NEONATAL
BETA-ENDORPHIN AND MORPHICEPTIN DURING DEVELOPMENT AND IN
ADULTHOOD. James E. Zadina, Abba J. Kastin, Penelope K. Manasco,
and Kent L. Nastiuk, Veterans Administration Medical Center and
Tulane University School of Medicine, New Orleans, LA 70146, USA.
Male rats were injected SC once daily during the first week of
life with beta-endorphin (BE), morphiceptin (a mu opiate
receptor-selective peptide), a putative endogenous antiopiate
Tyr-MIF-1 (Tyr-Pro-Leu-Gly-NH2), or one of the two opiate peptides
in combination with Tyr-MIF-1. They were then tested during early
development and in adulthood (4.5 months) for their responsiveness
to thermal pain. Pups treated with neonatal BE removed their tails
from a series of increasingly hot water baths significantly faster
than control animals on day 9, confirming our earlier studies. In
rats injected with both Tyr-MIF-1 and BE, however, the latency to
remove the tail was significantly longer than in the group given BE
alone, and was not different from control animals, indicating that
Tyr-MIF-1 blocked the effect of BE. Randomly chosen subgroups of
animals, which were statistically shown to adequately represent the
groups from which they were drawn, were retested in adulthood for
responsiveness to thermal pain using the hot plate.
a 50°C surface,
When placed on
the rank order of the treatment groups in their
latency to lick a hindpaw was similar to their ranking in the
tail-flick test on day 9. The latencies were significantly longer
in each of the 3 groups given Tyr-MIF-1 than in groups given BE
alone, morphiceptin alone, or the control vehicle. None of the
neonatal peptide treatments significantly affected the degree of
analgesia shown when animals were exposed to footshock and retested
on the hot plate. The mean tail-flick latencies of the animals on
day 9 correlated well with adult baseline scores on the hot plate
test, indicating that the effects of the peptides persisted into
adulthood. These results support the role of Tyr-MIF-1 as an
antiopiate and further illustrate the long-term effects of
neonatally administered peptides.
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PHENCYCLIDINE RECEPTOR IN BLOOD VESSELS. H. Zhu,
A.Z. Zhang, X.R. Xu* and W.L. Ye, *Dept. of Neurobiology,
Shanghai Medical University, Shanqhai Institute of
Materia Medica*, Shanghai, 200032, China
Binding studies of (3H) Phenclidine (PCP) to rabbit
mesenteric blood vessel detected a specific, saturable
and stereoselective binding site of which Kd=31.9±3.9
nM, Bmax=4.96±0.29 pmol/mg pr. IC50 of a series of
ligands are: PCP 0.39±0.04, dextrosin 3.01±0.19,
levorphanol 18.2 ± 1.2, dl-ketamine 0.17±0.02, dl-pen-
tazocine 0.14±0.03, d-SKF10,047 9.77±0.48, 1-SKF10,047
85.1±2.5, d-cyclazocine 2.57±0.11 and l-cyclazocine
4.07±0.17 uM. Naloxone and etorphine failed to inhibit
(3H) PCP binding at concentrations as high as 200 uM.
In vitro bioassay showed that PCP markedly enhanced
the electrical field stimulated contraction (ESC) of
rabbit central ear artery with a minimum eftective conc.
of 0.1 uM, which was naloxone irreversible. ED50
were: PCP 7.52±0.94, d-SKF10,047 1.52±0.23, pentazocine
6.44 and ketamine 1.43±0.14 uM. Such effect could be
abolished by 1 uM of phentolamine. HPLC detected a
significant increase of NE content (p<0.01) in the bath
medium after PCP administration.
Our finding of PCP and siqma opioid receptors in the
blood vessel and their vascular function may at least
partially explain the significant pressor effect of
these drugs, and also propose a dual system, i.e. kappa
(Neuropeptides, 1985,5;595) and PCP/sigma opioid recep-
tors which cooperatively modulate NE release and the
function of blood vessels.
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INVOLVEMENT OF ENDOGENOUS OPIOID PEPTIDES IN BURN-
INDUCED SHOCK. Y. X. Zhu, C. H. Wang and B. C. Lin,
Department of Physiology, Second Military Medical
College, Shanghai 200433, China
192 male Sprague-Dawley rats weighing 200-250g were
given III burn injury of 20% body surface area, and
equally divided into 6 groups: control, naloxone, anti-
-endorphin, anti-dynorphin A, anti-met-enkephalin, and
anti-leu-enkephalin. Each animal of these groups imme-
diately postburn was intravenously administrated 50µl
of normal rabbit serum, naloxone solution(1mg/kg),
antisera against -endorphin, antisera against dynorphin
a, antisera against met-enkephalin and antisera against
leu-enkephalin, respectively. There is no significant
difference(P>0.05) of survival rate at 6 hours postburn
between the control(21%) and anti-met-enkephalin(31%) or
anti-leu-enkephalin(2%) group. However, the survival
rate of the anti-dynorphin  A(61%) group at the same time
postburn was much hi her, and those of the naloxone(42%)
and anti -endorphin (44%) group were slightly higher
than that of the control group(3<0.05). The onset of
hypotension, bradycardia, hypothermia and dyspnea were
greatly delayed in the naloxone group, as compared with
the control group. Blood pressure showed a 62% reduction
at 180 minutes postburn in the naloxone group, while a
62% reduction was already seen at 90 minutes postburn in
the control group. It is suggested that endogenous
opioid peptides, especially dynorphin A and -endorphin,
might be involved in burn-induced shock, and naloxone
might to be effective in the treatment of burn-induced
shock.
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